<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000146.pub3" GROUP_ID="TOBACCO" ID="793499071913373258" MERGED_FROM="" MODIFIED="2012-10-17 14:44:50 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Updated 1999/3, 2000/3. Synopsis added 2000/3, replaced with consumer draft 2000/4. Updated 2001/3 with author change. Updated 2002/4 with 2 new trials. &lt;br&gt;Response to Pierce criticism entered 2/11/03&lt;br&gt;This version copied to Lindsay's RevMan for update 9/3/04&lt;br&gt;Updated 2004/3 with 12 new trials, no major changes. (Garvey data corrected, main comparison only compared 2mg to placebo, not 4+2mg)&lt;br&gt;Exported from Lindsay's RevMan for import to master, 12/5/04&lt;br&gt;Shiffman 2002b reinstated in graphs for 2005/1, so that data in text agrees with graphs again (for 2004/3-4 the text and graphs did not match, but text was correct).&lt;br&gt;'A response to a comment was added for issue 4, 2004.&lt;br&gt;Two corrections were made in issue 1, 2005; one on the description of stratification in Shiffman 2002A &amp;amp; Shiffman 2002B one in comparison 1 graph to include Shiffman 2002B in the tablet subgroup. Data in the text already included this study and remain unchanged.&lt;/p&gt;&lt;p&gt;Feb 07&lt;br&gt;Check that Tonnesen 1988 Addict Behav paper really is the same trial - checked - not it probably isn't -ref removed from study&lt;/p&gt;" NOTES_MODIFIED="2012-10-16 17:03:09 +0100" NOTES_MODIFIED_BY="Kate Cahill" REVIEW_NO="2" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="19.3">
<COVER_SHEET MODIFIED="2012-10-17 14:44:50 +0100" MODIFIED_BY="Lindsay Stead">
<TITLE>Nicotine replacement therapy for smoking cessation</TITLE>
<CONTACT MODIFIED="2012-10-17 14:44:50 +0100" MODIFIED_BY="Lindsay Stead"><PERSON ID="8169" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Lindsay</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Stead</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>lindsay.stead@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289285</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-17 14:44:50 +0100" MODIFIED_BY="Lindsay Stead"><PERSON ID="8169" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Lindsay</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Stead</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>lindsay.stead@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289285</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="16596" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rafael</FIRST_NAME><LAST_NAME>Perera</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>rafael.perera@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289308</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="7EEE2EAF82E26AA201E6E48B28F67476" ROLE="AUTHOR"><FIRST_NAME>Chris</FIRST_NAME><LAST_NAME>Bullen</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>c.bullen@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>National Institute for Health Innovation</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><ADDRESS_2>Auckland Mail Centre</ADDRESS_2><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>64 9 373 7599 ext 84730</PHONE_1><PHONE_2>+64 21415267</PHONE_2><FAX_1>+64 9 373 1710</FAX_1></ADDRESS></PERSON><PERSON ID="16587" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Mant</LAST_NAME><POSITION>Emeritus Professor of General Practice and Head of Department</POSITION><EMAIL_1>david.mant@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289288</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="18610660923872414930120124130151" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Jamie</FIRST_NAME><LAST_NAME>Hartmann-Boyce</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>jamie.hartmann-boyce@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865289206</PHONE_1><FAX_1>01865289287</FAX_1></ADDRESS></PERSON><PERSON ID="11120" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Kate</FIRST_NAME><LAST_NAME>Cahill</LAST_NAME><POSITION>Cochrane Tobacco Addiction Group</POSITION><EMAIL_1>kate.cahill@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289284</PHONE_1><PHONE_2>+44 1865 377427</PHONE_2><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="7767" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tim</FIRST_NAME><LAST_NAME>Lancaster</LAST_NAME><POSITION>Co-ordinating Editor,  Cochrane Tobacco Addiction Group</POSITION><EMAIL_1>tim.lancaster@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289285</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-10-03 09:37:17 +0100" MODIFIED_BY="L S">
<UP_TO_DATE>
<DATE DAY="19" MONTH="9" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2012-10-04 14:26:31 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-10-04 14:26:14 +0100" MODIFIED_BY="Lindsay Stead">
<DATE DAY="19" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Searches updated, 18 new studies added. Table of adverse events added. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-10-04 14:26:31 +0100" MODIFIED_BY="Lindsay Stead">
<DATE DAY="19" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Additional author. No major changes to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-10-02 16:15:42 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-02 16:15:42 +0100" MODIFIED_BY="Lindsay Stead">
<DATE DAY="22" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Additional table converted to appendix to correct pdf format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-06-22 10:27:24 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-05-08 10:37:50 +0100" MODIFIED_BY="L S">
<DATE DAY="1" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>New studies added, some comparisons reorganised, effect measure changed from odds ratio to risk ratio. Minor changes made to the conclusions about the evidence for combinations of NRT types. Authors changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MINOR" MODIFIED="2008-05-08 10:49:29 +0100" MODIFIED_BY="L S">
<DATE DAY="7" MONTH="4" YEAR="2004"/>
<DESCRIPTION>
<P>Twelve new studies added, no changes to main conclusions. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-05-08 13:19:13 +0100" MODIFIED_BY="L S">
<INTERNAL_SOURCES MODIFIED="2008-05-08 13:19:13 +0100" MODIFIED_BY="L S">
<SOURCE MODIFIED="2008-05-08 13:18:37 +0100" MODIFIED_BY="L S">
<NAME>Department of Primary Health Care, Oxford University</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Editorial base for the Cochrane Tobacco Addiction Group</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2008-05-08 13:19:13 +0100" MODIFIED_BY="L S">
<NAME>National Institute for Health Research School for Primary Care Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Support for the Department of Primary Health Care, Oxford University</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-05-08 13:17:56 +0100" MODIFIED_BY="L S">
<SOURCE MODIFIED="2008-05-08 13:17:56 +0100" MODIFIED_BY="L S">
<NAME>NHS Research and Development Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Infrastructure funding for the Cochrane Tobacco Addiction Group</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-10-15 10:07:46 +0100" MODIFIED_BY="L S">
<TITLE MODIFIED="2012-02-07 15:30:49 +0000" MODIFIED_BY="L S">Can nicotine replacement therapy (NRT) help people quit smoking?</TITLE>
<SUMMARY_BODY MODIFIED="2012-10-15 10:07:46 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>NRT aims to reduce withdrawal symptoms associated with stopping smoking by replacing the nicotine from cigarettes. NRT is available as skin patches that deliver nicotine slowly, and chewing gum, nasal and oral sprays, inhalers, and lozenges/tablets, all of which deliver nicotine to the brain more quickly than from skin patches, but less rapidly than from smoking cigarettes. This review includes 150 trials of NRT, with over 50,000 people in the main analysis. We found evidence that all forms of NRT made it more likely that a person's attempt to quit smoking would succeed. The chances of stopping smoking were increased by 50 to 70%. The evidence suggests no overall difference in effectiveness between different forms of NRT, nor a benefit for using patches beyond eight weeks. NRT works with or without additional counselling, and does not need to be prescribed by a doctor. Heavier smokers may need higher doses of NRT. People who use NRT during a quit attempt are likely to further increase their chance of success by using a combination of the nicotine patch and a faster acting form or by combining the patch with the antidepressant bupropion. Data suggest that starting to use NRT patches shortly before the planned quit date may increase the chance of success. Adverse effects from using NRT are related to the type of product, and include skin irritation from patches and irritation to the inside of the mouth from gum and tablets. There is no evidence that NRT increases the risk of heart attacks.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-10-15 10:07:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<ABS_BACKGROUND MODIFIED="2012-02-07 14:33:51 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>The aim of nicotine replacement therapy (NRT) is to temporarily replace much of the nicotine from cigarettes to reduce motivation to smoke and nicotine withdrawal symptoms, thus easing the transition from cigarette smoking to complete abstinence.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-08-22 14:14:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>The aims of this review were:<BR/>To determine the effect of NRT compared to placebo in aiding smoking cessation, and to consider whether there is a difference in effect for the different forms of NRT (chewing gum, transdermal patches, oral and nasal sprays, inhalers and tablets/lozenges) in achieving abstinence from cigarettes.<BR/>To determine whether the effect is influenced by the dosage, form and timing of use of NRT; the intensity of additional advice and support offered to the smoker; or the clinical setting in which the smoker is recruited and treated.<BR/>To determine whether combinations of NRT are more likely to lead to successful quitting than one type alone.<BR/>To determine whether NRT is more or less likely to lead to successful quitting compared to other pharmacotherapies.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-10-02 16:24:05 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>We searched the Cochrane Tobacco Addiction Group trials register for papers mentioning 'NRT' or any type of nicotine replacement therapy in the title, abstract or keywords. Date of most recent search July 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-02-07 14:40:03 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Randomized trials in which NRT was compared to placebo or to no treatment, or where different doses of NRT were compared. We excluded trials which did not report cessation rates, and those with follow-up of less than six months.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-02-16 16:48:15 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>We extracted data in duplicate on the type of participants, the dose, duration and form of nicotine therapy, the outcome measures, method of randomization, and completeness of follow-up.<BR/>The main outcome measure was abstinence from smoking after at least six months of follow-up. We used the most rigorous definition of abstinence for each trial, and biochemically validated rates if available. We calculated the risk ratio (RR) for each study. Where appropriate, we performed meta-analysis using a Mantel-Haenszel fixed-effect model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-10-15 10:07:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>We identified 150 trials; 117 with over 50,000 participants contributed to the primary comparison between any type of NRT and a placebo or non-NRT control group. The risk ratio (RR) of abstinence for any form of NRT relative to control was 1.60 (95% confidence interval [CI] 1.53 to 1.68). The pooled RRs for each type were 1.49 (95% CI 1.40 to 1.60, 55 trials) for nicotine gum; 1.64 (95% CI 1.52 to 1.78, 43 trials) for nicotine patch; 1.95 (95% CI 1.61 to 2.36, 6 trials) for oral tablets/lozenges; 1.90 (95% CI 1.36 to 2.67, 4 trials) for nicotine inhaler; and 2.02 (95% CI 1.49 to 2.73, 4 trials) for nicotine nasal spray. One trial of oral spray had an RR of 2.48 (95% CI 1.24 to 4.94). The effects were largely independent of the duration of therapy, the intensity of additional support provided or the setting in which the NRT was offered. The effect was similar in a small group of studies that aimed to assess use of NRT obtained without a prescription. In highly dependent smokers there was a significant benefit of 4 mg gum compared with 2 mg gum, but weaker evidence of a benefit from higher doses of patch. There was evidence that combining a nicotine patch with a rapid delivery form of NRT was more effective than a single type of NRT (RR 1.34, 95% CI 1.18 to 1.51, 9 trials). The RR for NRT used for a short period prior to the quit date was 1.18 (95% CI 0.98 to 1.40, 8 trials), just missing statistical significance, though the efficacy increased when we pooled only patch trials and when we removed one trial in which confounding was likely. Five studies directly compared NRT to a non-nicotine pharmacotherapy, bupropion; there was no evidence of a difference in efficacy (RR 1.01; 95% CI 0.87 to 1.18). A combination of NRT and bupropion was more effective than bupropion alone (RR 1.24; 95% CI 1.06 to 1.45, 4 trials). Adverse effects from using NRT are related to the type of product, and include skin irritation from patches and irritation to the inside of the mouth from gum and tablets. There is no evidence that NRT increases the risk of heart attacks.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-10-04 14:40:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>All of the commercially available forms of NRT (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) can help people who make a quit attempt to increase their chances of successfully stopping smoking. NRTs increase the rate of quitting by 50 to 70%, regardless of setting. The effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the individual. Provision of more intense levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-10-15 09:38:50 +0100" MODIFIED_BY="L S">
<P>Nicotine replacement therapy (NRT) aims to reduce motivation to smoke and the physiological and psychomotor withdrawal symptoms often experienced during an attempt to stop smoking, and therefore increase the likelihood of remaining abstinent (<LINK REF="REF-West-2001" TYPE="REFERENCE">West 2001</LINK>). Nicotine undergoes first pass metabolism in the liver, reducing the overall bioavailability of swallowed nicotine pills. A pill that could reliably produce high enough nicotine levels in the central nervous system would risk causing adverse gastrointestinal effects. To avoid this problem, nicotine replacement products are formulated for absorption through the oral or nasal mucosa (chewing gum, lozenges, sublingual tablets, inhaler/inhalator, spray) or through the skin (transdermal patches). Other products are also under development (<LINK REF="REF-Park-2002" TYPE="REFERENCE">Park 2002</LINK>; <LINK REF="REF-D_x0027_Orlando-2004" TYPE="REFERENCE">D'Orlando 2004</LINK>; <LINK REF="REF-Ikinci-2006" TYPE="REFERENCE">Ikinci 2006</LINK>; <LINK REF="STD-Bolliger-2007" TYPE="STUDY">Bolliger 2007</LINK>; <LINK REF="STD-McRobbie-2010" TYPE="STUDY">McRobbie 2010</LINK>).</P>
<P>Nicotine patches differ from the other products in that they deliver the nicotine dose slowly and passively. They do not replace any of the behavioural activities of smoking. In contrast the other types of NRT are faster acting, but require more effort on the part of the user. Transdermal patches are available in several different doses, and deliver between 5 mg and 52.5 mg of nicotine over a 24-hour period, resulting in plasma levels similar to the trough levels seen in heavy smokers (<LINK REF="REF-Fiore-1992" TYPE="REFERENCE">Fiore 1992</LINK>). Some brands of patch are designed to be worn for 24 hours whilst others are to be worn for 16 hours each day. Nicotine gum is available in both 2 mg and 4 mg strengths, and nicotine lozenges are available in 1 mg, 1.5 mg, 2 mg and 4 mg strengths, though the amount of nicotine absorbed by the user is less than the original dose. None of the available products deliver such high doses of nicotine as quickly as cigarettes. An average cigarette delivers between 1 and 3 mg of nicotine and the typical pack-per-day smoker absorbs 20 to 40 mg of nicotine each day (<LINK REF="REF-Henningfield-2005" TYPE="REFERENCE">Henningfield 2005</LINK>).</P>
<P>The availability of NRT products on prescription or for over-the-counter purchase varies from country to country. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> summarises the products currently licensed in the United Kingdom.</P>
<P>In earlier versions, this review focused on the effect of nicotine replacement therapy in comparison to placebo for helping people stop smoking. The evidence that NRT helps some people to stop smoking is now well accepted, and many clinical guidelines recommend NRT as a first line treatment for people seeking pharmacological help to stop smoking (<LINK REF="REF-West-2000" TYPE="REFERENCE">West 2000</LINK>; <LINK REF="REF-NZ-MoH-2007" TYPE="REFERENCE">NZ MoH 2007</LINK>; <LINK REF="REF-Woolacott-2002" TYPE="REFERENCE">Woolacott 2002</LINK>; <LINK REF="REF-Italy-ISS-2004" TYPE="REFERENCE">Italy ISS 2004</LINK>; <LINK REF="REF-Le-Foll-2005" TYPE="REFERENCE">Le Foll 2005</LINK>; <LINK REF="REF-Fiore-2008" TYPE="REFERENCE">Fiore 2008</LINK>; <LINK REF="REF-Zwar-2011" TYPE="REFERENCE">Zwar 2011</LINK>). This review still provides an estimate of the expected effect of using NRT, using meta-analysis. We also address questions about when and how to use NRT most effectively. This includes consideration of the effect of the type of NRT used, including the use of combinations of different types of NRT, the effect of the setting in which it is used (including purchasing over the counter versus prescription use), the effect of dosing according to characteristics of the individual quitter and whether the effect of NRT is altered by different levels of behavioural support. NRT is now one of several forms of pharmacotherapy available to support quit attempts, including some antidepressants and the nicotine receptor partial agonist varenicline. These pharmacotherapies are evaluated in separate Cochrane reviews (<LINK REF="REF-Hughes-2007" TYPE="REFERENCE">Hughes 2007</LINK>; <LINK REF="REF-Cahill-2007" TYPE="REFERENCE">Cahill 2007</LINK>). This review includes in its scope evaluations of randomized trials directly comparing NRT to these treatments, or combining NRT with them.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-10-16 16:02:36 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>To determine the effectiveness of nicotine replacement therapy (NRT), including gum, transdermal patch, intranasal spray and inhaled and oral preparations, in achieving long-term smoking cessation.</P>
<P>We addressed the following questions:<BR/>
</P>
<UL>
<LI>Is NRT more effective than a placebo or 'no NRT' intervention in promoting smoking cessation?</LI>
<LI>Is NRT relatively more effective when given with higher levels of behavioural support?</LI>
<LI>Is NRT relatively more effective for people who are highly motivated to quit smoking?</LI>
<LI>Is 4 mg nicotine gum more effective than 2 mg nicotine gum?</LI>
<LI>Are fixed dosing schedules for nicotine gum more effective than ad lib use?</LI>
<LI>Is higher dose nicotine patch therapy more effective than standard dose (~1 mg/hour) therapy?</LI>
<LI>Are nicotine patches worn for 24 hours more effective than 16-hour patches?</LI>
<LI>Is a longer duration of nicotine patch use more effective than shorter treatment?</LI>
<LI>Is weaning from nicotine patch use more effective than an abrupt end of therapy?</LI>
<LI>Are combinations of different forms of NRT more effective than the usual dose of a single type?</LI>
<LI>Does NRT assist cessation among people who have relapsed after recent use of NRT?</LI>
<LI>Is initiating NRT use before making a quit attempt more effective than starting on the quit day?</LI>
<LI>Is NRT more or less effective than bupropion for smoking cessation?</LI>
<LI>Is NRT combined with bupropion more effective than NRT alone?</LI>
<LI>Are there harms associated with using NRT?</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<CRIT_STUDIES>
<P>Randomized controlled trials. Trials where allocation to treatment was by a quasi-randomized method were also included, but appropriate sensitivity analysis was used to determine whether their inclusion altered the results.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Men or women who smoked and were motivated to quit were included irrespective of the setting from which they were recruited and/or their initial level of nicotine dependence. We included studies that randomized therapists, rather than smokers, to offer NRT or a control, provided that the specific aim of the study was to examine the effect of NRT on smoking cessation. Trials that randomized physicians or other therapists to receive an educational intervention, which included encouraging their patients to use NRT, were not included, but have been reviewed separately (<LINK REF="REF-Carson-2012" TYPE="REFERENCE">Carson 2012</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-15 09:46:24 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Comparisons of NRT (including chewing gum, transdermal patches, nasal and oral spray, inhalers and tablets or lozenges) versus placebo or no NRT control. The terms 'inhaler' and 'inhalator' (an oral device which delivers nicotine to the buccal mucosa by sucking) are used interchangeably in the literature. We have used the term 'inhaler' throughout the rest of this review.</P>
<P>We also included trials comparing different doses of NRT, comparing more than one type of NRT to a single type, comparing NRT with bupropion and combinations of the two, and comparing use of NRT prior to quit date as opposed to from quit date only.</P>
<P>In some analyses we categorized the trials into groups depending on the level of additional support provided (low or high). The definition of the low intensity category was intended to identify a level of support that could be offered as part of the provision of routine medical care. If the duration of time spent with the smoker (including assessment for the trial) exceeded 30 minutes at the initial consultation or the number of further assessment and reinforcement visits exceeded two, the level of additional support was categorized as high. The high intensity category included trials where there were a large number of visits to the clinic or trial centre, but these were often brief, spread over an extended period during treatment and follow-up, and did not include a specific counselling component. To provide a more fine-grained analysis and to distinguish between high intensity group-based support and other trials within the high intensity category, we have therefore specified where the support included multi-session group-based counselling with frequent sessions around the quit date.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-10-15 09:48:11 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>The review evaluates the effects of NRT versus control on smoking cessation, rather than on withdrawal symptoms. We excluded trials that followed up participants for less than six months, except for trials amongst pregnant women, where the interval between enrolment and delivery may have been shorter. For each study we chose the strictest available criteria to define abstinence. For example, in studies where biochemical validation of cessation was available, only those participants who met the criteria for biochemically confirmed abstinence were regarded as being abstinent. Wherever possible we chose a measure of sustained cessation rather than point prevalence. People who were lost to follow-up were regarded as being continuing smokers.<BR/>For the current update we collected data on adverse events in both the included and excluded studies, where they were reported. We have not attempted to pool these findings, apart from one meta-analysis of reports of palpitations, tachycardia or chest pains.<BR/>Trials that evaluated the effect of NRT for individuals who were attempting to reduce the number of cigarettes smoked rather than to quit are no longer included in this review. They are covered by a separate review on harm reduction approaches (<LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-10-15 09:52:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>We searched the specialized register of the Cochrane Tobacco Addiction Group in July 2012 for any reports of trials making reference to the use of nicotine replacement therapy of any type, by searching for 'NRT', or 'nicotine' near to terms for nicotine replacement products in the title, abstract or keywords. The most recent issues of the databases included in the register as searched for the current update of this review were: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library,</I> Issue 7, 2012), MEDLINE (Ovid) to update code 20120622, EMBASE (Ovid) to week 27 2012, PsycINFO (Ovid) to update 20120625. The search strategy for the Register is given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. For details of the searches used to create the specialized register see the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/TOBACCO/frame.html">Tobacco Addiction Group Module</A> in the <I>The Cochrane Library</I>. The trials register also includes trials identified by handsearching of abstract books from meetings of the Society for Research on Nicotine &amp; Tobacco. For earlier versions of this review we performed searches of additional databases: Cancerlit, Health Planning and Administration, Social Scisearch, Smoking &amp; Health and Dissertation Abstracts. Since the searches did not produce any additional trials we did not search these databases after December 1996. During preparation of the first version of this review, we also sent letters to manufacturers of NRT preparations. Since this did not result in additional data we have not repeat the exercise for subsequent updates.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-10-15 12:01:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-10-15 09:54:01 +0100" MODIFIED_BY="Lindsay Stead">
<P>One author (LS) screened records retrieved by searches, to exclude papers that were not reports of potentially relevant studies. Reports that linked to potentially relevant studies but did not report the outcomes of interest are listed along with the main study report in the References to Studies section. The primary reference to the study is indicated, and for most studies the first author and year used as the study identifier corresponds the primary reference. Where data for a study were extracted from more than one report this is noted in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-15 09:55:06 +0100" MODIFIED_BY="Lindsay Stead">
<P>Two individuals independently extracted data from the published reports and abstracts. We resolved disagreements by discussion or referral to a third party. We made no attempt to blind these individuals either to the results of the primary studies or to which treatment participants received. We examined reports published only in non-English language journals with the assistance of translators.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-10-15 09:55:33 +0100" MODIFIED_BY="Lindsay Stead">
<P>We assessed included studies for risks of selection bias, (methods of randomized sequence generation, and allocation concealment), performance and detection bias (the presence or absence of blinding), attrition bias (levels and reporting of loss to follow-up), and any other threats to study quality.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-10-15 09:57:03 +0100" MODIFIED_BY="Lindsay Stead">
<P>We extracted smoking cessation rates in the intervention and control groups from the reports at six or 12 months. Since not all studies reported cessation rates at exactly these intervals, we allowed a window period of six weeks at each follow-up point. For trials without 12-month follow-up we used six-month data. For trials which also reported follow-up for more than a year we used 12-month outcomes in most cases. (We note exceptions in the included study table.) For trials of NRT in pregnant women, we extracted smoking cessation outcomes at the closest follow-up to end of pregnancy, and also at longest follow-up postpartum if reported. Following the Cochrane Tobacco Addiction Group's recommended method of data analysis, we use the risk ratio for summarizing individual trial outcomes and for estimates of pooled effect. Whilst there are circumstances in which odds ratios may be preferable, there is a danger that they will be interpreted as if they are risk ratios, making the treatment effect seem larger (<LINK REF="REF-Deeks-2005" TYPE="REFERENCE">Deeks 2005</LINK>).</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2012-10-15 10:00:07 +0100" MODIFIED_BY="Lindsay Stead">
<P>We treated participants who dropped out or who were lost to follow-up after randomization as being continuing smokers. We noted in the risk of bias table the proportion of participants for whom the outcome was imputed in this way, and whether there was either high or differential loss to follow-up. The assumption that 'missing = smoking' will give conservative absolute quit rates, and will make little difference to the risk ratio unless drop-out rates differ substantially between groups.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-10-15 10:02:46 +0100" MODIFIED_BY="Lindsay Stead">
<P>To assess heterogeneity we use the I² statistic, given by the formula [(Q - df)/Q] x 100%, where Q is the Chi² statistic and df is its degrees of freedom (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). A value greater than 50% may be considered to indicate substantial heterogeneity. When there are large numbers of trials as in this review, the Chi² test for heterogeneity will be unduly powerful and may identify statistically significant but clinically unimportant heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-10-03 11:24:13 +0100" MODIFIED_BY="Lindsay Stead">
<P>We estimated a pooled weighted average of risk ratios using a Mantel-Haenszel method, with 95% confidence intervals.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-10-15 12:01:07 +0100" MODIFIED_BY="Lindsay Stead">
<P>In comparing NRT to placebo or control, we performed subgroup analysis for each form of NRT. We did additional subgroup analyses within type of NRT (gum, patch, etc) to investigate whether the relative treatment effect differed according to the way in which smoking cessation was defined, and the intensity of behavioural support. We also used subgroup analyses to compare effect sizes across nicotine patch trials using different lengths of treatment, durations of daily use and tapering of dose at the end of treatment and to compare effect sizes across nicotine gum trials by dose and schedule. Additionally, we conducted subgroup analysis based on clinical setting of treatment. Where the estimates of effect clearly differed across subgroups we used meta-regression to test for significance.</P>
<P>For descriptive purposes we calculated an average quit rate for the control groups in some subgroup analyses, weighting by the inverse variance. Quit rates will vary between studies depending on many factors, including the period in which the study was done and the definition of abstinence used by the study. To provide a clinical perspective in the Discussion we estimated the number of people who would need to be treated to benefit (NNTB) with NRT in order to produce one successful quitter at 12 months beyond that which would be achieved from a quit attempt without NRT. To do this we specified baseline quit rates and used the risk ratio derived from meta-analysis to calculate the quit rate likely with treatment; we then calculated the NNTB as the inverse of the difference between the treated and untreated quit rates (<LINK REF="REF-Altman-2002" TYPE="REFERENCE">Altman 2002</LINK>).</P>
<P>The Cochrane Tobacco Addiction Group's Glossary of smoking-related terms is included in this review (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-16 16:41:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-10-16 16:41:25 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<INCLUDED_STUDIES_DESCR MODIFIED="2012-10-16 16:41:25 +0100" MODIFIED_BY="Lindsay Stead">
<P>The review includes 150 studies, 18 of which are new in the 2012 update (<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK>; <LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK>; <LINK REF="STD-Cooney-2009" TYPE="STUDY">Cooney 2009</LINK>; <LINK REF="STD-Etter-2009" TYPE="STUDY">Etter 2009</LINK>; <LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK>; <LINK REF="STD-Hughes-2010" TYPE="STUDY">Hughes 2010</LINK>; <LINK REF="STD-Oncken-2008" TYPE="STUDY">Oncken 2008</LINK>; <LINK REF="STD-Ortega-2011" TYPE="STUDY">Ortega 2011</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK>; <LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK>; <LINK REF="STD-Rose-2010" TYPE="STUDY">Rose 2010</LINK>; <LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK>; <LINK REF="STD-Schnoll-2010b" TYPE="STUDY">Schnoll 2010b</LINK>; <LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK>; <LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-T_x00f8_nnesen-2012" TYPE="STUDY">Tønnesen 2012</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>). Trials were conducted in North America (77 studies), Europe (60 studies), Australasia (5 studies), Japan (2 studies), South America (2 studies), South Africa, Taiwan, Thailand, and in multiple regions (1 study each). The median sample size was around 240 but ranged from fewer than 50 to over 3500 participants.</P>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>Participants were typically adult cigarette smokers with an average age of 40 to 50. One trial recruited adolescents (<LINK REF="STD-Moolchan-2005" TYPE="STUDY">Moolchan 2005</LINK>). Most trials had approximately similar numbers of men and women. <LINK REF="STD-Kornitzer-1987" TYPE="STUDY">Kornitzer 1987</LINK> recruited only men in a workplace setting. Four trials recruited only pregnant women (<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK>; <LINK REF="STD-Oncken-2008" TYPE="STUDY">Oncken 2008</LINK>; <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007;</LINK> <LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK>) and a further four recruited only women (<LINK REF="STD-Cooper-2005" TYPE="STUDY">Cooper 2005</LINK>; <LINK REF="STD-Oncken-2007" TYPE="STUDY">Oncken 2007</LINK>; <LINK REF="STD-Pirie-1992" TYPE="STUDY">Pirie 1992</LINK>; <LINK REF="STD-Prapavessis-2007" TYPE="STUDY">Prapavessis 2007</LINK>). Two trials recruited African-American smokers (<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK>; <LINK REF="STD-Ahluwalia-2006" TYPE="STUDY">Ahluwalia 2006</LINK>).</P>
<P>Trials typically recruited people who smoked at least 15 cigarettes a day. Although some trials included lighter smokers as well, the average number smoked was over 20 per day in most studies. <LINK REF="STD-Ahluwalia-2006" TYPE="STUDY">Ahluwalia 2006</LINK> recruited only people who smoked 10 or fewer cigarettes per day and <LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK> recruited only people who smoked six to 15 cigarettes per day. <LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK> recruited people smoking 25 or more per day and two trials recruited only people smoking 30 or more per day (<LINK REF="STD-Hughes-1990" TYPE="STUDY">Hughes 1990</LINK>; <LINK REF="STD-Hughes-2003" TYPE="STUDY">Hughes 2003</LINK>). <LINK REF="STD-Cooney-2009" TYPE="STUDY">Cooney 2009</LINK> recruited participants who were alcohol-dependent at the time of the study and two trials recruited people with a history of alcohol dependence (<LINK REF="STD-Hughes-2003" TYPE="STUDY">Hughes 2003</LINK>; <LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK>). <LINK REF="STD-Joseph-1996" TYPE="STUDY">Joseph 1996</LINK> recruited people with a history of cardiac disease, and <LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK> recruited relapsed smokers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Type and dose of nicotine replacement therapy</HEADING>
<P>One hundred and seventeen studies (119 comparisons) contributed to the primary analysis of the efficacy of one or more types of NRT compared to a placebo or other control group not receiving any type of NRT. In this group of studies there were 55 trials of nicotine gum, 43 of transdermal nicotine patch, six of an oral nicotine tablet or lozenge, five offering a choice of products, four of intranasal nicotine spray, four of nicotine inhaler, one of oral spray (<LINK REF="STD-T_x00f8_nnesen-2012" TYPE="STUDY">Tønnesen 2012</LINK>), one providing patch and inhaler (<LINK REF="STD-Hand-2002" TYPE="STUDY">Hand 2002</LINK>) and one providing patch and lozenge (<LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>).</P>
<P>Trials that did not contribute to the primary analysis addressed a range of other questions including treatment duration, dose, combinations of different types of NRT compared to a single type, NRT compared to the smoking cessation pharmacotherapy bupropion, and use of NRT for a short period before the target quit day.</P>
<P>Most trials comparing nicotine gum to control provided the 2 mg dose. A few provided 4 mg gum to more highly addicted smokers, and two used only the 4mg dose (<LINK REF="STD-Blondal-1989" TYPE="STUDY">Blondal 1989</LINK>; <LINK REF="STD-Puska-1979" TYPE="STUDY">Puska 1979</LINK>). Five trials included a comparison of 2 mg and 4 mg doses (<LINK REF="STD-Garvey-2000" TYPE="STUDY">Garvey 2000</LINK>; <LINK REF="STD-Herrera-1995" TYPE="STUDY">Herrera 1995</LINK>; <LINK REF="STD-Hughes-1990" TYPE="STUDY">Hughes 1990</LINK>; <LINK REF="STD-Kornitzer-1987" TYPE="STUDY">Kornitzer 1987</LINK>; <LINK REF="STD-Tonnesen-1988" TYPE="STUDY">Tonnesen 1988</LINK>). In three trials the physician offered nicotine gum but participants did not necessarily accept or use it (<LINK REF="STD-Ockene-1991" TYPE="STUDY">Ockene 1991</LINK>; <LINK REF="STD-Page-1986" TYPE="STUDY">Page 1986</LINK>; <LINK REF="STD-Russell-1983" TYPE="STUDY">Russell 1983</LINK>). In one trial participants self selected 2 mg or 4 mg doses; the two groups are treated as separate trials in the meta-analysis (<LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK>; <LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>). Two trials compared a fixed dosage regimen with an ad lib regimen (<LINK REF="STD-Goldstein-1989" TYPE="STUDY">Goldstein 1989</LINK>
<LINK REF="STD-Killen-1990" TYPE="STUDY">Killen 1990</LINK>). The treatment period was typically two to three months, but ranged from 3 weeks to 12 months. Some trials did not specify how long the gum was available. Many of the trials included a variable period of dose tapering, but most encouraged participants to be gum-free by six to 12 months.</P>
<P>In nicotine patch trials the usual maximum daily dose was 15 mg for a 16-hour patch, or 21 mg for a 24-hour patch. Forty-two studies used a 24-hour formulation and 11 a 16-hour product. One study offered, among other dosage options, a 52.5 mg/24 hour patch (<LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>). If studies tested more than one dose we combined all active arms in the comparison to placebo. For one study we included an arm with a lower maximum dose of 14 mg but excluded a 7 mg dose arm (<LINK REF="STD-TNSG-1991" TYPE="STUDY">TNSG 1991</LINK>). One trial (<LINK REF="STD-Daughton-1991" TYPE="STUDY">Daughton 1991</LINK>) included a direct comparison between groups wearing 16-hour or 24-hour patches in addition to a placebo control. Eight trials directly compared a higher dose patch to a standard dose; in seven patch use was initiated on the quit date (<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK>; <LINK REF="STD-Dale-1995" TYPE="STUDY">Dale 1995</LINK>; <LINK REF="STD-Hughes-1999" TYPE="STUDY">Hughes 1999</LINK>; <LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK>; <LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK>; <LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK>; <LINK REF="STD-Paoletti-1996" TYPE="STUDY">Paoletti 1996</LINK>) and in one patch use was initiated two weeks before the target quit date (<LINK REF="STD-Rose-2010" TYPE="STUDY">Rose 2010</LINK>). The minimum duration of therapy ranged from three weeks (<LINK REF="STD-Glavas-2003a" TYPE="STUDY">Glavas 2003a</LINK>, half the participants of <LINK REF="STD-Glavas-2003b" TYPE="STUDY">Glavas 2003b</LINK>) to three months, with a tapering period, if required, in 38 of the trials. Five trials directly compared two durations of therapy (<LINK REF="STD-Bolin-1999" TYPE="STUDY">Bolin 1999</LINK>; <LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK>; <LINK REF="STD-Glavas-2003b" TYPE="STUDY">Glavas 2003b</LINK>; <LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK>; <LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK>).</P>
<P>There are six studies of nicotine sublingual tablets or lozenges. Three used 2 mg sublingual tablets (<LINK REF="STD-Glover-2002" TYPE="STUDY">Glover 2002</LINK>; <LINK REF="STD-Tonnesen-2006" TYPE="STUDY">Tonnesen 2006</LINK>; <LINK REF="STD-Wallstrom-2000" TYPE="STUDY">Wallstrom 2000</LINK>). One used a 1 mg nicotine lozenge (<LINK REF="STD-Dautzenberg-2001" TYPE="STUDY">Dautzenberg 2001</LINK>). One used 2 mg or 4 mg lozenges according to dependence level based on manufacturers' instructions (<LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>) and one used 2 mg or 4 mg based on participants' time to first cigarette of the day (TTFC); smokers whose TTFC was more than 30 minutes were randomized to 2 mg lozenges or placebo (<LINK REF="STD-Shiffman-2002-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2002 (2mg)</LINK>), whilst smokers with a TTFC less than 30 minutes had higher dose 4 mg lozenges or placebo (<LINK REF="STD-Shiffman-2002-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2002 (4mg)</LINK>). The two groups are treated in the meta-analysis as separate trials making seven in total. There are four trials of intranasal nicotine spray (<LINK REF="STD-Blondal-1997" TYPE="STUDY">Blondal 1997</LINK>; <LINK REF="STD-Hjalmarson-1994" TYPE="STUDY">Hjalmarson 1994</LINK>; <LINK REF="STD-Schneider-1995" TYPE="STUDY">Schneider 1995</LINK>; <LINK REF="STD-Sutherland-1992" TYPE="STUDY">Sutherland 1992</LINK>), one trial of oral nicotine spray (<LINK REF="STD-T_x00f8_nnesen-2012" TYPE="STUDY">Tønnesen 2012</LINK>) and four trials of nicotine inhaler (<LINK REF="STD-Hjalmarson-1997" TYPE="STUDY">Hjalmarson 1997</LINK>; <LINK REF="STD-Leischow-1996" TYPE="STUDY">Leischow 1996</LINK>; <LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK>; <LINK REF="STD-Tonnesen-1993" TYPE="STUDY">Tonnesen 1993</LINK>). One trial of a nicotine inhaler was excluded as follow-up was for only three months (<LINK REF="STD-Glover-1992" TYPE="STUDY">Glover 1992</LINK>). Leischow refers to another unpublished study by different investigators that did not demonstrate any benefit of a nicotine inhaler. One trial compared four different types of NRT (patch, gum, inhaler and nasal spray) but only followed patients for 12 weeks and was excluded (<LINK REF="STD-Hajek-1999" TYPE="STUDY">Hajek 1999</LINK>).</P>
<P>Nine trials compared combinations of two forms of nicotine therapy with only one form: patch with gum to patch alone (<LINK REF="STD-Cooney-2009" TYPE="STUDY">Cooney 2009</LINK>; <LINK REF="STD-Kornitzer-1995" TYPE="STUDY">Kornitzer 1995</LINK>); patch with gum to gum alone (<LINK REF="STD-Puska-1995" TYPE="STUDY">Puska 1995</LINK>); patch with nasal spray to patch alone (<LINK REF="STD-Blondal-1999" TYPE="STUDY">Blondal 1999</LINK>); patch with inhaler to inhaler alone (<LINK REF="STD-Bohadana-2000" TYPE="STUDY">Bohadana 2000</LINK>); patch with lozenge to either one alone (<LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>); patch with inhaler to either one alone (<LINK REF="STD-Tonnesen-2000" TYPE="STUDY">Tonnesen 2000</LINK>); and patch with nasal spray to either one alone (<LINK REF="STD-Croghan-2003" TYPE="STUDY">Croghan 2003</LINK>). In addition to these last four trials allowing a direct comparison between two single types, <LINK REF="STD-Lerman-2004" TYPE="STUDY">Lerman 2004</LINK> compared patch to nasal spray. Two unpublished trials of combination therapies with only three-month follow-up are excluded but contribute to a sensitivity analysis in the results (<LINK REF="STD-Finland-unpublished" TYPE="STUDY">Finland unpublished</LINK>; <LINK REF="STD-Sutherland-1999" TYPE="STUDY">Sutherland 1999</LINK>).</P>
<P>Five trials directly compared nicotine and bupropion (<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK>; <LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment setting</HEADING>
<P>Eighteen trials in the main comparison (12 gum, five patch and one offering a choice of NRT products) were conducted in a primary care setting where smokers were usually recruited in response to a specific invitation from their doctor during a consultation. A further two gum trials were undertaken in workplace clinics (<LINK REF="STD-Fagerstrom-1984" TYPE="STUDY">Fagerstrom 1984</LINK>; <LINK REF="STD-Roto-1987" TYPE="STUDY">Roto 1987</LINK>), and one in a university clinic (<LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK>). One trial recruited via community physicians (<LINK REF="STD-Niaura-1994" TYPE="STUDY">Niaura 1994</LINK>). Since participants in these trials were recruited in a similar way to primary care, we have aggregated them in the subgroup analysis by setting. One patch trial conducted in Veterans Affairs Medical Centers and recruiting patients with cardiac diseases (<LINK REF="STD-Joseph-1996" TYPE="STUDY">Joseph 1996</LINK>) was also included in the primary care category. Four trials recruiting pregnant women in antenatal clinics (<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK>; <LINK REF="STD-Oncken-2008" TYPE="STUDY">Oncken 2008</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK>) were kept in a separate category. Six of the gum trials, two of the nasal spray trials, and two of the inhaler/inhalator trials were carried out in specialized smoking cessation clinics to which participants had usually been referred. Ten trials (four patch, three gum, two giving a choice of products and one giving a combination of products) were undertaken with hospital in- or outpatients, some of who were recruited because they had a coexisting smoking-related illness. Three patch trials (<LINK REF="STD-Davidson-1998" TYPE="STUDY">Davidson 1998</LINK>; <LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK>; <LINK REF="STD-Sonderskov-1997" TYPE="STUDY">Sonderskov 1997</LINK>) and one gum trial (split into <LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK> and <LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>) were undertaken in settings intended to resemble 'over-the-counter' (OTC) use of NRT. One of these also allowed a comparison between purchased and free patches with minimal support (<LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK>). Two trials compared purchased NRT without behavioural support (simulating an OTC setting) to purchased NRT with brief physician support (using patch, <LINK REF="STD-Leischow-1999" TYPE="STUDY">Leischow 1999</LINK>; using inhaler, <LINK REF="STD-Leischow-2004" TYPE="STUDY">Leischow 2004</LINK>). These two trials did not have a non-NRT control so do not contribute to the primary comparison. One trial of pre-cessation NRT (<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK>) recruited participants who were all callers to a national quit line. One trial in a primary care setting evaluated the effect of cost on the use and efficacy of nicotine gum (<LINK REF="STD-Hughes-1991" TYPE="STUDY">Hughes 1991</LINK>). The remaining trials were undertaken in participants from the community, most of whom had volunteered in response to media advertisements, but who were treated in clinical settings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre-cessation use of NRT</HEADING>
<P>Eight trials tested the use of NRT compared to placebo or control prior to quit date: five initiated patch use two weeks before the quit date (<LINK REF="STD-Rose-1994" TYPE="STUDY">Rose 1994</LINK>; <LINK REF="STD-Rose-1998" TYPE="STUDY">Rose 1998</LINK>; <LINK REF="STD-Rose-2006" TYPE="STUDY">Rose 2006</LINK>; <LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK>; <LINK REF="STD-Schuurmans-2004" TYPE="STUDY">Schuurmans 2004</LINK>); one initiated patch or gum use two weeks before the quit date (<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK>); one initiated lozenge use three weeks prior to the quit date (<LINK REF="STD-Hughes-2010" TYPE="STUDY">Hughes 2010</LINK>); and one initiated gum use four weeks prior to the quit date (<LINK REF="STD-Etter-2009" TYPE="STUDY">Etter 2009</LINK>). Following the quit date all study arms received active NRT. Three of the studies included other factorial arms testing mecamylamine. We combined the arms with the same pre-quit NRT conditions in our analysis. <LINK REF="STD-Rose-2010" TYPE="STUDY">Rose 2010</LINK> compared two different doses of nicotine patch, both started two weeks before the target quit date and <LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK>/<LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK> was a placebo controlled trial in which participants were instructed to reduce cigarette consumption and increase gum use before quitting; neither of these trials were relevant to the pre-cessation analysis.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-10-15 10:58:26 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Studies that were potentially relevant but excluded are listed with reasons in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Some studies were excluded due to short follow-up. Some of these had as their primary outcome withdrawal symptoms rather than cessation. Studies that provided NRT or placebo to people trying to cut down their smoking but not make an immediate quit attempt are now excluded and are considered in detail in a separate review of interventions for reduction (<LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>). We excluded two trials in which NRT was provided to encourage a quit attempt but participants did not need to be planning to quit: <LINK REF="STD-Velicer-2006" TYPE="STUDY">Velicer 2006</LINK> proactively recruited people by telephone, with those in one intervention group being mailed a six-week course of nicotine patches if they were judged to be in the preparation stage or in contemplation and had more pros than cons for quitting; <LINK REF="STD-Carpenter-2011" TYPE="STUDY">Carpenter 2011</LINK> encouraged all participants to make a practice quit attempt, and gave the intervention group trial samples of nicotine lozenges. We excluded one trial (<LINK REF="STD-Ferguson-2012" TYPE="STUDY">Ferguson 2012</LINK>) in which callers to the NHS Quitline were randomized to be offered free NRT or not to receive the offer; the control group had access to and used free NRT and other stop smoking medication at high levels. We excluded <LINK REF="STD-Walker-2011" TYPE="STUDY">Walker 2011</LINK> in which callers to a quitline were randomized either to receive a sample box of NRT products to try out before their quit date and to choose one of two to use, or to receive usual care, in which patch, gum or a combination was provided based on discussion with the adviser.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-10-15 14:54:00 +0100" MODIFIED_BY="[Empty name]">
<P>Four trials are included based on data available from abstracts or conference presentations (<LINK REF="STD-Dautzenberg-2001" TYPE="STUDY">Dautzenberg 2001</LINK>; <LINK REF="STD-Kralikova-2002" TYPE="STUDY">Kralikova 2002</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>; <LINK REF="STD-Nakamura-1990" TYPE="STUDY">Nakamura 1990</LINK>), so had limited methodological details.</P>
<P>Thirty-eight studies (25%) reported allocation procedures in sufficient detail to be rated as being at low risk for their attempts to control selection bias, by using a system of treatment allocation which could not be known or predicted until a participant is enrolled and assigned to a study condition. Thirty-one of these low-risk trials (82%) also reported adequate sequence generation procedures. The majority of studies either did not report how randomization was performed and allocation concealed, or reported them in insufficient detail to determine whether a satisfactory attempt to control selection bias had been made (rated as being at unclear risk). A small number of nicotine gum trials randomized to treatment according to day or week of clinic attendance (<LINK REF="STD-Page-1986" TYPE="STUDY">Page 1986</LINK>; <LINK REF="STD-Richmond-1993" TYPE="STUDY">Richmond 1993</LINK>; <LINK REF="STD-Russell-1983" TYPE="STUDY">Russell 1983</LINK>), or to birth date (<LINK REF="STD-Fagerstrom-1984" TYPE="STUDY">Fagerstrom 1984</LINK>), and were consequently rated as being at high risk of bias. One study (<LINK REF="STD-Nebot-1992" TYPE="STUDY">Nebot 1992</LINK>) randomized by physician and there was no information about avoidance of selection bias in enrolment of smokers, so this was also rated as being at high risk. The main findings were not sensitive to the exclusion from the meta-analysis of trials at unclear risk, or of trials at unclear and at high risk of bias. A summary illustration of the risk of bias profile for each trial is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>Sixteen gum trials (<LINK REF="STD-Gilbert-1989" TYPE="STUDY">Gilbert 1989</LINK>; <LINK REF="STD-Gross-1995" TYPE="STUDY">Gross 1995</LINK>; <LINK REF="STD-Hall-1985" TYPE="STUDY">Hall 1985</LINK>; <LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK>; <LINK REF="STD-Killen-1984" TYPE="STUDY">Killen 1984</LINK>; <LINK REF="STD-Jensen-1991" TYPE="STUDY">Jensen 1991</LINK>; <LINK REF="STD-McGovern-1992" TYPE="STUDY">McGovern 1992</LINK>; <LINK REF="STD-Nakamura-1990" TYPE="STUDY">Nakamura 1990</LINK>; <LINK REF="STD-Nebot-1992" TYPE="STUDY">Nebot 1992</LINK>; <LINK REF="STD-Niaura-1994" TYPE="STUDY">Niaura 1994</LINK>; <LINK REF="STD-Niaura-1999" TYPE="STUDY">Niaura 1999</LINK>; <LINK REF="STD-Richmond-1993" TYPE="STUDY">Richmond 1993</LINK>; <LINK REF="STD-Roto-1987" TYPE="STUDY">Roto 1987</LINK>; <LINK REF="STD-Segnan-1991" TYPE="STUDY">Segnan 1991</LINK>; <LINK REF="STD-Villa-1999" TYPE="STUDY">Villa 1999</LINK>; <LINK REF="STD-Zelman-1992" TYPE="STUDY">Zelman 1992</LINK>), four patch trials (<LINK REF="STD-Cinciripini-1996" TYPE="STUDY">Cinciripini 1996</LINK>; <LINK REF="STD-Otero-2006" TYPE="STUDY">Otero 2006</LINK>; <LINK REF="STD-Velicer-2006" TYPE="STUDY">Velicer 2006</LINK>; <LINK REF="STD-Wong-1999" TYPE="STUDY">Wong 1999</LINK>) and three trials with choice of NRT product (<LINK REF="STD-Ortega-2011" TYPE="STUDY">Ortega 2011</LINK>; <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>) did not have a matched placebo control. A further two had both a placebo and a non-placebo control which were combined for the meta-analysis control group (<LINK REF="STD-Buchkremer-1988" TYPE="STUDY">Buchkremer 1988</LINK>; <LINK REF="STD-Russell-1983" TYPE="STUDY">Russell 1983</LINK>). The main findings were not sensitive to the exclusion of studies and arms without a placebo.</P>
<P>Definitions of abstinence varied considerably. One hundred and five trials (70%) reported some measure of sustained abstinence, which included continuous abstinence with not even a slip since quit day, repeated point prevalence abstinence (with or without biochemical validation) at multiple follow-ups, or self reported abstinence for a prolonged period. Forty (27%) reported only the point prevalence of abstinence at the longest follow-up. In five studies it was unclear exactly how abstinence was defined. In four trials, participants who smoked two or three cigarettes per week were still classified as abstinent (<LINK REF="STD-Abelin-1989" TYPE="STUDY">Abelin 1989</LINK>; <LINK REF="STD-Ehrsam-1991" TYPE="STUDY">Ehrsam 1991</LINK>; <LINK REF="STD-Glavas-2003a" TYPE="STUDY">Glavas 2003a</LINK>; <LINK REF="STD-Glavas-2003b" TYPE="STUDY">Glavas 2003b</LINK>). Sensitivity analyses excluding these four trials made no difference to the overall findings. Most studies reported follow-up at least 12 months from start of treatment. Eighteen gum trials, 13 patch trials, one patch and lozenge trial, and one lozenge trial in the primary analysis had only six months follow-up. We report the findings of a subgroup analysis by type of abstinence and length of follow-up in the results section. Four trials in pregnant women reported abstinence close to the time of delivery. Three of these also reported outcomes postpartum (<LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK>; <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK>; <LINK REF="STD-Oncken-2008" TYPE="STUDY">Oncken 2008</LINK>), at between six weeks and three months after delivery. In <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> we used the results at longest follow-up, but in a separate analysis we pooled peri-partum and postpartum results separately (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>).</P>
<P>Biochemical validation of self reported smoking cessation at longest follow-up was used in 129 (86%) of the trials. Validation of abstinence was carried out by measurement of nicotine metabolites in saliva, urine or blood in 32 trials. The most common form of validation was measurement of carbon monoxide (CO) in expired air. The 'cut-off' level of CO used to define abstinence varied from less than 4 to 11 parts per million. Some of the 21 trials that did not validate all self report at longest follow-up did use biochemical confirmation at earlier points, or validated some self reports. The main findings were not sensitive to the exclusion of 17 studies contributing to that analysis that did not attempt to validate all reported abstinence (<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK>; <LINK REF="STD-Buchkremer-1988" TYPE="STUDY">Buchkremer 1988</LINK>; <LINK REF="STD-Daughton-1991" TYPE="STUDY">Daughton 1991</LINK>; <LINK REF="STD-Davidson-1998" TYPE="STUDY">Davidson 1998</LINK>; <LINK REF="STD-Fagerstrom-1984" TYPE="STUDY">Fagerstrom 1984</LINK>; <LINK REF="STD-Huber-1988" TYPE="STUDY">Huber 1988</LINK>; <LINK REF="STD-Hughes-1990" TYPE="STUDY">Hughes 1990</LINK>; <LINK REF="STD-Ockene-1991" TYPE="STUDY">Ockene 1991</LINK>; <LINK REF="STD-Ortega-2011" TYPE="STUDY">Ortega 2011</LINK>; <LINK REF="STD-Otero-2006" TYPE="STUDY">Otero 2006</LINK>; <LINK REF="STD-Page-1986" TYPE="STUDY">Page 1986</LINK>; <LINK REF="STD-Perng-1998" TYPE="STUDY">Perng 1998</LINK>; <LINK REF="STD-Roto-1987" TYPE="STUDY">Roto 1987</LINK>; <LINK REF="STD-Russell-1983" TYPE="STUDY">Russell 1983</LINK>; <LINK REF="STD-Sonderskov-1997" TYPE="STUDY">Sonderskov 1997</LINK>; <LINK REF="STD-Villa-1999" TYPE="STUDY">Villa 1999</LINK>; <LINK REF="STD-Zelman-1992" TYPE="STUDY">Zelman 1992</LINK>).</P>
<P>Some of the studies examine NRT versus usual care, and are inevitably not double-blind in design. One third of the trials reported some measure of blinding, but we did not assess whether the integrity of the procedure was tested, in line with the CONSORT guidelines (<LINK REF="REF-CONSORT-2001" TYPE="REFERENCE">CONSORT 2001</LINK>). Where they are done, assessments of blinding integrity should always be carried out before the clinical outcome has been determined, and the findings reported (<LINK REF="REF-Altman-2004" TYPE="REFERENCE">Altman 2004</LINK>). <LINK REF="REF-Mooney-2004" TYPE="REFERENCE">Mooney 2004</LINK> notes that few published trials report this information. While those that do provide some evidence that participants are likely to assess their treatment assignment correctly, it is insufficient to assess whether this is associated with differences in treatment effects. Further, there may be an apparent breaking of the blinding in trials where the treatment effect is marked, for either an intended outcome or an adverse effect, but participants who successfully decipher assignment may disguise their unblinding actions (<LINK REF="REF-Altman-2004" TYPE="REFERENCE">Altman 2004</LINK>). It is also possible that those who believe that they are receiving a placebo may be more likely to stop trying to quit.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-10-16 16:41:25 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<SUBSECTION>
<HEADING LEVEL="3">Any type of NRT versus placebo or no NRT control</HEADING>
<P>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> included 117 trials, with over 50,000 participants (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). A small number of trials contributed to more than one sub group and two trials were treated as two separate studies in the analyses. Each of the six forms of nicotine replacement therapy (NRT) significantly increased the rate of cessation compared to placebo or no NRT, as did a choice of product. The pooled risk ratio for abstinence for any form of NRT relative to control was 1.60 (95% CI 1.53 to 1.68). The risk ratio and 95% CI for each type are tabulated below. The inclusion of two small trials that compared a combination of types to no NRT did not affect the overall estimate.</P>
<TABLE COLS="6" ROWS="11">
<TR>
<TH>
<P>Type of NRT</P>
</TH>
<TH>
<P>RR</P>
</TH>
<TH>
<P>95% CI</P>
</TH>
<TH>
<P>I²</P>
</TH>
<TH>
<P>N of studies</P>
</TH>
<TH>
<P>N of participants Intervention/ Control</P>
</TH>
</TR>
<TR>
<TD>
<P>Gum</P>
</TD>
<TD>
<P>1.49</P>
</TD>
<TD>
<P>1.40 to 1.60</P>
</TD>
<TD>
<P>40%</P>
</TD>
<TD>
<P>56*</P>
</TD>
<TD>
<P>10,596/ 11,985</P>
</TD>
</TR>
<TR>
<TD>
<P>Patch</P>
</TD>
<TD>
<P>1.64</P>
</TD>
<TD>
<P>1.52 to 1.78</P>
</TD>
<TD>
<P>19%</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>11,746/ 7,840</P>
</TD>
</TR>
<TR>
<TD>
<P>Inhaler/inhalator</P>
</TD>
<TD>
<P>1.90</P>
</TD>
<TD>
<P>1.36 to 2.67</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>490/ 486</P>
</TD>
</TR>
<TR>
<TD>
<P>Intranasal spray</P>
</TD>
<TD>
<P>2.02</P>
</TD>
<TD>
<P>1.49 to 2.73</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>448/ 439</P>
</TD>
</TR>
<TR>
<TD>
<P>Tablets/lozenges</P>
</TD>
<TD>
<P>1.95</P>
</TD>
<TD>
<P>1.61 to 2.36</P>
</TD>
<TD>
<P>24%</P>
</TD>
<TD>
<P>7*</P>
</TD>
<TD>
<P>1808/ 1597</P>
</TD>
</TR>
<TR>
<TD>
<P>Oral spray</P>
</TD>
<TD>
<P>2.48</P>
</TD>
<TD>
<P>1.24 to 4.94</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>318/ 161</P>
</TD>
</TR>
<TR>
<TD>
<P>Choice of product</P>
</TD>
<TD>
<P>1.60</P>
</TD>
<TD>
<P>1.39 to 1.84</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>1449/ 1349</P>
</TD>
</TR>
<TR>
<TD>
<P>Patch and inhaler</P>
</TD>
<TD>
<P>1.07</P>
</TD>
<TD>
<P>0.57 to 1.99</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>136/ 109</P>
</TD>
</TR>
<TR>
<TD>
<P>Patch and lozenge</P>
</TD>
<TD>
<P>1.83</P>
</TD>
<TD>
<P>1.01 to 3.31</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>267/ 41</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>* includes 1 study treated as 2 for analysis</P>
</TD>
</TR>
</TABLE>
<P>Although the estimated effect sizes varied across the different products, confidence intervals were wide for the products with higher estimates which had small numbers of trials. In a meta-regression with gum as baseline, no significant difference between the products was detected. The I² statistic was 41%, indicating that little of the variability was attributable to between-trial differences. Seven nicotine gum and two patch trials had lower quit rates in the treatment than control groups at the end of follow-up, and in a further 64 (55%) of trials the 95% confidence interval for the risk ratio included 1 (i.e. the trials did not detect a significant treatment effect). Many of these trials had small numbers of smokers, and hence insufficient power to detect a modest treatment effect with reasonable certainty. One large trial of nicotine patches for people with cardiovascular disease had lower quit rates in the intervention than in the control group (<LINK REF="STD-Joseph-1996" TYPE="STUDY">Joseph 1996</LINK>); at six months the quit rates were 14% for active patch and 11% for placebo, but after 48 weeks there had been greater relapse in the active group and rates were 10% and 12% respectively.</P>
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity to definition of abstinence</HEADING>
<P>For the nicotine gum and patch we assessed whether trials that reported sustained abstinence at 12 months had different treatment effects from those that only reported a point prevalence outcome, or had shorter follow-up (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). Subgroup categories were sustained abstinence at 12 months or more, sustained abstinence at six months, point prevalence or unclear definition at 12 months, and point prevalence/unclear at six months. For nicotine gum 32/55 studies (58%) reported sustained 12-month abstinence and the estimate was similar to that for all 55 studies (sustained 12-month RR 1.43, 95% CI 1.31 to 1.56 compared with RR 1.49, 95% CI 1.40 to 1.60). The highest estimate was for the subgroup of six studies reporting sustained abstinence at six months, which was significantly higher in a meta-regression (RR 2.77, 95% CI 2.14 to 3.59). This seems to be attributable to one new study (<LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK>; <LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>) and is unlikely to be of methodological or clinical significance. For nicotine patch, 21/43 studies (49%) reported sustained 12-month abstinence, and the relative risk estimate was also similar to that for all 43 studies (sustained 12-month RR 1.51, 95% CI 1.35 to 1.70, compared with RR 1.64, 95% CI 1.52 to 1.78 overall). For patch studies there was no evidence that the risk ratios differed significantly between subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity to intensity of behavioural support</HEADING>
<P>Almost all trials provided the same behavioural support in terms of advice, counselling, and number of follow-up visits to the active pharmacotherapy and control groups, but different trials provided different amounts of support. One pre-cessation trial gave both arms the same amount of counselling but sessions were offered at different time points relative to quit date and gave different advice depending on study arm (<LINK REF="STD-Hughes-2010" TYPE="STUDY">Hughes 2010</LINK>). We conducted subgroup analyses by intensity of support for gum and patch trials separately (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). For nicotine gum the relative risk estimate was similar across all three subgroups. The control group quit rates varied as expected, averaging 3.5% with low intensity support, 9% with high intensity individual support and 11.7% with group-based support. Nicotine patch trials showed the same pattern; the relative risk estimates were similar for each subgroup and the average control group quit rates were 6.3% with low intensity support, 6.8% with high intensity individual support and 14.8% with group-based support. Using meta-regression we confirmed that there was no evidence that the relative effect differed by type of support.</P>
<P>Two small studies in primary care directly compared the effect of providing high versus low intensity follow-up to participants receiving nicotine gum (<LINK REF="STD-Fagerstrom-1984" TYPE="STUDY">Fagerstrom 1984</LINK>; <LINK REF="STD-Marshall-1985" TYPE="STUDY">Marshall 1985</LINK>). The pooled results favoured intensive follow-up but the result was not statistically significant. In the one patch trial that compared minimal counselling with two forms of more intensive counselling in patients receiving one of two nicotine doses, the intensive intervention did not lead to improved outcomes (<LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK>). Pooling all three studies showed no effect of increased behavioural support (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>, RR 1.14, 95% CI 0.88 to 1.47). It should be emphasised that these three studies do not address the efficacy of NRT and that only a factorial placebo-controlled trial with different intensities of support can adequately investigate whether pharmacotherapy and behavioural interventions have interactive effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity to treatment settings</HEADING>
<P>We conducted further subgroup analysess for each type of setting in which smokers were recruited or treated (with type of NRT as a subgroup beneath setting). The pooled RR for trials in community volunteers where care was provided in a medical setting was 1.60 (95% CI 1.51 to 1.70, 66 trials, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and was similar to that of trials conducted in smoking clinics (RR 1.73, 95% CI 1.48 to 2.03, 10 trials, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>), trials conducted in primary care settings (RR 1.52, 95% CI 1.34 to 1.71, 23 trials, <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>) and trials conducted in hospitals (RR 1.44, 95% CI 1.28 to 1.62, 10 trials, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). Pooled results from four trials in antenatal clinics were lower than in other settings (RR 1.22, 95% CI 0.92 to 1.62, <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>); this was the only setting in which results did not show a statistically significant effect of the intervention. Pooled results from the five trials in community volunteers in which treatment was provided in an 'over-the-counter' (OTC) setting were significantly higher than in other settings (RR 2.71, 95% CI 2.11 to 3.49, <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>), though heterogeneity was present (I² = 51%). In a meta-regression we checked whether there was any evidence of interaction between the treatment setting and type of NRT used. The effect of nicotine gum was highest in the OTC setting and this seems to be attributable to the same study that contributed heterogeneity in the abstinence subgroup analysis above (<LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK>; <LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>.</P>
<P>Control group quit rates varied by setting; as expected, the lowest rate was found in OTC studies (2.1%) and the highest rate in smoking clinics (12.1%). Falling within this range, control group rates were 5.7% in primary care settings, 8.8% in antenatal clinics, 9.5% in community volunteers where treatment was provided in a medical setting, and 10% in hospitals. Though the RR in OTC settings was significantly higher than in other settings, it should be noted that the control group quit rate was lowest in this group, meaning the difference between absolute numbers quit in this setting when compared with other settings would not be as marked as the RR suggests.</P>
<P>Two trials compared patch (<LINK REF="STD-Leischow-1999" TYPE="STUDY">Leischow 1999</LINK>) or inhaler (<LINK REF="STD-Leischow-2004" TYPE="STUDY">Leischow 2004</LINK>) with minimal physician support and patch/inhaler with no support in a simulated OTC setting. Abstinence rates were low in both conditions and confidence intervals wide, but when pooled there was a significant advantage for physician support compared with no support (RR 4.58, 95% CI 1.18 to 17.88, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nicotine gum - effects of dose and scheduling</HEADING>
<P>Most trials used the 2 mg dose so we did not conduct a subgroup analysis for indirect comparison. Four trials directly compared 4 mg and 2 mg gum for treating highly dependent smokers, with a pooled estimate suggesting a significant benefit of the higher dose (RR 1.85, 95% CI 1.36 to 2.50, <LINK REF="STD-Garvey-2000" TYPE="STUDY">Garvey 2000</LINK>; <LINK REF="STD-Herrera-1995" TYPE="STUDY">Herrera 1995</LINK>; <LINK REF="STD-Kornitzer-1987" TYPE="STUDY">Kornitzer 1987</LINK>; <LINK REF="STD-Tonnesen-1988" TYPE="STUDY">Tonnesen 1988</LINK>, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.1). In low dependence or unselected smokers there was no evidence for an effect (RR 0.77, 95% CI 0.49 to 1.21, <LINK REF="STD-Garvey-2000" TYPE="STUDY">Garvey 2000</LINK>; <LINK REF="STD-Hughes-1990" TYPE="STUDY">Hughes 1990</LINK>; <LINK REF="STD-Kornitzer-1987" TYPE="STUDY">Kornitzer 1987</LINK>, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.2).</P>
<P>Two trials compared a fixed dose regimen of 2 mg nicotine gum against use of an ad lib regimen (<LINK REF="STD-Goldstein-1989" TYPE="STUDY">Goldstein 1989</LINK>; <LINK REF="STD-Killen-1990" TYPE="STUDY">Killen 1990</LINK>). The fixed dose regimen had higher quit rates but the difference was non-significant (RR 1.22, 95% CI 0.92 to 1.61, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nicotine patch - effects of dose and scheduling</HEADING>
<P>Eight trials have compared a high dose patch to standard dose (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). Four used 24-hour patches and compared 42/44 mg doses to standard 21/22 mg doses (<LINK REF="STD-Dale-1995" TYPE="STUDY">Dale 1995</LINK>; <LINK REF="STD-Hughes-1999" TYPE="STUDY">Hughes 1999</LINK>; <LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK>; <LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK>). Three used 16-hour patches and compared a 25 mg high dose to 15 mg standard dose (<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK>; <LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK>; <LINK REF="STD-Paoletti-1996" TYPE="STUDY">Paoletti 1996</LINK>). <LINK REF="STD-Rose-2010" TYPE="STUDY">Rose 2010</LINK> used 16-hour patches started two weeks before the target quit date and compared at 42 mg high dose to a 21 mg standard dose. Three studies (<LINK REF="STD-Hughes-1999" TYPE="STUDY">Hughes 1999</LINK>; <LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK>; <LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK>) specifically recruited heavy smokers, and one selected smokers with baseline cotinine levels of over 250 mg/ml (<LINK REF="STD-Paoletti-1996" TYPE="STUDY">Paoletti 1996</LINK>). One study was in heavy smokers with a history of alcohol dependence (<LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK>). Pooling all eight studies gives an estimated RR 1.14 (95% CI 1.01 to 1.29, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>), providing only marginal evidence of a small benefit from higher doses. Three studies had point estimates favouring the lower dose group, with no evidence of significant heterogeneity in the results (I² = 25%). Only one study showed a significantly higher quit rate with the higher dose (<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK>).</P>
<P>Indirect comparison failed to detect evidence of a difference in effect between 16-hour and 24-hour patch, with similar point estimates and overlapping confidence intervals in the two subgroups. There was some evidence of heterogeneity in the results of the 11 trials that used a 16-hour patch (I² = 53%, <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>). One trial directly compared the effect of 16-hour and 24-hour patch use (<LINK REF="STD-Daughton-1991" TYPE="STUDY">Daughton 1991</LINK>). The study did not detect a significant difference, but with just 106 participants had low power (24-hour patch versus 16-hour patch: RR 0.70, 95% CI 0.36 to 1.34).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nicotine patch - effect of treatment duration and dose tapering</HEADING>
<P>Indirect comparisons did not suggest a significant difference in treatment effect between 17 trials providing up to eight weeks of pharmacotherapy and 26 offering a longer period (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). One large trial that compared a 28- to a 12-week course of treatment did not detect evidence of benefit from longer treatment (<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK>, <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>). Smaller trials comparing a three-week to a 12-week course (<LINK REF="STD-Bolin-1999" TYPE="STUDY">Bolin 1999</LINK>), a three-week to a six-week course (<LINK REF="STD-Glavas-2003b" TYPE="STUDY">Glavas 2003b</LINK>), and an eight-week to a 24-week course (<LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK>) also found no evidence of a difference; <LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK> reported a benefit at the end of treatment but the difference was lost over the following six months.</P>
<P>Indirect comparison did not detect a significant difference between rates of success in nine trials where end of treatment was abrupt versus 32 trials where participants were weaned from patch use by tapering the dose (RR 1.89, 95% CI 1.50 to 2.37 and RR 1.58, 95% CI 1.44 to 1.72, respectively; <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>). A subgroup comparison indicated significant variability in effect estimates due to genuine subgroup differences (I²= 52.2%). This could, however, be attributable to confounding factors between the two groups. No difference was detected in the two trials that directly compared weaning with abrupt withdrawal (<LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK>; <LINK REF="STD-Stapleton-1995" TYPE="STUDY">Stapleton 1995</LINK>, <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combinations of different forms of nicotine therapy</HEADING>
<P>Nine trials compared the use of two types of NRT with the use of a single type only. When pooled, the trials suggest a statistically significant benefit (RR 1.34, 95% CI 1.18 to 1.51, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>), with little statistical heterogeneity (I²=34%), but the trials are relatively clinically heterogeneous in the combinations and comparison therapies used. Only two of the trials, one comparing nasal spray and patch with patch alone (<LINK REF="STD-Blondal-1999" TYPE="STUDY">Blondal 1999</LINK>) and one comparing patch plus lozenge versus either one alone (<LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>), showed a significantly higher rate of sustained abstinence at one year with the combined therapy. We are aware of two unpublished studies that failed to detect significant short-term effects and did not have long-term follow-up (<LINK REF="STD-Finland-unpublished" TYPE="STUDY">Finland unpublished</LINK>; <LINK REF="STD-Sutherland-1999" TYPE="STUDY">Sutherland 1999</LINK>, brief details in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). In case their exclusion biased the outcome we tested the sensitivity of the meta-analysis to including their results for cessation at three months. The meta-analysis maintained a significant, though slightly smaller, effect. We also tested the sensitivity to including only comparisons between a combination therapy and a nicotine patch only control. The effect remained significant, with or without the relevant unpublished study. Two trials also compared two types to no NRT (<LINK REF="STD-Hand-2002" TYPE="STUDY">Hand 2002</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>); these data are included in the primary analysis but not in <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>, which now includes only data comparing a combination of NRT products to a single type of NRT product.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Direct comparison between different types of NRT</HEADING>
<P>Six trials have directly compared types of NRT (<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>). None detected significant differences. Pooling the two that compared nasal spray with patch (RR 0.90, 95% CI 0.64 to 1.27) and pooling the three that compared lozenge with patch (RR 0.94, 95% CI 0.79 to 1.12) also failed to find significant effect. Whilst confidence intervals are wide, the direct comparison is consistent with indirect comparisons reported above in the primary analysis, suggesting that the different types have similar effects. In one open label study in which success rates were higher for patch than lozenge, more participants had expressed a preference for patch, and use of lozenge was lower than the recommended dose (<LINK REF="STD-Schnoll-2010b" TYPE="STUDY">Schnoll 2010b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre-cessation use of NRT</HEADING>
<P>The pooled estimate from seven trials shows a moderate but non significant increase in quit rates from using NRT for a brief period before the target quit day compared with initiating active NRT use on the quit day (RR 1.18, 95% CI 0.98 to 1.41, <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>). The effect is slightly more pronounced when pooling together only the patch trials (RR 1.34, 95% CI 1.08 to 1.65, 6 trials), though only one of the patch trials independently detected a significant effect (<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK>). No significant effects were detected in the trials of pre-cessation NRT other than patch (<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK>; <LINK REF="STD-Etter-2009" TYPE="STUDY">Etter 2009</LINK>; <LINK REF="STD-Hughes-2010" TYPE="STUDY">Hughes 2010</LINK>). <LINK REF="STD-Hughes-2010" TYPE="STUDY">Hughes 2010</LINK> was a study of gradual cessation versus abrupt cessation using nicotine lozenges and results may have been confounded by the differences in counselling and instructions on cigarette reduction prior to quit date between the two arms. When we excluded this study from pooled results of any type of pre-cessation NRT, the results became significant (RR 1.25, 95% CI 1.03 to 1.50, <I>analysis not shown</I>). A further trial which included groups who began using nicotine gum or placebo gum a week before quit day (<LINK REF="STD-Herrera-1995" TYPE="STUDY">Herrera 1995</LINK>) found that pre-cessation use did not significantly increase quitting at six weeks, but long-term outcomes were not reported. One other trial asked smokers to gradually cut down cigarette use and increase gum use before making a quit attempt; this was included in the main analysis and not here because participants continued to use nicotine or placebo gum throughout the treatment phase <LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK>; <LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>. We also excluded a study in which callers to a quitline were sent a sample of NRT products to try and then choose one or more, compared with being provided with patch or gum after discussion with the quitline adviser (<LINK REF="STD-Walker-2011" TYPE="STUDY">Walker 2011</LINK>). Since only one of each product was provided we did not regard this as pre-cessation use.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pregnant women</HEADING>
<P>Four trials evaluated the effectiveness of NRT use in pregnant women. Cessation outcomes at longest follow-up (delivery in <LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK> and postpartum in <LINK REF="STD-Oncken-2008" TYPE="STUDY">Oncken 2008</LINK>, <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK>, and <LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK>) are used in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1.</LINK> In a separate analysis (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>) we pooled peri-partum and postpartum effects separately. For abstinence close to the time of delivery the benefit of NRT was of borderline statistical significance (RR 1.30, 95% CI 1.00 to 1.68). The largest trial (<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK>) did not detect a significant effect and the pooled estimate is sensitive to the inclusion of <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK>, which showed a larger and statistically significant benefit. Pooling the postpartum outcomes from three trials did not demonstrate a significant difference between NRT and control groups (RR 1.20, 95% CI 0.80 to 1.80).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Relapsed smokers</HEADING>
<P>Although many of the trials reported here did not specifically exclude people who had previously tried and failed to quit with NRT, one trial recruited people who had relapsed after patch and behavioural support in an earlier phase of the study but were motivated to make a second attempt (<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK>). This study did not detect an effect on continuous abstinence (RR 1.25, 95% CI 0.34 to 4.60, <I>analysis not shown</I>), although it did detect a significant increase in 28-day point prevalence abstinence (RR 2.49, 95% CI 1.11 to 5.57). Quit rates were low in both groups with either definition of abstinence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cost of therapy</HEADING>
<P>One study comparing the effectiveness of free and purchased patch in an OTC model setting found no significant difference in quit rates between the two conditions; 8.7% (28/321) quit with free patch, 11% (34/315) with purchased patch, RR 0.81, 95% CI 0.50 to 1.30 (<LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK>). Those receiving free NRT were part of a placebo-controlled substudy. One small study of the cost of nicotine gum for patients receiving brief physician advice found non-significantly higher quit rates for participants who could obtain free gum compared to those paying close to full price; 6/32 (22%) versus 3/38 (12%). People who could get free gum were much more likely to obtain it (<LINK REF="STD-Hughes-1991" TYPE="STUDY">Hughes 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison and combination with bupropion</HEADING>
<P>Pooled together, the five studies directly comparing three different types of NRT with bupropion found no difference between the two (RR 1.01, CI 95% 0.87 to 1.18, <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>). There was heterogeneity, especially in the subgroup of four trials that used nicotine patch, attributable to one study in which the cessation rate was significantly lower for nicotine patch plus placebo tablet than for bupropion plus placebo patch (<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>); no other studies directly comparing patch, gum or lozenge versus bupropion detected a significant difference.</P>
<P>The combination of NRT and bupropion had a modest but significant effect when compared with bupropion alone (RR 1.24, CI 95% 1.06 to 1.45, 4 studies, <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>). The combination of bupropion and NRT significantly increased the rate of cessation over placebo alone (RR 2.61, CI 95% 1.65 to 4.12, <LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK>), but there was heterogeneity between the two studies, with <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK> not detecting a significant benefit, although with wide confidence intervals, so whilst the combination would be expected to be effective, the size of effect is uncertain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse Effects</HEADING>
<P>We have made no systematic attempt in this review to synthesize quantitatively the incidence of the various side effects reported with the different NRT preparations. This was because of the extensive variation in reporting the nature, timing and duration of symptoms. The major side effects usually reported with nicotine gum include hiccoughs, gastrointestinal disturbances, jaw pain, and orodental problems (<LINK REF="REF-Fiore-1992" TYPE="REFERENCE">Fiore 1992</LINK>; <LINK REF="REF-Palmer-1992" TYPE="REFERENCE">Palmer 1992</LINK>). The only side effect that appears to interfere with use of the patch is skin sensitivity and irritation; this may affect up to 54% of patch users, but it is usually mild and rarely leads to withdrawal of patch use (<LINK REF="REF-Fiore-1992" TYPE="REFERENCE">Fiore 1992</LINK>). The major side effects reported with the nicotine inhaler and nasal and oral sprays are related to local irritation at the site of administration (mouth and nose respectively). For example, symptoms such as throat irritation, coughing, and oral burning were reported significantly more frequently with subjects allocated to the nicotine inhaler than to placebo control (<LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK>); none of the experiences, however, were reported as severe. With the nasal spray, nasal irritation and runny nose are the most commonly reported side effects. In the study of oral spray, hiccoughs and throat irritation were the most commonly reported adverse events (<LINK REF="STD-T_x00f8_nnesen-2012" TYPE="STUDY">Tønnesen 2012</LINK>). Nicotine sublingual tablets have been reported to cause hiccoughs, burning and smarting sensation in the mouth, sore throat, coughing, dry lips and mouth ulcers (<LINK REF="REF-Wallstrom-1999" TYPE="REFERENCE">Wallstrom 1999</LINK>).</P>
<P>A review of adverse effects based on 35 trials with over 9,000 participants did not find evidence of excess adverse cardiovascular events amongst those assigned to nicotine patch, and the total number of such events was low (<LINK REF="REF-Greenland-1998" TYPE="REFERENCE">Greenland 1998</LINK>). When first licensed there was concern about the safety of NRT in smokers with cardiac disease (<LINK REF="REF-TNWG-1994" TYPE="REFERENCE">TNWG 1994</LINK>). A trial of nicotine patch (<LINK REF="STD-Joseph-1996" TYPE="STUDY">Joseph 1996</LINK>) that recruited smokers aged over 45 with at least one diagnosis of cardiovascular disease found no evidence that serious adverse events were more common in smokers in the nicotine patch group. Events related to cardiovascular disease such as an increase in angina severity occurred in approximately 16% of patients, but did not differ according to whether or not patients were receiving NRT. A review of safety in patients with cardiovascular disease found no evidence of an increased risk of cardiac events (<LINK REF="REF-Joseph-2003" TYPE="REFERENCE">Joseph 2003</LINK>). This included data from two randomized trials with short-term follow-up that are excluded from the present review (<LINK REF="STD-Tzivoni-1998" TYPE="STUDY">Tzivoni 1998</LINK>; <LINK REF="STD-Working-Group-1994" TYPE="STUDY">Working Group 1994</LINK>) and a case-control study in a population-based sample. An analysis of 187 smokers admitted to hospital with acute coronary syndromes who received nicotine patches showed no evidence of difference in short- or long-term mortality compared to a propensity-matched sample of smokers in the same database who did not receive NRT (<LINK REF="REF-Meine-2005" TYPE="REFERENCE">Meine 2005</LINK>).</P>
<P>A recent meta-analysis of adverse events associated with NRT (<LINK REF="REF-Mills-2010" TYPE="REFERENCE">Mills 2010</LINK>) across 92 RCTs and 28 observational studies addressed a possible excess of chest pains and heart palpitations among users of NRT compared with placebo groups. The authors report an OR of 2.06 (95% CI 1.51 to 2.82) across 12 studies. We replicated this data collection exercise and analysis where data were available across the 260 RCTs (included and excluded) in this review, and detected a similar but slightly lower estimate, OR 1.88 (95% CI 1.37 to 2.57; <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>; OR rather than RR calculated for comparison) across 15 studies. This is potentially the only clinically significant serious adverse event to emerge from the trials, and constitutes an extremely rare event, occurring at a rate of 2.5% in the NRT groups compared with 1.4% in the control groups in the 15 trials in which it was reported at all. <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> summarises the main adverse events reported in the included and excluded studies, where the data were available.</P>
<P>The four trials assessing NRT use in pregnant women did not detect significant increases in serious adverse events amongst the treatment groups (<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK>; <LINK REF="STD-Oncken-2008" TYPE="STUDY">Oncken 2008</LINK>; <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK>; <LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK>). Recruitment for <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK> was suspended early when interim analysis found a higher rate of negative birth outcomes in the NRT arm (primarily preterm birth); however, when adjusted for previous birth outcomes the adverse event rate between the two groups was not significantly different in final analysis. The effects of NRT use on neonatal health are discussed further in a separate Cochrane review, which found no statistically significant differences in rates of any serious adverse events between treatment and control groups (<LINK REF="REF-Coleman-2012a" TYPE="REFERENCE">Coleman 2012a</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-10-16 16:55:28 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>This review provides reliable evidence from trials including over 50,000 participants that offering nicotine replacement therapy (NRT) to dependent smokers who are prepared to try to quit increases their chance of success over that achieved with the same level of support without NRT. This applies to all forms of NRT and is independent of any variations in methodology or design characteristics of trials included in the meta-analysis. In particular we did not find evidence that the relative effect of NRT was smaller in trials with longer follow-up beyond our six-month minimum for inclusion. We did not compare end of treatment risk ratios with post-treatment follow-up, and relapse rates may be higher in active treatment participants once they stop using NRT products, but later relapse is probably unrelated to NRT use.</P>
<P>The absolute effects of NRT use will depend on the baseline quit rate, which varies in different clinical settings. Studies of people attempting to quit on their own suggest that success rates after six to 12 months are 3 to 5% (<LINK REF="REF-Hughes-2004a" TYPE="REFERENCE">Hughes 2004a</LINK>). Use of NRT might be expected to increase the rate by 2 to 3%, giving a number needed to treat to benefit (NNTB) of 56. If however the quit rate without pharmacotherapy was estimated to be 15%, either because the population had other predictors of successful quitting or received intensive behavioural support, then another 8% might be expected to quit, giving an NNTB of 11.</P>
<SUBSECTION>
<HEADING LEVEL="3">Type and dose of NRT</HEADING>
<P>The conclusion that the relative effects of the different forms of NRT are similar is largely based on indirect comparisons. Although the estimated risk ratio was highest for the nasal and oral sprays the confidence intervals are wide. In this update we did not find evidence using meta-regression of a significant difference between any forms. Most of the trials included in the comparison of nicotine gum versus placebo used 2 mg gum, although the 4 mg dose has been shown to be better for highly dependent smokers. A recent trial, in which 4 mg gum could be used by dependent smokers, has increased the estimate for nicotine gum (<LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>). This trial also instructed participants to gradually reduce cigarette consumption while using gum. Although the treatment effects were large, especially for 4 mg gum, the control quit rates were notably low. The study provided very low levels of behavioural support, and many participants did not achieve initial abstinence. One lozenge study used a 4 mg dose, and excluding this would reduce the difference between gum and tablet/lozenge subgroups. There have been no direct comparisons between these different forms. Six studies have directly compared different types, and non-significant differences between them at individual and pooled level. One study that randomized people to use nicotine gum, patch, spray or inhaler did not detect significant differences in abstinence rates after 12 weeks (<LINK REF="STD-Hajek-1999" TYPE="STUDY">Hajek 1999</LINK>), supporting the indirect estimates from the longer term studies. Where a range of products are available, choice of product may be guided by patients' preferences (<LINK REF="REF-McClure-2006" TYPE="REFERENCE">McClure 2006</LINK>), although one study showed that allowing people to try different products may alter their perceptions (<LINK REF="STD-Schneider-2004" TYPE="STUDY">Schneider 2004</LINK>). In one study directly comparing nicotine patch and nasal spray there were no overall differences in quit rates but there were three significant subgroup/treatment interactions (<LINK REF="STD-Lerman-2004" TYPE="STUDY">Lerman 2004</LINK>). The patch showed better results for white smokers, while the spray showed better results for obese smokers and for highly nicotine-dependent smokers. These effects need confirmation in additional studies before they can be relied on for treatment matching.</P>
<P>Direct comparisons support the use of 4 mg gum for more nicotine-dependent smokers. There is borderline evidence for a small benefit of nicotine patch at doses above the standard dose (21 mg for 24 hours or 15 mg for 16 hours). Use of these may be considered for heavy smokers (i.e. smoking 30 or more cigarettes a day) or for patients relapsing because of persistent craving and withdrawal symptoms on standard dose therapy (<LINK REF="REF-Hughes-1995" TYPE="REFERENCE">Hughes 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intensity of additional support</HEADING>
<P>We did not detect important differences in relative effect within patch or gum studies by our classification of level of support. A letter (<LINK REF="REF-Walsh-2007" TYPE="REFERENCE">Walsh 2007</LINK>) prior to the previous update of this review identified inconsistencies in the classification of low and high intensity support in this review. In response we changed the classification of a small number of trials. This did not alter the conclusion that intensity of support does not appear to be an important moderator of NRT effect. Most of the trials in the low intensity category were conducted in medical settings and the cut-off for level of support was not intended to distinguish between 'over-the-counter' (OTC) use of NRT and use with support from healthcare providers. We performed a separate analysis of OTC-type trials in the treatment setting subgroup analysis. As judged by the average control group quit rate, people receiving support and placebo had similar quit rates in low intensity and high intensity individual support groups. One interpretation of this is that although the latter group typically had more frequent contact with study co-ordinators, this did not markedly increase quitting or prevent relapse. Control group quit rates were, however, higher when people had intensive group-based support provided by specialists.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment setting</HEADING>
<P>We did not detect differences in relative effect according to the setting of recruitment and treatment, and in a post hoc meta-regression there was no evidence that the type of NRT influenced effect sizes differently in different settings. This subgroup analysis had considerable overlap with the support subgroup since, for example, people recruited in primary care settings typically had lower intensity support. Again there was variation between the control group quit rates, attributable to differences in motivation and to the level of behavioural support. People recruited from primary care who received placebo had average quit rates around 5 to 7%. The weighted average rate amongst community volunteers who were treated in OTC settings is lower in this update, at just 2%, due to one study with low control group quit rates <LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK>; <LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK>, which also had a large treatment effect. This makes the relative effect in trials in OTC settings higher than in other settings, even though the absolute increase in quit rates is small. People recruited in smoking clinics had much higher control group quit rates, averaging 15%, but this reflects both their motivation and the high level of behavioural support provided. Although some trials of NRT use in hospital inpatients have reported relatively less successful results, there was evidence of benefit in the subgroups of four studies of nicotine patch and two studies of choice of NRT amongst people recruited in inpatient and outpatient settings. The effects for nicotine gum and a single trial of a combination of products were smaller and not statistically significant.</P>
<P>There has been continuing debate about the amount of evidence for efficacy of NRT when obtained OTC without advice or support from a healthcare professional (<LINK REF="REF-Hughes-2001" TYPE="REFERENCE">Hughes 2001</LINK>; <LINK REF="REF-Walsh-2000" TYPE="REFERENCE">Walsh 2000</LINK>; <LINK REF="REF-Walsh-2001" TYPE="REFERENCE">Walsh 2001</LINK>). The small number of placebo-controlled trials in settings intended to replicate OTC settings support the conclusion that the relative effect of NRT is similar to settings where more advice and behavioural support is provided, although quit rates in both control and intervention groups have been low. One other meta-analysis supports the conclusion of efficacy, although it differs in its inclusion criteria (<LINK REF="STD-Hughes-2003" TYPE="STUDY">Hughes 2003</LINK>). In addition to the same three trials comparing nicotine patch to placebo in an OTC setting (<LINK REF="STD-Davidson-1998" TYPE="STUDY">Davidson 1998</LINK>; <LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK>; <LINK REF="STD-Sonderskov-1997" TYPE="STUDY">Sonderskov 1997</LINK>), that review includes one study excluded here due to short follow-up (<LINK REF="STD-Shiffman-2002a" TYPE="STUDY">Shiffman 2002a</LINK>). It also pools four trials comparing NRT provided OTC to NRT provided under prescription. We exclude one trial that compared both gum and patch in these settings, but was not randomized (<LINK REF="STD-Shiffman-2002b" TYPE="STUDY">Shiffman 2002b</LINK>), and another that has not been published and for which we have been unable to obtain reliable data for inclusion (<LINK REF="STD-Korberly-1999" TYPE="STUDY">Korberly 1999</LINK>). The abstract reported that there were no significant differences in quit rates between users of nicotine patch who purchased it via a non-healthcare facility, and those receiving it on prescription. On the basis of one published and one unpublished study we find a marginally significant benefit of NRT with prescription compared to OTC, but the confidence intervals are wide.</P>
<P>A report of a recent prospective cohort study questioned the effectiveness of NRT outside of the clinical trial setting after finding no difference in relative relapse rates between smokers trying to quit who used NRT and those who did not use NRT (<LINK REF="REF-Alpert-2012" TYPE="REFERENCE">Alpert 2012</LINK>). The design of this study has been criticised for not addressing initial quit rates in the two groups (<LINK REF="REF-Stapleton-2012" TYPE="REFERENCE">Stapleton 2012</LINK>). It has also been suggested that the 'real world' effectiveness of NRT declines or disappears once it becomes available to purchase without requiring contact with a health professional who can offer behavioural support and guidance on appropriate use (<LINK REF="REF-Pierce-2002" TYPE="REFERENCE">Pierce 2002</LINK>). Based on a comparison of two cross sectional surveys in California, the latter study finds that prior to OTC availability quit rates for self selected NRT users were higher than rates for non-users, but after the switch to OTC this difference disappeared. We and others have questioned the conclusions from this study (<LINK REF="REF-Franzon-2002" TYPE="REFERENCE">Franzon 2002</LINK>; <LINK REF="REF-Stead-2002" TYPE="REFERENCE">Stead 2002</LINK>). The level of addiction of people who chose to use NRT compared to those who did not is a source of confounding which may have been incompletely controlled (<LINK REF="REF-Shiffman-2005" TYPE="REFERENCE">Shiffman 2005</LINK>). People who have used NRT may also be more likely to recall quit attempts. A third study suggested that both use of NRT and quit rates rose in the immediate aftermath of OTC availability (<LINK REF="REF-Hyland-2005" TYPE="REFERENCE">Hyland 2005</LINK>). In this longitudinal study of smokers in the COMMIT study cohort there was a small reduction in the average success rates for patch users after the switch but no reduction in success rates for gum users. However a review on the impact of NRT on population trends in smoking behaviour at that time concluded that not enough smokers had been using NRT during quit attempts for there to have been a measurable effect (<LINK REF="REF-Cummings-2005" TYPE="REFERENCE">Cummings 2005</LINK>). A multi-country prospective study (<LINK REF="REF-West-2007" TYPE="REFERENCE">West 2007</LINK>) found that NRT users who did not use formal behavioural support had higher quit rates than non-users, even when controlling for baseline differences in motivation and other possible predictors of success. Another multi-country prospective cohort analysis using the International Tobacco Control Four Country Survey which controlled for possible bias in recall of quit attempts found that people who attempted to quit with nicotine patch, varenicline or bupropion had higher quit rates than those not using medication, but no effect was detected for oral nicotine products (<LINK REF="REF-Kasza-2012" TYPE="REFERENCE">Kasza 2012</LINK>). Although no study in which participants self select treatment can be free from the possibility of bias due to unmeasured confounders, some results from these studies provide additional evidence for real world effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials in special populations</HEADING>
<P>Four trials of NRT in pregnant women are now included in the review (<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK>; <LINK REF="STD-Oncken-2007" TYPE="STUDY">Oncken 2007</LINK>; <LINK REF="STD-Pollak-2007" TYPE="STUDY">Pollak 2007</LINK>; <LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK>) with <LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK> contributing over 1000 of ~1600 participants. For these trials we evaluated cessation at the closest follow-up to end of pregnancy as well as at the longest follow-up. At the end of pregnancy the confidence interval just reached significance, but this was sensitive to the inclusion of the smallest trial, while results of the largest trial were not statistically significant. No significant benefit of treatment was detected at longest follow-up/postpartum follow-up. Two of the studies (<LINK REF="STD-Oncken-2007" TYPE="STUDY">Oncken 2007 </LINK>and <LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK>) found significant increases in birth weight amongst the NRT arms (a better perinatal outcome). None of the studies found evidence of a significant increase in serious adverse events in the NRT arms. Adherence to recommended use of NRT was low in all four included studies. We excluded two small trials of nicotine patch in pregnancy: <LINK REF="STD-Kapur-2001" TYPE="STUDY">Kapur 2001</LINK> had follow-up only to end of treatment at 12 weeks. In this trial 0/13 in the placebo group quit compared to 4/17 (24%) in the active treatment group. Enrolment was ended early in this study because of a possible adverse event in the placebo arm. A second small study without placebo control had high rates of withdrawal and non-compliance (<LINK REF="STD-Hotham-2006" TYPE="STUDY">Hotham 2006</LINK>), although 3/20 in the patch group were abstinent at delivery compared to 0/20 in the counselling-only control. A study measuring nicotine metabolism in smokers during their pregnancy and postpartum has suggested that nicotine is metabolised more quickly by pregnant women and that this may affect the dose of NRT required (<LINK REF="REF-Dempsey-2002" TYPE="REFERENCE">Dempsey 2002</LINK>). More studies are needed to establish whether or not NRT does aid quitting in pregnancy and what effects there are on birth outcomes (<LINK REF="REF-Benowitz-2000" TYPE="REFERENCE">Benowitz 2000</LINK>). There is now a separate Cochrane review (<LINK REF="REF-Coleman-2012a" TYPE="REFERENCE">Coleman 2012a</LINK>) on pharmacotherapies for smoking cessation in pregnancy. That review did not detect a benefit of NRT (RR for cessation in later pregnancy 1.33, 95% CI 0.93 to 1.91). It included <LINK REF="STD-Kapur-2001" TYPE="STUDY">Kapur 2001</LINK> and <LINK REF="STD-Hotham-2006" TYPE="STUDY">Hotham 2006</LINK>, but our results are broadly consistent with its findings. Differences in the point estimates and confidence intervals between <LINK REF="REF-Coleman-2012a" TYPE="REFERENCE">Coleman 2012a</LINK> and this review are attributable to our use of a fixed-effect rather than a random effects model. These results do not provide conclusive evidence that NRT helps pregnant women to quit, but the confidence intervals in our analysis do not exclude a small clinical benefit. As the confidence intervals overlap the point estimate of the effect in non-pregnant populations, our results also do not rule out the possibility that NRT is as effective in pregnant women as it is in non-pregnant people.</P>
<P>Trials generally restricted recruitment to adults over the age of 18; in a small number of trials the age range was not specified. One trial in adolescents, which is now included (<LINK REF="STD-Moolchan-2005" TYPE="STUDY">Moolchan 2005</LINK>), compared nicotine patch, gum, and double placebo. Two trials in adolescents with less than six months follow-up were excluded: one trial examining the effects of the nicotine patch on craving and withdrawal symptoms, safety, and compliance among 100 adolescents had 10 weeks follow-up, with no significant difference detected at that point (<LINK REF="STD-Hanson-2003" TYPE="STUDY">Hanson 2003</LINK>). In a second trial of the patch with 13 weeks follow-up there were no quitters in either group at that point (<LINK REF="STD-Roddy-2006" TYPE="STUDY">Roddy 2006</LINK>). Adherence to therapy and participant retention were both reported to be problems.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Evidence for differential treatment effects in different subgroups</HEADING>
<P>We made no attempt to conduct separate analyses for any subgroups of trial participants, because subgroup results are uncommon in trial reports, and where data cannot be obtained from all studies there is a risk of bias from using incomplete data. Munafo and colleagues have reported the results of a meta-analysis of nicotine patch by sex (<LINK REF="REF-Munafo-2004a" TYPE="REFERENCE">Munafo 2004a</LINK>). They were able to include data from 11 out of 31 (35%) of eligible trials and 36% of study participants. They found no evidence that the nicotine patch was more effective for men than women as has been hypothesised; although men showed a somewhat bigger benefit from NRT at 12 months, the difference was not significant. There was also no difference in average placebo quit rates between men and women, which has been reported in some studies. In a commentary (<LINK REF="REF-Perkins-2004" TYPE="REFERENCE">Perkins 2004</LINK>) some additional data were identified, but this did not alter the conclusions (<LINK REF="REF-Munafo-2004b" TYPE="REFERENCE">Munafo 2004b</LINK>). A second meta-analysis of any type of NRT (<LINK REF="REF-Cepeda_x002d_Benito-2004" TYPE="REFERENCE">Cepeda-Benito 2004</LINK>) reported that in women the odds ratio for cessation declined with increasing length of follow-up, with a non-significant difference at 12 months. Amongst males the odds ratio declined less over time and remained significant. Based on a further subgroup analysis they also reported that the decline in long-term efficacy in women was greater in trials with low intensity support than with high intensity support, suggesting that the more intensive support helped prevent late relapse in women who had initially received NRT. Although there was no evidence of bias, the review could only include a subset of published studies, so the finding should be regarded as hypothesis-generating. All review authors agreed that trials are underpowered to identify any interaction between treatment and any type of individual characteristics, and recommended public archiving of data from studies, as well as new research specifically designed to test group-by-treatment interactions. At the moment there does not appear to be sufficient evidence of clinically important differences between men and women to guide treatment matching.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combinations of NRT products</HEADING>
<P>The evidence now suggests more strongly that using a combination of NRT products is better than one product alone. Two recent trials (<LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>) have increased the evidence base. Both compared a combination of patch and lozenge with either alone. The trials showed fairly consistent effects, with a range of different comparators. The combined therapies all included the patch and an acute dosing type. In a sensitivity analysis we did not find any difference according to whether the control was the patch or an acute dosing form. The 2008 US clinical practice guidelines (<LINK REF="REF-Fiore-2008" TYPE="REFERENCE">Fiore 2008</LINK>) state that the long-term use of nicotine patch with another form of ad lib<I> </I>NRT is more effective than nicotine patch alone and recommend that physicians consider this option. It is not entirely clear whether the benefit of combination therapy is due to the sensory effects provided by multiple types of delivery systems, to the higher percentage of nicotine substitution achieved, the better relief of craving by ad lib use of acute dosing forms or some combination of these and other factors (<LINK REF="REF-Sweeney-2001" TYPE="REFERENCE">Sweeney 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre-cessation use of NRT</HEADING>
<P>When nicotine replacement therapies were first introduced there was concern that any smoking whilst using a product would increase the potential for adverse effects such as nausea and vomiting, due to nicotine overdose. However studies with higher dose products and combinations of products have found no evidence of harm from moderate increases in nicotine intake. There is some evidence that smokers who use NRT whilst not trying to alter their smoking behaviour either smoke less or reduce their nicotine from cigarettes, especially when using acute dosing types of NRT (<LINK REF="REF-Fagerstrom-2002" TYPE="REFERENCE">Fagerstrom 2002</LINK>). Trials have now investigated two situations in which it has been proposed that use of an NRT product can help long-term abstinence if initially used while continuing to smoke. The first of these is to begin using NRT for a short period before a quit attempt on the theoretical basis that it might diminish the reinforcing effects of cigarette smoking or reduce the dependence on inhaled nicotine (<LINK REF="STD-Rose-2006" TYPE="STUDY">Rose 2006</LINK>). This is often referred to as 'preloading'. Meta-analysis of seven trials now included in this review suggests a moderate but non-significant increase in quit rates in those using NRT pre-cessation over those achieved by post-quit use of NRT alone. However, of the seven trials pooled only one detected a significant effect (<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK>), and a recent large trial of pre-cessation use of choice of NRT product did not detect a significant effect (<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK>). Findings suggest patch use pre-quit date may be more effective than pre-cessation use of acute forms of NRT, and are consistent with results from a recent meta-analysis of nicotine preloading (<LINK REF="REF-Lindson-2011" TYPE="REFERENCE">Lindson 2011</LINK>).</P>
<P>The second proposed use of NRT pre-cessation is for a period of weeks to months while people not willing or able to quit abruptly gradually reduce the number of cigarettes, before quitting completely. The use of two forms of NRT, gum and inhaler, has now been approved by licensing authorities in some European countries for this cessation approach, described variously as 'Reduce to Stop' or 'Cut Down to Quit'. Trials of this approach are included in a Cochrane review of interventions for reducing harm from continued smoking (<LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>). The long-term use of NRT whilst continuing to smoke smaller numbers of cigarettes cannot be supported by the evidence because it is not clear what reduction in consumption is needed for a useful health benefit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Re-treating relapsed smokers</HEADING>
<P>Whilst end of treatment success rates may be quite high, many people relapse after the end of therapy. There is suggestive evidence (<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK>) that repeated use of NRT in patients who have relapsed after an initial course may produce further quitters, though the absolute effect is small. A subgroup analysis in another trial (<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>, reported in <LINK REF="REF-Durcan-2002" TYPE="REFERENCE">Durcan 2002</LINK>) indicated that the relative effect of treatment with nicotine patch compared to placebo was at least as high for people who had used NRT before. The authors noted that there was no way to distinguish between people who had completely failed to quit using NRT and those who had been initially successful but relapsed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Direct comparison and combination with non-nicotine pharmacotherapies</HEADING>
<P>Five trials directly comparing nicotine with bupropion are now included in this review; pooled together they do not suggest a difference between the two in terms of long-term cessation. However, there was a significant increase in long-term cessation with a combination of NRT and bupropion, as opposed to nicotine or bupropion alone. There has not yet been a trial of a direct comparison between NRT and varenicline with follow-up long enough to include in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Addictive potential of NRT</HEADING>
<P>Some successful quitters continue to use NRT products beyond the recommended treatment period (<LINK REF="REF-Shiffman-2003" TYPE="REFERENCE">Shiffman 2003</LINK>), but few develop true dependence (<LINK REF="REF-Hughes-2004b" TYPE="REFERENCE">Hughes 2004b</LINK>; <LINK REF="REF-Hughes-2005" TYPE="REFERENCE">Hughes 2005</LINK>). Although nicotine has the potential to cause harm, it is very much less harmful than tobacco smoke, so while complete abstinence from nicotine is preferred, the risk to health from NRT use is small compared to the risk from continued smoking.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methodological limitations</HEADING>
<P>There are two possible methodological limitations of this review, which need to be borne in mind: use of data predominantly derived from published reports (<LINK REF="REF-Stewart-1993" TYPE="REFERENCE">Stewart 1993</LINK>), and publication bias (<LINK REF="REF-Simes-1986" TYPE="REFERENCE">Simes 1986</LINK>). We tried to partly address any shortcomings from having limited our analysis to reported data by approaching investigators, where necessary, to obtain additional unpublished data or to clarify areas of uncertainty. Although steps were taken to minimize publication bias by writing to the manufacturers of NRT products when this review was first prepared, the response was poor and we have not repeated this exercise. It is therefore possible that there are some unpublished trials, with less favourable results, that we have not identified despite our efforts to do so. A statistical analysis (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>, personal communication) suggests that this is the case. A funnel plot (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) shows some evidence of asymmetry for trials in the main comparison, with a few small to moderately sized trials producing RRs to the left of the pooled RR; however, given the large number of trials in the review, the funnel plot does not suggest the results would be altered significantly were smaller studies with lower RRs included. A meta-analysis has also demonstrated that nicotine gum and patch studies that received pharmaceutical industry funding have on average slightly higher effect sizes than other studies after controlling for some trial characteristics (<LINK REF="REF-Etter-2007" TYPE="REFERENCE">Etter 2007</LINK>). The practical effect of these considerations is that the magnitude of the effectiveness of NRT may be smaller than our estimates suggest.</P>
<P>This review excludes studies with less than a six month follow-up from the start of treatment; the outcome used reflects the effect of NRT after the end of active treatment. A comparison of abstinence rates during treatment and abstinence at one year (<LINK REF="REF-Fagerstrom-2003" TYPE="REFERENCE">Fagerstrom 2003</LINK>) suggests that the relative effect of NRT declines once active therapy stops, that is, people who quit with the help of NRT are a little more likely to relapse after they discontinue treatment than those on placebo. The relative effect of NRT could continue to decline even after a year of follow-up. A meta-analysis comparing one-year and long-term outcomes in twelve NRT trials with follow-up beyond one year suggested that the relative efficacy did not change, with similar relapse rates in the active and placebo groups, but further relapse does reduce the absolute difference in quit rates (<LINK REF="REF-Etter-2006" TYPE="REFERENCE">Etter 2006</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-10-15 14:46:32 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<IMPLICATIONS_PRACTICE MODIFIED="2012-10-15 14:45:25 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. All of the commercially available forms of nicotine replacement therapy (NRT), i.e. gum, transdermal patch, nasal spray, inhaler, oral spray, lozenge and sublingual tablet, are effective as part of a strategy to promote smoking cessation. They increase the rate of long-term quitting by approximately 50% to 70% regardless of setting. These conclusions apply to smokers who are motivated to quit and who have high levels of nicotine dependence. There is little evidence about the role of NRT for individuals smoking fewer than 10 to 15 cigarettes a day.</P>
<P>2. The choice of which form to use should reflect patient needs, tolerability and cost considerations. Patches are likely to be easier to use than gum, nasal spray or inhaler, but patches cannot be used for relief of acute cravings.</P>
<P>3. Eight weeks of patch therapy is as effective as longer courses, and there is no evidence that tapered therapy is better than abrupt withdrawal. Wearing the patch during waking hours only (16 hours a day) is as effective as wearing one for 24 hours a day.</P>
<P>4. If gum is used, it may be offered on a fixed dose or ad lib basis. For highly dependent smokers, or those who have failed with 2 mg gum, 4 mg gum should be offered.</P>
<P>5. There is borderline evidence for a small benefit from use of the nicotine patch at doses higher than the standard dose (21 mg for 24 hours or 15 mg for 16 hours).</P>
<P>6. There is evidence of benefit from combining the nicotine patch with an acute dosing type (e.g. gum) to allow ad lib dosing compared to use of a single form.<BR/>
<BR/>7. The effectiveness of NRT in terms of the risk ratio appears to be largely independent of the intensity of additional support provided. Provision of more intensive levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT. But it should be noted that the absolute increase in success rates attributable to the use of NRT will be larger when the baseline chance of success is already raised by the provision of intensive behavioural support.</P>
<P>8. There is minimal evidence that a repeated course of NRT in patients who have relapsed after recent use of nicotine patches will result in a small additional probability of quitting.</P>
<P>9. NRT does not lead to an increased risk of adverse cardiovascular events in smokers with a history of cardiovascular disease.</P>
<P>10. NRT appears as effective as bupropion. Any decision about which pharmacotherapies to use should take into account potential adverse effects as well as benefits.</P>
<P>11. Initiating patch use for a short period before making a quit attempt is moderately more effective than patch use initiated on the quit date itself. There is no evidence that suggests use of other forms of NRT pre-cessation is more effective than starting use on the quit day.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-10-15 14:46:32 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Further research is required in several areas:</P>
<P>1. Direct comparisons between the various forms of NRT and between different doses and durations of treatment.<BR/>2. Use of combinations of different forms of NRT.<BR/>3. Direct comparisons between NRT and newer pharmacotherapies including varenicline.<BR/>4. Use of combinations of NRT and newer pharmacotherapies including varenicline.<BR/>5. Safety and benefits of NRT use during pregnancy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-03-02 11:37:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Chris Silagy was original first author, contributed to updates until his death in 2001 and was listed as an author until 2008. Godfrey Fowler was also an author until 2008. Mark Lodge assisted in the preparation of the initial version of this review. Ruth Ashenden provided technical support. Drs. Tjeder-Burton, Campbell, Hjalmarson, Fagerstrom, Mori, Glover, Hughes, Fortmann, Killen, Varady, Ortega and Rose co-operated with our requests for clarification of previously reported data. Z. Ilic and L. Silagy assisted with translation of foreign language reports. P. Yudkin provided statistical advice on early updates. Marc Mooney provided copies of two papers we had not been able to obtain. John Hughes and Paul Aveyard provided helpful comments for the most recent update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-02-16 16:40:44 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Chris Bullen was involved in a trial on pre-cessation use of NRT (<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK>) and David Mant was involved in a trial of transdermal nicotine (<LINK REF="STD-ICRF-1994" TYPE="STUDY">ICRF 1994</LINK>). Chris Silagy, an original author, received funds for consultancy work undertaken (at various times) on behalf of Pharmacia and Upjohn, Marion Merrell Dow, Glaxo Wellcome and SmithKline Beecham.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-10-15 14:48:09 +0100" MODIFIED_BY="Kate Cahill">
<P>JHB and LS have extracted data for the most recent update. The review text was updated by LS and JHB with review and suggestions from all other authors. KC extracted data on adverse effects for the most recent update, and completed risk of bias assessments for all included studies. CB contributed in particular to the sections on pre-cessation use of NRT. We thank Annette Pluddemann for help in translating study reports.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>Prof Chris Silagy died in December 2001. In recognition of his major contribution he remained as first author until 2007. The authorship changed from 2008 issue 1.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-16 17:03:09 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-10-16 16:54:05 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-10-16 16:41:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abelin-1989" NAME="Abelin 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abelin T, Buehler A, Muller P, Vesanen K, Imhof PR</AU>
<TI>Controlled trial of transdermal nicotine patch in tobacco withdrawal</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8628</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abelin T, Ehrsam R, Buhler-Reichert A, Imhof PR, Muller P, Thommen A</AU>
<TI>Effectiveness of a transdermal nicotine system in smoking cessation studies</TI>
<SO>Methods and Findings in Experimental and Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added as additional reference 2007&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller P, Abelin T, Ehrsam R, Imhof P, Howald H, Mauli D</AU>
<TI>The use of transdermal nicotine in smoking cessation</TI>
<SO>Lung</SO>
<YR>1990</YR>
<VL>168</VL>
<PG>445-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahluwalia-1998" NAME="Ahluwalia 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;new 1998&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahluwalia JS, McNagny SE, Clark WS</AU>
<TI>Smoking cessation among inner-city African Americans using the nicotine transdermal patch</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahluwalia-2006" MODIFIED="2012-10-16 16:35:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ahluwalia 2006" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;New 2007&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahluwalia JS, Okuyemi K, Nollen N, Choi WS, Kaur H, Pulvers K et al</AU>
<TI>The effects of nicotine gum and counseling among African American light smokers: A 2 x 2 factorial design</TI>
<SO>Addiction</SO>
<YR>2006</YR>
<VL>101</VL>
<PG>883-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-21 17:46:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berg CJ, Thomas JL, Guo H, An LC, Okuyemi KS, Collins TC et al</AU>
<TI>Predictors of smoking reduction among Blacks</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>423-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nollen NL, Mayo MS, Sanderson CL, Okuyemi KS, Choi WS, Kaur H et al</AU>
<TI>Predictors of quitting among African American light smokers enrolled in a randomized, placebo-controlled trial</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>590-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuyemi KS, Cox LS, Nollen NL, Snow TM, Kaur H, Choi W et al</AU>
<TI>Baseline characteristics and recruitment strategies in a randomized clinical trial of African-American light smokers</TI>
<SO>American Journal of Health Promotion</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>183-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-21 11:33:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuyemi KS, Faseru B, Sanderson CL, Bronars CA, Ahluwalia JS</AU>
<TI>Relationship between menthol cigarettes and smoking cessation among African American light smokers</TI>
<SO>Addiction</SO>
<YR>2007</YR>
<VL>102</VL>
<PG>1979-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-21 11:53:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuyemi KS, Pulvers KM, Cox LS, Thomas JL, Kaur H, Mayo MS et al</AU>
<TI>Nicotine dependence among African American light smokers: a comparison of three scales</TI>
<SO>Addictive Behaviors</SO>
<YR>2007</YR>
<VL>32</VL>
<PG>1989-2002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuyemi KS, Thomas JL, Warren J, Guo H, Ahluwalia JS</AU>
<TI>Relationship between smoking reduction and cessation among light smokers</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>10</NO>
<PG>1005-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuyemi KS, Zheng H, Guo H, Ahluwalia JS</AU>
<TI>Predictors of adherence to nicotine gum and counseling among African-American light smokers</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>9</NO>
<PG>969-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-21 12:07:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas JL, Bronars CA, Stewart DW, Okuyemi KS, Befort CA, Nazir N et al</AU>
<TI>Psychometric properties of a Brief Smoking Consequences Questionnaire for Adults (SCQ-A) among African American light smokers</TI>
<SO>Substance Abuse</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>1</NO>
<PG>14-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-16 16:35:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warren JR, Okuyemi KS, Guo H, Thomas JL, Ahluwalia JS</AU>
<TI>Predicting home smoking restrictions among African American light smokers</TI>
<SO>American Journal of Health Behavior</SO>
<YR>2010</YR>
<VL>34</VL>
<PG>110-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warren JR, Thomas JL, Okuyemi KS, Lindgren B, Ahluwalia JS</AU>
<TI>Development and validation of a multidimensional measure of stress among African American light smokers</TI>
<SO>Journal of the National Medical Association</SO>
<YR>2010</YR>
<VL>102</VL>
<NO>10</NO>
<PG>890-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Areechon-1988" NAME="Areechon 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Areechon W, Punnotok J</AU>
<TI>Smoking cessation through the use of nicotine chewing gum: a double-blind trial in Thailand</TI>
<SO>Clinical Therapeutics</SO>
<YR>1988</YR>
<VL>10</VL>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blondal-1989" NAME="Blondal 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Review used point prevalence (validated) quits from table 1, 37/92 vs 24/90 until 2007 update. Changed to Lapse free rate in table 5, 30/92 vs 22/90 in 2007. Effect smaller and ns.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blondal T</AU>
<TI>Controlled trial of nicotine polacrilex gum with supportive measures</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1989</YR>
<VL>149</VL>
<PG>1818-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blondal-1997" NAME="Blondal 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;new 1997&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blondal T, Franzon M, Westin A</AU>
<TI>A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>1585-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blondal T, Olafsdottir I, Gunnarsdottir R, Franzon M, Westin A</AU>
<TI>Controlled trial of nicotine nasal spray as an aid to stopping smoking [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>Suppl 17</NO>
<PG>631S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blondal-1999" NAME="Blondal 1999" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;New trial 1998/3 update, based on abstract. Full report published 1999 with same outcome data, study ID changed from Blondal 1997b&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A</AU>
<TI>Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<PG>285-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Blondal T, Ludviksdottir D, Gudmundsson L, Olafsdottir I, Gustavsson G, Westin A</AU>
<TI>Efficacy of nicotine nasal spray added to transdermal nicotine patches in smoking cessation [Abstract]</TI>
<SO>Proceedings of the 10th World Conference on Tobacco or Health; Aug 24-28; Beijing, China</SO>
<YR>1997</YR>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohadana-2000" NAME="Bohadana 2000" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohadana A, Nilsson F, Rasmussen T, Martinet Y</AU>
<TI>Gender differences in quit rates following smoking cessation with combination nicotine therapy: influence of baseline smoking behavior</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>1</NO>
<PG>111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;First included 2000/3 based on abstract, full details added 2001/3 (author name corrected, year changed, 1 more quitter in int group).&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bohadana A, Nilsson F, Rasmussen T, Martinet Y</AU>
<TI>Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation - A randomized, double-blind, placebo-controlled trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>3128-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohandana AB, Nilsson F, Martinet Y</AU>
<TI>Nicotine inhaler and nicotine patch: a combination therapy for smoking cessation [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>2</NO>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolin-1999" NAME="Bolin 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;New trial 2000/3 update&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolin LJ, Antonuccio DO, Follette WC, Krumpe P</AU>
<TI>Transdermal nicotine: the long and the short of it</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>152-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolliger-2000a" MODIFIED="2012-10-09 14:35:02 +0100" MODIFIED_BY="Kate Cahill" NAME="Bolliger 2000a" YEAR="2000">
<REFERENCE MODIFIED="2012-10-09 14:35:02 +0100" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A et al</AU>
<TI>Influence of long-term smoking reduction on health risk markers and quality of life</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>433-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-09 14:35:02 +0100" MODIFIED_BY="Kate Cahill" NOTES="&lt;p&gt;new 2001/3 update, moved to excluded 2008&lt;/p&gt;" NOTES_MODIFIED="2012-10-09 14:35:02 +0100" NOTES_MODIFIED_BY="Kate Cahill" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A et al</AU>
<TI>Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<NO>7257</NO>
<PG>329-333</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-09 14:35:02 +0100" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT</AU>
<TI>Practical experiences in smoking reduction and cessation</TI>
<SO>Addiction</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>1 S1</NO>
<PG>S19-S24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brantmark-1973a" MODIFIED="2012-10-09 14:34:18 +0100" MODIFIED_BY="Kate Cahill" NAME="Brantmark 1973a" YEAR="1973">
<REFERENCE MODIFIED="2012-10-09 14:34:18 +0100" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brantmark B, Ohlin P, Westling H</AU>
<TI>Nicotine-containing chewing gum as an anti-smoking aid</TI>
<SO>Psychopharmacologia</SO>
<YR>1973</YR>
<VL>31</VL>
<PG>191-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Br-Thor-Society-1983" NAME="Br Thor Society 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Research Committee of the British Thoracic Society</AU>
<TI>Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society</TI>
<SO>British Medical Journal</SO>
<YR>1983</YR>
<VL>286</VL>
<NO>6365</NO>
<PG>595-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchkremer-1988" MODIFIED="2012-02-20 15:14:10 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Buchkremer 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-02-20 15:14:10 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Buchkremer G, Bents H, Horstmann M, Opitz K, Tolle R</AU>
<TI>Combination of behavioral smoking cessation with transdermal nicotine substitution</TI>
<SO>Addictive Behaviors</SO>
<YR>1989</YR>
<VL>14</VL>
<PG>229-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchkremer G, Bents H, Minneker E, Opitz K</AU>
<TI>Long-term effects of a combination of transdermal nicotine administration with behavior therapy for smoking cessation</TI>
<TO>Langfristige Effekte einer Kombination von transdermaler Nikotinzufuhr mit Verhaltenstherapie zur Raucherentwohnung</TO>
<SO>Nervenarzt</SO>
<YR>1988</YR>
<VL>59</VL>
<PG>488-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bullen-2010" MODIFIED="2012-02-21 12:07:19 +0000" MODIFIED_BY="[Empty name]" NAME="Bullen 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-02-21 12:07:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H et al</AU>
<TI>Pre-cessation nicotine replacement therapy: pragmatic randomized trial</TI>
<SO>Addiction</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>8</NO>
<PG>1474-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-1987" NAME="Campbell 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell IA, Lyons E, Prescott R</AU>
<TI>Do nicotine chewing-gum and postal encouragement add to doctors' advice</TI>
<SO>Practitioner</SO>
<YR>1987</YR>
<VL>231</VL>
<PG>114-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-1991" NAME="Campbell 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell IA, Prescott RJ, Tjeder-Burton SM</AU>
<TI>Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum</TI>
<SO>Respiratory Medicine</SO>
<YR>1991</YR>
<VL>85</VL>
<PG>155-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-1996" NAME="Campbell 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burton S, Campbell IA, Prescott RJ</AU>
<TI>Nicotine patches versus placebo in 235 hospital patients [abstract 191]</TI>
<SO>Abstracts from the 8th World Conference on Tobacco or Health, Mar 30-Apr 3; Buenos Aires, Argentina</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Replaces study ID Burton 1992 which was an abstract of the same trial. Another reference to Thorax 1992 deleted in 2007 as found to be an error&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Campbell IA, Prescott RJ, Tjeder-Burton SM</AU>
<TI>Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study</TI>
<SO>Respiratory Medicine</SO>
<YR>1996</YR>
<VL>90</VL>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CEASE-1999" NAME="CEASE 1999" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;New study for 1999/3 update&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A et al</AU>
<TI>Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>238-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cinciripini-1996" NAME="Cinciripini 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;New 2001/3. 2003 paper added and notes amended to indicate that not all participants reported at 1 year&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W</AU>
<TI>Behavior therapy and the transdermal nicotine patch: Effects on cessation outcome, affect, and coping</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1996</YR>
<VL>64</VL>
<PG>314-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cinciripini PM, Wetter DW, Fouladi RT, Blalock JA, Carter BL, Cinciripini LG et al</AU>
<TI>The effects of depressed mood on smoking cessation: mediation by postcessation self-efficacy</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2003</YR>
<VL>71</VL>
<PG>292-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clavel-1985" MODIFIED="2012-02-21 12:07:32 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Clavel 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clavel F, Benhamou S, Company Huertas A, Flamant R</AU>
<TI>Helping people to stop smoking: randomised comparison of groups being treated with acupuncture and nicotine gum with control group</TI>
<SO>British Medical Journal</SO>
<YR>1985</YR>
<VL>291</VL>
<PG>1538-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-21 12:07:32 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NOTES="&lt;p&gt;Added as second ref 2007&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-02-21 12:07:32 +0000" NOTES_MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clavel F, Benhamou S</AU>
<TI>Tobacco withdrawal. Comparison of the efficacy of various methods. Intermediate results of a comparative study [French]</TI>
<TO>Désintoxcation tabagique. Comparison de l'efficacité de differentes méthodes. Résultats intermédiaires d'une étude comparative</TO>
<SO>Presse Médicale</SO>
<YR>1984</YR>
<VL>13</VL>
<PG>975-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clavel_x002d_Chapelon-1992" NAME="Clavel-Chapelon 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clavel-Chapelon F, Paoletti C, Benhamou S</AU>
<TI>A randomised 2 x 2 factorial design to evaluate different smoking cessation methods</TI>
<SO>Revue d'Epidemiologie et de Sante Publique</SO>
<YR>1992</YR>
<VL>40</VL>
<PG>187-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coleman-2012" MODIFIED="2012-10-16 15:05:47 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Coleman 2012" YEAR="2007">
<REFERENCE MODIFIED="2012-03-02 13:44:45 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts K Britton J et al</AU>
<TI>A randomized trial of nicotine-replacement therapy patches in pregnancy</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<NO>9</NO>
<PG>808-819</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-16 15:05:47 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coleman T, Thornton J, Britton J, Lewis S, Watts K, Coughtrie MWH et al</AU>
<TI>Protocol for the Smoking, Nicotine and Pregnancy (SNAP) trial: Double-blind, placebo-randomised, controlled trial of nicotine replacement therapy in pregnancy</TI>
<SO>BMC Health Services Research</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-02 12:27:19 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornton JG, Coleman T, Britton J, Cooper S, Watts K, Lewis S et al</AU>
<TI>The smoking, nicotine and pregnancy (SNAP) trial: Main results</TI>
<SO>Archives of Disease in Childhood: Fetal and Neonatal Edition</SO>
<YR>2011</YR>
<VL>96</VL>
<PG>Fa109</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooney-2009" MODIFIED="2012-02-21 12:07:43 +0000" MODIFIED_BY="[Empty name]" NAME="Cooney 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-21 12:07:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg H et al</AU>
<TI>Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum</TI>
<SO>Addiction</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>9</NO>
<PG>1588-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-2005" NAME="Cooper 2005" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Added as primary reference 2007, Study ID changed from Cooper 2003&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cooper TV, Klesges RC, Debon MW, Zbikowski SM, Johnson KC, Clemens LH</AU>
<TI>A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women</TI>
<SO>Addictive Behaviors</SO>
<YR>2005</YR>
<VL>30</VL>
<PG>61-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cooper TV, Montgomery GV, Debon MW, Zbikowski SM, Klesges RC, Johnson KC</AU>
<TI>The effects of PPA and nicotine gum on cessation rates and post cessation weight gain in women [POS3-46]</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croghan-2003" NAME="Croghan 2003" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croghan GA, Hurt RD, Croghan IT, Sloan J, Novotny P, Loprinzi C</AU>
<TI>Comparison of a 15 mg transdermal nicotine patch alone versus nicotine nasal spray alone versus both for smoking cessation</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>121</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New for 2004 update. Other ref previously in Awaiting Assessment&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL et al</AU>
<TI>Comparison of nicotine patch alone versus nicotine nasal sparay alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized setting</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dale-1995" NAME="Dale 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR</AU>
<TI>High-dose nicotine patch therapy - percentage of replacement and smoking cessation</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>1353-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added to refs 2000/3&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dale LC, Schroeder DR, Wolter TD, Croghan IT, Hurt RD, Offord KP</AU>
<TI>Weight change after smoking cessation using variable doses of transdermal nicotine replacement</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daughton-1991" NAME="Daughton 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN et al</AU>
<TI>Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1991</YR>
<VL>151</VL>
<PG>749-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN et al</AU>
<TI>Effects of transdermal nicotine as an adjunct in smoking cessation therapy. A double-blind randomized study controlled with placebo [Italian]</TI>
<TO>Effetti del rilascio transdermico di nicotina come terapia di supporto per lo svezzamento dal fumo di sigaretta. Uno studio randomizzato in doppio cieco con controlli trattati con placebo.</TO>
<SO>Archivio Monaldi</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>17-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daughton-1998" NAME="Daughton 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;New trial 1999/3 update&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daughton D, Susman J, Sitorius M, Belenky S, Millatmal T, Nowak R et al</AU>
<TI>Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group</TI>
<SO>Archives of Family Medicine</SO>
<YR>1998</YR>
<VL>7</VL>
<PG>425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dautzenberg-2001" MODIFIED="2008-05-08 11:02:03 +0100" MODIFIED_BY="L S" NAME="Dautzenberg 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dautzenberg B, Peiffer G, Toulouse F, Yvinec MJ, Jacob N, Kienzler JL</AU>
<TI>Randomized trial assessment of nicotinell lozenge 1mg, a new oral nicotine replacement therapy</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 3rd European Conference, Paris</SO>
<YR>2001</YR>
<PG>55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-05-08 11:02:03 +0100" MODIFIED_BY="L S" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dautzenberg B, Ruff F, Vaucher M, Maillon P, Jacob N, Kienzler JL et al</AU>
<TI>First demonstration of the good efficacy/safety ratio of Nicotinell® 1mg Lozenge (NL 1mg), a new form of nicotine substitution, by randomised clinical trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18 Suppl 33</VL>
<PG>12s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1998" NAME="Davidson 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;New trial 1999/3 update.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A</AU>
<TI>Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation</TI>
<SO>Archives of Family Medicine</SO>
<YR>1998</YR>
<VL>7</VL>
<PG>569-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehrsam-1991" NAME="Ehrsam 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Abelin T, Ehrsam R, Imhof P Muller P, Howald H</AU>
<TI>Clinical experience with a transdermal nicotine system in healthy nicotine-dependent smokers</TI>
<SO>Smoking as a cardiovascular risk factor - new strategies for smoking cessation</SO>
<YR>1991</YR>
<PG>35-46</PG>
<ED>Wilhemsen L</ED>
<PB>Hogrefe &amp; Huber</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abelin T, Ehrsam R. Buhler-Reichert A, Imhof PR, Muller P, Thommen A et al</AU>
<TI>Effectiveness of a transdermal nicotine system in smoking cessation studies</TI>
<SO>Methods and Findings in Experimental and Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ehrsam RE, Buhler A, Muller P, Mauli D, Schumacher PM, Howald H et al</AU>
<TI>Weaning of young smokers using a transdermal nicotine patch [German]</TI>
<TO>Entwohnung junger Raucher mit Hilfe eines transdermalen Nikotinpflasters</TO>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1991</YR>
<VL>80</VL>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added as additional reference 2007&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller P, Abelin T, Ehrsam R, Imhof P, Howald H, Mauli D</AU>
<TI>The use of transdermal nicotine in smoking cessation</TI>
<SO>Lung</SO>
<YR>1990</YR>
<VL>168</VL>
<PG>445-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etter-2009" MODIFIED="2012-02-13 09:36:25 +0000" MODIFIED_BY="[Empty name]" NAME="Etter 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-13 09:36:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etter JF, Huguelet P, Perneger TV, Cornuz J</AU>
<TI>Nicotine gum treatment before smoking cessation: a randomized trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>11</NO>
<PG>1028-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fagerstrom-1982" NAME="Fagerstrom 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Outcome data checked 2007 - possible that it should be 22/50 in control, but not altered. Also discussion gives 12 month rates but also not changed&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO</AU>
<TI>A comparison of psychological and pharmacological treatment in smoking cessation</TI>
<SO>Journal of Behavioral Medicine</SO>
<YR>1982</YR>
<VL>5</VL>
<PG>343-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO</AU>
<TI>Tolerance, withdrawal and dependence on tobacco and smoking termination</TI>
<SO>International Review of Applied Psychology</SO>
<YR>1983</YR>
<VL>32</VL>
<PG>29-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fagerstrom-1984" NAME="Fagerstrom 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Data checked 2007. Unclear where denominator of 106 comes from, 96 seems more likely but not changed. Total even including 6 drop outs should only be 151 so total of 155&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO</AU>
<TI>Effects of nicotine chewing gum and follow-up appointments in physician-based smoking cessation</TI>
<SO>Preventive Medicine</SO>
<YR>1984</YR>
<VL>13</VL>
<PG>517-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fee-1982" NAME="Fee 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fee WM, Stewart MJ</AU>
<TI>A controlled trial of nicotine chewing gum in a smoking withdrawal clinic</TI>
<SO>Practitioner</SO>
<YR>1982</YR>
<VL>226</VL>
<PG>148-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiore-1994A" NAME="Fiore 1994A" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Elan Pharmaceutical Research Corp</AU>
<TI>NDA 19-983 for Approval of PROSTEP</TI>
<SO>Study 90-03</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB</AU>
<TI>Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<PG>524-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB</AU>
<TI>Predicting smoking cessation. Who will quit with and without the nicotine patch</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<PG>589-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiore-1994B" NAME="Fiore 1994B" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB</AU>
<TI>Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<PG>524-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fortmann-1995" NAME="Fortmann 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fortmann SP, Killen JD</AU>
<TI>Nicotine gum and self-help behavioral treatment for smoking relapse prevention - resuIts from a trial using population-based recruitment</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1995</YR>
<VL>63</VL>
<PG>460-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-1989" NAME="Garcia 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quilez Garcia C, Hernando Arizaleta L, Rubio Diaz A, Estruch Riba J, Fornes Ramis MV</AU>
<TI>Treatment for smoking with nicotine gum in primary care. A double blind trial [Spanish]</TI>
<TO>Tratamiento del tabaquismo, con chicle de nicotina, en atencion primaria. Estudio a doble ciego</TO>
<SO>Revista Clinica Espanol</SO>
<YR>1993</YR>
<VL>192</VL>
<NO>4</NO>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Quilez Garcia C, Hernando Arizaleta L, Rubio Diaz A, Granero Fernandez EJ, Vila Coll MA, Estruch Riba JSO</AU>
<TI>Double-blind study of the efficacy of nicotine chewing gum for smoking cessation in the primary care setting [Spanish]</TI>
<TO>Estudio doble ciego de la eficacia del chicle de nicotina en la deshabituacion tabaquica dentro del ambito de la atencion primaria</TO>
<SO>Atencion Primaria</SO>
<YR>1989</YR>
<VL>6</VL>
<PG>719-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gariti-2009" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Gariti 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K</AU>
<TI>Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>3</NO>
<PG>247-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garvey-2000" MODIFIED="2011-08-17 14:34:13 +0100" MODIFIED_BY="[Empty name]" NAME="Garvey 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doherty K, Militello FS, Kinnunen T, Garvey AJ</AU>
<TI>Nicotine gum dose and weight gain after smoking cessation</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1996</YR>
<VL>64</VL>
<PG>799-807</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-21 17:31:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson SG, Shiffman S, Rohay JM, Gitchell JG, Garvey AJ</AU>
<TI>Effect of compliance with nicotine gum dosing on weight gained during a quit attempt</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<PG>651-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New 2001&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B et al</AU>
<TI>Effects of nicotine gum dose by level of nicotine dependence</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2000</YR>
<VL>2</VL>
<PG>53-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 14:34:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinnunen T, Doherty K, Militello FS, Garvey AJ</AU>
<TI>Depression and smoking cessation - characteristics of depressed smokers and effects of nicotine replacement</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1996</YR>
<VL>64</VL>
<PG>791-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nordstrom BL, Kinnunen T, Utman CH, Garvey AJ</AU>
<TI>Long-term effects of nicotine gum on weight gain after smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>259-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilbert-1989" NAME="Gilbert 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert JR, Wilson DM, Best JA, Taylor DW, Lindsay EA, Singer J et al</AU>
<TI>Smoking cessation in primary care. A randomized controlled trial of nicotine-bearing chewing gum</TI>
<SO>Journal of Family Practice</SO>
<YR>1989</YR>
<VL>28</VL>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glavas-2003a" NAME="Glavas 2003a" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glavas D, Rumboldt M, Rumboldt Z</AU>
<TI>Smoking cessation with nicotine replacement therapy among health care workers: randomized double-blind study</TI>
<SO>Croatian Medical Journal</SO>
<YR>2003</YR>
<VL>44</VL>
<PG>219-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glavas-2003b" NAME="Glavas 2003b" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;New 2004&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glavas D, Rumboldt Z</AU>
<TI>Smoking cessation using the transdermal nicotine system [Croatian]</TI>
<TO>Odvikavanje od pusenja transdermalnim nikotinskim sustavom</TO>
<SO>Lijecnicki Vjesnik</SO>
<YR>2003</YR>
<VL>125</VL>
<NO>1-2</NO>
<PG>8-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glover-2002" NAME="Glover 2002" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Glover E, Glover P, Franzon M, Sullivan R, Cerullo C</AU>
<TI>Safety and efficacy of a nicotine sublingual tablet for smoking cessation [abstract]</TI>
<SO>Smoke Free 21st Century, 2nd European Conference on Tobacco or Health; Las Palmas de Gran Canaria</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;This ref added 2002/4&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Glover ED, Franzon M, Sullivan CR, Cerullo CL</AU>
<TI>A nicotine sublingual tablet for treating tobacco dependence [Abstract]</TI>
<SO>Society for Research on Nicotine and Tobacco 3rd Europe Conference, Paris September 2001 Abstract Book</SO>
<YR>2001</YR>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Full ref added 2004. First included as Glover 1999 based on abstract&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM et al</AU>
<TI>A comparison of a nicotine sublingual tablet and placebo for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>441-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Glover ED, Glover PN, Franzon M, Sullivan R, Sullivan P, Howell R et al</AU>
<TI>A nicotine sublingual tablet for smoking cessation: 6-month data [Abstract]</TI>
<SO>Proceedings of the 10th World Conference on Tobacco or Health; Aug 24-28 Beijing, China</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldstein-1989" NAME="Goldstein 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Added 2000/3&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein MG, Niaura R, Follick MJ, Abrams DB</AU>
<TI>Effects of behavioral skills training and schedule of nicotine gum administration on smoking cessation</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<PG>56-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gourlay-1995" NAME="Gourlay 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ</AU>
<TI>Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<NO>7001</NO>
<PG>363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gross-1995" NAME="Gross 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Added 2000/3 update&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gross J, Johnson J, Sigler L, Stitzer ML</AU>
<TI>Dose effects of nicotine gum</TI>
<SO>Addictive Behaviors</SO>
<YR>1995</YR>
<VL>20</VL>
<PG>371-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-1985" NAME="Hall 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Added 1998/3 update.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Tunstall C, Rugg D, Jones R, Benowitz N</AU>
<TI>Nicotine gum and behavioral treatment in smoking cessation</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1985</YR>
<VL>53</VL>
<PG>256-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-1987" NAME="Hall 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, Jones RT</AU>
<TI>Nicotine gum and behavioral treatment: a placebo controlled trial</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1987</YR>
<VL>55</VL>
<PG>603-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-1996" NAME="Hall 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;New trial 1998&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Munoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL et al</AU>
<TI>Mood management and nicotine gum in smoking treatment - a therapeutic contact and placebo-controlled study</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1996</YR>
<VL>64</VL>
<PG>1003-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hand-2002" NAME="Hand 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hand S, Edwards S, Campbell IA, Cannings R</AU>
<TI>Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>715-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harackiewicz-1988" NAME="Harackiewicz 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN</AU>
<TI>Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context</TI>
<SO>Addictive Behaviors</SO>
<YR>1988</YR>
<VL>13</VL>
<PG>319-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hays-1999" NAME="Hays 1999" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;New trial 1999/3 based on abstract. Full publication details added 2000/3.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hays JT, Croghan GA, Offord KP, Hurt RD, Schroeder DR, Wolter TD et al</AU>
<TI>Over-the-counter nicotine patch therapy for smoking cessation: Results from randomized, double-blind, placebo-controlled and open label trials</TI>
<SO>American Journal of Public Health</SO>
<YR>1999</YR>
<VL>89</VL>
<PG>1701-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hays JT, Croghan GA, Offord KP, Wolter TD, Nides MA, Davidson M</AU>
<TI>Over-the-Counter (OTC) transdermal nicotine patch therapy [abstract]</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>136</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Hays JT, Croghan IT, Offord KP, Hurt RD, Schroeder DR, Wolter TD et al</AU>
<TI>Over the counter 22mg nicotine patch therapy for smoking cessation: results from randomized double-blind placebo-controlled and open label trials</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 5th Annual Meeting, San Diego (CA)</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera-1995" NAME="Herrera 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Added to support subgroup analysis 2004&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom KO</AU>
<TI>Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>447-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilleman-1994" NAME="Hilleman 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Added 2001/3&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilleman DE, Mohiuddin SM, Delcore MG</AU>
<TI>Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1994</YR>
<VL>34</VL>
<NO>3</NO>
<PG>222-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hjalmarson-1984" NAME="Hjalmarson 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hjalmarson AI</AU>
<TI>Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study</TI>
<SO>JAMA</SO>
<YR>1984</YR>
<VL>252</VL>
<PG>2835-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hjalmarson-1994" NAME="Hjalmarson 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hjalmarson AI, Franzon M, Westin A, Wiklund O</AU>
<TI>Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>2567-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hjalmarson-1997" NAME="Hjalmarson 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;New trial 1998/3 update&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O</AU>
<TI>The nicotine inhaler in smoking cessation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1997</YR>
<VL>157</VL>
<PG>1721-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-1988" NAME="Huber 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Trial added 1998&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber D</AU>
<TI>Combined and separate treatment effects of nicotine chewing gum and self-control method</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1988</YR>
<VL>21</VL>
<PG>461-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1989" NAME="Hughes 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Gust SW, Keenan R, Fenwick JW, Skoog K, Higgins ST</AU>
<TI>Long-term use of nicotine vs placebo gum</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1991</YR>
<VL>151</VL>
<PG>1993-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML</AU>
<TI>Nicotine vs placebo gum in general medical practice</TI>
<SO>JAMA</SO>
<YR>1989</YR>
<VL>261</VL>
<PG>1300-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1990" NAME="Hughes 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Gust SW, Keenan RM, Fenwick JW</AU>
<TI>Effect of dose on nicotine's reinforcing, withdrawal-suppression and self-reported effects</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1990</YR>
<VL>252</VL>
<PG>1175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1991" NAME="Hughes 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Only included in 2008 update following comment by JRH&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Wadland WC, Fenwick JW, Lewis J, Bickel WK</AU>
<TI>Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study</TI>
<SO>Preventive Medicine</SO>
<YR>1991</YR>
<VL>20</VL>
<PG>486-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1999" NAME="Hughes 1999" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;New trial 2000&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE et al</AU>
<TI>Are higher doses of nicotine replacement more effective for smoking cessation?</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>169-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-2003" NAME="Hughes 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW</AU>
<TI>Efficacy of nicotine patch in smokers with a history of alcoholism</TI>
<SO>Alcoholism-Clinical and Experimental Research</SO>
<YR>2003</YR>
<VL>27</VL>
<PG>946-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-2010" MODIFIED="2012-06-27 16:34:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Hughes 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-27 16:34:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Solomon LJ, Livingston AE, Callas PW, Peters EN</AU>
<TI>A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit</TI>
<SO>Drug &amp; Alcohol Dependence</SO>
<YR>2010</YR>
<VL>111</VL>
<NO>1-2</NO>
<PG>105-13</PG>
<IDENTIFIERS MODIFIED="2012-06-27 16:34:39 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2012-06-27 16:34:39 +0100" MODIFIED_BY="Lindsay Stead" TYPE="OTHER" VALUE="NCT00297492"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurt-1990" NAME="Hurt 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Elan Pharmaceutical Research Corp</AU>
<TI>NDA 19-983 for Approval of PROSTEP</TI>
<SO>Study 88-02</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC</AU>
<TI>Nicotine-replacement therapy with use of a transdermal nicotine patch-a randomized double-blind placebo-controlled trial</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1990</YR>
<VL>65</VL>
<PG>1529-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurt-1994" NAME="Hurt 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP et al</AU>
<TI>Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: One-year outcome and percentage of nicotine replacement</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<PG>595-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ICRF-1994" NAME="ICRF 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC</AU>
<TI>The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>2</NO>
<PG>225-231</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imperial Cancer Research Fund General Practice Research Group</AU>
<TI>Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice.</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>1304-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Imperial Cancer Research Fund General Practice research Group</AU>
<TI>Randomised trial of nicotine patches in general practice: results at one year.</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>1476-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnstone EC, Yudkin Pl, Hey K, Roberts SJ, Welch SJ, Murphy MF et al</AU>
<TI>Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch</TI>
<SO>Pharmacogenetics</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>2</NO>
<PG>83-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yudkin P, Hey K, Roberts S, Welch S, Murphy M, Walton R</AU>
<TI>Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7405</NO>
<PG>28-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yudkin P, Munafo M, Hey K, Roberts S, Welch S, Johnstone E et al</AU>
<TI>Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7446</NO>
<PG>989-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jamrozik-1984" NAME="Jamrozik 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jamrozik K, Fowler G, Vessey M, Wald N</AU>
<TI>Placebo controlled trial of nicotine chewing gum in general practice</TI>
<SO>British Medical Journal</SO>
<YR>1984</YR>
<VL>289</VL>
<PG>794-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarvis-1982" NAME="Jarvis 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvis MJ, Raw M, Russell MAH, Feyerabend C</AU>
<TI>Randomised controlled trial of nicotine chewing-gum</TI>
<SO>British Medical Journal</SO>
<YR>1982</YR>
<VL>285</VL>
<PG>537-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1991" NAME="Jensen 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Added as additional reference 2007. Reports 12m outcomes, used since then. (6m rates differ slightly from Int J Addictions paper).&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen EJ, Schmidt E, Pedersen B, Dahl R</AU>
<TI>Effect of nicotine, silver acetate, and ordinary chewing gum in combination with group counselling on smoking cessation</TI>
<SO>Thorax</SO>
<YR>1990</YR>
<VL>45</VL>
<PG>831-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Additional ref from 2007&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen EJ, Schmidt E, Pedersen B, Dahl R</AU>
<TI>Effect on smoking cessation of silver acetate, nicotine and ordinary chewing gum. Influence of smoking history</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>1991</YR>
<VL>104</VL>
<PG>470-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jensen EJ, Schmidt E, Pedersen B, Dahl R</AU>
<TI>The effect of nicotine, silver acetate, and placebo chewing gum on the cessation of smoking. The influence of smoking type and nicotine dependence</TI>
<SO>International Journal of the Addictions</SO>
<YR>1991</YR>
<VL>26</VL>
<PG>1223-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorenby-1995" NAME="Jorenby 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;New trial 1999&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Crogham IT et al</AU>
<TI>Varying nicotine patch dose and type of smoking cessation counseling</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>1347-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorenby-1999" NAME="Jorenby 1999" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;In additional refs as cited in text as well as secondary paper to Jorenby 1999&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ et al</AU>
<TI>Impact of prior nicotine replacement therapy on smoking cessation efficacy</TI>
<SO>American Journal of Health Behaviors</SO>
<YR>2002</YR>
<VL>26</VL>
<PG>213-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Reanalysis of Jorenby trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA et al</AU>
<TI>Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo</TI>
<SO>Clinical Therapeutics</SO>
<YR>2001</YR>
<VL>23</VL>
<PG>744-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al</AU>
<TI>A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>685-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joseph-1996" NAME="Joseph 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;New trial 1998/3 update using 6 month outcomes, 12m from 1999&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joseph AM, Antonnucio DO</AU>
<TI>Lack of efficacy of transdermal nicotine in smoking cessation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1157-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New trial 1998/3 update using 6 month outcomes. 12 month outcomes reported 1999, used from 2000/3 update&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG et al</AU>
<TI>The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<PG>1792-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalman-2006" NAME="Kalman 2006" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;citation corrected for 2002 update&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kalman D, Denison H, Penk W, Peer J, Kresman D, Monti P</AU>
<TI>Early findings from a treatment study of heavy smokers in alcohol recovery (PO2 34)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23-23 Seattle, Washington</SO>
<YR>2001</YR>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New 2007, previously excluded as short-term (Kalman 2004)&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kalman D, Kahler CW, Garvey AJ, Monti PM</AU>
<TI>High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2006</YR>
<VL>30</VL>
<PG>213-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added to excluded studies 2004&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalman D, Kahler CW, Tirch D, Kaschub C, Penk W, Monti PM</AU>
<TI>Twelve-week outcomes from an investigation of high-dose nicotine patch therapy for heavy smokers with a past history of alcohol dependence</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>78-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalman D, Tirch D, Penk W, Denison H</AU>
<TI>An investigation of predictors of nicotine abstinence in a smoking cessation treatment study of smokers with a past history of alcohol dependence</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>346-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kalman D, Tirch D, Penk W, Kaschub C</AU>
<TI>Preliminary findings from a treatment study of heavy smokers in alcohol recovery: end of treatment outcomes (PO2 38)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 8th Annual Meeting February 20-23 Savannah, Georgia</SO>
<YR>2002</YR>
<PG>58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-1984" NAME="Killen 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Maccoby N, Taylor CB</AU>
<TI>Nicotine gum and self-regulation training in smoking relapse prevention</TI>
<SO>Behavior Therapy</SO>
<YR>1984</YR>
<VL>15</VL>
<PG>234-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-1990" NAME="Killen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fortmann SP, Killen JD, Telch MJ, Newman B</AU>
<TI>Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford Stop Smoking Project</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>260</VL>
<PG>1575-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Unclear why this is categorised as high support, but have not altered it&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Fortmann SP, Newman B, Varady A</AU>
<TI>Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1990</YR>
<VL>58</VL>
<PG>85-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-1997" MODIFIED="2011-07-21 17:44:42 +0100" MODIFIED_BY="[Empty name]" NAME="Killen 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-07-21 17:44:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey SR, Fong DM, Bryson SW, Fortmann SP, Killen JD</AU>
<TI>Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2010</YR>
<VL>32</VL>
<PG>150-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-21 17:44:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New trial 1998. Originally S-H not collapsed. Combined for 2007&lt;/p&gt;" NOTES_MODIFIED="2011-07-21 17:44:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Fortmann SP, Davis L, Varady A</AU>
<TI>Nicotine patch and self-help video for cigarette smoking cessation</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1997</YR>
<VL>65</VL>
<PG>663-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-1999" NAME="Killen 1999" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;New trial 2000&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A</AU>
<TI>Do heavy smokers benefit from higher dose nicotine patch therapy?</TI>
<SO>Experimental and Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>226-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornitzer-1987" NAME="Kornitzer 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornitzer M, Kittel F, Dramaix M, Bourdoux P</AU>
<TI>A double blind study of 2 mg versus 4 mg nicotine-gum in an industrial setting</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>1987</YR>
<VL>31</VL>
<PG>171-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornitzer-1995" NAME="Kornitzer 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G</AU>
<TI>Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial</TI>
<SO>Preventive Medicine</SO>
<YR>1995</YR>
<VL>24</VL>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added as additional ref 2007&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornitzer M, Boutsen M, Thijs J, Gustavsson G</AU>
<TI>Efficiency and safety of combined use of nicotine patches and nicotine gum in smoking cessation: a placebo controlled double-blind trial [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>Suppl 17</NO>
<PG>630S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kralikova-2002" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kralikova 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kralikova E, Kozak J, Rasmussen T, Cort N</AU>
<TI>The clinical benefits of NRT-supported smoking reduction</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>243</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kralikova E, Kozak JT, Rasmussen T, Gustavsson G, Le Houezec J</AU>
<TI>Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler</TI>
<SO>BMC Public Health</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>433</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leischow-1996" NAME="Leischow 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;New trial 1998&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP</AU>
<TI>Efficacy of the nicotine inhaler as an adjunct to smoking cessation</TI>
<SO>American Journal of Health Behavior</SO>
<YR>1996</YR>
<VL>20</VL>
<PG>364-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leischow-1999" NAME="Leischow 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;New trial 2000/3 update.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leischow SJ, Muramoto ML, Cook GN, Merikle EP, Castellini SM, Otte PS</AU>
<TI>OTC nicotine patch: effectiveness alone and with brief physician intervention</TI>
<SO>American Journal of Health Behavior</SO>
<YR>1999</YR>
<VL>23</VL>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leischow-2004" NAME="Leischow 2004" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E</AU>
<TI>Effectiveness of the nicotine inhaler for smoking cessation in an OTC setting</TI>
<SO>American Journal of Health Behavior</SO>
<YR>2004</YR>
<VL>28</VL>
<PG>291-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E</AU>
<TI>The safety and effectiveness of the nicotine inhaler for smoking cessation in an over-the-counter setting (POS4-78)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA</SO>
<YR>2003</YR>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lerman-2004" NAME="Lerman 2004" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F et al</AU>
<TI>Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>1</NO>
<PG>231-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added as new ref 2007&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain McGovern J et al</AU>
<TI>Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<PG>426-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A et al</AU>
<TI>Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2006</YR>
<VL>79</VL>
<PG>600-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S et al</AU>
<TI>The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial</TI>
<SO>Pharmacogenomics Journal</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>3</NO>
<PG>184-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF</AU>
<TI>Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy</TI>
<SO>Molecular Psychiatry</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>4</NO>
<PG>400-409</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson F, Jepson C, Kaufmann V, Rukstalis M, Audrain-McGovern J, Kucharski S et al</AU>
<TI>Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2003</YR>
<VL>72</VL>
<PG>123-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1998" NAME="Lewis 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;New trial for 1999/3 update.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB</AU>
<TI>Transdermal nicotine replacement for hospitalized patients: A randomized clinical trial</TI>
<SO>Preventive Medicine</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>2</NO>
<PG>296-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Llivina-1988" NAME="Llivina 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Intensity changed from low to high for 2007&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salvador Llivina T, Marin Tuya D, Gonzalez Quintana J, Iniesta Torres C, Castellvi Barrera E, Muriana Saez C et al</AU>
<TI>Treatment of smoking: efficacy of the use of nicotine chewing gum. Double-blind study [Spanish]</TI>
<TO>Tratamiento del tabaquismo: eficacia de la utilizacion del chicle de nicotina. Estudio a doble ciego</TO>
<SO>Medicina Clinica Barcelona</SO>
<YR>1988</YR>
<VL>90</VL>
<PG>646-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-1980" NAME="Malcolm 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm RE, Sillett RW, Turner JA, Ball KP</AU>
<TI>The use of nicotine chewing gum as an aid to stopping smoking</TI>
<SO>Psychopharmacology Series</SO>
<YR>1980</YR>
<VL>70</VL>
<PG>295-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marshall-1985" NAME="Marshall 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marshall A, Raw M</AU>
<TI>Nicotine chewing gum in general practice: effect of follow up appointments</TI>
<SO>British Medical Journal</SO>
<YR>1985</YR>
<VL>290</VL>
<PG>1397-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGovern-1992" NAME="McGovern 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGovern PG, Lando HA</AU>
<TI>An assessment of nicotine gum as an adjunct to Freedom from Smoking cessation clinics</TI>
<SO>Addictive Behaviors</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>137-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molyneux-2003" NAME="Molyneux 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge A et al</AU>
<TI>Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients</TI>
<SO>Thorax</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>6</NO>
<PG>484-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moolchan-2005" MODIFIED="2012-02-21 12:08:24 +0000" MODIFIED_BY="[Empty name]" NAME="Moolchan 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-07-21 17:50:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins CC, Epstein DH, Parzynski CS, Zimmerman D, Moolchan ET, Heishman SJ</AU>
<TI>Puffing behavior during the smoking of a single cigarette in tobacco-dependent adolescents</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>164-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franken FH, Pickworth WB, Epstein DH, Moolchan ET</AU>
<TI>Smoking rates and topography predict adolescent smoking cessation following treatment with nicotine replacement therapy</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>154-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-21 12:08:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaszyna-Gasior M, Schroeder JR, Thorner ED, Heishman SJ, Collins CC, Lo S et al</AU>
<TI>Age at menarche and weight concerns in relation to smoking trajectory and dependence among adolescent girls enrolled in a smoking cessation trial</TI>
<SO>Addictive Behaviors</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>1</NO>
<PG>92-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ et al</AU>
<TI>Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>4</NO>
<PG>e407-e414</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson ML, Schroeder JR, Moolchan ET</AU>
<TI>Adolescent smokers screened for a nicotine replacement treatment trial: Correlates of eligibility and enrollment</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>447-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorner-Bantug E, Jaszyna-Gasior M, Schroeder JR, Collins CC, Moolchan ET</AU>
<TI>Weight gain, related concerns, and treatment outcomes among adolescent smokers enrolled in cessation treatment</TI>
<SO>Journal of the National Medical Association</SO>
<YR>2009</YR>
<VL>101</VL>
<NO>10</NO>
<PG>1009-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mori-1992" NAME="Mori 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Mori T, Shimao T, Yulchiro G, Namiki M, Hyachi T</AU>
<TI>A clinical trial of nicotine chewing gum for smoking cessation [abstract 428]</TI>
<SO>8th World Conference on Tobacco or Health; Buenos Aires, Argentina</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Nakamura-1990" NAME="Nakamura 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nakamura M, Saito J, Oshima A, Miyamoto M, Matushita A, Endo S</AU>
<TI>Effect of nicotine chewing gun in smoking cessation classes</TI>
<SO>The Global War. Proceedings of the 7th World Conference on Tobacco and Health; Perth, Western Australia</SO>
<YR>1990</YR>
<PG>665-7</PG>
<ED>Durston B, Jamrozik K</ED>
<PB>Health Department of Western Australia</PB>
<CY>Perth</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nebot-1992" NAME="Nebot 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nebot M, Cabezas C</AU>
<TI>Does nurse counseling or offer of nicotine gum improve the effectiveness of physician smoking-cessation advice?</TI>
<SO>Family Practice Research Journal</SO>
<YR>1992</YR>
<VL>12</VL>
<PG>263-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niaura-1994" NAME="Niaura 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Added for 1998 update&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niaura R, Goldstein MG, Abrams DB</AU>
<TI>Matching high and low-dependence smokers to self-help treatment with or without nicotine replacement</TI>
<SO>Preventive Medicine</SO>
<YR>1994</YR>
<VL>23</VL>
<PG>70-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niaura-1999" NAME="Niaura 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;New 2001&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niaura R, Abrams DB, Shadel WG, Rohsenow DJ, Monti PM, Sirota AD</AU>
<TI>Cue exposure treatment for smoking relapse prevention: A controlled clinical trial</TI>
<SO>Addiction</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>5</NO>
<PG>685-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ockene-1991" NAME="Ockene 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ockene JK, Kristeller J, Goldberg R, Amick TL, Pekow PS, Hosmer D et al</AU>
<TI>Increasing the efficacy of physician-delivered smoking interventions: a randomized clinical trial</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ockene JK, Kristeller J, Pbert L, Hebert JR, Luippold R, Goldberg RJ et al</AU>
<TI>The physician-delivered smoking intervention project: can short-term interventions produce long-term effects for a general outpatient population?</TI>
<SO>Health Psychology</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>278-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oncken-2007" MODIFIED="2011-07-20 11:53:58 +0100" MODIFIED_BY="[Empty name]" NAME="Oncken 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-07-20 11:53:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleppinger A, Litt MD, Kenny AM, Oncken CA</AU>
<TI>Effects of smoking cessation on body composition in postmenopausal women</TI>
<SO>Journal of Women's Health</SO>
<YR>2010</YR>
<VL>19</VL>
<PG>1651-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR</AU>
<TI>Transdermal nicotine for smoking cessation in postmenopausal women</TI>
<SO>Addictive Behaviors</SO>
<YR>2007</YR>
<VL>32</VL>
<PG>296-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Oncken C, Cooney J, Lando H, Feinn R, Kranzler H</AU>
<TI>Transdermal nicotine for smoking cessation in postmenopausal women (POS1-045)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 11th Annual Meeting, Prague</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oncken-2008" MODIFIED="2012-02-21 12:08:41 +0000" MODIFIED_BY="[Empty name]" NAME="Oncken 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-02-09 14:22:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fish LJ, Peterson BL, Namenek Brouwer RJ, Lyna P, Oncken CA, Swamy G et al</AU>
<TI>Adherence to nicotine replacement therapy among pregnant smokers</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>5</NO>
<PG>514-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-21 12:08:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oncken C, Dornelas E, Greene J, Sankey H, Glasmann A, Feinn R et al</AU>
<TI>Nicotine gum for pregnant smokers: a randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2008</YR>
<VL>112</VL>
<NO>4</NO>
<PG>859-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-09 14:23:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swamy GK, Roelands JJ, Peterson BL, Fish LJ, Oncken CA, Pletsch P et al</AU>
<TI>Predictors of adverse events among pregnant smokers exposed in a nicotine replacement therapy trial</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>2009</YR>
<VL>201</VL>
<NO>4</NO>
<PG>354-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ortega-2011" MODIFIED="2012-02-21 12:08:56 +0000" MODIFIED_BY="[Empty name]" NAME="Ortega 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-21 12:08:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortega F, Vellisco A, Márquez E, López-Campos J L, Rodríguez A, de los Ángeles Sánchez M et al</AU>
<TI>Effectiveness of a cognitive orientation program with and without nicotine replacement therapy in stopping smoking in hospitalised patients</TI>
<SO>Archivos de Bronconeumologia</SO>
<YR>2011</YR>
<VL>47</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otero-2006" NAME="Otero 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Otero UB, Perez CA, Szklo M, Esteves GA, dePinho MM, Szklo AS et al</AU>
<TI>Randomized clinical trial: effectiveness of the cognitive-behavioral approach and the use of nicotine replacement transdermal patches for smoking cessation among adults in Rio de Janeiro, Brazil [Portugese]</TI>
<TO>Ensaio clinico randomizado: efetividade da abordagem cognitivo-comportamental e uso de adesivos transdermicos de reposicao de nicotina, na cessacao de fumar, em adultos residentes no Municipio do Rio de Janeiro, Brasil</TO>
<SO>Cadernos de Saude Publica</SO>
<YR>2006</YR>
<VL>22</VL>
<PG>439-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Page-1986" NAME="Page 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Page AR, Walters DJ, Schlegel RP, Best JA</AU>
<TI>Smoking cessation in family practice: the effects of advice and nicotine chewing gum prescription</TI>
<SO>Addictive Behaviors</SO>
<YR>1986</YR>
<VL>11</VL>
<PG>443-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paoletti-1996" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Paoletti 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cosci F, Corlando A, Fornai E, Pistelli F, Paoletti P, Carrozzi L</AU>
<TI>Nicotine dependence, psychological distress and personality traits as possible predictors of smoking cessation. Results of a double-blind study with nicotine patch</TI>
<SO>Addictive Behaviors</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>1</NO>
<PG>28-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 14:47:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fornai E, Desideri M, Pistelli F, Carrozzi L, Puntoni R, Avino S et al</AU>
<TI>Smoking reduction in smokers compliant to a smoking cessation trial with nicotine patch</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>5-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 14:47:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Paoletti P, Fornai E, Maggiorelli F, Puntoni R, Viegi G, Carrozzi L et al</AU>
<TI>Importance of baseline cotinine plasma values in smoking cessation: results from a double blind study with nicotine patch</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>643-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perng-1998" NAME="Perng 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ</AU>
<TI>Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>3SS</NO>
<PG>A735</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New for 1999&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ</AU>
<TI>Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>1998</YR>
<VL>97</VL>
<PG>547-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piper-2007" NAME="Piper 2007" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Piper ME, Federman EB, Bolt DM, Smith SS, Fiore MC, Baker TB</AU>
<TI>Mediators of bupropion treatment effects (PA5-6)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 12th Annual Meeting, Orlando, FL</SO>
<YR>2006</YR>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC et al</AU>
<TI>Efficacy of bupropion alone and in combination with nicotine gum</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>947-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Piper ME, Federman EB, Smith SS, Fiore MC, Baker TB</AU>
<TI>Efficacy of bupropion SR alone and combined with 4-mg gum (PA2-2)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 10th Annual Meeting, Phoenix, AZ</SO>
<YR>2004</YR>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piper-2009" MODIFIED="2012-07-11 13:23:15 +0100" MODIFIED_BY="[Empty name]" NAME="Piper 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asthana A, Johnson HM, Piper ME, Fiore MC, Baker TB, Stein JH</AU>
<TI>Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers</TI>
<SO>American Heart Journal</SO>
<YR>2010</YR>
<VL>160</VL>
<NO>3</NO>
<PG>458-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH</AU>
<TI>Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial</TI>
<SO>American Heart Journal</SO>
<YR>2011</YR>
<VL>161</VL>
<NO>1</NO>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB</AU>
<TI>The effect of five smoking cessation pharmacotherapies on smoking cessation milestones</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>2011</YR>
<VL>79</VL>
<NO>1</NO>
<PG>34-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-21 12:09:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson HM, Gossett LK, Piper ME, Aeschlimann SE, Korcarz CE, Baker TB et al</AU>
<TI>Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>18</NO>
<PG>1988-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Cook JW, Schlam TR, Jorenby DE, Baker TB</AU>
<TI>Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>2</NO>
<PG>418-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-21 12:09:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D et al</AU>
<TI>A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>11</NO>
<PG>1253-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-11 13:23:15 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2012-07-11 13:23:15 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00332644"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pirie-1992" NAME="Pirie 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pirie PL, McBride CM, Hellerstedt WL, Jeffery RW, Hatsukami DK, Allen S et al</AU>
<TI>Smoking cessation in women concerned about weight</TI>
<SO>American Journal of Public Health</SO>
<YR>1992</YR>
<VL>82</VL>
<PG>1238-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pollak-2007" MODIFIED="2012-10-16 16:36:35 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Pollak 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-16 16:36:35 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pollak KI, Oncken C, Lipkus IM, Peterson BL, Swamy GK, Pletsch PK et al</AU>
<TI>Effectiveness of adding nicotine replacement therapy to cognitive behavioral therapy for smoking cessation in pregnant smokers: the Baby Steps trial (PA6-3)</TI>
<SO>Society for Research on Nicotine and Tobacco 13th Annual Meeting February 21-24, Austin, Texas</SO>
<YR>2007</YR>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-14 11:50:58 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, Pletsch PK et al</AU>
<TI>Nicotine replacement and behavioral therapy for smoking cessation in pregnancy</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2007</YR>
<VL>33</VL>
<PG>297-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prapavessis-2007" NAME="Prapavessis 2007" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;First epub 2006&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prapavessis H, Cameron L, Baldi JC, Robinson S, Borrie K, Harper T et al</AU>
<TI>The effects of exercise and nicotine replacement therapy on smoking rates in women</TI>
<SO>Addictive Behaviors</SO>
<YR>2007</YR>
<VL>32</VL>
<PG>1416-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puska-1979" NAME="Puska 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puska P, Bjorkqvist S, Koskela K</AU>
<TI>Nicotine-containing chewing gum in smoking cessation: a double blind trial with half year follow-up</TI>
<SO>Addictive Behaviors</SO>
<YR>1979</YR>
<VL>4</VL>
<PG>141-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puska-1995" NAME="Puska 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puska P, Korhonen HJ, Vartiainen E, Urjanheimo EL, Gustavsson G, Westin A</AU>
<TI>Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia</TI>
<SO>Tobacco Control</SO>
<YR>1995</YR>
<VL>4</VL>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richmond-1993" NAME="Richmond 1993" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richmond R, Heather N</AU>
<TI>General Practitioner interventions for smoking cessation: past results and future prospects</TI>
<SO>Behaviour Change</SO>
<YR>1990</YR>
<VL>7</VL>
<PG>110-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Richmond RL, Makinson RJ, Giugni AA, Webster IW</AU>
<TI>General Practitioner smoking interventions in Australia: results of studies over the past ten years</TI>
<SO>The Global War, Proceedings of the 7th World Conference on Tobacco and Health. Perth, Western Australia</SO>
<YR>1990</YR>
<PG>657-60</PG>
<ED>Durston B, Jamrozik K,</ED>
<PB>Health Department of Western Australia</PB>
<CY>Perth</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added as primary reference for 2008 update&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Richmond RL, Makinson RJ, Kehoe LA, Giugni AA, Webster IW</AU>
<TI>One-year evaluation of three smoking cessation interventions administered by general practitioners</TI>
<SO>Addictive Behaviors</SO>
<YR>1993</YR>
<VL>18</VL>
<PG>187-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richmond-1994" NAME="Richmond 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Richmond RL, Harris K, de Almeida Neto A</AU>
<TI>The transdermal nicotine patch: results of a randomised placebo-controlled trial</TI>
<SO>Medical Journal of Australia</SO>
<YR>1994</YR>
<VL>161</VL>
<PG>130-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richmond RL, Kehoe L, Neto ACdA</AU>
<TI>Effectiveness of a 24-hour transdermal nicotine patch in conjunction with a cognitive behavioural programme: One year outcome</TI>
<SO>Addiction</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-1994" NAME="Rose 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV</AU>
<TI>Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1994</YR>
<VL>56</VL>
<PG>86-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Westman EC, Behm FM</AU>
<TI>Nicotine/mecamylamine combination treatment for smoking cessation [published erratum appears in Drug Development Research 1997;40:215]</TI>
<SO>Drug Development Research</SO>
<YR>1996</YR>
<VL>38</VL>
<PG>243-256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-1998" NAME="Rose 1998" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Behm FM, Westman EC</AU>
<TI>Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy</TI>
<SO>Experimental and Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>331-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Westman EC, Behm FM</AU>
<TI>Nicotine/mecamylamine combination treatment for smoking cessation [published erratum appears in Drug Development Research 1997;40:215]</TI>
<SO>Drug Development Research</SO>
<YR>1996</YR>
<VL>38</VL>
<PG>243-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-2006" NAME="Rose 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Behm FM, Westman EC, Kukovich P</AU>
<TI>Precessation treatment with nicotine skin patch facilitates smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>89-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rose-2009" MODIFIED="2012-02-22 08:43:46 +0000" MODIFIED_BY="[Empty name]" NAME="Rose 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-14 13:04:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Herskovic JE, Behm FM, Westman EC</AU>
<TI>Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1067-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-14 13:04:24 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE</AU>
<TI>Nicotine preloading: The importance of a pre-cessation reduction in smoking behavior</TI>
<SO>Psychopharmacology</SO>
<YR>2011</YR>
<VL>217</VL>
<NO>3</NO>
<PG>453-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rose-2010" MODIFIED="2012-03-02 14:46:08 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Rose 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-02 11:18:20 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR</AU>
<TI>Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score</TI>
<SO>Molecular Medicine</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>7-8</NO>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-02 11:18:20 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE</AU>
<TI>Nicotine preloading: The importance of a pre-cessation reduction in smoking behavior</TI>
<SO>Psychopharmacology</SO>
<YR>2011</YR>
<VL>217</VL>
<NO>3</NO>
<PG>453-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-02 11:18:20 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uhl GR, Drgon T, Johnson C, Ramoni MF, Behm FM, Rose JE</AU>
<TI>Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement</TI>
<SO>Molecular Medicine</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>11-12</NO>
<PG>513-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roto-1987" NAME="Roto 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Added 2001&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roto P, Ojala A, Sundman K, Jokinen K, Peltomakl R</AU>
<TI>Nicotine gum and withdrawal from smoking</TI>
<SO>Suomen Laakarllehtl</SO>
<YR>1987</YR>
<VL>36</VL>
<PG>3445-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1983" NAME="Russell 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell MA, Merriman R, Stapleton J, Taylor W</AU>
<TI>Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking</TI>
<SO>British Medical Journal (Clinical Research Ed.)</SO>
<YR>1983</YR>
<VL>287</VL>
<PG>1782-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachs-1993" NAME="Sachs 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sachs DPL, Sawe U, Leischow SJ</AU>
<TI>Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1993</YR>
<VL>153</VL>
<PG>1881-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1985A" NAME="Schneider 1985A" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvik ME, Schneider NG</AU>
<TI>Degree of addiction and effectiveness of nicotine gum therapy for smoking</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<PG>790-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A</AU>
<TI>Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial</TI>
<SO>Addictive Behaviors</SO>
<YR>1983</YR>
<VL>8</VL>
<PG>253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Jarvik ME</AU>
<TI>Nicotine gum vs. placebo gum: comparisons of withdrawal symptoms and success rates</TI>
<SO>NIDA Research Monograph</SO>
<YR>1985</YR>
<VL>53</VL>
<PG>83-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1985B" NAME="Schneider 1985B" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Made primary reference 2007. Data not included in comparison 1 until 2007. Data in low intensity group incorrect until then (2/13 vs 2/ 23 should be 1/13 vs 3/23)&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A</AU>
<TI>Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial</TI>
<SO>Addictive Behaviors</SO>
<YR>1983</YR>
<VL>8</VL>
<PG>253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Entered as a separate study ID for study B in 1985 paper from 2007&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Jarvik ME</AU>
<TI>Nicotine gum vs. placebo gum: comparisons of withdrawal symptoms and success rates</TI>
<SO>NIDA Research Monograph</SO>
<YR>1985</YR>
<VL>53</VL>
<PG>83-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1995" NAME="Schneider 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME et al</AU>
<TI>Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial</TI>
<SO>Addiction</SO>
<YR>1995</YR>
<VL>90</VL>
<PG>1671-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1996" NAME="Schneider 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K</AU>
<TI>Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial [abstract]</TI>
<SO>Addiction</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>630</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K</AU>
<TI>Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo controlled trial</TI>
<SO>Addiction</SO>
<YR>1996</YR>
<VL>91</VL>
<PG>1293-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnoll-2010a" MODIFIED="2012-10-10 16:02:30 +0100" MODIFIED_BY="[Empty name]" NAME="Schnoll 2010a" YEAR="2010">
<REFERENCE MODIFIED="2012-02-21 12:09:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M et al</AU>
<TI>Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2010</YR>
<VL>87</VL>
<NO>5</NO>
<PG>553-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-10 10:36:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA et al</AU>
<TI>Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010</YR>
<VL>152</VL>
<NO>3</NO>
<PG>144-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-07 16:27:33 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnoll RA, Wileyto EP, Lerman C</AU>
<TI>Extended duration therapy with transdermal nicotine may attenuate weight gain following smoking cessation</TI>
<SO>Addictive Behaviors</SO>
<YR>2012</YR>
<VL>37</VL>
<PG>565-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-08-17 16:53:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-17 16:53:21 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="00364156"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnoll-2010b" MODIFIED="2012-10-10 16:02:40 +0100" MODIFIED_BY="[Empty name]" NAME="Schnoll 2010b" YEAR="2010">
<REFERENCE MODIFIED="2012-02-10 11:50:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D et al</AU>
<TI>Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatment</TI>
<SO>Addictive Behaviors</SO>
<YR>2011</YR>
<VL>36</VL>
<NO>1-2</NO>
<PG>144-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-10 11:51:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D et al</AU>
<TI>Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology Program</TI>
<SO>Drug &amp; Alcohol Dependence</SO>
<YR>2010</YR>
<VL>107</VL>
<NO>2-3</NO>
<PG>237-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-08-17 16:52:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-17 16:52:19 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="00365508"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuurmans-2004" NAME="Schuurmans 2004" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;2004&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT</AU>
<TI>Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>634-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added 2004&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schuurmans MM, Diacon AH, van Biljon X, Westin A, Landfeldt B, Bolliger CT</AU>
<TI>Effect of pre-treatment with nicotine patch on withdrawal symptoms in smokers subsequently quitting with the nicotine patch: a double-blind randomised controlled trial [https://www.ersnetsecure.org/public/prg_congres.abstract?ww_i_presentation=6711)</TI>
<SO>European Respiratory Society Annual Congress, Stockholm</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Segnan-1991" NAME="Segnan 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Added to support subgroup analysis 2004&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Segnan N, Ponti A, Battista RN, Senore C, Rosso S, Shapiro SH et al</AU>
<TI>A randomized trial of smoking cessation interventions in general practice in Italy</TI>
<SO>Cancer Causes and Control</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added 2007&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Senore C, Battista RN, Ponti A, Segnan N, Shapiro SH, Rosso S et al</AU>
<TI>Comparing participants and nonparticipants in a smoking cessation trial: Selection factors associated with general practitioner recruitment activity</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1999</YR>
<VL>52</VL>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ref added 2007&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Senore C, Battista RN, Shapiro SH, Segnan N, Ponti A, Rosso S et al</AU>
<TI>Predictors of smoking cessation following physicians' counseling</TI>
<SO>Preventive Medicine</SO>
<YR>1998</YR>
<VL>27</VL>
<PG>412-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2002-_x0028_2mg_x0029_" NAME="Shiffman 2002 (2mg)" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;secondary reference to main trial report&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dresler CM, Shiffman S, Strahs KR</AU>
<TI>Safety profile of the new nicotine polacrilex lozenge (PO1 36)</TI>
<SO>Society for Research on Nicotine and Tobacco 8th Annual Meeting: Savannah, Georgia</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New trial 2002&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR</AU>
<TI>Efficacy of a nicotine lozenge for smoking cessation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>1267-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Dresler CM, Rohay JM</AU>
<TI>Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>83-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;added 2007&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S</AU>
<TI>Nicotine lozenge efficacy in light smokers</TI>
<SO>Drug &amp; Alcohol Dependence</SO>
<YR>2005</YR>
<VL>77</VL>
<PG>311-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S</AU>
<TI>Use of more nicotine lozenges leads to better success in quitting smoking</TI>
<SO>Addiction</SO>
<YR>2007</YR>
<VL>102</VL>
<PG>809-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2002-_x0028_4mg_x0029_" NAME="Shiffman 2002 (4mg)" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR</AU>
<TI>Efficacy of a nicotine lozenge for smoking cessation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>1267-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2009-_x0028_2mg_x0029_" MODIFIED="2012-02-10 15:09:53 +0000" MODIFIED_BY="[Empty name]" NAME="Shiffman 2009 (2mg)" YEAR="2009">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Ferguson SG, Strahs KR</AU>
<TI>Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>2</NO>
<PG>96-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2009-_x0028_4mg_x0029_" MODIFIED="2012-02-10 15:10:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Shiffman 2009 (4mg)" YEAR="2009">
<REFERENCE MODIFIED="2012-02-10 15:10:02 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Ferguson SG, Strahs KR</AU>
<TI>Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>2</NO>
<PG>96-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2009" MODIFIED="2012-08-10 14:41:22 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-21 12:09:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE et al</AU>
<TI>Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>22</NO>
<PG>2148-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sonderskov-1997" NAME="Sonderskov 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sonderskov J, Olsen J, Meillier L, Overvad OK, Sabroe S</AU>
<TI>[The effect of transdermal nicotine patches in smoking cessation. A randomized trial in pharmacy customers in Denmark] [Danish]</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1999</YR>
<VL>161</VL>
<PG>593-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New trial 1998/3 update&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K</AU>
<TI>Nicotine patches in smoking cessation: A randomized trial among over- the-counter customers in Denmark</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1997</YR>
<VL>145</VL>
<PG>309-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stapleton-1995" MODIFIED="2012-02-21 12:10:14 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Stapleton 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-02-21 12:10:14 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NOTES="&lt;p&gt;reference adde 2001/3&lt;/p&gt;" NOTES_MODIFIED="2012-02-21 12:10:14 +0000" NOTES_MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell MAH, Stapleton JA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U et al</AU>
<TI>Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6888</NO>
<PG>1308-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stapleton JA, Russell MAH, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U et al</AU>
<TI>Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice</TI>
<SO>Addiction</SO>
<YR>1995</YR>
<VL>90</VL>
<PG>31-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutherland-1992" NAME="Sutherland 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stapleton JA, Sutherland G, Russell MAH</AU>
<TI>How much does relapse after one year erode effectiveness of smoking cessation treatments? Long term follow up of randomised trial of nicotine nasal spray</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7134</NO>
<PG>830-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M et al</AU>
<TI>Randomised controlled trial of nasal nicotine spray in smoking cessation</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>324-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TNSG-1991" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="TNSG 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E et al</AU>
<TI>The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day</TI>
<SO>Preventive Medicine</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson SG, Gitchell JG, Shiffman S, Sembower MA</AU>
<TI>Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers</TI>
<SO>Clinical Therapeutics</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1957-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Based on TNSG 1991 results. Add to refs&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Jack LM, Ward MM</AU>
<TI>Subgroups of smokers with different success rates after use of transdermal nicotine</TI>
<SO>Addiction</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>207-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Transdermal Nicotine Study Group</AU>
<TI>Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>266</VL>
<PG>3133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnesen-1988" MODIFIED="2012-03-26 10:14:38 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Tonnesen 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, Forchammer H et al</AU>
<TI>Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnesen-1991" NAME="Tonnesen 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikkelsen KL, Tonnesen P, Norregaard J</AU>
<TI>Three-year outcome of two- and three-year sustained abstainers from a smoking cessation study with nicotine patches</TI>
<SO>Journal of Smoking-Related Disorders</SO>
<YR>1994</YR>
<VL>5</VL>
<PG>95-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norregaard J, Tonnesen P, Petersen L</AU>
<TI>Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches</TI>
<SO>Preventive Medicine</SO>
<YR>1993</YR>
<VL>22</VL>
<PG>261-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Placebo n quit corrected from 2 to 4 in 2007&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Norregaard J, Sawe U</AU>
<TI>Two-year outcome in a smoking cessation trial with a nicotine patch</TI>
<SO>Journal of Smoking-Related Disorders</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>241-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Placebo n quit corrected from 2 to 4 in 2007&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Norregaard J, Simonsen K, Sawe U</AU>
<TI>A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>311-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Norregaard J, Simonsen K, Sawe U</AU>
<TI>A double-blind trial of nicotine patches in smoking cessation [Danish]</TI>
<TO>En dobbeltblind undersogelse af nikotinplaster ved rygeafvaenning</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1992</YR>
<VL>154</VL>
<PG>251-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnesen-1993" NAME="Tonnesen 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F</AU>
<TI>A double-blind trial of a nicotine inhaler for smoking cessation</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>269</VL>
<PG>1268-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnesen-2000" NAME="Tonnesen 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;New for 2001&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Mikkelsen KL</AU>
<TI>Smoking cessation with four nicotine replacement regimes in a lung clinic</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>717-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnesen-2006" NAME="Tonnesen 2006" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pbert L</AU>
<TI>Nurse-conducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>130</VL>
<PG>314-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Mikkelsen K, Bremann L</AU>
<TI>Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>130</VL>
<PG>334-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-T_x00f8_nnesen-2012" MODIFIED="2012-10-16 16:41:53 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Tønnesen 2012" YEAR="2011">
<REFERENCE MODIFIED="2012-10-16 16:41:41 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="OTHER">
<AU>Tønnesen P, Lauri H, Perfekt R, Mann K, Batra A</AU>
<TI>Efficacy and safety of a novel nicotine mouth spray in smoking cessation: A randomized, placebo-controlled, double blind, multicenter study with 52-week follow up</TI>
<SO>Poster Presented at SRNT, Feb 16-19th, 2011, Toronto, Canada</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-16 16:41:53 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tønnesen P, Lauri H, Perfekt R, Mann K, Batra A</AU>
<TI>Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double blind trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2012</YR>
<VL>40</VL>
<NO>3</NO>
<PG>548-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1183/09031936.00155811"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villa-1999" NAME="Villa 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;New study for 2000&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villa RS, Alvarez ABD, Hermida JRF</AU>
<TI>Effectiveness of a multicomponent program to quit smoking with and without nicotine chewing gum [Spanish]</TI>
<TO>Eficacia de un programa multicomponente para dejar de fumar con y sin chicle de nicotina</TO>
<SO>Psicologia Conductual</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>107-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallstrom-2000" NAME="Wallstrom 2000" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Pharmacia &amp; Upjohn</AU>
<SO>Nicorette Nicotine Microtab Monograph</SO>
<YR>1998</YR>
<PG>Adis International, 1998</PG>
<PB>Adis International</PB>
<CY>Chester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Wallstrom M, Nilsson F, Hirsch JM</AU>
<TI>A double-blind placebo controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>Suppl 25</NO>
<PG>440S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New study for 1999/3 update based on unpublished data. Details from full publication added 2001/3 and year changed&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wallstrom M, Nilsson F, Hirsch JM</AU>
<TI>A randomized double-blind placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation</TI>
<SO>Addiction</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>8</NO>
<PG>1161-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wennike-2003a" MODIFIED="2012-10-09 14:35:38 +0100" MODIFIED_BY="Kate Cahill" NAME="Wennike 2003a" YEAR="2003">
<REFERENCE MODIFIED="2012-10-09 14:35:38 +0100" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P</AU>
<TI>Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up</TI>
<SO>Addiction</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>10</NO>
<PG>1395-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Westman-1993" NAME="Westman 1993" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Westman EC, Levin ED, Rose JE</AU>
<TI>The nicotine patch in smoking cessation. A randomized trial with telephone counseling</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1993</YR>
<VL>153</VL>
<PG>1917-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wisborg-2000" NAME="Wisborg 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;New study 2002, previously omitted from NRT review in error&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wisborg K, Henriksen TB, Jespersen LB, Secher NJ</AU>
<TI>Nicotine patches for pregnant smokers: A randomized controlled study</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>6</NO>
<PG>967-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wittchen-2011" MODIFIED="2012-10-16 15:17:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Wittchen 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-16 15:17:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wittchen HU, Hoch E, Klotsche J, Muehlig S</AU>
<TI>Smoking cessation in primary care - a randomized controlled trial of bupropion, nicotine replacements, CBT and a minimal intervention</TI>
<SO>International Journal of Methods in Psychiatric Research</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>1</NO>
<PG>28-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-1999" NAME="Wong 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD</AU>
<TI>A randomized trial of naltrexone for smoking cessation</TI>
<SO>Addiction</SO>
<YR>1999</YR>
<VL>94</VL>
<PG>1227-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zelman-1992" NAME="Zelman 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zelman DC, Brandon TH, Jorenby DE, Baker TB</AU>
<TI>Measures of affect and nicotine dependence predict differential response to smoking cessation treatments</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1992</YR>
<VL>60</VL>
<PG>943-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-10-16 16:54:05 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adelman-2009" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Adelman 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adelman WP</AU>
<TI>Nicotine nasal spray neither effective nor well-tolerated by adolescent smokers</TI>
<SO>Journal of Pediatrics</SO>
<YR>2009</YR>
<VL>154</VL>
<NO>3</NO>
<PG>462-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-2005" NAME="Allen 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allen SS, Hatsukami D, Brintnell DM, Bade T</AU>
<TI>Effect of nicotine replacement therapy on post-cessation weight gain and nutrient intake: A randomized controlled trial of postmenopausal female smokers</TI>
<SO>Addictive Behaviors</SO>
<YR>2005</YR>
<VL>30</VL>
<PG>1273-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen SS, Hatsukami DK, Bade T, Center B</AU>
<TI>Transdermal nicotine use in postmenopausal women: does the treatment efficacy differ in women using and not using hormone replacement therapy?</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>5</NO>
<PG>777-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-2011" MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen MH, Debanne M, Lazignac C, Adam E, Dickinson LM, Damsa C</AU>
<TI>Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2011</YR>
<VL>168</VL>
<NO>4</NO>
<PG>395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aubin-2006" NAME="Aubin 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aubin HJ, Luthringer R, Demazieres A, Dupont C, Lagrue G</AU>
<TI>Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>193-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Batra-2005" NAME="Batra 2005" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T</AU>
<TI>Smoking reduction treatment with 4-mg nicotine gum: A double-blind, randomized, placebo-controlled study</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2005</YR>
<VL>78</VL>
<PG>689-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Landfeldt B, Batra A, Friederich HM, Klingler K, Westin A</AU>
<TI>Smoking reduction with a 4 mg nicotine gum - final results from a placebo-controlled trial over 13 months</TI>
<SO>Society for Research on Nicotine and Tobacco 5th European Meeting November 20-22 2003 Padua: Abstract book</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlin-2011" MODIFIED="2012-02-13 13:03:09 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Berlin 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-13 13:03:09 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berlin I, Jacob N, Coudert M, Perriot J, Schultz L, Rodon N</AU>
<TI>Adjustment of nicotine replacement therapies according to saliva cotinine concentration: the ADONIS* trial-a randomized study in smokers with medical comorbidities</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>4</NO>
<PG>833-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-13 13:03:09 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlin I, Singleton EG, Heishman SJ</AU>
<TI>Validity of the 12-item French version of the Tobacco Craving Questionnaire in treatment-seeking smokers</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>5</NO>
<PG>500-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bock-2010" MODIFIED="2012-02-09 09:17:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Bock 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-02-09 09:17:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bock BC, Hudmon KS, Christian J, Graham AL, Bock FR</AU>
<TI>A tailored intervention to support pharmacy-based counseling for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>217-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolliger-2000" NAME="Bolliger 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A et al</AU>
<TI>Influence of long-term smoking reduction on health risk markers and quality of life</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>433-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;new 2001/3 update, moved to excluded 2008&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A et al</AU>
<TI>Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<NO>7257</NO>
<PG>329-333</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT</AU>
<TI>Practical experiences in smoking reduction and cessation</TI>
<SO>Addiction</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>1 S1</NO>
<PG>S19-S24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolliger-2007" NAME="Bolliger 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT, van B, X, Axelsson A</AU>
<TI>A Nicotine Mouth Spray for Smoking Cessation: A Pilot Study of Preference, Safety and Efficacy</TI>
<SO>Respiration</SO>
<YR>2007</YR>
<VL>74</VL>
<PG>196-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brantmark-1973" NAME="Brantmark 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brantmark B, Ohlin P, Westling H</AU>
<TI>Nicotine-containing chewing gum as an anti-smoking aid</TI>
<SO>Psychopharmacologia</SO>
<YR>1973</YR>
<VL>31</VL>
<PG>191-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-2003" NAME="Carpenter 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter MJ, Hughes JR, Keely JP</AU>
<TI>Effect of smoking reduction on later cessation: a pilot experimental study</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>155-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-2011" MODIFIED="2012-02-13 13:44:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Carpenter 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-13 13:44:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter MJ, Alberg AJ, Gray KM, Saladin ME</AU>
<TI>Motivating the unmotivated for health behavior change: a randomized trial of cessation induction for smokers</TI>
<SO>Clinical Trials</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>2</NO>
<PG>157-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-13 13:44:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ</AU>
<TI>Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2011</YR>
<VL>171</VL>
<NO>21</NO>
<PG>1901-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2010" MODIFIED="2012-02-21 12:10:38 +0000" MODIFIED_BY="[Empty name]" NAME="Chan 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-02-21 12:10:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan SS, Leung DY, Abdullah AS, Lo SS, Yip AW, Kok WM et al</AU>
<TI>Smoking-cessation and adherence intervention among Chinese patients with erectile dysfunction</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>3</NO>
<PG>251-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2011" MODIFIED="2012-02-13 13:53:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Chan 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-13 13:53:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan SS, Leung DY, Abdullah AS, Wong VT, Hedley AJ, Lam TH</AU>
<TI>A randomized controlled trial of a smoking reduction plus nicotine replacement therapy intervention for smokers not willing to quit smoking</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1155-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chou-2004" NAME="Chou 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou KR, Chen R, Lee JF, Ku CH, Lu RB</AU>
<TI>The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia</TI>
<SO>International Journal of Nursing Studies</SO>
<YR>2004</YR>
<VL>41</VL>
<PG>321-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christen-1984" NAME="Christen 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christen AG, Drook C, McDonald JL, Stookey G, Olson B</AU>
<TI>Efficacy of nicotine chewing gum in facilitating smoking cessation</TI>
<SO>Journal of the American Dental Association</SO>
<YR>1984</YR>
<VL>108</VL>
<PG>594-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1989a" NAME="Cohen 1989a" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen SJ, Stookey GK, Katz BP, Drook CA, Christen AG</AU>
<TI>Helping smokers quit: a randomized controlled trial with private practice dentists</TI>
<SO>Journal of the American Dental Association</SO>
<YR>1989</YR>
<VL>118</VL>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1989b" NAME="Cohen 1989b" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen SJ, Stookey GK, Katz BP, Drook CA, Smith DM</AU>
<TI>Encouraging primary care physicians to help smokers quit. A randomised, controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1989</YR>
<VL>110</VL>
<PG>648-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croghan-2007" MODIFIED="2012-02-21 12:10:53 +0000" MODIFIED_BY="[Empty name]" NAME="Croghan 2007" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clark MM, Hurt RD, Croghan I, Patten CA, Novotny P, Sloan JA et al</AU>
<TI>The prevalence of weight concerns in a smoking abstinence clinical trial (POS2-84)</TI>
<SO>Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croghan IT, Hurt RD, Croghan GA, Sloan JA</AU>
<TI>Comparing nicotine inhaler, bupropion and nicotine inhaler plus bupropion in treating tobacco dependence [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>4</NO>
<PG>680-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ et al</AU>
<TI>Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2007</YR>
<VL>82</VL>
<PG>186-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-21 12:10:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croghan IT, Hurt RD, Ebbert JO, Croghan GA, Polk J, Stella PJ et al</AU>
<TI>Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States</TI>
<SO>Journal of Public Health</SO>
<YR>2010</YR>
<VL>18</VL>
<PG>59-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-2011" MODIFIED="2012-02-13 13:57:04 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Cummings 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-13 13:57:03 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings KM, Hyland A, Carlin-Menter S, Mahoney MC, Willett J, Juster HR</AU>
<TI>Costs of giving out free nicotine patches through a telephone quit line</TI>
<SO>Journal of Public Health Management &amp; Practice</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>3</NO>
<PG>E16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dey-1999" NAME="Dey 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dey P, Foy R, Woodman M, Fullard B, Gibbs A</AU>
<TI>Should smoking cessation cost a packet? A pilot randomized controlled trial of the cost-effectiveness of distributing nicotine therapy free of charge</TI>
<SO>British Journal of General Practice</SO>
<YR>1999</YR>
<VL>49</VL>
<PG>127-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donny-2009" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Donny 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donny EC, Jones M</AU>
<TI>Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine</TI>
<SO>Drug &amp; Alcohol Dependence</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>1-2</NO>
<PG>23-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebbert-2009" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Ebbert 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR</AU>
<TI>A randomized clinical trial of nicotine lozenge for smokeless tobacco use</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>12</NO>
<PG>1415-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebbert-2010" MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" NAME="Ebbert 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR</AU>
<TI>A pilot study of mailed nicotine lozenges with assisted self-help for the treatment of smokeless tobacco users</TI>
<SO>Addictive Behaviors</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>5</NO>
<PG>522-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elan-Pharm-88_x002d_02" NAME="Elan Pharm 88-02" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Elan Pharmaceutical Research Corp</AU>
<TI>NDA 19-983 for Approval of PROSTEP</TI>
<SO>Study 88-02</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elan-Pharm-90_x002d_03" NAME="Elan Pharm 90-03" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Elan Pharmaceutical Research Corp</AU>
<TI>NDA 19-983 for Approval of PROSTEP</TI>
<SO>Study 90-03</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etter-2004" NAME="Etter 2004" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dar R, Stronguin F, Etter JF</AU>
<TI>Assigned versus perceived placebo effects in nicotine replacement therapy for smoking reduction in Swiss smokers</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>2005</YR>
<VL>73</VL>
<PG>350-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Long term data added 2007&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Etter JF, Laszlo E, Perneger TV</AU>
<TI>Postintervention effect of nicotine replacement therapy on smoking reduction in smokers who are unwilling to quit: Randomized trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2</NO>
<PG>174-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV</AU>
<TI>Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>487-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fagerstrom-1993" NAME="Fagerstrom 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO, Schneider NG, Lunell E</AU>
<TI>Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>1993</YR>
<VL>111</VL>
<PG>271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fagerstrom-1997" NAME="Fagerstrom 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO, Tejding R, Westin A, Lunell E</AU>
<TI>Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?</TI>
<SO>Tobacco Control</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>311-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fagerstrom-2000" NAME="Fagerstrom 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;added 2001/3&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO, Hughes JR, Rasmussen T, Callas PW</AU>
<TI>Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit</TI>
<SO>Tobacco Control</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>327-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferguson-2012" MODIFIED="2012-08-22 14:02:46 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Ferguson 2012" YEAR="2009">
<REFERENCE MODIFIED="2012-08-22 14:02:45 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coleman T, McEwen A, Bauld L, Ferguson J, Lorgelly P, Lewis S</AU>
<TI>Protocol for the Proactive Or Reactive Telephone Smoking CeSsation Support (PORTSSS) trial</TI>
<SO>Trials [Electronic Resource]</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-22 14:02:45 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson J, Docherty G, Bauld L, Lewis S, Lorgelly P, Boyd KA et al</AU>
<TI>Effect of offering different levels of support and free nicotine replacement therapy via an English national telephone quitline: randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>March 2012</YR>
<VL>344</VL>
<PG>e1696</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1136/bmj.e1696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Finland-unpublished" NAME="Finland unpublished" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Booklet in file. Not found online 2007&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Combination NRT; Improving efficacy in smoking cessation</TI>
<SO>McNeil Consumer Healthcare booklet, 2007. Short term outcomes reported on p17</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foulds-1993" NAME="Foulds 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foulds J, Stapleton J, Hayward M, Russell MA, Feyerabend C, Fleming T et al</AU>
<TI>Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial</TI>
<SO>Archives of Family Medicine</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Garvey-2006" MODIFIED="2012-02-14 10:22:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Garvey 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-02-14 10:22:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Garvey AJ, Hoskinson RA, Wadler BM, Kinnunen T, Sachs DPL</AU>
<TI>Individualising nicotine patch dose to match smokers' usual nicotine intake levels (PA9-4)</TI>
<SO>Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida</SO>
<YR>2006</YR>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-14 10:22:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mustonen TK, Spencer SM, Hoskinson RA, Sachs DPL, Garvey AJ</AU>
<TI>The influence of gender, race, and menthol content on tobacco exposure measures</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>581-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glover-1992" NAME="Glover 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Needs reason for exclusion - when added?&lt;/p&gt;" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Glover ED, Glover PN, Sullivan CR, Sullivan P, Nilsson F, Sawe U</AU>
<TI>Nicotine inhaler versus placebo in smoking cessation [abstract 237]</TI>
<SO>Abstracts from the 8th World Conference on Tobacco or Health, Buenos Aires, Argentina</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gross-1989" MODIFIED="2011-08-17 15:14:55 +0100" MODIFIED_BY="[Empty name]" NAME="Gross 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-08-17 15:14:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gross J, Stitzer ML, Maldonado J</AU>
<TI>Nicotine replacement: effects on postcessation weight gain</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1989</YR>
<VL>57</VL>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2006" MODIFIED="2012-02-14 13:32:34 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Guo 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-02-14 13:32:34 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo S, Sun H, Niu G, Gao J, Yang X, Zhou D</AU>
<TI>The smoking cessation efficacy of nicotine sublingual tablet: A double-blind, placebo controlled trial</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>39</VL>
<NO>2</NO>
<PG>102-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hajek-1999" NAME="Hajek 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A</AU>
<TI>Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>2033-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;NRT discussion&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A</AU>
<TI>A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2000</YR>
<VL>149</VL>
<PG>198-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanson-2003" MODIFIED="2012-10-03 08:43:45 +0100" MODIFIED_BY="[Empty name]" NAME="Hanson 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dickmann PJ, Mooney ME, Allen SS, Hanson K, Hatsukami DK</AU>
<TI>Nicotine withdrawal and craving in adolescents: effects of sex and hormonal contraceptive use</TI>
<SO>Addictive Behaviors</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>6-7</NO>
<PG>620-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-03 08:43:45 +0100" MODIFIED_BY="Kate Cahill" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanson K, Allen S, Jensen S, Hatsukami D</AU>
<TI>Treatment of adolescent smokers with the nicotine patch</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>4</NO>
<PG>515-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haustein-2003" NAME="Haustein 2003" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haustein KO, Batra A, Landfeldt B, Westin A</AU>
<TI>The effect of short-term or long-term reduction on smoking cessation; results from a placebo controlled smoking reduction study with the nicotine gum</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>278</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Pfizer document does not have a clear explanatory title. The title is my description of the report.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Pfizer</AU>
<TI>Summary of Clinical Efficacy. Application for licensing of Nicorette Inhalator/Gum for smoking reduction leading to cessation</TI>
<SO>Company data NICORE-1013-273-SU</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoch-2006" MODIFIED="2012-02-14 10:24:31 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Hoch 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-02-14 10:24:31 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Hoch E, Wittchen HU</AU>
<TI>Population health perspective on smoking cessation: A randomized controlled trial of different methods in primary health care (RPOS 3-71)</TI>
<SO>Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-14 10:24:31 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sonntag H, Hoch E, Jahn B, Spiegel B, Pfister H, Wittchen HU</AU>
<TI>Smoking cessation in primary care: implementation effectiveness and optimized allocation</TI>
<SO>Suchtmedizin in Forschung und Praxis</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hotham-2006" NAME="Hotham 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hotham ED, Gilbert AL, Atkinson ER</AU>
<TI>A randomised-controlled pilot study using nicotine patches with pregnant women</TI>
<SO>Addictive Behaviors</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>641-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1989b" NAME="Hughes 1989b" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Gulliver SB, Amori G, Mireault GC, Fenwick JF</AU>
<TI>Effect of instructions and nicotine on smoking cessation, withdrawal symptoms and self-administration of nicotine gum</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>1989</YR>
<VL>99</VL>
<PG>486-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurt-1995" NAME="Hurt 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Dale LC, Offord KP, Croghan IT, Hays JT, Gomez Dahl L</AU>
<TI>Nicotine patch therapy for smoking cessation in recovering alcoholics</TI>
<SO>Addiction</SO>
<YR>1995</YR>
<VL>90</VL>
<NO>11</NO>
<PG>1541-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurt-2003" NAME="Hurt 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ et al</AU>
<TI>Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>5</NO>
<PG>914-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarvik-1984" NAME="Jarvik 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvik ME, Schneider NG</AU>
<TI>Degree of addiction and effectiveness of nicotine gum therapy for smoking</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<PG>790-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jibrail-2010" MODIFIED="2012-02-03 11:31:14 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Jibrail 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-02-03 11:31:14 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jibrail JJ, Cortas NK, Sarieddine DS, Kanj NA, Zaatari GS, Daher RT</AU>
<TI>Impact of nicotine metabolite monitoring on the efficacy of smoke cessation and usefulness of sequential CRP measurements</TI>
<SO>American Journal of Respiratory Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<PG>A2652</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapur-2001" NAME="Kapur 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Not found in Medline&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapur B, Hackman R, Selby P, Klein J, Koren G</AU>
<TI>Randomized, double-blind, placebo-controlled trial of nicotine replacement therapy in pregnancy</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>2001</YR>
<VL>62</VL>
<PG>274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Korberly-1999" NAME="Korberly 1999" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Ref added 2004. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Korberly B, Gustavsson G, Kruse E</AU>
<TI>Over-the-counter efficacy of a 15 mg daytime nicotine patch for smoking cessation: a randomized multicenter trial</TI>
<SO>Abstract book. Society for Research on Nicotine and Tobacco 4th European Conference October 3-5 Santander, Spain</SO>
<YR>2002</YR>
<PG>23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Korberly BH, Maguire MK</AU>
<TI>An open label multicenter trial to evaluate and compare the efficacy of nicotrol 15mg as part of an OTC intervention package or as a prescription as an aid in smoking cessation</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco Fifth Annual Meeting, San Diego CA</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kozak-1995" NAME="Kozak 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kozak J, Fagerstrom KO, Sawe U</AU>
<TI>High-dose treatment with the nicotine patch</TI>
<SO>International Journal of Smoking Cessation</SO>
<YR>1995</YR>
<VL>4</VL>
<NO>2</NO>
<PG>26-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kras-2010" MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kras 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kras M, Stough C, Scholey A, Kure C, Camfield D</AU>
<TI>Hypericum perforatum, nicotine patches and combination hypericum perforatum/nicotine patches for smoking cessation</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>20</VL>
<PG>S608-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krumpe-1989" NAME="Krumpe 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krumpe P, Malani N, Adler J</AU>
<TI>Efficacy of transdermal nicotine administration as an adjunct for smoking cessation in heavily nicotine addicted smokers</TI>
<SO>Annual Review of Respiratory Disease</SO>
<YR>1989</YR>
<VL>139</VL>
<PG>A337</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kupecz-1996" NAME="Kupecz 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kupecz D, Prochazka A</AU>
<TI>A comparison of nicotine delivery systems in a multimodality smoking cessation program</TI>
<SO>Nurse Practitioner</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>2</NO>
<PG>73,77-8,81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Landfeldt-1998" NAME="Landfeldt 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landfeldt B, Kruse E, Westin A, Mattson K, Lojander J</AU>
<TI>Nicotine replacement treatment in heavy smokers: nicotine nasal spray combined with nicotine patch in a double-blind controlled study (abstract)</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>Suppl 28</NO>
<PG>154S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leischow-1996b" NAME="Leischow 1996b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leischow SJ, Hill A, Cook G</AU>
<TI>The effects of transdermal nicotine for the treatment of hispanic smokers</TI>
<SO>American Journal of Health Behavior</SO>
<YR>1996</YR>
<VL>20</VL>
<PG>304-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-1994" NAME="Levin 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S et al</AU>
<TI>Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>41-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1996" NAME="Lin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin HN</AU>
<TI>The effectiveness of nicotine patch for smoking cessation</TI>
<SO>Chinese Psychiatry</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>29-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marsh-2005" NAME="Marsh 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marsh HS, Dresler CM, Choi JH, Targett DA, Gamble ML, Strahs KR</AU>
<TI>Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: A 12-week, randomized, open-label study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1571-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarthy-2006" NAME="McCarthy 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy DE, Piasecki TM, Fiore MC, Baker TB</AU>
<TI>Life before and after quitting smoking: an electronic diary study</TI>
<SO>Journal of Abnormal Psychology</SO>
<YR>2006</YR>
<VL>115</VL>
<NO>3</NO>
<PG>454-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McRobbie-2010" MODIFIED="2012-02-21 12:11:13 +0000" MODIFIED_BY="[Empty name]" NAME="McRobbie 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-02-21 12:11:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M et al</AU>
<TI>A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction</TI>
<SO>Addiction</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>7</NO>
<PG>1290-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meier-1990" NAME="Meier 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meier Lammermann E, Mayer M, Boleski PL</AU>
<TI>Combination of transdermal nicotine substitution and behavioural group therapy in smoking cessation</TI>
<SO>European Respiratory Journal</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>Suppl 10</NO>
<PG>168S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merz-1993" NAME="Merz 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Merz PG, Keller Stanislawski B, Huber T, Woodcock BG, Rietbrock N</AU>
<TI>Transdermal nicotine in smoking cessation and involvement of non- specific influences</TI>
<SO>International Journal of Clinical Pharmacology Therapy and Toxicology</SO>
<YR>1993</YR>
<VL>31</VL>
<PG>476-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2009" MODIFIED="2012-02-09 14:10:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Miller 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-09 14:10:39 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller CL, Sedivy V</AU>
<TI>Using a quitline plus low-cost nicotine replacement therapy to help disadvantaged smokers to quit</TI>
<SO>Tobacco Control</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>2</NO>
<PG>144-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millie-1989" NAME="Millie 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millie A, Berriau T, Paget D, Philardeau V, Postal MJ, Dautzenberg B et al</AU>
<TI>Can weight gain during weaning from smoking be limited using nicotine gum? [French]</TI>
<TO>Peut-on limiter la prise de poids chez les fumeurs lors du sevrage tabagique en utilisant la gomme a la nicotine?</TO>
<SO>Revue de Pneumonologie Clinique</SO>
<YR>1989</YR>
<VL>45</VL>
<PG>243-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minneker-1989" NAME="Minneker 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;added 2001/3&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minneker E, Buchkremer G, Block M</AU>
<TI>The effect of different dosages of a transdermal nicotine substitution system on the success rate of smoking cessation therapy</TI>
<SO>Methods and Findings in Experimental and Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molander-2000" NAME="Molander 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Added 2001/3&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molander L, Lunell E, Fagerstrom KO</AU>
<TI>Reduction of tobacco withdrawal symptoms with a sublingual nicotine tablet: a placebo controlled study</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2000</YR>
<VL>2</VL>
<PG>187-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mooney-2005" NAME="Mooney 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mooney M, Babb D, Jensen J, Hatsukami D</AU>
<TI>Interventions to increase use of nicotine gum: A randomized, controlled, single-blind trial</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>4</NO>
<PG>565-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulligan-1990" NAME="Mulligan 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulligan SC, Masterson JG, Devane JG, Kelly JG</AU>
<TI>Clinical and pharmacokinetic properties of a transdermal nicotine patch</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>331-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nackaerts-2009" MODIFIED="2012-10-16 16:42:37 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Nackaerts 2009" YEAR="2008">
<REFERENCE MODIFIED="2012-10-16 16:42:37 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nackaerts K, Salhi B, Devolder A, Meysman M, Boudrez H, Van-Dyck L</AU>
<TI>A randomised, double-blind, placebo-controlled phase 3 study investigating the efficacy of nicotine substitution (NS) on nicotine withdrawal symptoms (NWS) in hospitalised smokers (HS) [Abstract]</TI>
<SO>European Respiratory Society Annual Congress, Vienna, Austria, September 12-16</SO>
<YR>2009</YR>
<PG>4632</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okuyemi-2007" NAME="Okuyemi 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuyemi KS, James AS, Mayo MS, Nollen N, Catley D, Choi WS et al</AU>
<TI>Pathways to health: a cluster randomized trial of nicotine gum and motivational interviewing for smoking cessation in low-income housing</TI>
<SO>Health Education &amp; Behavior</SO>
<YR>2007</YR>
<VL>34</VL>
<PG>43-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oncken-2009" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Oncken 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oncken C, Campbell W, Chan G, Hatsukami D, Kranzler HR</AU>
<TI>Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>9</NO>
<PG>751-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pomerleau-2003" NAME="Pomerleau 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;2004&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lerman C, Audrain J, Patterson F, Kaufmann V, Rukstalis M, Wileyto EP et al</AU>
<TI>Differential response to nicotine replacement therapies in obese and non-obese women (PA2-6)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;2004&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pomerleau OF, Pomerleau CS, Marks JL, Snedecor SM, Mehringer AM, Namenek-Brouwer RJ et al</AU>
<TI>Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>1</NO>
<PG>13-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rennard-2006" NAME="Rennard 2006" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Tobias says submitted for publication&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rennard SI, Glover E, Leischow S, Daughton DM, Glover P, Muramoto M</AU>
<TI>Efficacy of nicotine inhaler in smoking reduction</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>380</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M et al</AU>
<TI>Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>555-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rey-2009" MODIFIED="2012-10-16 15:26:11 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Rey 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-16 15:26:11 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rey L, Vaucher P, Secretan F, Zellweger JP, Bodenmann P</AU>
<TI>Use of nicotine substitute prescribed at hourly plus ad libitum intake or ad libitum for heavy smokers willing to quit: a randomized controlled trial</TI>
<SO>Substance Abuse Treatment, Prevention, &amp; Policy</SO>
<YR>2009</YR>
<VL>4</VL>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rigotti-2009" MODIFIED="2012-02-09 15:58:24 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Rigotti 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-09 15:58:20 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y, CIRRUS Study Group</AU>
<TI>A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain</TI>
<SO>Addiction</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>2</NO>
<PG>266-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roddy-2006" NAME="Roddy 2006" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roddy E, Romilly N, Challenger A, Lewis S, Britton J</AU>
<TI>Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial</TI>
<SO>Tobacco Control</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>373-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-1990" NAME="Rose 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Levin ED, Behm FM, Adivi C, Schur C</AU>
<TI>Transdermal nicotine facilitates smoking cessation</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>323-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubinstein-2008" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Rubinstein 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB</AU>
<TI>A randomized trial of nicotine nasal spray in adolescent smokers</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>3</NO>
<PG>e595-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachs-1995" NAME="Sachs 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sachs DPL</AU>
<TI>Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<PG>1973-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-2004" MODIFIED="2012-10-16 16:54:05 +0100" MODIFIED_BY="[Empty name]" NAME="Schneider 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-10-16 16:54:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Olmstead RE, Nides M, Mody FV, Otte Colquette P, Doan K et al</AU>
<TI>Comparative testing of 5 nicotine systems: initial use and preferences</TI>
<SO>Amercian Journal of Health Behavior</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>1</NO>
<PG>72-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-2008" MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" NAME="Schneider 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Cortner C, Gould JL, Koury MA, Olmstead RE</AU>
<TI>Comparison of craving and withdrawal among four combination nicotine treatments</TI>
<SO>Human Psychopharmacology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>6</NO>
<PG>513-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shahab-2011" MODIFIED="2012-02-13 16:15:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Shahab 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-13 16:14:50 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shahab L, McEwen A, West R</AU>
<TI>Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial</TI>
<SO>Psychopharmacology</SO>
<YR>2011</YR>
<VL>216</VL>
<NO>2</NO>
<PG>187-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2000a" NAME="Shiffman 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Khayrallah M, Nowak R</AU>
<TI>Efficacy of the nicotine patch for relief of craving and withdrawal 7-10 weeks after cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2000</YR>
<VL>2</VL>
<PG>371-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2000b" NAME="Shiffman 2000b" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB et al</AU>
<TI>Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving</TI>
<SO>Addiction</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>8</NO>
<PG>1185-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2002a" MODIFIED="2012-09-19 13:08:36 +0100" MODIFIED_BY="Lindsay Stead" NAME="Shiffman 2002a" YEAR="2002">
<REFERENCE MODIFIED="2012-09-19 13:08:33 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson SG, Gitchell JG, Shiffman S</AU>
<TI>Continuing to wear nicotine patches after smoking lapses promotes recovery of abstinence</TI>
<SO>Addiction</SO>
<YR>2012</YR>
<VL>107</VL>
<NO>7</NO>
<PG>1349-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Shiffman S, Dresler CM, Gorsline J, Dimarino ME</AU>
<TI>The efficacy of nicotine patch in an over-the-counter environment: results from a randomized, double-blind, placebo-controlled trial (PO130)</TI>
<SO>Abstract book, 11th World Conference on Tobacco or Health, 6-11 August, Chicago, Illinois</SO>
<YR>2000</YR>
<VL>1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added 2004 and excluded study ID changed&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Gorsline J, Gorodetzky CW</AU>
<TI>Efficacy of over-the-counter nicotine patch</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>477-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2002b" NAME="Shiffman 2002b" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang YK et al</AU>
<TI>Real-world efficacy of prescription and over-the-counter nicotine replacement therapy</TI>
<SO>Addiction</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>505-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2006" MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Shiffman 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson SG, Shiffman S, Gwaltney CJ</AU>
<TI>Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2006</YR>
<VL>74</VL>
<PG>1153-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-21 18:14:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson SG, Shiffman S</AU>
<TI>Effect of high-dose nicotine patch on the characteristics of lapse episodes</TI>
<SO>Health Psychology</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>358-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG</AU>
<TI>Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>184</VL>
<NO>3-4</NO>
<PG>637-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Ferguson SG, Gwaltney CJ</AU>
<TI>Immediate hedonic response to smoking lapses: Relationship to smoking relapse, and effects of nicotine replacement therapy</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>184</VL>
<NO>3-4</NO>
<PG>608-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-18 12:56:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Kirchner TR</AU>
<TI>Cigarette-by-cigarette satisfaction during ad libitum smoking</TI>
<SO>Journal of Abnormal Psychology</SO>
<YR>2009</YR>
<VL>118</VL>
<NO>2</NO>
<PG>348-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM et al</AU>
<TI>Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>2006</YR>
<VL>74</VL>
<PG>276-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH</AU>
<TI>Attentional bias predicts outcome in smoking cessation</TI>
<SO>Health Psychology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>378-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH</AU>
<TI>Cue-provoked craving and nicotine replacement therapy in smoking cessation</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2004</YR>
<VL>72</VL>
<NO>6</NO>
<PG>1136-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stapleton-2011" MODIFIED="2012-02-13 16:21:01 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Stapleton 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-13 16:20:36 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stapleton JA, Sutherland G</AU>
<TI>Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>4</NO>
<PG>824-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2009" MODIFIED="2012-02-21 12:11:38 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-21 12:11:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun HQ, Guo S, Chen DF, Jiang ZN, Liu Y, Di XL et al</AU>
<TI>Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in Chinese smokers</TI>
<SO>American Journal of Drug &amp; Alcohol Abuse</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>3</NO>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sussman-2004" MODIFIED="2012-02-14 13:00:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Sussman 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-02-14 13:00:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sussman S, McCuller WJ, Zheng H, Pfingston YM, Miyano J, Dent CW</AU>
<TI>Project EX: A Program of Empirical Research on Adolescent Tobacco Use Cessation</TI>
<SO>Tob Induc Dis</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>3</NO>
<PG>119-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutherland-1999" NAME="Sutherland 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Booklet in file. Not found online 2007&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Combination NRT; Improving efficacy in smoking cessation</TI>
<SO>McNeil Consumer Healthcare booklet. Short term outcomes reported on p18</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added to excluded studies 2002/4 update&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland G</AU>
<TI>A placebo-controlled double-blind combination trial of nicotine spray and patch [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>186</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutherland-2005" NAME="Sutherland 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland G, Stapleton JA, Russell MA</AU>
<TI>Randomized placebo-controlled trial of nicotine nasal spray in general practice</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>4</NO>
<PG>686</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-1987" NAME="Sutton 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutton S, Hallett R</AU>
<TI>Randomized trial of brief individual treatment for smoking using nicotine chewing gum in a workplace setting</TI>
<SO>American Journal of Public Health</SO>
<YR>1987</YR>
<VL>77</VL>
<PG>1210-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87296451"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-1988" NAME="Sutton 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutton S, Hallett R</AU>
<TI>Smoking intervention in the workplace using videotapes and nicotine chewing gum</TI>
<SO>Preventive Medicine</SO>
<YR>1988</YR>
<VL>17</VL>
<PG>48-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thorsteinsson-2001" NAME="Thorsteinsson 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;One year follow-up planned but not reported here. Add to excluded studies.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorsteinsson HS, Gillin JC, Patten CA, Golshan S, Sutton LD, Drummond S et al</AU>
<TI>The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>4</NO>
<PG>350-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnesen-1996" MODIFIED="2011-08-17 14:41:42 +0100" MODIFIED_BY="[Empty name]" NAME="Tonnesen 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-08-17 14:41:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Mikkelsen K, Norregaard J, Jorgensen S</AU>
<TI>Recycling of hard-core smokers with nicotine nasal spray</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>1619-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsukahara-2010" MODIFIED="2012-02-09 16:17:50 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Tsukahara 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-02-09 16:17:28 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsukahara H, Noda K, Saku K</AU>
<TI>A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study)</TI>
<SO>Circulation Journal</SO>
<YR>2010</YR>
<VL>74</VL>
<NO>4</NO>
<PG>771-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tundulawessa-2010" MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" NAME="Tundulawessa 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-17 17:56:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tundulawessa Y, Yongchaiyud P, Chutrthong W, Tundulawessa K</AU>
<TI>The bioequivalent and effect of nicotine formulation gum on smoking cessation</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2010</YR>
<VL>93</VL>
<NO>5</NO>
<PG>574-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tzivoni-1998" NAME="Tzivoni 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Added 2004&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P</AU>
<TI>Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>239-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Uyar-2005" NAME="Uyar 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uyar M, Bayram N, Filiz A, Elbek O, Topçu A, Dikensoy O et al</AU>
<TI>Comparison of nicotine patch and bupropion in treating tobacco dependence</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>Suppl 49</NO>
<PG>388s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Velicer-2006" NAME="Velicer 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Velicer WF, Friedman RH, Fava JL, Gulliver SB, Keller S, Sun X et al</AU>
<TI>Evaluating nicotine replacement therapy and stage-based therapies in a population-based effectiveness trial</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>2006</YR>
<VL>74</VL>
<PG>1162-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Velicer WF, Keller S, Friedman RH, Fava JL, Gulliver SB, Ward RM et al</AU>
<TI>Comparing participants and nonparticipants recruited for an effectiveness study of nicotine replacement therapy</TI>
<SO>Annals of Behavioral Medicine</SO>
<YR>2005</YR>
<VL>29</VL>
<PG>181-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vial-2002" NAME="Vial 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vial RJ, Jones TE, Ruffin RE, Gilbert AL</AU>
<TI>Smoking cessation program using nicotine patches linking hospital to the community</TI>
<SO>Journal of Pharmacy Practice and Research</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vikhireva-2003" MODIFIED="2012-02-14 08:16:44 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Vikhireva 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-02-14 08:16:44 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vikhireva O, Shalnova S, Deev A, Levshin V, Radkevich N, Kalinina A</AU>
<TI>NRT-assisted cessation in Russia: individual and population level benefits</TI>
<SO>Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-14 08:16:44 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NOTES="&lt;p&gt;2004&lt;/p&gt;" NOTES_MODIFIED="2012-02-14 08:16:44 +0000" NOTES_MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Vikhireva O, Shalnova S, Deev A</AU>
<TI>Nicotine replacement therapy in Russia: old wine in new skins? Randomized parallel study of nicotine gum/inhaler in smoking cessation/reduction</TI>
<SO>Abstract book. Society for Research on Nicotine and Tobacco. Fifth European Conference. November 20-22nd, Padua, Italy</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-2011" MODIFIED="2012-02-21 12:11:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Walker 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-21 12:11:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H et al</AU>
<TI>Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1176-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warner-2005" NAME="Warner 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warner DO, Patten CA, Ames SC, Offord KP, Schroeder DR</AU>
<TI>Effect of nicotine replacement therapy on stress and smoking behavior in surgical patients</TI>
<SO>Anesthesiology</SO>
<YR>2005</YR>
<VL>102</VL>
<NO>6</NO>
<PG>1138-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wennike-2003" NAME="Wennike 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P</AU>
<TI>Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up</TI>
<SO>Addiction</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>10</NO>
<PG>1395-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Williams-2007" MODIFIED="2011-08-17 15:52:04 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-08-17 15:51:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Williams JM, Gandhi KK, Foulds J, Steinberg M, Lou S, Masumova F et al</AU>
<TI>No advantage for high dose compared to regular dose nicotine patch on short-term abstinence rates in schizophrenia (PA2-3)</TI>
<SO>Society for Research on Nicotine and Tobacco 13th Annual Meeting February 21-24, Austin, Texas</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-08-17 15:50:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-17 15:50:27 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00046813"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiseman-2005" NAME="Wiseman 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiseman EJ, Williams DK, McMillan DE</AU>
<TI>Effectiveness of payment for reduced carbon monoxide levels and noncontingent payments on smoking behaviors in cocaine-abusing outpatients wearing nicotine or placebo patches</TI>
<SO>Experimental and Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>2</NO>
<PG>102-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Working-Group-1994" NAME="Working Group 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Working Group for the Study of Transdermal Nicotine</AU>
<TI>Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>989-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-02-14 13:32:34 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-10-16 16:45:00 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Williams-2009" MODIFIED="2012-10-16 16:45:00 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-16 16:45:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Williams JM</AU>
<TI>Trial of nicotine nasal spray as an aid for smoking cessation in schizophrenia</TI>
<SO>ClinicalTrials gov [www clinicaltrials gov]</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-10-16 17:03:09 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-10-16 17:01:37 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alpert-2012" MODIFIED="2012-10-16 16:50:30 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Alpert 2012" TYPE="OTHER">
<AU>Alpert HR, Connolly GN, Biener L</AU>
<TI>A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation</TI>
<SO>Tobacco Control</SO>
<YR>2012</YR>
<PG>np</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2002" MODIFIED="2012-02-21 12:12:26 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Altman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Deeks JJ</AU>
<TI>Meta-analysis, Simpson's paradox, and the number needed to treat</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2004" NAME="Altman 2004" NOTES="&lt;p&gt;added 2004/4 in methodological quality section&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Schulz KF, Moher D</AU>
<TI>Turning a blind eye: testing the success of blinding and the CONSORT statement</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7448</NO>
<PG>1135</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benowitz-2000" NAME="Benowitz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Benowitz NL, Dempsey DA, Goldenberg RL, Hughes JR, Dolan-Mullen P, Ogburn PL et al</AU>
<TI>The use of pharmacotherapies for smoking cessation during pregnancy</TI>
<SO>Tobacco Control</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cahill-2007" MODIFIED="2008-05-08 13:09:05 +0100" MODIFIED_BY="L S" NAME="Cahill 2007" TYPE="COCHRANE_REVIEW">
<AU>Cahill K, Stead LF, Lancaster T</AU>
<TI>Nicotine receptor partial agonists for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-05-08 13:09:05 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2008-05-08 13:09:05 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD006103.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carson-2012" MODIFIED="2012-10-16 16:59:55 +0100" MODIFIED_BY="L S" NAME="Carson 2012" TYPE="COCHRANE_REVIEW">
<AU>Carson KV, Verbiest MEA, Crone MR, Brinn MP, Esterman AJ, Assendelft WJJ et al</AU>
<TI>Training health professionals in smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2012-10-16 16:59:33 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2012-10-16 16:59:33 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000214.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cepeda_x002d_Benito-2004" NAME="Cepeda-Benito 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cepeda-Benito A, Reynoso JT, Erath S</AU>
<TI>Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2004</YR>
<VL>72</VL>
<PG>712-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coleman-2012a" MODIFIED="2012-10-16 16:49:10 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Coleman 2012a" TYPE="COCHRANE_REVIEW">
<AU>Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J</AU>
<TI>Pharmacological interventions for promoting smoking cessation during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2012-10-16 16:49:10 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<IDENTIFIER MODIFIED="2012-10-16 16:49:10 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" TYPE="DOI" VALUE="10.1002/14651858.CD010078"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CONSORT-2001" MODIFIED="2011-06-28 09:05:53 +0100" MODIFIED_BY="[Empty name]" NAME="CONSORT 2001" NOTES="&lt;p&gt;Begg, C., Cho, M., Eastwood, S., Horton, R., Moher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz, K. F., Simel, D. and Stroup, D. F. (1996) Improving the quality of reporting of randomized controlled trials: the CONSORT statement, Journal of the American Medical Association, 276, 637&amp;#8211;639.[Medline]&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-06-28 09:05:53 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D et al</AU>
<TI>The revised CONSORT statement for reporting randomized trials: explanation and elaboration</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<PG>663-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cummings-2005" NAME="Cummings 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cummings KM, Hyland A</AU>
<TI>Impact of nicotine replacement therapy on smoking behavior</TI>
<SO>Annual Review of Public Health</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>583-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Orlando-2004" NAME="D'Orlando 2004" TYPE="JOURNAL_ARTICLE">
<AU>D'Orlando K, Fox B</AU>
<TI>Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>63-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2005" NAME="Deeks 2005" NOTES="&lt;p&gt;Citation based on Handbook &amp;amp; Revman advice&lt;br&gt;&lt;/p&gt;" TYPE="OTHER">
<AU>Deeks J, Higgins JPT, Altman DG. In: Higgins JPT, Green S, editors</AU>
<TI>Analysing and presenting results: Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8</TI>
<SO>http://www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 30th October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dempsey-2002" NAME="Dempsey 2002" NOTES="&lt;p&gt;Added to draft for update 2002/4&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dempsey D, Jacob P, Benowitz L</AU>
<TI>Accelerated metabolism of nicotine and cotinine in pregnant smokers</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>2002</YR>
<VL>301</VL>
<PG>594-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Durcan-2002" NAME="Durcan 2002" NOTES="&lt;p&gt;In additional refs as cited in text as well as secondary paper to Jorenby 1999&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ et al</AU>
<TI>Impact of prior nicotine replacement therapy on smoking cessation efficacy</TI>
<SO>American Journal of Health Behaviors</SO>
<YR>2002</YR>
<VL>26</VL>
<PG>213-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder CE</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Etter-2006" NAME="Etter 2006" TYPE="JOURNAL_ARTICLE">
<AU>Etter JF, Stapleton JA</AU>
<TI>Nicotine replacement therapy for long-term smoking cessation: a meta-analysis</TI>
<SO>Tobacco Control</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>280-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Etter-2007" NAME="Etter 2007" TYPE="JOURNAL_ARTICLE">
<AU>Etter JF, Burri M, Stapleton J</AU>
<TI>The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis (PA9-6)</TI>
<SO>Addiction</SO>
<YR>2007</YR>
<VL>102</VL>
<PG>815-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fagerstrom-2002" MODIFIED="2012-02-21 12:12:43 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Fagerstrom 2002" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO, Hughes JR</AU>
<TI>Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>Suppl 2</NO>
<PG>S73-S79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fagerstrom-2003" NAME="Fagerstrom 2003" NOTES="&lt;p&gt;Suggested reference by JRH&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom KO</AU>
<TI>Clinical treatment of tobacco dependence: The endurance of pharmacologic efficacy</TI>
<SO>Journal of Clinical Psychiatry Monograph</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fiore-1992" NAME="Fiore 1992" TYPE="JOURNAL_ARTICLE">
<AU>Fiore MC, Jorenby DE, Baker TB, Kenford SL</AU>
<TI>Tobacco dependence and the nicotine patch. Clinical guidelines for effective use</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>268</VL>
<PG>2687-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fiore-2008" MODIFIED="2012-02-17 10:48:06 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Fiore 2008" TYPE="BOOK">
<AU>Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al</AU>
<SO>Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline</SO>
<YR>May 2008</YR>
<PB>U.S. Department of Health and Human Services. Public Health Service</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franzon-2002" NAME="Franzon 2002" TYPE="JOURNAL_ARTICLE">
<AU>Franzon M, Gustavsson G, Korberly BH</AU>
<TI>Effectiveness of over-the-counter nicotine replacement therapy</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>3109-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenland-1998" NAME="Greenland 1998" TYPE="JOURNAL_ARTICLE">
<AU>Greenland S, Satterfield MH, Lanes SF</AU>
<TI>A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch</TI>
<SO>Drug Safety</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>297-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henningfield-2005" NAME="Henningfield 2005" TYPE="JOURNAL_ARTICLE">
<AU>Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML</AU>
<TI>Pharmacotherapy for nicotine dependence</TI>
<SO>CA Cancer Journal for Clinicians</SO>
<YR>2005</YR>
<VL>55</VL>
<PG>281-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" NOTES="&lt;p&gt;added with description of I2 statistic 2004&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1995" NAME="Hughes 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR</AU>
<TI>Treatment of nicotine dependence. Is more better?</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>1390-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2001" NAME="Hughes 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR</AU>
<TI>The effectiveness of over-the-counter nicotine replacement: a rebuttal</TI>
<SO>Drug and Alcohol Review</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>319-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2004a" NAME="Hughes 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Keely J, Naud S</AU>
<TI>Shape of the relapse curve and long-term abstinence among untreated smokers</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>29-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2004b" NAME="Hughes 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Pillitteri JL, Callas PW, Callahan R, Kenny M</AU>
<TI>Misuse of and dependence on over-the-counter nicotine gum in a volunteer sample</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2005" NAME="Hughes 2005" NOTES="&lt;p&gt;2007&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Adams EH, Franzon MA, Maguire MK, Guary J</AU>
<TI>A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler</TI>
<SO>Tobacco Control</SO>
<YR>2005</YR>
<VL>14</VL>
<PG>49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007" MODIFIED="2008-05-08 12:48:46 +0100" MODIFIED_BY="L S" NAME="Hughes 2007" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-05-08 12:48:22 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2008-05-08 12:48:22 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000031.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hyland-2005" NAME="Hyland 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hyland A, Rezaishiraz H, Giovino G, Bauer JE, Cummings KM</AU>
<TI>Over-the-counter availability of nicotine replacement therapy and smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>547-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ikinci-2006" NAME="Ikinci 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ikinci G, Senel S, Tokgozoglu L, Wilson CG, Sumnu M</AU>
<TI>Development and in vitro/in vivo evaluations of bioadhesive buccal tablets for nicotine replacement therapy</TI>
<SO>Pharmazie</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Italy-ISS-2004" NAME="Italy ISS 2004" TYPE="BOOK">
<AU>Osservatorio Fumo, Alcol e Droga</AU>
<SO>Linee guida cliniche per promuovere la cessazione dell&#8217;abitudine al fumo</SO>
<YR>2004</YR>
<PB>Istituto Superiore di Sanita</PB>
<CY>Rome</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joseph-2003" NAME="Joseph 2003" TYPE="JOURNAL_ARTICLE">
<AU>Joseph AM, Fu SS</AU>
<TI>Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>2003</YR>
<VL>45</VL>
<PG>429-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kasza-2012" MODIFIED="2012-10-16 17:01:37 +0100" MODIFIED_BY="Lindsay Stead" NAME="Kasza 2012" TYPE="OTHER">
<AU>Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV et al</AU>
<TI>Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey</TI>
<SO>Addiction</SO>
<YR>2012</YR>
<IDENTIFIERS MODIFIED="2012-10-04 12:59:12 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2012-10-04 12:59:12 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1111/j.1360-0443.2012.04009.x"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Le-Foll-2005" NAME="Le Foll 2005" TYPE="JOURNAL_ARTICLE">
<AU>Le Foll B, Melihan-Cheinin P, Rostoker G, Lagrue G</AU>
<TI>Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency</TI>
<SO>European Psychiatry</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>431-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindson-2011" MODIFIED="2012-02-21 12:12:54 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Lindson 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lindson N, Aveyard P</AU>
<TI>An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect</TI>
<SO>Psychopharmacology</SO>
<YR>2011</YR>
<VL>214</VL>
<PG>579-592</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McClure-2006" NAME="McClure 2006" TYPE="JOURNAL_ARTICLE">
<AU>McClure JB, Swan GE</AU>
<TI>Tailoring nicotine replacement therapy: rationale and potential approaches</TI>
<SO>Central Nervous System Drugs</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>281-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meine-2005" NAME="Meine 2005" TYPE="JOURNAL_ARTICLE">
<AU>Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG</AU>
<TI>Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes</TI>
<SO>American Journal of Cardiology</SO>
<YR>2005</YR>
<VL>95</VL>
<PG>976-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mills-2010" MODIFIED="2012-10-09 15:11:37 +0100" MODIFIED_BY="Kate Cahill" NAME="Mills 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO</AU>
<TI>Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals</TI>
<SO>Tobacco Induced Diseases</SO>
<YR>2010</YR>
<VL>8</VL>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mooney-2004" NAME="Mooney 2004" NOTES="&lt;p&gt;Added 2004/4, in methodological quality section&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mooney M, White T, Hatsukami D</AU>
<TI>The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials</TI>
<SO>Addictive Behaviors</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>4</NO>
<PG>673-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munafo-2004a" NAME="Munafo 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Munafo M, Bradburn M, Bowes L, David S</AU>
<TI>Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>769-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munafo-2004b" NAME="Munafo 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Munafo M, Bradburn M, Bowes L, David S</AU>
<TI>Investigating subgroups in smoking cessation treatment response: Response to Perkins</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>865-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NZ-MoH-2007" MODIFIED="2012-09-27 15:19:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="NZ MoH 2007" TYPE="BOOK">
<AU>Ministry of Health</AU>
<SO>New Zealand Smoking Cessation Guidelines</SO>
<YR>2007</YR>
<PB>Ministry of Health</PB>
<CY>Wellington, New Zealand</CY>
<IDENTIFIERS MODIFIED="2012-09-27 15:19:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce"/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-1992" NAME="Palmer 1992" TYPE="JOURNAL_ARTICLE">
<AU>Palmer KJ, Buckley MM, Faulds D</AU>
<TI>Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation</TI>
<SO>Drugs</SO>
<YR>1992</YR>
<VL>44</VL>
<PG>498-529</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-2002" NAME="Park 2002" TYPE="JOURNAL_ARTICLE">
<AU>Park CR, Munday DL</AU>
<TI>Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy</TI>
<SO>International Journal of Pharmaceutics</SO>
<YR>2002</YR>
<VL>237</VL>
<NO>1-2</NO>
<PG>215-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perkins-2004" NAME="Perkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Perkins KA</AU>
<TI>Obstacles to determining individual differences in the efficacy of smoking cessation medications</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>765-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pierce-2002" NAME="Pierce 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pierce JP, Gilpin EA</AU>
<TI>Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>1260-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shiffman-2003" NAME="Shiffman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Hughes JR, Pillitteri JL, Burton SL</AU>
<TI>Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample</TI>
<SO>Tobacco Control</SO>
<YR>2003</YR>
<VL>12</VL>
<PG>310-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shiffman-2005" NAME="Shiffman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Di Marino ME, Sweeney CT</AU>
<TI>Characteristics of selectors of nicotine replacement therapy</TI>
<SO>Tobacco Control</SO>
<YR>2005</YR>
<VL>14</VL>
<PG>346-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simes-1986" NAME="Simes 1986" TYPE="JOURNAL_ARTICLE">
<AU>Simes RJ</AU>
<TI>Publication bias: the case for an international registry of clinical trials</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>10</NO>
<PG>1529-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stapleton-2012" MODIFIED="2012-10-16 16:51:09 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Stapleton 2012" TYPE="OTHER">
<AU>Stapleton, JA</AU>
<TI>Perverse conclusion from results</TI>
<SO>Tobacco Control</SO>
<YR>2012</YR>
<PG>np</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stead-2002" NAME="Stead 2002" TYPE="JOURNAL_ARTICLE">
<AU>Stead LF, Davis RM, Fiore MC, Hatsukami DK, Raw M, West R</AU>
<TI>Effectiveness of over-the-counter nicotine replacement therapy</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>3109-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stead-2007" MODIFIED="2008-05-08 12:55:19 +0100" MODIFIED_BY="L S" NAME="Stead 2007" TYPE="COCHRANE_REVIEW">
<AU>Stead LF, Lancaster T</AU>
<TI>Interventions to reduce harm from continued tobacco use</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-08 12:55:19 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2008-05-08 12:55:19 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD005231.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1993" NAME="Stewart 1993" TYPE="JOURNAL_ARTICLE">
<AU>Stewart LA, Parmar MK</AU>
<TI>Meta-analysis of the literature or of individual patient data: is there a difference?</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8842</NO>
<PG>418-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweeney-2001" NAME="Sweeney 2001" NOTES="&lt;p&gt;LS has the copy&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE</AU>
<TI>Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability</TI>
<SO>CNS Drugs</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>453-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TNWG-1994" NAME="TNWG 1994" TYPE="JOURNAL_ARTICLE">
<AU>Transdermal Nicotine Working Group</AU>
<TI>Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>989-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wallstrom-1999" NAME="Wallstrom 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wallstrom M, Sand L, Nilsson F, Hirsch JM</AU>
<TI>The long-term effect of nicotine on the oral mucosa</TI>
<SO>Addiction</SO>
<YR>1999</YR>
<VL>94</VL>
<PG>417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-2000" NAME="Walsh 2000" TYPE="JOURNAL_ARTICLE">
<AU>Walsh RA, Penman AG</AU>
<TI>The effectiveness of nicotine replacement therapy over-the-counter</TI>
<SO>Drug and Alcohol Review</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-2001" NAME="Walsh 2001" TYPE="JOURNAL_ARTICLE">
<AU>Walsh RA,.Penman AG</AU>
<TI>The effectiveness of over-the-counter nicotine replacement: reply to Hughes</TI>
<SO>Drug and Alcohol Review</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>322-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-2007" NAME="Walsh 2007" NOTES="&lt;p&gt;2007&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Walsh RA, Stead L, Lancaster T</AU>
<TI>The Cochrane review on nicotine replacement therapy: incorrect or uncertain classifications of additional support levels &amp; Authors' response</TI>
<SO>Tobacco Control</SO>
<YR>2007</YR>
<VL>16</VL>
<PG>215-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2000" NAME="West 2000" TYPE="JOURNAL_ARTICLE">
<AU>West R, McNeill A, Raw M</AU>
<TI>Smoking cessation guidelines for health professionals: an update</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>987-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2001" NAME="West 2001" NOTES="&lt;p&gt;Added 2007&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>West R,.Shiffman S</AU>
<TI>Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review</TI>
<SO>Psychopharmacology Berl</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>115-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2007" NAME="West 2007" TYPE="JOURNAL_ARTICLE">
<AU>West R, Zhou X</AU>
<TI>Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study</TI>
<SO>Thorax</SO>
<YR>2007</YR>
<VL>62</VL>
<PG>998-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woolacott-2002" NAME="Woolacott 2002" NOTES="&lt;p&gt;2007&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al</AU>
<TI>The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>1-245</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zwar-2011" MODIFIED="2012-02-21 10:01:04 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NAME="Zwar 2011" TYPE="BOOK">
<AU>Zwar N, Borland R, Peters M, Litt J, Bell J, Caldwell B et al</AU>
<SO>Supporting Smoking Cessation: A Guide for Health Professionals</SO>
<YR>2011</YR>
<PB>The Royal Australian College of General Practitioners</PB>
<CY>Melbourne</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-10-16 17:03:09 +0100" MODIFIED_BY="L S">
<REFERENCE ID="REF-Silagy-1994a" NAME="Silagy 1994a" TYPE="JOURNAL_ARTICLE">
<AU>Silagy C, Mant D, Fowler G, Lodge M</AU>
<TI>Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>139-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silagy-1994b" NAME="Silagy 1994b" TYPE="JOURNAL_ARTICLE">
<AU>Silagy C, Mant D, Fowler G, Lancaster T</AU>
<TI>The effectiveness of nicotine replacement therapies in smoking cessation</TI>
<SO>Online Journal of Current Clinical Trials</SO>
<YR>1994</YR>
<VL>Doc No</VL>
<PG>113</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silagy-1996" NAME="Silagy 1996" TYPE="COCHRANE_REVIEW">
<AU>Silagy C, Lancaster T, Stead L, Mant D, Fowler G</AU>
<TI>Nicotine replacement therapy for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1996</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silagy-2001" MODIFIED="2012-10-03 14:52:45 +0100" MODIFIED_BY="L S" NAME="Silagy 2001" TYPE="COCHRANE_REVIEW">
<AU>Silagy C, Lancaster T, Stead L, Mant D, Fowler G</AU>
<TI>Nicotine replacement therapy for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-10-03 14:52:45 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2012-10-03 14:52:45 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Silagy-2002" MODIFIED="2008-05-08 13:03:15 +0100" MODIFIED_BY="L S" NAME="Silagy 2002" TYPE="COCHRANE_REVIEW">
<AU>Silagy C, Lancaster T, Stead L, Mant D, Fowler G</AU>
<TI>Nicotine replacement therapy for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-05-08 13:03:15 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2008-05-08 13:03:15 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Silagy-2004" MODIFIED="2012-10-16 17:03:09 +0100" MODIFIED_BY="L S" NAME="Silagy 2004" TYPE="COCHRANE_REVIEW">
<AU>Silagy C, Lancaster T, Stead L, Mant D, Fowler G</AU>
<TI>Nicotine replacement therapy for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-10-16 17:03:09 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2012-10-16 17:03:09 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stead-2008" MODIFIED="2012-10-03 14:52:21 +0100" MODIFIED_BY="Lindsay Stead" NAME="Stead 2008" TYPE="COCHRANE_REVIEW">
<AU>Stead LF, Perera R, Bullen C, Mant D, Lancaster T</AU>
<TI>Nicotine replacement therapy for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-10-03 14:52:11 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2012-10-03 14:52:11 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1002/14651858.CD000146.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-10-03 16:29:56 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Sjoberg-2011" MODIFIED="2012-02-09 18:15:03 +0000" MODIFIED_BY="Lindsay Stead" NAME="Sjoberg 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sjoberg N, Saint DA</AU>
<TI>A single 4 mg dose of nicotine decreases heart rate variability in healthy nonsmokers: implications for smoking cessation programs</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>5</NO>
<PG>369-72</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-10-16 16:31:03 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-10-16 16:15:34 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Abelin-1989">
<CHAR_METHODS MODIFIED="2012-02-21 11:24:04 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Switzerland<BR/>Recruitment: 21 primary care clinics<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 08:58:51 +0000" MODIFIED_BY="Kate Cahill">
<P>199 primary care patients<BR/>40% F, av.age 41, av.cpd 27.<BR/>Pts were motivated to quit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:15:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine patch, 24hr, 12 wks with weaning; 21 mg smokers of &gt;20 cpd, 14 mg for &lt;20 cpd<BR/>2. Placebo patch<BR/>Level of support: low (number of visits unclear)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (0-3 cigs/wk)<BR/>Validation: expired CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-21 11:24:43 +0000" MODIFIED_BY="Kate Cahill">
<P>Methods in Lancet paper, final follow up in Muller 1990.<BR/>Sources of support not reported.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:02:41 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Ahluwalia-1998">
<CHAR_METHODS MODIFIED="2011-02-02 10:27:59 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: hospital in- and outpatients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 08:59:07 +0000" MODIFIED_BY="Kate Cahill">
<P>410 African American smokers<BR/>Av.age 47, FTND 6.<BR/>Pts were motivated to quit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:41 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg with weaning, 10 wks)<BR/>2. Placebo patch<BR/>Level of support: high (1 hr initial visit and brief follow-up visits)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prolonged abstinence at 6m (self report of no smoking since end of treatment)<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 11:46:43 +0000" MODIFIED_BY="Kate Cahill">
<P>Study funded by American Cancer Society Career Development Award, Marion Merrell Dow Inc, and Emory Medical Care Foundation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:16:09 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Ahluwalia-2006">
<CHAR_METHODS MODIFIED="2011-02-02 10:27:52 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 14:56:17 +0100" MODIFIED_BY="Kate Cahill">
<P>755 African American light smokers (&#8804; 10 cpd)<BR/>67% F, av.age 45, av.cpd 8<BR/>Pts were motivated to quit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:16:09 +0100" MODIFIED_BY="Kate Cahill">
<P>Factorial trial, behavioural interventions collapsed for this review<BR/>1. Nicotine gum (2 mg), recommended use tailored to cpd. Highest 10/day for 4 wks, tapering for 4 wks<BR/>2. Placebo gum, 8 wks<BR/>Level of support: high: 3 in-person visits at randomization, wk 1, wk 8, and phone contact at wk 3, wk 6, wk 16, content based on either motivational interviewing or health education principles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-15 14:59:58 +0100" MODIFIED_BY="Kate Cahill">
<P>PP abstinence at 6m (7 day PP)<BR/>Validation: cotinine &#8804;20 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 11:49:18 +0000" MODIFIED_BY="Kate Cahill">
<P>New for 2008 update<BR/>Study funded by National Cancer Institute; products supplied by Glaxo-SmithKline.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-15 15:01:19 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Areechon-1988">
<CHAR_METHODS MODIFIED="2011-02-02 10:27:43 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Thailand<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:01:19 +0100" MODIFIED_BY="Kate Cahill">
<P>200 smokers (&#8805;15 cpd)<BR/>6% F, av.age 39, av.cpd 24.<BR/>Pts were motivated to quit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Gum (2 mg) x 8 boxes<BR/>2. Placebo gum x 8 boxes <BR/>Level of support: high (weekly visits with physician, unspecified frequency &amp; duration)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 11:42:24 +0000" MODIFIED_BY="Kate Cahill">
<P>Support level reclassified as high, 2008.<BR/>Study funded by Merrel Dow (Bangkok, Thailand), with products supplied by A.B. Leo, Helsinborg, Sweden.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:09 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Blondal-1989">
<CHAR_METHODS MODIFIED="2011-02-02 10:28:19 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Iceland<BR/>Recruitment: community volunteers invited to attend a smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 11:30:35 +0000" MODIFIED_BY="Kate Cahill">
<P>182 smokers (included pipe &amp; cigar users, smoked at least once a day)<BR/>57% F, av.age 42, av. tobacco use 21g/day.<BR/>Pts were volunteers, but motivation not required or assessed.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:09 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Gum (4 mg) for at least 1m<BR/>2. Placebo gum (containing pepper) for 1m or more<BR/>Level of support: high (group therapy, 5x1hr sessions, TQD at session 1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lapse-free abstinence at 12m (24m also reported, no validation)<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 11:36:33 +0000" MODIFIED_BY="Kate Cahill">
<P>Lapse-free abstinence used since 2008.<BR/>Study funded by Icelandic Ministry of Health and Social Security.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:07:50 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Blondal-1997">
<CHAR_METHODS MODIFIED="2011-02-02 13:30:34 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Iceland<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:04:58 +0100" MODIFIED_BY="Kate Cahill">
<P>159 smokers (&#8805;1 cpd)<BR/>44% F, av.age 42, av. tobacco use 25g/day.<BR/>Pts had to be motivated to quit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:43 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine nasal spray (NNS) ad lib use. Each dose (2 squirts) delivered 1 mg nicotine. Maximum dose 5 mg/hr and 40 mg/day. Recommended duration of use 3m.<BR/>2. Placebo nasal spray containing piperine to mimic sensory effect of nicotine.<BR/>Level of support: high (Group therapy 6x1hr sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:07:50 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 1yr (continuous abstinence from quit day, follow-up also at 2yrs)<BR/>Validation: CO&lt;10ppm at each of 5 follow-ups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 14:19:37 +0000" MODIFIED_BY="Kate Cahill">
<P>Abstinence at 24m 15/79 vs 11/78. OR 1.4.<BR/>Study funded by Icelandic Ministry of Health and Social Security, with consumables supplied by Pharmacia &amp; Upjohn.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:22 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Blondal-1999">
<CHAR_METHODS MODIFIED="2011-02-02 13:31:53 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Iceland<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:14:45 +0100" MODIFIED_BY="Kate Cahill">
<P>237 smokers (&#8805;1 cpd)<BR/>67% F, av.age 41-43, av. tobacco use 25g/day</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine nasal spray (NNS) (0.5 mg/dose) + 15 mg nicotine patches for 3m, weaning over further 2m. NNS could be continued for 1 yr<BR/>2. Placebo nasal spray + 15 mg nicotine patches on same schedule<BR/>Level of support: high (4 supportive group meetings)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (6 yr data also reported)<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 14:19:31 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparisons, only combination.<BR/>6yr abstinence 19/118 vs 10/119, OR 2.1<BR/>Study supported by Pharmacia &amp; Upjohn.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:16:25 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Bohadana-2000">
<CHAR_METHODS MODIFIED="2011-02-02 14:09:18 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: France<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:16:50 +0100" MODIFIED_BY="Kate Cahill">
<P>400 smokers, 18-70 yrs, &gt;10 cpd, &gt;1 previous quit attempt, motivated.<BR/>51% F, Av cpd: Group 1: 26.1, Group 2: 23.5; FTND&gt;6<BR/>Pts required to be motivated to quit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:24 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1: Nicotine inhaler, 26 wks, combined with nicotine patch (15 mg/16hr) for first 6 wks, placebo patch for next 6 wks<BR/>2: Nicotine inhaler, 26 wks, placebo patch for first 12 wks<BR/>Level of support: high. All received brief counselling and support from investigator at each visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:16:25 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Sustained abstinence at 12m (prolonged from wk 2, no slips allowed)<BR/>Validation: CO&lt;10ppm at each visit (2 wks, 6 wks, 6m, 12m)<BR/>(Study also reports respiratory symptoms and pulmonary function tests for completely abstinent subjects)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 14:19:19 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparisons, only combination.<BR/>Gender subgroup results reported 2003<BR/>Study funded by Pharmacia &amp; Upjohn.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:16:48 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Bolin-1999">
<CHAR_METHODS MODIFIED="2011-02-02 14:28:58 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>98 smokers<BR/>16% F, av.age 54, av.cpd 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:46 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine patch for 12 wks (21 mg/3 wks, 14 mg/3 wks, 7mg/3 wks)<BR/>2. Nicotine patch for 3 wks (21 mg/1 wk, 14 mg/1 wk, 7mg/1 wk)<BR/>Level of support: high (group). All received intensive group programme, 5 sessions prior to quit day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Continuous abstinence at 5m (PP also recorded)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:16:48 +0100" MODIFIED_BY="Kate Cahill">
<P>Contributes only to length of treatment comparison<BR/>Borderline follow-up length - 20 wks from beginning of programme, 16 wks since start of NRT<BR/>Sources of support not reported.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-09 14:36:54 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Bolliger-2000a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-10-09 14:36:54 +0100" MODIFIED_BY="Kate Cahill">
<P>Excluded study, but contributing data on adverse events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:56:59 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Br-Thor-Society-1983">
<CHAR_METHODS MODIFIED="2011-02-02 14:49:02 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK (95 centres)<BR/>Recruitment: hospital chest clinics (80%) and inpatient wards<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1618 clinic patients age 18-65 with a smoking-related illness (pulmonary or vascular)<BR/>39% F, av.age 49, av.cpd 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:56:59 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Brief advice from physician<BR/>2. Brief advice + booklet<BR/>3. Brief advice + booklet + placebo chewing gum<BR/>4. Brief advice + booklet + nicotine chewing gum (2 mg for up to 3m, up to 6m on request)<BR/>Level of support: low (1m &amp; 3m follow-up visits)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained validated abstinence at 6m and 12m<BR/>Validation: Venous carboxyhaemoglobin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 15:01:19 +0000" MODIFIED_BY="Kate Cahill">
<P>Includes both placebo and no-placebo groups. 4 vs 1+2+3 used in main comparison. 4 vs 3 has lower OR (0.8) but does not alter MA notably.<BR/>Study was funded by Health Education Council and Lundbeck Ltd.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-09 14:37:11 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Brantmark-1973a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-10-09 14:37:11 +0100" MODIFIED_BY="Kate Cahill">
<P>Excluded study, but contributing data on adverse events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:45:00 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Buchkremer-1988">
<CHAR_METHODS MODIFIED="2011-02-02 15:03:57 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Germany<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 15:09:39 +0000" MODIFIED_BY="Kate Cahill">
<P>131 smokers<BR/>50% F, av.age 35, av.cpd 29.<BR/>Pts were motivated to give up.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:45:00 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine patch (24hr/day, 8 wks, 15cm with weaning) + behavioural therapy<BR/>2. Placebo patch + behavioural therapy<BR/>3. Behavioural therapy alone<BR/>Level of support: high (9 weekly group sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence (not stated how assessed) at 12m<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 15:08:34 +0000" MODIFIED_BY="Kate Cahill">
<P>Placebo &amp; no-placebo groups. 1 vs 2+3 used in main comparison.<BR/>Study was funded by Deutsche Forschungsgemeinschaft.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:45:04 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Bullen-2010">
<CHAR_METHODS MODIFIED="2012-02-21 11:29:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: New Zealand<BR/>Recruitment: callers to New Zealand Quitline<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-31 09:39:04 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1100 smokers. 60% F, mean age 40, av.cpd 19.</P>
<P>Motivated to quit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:45:04 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of precessation NRT</P>
<P>Intervention: NRT initiated 14 days before quit date, continued for 8 wks after quit date. 91% used patch only, 6% gum only, 3% both</P>
<P>Control: NRT for 8 wks from quit date. 85% patch, 11% gum, 4% both</P>
<P>Level of support: high (counselling offered via Quitline)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-15 15:24:01 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Continuous abstinence at 6m (data supplied by 1st author) (Self reported 7d PP at 6m reported in paper)</P>
<P>Validation: salivary cotinine in subgroup only. Self reported outcomes used in analysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 15:25:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Contributes to pre-cessation analysis only.</P>
<P>Participants able to select their treatment (patch, gum, or patch+gum) after discussion with adviser. Patch and gum outcomes supplied by 1st author, contribute to separate subgroups, 39 participants using combination not included in analysis.</P>
<P>Study funded by Health Research Council and Heart Foundation of New Zealand.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:00 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Campbell-1987">
<CHAR_METHODS MODIFIED="2011-02-02 15:22:45 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: primary care (45 GPs in 11 centres)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>836 primary care patients agreeing to try to stop smoking after brief advice from their doctor<BR/>61% F, av.age 39<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:00 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg) x 6 boxes<BR/>2. Placebo gum x 6 boxes<BR/>Level of support: low (no further face-to-face contact, 2/3rds received a letter after 1m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 15:28:20 +0000" MODIFIED_BY="Kate Cahill">
<P>Study funded by Chest, Heart and Stroke Association; discounted Nicorette gum supplied by Lunbeck, free chewing gum by Wrigleys. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:14 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Campbell-1991">
<CHAR_METHODS MODIFIED="2011-02-02 15:41:05 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: hospital inpatients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:29:47 +0100" MODIFIED_BY="Kate Cahill">
<P>212 patients with smoking-related diseases<BR/>44% F, 53% aged 50+, 61% smoked &gt;15cpd</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:14 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum 2-4 mg (3m)<BR/>2. Placebo gum<BR/>Level of support: high (support at 2, 3, 5 wks, 3m, 6m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-02 15:53:07 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by Pharmacia LEO.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:02:49 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Campbell-1996">
<CHAR_METHODS MODIFIED="2011-02-16 11:29:57 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: hospital inpatients and outpatients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-16 11:16:34 +0000" MODIFIED_BY="Kate Cahill">
<P>234 adult smokers (&gt;1 cpd in previous wk) (172 outpatients, 62 inpatients) Stratified on FTND. Pts were motivated to quit.<BR/>54% F, av.age 49</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:49 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg, 24hr, 12 wks with dose tapering)<BR/>2. Placebo patch<BR/>Level of support: high (counselling at 2, 4, 8,12 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Continuous abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-16 11:29:37 +0000" MODIFIED_BY="Kate Cahill">
<P>Originally included as Burton 1992 which was an abstract of the same trial.<BR/>Study was funded and supplied by Ciba-Geigy Ltd.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:30 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-CEASE-1999">
<CHAR_METHODS MODIFIED="2012-10-15 15:31:36 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Multi-centre - 36 clinic centres in 17 European countries<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>3575 smokers (&gt;14 cpd)<BR/>48% F, av.age 41, av.cpd 27<BR/>(34% had previously used NRT)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:30 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Factorial design compared 2 patch doses and 2 treatment durations. Dose 15 mg or 25 mg (16hr), duration of active treatment 28 wks (incl 4 wk fading) or 12 wks (incl 4 wk fading).<BR/>1. 25 mg patch for 28 wks<BR/>2. 25 mg patch for 12 wks<BR/>3. 15 mg patch for 28 wks<BR/>4. 15 mg patch for 12 wks<BR/>5. Placebo<BR/>Level of support: high (brief advice &amp; self help brochure, visits at enrolment, TQD, wk 1, 2, 4, 8, 12, 22, 26)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prolonged abstinence at 12m, sustained from wk 2<BR/>Validation: expired CO&lt;10ppm at each clinic visit<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 13:39:39 +0100" MODIFIED_BY="Kate Cahill">
<P>Doses and durations collapsed in main analyses. Durations compared in <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK> dosages in <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>
<BR/>Level of support reclassified to high for 2007 because of repeated visits. Limited support at these visits.<BR/>Study was sponsored by the European Respiratory Society, with support from Pharmacia &amp; Upjohn, Sweden.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:02:50 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Cinciripini-1996">
<CHAR_METHODS MODIFIED="2011-02-16 13:14:13 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>64 smokers (&gt;15 cpd)<BR/>70% F, av.cpd 29/22<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:50 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg, 12 wks incl weaning)<BR/>2. Behaviour therapy only (no placebo)<BR/>Level of support: High (group therapy weekly for 9 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence, 12m post-treatment and all previous points (EOT, 1, 3, 6m)<BR/>Validation: CO&lt;6ppm at each point</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-16 13:56:24 +0000" MODIFIED_BY="Kate Cahill">
<P>121 smokers recruited but only the first 64 followed up for 1 yr. 6m quit rates for whole cohort were approx 53% vs 30% (personal communication 2004).<BR/>Study was supported by a DHHS grant, and by Ciba Geigy Corporation and Marion Merrell Dow.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:03 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Clavel-1985">
<CHAR_METHODS MODIFIED="2011-02-16 14:17:41 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: France<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:34:47 +0100" MODIFIED_BY="Kate Cahill">
<P>427 smokers (&#8805;5 cpd)<BR/>51% F, av.age 34, av.cpd 22 for intermediate group (Clavel 1984). Pts were motivated to quit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:03 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg) x 1 box<BR/>2. Control group (time lock controlled cigarette case)<BR/>(Acupuncture arm not included in this review)<BR/>Level of support: High (3x1hr group therapy sessions in first month)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-15 15:35:35 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 13m<BR/>Validation: "Smoking cessation adjusted using exhaled CO figures from published trials"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-16 14:16:43 +0000" MODIFIED_BY="Kate Cahill">
<P>Classification of support corrected to high in 2008 update.<BR/>Study was supported by the Haut Comité d'Aide à la Lutte Contre le Cancer, and Laboratoire Léo, Sweden.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:08:32 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Clavel_x002d_Chapelon-1992">
<CHAR_METHODS MODIFIED="2011-02-16 15:06:09 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: France<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:36:26 +0100" MODIFIED_BY="Kate Cahill">
<P>996 smokers (&#8805;10 cpd)<BR/>45% F, av.age 34<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:51 +0100" MODIFIED_BY="Kate Cahill">
<P>Factorial trial with active/placebo acupuncture arms, collapsed for this review<BR/>1. Nicotine gum (2 mg) for up to 6m, max 30/day<BR/>2. Placebo gum (contained 1 mg unbuffered nicotine)<BR/>Level of support: high (3 acupuncture session at 0, 7, 28 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:08:32 +0100" MODIFIED_BY="Kate Cahill">
<P>Abstinence at 13m (1m quitters followed up). 4yr follow-up reported in 1997 with different 1yr results<BR/>Validation: none at 1yr</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 15:37:23 +0100" MODIFIED_BY="Kate Cahill">
<P>First included in 2008 update. Question over inclusion because placebo contained small amount of nicotine.<BR/>Abstinence at 4yrs 30/481 vs 32/515.<BR/>Study was supported by CIBA-GEIGY.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:17:52 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Coleman-2012">
<CHAR_METHODS MODIFIED="2012-03-14 10:08:21 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: UK</P>
<P>Recruitment: pregnant women attending hospital clinics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 15:45:30 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1050 pregnant women at 12-24 wks gestation smoking &#8805;5cpd</P>
<P>av.age 26, av.cpd at time of recruitment 14, av.cpd before pregnancy 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:17:52 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine patch 15 mg/16hrs for 8 wks (participants given 4 wk supply at outset, if not smoking at 4 wks given another 4 wk supply)</P>
<P>2. 'Visually identical' placebo on same schedule</P>
<P>Level of support: high. Behavioural cessation support &#8804;1hr at enrolment + 3 phone calls (on quit date, 3d after quit date, 4 wks after quit date). If collecting another 4 wk supply of NRT/placebo, participants given another face-to-face session.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-15 15:42:18 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Continuous abstinence from quit date to delivery. Lapses of up to 5 cigs (on 5 occasions) permitted.</P>
<P>Validation: salivary cotinine &lt;10ng/ml, CO&#8805;8ppm, primary outcomes required saliva cotinine validation, with or without CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-08 11:38:36 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update (previously listed as Coleman 2007 in ongoing studies).</P>
<P>Funded by NIHR Health Assessment Technology Programme.</P>
<P>Similar rates of adverse pregnancy and birth outcomes in both groups.</P>
<P>Low compliance in both arms (7.2% active treatment and 2.8% placebo group reported using patch for more than 1m).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:02:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Cooney-2009">
<CHAR_METHODS MODIFIED="2012-02-09 10:39:12 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers and referrals from substance abuse clinic</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:43:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>96 alcohol-dependent tobacco smokers (&#8805;15 cpd)</P>
<P>25% F, av.age 45, av.cpd 25, motivated to quit, av.FTND 6, 31% veterans</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine patch (titrated, 21 mg/d for 8 wks, 14 mg/d for 2 wks, 7mg/d for 2 wks) + nicotine gum (2 mg for 24 wks, ad lib but advised 6-20/day)</P>
<P>2. Nicotine patch + placebo gum (doses as above)</P>
<P>Level of support: high. 16 individual 1hr weekly outpatient sessions of behavioural alcohol and smoking treatment over 6m.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-09 11:16:02 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Continuous abstinence at 12m (with 30d grace period immediately following quit date)</P>
<P>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 15:44:08 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update. </P>
<P>Used in combinations of NRT <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK> only.</P>
<P>Funding from National Institute on Alcohol Abuse and Alcoholism and Department of Veterans Affairs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:06 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Cooper-2005">
<CHAR_METHODS MODIFIED="2011-02-16 15:41:33 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:44:50 +0100" MODIFIED_BY="Kate Cahill">
<P>439 female smokers (&#8805;10 cpd)<BR/>Av.age 38, av.cpd 23</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:06 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg), 10-12 pieces/day recommended, for 9 wks, weaning last 3 wks.<BR/>2. Placebo gum<BR/>Level of support: high. 13x1hr weekly cognitive behavioural group sessions. Reduction prior to TQD wk 5<BR/>(3rd arm tested phenylpropanolamine gum, not included in review)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: CO&lt;10ppm<BR/>(Weight change in quitters was also a primary outcome in the trial)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-16 15:36:32 +0000" MODIFIED_BY="Kate Cahill">
<P>First included as Cooper 2003. Published report from 2007.<BR/>Sources of support not reported.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:33 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Croghan-2003">
<CHAR_METHODS MODIFIED="2012-10-15 15:46:14 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: multi-centre community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-15 15:47:09 +0100" MODIFIED_BY="Kate Cahill">
<P>1384 smokers (&#8805;15cpd)<BR/>58% F, av.age 42, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:33 +0100" MODIFIED_BY="Kate Cahill">
<P>1. 15 mg/16hr nicotine patch plus 0.5 mg/dose nasal spray, max 5/hr, 40/day, for 6 wks<BR/>2. Nicotine nasal spray only<BR/>3. Nicotine patch only<BR/>Level of support: low (advice at each visit, 30-45 mins total)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-16 15:47:51 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison, combination only.<BR/>Study was funded by the National Cancer Institute; Medication provided by McNeil Consumer Products.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:18:11 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Dale-1995">
<CHAR_METHODS MODIFIED="2011-02-17 15:08:17 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers and smoking clinic attenders.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-17 15:02:31 +0000" MODIFIED_BY="Kate Cahill">
<P>71 smokers stratified according to light, moderate and heavy smoking rates, and motivated to quit.<BR/>56% F, av.age 48, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:18:11 +0100" MODIFIED_BY="Kate Cahill">
<P>1. 11 mg/24hr nicotine patch<BR/>2. 22 mg/24hr nicotine patch<BR/>3. 44 mg/24hr nicotine patch<BR/>4. Placebo patch for 1 wk followed by 11 or 22 mg patch for 7 wks.<BR/>Duration of patch use 8 wks.<BR/>Level of support: high (including 6-day inpatient stay)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: Blood cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-17 15:03:17 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison. Contributes to comparison 8 of high and standard dose patch.<BR/>Study was supported by Lederie Laboratories, Pearl River, NY<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:46:43 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Daughton-1991">
<CHAR_METHODS MODIFIED="2011-02-17 15:54:50 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers at 2 sites<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 10:05:13 +0100" MODIFIED_BY="Kate Cahill">
<P>158 smokers (at least 1 pack cpd)<BR/>53% F, av.age 42, av.cpd 33</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:46:41 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (15cm², 4 wks) worn for 16hr/day<BR/>2. Nicotine patch (15cm², 4 wks) worn for 24hr/day<BR/>3. Placebo patch, 4 wks<BR/>Level of support: unclear &amp; differed between sites</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:46:43 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 6m<BR/>Validation: None after 4 wks (CO at 2-4 wks)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 13:39:35 +0100" MODIFIED_BY="Kate Cahill">
<P>1 +2 vs 3 in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. 16 vs 24 hr in <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>. Not used in support intensity subgroup analysis.<BR/>Study was funded by ALZA Corp, Palo Alto, CA, through a contract with the Merrel Dow Research Institute, Cincinnati, OH.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:18:33 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Daughton-1998">
<CHAR_METHODS MODIFIED="2012-10-16 10:06:35 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA (21 sites)<BR/>Recruitment: patients at family practices - self referred to study or recruited by physician.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-21 08:54:43 +0000" MODIFIED_BY="Kate Cahill">
<P>369 smokers (&gt; 20 cpd)<BR/>Av.age 37, av.cpd 27-30; Pts were variously motivated to quit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:18:33 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg, 16hr, 10 wks with weaning)<BR/>2. Placebo patch<BR/>Level of support: low (Nicoderm Committed Quitters Programme support booklet + follow-up visit 1 wk after quit day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 10:07:51 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence (continuous self reported from quit day) at 12m<BR/>Validation: CO &#8804; 8ppm and saliva cotinine &lt; 20mg/mL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 10:07:58 +0100" MODIFIED_BY="Kate Cahill">
<P>There were differences in quit rates between self referred and physician-selected recruits and between smokers recruited during an illness and at another visit.<BR/>Study was funded by Marion Merrell Dow Inc.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:02:59 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Dautzenberg-2001">
<CHAR_METHODS MODIFIED="2011-02-21 08:58:38 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: France<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>433 smokers (excludes 25 from ITT population)<BR/>52% F, av.age 39, av.cpd 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:02:59 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine lozenge (1 mg, 8-24/day, 6 wks + 6 wks weaning for quitters)<BR/>2. Placebo lozenge<BR/>Level of support: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:46:48 +0100" MODIFIED_BY="Kate Cahill">
<P>PP abstinence at 26 wks<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 08:58:33 +0000" MODIFIED_BY="Kate Cahill">
<P>Based on published abstract.<BR/>Study was funded by Novartis Consumer Health.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:18:47 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Davidson-1998">
<CHAR_METHODS MODIFIED="2011-02-21 09:04:22 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA (4 centres)<BR/>Recruitment: community volunteers in shopping malls (OTC setting)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-21 09:05:28 +0000" MODIFIED_BY="Kate Cahill">
<P>802 smokers (&gt;20 cpd) who scored 5+ on a questionnaire assessing motivation.<BR/>54% F, av.age 39, av.cpd 29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:16 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (22 mg, 24hr, for up to 6 wks)<BR/>2. Placebo patch<BR/>Level of support: low (self help book provided. Participants visited mall weekly to obtain patches. CO levels were monitored)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:18:47 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 24 wks (from wk 2)<BR/>Validation: Expired CO&#8804;8ppm at each weekly visit, but 24 wk quit based on self report</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 09:05:19 +0000" MODIFIED_BY="Kate Cahill">
<P>541/802 did not complete the 6 weekly visits.<BR/>Study was funded by Elan Pharmaceutical Corporation.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:20 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Ehrsam-1991">
<CHAR_METHODS MODIFIED="2012-10-16 10:12:14 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: Switzerland<BR/>Recruitment: University (primary care)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>112 smokers at 2 universities<BR/>Av.age 26, av.cpd 23</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:20 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 or 14 mg/24hr, 9 wks, tapered)<BR/>2. Placebo patch<BR/>Level of support: high (no counselling)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-21 11:57:58 +0000" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m (0-3 cigs per wk)<BR/>Validation: urinary cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 09:18:06 +0000" MODIFIED_BY="Kate Cahill">
<P>Study funding not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Etter-2009">
<CHAR_METHODS MODIFIED="2012-02-21 11:40:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: Switzerland<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-09 11:33:01 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>314 adult smokers motivated to quit.</P>
<P>58% M, av.age 43, av.cpd 24, av.FTND 5.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Gum pre- and postquit date (4 mg, min. 10/d, 4 wks pre- and 8 wks postquit date)</P>
<P>2. Gum postquit date only (dosage as above, 8 wks postquit date)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:47:03 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Abstinence at 12m for 4 wks (sustained self reported abstinence also recorded but not validated)</P>
<P>Validation: cotinine &lt;10ng/mL; secondary test of CO&lt;10ppm as required</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 13:39:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Included in pre-cessation <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK> only. Choice of outcome has no effect on analysis.</P>
<P>Funding from Swiss National Science Foundation. Nicotine gum provided at no charge by Pfizer.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:17 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fagerstrom-1982">
<CHAR_METHODS MODIFIED="2011-02-21 09:43:29 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Sweden<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-21 09:44:43 +0000" MODIFIED_BY="Kate Cahill">
<P>100 consecutive smokers; 43 referred by physician, 57 applied by phone to SC clinic.<BR/>59% F</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:17 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg) for at least 4 wks<BR/>2. Placebo gum for at least 4 wks<BR/>Level of support: high (individual counselling, average 7.7 sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 09:26:41 +0000" MODIFIED_BY="Kate Cahill">
<P>Study funding source not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:23 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fagerstrom-1984">
<CHAR_METHODS MODIFIED="2011-02-21 09:52:22 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Sweden<BR/>Recruitment: general practices and industrial clinics (primary care)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 10:17:20 +0100" MODIFIED_BY="Kate Cahill">
<P>145 smokers motivated to quit<BR/>56% F, av.age 40 years, av. cpd 19<BR/>Therapists: 10 Swedish GPs, 3 Swedish industrial physicians</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:23 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Short follow-up (advice plus 1 appointment)<BR/>2. Long follow-up (advice plus 2 appointments, phone call + letter)<BR/>3. Short follow-up plus nicotine gum (2 or 4 mg)<BR/>4. Long follow-up plus nicotine gum<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 10:18:10 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (and at 1, 6m)<BR/>Validation: 15% deception rate detected by expired CO&gt;4ppm in a random subset of claimed non-smokers at 6m. Self reported 12m rates used in MA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 09:57:38 +0000" MODIFIED_BY="Kate Cahill">
<P>3 &amp; 4 vs 1 &amp; 2 in Comparison 1. 1 vs 2 in Comparison 3.3<BR/>Study funding not reported.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:17 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fee-1982">
<CHAR_METHODS MODIFIED="2011-02-21 10:25:25 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>352 smokers, no other demographic data</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:17 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Gum (2 mg) given for 5 wks<BR/>2. Placebo gum given for 5 wks<BR/>Level of support: high (10 group therapy sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: Blood carboxyhaemoglobin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 10:30:54 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by LEO Laboratories, Sweden</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:19 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fiore-1994A">
<CHAR_METHODS MODIFIED="2011-02-21 11:11:13 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-21 11:12:14 +0000" MODIFIED_BY="Kate Cahill">
<P>88 smokers (&gt;15 cpd), motivated to quit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:19 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (22 mg/24hr, 8 wks, no weaning)<BR/>2. Placebo patch<BR/>Level of support: high (intensive group counselling)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m (7 days PP)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 11:13:08 +0000" MODIFIED_BY="Kate Cahill">
<P>Reported in same paper as Fiore 1994B.<BR/>Studies supported by Elan Pharmaceutical Research Corporation.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:20 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fiore-1994B">
<CHAR_METHODS MODIFIED="2011-02-21 11:49:05 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>112 smokers (&gt;15 cpd)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:20 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (22 mg/24hr, 6 wks incl weaning)<BR/>2. Placebo patch<BR/>Level of support: high (8 weekly 10-20 min individual counselling)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m (7 days PP)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 11:45:29 +0000" MODIFIED_BY="Kate Cahill">
<P>Reported in same paper as Fiore 1994A.<BR/>Studies supported by Elan Pharmaceutical Research Corporation.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:20 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fortmann-1995">
<CHAR_METHODS MODIFIED="2011-02-21 12:57:03 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Setting: community volunteers (telephone recruitment)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 10:21:42 +0100" MODIFIED_BY="Kate Cahill">
<P>1044 smokers aged 18-65, able to quit for 24hr, and without serious illness. Motivated to maintain abstinence.<BR/>42% F, av.age 40, av.cpd 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:20 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg, 1 per hr, at least 10/day and not more than 30/day)<BR/>2. Self help materials<BR/>3. Nicotine gum plus materials<BR/>4. Incentive alone.<BR/>All groups offered incentive of US$100 for quitting at 6m.<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: CO&lt;9 ppm/salivary cotinine&lt;20 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 10:22:27 +0100" MODIFIED_BY="Kate Cahill">
<P>Until 2008 only groups 1 and 4 compared. Since the trial was factorial and shows no evidence of interaction, both gum groups now used; 1&amp;3 vs 2&amp;4. The RR is unaltered but CIs narrow.<BR/>Study was funded by the National Heart, Lung, and Blood Institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:21 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Garcia-1989">
<CHAR_METHODS MODIFIED="2011-02-21 13:59:35 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Spain<BR/>Recruitment: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>106 adult smokers (excludes 81 not beginning treatment)<BR/>65% F, av.age 36, av.cpd 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:21 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Gum (2 mg) for 3-4m<BR/>2. Placebo gum for 3-4m<BR/>Level of support: high (group therapy, 7 sessions over 3m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 10:23:26 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 6m<BR/>Validation: CO&#8804;7ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 14:13:35 +0000" MODIFIED_BY="Kate Cahill">
<P>Sources of support not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:01 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Gariti-2009">
<CHAR_METHODS MODIFIED="2012-02-09 13:49:51 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-09 13:50:49 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>260 light smokers (6-15 cpd) motivated to quit</P>
<P>57% F, av.age 54, av.cpd 11, av.FTND 4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:01 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Patch (for participants&gt;10 cpd: 21 mg/day for wks1-4, 14 mg/day wks 5-6, 7mg/day wks 7-8; participants &#8804;10cpd: 14 mg/day for 6 wks, 7mg/day for wks 7-8) + 9 wks placebo bupropion + 10 wks individualized counselling sessions</P>
<P>2. Patch (dose as above) for 8 wks + 9 wks placebo bupropion + four 5-10min counselling sessions</P>
<P>3. Placebo patch for 8 wks + 9 wks bupropion SR + 10 wks individualized counselling sessions</P>
<P>4. Placebo patch for 8 wks + 9 wks bupropion SR + 4x5-10min counselling sessions</P>
<P>Level of support: high</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-09 13:58:17 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>7d PP at 12m.</P>
<P>Validation: CO&lt;10ppm; urinary cotinine &lt;200ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-08 10:32:19 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Used in direct comparison of NRT and bupropion only, pooling 1+2 versus 3+4.</P>
<P>Funding: National Institute on Drug Abuse.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:27 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Garvey-2000">
<CHAR_METHODS MODIFIED="2011-02-21 15:00:31 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>608 smokers, aged&gt;20, smoking&gt;5 cpd. <BR/>51% F, av.cpd 23<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:26 +0100" MODIFIED_BY="Kate Cahill">
<P>1. 4 mg nicotine gum (recommended 9-15 pieces), weaning from 2m<BR/>2. 2 mg nicotine gum, use as 1.<BR/>3. Placebo gum<BR/>All received brief counselling (5-10 mins) at each study visit (1, 7, 14, 30 days, 2, 3, 6, 9, 12m)<BR/>Level of support: high</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 10:26:48 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (relapse defined as 7+ consecutive days or episodes of smoking)<BR/>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:00:27 +0100" MODIFIED_BY="Kate Cahill">
<P>4 + 2 mg doses combined in main comparison.<BR/>4 mg compared to 2 mg in comparison of doses.<BR/>Study was funded by National Institute of Drug Abuse and Department of Veterans Affairs. Gum supplied by Marion Merrell Dow.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:28 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Gilbert-1989">
<CHAR_METHODS MODIFIED="2011-02-21 15:11:28 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Canada<BR/>Recruitment: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>223 patients presenting to primary care doctors and smoking at least 1 cpd (not selected by motivation)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:28 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Support from physician plus offer of nicotine gum prescription (2 mg)<BR/>2.Support from physician (no placebo)<BR/>Level of support: low (enrolment, quit day, offer of 4 support visits, 2 in wk 1, 1m, 2m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (for 3m)<BR/>Validation: salivary cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 15:28:04 +0000" MODIFIED_BY="Kate Cahill">
<P>~30% of gum group did not use any, 14% of support only group did use gum. ~70% attended quit day visit, ~43% attendance for follow-up visits.<BR/>Study was funded by US National Insititutes of Health.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glavas-2003a">
<CHAR_METHODS MODIFIED="2011-02-21 15:29:39 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Croatia<BR/>Recruitment: hospital health professionals<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>112 healthcare professionals smoking at least 1 cpd. 26% had FTND score 6+.<BR/>66% F, av.age 34, av.cpd: 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:37 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch, 24hr, 25 mg/15 mg/8mg starting dose depending on baseline cpd. 3 wks<BR/>2. Placebo patch<BR/>Level of support: low (visits to pick up patch at 7, 14, 21 days, no details about advice given)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 10:30:36 +0100" MODIFIED_BY="[Empty name]">
<P>Sustained abstinence (3 or fewer cigs/wk) at 1yr (5yr abstinence also reported, not used in MA)<BR/>Validation: CO&lt;11ppm<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 15:43:38 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by Novartis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:42 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Glavas-2003b">
<CHAR_METHODS MODIFIED="2011-02-21 15:45:32 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Croatia<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>160 smokers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:42 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch, 24hr, 25 mg/15 mg/8mg starting dose depending on baseline cpd. 6 wks<BR/>2. Nicotine patch, 24hr, 25 mg/15 mg starting dose depending on baseline cpd. 3 wks<BR/>3. Placebo patch. 6 wks<BR/>4. Placebo patch 3 wks<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m after EOT<BR/>Validation: CO&lt;11ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 15:53:02 +0000" MODIFIED_BY="Kate Cahill">
<P>Both durations pooled for main comparison.<BR/>Study funding information not reported.<BR/>Author supplied additional details in personal communication.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:30 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Glover-2002">
<CHAR_METHODS MODIFIED="2011-02-22 08:54:40 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 10:32:23 +0100" MODIFIED_BY="Kate Cahill">
<P>241 smokers (&#8805;10 cpd), motivated to quit.<BR/>54%F, av.age 42, av.cpd 29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:30 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine sublingual tablet (2 mg). Recommended dosage 1 tab/hr for smokers with FTND&lt;7, 2 tabs/hr for scores &#8805;7. After 3m treatment, tapering period of 3m if necessary<BR/>2. Placebo tablet<BR/>Level of support: high (brief counselling at all visits 1, 2, 3, 6 wks, 3, 6,12m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 08:36:01 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was funded by Pharmacia &amp; Upjohn.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:31 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Goldstein-1989">
<CHAR_METHODS MODIFIED="2011-02-22 08:58:34 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>89 smokers (excluding 18 early treatment drop-outs not included in results)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:31 +0100" MODIFIED_BY="Kate Cahill">
<P>Factorial design of 2 types of group treatment, and 2 schedules for use of nicotine gum. Behaviour therapy arms collapsed<BR/>1. Fixed schedule nicotine gum (2 mg); 1 piece/hr for 1st wk with tapering over 10 wks<BR/>2. Ad lib nicotine gum; to be used when urge to smoke, max 30/day<BR/>Level of support: high (10x1hr sessions of either intensive cognitive and behavioural skills training or non-specific education and support)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m<BR/>Validation: Saliva cotinine&lt;10ng/ml or CO&lt;8ppm for people still using gum</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 08:58:27 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison. Used in comparison of fixed to ad lib schedule gum.<BR/>Study was funded by American Cancer Society and National Heart, Lung, and Blood Institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:02 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Gourlay-1995">
<CHAR_METHODS MODIFIED="2011-02-22 09:17:29 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Australia<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>629 smokers (&gt;15 cpd) who had relapsed after transdermal nicotine and behavioural counselling in an earlier phase of the study.<BR/>Minimal additional support</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:02 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch 30cm² (21 mg/24 hr) for 4 wks, 20cm² (14 mg/24hr) for 4 wks, 10cm² (7mg/24 hrs) for 4 wks.<BR/>2. Placebo patch</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 6m<BR/>Validation: expired CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 09:19:54 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison. Test of patches vs placebo in recently relapsed smokers. Results given in text.<BR/>Study was funded by Ciba-Geigy Australia, the Anti-Cancer Council of Australia and the Victorian Health Promotion Foundation.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:20:08 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Gross-1995">
<CHAR_METHODS MODIFIED="2011-02-22 09:57:24 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:09:59 +0100" MODIFIED_BY="Kate Cahill">
<P>177 smokers<BR/>51% F, av. age 42, av.cpd 33, av. FTND 7.8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:20:02 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg), tapered from wk 12. Active gum groups further randomized to chew 7, 15 or 30 pieces of gum.<BR/>2. No gum<BR/>Level of support: high (1 pre-quit group counselling session, 14 clinic visits in 10 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:20:08 +0100" MODIFIED_BY="Lindsay Stead">
<P>Continuous abstinence at 6m (up to 3 cigs allowed)<BR/>Validation: CO&#8804;10ppm. Saliva thiocyanate in wk 2.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 10:05:53 +0000" MODIFIED_BY="Kate Cahill">
<P>No placebo. Long-term abstinence rates not affected by amount of gum, so these groups collapsed for comparison with no gum condition.<BR/>Study was funded by National Institute of Drug Abuse, and supported by Marion Merrell Dow.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:20:13 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hall-1985">
<CHAR_METHODS MODIFIED="2011-02-22 10:07:39 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers and physician referrals<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 smokers (77 in arms contributing to MA)<BR/>47% F, av. age 38, av.cpd 31</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:20:13 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Intensive behavioural treatment (14 group sessions over an 8 wk period)<BR/>2. Combined - 2 mg nicotine gum (period of use not specified) and intensive behavioural treatment<BR/>3. Low contact behavioural treatment (4 meetings over 3 wks) and 2 mg gum<BR/>Level of support: high</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m<BR/>Validation: CO&lt;10ppm and blood thiocyanate&lt;85 mg/mL. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 11:14:13 +0000" MODIFIED_BY="Kate Cahill">
<P>No placebo. 2 vs 1 in main comparison. 3 not used in MA. Quit rate higher than arm 1.<BR/>Study was funded by National Institute of Drug Abuse and Department of Veterans Affairs.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:35 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hall-1987">
<CHAR_METHODS MODIFIED="2011-02-22 10:16:28 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:12:05 +0100" MODIFIED_BY="Kate Cahill">
<P>139 adult smokers<BR/>47% F, av.age 39, av.cpd 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:35 +0100" MODIFIED_BY="Kate Cahill">
<P>2x2 factorial trial of gum and behavioural support<BR/>1. Nicotine gum (2 mg) up to 12m<BR/>2. Placebo gum up to 12m<BR/>Both levels of behavioural support classified as high intensity &amp; collapsed in analysis (both group-based, 14x75 min sessions, or 5x60min sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: CO&lt;8ppm &amp; serum thiocyanate&lt;95 mm/l</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 11:13:55 +0000" MODIFIED_BY="Kate Cahill">
<P>Study funded by National Institute of Drug Abuse and Department of Veterans Affairs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:36 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hall-1996">
<CHAR_METHODS MODIFIED="2011-02-22 11:02:16 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>207 smokers of which 6 excluded from analyses because of protocol breaches<BR/>52% F, av.age 40, av.cpd 24<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:36 +0100" MODIFIED_BY="Kate Cahill">
<P>2x2 factorial trial of gum and psychological treatment<BR/>1. Nicotine gum (2 mg) for 8 wks, 1 piece/hr for 12 hrs/day recommended<BR/>2. Placebo gum, same schedule<BR/>Both levels of behavioural support classified as high intensity &amp; collapsed in analysis (both group-based, 10 sessions over 8 wks, TQD session 3)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:48:08 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (abstinent at all assessments)<BR/>Validation: CO&#8804;10ppm at 8, 12, 26 wks and urinary cotinine&#8804;60ng/ml at 52 wks<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 11:14:31 +0000" MODIFIED_BY="Kate Cahill">
<P>Psychological treatment arms collapsed, no evidence of a significant interaction.<BR/>Study was funded by National Institute of Drug Abuse and Department of Veterans Affairs.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:48:11 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hand-2002">
<CHAR_METHODS MODIFIED="2011-02-22 11:15:27 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: hospital in- or outpatients referred by hospital doctor<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-22 11:18:33 +0000" MODIFIED_BY="Kate Cahill">
<P>245 patients with smoking-related disease.<BR/>46% M, typically aged 50+, smoking 15+ cpd; Pts were motivated to try and quit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:48:11 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (initially 30 or 20mg based on smoking rate) and inhaler for 3 wks including patch tapering. Same counselling as control<BR/>2. Individual counselling, 4 sessions in 4 wks. No placebo<BR/>Level of support: high</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (abstinent at all assessments)<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 11:17:38 +0000" MODIFIED_BY="Kate Cahill">
<P>No placebo. Compliance with NRT was low, 28% did not use, 30% used full supply.<BR/>Used in main comparisons and comparison 9, combination.<BR/>Study was funded from one author's endowment fund.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:36 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Harackiewicz-1988">
<CHAR_METHODS MODIFIED="2011-02-22 11:28:37 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: primary care (University Health Centre)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-22 11:30:54 +0000" MODIFIED_BY="Kate Cahill">
<P>197 smokers (151 used in MA), motivated to quit.<BR/>63% F, av.age 36, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:36 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg, 6 wks initial supply, suggested tapering after 3m, available for 6m) plus self help manual<BR/>2. Self help manual<BR/>3. Control (booklet)<BR/>Level of support: low (single appointment with doctor or nurse, length not specified)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 11:15:55 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m<BR/>Validation: CO in all subjects, cotinine and carboxyhemaglobin in a subsample of subjects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No placebo. Arm 3 not included in MA control group - it had a lower quit rate so inclusion would increase the gum treatment effect</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:39 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hays-1999">
<CHAR_METHODS MODIFIED="2012-09-27 14:52:47 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA (3 sites)<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:17:02 +0100" MODIFIED_BY="Kate Cahill">
<P>958 smokers, &gt;15 cpd, motivated to quit.<BR/>50% F, av.age 44, typically smoked 21-40 cpd</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:39 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patches (22 mg, 24hr for 6 wks) purchased by participants, open label<BR/>2. Nicotine patches (22 mg, 24hr for 6 wks) provided, double blind<BR/>3. Placebo patches provided<BR/>The intervention replicated an OTC environment, with no counselling intervention and minimal study recording. Weekly visits required for CO measurement &amp; adverse experience recording, but study sites were not in medical centres and there was no advice, counselling or interaction with medical personnel.<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 11:17:47 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m (7 day PP)<BR/>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 11:49:06 +0000" MODIFIED_BY="Kate Cahill">
<P>1 &amp; 2 vs 3 in patch vs placebo comparisons<BR/>2 vs 1 in free versus paid comparison (Comparison 12.1).<BR/>Study was supported by Elan Pharmaceutical Research Corp.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:20:34 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Herrera-1995">
<CHAR_METHODS MODIFIED="2011-02-22 13:45:53 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Venezuela<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 15:48:15 +0100" MODIFIED_BY="Kate Cahill">
<P>322 smokers &gt;10 cpd, scoring &#8805;4 on FTND, no serious illness. Only those who were ready to quit after 4 wks of behavioural treatment were randomized.<BR/>43% F, av.age ~38, av. cpd 33 for high dependence, 16 for low dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:20:34 +0100" MODIFIED_BY="Kate Cahill">
<P>Low dependence smokers (FTND 4-6):<BR/>1. 2 mg nicotine gum<BR/>2. Placebo gum<BR/>High dependence smokers (FTND 7-11):<BR/>1. 4 mg nicotine gum plus<BR/>2. 2 mg nicotine gum<BR/>Level of support: high for all (12 group sessions over 6 wks + 6 weekly maintenance sessions)<BR/>Participants also randomized to starting medication with increasing dose for 1 wk before TQD, or to start at full dose on TQD - there was no blinding for this.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 11:20:28 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 2yrs (1yr also reported)<BR/>Validation: expired CO&lt;6ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:00:32 +0100" MODIFIED_BY="Kate Cahill">
<P>Low dependence smokers included in comparison 1. High dependence smokers in comparison 2, 4 mg vs 2 mg gum.<BR/>Relapse between 1 &amp; 2 yrs similar between low dependence groups. Higher relapse in 4 mg high dependence than 2 mg.<BR/>No information on support or funding.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:04 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hilleman-1994">
<CHAR_METHODS MODIFIED="2011-02-22 13:56:03 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:21:30 +0100" MODIFIED_BY="Kate Cahill">
<P>140 smokers (excluding a buspirone treatment group), smoking&gt;20/day, FTND&#8805;8<BR/>55%F, av.age 46, av.cpd 25-26<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:04 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg/24hr) for 6 wks, no weaning<BR/>2. Nicotine patch, 21 mg 4 wks, weaning to 14 mg 4 wks, 7mg 4 wks<BR/>Level of support: high (12 weekly behaviour therapy sessions), does not contribute to intensity subgroup comparison<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m<BR/>Validation: Plasma thiocyanate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 14:35:59 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison. Contributes to both tapering versus no tapering and length of treatment comparisons.<BR/>No information on support or funding.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:45 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hjalmarson-1984">
<CHAR_METHODS MODIFIED="2011-02-22 14:38:06 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Sweden<BR/>Recruitment: smoking cessation clinic.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>206 smokers <BR/>56% F, av.age 42, av. cpd 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:45 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg) (no restrictions on amount or duration of use)<BR/>2. Placebo gum<BR/>Level of support: high (6 group sessions in 6 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 14:39:17 +0000" MODIFIED_BY="Kate Cahill">
<P>No information on support or funding.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:43 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hjalmarson-1994">
<CHAR_METHODS MODIFIED="2011-02-22 15:07:09 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Sweden<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>248 smokers<BR/>57% F, av.age 45, av. cpd 22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:43 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine nasal spray (0.5 mg/spray) used as required up to 40mg/day for up to 1yr.<BR/>2. Placebo spray<BR/>Level of support: high (8x45-60 min group sessions over 6 wks with clinical psychologist)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 15:04:51 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by Kabi Pharmacia AB, Sweden.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:48:43 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hjalmarson-1997">
<CHAR_METHODS MODIFIED="2011-02-22 15:34:18 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Sweden<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-22 15:17:16 +0000" MODIFIED_BY="Kate Cahill">
<P>247 smokers (&gt;10 cpd) who had previously made a serious attempt to stop using nicotine gum, and were motivated to quit.<BR/>64% F, av.age 48, av.cpd 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:48:42 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine Inhaler (recommended minimum 4/day, tapering after 3m, use permitted to 6m)<BR/>2. Placebo inhaler<BR/>Level of support: high (8 group meetings over 6 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:48:43 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m<BR/>Validation: CO&lt;10ppm at 2 and 6 wks and 3, 6, 12m.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 15:17:47 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was funded by Pharmacia &amp; Upjohn, Sweden.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 15:44:20 +0000" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Huber-1988">
<CHAR_METHODS MODIFIED="2011-02-22 15:41:10 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Germany<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>225 smokers (109 contribute to MA)<BR/>No demographic information</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nicotine gum alone<BR/>2. Behaviour therapy, 5 weekly group meetings<BR/>3. Nicotine gum (no details of dose) and behaviour therapy<BR/>Level of support: high<BR/>4. 6m waiting list control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 15:44:20 +0000" MODIFIED_BY="Kate Cahill">
<P>3 vs 2 in comparison 1. No placebo. Quit rates derived from graphs. The nicotine alone group was not used in the MA; quit rates were higher than intervention 2.<BR/>Study funding and support not reported.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:46 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hughes-1989">
<CHAR_METHODS MODIFIED="2011-02-22 15:48:04 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:37:52 +0100" MODIFIED_BY="Kate Cahill">
<P>315 daily smokers, motivated to quit.<BR/>56% F, av. age 37, av.cpd 29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:46 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg for 3-4m)<BR/>2. Placebo gum<BR/>Level of support: low (29-35 min at 1st visit including nurse &amp; physician advice, &amp; materials, follow-up appointment 1-2 wks later)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: salivary cotinine&lt;15ng/mL or thiocyanate&lt;1.6mmol/L</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 15:56:12 +0000" MODIFIED_BY="Kate Cahill">
<P>Time spent at 1st visit is marginal for inclusion in low intensity support category.<BR/>Study was funded by National Institute on Drug Abuse; gum supplied by Merrel-Dow Research Institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:45 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hughes-1990">
<CHAR_METHODS MODIFIED="2011-03-01 12:39:17 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:39:29 +0100" MODIFIED_BY="Kate Cahill">
<P>78 smokers, motivated to quit.<BR/>54% F, av.age 34-44, av.cpd 24-30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:45 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Placebo gum<BR/>2. 1 mg nicotine gum (unbuffered formula, available dose approx 0.5 mg)<BR/>3. 2 mg nicotine gum<BR/>4. 4 mg nicotine gum<BR/>Gum use not recommended for longer than 3m<BR/>Level of support: low (similar to Hughes 1989)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 6m<BR/>Validation: Independent observer report</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 09:14:07 +0000" MODIFIED_BY="Kate Cahill">
<P>2+3+4 vs 1 in Comparison 1. Excluding the lowest dose would increase the treatment effect. 4 vs 3 in Comparison 2, low dependence smokers.<BR/>Study was funded by National Institute on Drug Abuse.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:49 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hughes-1991">
<CHAR_METHODS MODIFIED="2011-03-01 12:39:04 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: primary care patients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-01 11:42:03 +0000" MODIFIED_BY="Kate Cahill">
<P>106 smokers, motivation to quit not required.<BR/>52% F, av.age 38, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:49 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Free prescription for nicotine gum for up to 6m<BR/>2. Nicotine gum at cost of US$6/box (96 pieces 2 mg)<BR/>2. Nicotine gum at US$20/box<BR/>All participants received brief physician advice with 1 follow-up.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m<BR/>Validation: observer verification of all 6m quitters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 11:41:29 +0000" MODIFIED_BY="Kate Cahill">
<P>Tested effect of price on gum use and efficacy. Results given in text, not included in any MA.<BR/>Study was funded by National Institute on Drug Abuse, and supported by Merrell-Dow Research institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:47 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hughes-1999">
<CHAR_METHODS MODIFIED="2011-03-01 12:43:18 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA (12 sites), Australia (1 site)<BR/>Recruitment: community volunteers &amp; referrals<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:42:33 +0100" MODIFIED_BY="Kate Cahill">
<P>1039 smokers (&#8805;30 cpd) who had made a prior quit attempt, motivated to try again<BR/>50% M, av.age 43, av.cpd 38<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:47 +0100" MODIFIED_BY="Kate Cahill">
<P>1. 42 mg nicotine patch (24hr, 6 wks + 10 wks tapering)<BR/>2. 35 mg nicotine patch<BR/>3. 21 mg nicotine patch<BR/>4. Placebo patch<BR/>Level of support: high (group behaviour therapy for 7 wks, brief individual counselling at 5 dose tapering meetings. Self help booklet)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:48:49 +0100" MODIFIED_BY="Lindsay Stead">
<P>Prolonged abstinence at 6m (from 2 wks postquit) verified at each follow-up visit.<BR/>(12m follow-up only completed for 11/13 sites)<BR/>Validation: CO&#8804;10ppm<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:00:50 +0100" MODIFIED_BY="Kate Cahill">
<P>All doses pooled in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> against placebo. 44 mg vs 22 mg in <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>
<BR/>6m abstinence rates used in analyses since not all centres completed 12m follow-up due to sponsor termination of study. Denominators confirmed by author.<BR/>Study was funded by National Institute on Drug Abuse, ALZA and Hoechst Marion Roussel.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:08 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hughes-2003">
<CHAR_METHODS MODIFIED="2011-03-01 13:12:08 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:56:26 +0100" MODIFIED_BY="Kate Cahill">
<P>115 smokers with a history of alcohol dependence, motivated to quit, &#8805;30 cpd<BR/>68% M, av.cpd 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:08 +0100" MODIFIED_BY="Kate Cahill">
<P>1.Nicotine patch ( 21 mg, 24hr, 6 wks + 4 wks tapering + 2 wks placebo)<BR/>2. Placebo patch 12 wks<BR/>Level of support: high (Group behaviour therapy x 6, brief individual counselling x3)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:48:55 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 6m (from 2 wks postquit)<BR/>Validation: CO&#8804;10ppm at each follow-up visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 13:20:22 +0000" MODIFIED_BY="Kate Cahill">
<P>Unadjusted ORs used in MA not significant, significant when adjusted for smoking variables.<BR/>Study was supported by GlaxoSmithKline, and funded by National Institute on Drug Abuse.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Hughes-2010">
<CHAR_METHODS MODIFIED="2012-09-27 14:53:58 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 11:57:35 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>746 smokers of &#8805;15cpd, wanting to quit gradually</P>
<P>54% F, av.age 48, av.cpd 23, av.FTND 5.9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Gradual cessation: 2 or 4 mg lozenges according to recommended labelling (4 mg for those who smoked within 30min of waking, 2 mg for everyone else) for 3 wks pre-cessation and 12 wks post-cessation; instructions to cut down cpd gradually pre-quit date; 5 counselling sessions</P>
<P>2. Abrupt cessation: 2 or 4 mg lozenges according to dosage instructions above for 12 wks post-cessation; 5 counselling sessions</P>
<P>3. Minimal intervention: 2 or 4 mg lozenges according to dosage instructions above for 12 wks post-cessation; 2 short counselling sessions</P>
<P>Level of support: high. Gradual: 4 calls pre- and 1 call postquit date; abrupt 2 calls pre- and 3 calls post; minimal intervention: 1 pre-, 1 postquit date.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-16 16:14:50 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>6m sustained abstinence</P>
<P>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 13:39:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 analysis.</P>
<P>1 and 2 used in pre-cessation <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>; 3 does not contribute to review.</P>
<P>Study of gradual cessation aided by NRT vs abrupt cessation with NRT use from quit date. pre-cessation NRT may be confounded with other gradual cessation techniques.</P>
<P>Funding provided by US National Institute on Drug Abuse.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:21:27 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hurt-1990">
<CHAR_METHODS MODIFIED="2011-03-01 13:27:03 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:00:01 +0100" MODIFIED_BY="Kate Cahill">
<P>62 adult smokers (&gt;20 cpd); only accepted if willing to make a quit attempt.<BR/>53% F, av.age 39, av.cpd 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:49:03 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (30mg 24hrs, 6 wks + option of further 12 wks +/- tapering)<BR/>2. Placebo patch (continuing smokers at 6 wks were offered active patch)<BR/>Level of support: high (brief advice from nurse co-ordinator at 6 weekly visits)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:21:27 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (quit by wk 6, &amp; all subsequent visits)<BR/>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 13:44:24 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was in part supported by Elan Pharmaceutical Research Corporation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:21:36 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hurt-1994">
<CHAR_METHODS MODIFIED="2011-03-01 13:57:03 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:01:16 +0100" MODIFIED_BY="Kate Cahill">
<P>240 adult smokers (&gt;20 cpd), motivated to quit.<BR/>53% F, av.age 43, av.cpd 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:21:36 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (22 mg/24hr, 8 wks, no tapering)<BR/>2. Placebo patch<BR/>Level of support: high (nurse counselling at 8 weekly visits, weekly phone calls to wk 12)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:01:38 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12m (no puff since 9m visit)<BR/>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 12:01:46 +0100" MODIFIED_BY="Kate Cahill">
<P>Study was supported by Lederle Laboratories, NY.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:21:42 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-ICRF-1994">
<CHAR_METHODS MODIFIED="2011-03-01 15:05:31 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Setting: primary care (19 general practices)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:02:27 +0100" MODIFIED_BY="Kate Cahill">
<P>1686 smokers (&gt;15 cpd), not necessarily motivated to quit.<BR/>55% F, av.age 43, av.cpd 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:10 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg/24hr, 12 wks incl tapering)<BR/>2. Placebo patch<BR/>Level of support: high (brief advice from nurse at 4 study visits)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:21:42 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m (from wk 1)<BR/>Validation: Salivary cotinine or CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:08:39 +0100" MODIFIED_BY="Kate Cahill">
<P>8yr follow-up in Yudkin 2003, OR remained similar.<BR/>Study supported by Ciba-Geigy Pharmaceuticals.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:57:55 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Jamrozik-1984">
<CHAR_METHODS MODIFIED="2012-09-27 14:54:12 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: UK<BR/>Recruitment: primary care (6 general practices)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>200 adult smokers who had failed to stop smoking during a previous study of the effect of physician advice<BR/>No demographic information</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:57:55 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg) for 3m+<BR/>2. Placebo gum<BR/>Level of support: low (follow-up visits at 2, 4, 12 wks for data collection, no counselling reported)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:03:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>PP abstinence at 6m<BR/>Validation: expired CO&#8804;12ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 15:48:50 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was funded by Oxford District Research Committee and Nuffield Dominions Trust, and supported by Lundbeck Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:11 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Jarvis-1982">
<CHAR_METHODS MODIFIED="2011-03-01 15:55:01 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:04:28 +0100" MODIFIED_BY="Kate Cahill">
<P>116 clinic attenders, motivated to quit.<BR/>55% F, av.age 41/38, av.cpd 31/27 (P&lt;0.05)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:11 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. NicotineU gum (2 mg) unrestricted amount for at least 3m<BR/>2. Placebo gum (1 mg unbuffered nicotine)<BR/>Level of support: high (group therapy 6x1hr weekly)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (6m &amp; 12m PP)<BR/>Validation: CO (small number by confirmation from friend/relative only)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 15:53:47 +0000" MODIFIED_BY="Kate Cahill">
<P>The placebo gum was intended to match the active gum in taste but deliver minimal amounts of nicotine.<BR/>Study was funded by Medical Research Council and Dept of Health and Social Security, and supported by AB Leo.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:21:49 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Jensen-1991">
<CHAR_METHODS MODIFIED="2011-03-02 13:18:15 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:06:08 +0100" MODIFIED_BY="Kate Cahill">
<P>293 adult smokers (&gt;10 cpd) in relevant arms<BR/>54% F, av. age 42, av.cpd 21-22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:21:49 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg for 3m)<BR/>2. Silver acetate chewing gum (not used in MA)<BR/>3. Standard chewing gum<BR/>Level of support: high (9 group meetings over a year, weekly to wk 4)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-02 13:20:55 +0000" MODIFIED_BY="Kate Cahill">
<P>12m data reported in Thorax 1990 paper, used from 2008. <BR/>Sources of support not stated. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:22:01 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Jorenby-1995">
<CHAR_METHODS MODIFIED="2011-03-02 13:25:09 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:07:09 +0100" MODIFIED_BY="Kate Cahill">
<P>504 adult smokers (&#8805;15 cpd)<BR/>53% F, av.age 44, av.cpd ~27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:18 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch 22 mg for 6 wks then 2 wks 11 mg with minimal counselling<BR/>2. Same patch, individual counselling<BR/>3. Same patch, group counselling.<BR/>4. 44 mg patch for 4 wks then 2 wks 22 mg then 2 wks 11 mg with minimal counselling<BR/>5. Same patch, individual counselling<BR/>6. Same patch, group counselling.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:22:01 +0100" MODIFIED_BY="Kate Cahill">
<P>Abstinence (&gt;1 wk) at 6m<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-02 13:26:41 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to comparison 1.<BR/>Support levels collapsed in comparison 8 between high and standard dose.<BR/>Study was funded by Elan Pharmaceutical Research Corporation.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:22:14 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Jorenby-1999">
<CHAR_METHODS MODIFIED="2011-03-02 14:11:11 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA (4 sites)<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:08:28 +0100" MODIFIED_BY="Kate Cahill">
<P>893 smokers, motivated to quit, (&gt;15 cpd) 52% F, av.age 42-44, av.cpd 25-28</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:22:14 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg/24hr for 6 wks, tapered for 2 wks) and sustained release bupropion 300mg for 9 wks from 1 wk before quit day<BR/>2. Bupropion 300mg and placebo patch<BR/>3. Nicotine patch and placebo tablets<BR/>4. Placebo patch and placebo tablets<BR/>Level of support: high, &lt;15 min individual counselling session at each weekly assessment. One phone call 3 days after quit day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (primary outcome for study was PP abstinence; this analysis uses continuous abstinence since quit day)<BR/>Validation: Expired CO&lt;10ppm at each clinic visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-04 16:45:03 +0100" MODIFIED_BY="Kate Cahill">
<P>3 vs 4 in main analyses. NRT vs bupropion in <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK> and as adjunct to bupropion in <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>. Bupropion as adjunct to NRT no longer assessed in this review.<BR/>Study was funded by Glaxo Wellcome.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:23 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Joseph-1996">
<CHAR_METHODS MODIFIED="2012-09-27 14:54:25 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA, multicentre trial<BR/>Recruitment: 10 Veterans Affairs Medical Centers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 15:49:34 +0100" MODIFIED_BY="Kate Cahill">
<P>584 smokers (&gt;15 cpd) with a history of cardiac disease. Patients with cardiac events within the last 2 wks were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:23 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch, (21 mg/24hr for 6 wks, 14 mg for 2 wks, 7mg for 2 wks)<BR/>2. Placebo patch<BR/>Level of support: High (self help pamphlets and brief behavioural counselling on 3 occasions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:10:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>PP abstinence at 6m (Joseph 1996), 12m (Joseph 1999)<BR/>Validation: CO&#8804;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-02 14:25:10 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was funded by Hoechst Marion Roussel.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:26 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Kalman-2006">
<CHAR_METHODS MODIFIED="2011-03-02 14:48:25 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: Veterans Admin Medical Centre and community-based substance abuse treatment facility<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:11:31 +0100" MODIFIED_BY="Kate Cahill">
<P>130 smokers (&#8805;20 cpd with history of alcohol dependence &amp; &#8805;2m abstinence from alcohol &amp; illicit drugs)<BR/>84%M, av.age 47, av.cpd 32</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:26 +0100" MODIFIED_BY="Kate Cahill">
<P>Dose response trial<BR/>1. Nicotine patch (42 mg (2x21 mg)) 4 wks, then tapered for 8 wks<BR/>2. Nicotine patch (21 mg &amp; placebo) for 4 wks then same tapering as 1.<BR/>(Level of support: high (5x1hr weekly group counselling sessions, 2 before TQD)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:49:44 +0100" MODIFIED_BY="Kate Cahill">
<P>Abstinence at 36 wks (26 wks post EOT) (7 day PP)<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-02 14:52:32 +0000" MODIFIED_BY="Kate Cahill">
<P>New for 2008 update.<BR/>Study was funded by National Institute on Drug Abuse.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:01 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Killen-1984">
<CHAR_METHODS MODIFIED="2011-03-02 14:59:25 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:13:07 +0100" MODIFIED_BY="Kate Cahill">
<P>64 adult smokers<BR/>72% F, av.age 44, av.cpd 32</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:01 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg) for 7 wks<BR/>2. Skills training<BR/>3. Skills training plus nicotine gum<BR/>Level of support: high (group therapy)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 10.5m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-08 10:24:53 +0000" MODIFIED_BY="Kate Cahill">
<P>1+3 vs 2 used in comparison. 3 vs 2 would increase effect.<BR/>Study was funded by the National Institute of Health, and supported by Merrell-Dow Pharmaceuticals Inc.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:02 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Killen-1990">
<CHAR_METHODS MODIFIED="2011-03-02 15:11:54 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers who had abstained from smoking for 48 hrs<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:14:00 +0100" MODIFIED_BY="Kate Cahill">
<P>1218 adult smokers<BR/>52% F, av.age 43, av.cpd 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:02 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg, 8 wks) ad lib dosing<BR/>2. Nicotine gum on a fixed dose<BR/>3. Placebo gum<BR/>4. No gum<BR/>Each group was also factorially randomized to 1 of 3 psychological interventions (all high support).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:14:22 +0100" MODIFIED_BY="Kate Cahill">
<P>PP abstinence at 12m (7 day PP)<BR/>Validation: cotinine, except participants who moved away</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-02 15:24:07 +0000" MODIFIED_BY="Kate Cahill">
<P>Quit rates were higher on fixed dose than ad lib gum.<BR/>Quit rates identical (18%) in placebo and no gum groups at 12m.<BR/>Study was funded by National Cancer Institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:27 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Killen-1997">
<CHAR_METHODS MODIFIED="2011-03-02 15:37:27 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:14:53 +0100" MODIFIED_BY="Kate Cahill">
<P>424 smokers<BR/>~50% F, av.age ~45, av.cpd ~23</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:27 +0100" MODIFIED_BY="Kate Cahill">
<P>2x2 factorial design, comparison between video &amp; self help manuals and manuals alone collapsed.<BR/>1. Nicotine patch (21 mg/24hr) for 8 wks, 14 mg for 4 wks, 7mg for 4 wks<BR/>2. Placebo patch<BR/>3. Nicotine patch and video (The video was shown at initial visit and a copy supplied for home use)<BR/>4. Placebo patch and video<BR/>Level of support: low (All treatment groups received a self help treatment manual designed to develop self regulatory skills.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (7 day PP at 6 and 12m)<BR/>Validation: saliva cotinine&lt;20ng/ml with the exception of participants living outside the area</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 12:16:01 +0100" MODIFIED_BY="Kate Cahill">
<P>There was evidence of an interaction between NRT and video/self help conditions but this does not alter the MA so the conditions are combined from 2007. Both self help conditions treated as low intensity - classifying video as high intensity would marginally reduce effect in high intensity subgroup.<BR/>Study was funded by National Heart, Lung, and Blood Institute, and supported by Hoechst Marion Roussel Inc and Blue Shield Management.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:48 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Killen-1999">
<CHAR_METHODS MODIFIED="2011-03-02 15:50:44 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers responding to advertisements - heavy smokers selected from responders<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:16:50 +0100" MODIFIED_BY="Kate Cahill">
<P>408 heavy smokers (&gt;25 cpd)<BR/>59% M, av.age 47, av.cpd 36, modified FTND score 18<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:48 +0100" MODIFIED_BY="Kate Cahill">
<P>1. 25 mg nicotine patch for 6 wks (16hr, no tapering)<BR/>2. 15 mg nicotine patch for 6 wks<BR/>Self help treatment manual, short video showing patch use and placement</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (7 day PP abstinence at both 6 and 12m)<BR/>Validation: Saliva cotinine&lt;20 ng/ml (not required for 3 individuals not in area)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 12:17:22 +0100" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to comparison 1.<BR/>85% of self reported quitters provided samples for validation at 12m</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:00:59 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Kornitzer-1987">
<CHAR_METHODS MODIFIED="2011-03-08 09:51:04 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Belgium<BR/>Recruitment: worksite primary care clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>199 smokers (av cpd 24-5)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:00:58 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (4 mg) for at least 3m<BR/>2. Nicotine gum (2 mg) for same time period<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:30:54 +0100" MODIFIED_BY="Kate Cahill">
<P>PP abstinence at 12m<BR/>Validation: cotinine and carboxyhemaglobin in a subsample of subjects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:00:59 +0100" MODIFIED_BY="Kate Cahill">
<P>Contributes data only to 4 mg vs 2 mg Comparison 2.<BR/>Sources of funding and support not stated.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:53 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Kornitzer-1995">
<CHAR_METHODS MODIFIED="2011-03-08 10:10:21 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Belgium<BR/>Recruitment: worksite volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:31:29 +0100" MODIFIED_BY="Kate Cahill">
<P>374 healthy smokers (&gt;10 cpd for &gt;3yrs), motivated to quit.<BR/>61% M, av. age 40, av.cpd 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:53 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (12 wks 15 mg/16hr, 6 wks 10mg, 6 wks 5 mg) and nicotine gum (2 mg, as required)<BR/>2. Nicotine patch and placebo gum<BR/>3. Placebo patch and placebo gum. Level of support: high (nurse counselling)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO&lt;10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-08 11:23:42 +0000" MODIFIED_BY="Kate Cahill">
<P>Contributes data to main comparison (2 vs 3) and to patch plus gum vs patch alone comparison.<BR/>Study was supported by Pharmacia Consumer Pharma.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kralikova-2002">
<CHAR_METHODS MODIFIED="2011-03-08 11:40:59 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Czech Republic<BR/>Recruitment: community volunteers 'wanting to reduce'<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:32:43 +0100" MODIFIED_BY="Kate Cahill">
<P>314 smokers (&#8805;15 cpd)<BR/>58% F, av.age 46, av.cpd 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:00 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Choice of 4 mg nicotine gum (up to 24/day) or 10mg inhaler (6-12 daily) for up to 6m with further 3m tapering<BR/>2. Placebo gum or inhaler<BR/>Common components: brief behavioural cessation/reduction support at clinic visits (9 scheduled)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m <BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-08 10:29:20 +0000" MODIFIED_BY="[Empty name]">
<P>Trial also included assessment of reduction. Reduction outcomes contribute to Cochrane review on harm reduction.<BR/>Study details are taken from a conference abstract. Published 2009<BR/>Study supported by Pharmacia CHC, Sweden.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 12:33:51 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Leischow-1996">
<CHAR_METHODS MODIFIED="2011-03-08 11:46:17 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:33:28 +0100" MODIFIED_BY="Kate Cahill">
<P>222 smokers (&gt;20 cpd). (2 excluded from analysis having received incorrect prescription)<BR/>55% F, av.age 44, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nicotine Inhaler (10mg). Advised to use 4-20 cartridges/day for 3m. After this tapering was encouraged until 6m.<BR/>2. Placebo inhaler <BR/>Participants received advice and watched a video showing proper use of the inhaler. <BR/>Level of support: high (brief individual smoking cessation support at each study visit, 10 in all)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:33:51 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m<BR/>Validation: CO&lt;10ppm at each follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-08 12:02:52 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was funded by Pharmacia Upjohn, Sweden.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:22:42 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Leischow-1999">
<CHAR_METHODS MODIFIED="2011-03-08 13:02:07 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:34:13 +0100" MODIFIED_BY="Kate Cahill">
<P>300 smokers prepared to purchase patch and make a quit attempt<BR/>45% F, av.age 43, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:22:42 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (15 mg/16hr) which could be purchased (1 wk supply for US$15) for up to 26 wks. No behavioural support apart from patch package insert.<BR/>2. Nicotine patch for purchase as 1. Prescription for 12 wks provided after physician visit. Prescription renewed on request up to 26 wks. Behavioural support based on NCI guidelines, 5-10 mins. Study staff also allowed to give behavioural support.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:35:08 +0100" MODIFIED_BY="Kate Cahill">
<P>Continuous abstinence from date of first patch purchase at 12m (non-purchasers counted as failures)<BR/>(PP rates also reported)<BR/>Validation: CO&lt;9ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-08 13:04:33 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison.<BR/>Compared different ways of buying patch - simulating OTC, or with physician prescription and support.<BR/>Study was funded by DHHS and Arizona Disease Control Commission, and supported by McNeil Pharmaceuticals.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:22:52 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Leischow-2004">
<CHAR_METHODS MODIFIED="2011-03-08 13:30:09 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:36:11 +0100" MODIFIED_BY="Kate Cahill">
<P>520 smokers prepared to purchase inhaler and make a quit attempt<BR/>51% F, av.age 48, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:22:52 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine inhaler could be purchased ad lib. Standard package information, no further behavioural support<BR/>2. Nicotine inhaler could be purchased ad lib via healthcare provider. Support materials and brief behavioural intervention given at 1st clinic visit and wk 2, av time 8 mins, 47% discussed inhaler use</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Continuous abstinence at 12m<BR/>Validation: CO<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-08 13:47:55 +0000" MODIFIED_BY="Kate Cahill">
<P>First included as Leischow 2003 based on abstract.<BR/>Does not contribute to comparison 1. See Leischow 1999.<BR/>Study was funded by DHHS and supported by Pharmacia &amp; Upjohn.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:23:01 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Lerman-2004">
<CHAR_METHODS MODIFIED="2011-03-08 15:09:15 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers and referrals<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:37:17 +0100" MODIFIED_BY="Kate Cahill">
<P>350 smokers (&#8805;10 cpd) (includes 51 who withdrew before treatment)<BR/>54% F, av.age 46, av.cpd 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:23:01 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg/24hr) for 8 wks incl tapering<BR/>2. Nicotine nasal spray (8-40 doses/day, max 5/hr) for 8 wks, tapering over final 4 wks<BR/>Level of support: 7x90 min behavioural group counselling sessions. TQD in wk 3.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m (Continuous no slips and prolonged lapse-free unvalidated outcomes also reported) <BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-08 15:17:53 +0000" MODIFIED_BY="Kate Cahill">
<P>First included 2004 based on Patterson 2003 paper. Minor changes to data using Lerman 2004 in 2008 update.<BR/>Choice of outcome does not change conclusion of no significant difference.<BR/>Does not contribute to main comparison, only head-to-head comparison.<BR/>Study was funded by National Cancer Institute, National Institute on Drug Abuse and National Institutes of Health.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:30 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Lewis-1998">
<CHAR_METHODS MODIFIED="2011-03-09 08:39:48 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: hospitalised patients willing to make a quit attempt<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:38:36 +0100" MODIFIED_BY="Kate Cahill">
<P>185 smokers (&#8805;10 cpd), motivated to quit<BR/>46% F, av.age 43-44, cpd 23-24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:30 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Minimal intervention, 2-3 mins motivational message and self help pamphlet<BR/>2. As 1. plus placebo patch. Nurse provided brief telephone counselling at 1, 3, 6 and 24 wks<BR/>3. As 2. plus nicotine patch (22 mg/ 24hrs for 3 wks, tapered to 11 mg for 3 wks)<BR/>Level of support: low (since initial support was brief and further contacts in 2 were by phone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:39:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>PP abstinence at 6m Validation: CO&#8804;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 12:39:58 +0100" MODIFIED_BY="Kate Cahill">
<P>3 vs 1+2 used in MAs (Restricting control to 2 only would reduce the OR to 1.6).<BR/>Study was funded by Elan Pharmaceutical Research Corporation.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 12:40:28 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Llivina-1988">
<CHAR_METHODS MODIFIED="2011-03-09 10:28:59 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Spain<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:40:28 +0100" MODIFIED_BY="Kate Cahill">
<P>216 smokers<BR/>Av.cpd 28-30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nicotine gum (dose not stated) for 1m<BR/>2. Placebo gum<BR/>Level of support: High (group support)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-09 11:26:50 +0000" MODIFIED_BY="Kate Cahill">
<P>Reclassified as high support 2008.<BR/>Study was funded by el Fondo de Investigaciones Sanitarias de la Seguridad Social, la Sociedad Española de Patologia Respiratoria, and los Laboratorios PENSA-ESTEVE.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:09 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Malcolm-1980">
<CHAR_METHODS MODIFIED="2011-03-09 11:27:24 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:41:05 +0100" MODIFIED_BY="Kate Cahill">
<P>194 smokers<BR/>40-43% F, av.age 44-46, av.cpd 25-26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:09 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg) at least 10/day for at least 3m<BR/>2. Placebo gum<BR/>3. Control<BR/>Level of support: high (weekly individual counselling for 1m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:41:18 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 6m<BR/>Validation: venous carboxyhaemoglobin&#8804;1.6%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-09 11:28:43 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by AB Leo &amp; Company, Helsinborg, Sweden.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 12:41:50 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Marshall-1985">
<CHAR_METHODS MODIFIED="2011-03-09 11:43:38 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Setting: primary care - patients responding to a postcard from a GP (i.e. selected by motivation)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:41:50 +0100" MODIFIED_BY="Kate Cahill">
<P>200 smokers, motivated to quit; 21% had a smoking-related disease<BR/>Av. age 41, av.cpd 22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Physician advice plus nicotine gum<BR/>2. As 1. and offer of 4 follow-up visits over 3m</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-03 14:07:35 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (and 6m)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-09 11:44:45 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to comparison 1. Test of different intensity of support.<BR/>Study received running expenses and gum from Lundbeck Ltd.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:11 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-McGovern-1992">
<CHAR_METHODS MODIFIED="2011-03-23 09:39:39 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:42:32 +0100" MODIFIED_BY="Kate Cahill">
<P>293 adult smokers. Av.cpd not stated. 58% smoked &gt;25 cpd.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:11 +0100" MODIFIED_BY="Kate Cahill">
<P>1. ALA Freedom from Smoking clinic program plus nicotine gum (2 mg for 3m)<BR/>2. ALA Freedom from Smoking clinic program alone (no placebo gum)<BR/>Level of support: high (group)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: salivary thiocyanate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 09:40:51 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by Merrell-Dow Pharmaceuticals.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:56 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Molyneux-2003">
<CHAR_METHODS MODIFIED="2011-03-23 09:56:58 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: hospital<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>274 smokers (182 in relevant arms) admitted to medical and surgical wards, smoked in last 28 days<BR/>60% M, av.age 60, median cpd 17, 81% had previous quit attempt</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:56 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Choice of NRT products (15 mg 16hr patch/2 mg or 4 mg gum, 10mg inhalator/2 mg sublingual tablet, 0.5 mg spray), Brief (20 min) bedside counselling from a research doctor or nurse.<BR/>2. Brief counselling only<BR/>3. Usual Care, no smoking advice (not used in MA)<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Continuous abstinence at 12m<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 10:13:10 +0000" MODIFIED_BY="Kate Cahill">
<P>No placebo. 63% chose patch, 13% inhalator, 11% gum, 8% tablets and 1% nasal spray, 4% declined use.<BR/>Study was supported by Pharmacia Consumer Healthcare, Sweden.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:31 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Moolchan-2005">
<CHAR_METHODS MODIFIED="2011-03-23 11:02:02 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:45:09 +0100" MODIFIED_BY="Kate Cahill">
<P>120 adolescent (age 13-17) smokers (&#8805;10 cpd), motivated to quit.<BR/>70% F, av.age 15, av.cpd 19</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:31 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg, or 14 mg for &lt;20 cpd) for 6 wks +placebo gum<BR/>2. Nicotine gum (4 mg, or 2 mg for &lt;24 cpd) for 6 wks + placebo patch<BR/>3. Double placebo<BR/>Level of support: high (11x45-min individual counselling over 12 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m<BR/>Validation: CO &amp; cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 11:29:06 +0000" MODIFIED_BY="Kate Cahill">
<P>New for 2008 update<BR/>Placebo group contributes twice to MA - too small to affect total<BR/>Sustained abstinence at 3&amp;6m could be derived from text, relative effect greater since no quitters on placebo.<BR/>Study was funded by National Institute on Drug Abuse, and supported by GlaxoSmithKline.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:15 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Mori-1992">
<CHAR_METHODS MODIFIED="2011-03-23 11:35:26 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Japan<BR/>Recruitment: hospital<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-23 11:41:38 +0000" MODIFIED_BY="Kate Cahill">
<P>364 smokers with smoking-related illness. Number of cpd not stated. Motivation to quit probably not required.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:15 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum 2 mg for 3m<BR/>2. Placebo gum<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence (not defined) at 6m<BR/>Validation: serum thiocyanate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 11:37:57 +0000" MODIFIED_BY="Kate Cahill">
<P>"Supported partially by FISss 90/0431 and SEPAR". Trial report was abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:16 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Nakamura-1990">
<CHAR_METHODS MODIFIED="2011-03-23 11:42:35 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Japan<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 adult smokers. <BR/>Av. cpd 31</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:16 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg, 2m or longer)<BR/>2. Non-placebo control group received counselling<BR/>Level of support: high</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 6m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 11:54:23 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by Merrell-Dow Pharmaceuticals.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 12:47:52 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Nebot-1992">
<CHAR_METHODS MODIFIED="2011-03-23 13:39:10 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Spain<BR/>Recruitment: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:47:52 +0100" MODIFIED_BY="Kate Cahill">
<P>425 unselected smokers. 60-70% smoking &gt;15 cpd</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-23 13:38:15 +0000" MODIFIED_BY="Kate Cahill">
<P>A. Brief counselling from physician<BR/>B. Physician counselling plus nicotine gum<BR/>C. Health education from nurse<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 12:58:40 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by the Fondo de Investigaciones Sanitarias de la Seguridad Social.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:16 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Niaura-1994">
<CHAR_METHODS MODIFIED="2011-03-23 13:43:07 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: outpatient settings and physician referrals (primary care subgroup)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:57:31 +0100" MODIFIED_BY="Kate Cahill">
<P>77 low dependence (FTND&#8804;6) and 96 high dependence smokers<BR/>50% F, av.age 42, av.cpd 29, FTND 4.7 for low dependence, 8.0 for high dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:16 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum 2 mg, ad lib for up to 4m (participants given prescription for gum, not free)<BR/>2. No gum<BR/>Level of support: high (4 individual counselling sessions and ALA self help treatment manuals)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Continuous abstinence at 12m<BR/>Validation: saliva cotinine, or CO for gum users</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 13:46:19 +0000" MODIFIED_BY="Kate Cahill">
<P>No placebo used. Data collapsed across dependence levels. As predicted by the study, smokers with lower dependence had lower quit rates with than without gum. The OR would be higher (4.40) if inclusion restricted to the high dependence group.<BR/>Study was supported by National Cancer Institute and National Heart, Lung, and Blood Institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:18 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Niaura-1999">
<CHAR_METHODS MODIFIED="2011-03-23 14:45:45 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:58:45 +0100" MODIFIED_BY="Kate Cahill">
<P>62 smokers in relevant arms<BR/>50% F, av.cpd 28, av.age 43.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:18 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Brief cognitive behavioral relapse prevention (CBRP) , 15 min sessions<BR/>2. Intensive CBRP with nicotine gum (2 mg)<BR/>3. Intensive CBRP with cue exposure<BR/>4. Intensive CBRP with cue exposure + nicotine gum<BR/>Level of support: high (5 group sessions within 3 wks of TQD)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 12:59:25 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence, 12m and all previous follow-ups (1, 3, 6m)<BR/>Validation: CO&lt;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 15:03:40 +0000" MODIFIED_BY="Kate Cahill">
<P>4 vs 3, behavioural support not identical in others. No placebo.<BR/>Study was supported by Department of Veterans Affairs<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:19 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Ockene-1991">
<CHAR_METHODS MODIFIED="2011-03-23 15:25:06 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 12:59:55 +0100" MODIFIED_BY="Kate Cahill">
<P>1223 unselected smokers, 57% F, av.age 35, av.cpd 22-23</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:19 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Advice only<BR/>2. Patient-centred counselling<BR/>3. Patient-centred counselling and offer of nicotine gum (2 mg) plus minimal or intensive follow-up by telephone.<BR/>Level of support: mixed (not used in subgroup analysis)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (quit at 6m &amp; 12m, reported in Ockene 1994)<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 15:25:36 +0000" MODIFIED_BY="Kate Cahill">
<P>69% of group 3 accepted prescription and received at least 1 box of gum.<BR/>12m sustained rates, 3 vs 2, used in MA since 2008.<BR/>Study was funded by the National Cancer Institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:31 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Oncken-2007">
<CHAR_METHODS MODIFIED="2011-03-23 15:51:51 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:01:02 +0100" MODIFIED_BY="Kate Cahill">
<P>152 postmenopausal women (&#8805;10 cpd)<BR/>Av.cigs/day 22, av.age 54/56.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:31 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg for 13 wks incl 4 wks tapering)<BR/>2. Placebo patch<BR/>Level of support: high (7 visits incl 4 x 2hr group counselling, 1 pre-TQD)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 16m (12m post-EOT)<BR/>Validation: CO&lt;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 17:13:04 +0100" MODIFIED_BY="Kate Cahill">
<P>Study was supported by The Patrick and Catherine Weldon Donaghue Foundation, The University of Connecticut Center on Aging, University of Connecticut General Clinical Research Center and the National Institute for Health. Pharmaceuticals supplied by GlaxoSmithKline.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:23:19 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Oncken-2008">
<CHAR_METHODS MODIFIED="2012-02-21 11:42:06 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: volunteers from antenatal clinics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:13:23 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>194 pregnant women smoking at least 1cpd.</P>
<P>Av.age 25, av.cpd 10 in wk before study enrolment, av.cpd 18 prepregnancy, mean FTND&lt;4.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:23:19 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. 2 mg nicotine gum (first 6 wks: instructed to chew one piece for every cig usually smoked per day, not exceeding 20, followed by 6 wk tapering period)</P>
<P>2. Placebo gum, dosing and duration as above</P>
<P>Level of support: high. In-person and telephone individual smoking cessation counselling.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:50:20 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Abstinence at 32-34 wks of gestation and 7d PP at 6-12 wks postpartum (abstinence at 6 wks postquit date also reported)</P>
<P>Validation: CO and urinary cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-23 15:26:48 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Varying lengths of follow-up. Longest follow-up used in primary analysis</P>
<P>NRT group had significantly higher birth weight and gestational age than placebo group. NRT group significantly more likely to attend follow-up visits.</P>
<P>Funded by the National Institutes of Health.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:23:31 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Ortega-2011">
<CHAR_METHODS MODIFIED="2012-02-21 11:44:16 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: Spain</P>
<P>Recruitment: hospital inpatients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-21 11:44:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1843 hospital inpatients who identified as smokers. 88% M, av.age 62, av. 56 packs/year.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:23:31 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine patch or gum (max 12 wks; participant's choice) + CBT</P>
<P>2. CBT only</P>
<P>3. Declined to participate</P>
<P>Level of support: high (standardized 30-45 min sessions every 3d until patient discharged from hospital; postdischarge participant could have telephone or in-person sessions at 1 wk, 15d, 2, 3, 6, and 12m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-21 11:46:01 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Continuous abstinence from quit day at 12m</P>
<P>Validation: 34% of participants verified with CO measurement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 13:15:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>No placebo. Groups 1 and 2 included in primary analysis under 'choice of NRT'. 'No significant outcome differences between NRT types' (personal communication from author).</P>
<P>717 declined to participate but followed up at 12m.</P>
<P>Funding not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:32 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Otero-2006">
<CHAR_METHODS MODIFIED="2011-03-25 08:52:15 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Brazil<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-25 09:00:13 +0000" MODIFIED_BY="Kate Cahill">
<P>1199 smokers (includes 254 non-attenders), motivated to quit.<BR/>63%F, av.age 42, 46% smoked &gt;20 cpd</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:32 +0100" MODIFIED_BY="Kate Cahill">
<P>Factorial design with multiple levels of behavioural support<BR/>1. Nicotine patch (21 mg, 14 mg for FTND&lt;5) 8 wks incl tapering + behavioural support<BR/>2. Cognitive behavioural support only<BR/>Level of support: Mixed - Low=single 20 min session. High= 1, 2, 3 or 4 weekly 1hr sessions. Maintenance or recycling sessions provided at 3, 6, 12m.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-03 10:25:28 +0100" MODIFIED_BY="Kate Cahill">
<P>Contributes to both high &amp; low support subgroups.<BR/>No placebo.<BR/>Study was supported by the Institute for Global Tobacco Control and the Fogarty International Center of the National Institutes of Health.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:21 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Page-1986">
<CHAR_METHODS MODIFIED="2011-03-25 09:15:38 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Canada<BR/>Recruitment: primary care (5 family practices in Ontario)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>275 unselected smokers. Primary care attenders aged 18-65 yrs <BR/>Number of cpd not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:21 +0100" MODIFIED_BY="Kate Cahill">
<P>1. No advice<BR/>2. Advice to quit<BR/>3. Advice to quit plus offer of nicotine chewing gum prescription (2 mg)<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 6m<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 09:19:40 +0000" MODIFIED_BY="Kate Cahill">
<P>3 vs 1+2<BR/>No placebo.<BR/>Study was funded by the Canadian College of Family Physicians of Canada and by the University of Waterloo Social Sciences and Humanities Research Grant Fund.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:58 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Paoletti-1996">
<CHAR_METHODS MODIFIED="2011-03-25 09:57:34 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Italy<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:18:37 +0100" MODIFIED_BY="Kate Cahill">
<P>297 smokers (&#8805;10 cpd), motivated to quit.<BR/>Stratified according to baseline cotinine levels<BR/>40% F, av.age 43, av. cpd 24 in low cotinine group (n=120), 30 in high group (n= 177)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:58 +0100" MODIFIED_BY="Kate Cahill">
<P>Stratum A (Baseline cotinine&lt;250ng/ml)<BR/>1. Nicotine patch (15 mg/16hr, 18 wks incl taper)<BR/>2. Placebo patch<BR/>Stratum B (Baseline cotinine&gt;250ng/ml)<BR/>3. Nicotine patch 15 mg<BR/>4. Nicotine patch 25 mg<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: CO and plasma cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 09:58:45 +0000" MODIFIED_BY="Kate Cahill">
<P>Stratum A in Comparison 1<BR/>Stratum B in Comparison 8 (high versus standard dose patch).<BR/>Study was funded by Pharmacia.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:07 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Perng-1998">
<CHAR_METHODS MODIFIED="2011-03-25 10:11:47 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Taiwan<BR/>Recruitment: outpatient chest clinics, volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:19:31 +0100" MODIFIED_BY="Kate Cahill">
<P>62 smokers (&gt;20 cpd)<BR/>94% M, av.age 62, av.cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:07 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (24 mg/24 hr for 6 wks, no weaning)<BR/>2. Placebo patch<BR/>Level of support: High (weekly visit to outpatient department for assessment, unclear if counselling was provided)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m<BR/>Validation: CO&lt;10ppm during patch use, but no validation at 12m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 10:28:19 +0000" MODIFIED_BY="Kate Cahill">
<P>Level of support reclassified as high, 2008 update.<BR/>Study was funded by Orient Europharma Company Ltd, Taipei, Taiwan.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:08 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Piper-2007">
<CHAR_METHODS MODIFIED="2011-03-25 10:49:55 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-25 11:11:02 +0000" MODIFIED_BY="Kate Cahill">
<P>608 smokers, motivated to quit.<BR/>58% F, av.age 42, av cpd 22, no details of depression history</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:08 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (4 mg, 8 wks) and bupropion (300mg, 9 wks)<BR/>2. Placebo gum and bupropion<BR/>3. Double placebo (Not used in MA)<BR/>All arms: 3x10 min counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 12m<BR/>Validation: CO &amp; cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-03 10:25:57 +0100" MODIFIED_BY="Kate Cahill">
<P>Identified from conference abstracts, we use data from paper published after date of search. Contributes to comparison of NRT + bupropion versus bupropion alone.<BR/>Study was funded by National Institutes of Health.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:23:50 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Piper-2009">
<CHAR_METHODS MODIFIED="2012-02-07 09:58:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Participants: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-21 11:46:26 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1504 smokers motivated to quit. </P>
<P>58% F, av.age 45, av.cpd 21.4.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:23:50 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine lozenge 2 or 4 mg for 12 wks (based on dose-for-dependence level as per instructions)</P>
<P>2. Nicotine patch (24hr, 21, 14, and 7mg titrated down over 8 wk period postquit)</P>
<P>3. Bupropion SR (150mg bid, 1 wk pre-quit, 8 wks postquit)</P>
<P>4. Lozenge + patch (duration and dosage as above)</P>
<P>5. Bupropion + lozenge (duration and dosage as above)</P>
<P>6. Placebo (5 groups matched to above 5 interventions)</P>
<P>Level of support: high. All participants received 7 one-to-one 10-20min counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:22:01 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>7d PP abstinence at 6m; initial cessation.</P>
<P>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 13:24:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Placebo outcomes not reported by subgroup; outcomes generated by applying overall percentage of events in placebo group to individual subgroups. 1, 2, 4 and 6 included in primary analysis. 1, 2 and 4 included in <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>, combinations of different types of NRT. 1 and 2 included in <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK> direct comparisons between NRT types. 1, 2, 3, 5 and 6 included in comparisons and combinations of NRT and bupropion, <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>. Numbers used for bupropion comparison divided between analysis 16.1.1 and 16.1.2 to avoid double counting. Bupropion as adjunct to NRT not assessed in this review.</P>
<P>Analyses conducted using ITT.</P>
<P>Majority of funding from National Institute on Drug Abuse and National Center for Research Resources. Medication provided to participants at no extra cost by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:22 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Pirie-1992">
<CHAR_METHODS MODIFIED="2011-03-25 11:12:07 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:25:53 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>417 women smokers. Av.cpd 25-27.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:22 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Group therapy<BR/>2. Group therapy plus weight control programme<BR/>3. Group therapy plus nicotine gum<BR/>4. Group therapy plus weight control programme and nicotine gum.<BR/>Gum type: 2 mg ad lib<BR/>Level of support: high</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-03 14:10:03 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 11:16:10 +0000" MODIFIED_BY="Kate Cahill">
<P>3 &amp; 4 compared to 1 &amp; 2.<BR/>Study was funded by the National Cancer Institute.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Pollak-2007">
<CHAR_METHODS MODIFIED="2012-02-14 11:38:36 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: volunteers from antenatal clinic</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:26:36 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>181 pregnant women smoking at least 5 cpd</P>
<P>Av.age 27, av.cpd pre-pregnancy 19</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. CBT</P>
<P>2. CBT + free NRT (Choice of patch, gum, lozenge or no NRT. Patch: 16hr, encouraged to use for 6 wks, dose based on woman's smoking level, fewer than 10 cpd=7mg/d, 10-14 cpd=14 mg/d, &#8805;15 cpd=21 mg/d; gum or lozenge: 2 mg for every cpd)</P>
<P>Level of support: high (6 one-to-one counselling sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:50:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>7d PP at 38 wks of gestation and 3m postpartum</P>
<P>Validation: salivary cotinine at 38 wks, self report ps</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-14 11:39:15 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Varying lengths of follow-up.</P>
<P>Recruitment suspended early when interim analysis found higher rate of negative birth outcomes in CBT+NRT arm; not statistically different when adjusted for previous history of birth outcomes in final analysis.</P>
<P>6 in NRT group opted to use no NRT; 4 in CBT-only arm reported use of NRT.</P>
<P>Funded by the National Cancer Institute.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:35 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Prapavessis-2007">
<CHAR_METHODS MODIFIED="2011-03-25 11:27:36 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: New Zealand<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>121 women smokers (&gt;10 cpd) (excludes drop-outs not starting programme)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:35 +0100" MODIFIED_BY="Kate Cahill">
<P>NRT as adjunct to either CBT or exercise programmes, collapsed for this review<BR/>1. Nicotine patch (21 mg/24hr for 10 wks, no weaning)<BR/>2. No patch<BR/>Level of support: High (36x45 min session over 12 wks of group CBT or supervised vigorous exercise, starting 6 wks before TQD)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:32:33 +0100" MODIFIED_BY="Kate Cahill">
<P>Continuous abstinence since TQD at 12m from end of programme<BR/>Validation: CO&lt;10ppm, cotinine&lt;0 ng/mL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-03 10:26:32 +0100" MODIFIED_BY="Kate Cahill">
<P>No placebo.<BR/>Study was funded by the National Heart Foundation of New Zealand, and supported by GlaxoSmithKline.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:13 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Puska-1979">
<CHAR_METHODS MODIFIED="2011-03-25 11:53:00 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Finland<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>229 adult smokers, 80% smoking&gt;5 cpd</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:13 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (4 mg) for 3 wks<BR/>2. Placebo gum for 3 wks<BR/>Level of support: high (group therapy)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PP abstinence at 6m. <BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 11:53:55 +0000" MODIFIED_BY="Kate Cahill">
<P>Study was supported by AB Leo and Co, Helsinborg, Sweden.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:05:59 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Puska-1995">
<CHAR_METHODS MODIFIED="2011-03-25 12:00:03 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Finland<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>300 volunteers aged 20-65, smoking &gt;10 cpd for &gt;3 yrs, no serious illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:05:59 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (15 mg/16hrs, 12 wks+ 6 wks taper) plus nicotine gum (2 mg at least 4 daily)<BR/>2. Placebo patch plus nicotine gum (same regimen)<BR/>Level of support: low (advice from study nurses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: expired CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 12:04:07 +0000" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison &amp; subgroups, only combinations.<BR/>Sources of support not stated.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:24:12 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Richmond-1993">
<CHAR_METHODS MODIFIED="2011-03-25 12:58:43 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Australia<BR/>Recruitment: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:34:21 +0100" MODIFIED_BY="Kate Cahill">
<P>450 adult smokers (350 in included arms). Av.cpd 15-21.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Smokescreen programme plus nicotine gum, dose and duration not stated<BR/>2. Smokescreen programme alone<BR/>3. Brief advice &amp; gum (Not included in MA)<BR/>Level of support: high (5 visits during first 3m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:24:12 +0100" MODIFIED_BY="Kate Cahill">
<P>Continuous abstinence (from wk 1) at 12m<BR/>Validation: expired CO&lt;14ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 13:38:07 +0000" MODIFIED_BY="Kate Cahill">
<P>No placebo<BR/>Continuous abstinence rates from Richmond 1993 paper used from 2007. Group 3 not included.<BR/>Study was funded by the Department of Health, Housing and Community Services, Community Health Anti-Tuberculosis Association, Glaxo Australia, and the Drug and Alcohol Directorate, NSW Department of Health.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:28 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Richmond-1994">
<CHAR_METHODS MODIFIED="2011-03-25 13:38:30 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Australia<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:35:01 +0100" MODIFIED_BY="Kate Cahill">
<P>315 smokers, av.cpd 29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:28 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (24 hr, 22 mg/24 hr, 10 wks incl tapering)<BR/>2. Placebo patch<BR/>Level of support: high (group therapy)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:35:19 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (reported in Richmond 1997, which also reports 3yr follow-up, not used in MA)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 13:35:23 +0100" MODIFIED_BY="Kate Cahill">
<P>3yr abstinence 21/153 vs 8/152, OR 2.9 - higher than at 12m.<BR/>Study was funded by Marion Merrell Dow, and supported by the Drug and Alcohol Directorate, NSW Department of Health, and the Lifestyle Unit, Prince of Wales Hospital, Sydney.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:36 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Rose-1994">
<CHAR_METHODS MODIFIED="2011-03-25 14:30:30 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:36:10 +0100" MODIFIED_BY="Kate Cahill">
<P>48 smokers (&#8805;20 cpd)<BR/>60% F, av.age 34, av.cpd 27-29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:36 +0100" MODIFIED_BY="Kate Cahill">
<P>2x2 factorial trial. Mecamylamine arms collapsed.<BR/>1. Nicotine patch (21 mg/24 hr for 2 wks before TQD)<BR/>2. Placebo<BR/>After TQD both groups received active patch for 6 wks, counselling at clinic visits &amp; self help materials</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:36:36 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m<BR/>Validation: CO&#8804;8ppm<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 14:34:09 +0000" MODIFIED_BY="Kate Cahill">
<P>Contributes only to pre-cessation comparison.<BR/>Study was funded by the American Cancer Society, the National institute on Drug Abuse and the Department of Veterans Affairs.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:37 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Rose-1998">
<CHAR_METHODS MODIFIED="2011-03-25 14:42:49 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:37:03 +0100" MODIFIED_BY="Kate Cahill">
<P>80 smokers (&#8805;20 cpd)<BR/>49% F, av.age 41, av.cpd 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:37 +0100" MODIFIED_BY="Kate Cahill">
<P>2x2 factorial trial. Mecamylamine pretreatment arms collapsed.<BR/>1. Nicotine patch (21 mg/24 hr for 4 wks before TQD)<BR/>2. Placebo<BR/>After TQD both groups received active patch &amp; mecamylamine for 6 wks, counselling at clinic visits &amp; self help materials</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:37:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 6m<BR/>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 14:45:39 +0000" MODIFIED_BY="Kate Cahill">
<P>Contributes only to pre-cessation comparison.<BR/>Study was funded by the American Cancer Society and the Department of Veterans Affairs.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:02 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Rose-2006">
<CHAR_METHODS MODIFIED="2011-03-25 14:56:58 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:38:17 +0100" MODIFIED_BY="Kate Cahill">
<P>96 smokers (&#8805;20 cpd), motivated to quit.<BR/>53% F, av.age 45, av.cpd 29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:02 +0100" MODIFIED_BY="Kate Cahill">
<P>2x3x3 factorial trial - only pre-cessation patch condition contributes to MA, other conditions collapsed.<BR/>1. Nicotine patch (21 mg/24hr for 2 wks before TQD)<BR/>2. Placebo<BR/>All participants received mecamylamine 2.5 mg bid for 4 wks post-TQD, and either 0, 21 or 42 mg patch.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:38:47 +0100" MODIFIED_BY="Lindsay Stead">
<P>PP abstinence at 6m<BR/>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 13:38:52 +0100" MODIFIED_BY="Kate Cahill">
<P>Contributes only to pre-cessation comparison. Postquit conditions did not affect cessation, data not reported in paper.<BR/>Study was funded by the National Institute on Drug Abuse<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:41 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Rose-2009">
<CHAR_METHODS MODIFIED="2012-02-10 10:18:43 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:39:20 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>379 participants, smoking &gt;15cpd for &#8805;3yrs, motivated to quit.</P>
<P>43% M, av.age 42, av.cpd 23, av.FTND 6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:41 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Usual brand of cig + 21 mg/24hr patch for 2 wks pre-quit</P>
<P>2. Usual brand of cig + placebo patch for 2 wks pre-quit</P>
<P>3. Low tar and nic cig + 21 mg/24hr patch for 2 wks pre-quit</P>
<P>4. Low tar and nic cig + placebo patch for 2 wks pre-quit</P>
<P>All groups received same treatment postquit: 6 wks 21 mg/24hr, following 2 wks 14 mg/24hr, remaining 2 wks 7mg/24hr</P>
<P>Level of support: Not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:39:57 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Continuous abstinence at 6m</P>
<P>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 13:43:25 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update. </P>
<P>Used in pre-cessation analysis only. Data from graph confirmed by author.</P>
<P>No effect by cig condition; 1+3 vs 2+4 in analysis. Treatment had greater effect for those with low FTND.</P>
<P>Funding provided through grant to Duke University by Philip Morris, USA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:24:49 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Rose-2010">
<CHAR_METHODS MODIFIED="2012-03-02 11:21:25 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:40:47 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>479 smokers of &#8805;10cpd, motivated to quit</P>
<P>43% M, av.age 44, av.cpd 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:24:49 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine patch, 21 mg group: wks 1-7 21 mg/24hr (1 active 21 mg/24hr patch, 1 placebo patch)</P>
<P>2. Nicotine patch, 42 mg group: wks 1-7 42 mg/24hr (2 active 21 mg/24hr patches)</P>
<P>TQD set at 2 wks. Wks 7-12: all participants receive same NRT dose (wks 7-8 21 mg/24hr, wks 9-10 14 mg/24hr, wks 11-12 7mg/24hr). All participants provided with denicotinized cigarettes during 2 wk pre-cessation period to minimize adverse effects of high dose NRT.</P>
<P>Level of support: high (7 in person counselling sessions &#8804;15min)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:42:08 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Point abstinence at 6m</P>
<P>Validation: CO&#8804;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 13:42:13 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update. </P>
<P>Primarily a study of effects of genotype on smoking cessation. Included in higher vs. standard dose patches <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK> only.</P>
<P>Funded by National Institutes of Health, National Institute on Drug Abuse, Department of Health and Social Services, grant to Duke University from Philip Morris, USA.</P>
<P>Number of successful quitters at 6m obtained through communication with author.</P>
<P>Subjects with difficulty sleeping instructed to remove patch at bedtime and apply new ones when they awoke. Subjects with other symptoms of nicotine toxicity instructed to reduce dose.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:16 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Roto-1987">
<CHAR_METHODS MODIFIED="2011-03-25 15:20:03 +0000" MODIFIED_BY="Kate Cahill">
<P>Country: Finland<BR/>Recruitment: primary care (occupational health centres)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>121 smokers (&gt;10 cpd, &gt;1 yr)<BR/>43% F</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:16 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg and 4 mg), + advice<BR/>2. Advice only (no placebo)<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (not defined)<BR/>Validation: not described</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-25 15:24:33 +0000" MODIFIED_BY="Kate Cahill">
<P>Study funding and support not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 13:44:29 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Russell-1983">
<CHAR_METHODS MODIFIED="2011-03-30 09:14:11 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: primary care - consecutive attenders admitting to being cigarette smokers and consenting to participate at 6 general practices<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:44:29 +0100" MODIFIED_BY="Kate Cahill">
<P>2106 unselected adult smokers. Av.cpd 17.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. No intervention <BR/>2. Advised to stop smoking plus provided with a "give up smoking" booklet <BR/>3. As group 2, plus offer of nicotine gum prescription, Individual therapy, Single visit, 1 minimal content, 1 more intensive content, untrained therapist<BR/>Level of support: low</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 4 and 12m<BR/>Validation: 66% of those claiming to have quit validated with CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 09:30:06 +0100" MODIFIED_BY="Kate Cahill">
<P>3 vs 2+1 used in comparison. Using only 2 as control has negligible effect on OR<BR/>Only 53% of group 3 tried the gum<BR/>Use of quit rates adjusted for estimated validation failure and protocol violation would increase relative effect of gum.<BR/>Study was funded by the Medical Research Council, and the AB Leo Research Foundation, Sweden.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:03 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Sachs-1993">
<CHAR_METHODS MODIFIED="2011-03-30 08:44:50 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:46:45 +0100" MODIFIED_BY="Kate Cahill">
<P>220 adult smokers. Av.cpd 28-9.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:03 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (15 mg/16hr, 12 wks + 6 wks tapering)<BR/>2. Placebo patch<BR/>Level of support: high (physician advice, 8 visits during treatment period)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 08:46:21 +0100" MODIFIED_BY="Kate Cahill">
<P>Study was funded by National Institute on Drug Abuse, Kabi Pharmacia AB and Parke-Davis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:33 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Schneider-1985A">
<CHAR_METHODS MODIFIED="2011-03-30 09:17:22 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:47:22 +0100" MODIFIED_BY="Kate Cahill">
<P>60 heavy smokers (&gt;1 pack/day)<BR/>60%F, av.age 40/37, av.cpd 35/31</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:33 +0100" MODIFIED_BY="Kate Cahill">
<P>Study A (clinic support):<BR/>1. Nicotine gum, (2 mg duration not stated)<BR/>2. Placebo gum<BR/>Level of support: high (individual support at multiple clinic assessment visits, daily during week 1, weekly to wk 5)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 09:20:12 +0100" MODIFIED_BY="Kate Cahill">
<P>Reported in same papers as Schneider 1985B. Shared study ID until 2008. Schneider 1983 provides demographic data so now used as primary reference.<BR/>Jarvik &amp; Schneider 1984 reports outcomes by dependency score for 48/60 participants.<BR/>Study was funded by National Institute on Drug Abuse and by the Medical Research Service of the Veterans Administration.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:58:34 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Schneider-1985B">
<CHAR_METHODS MODIFIED="2011-03-30 09:20:48 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 heavy smokers (&gt;1 pack/day)<BR/>no demographic details</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:34 +0100" MODIFIED_BY="Kate Cahill">
<P>Study B (pilot dispensary study):<BR/>1. Nicotine gum, (2 mg duration not stated)<BR/>2. Placebo gum<BR/>Level of support: low (weekly laboratory visits for 5 wks but no support provided)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 09:20:34 +0100" MODIFIED_BY="Kate Cahill">
<P>Reported in same papers as Schneider 1985A. Shared study ID until 2008.<BR/>Study was funded by National Institute on Drug Abuse and by the Medical Research Service of the Veterans Administration.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:04 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Schneider-1995">
<CHAR_METHODS MODIFIED="2011-03-30 09:43:55 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers (radio and newspaper ads)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:49:33 +0100" MODIFIED_BY="Kate Cahill">
<P>255 adults with no serious illness, motivated to quit, smoking &gt;15 cpd for &gt;2 yrs with baseline CO level &gt;20ppm. Av.cpd 28-29.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:04 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine nasal spray<BR/>2. Placebo spray<BR/>Nicotine dosage: 0.5 mg of nicotine per spray. No fewers than 8 and no more than 32 doses/day for 6 wks, with free use for further 6m<BR/>Level of support: high (repeated clinic visits for assessment)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-30 09:59:12 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m<BR/>Validation: CO&lt;8 ppm.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 09:59:55 +0100" MODIFIED_BY="Kate Cahill">
<P>Study was funded by Veteran Affairs and Pharmacia (Sweden).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 13:50:53 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Schneider-1996">
<CHAR_METHODS MODIFIED="2011-03-30 10:06:18 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:50:53 +0100" MODIFIED_BY="Kate Cahill">
<P>223 adult smokers (&#8805;10 cpd)<BR/>37% F, av.age 44, av.cpd 29/26 (significantly higher in active group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nicotine inhaler (4-20 inhalers per day) for up to 6m, with weaning from 3m<BR/>2. Placebo inhaler<BR/>Level of support: high (repeated clinic visits for assessment)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO and salivary cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 10:07:21 +0100" MODIFIED_BY="Kate Cahill">
<P>Study was funded by Veteran Affairs and by Pharmacia &amp; Upjohn (Sweden).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:50 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Schnoll-2010a">
<CHAR_METHODS MODIFIED="2012-02-21 11:48:01 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-04 15:26:38 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>575 adult smokers of &gt;10cpd for &gt;1yr, motivated to quit</P>
<P>47% F, av.age 48, av.cpd 21.1, av.FTND 5.3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:50 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. 21 mg/24hr patch for 24 wks</P>
<P>2. 21 mg/24hr patch for 8 wks, followed by 16 wks placebo patch</P>
<P>Level of support: high. Behavioural counselling provided at wks -2, 0, 1, 4, 8, 12, 16, and 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:52:03 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>7d PP at 12m (also reported for 24 wks).</P>
<P>Validation: CO&#8804;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 15:52:08 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Included in duration of treatment <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK> only.</P>
<P>Extended therapy group reported higher levels of adherence at wks 12, 16, 20 and 24. Significant effect of treatment at wk24.</P>
<P>Funding provided by National Institutes of Health.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:51 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Schnoll-2010b">
<CHAR_METHODS MODIFIED="2012-02-10 12:22:01 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Coutry: USA</P>
<P>Recruitment: Community volunteers and physician referrals</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:53:06 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>642 treatment-seeking smokers smoking &#8805;10cpd</P>
<P>57% F, av.age 45, av.cpd 20.3, av.FTND 5.1; av.yrs smoking 26.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:51 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Direct comparison of patch vs lozenge.</P>
<P>1. Patch: 21 mg/d for first 6 wks, 14 mg/d for wks 7+8, 7mg/d for wks 9-12</P>
<P>2. Lozenge: 4 mg for participants who smoked first cig of day w/in 30min of waking; 2 mg for all other participants. Asked to use 9/d for first 6 wks, 5/d for wks 7-9, 3/d for wks10-12.</P>
<P>Level of support: high. 5 individual counselling sessions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 13:53:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>24hr PP at 6m</P>
<P>Validation: CO&#8804;10ppm  </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 13:54:05 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update. </P>
<P>Used in direct comparison of NRT types only.</P>
<P>Funded by American Cancer Society and National Institutes of Health.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:05 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Schuurmans-2004">
<CHAR_METHODS MODIFIED="2011-03-30 10:25:45 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: South Africa<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:56:05 +0100" MODIFIED_BY="Kate Cahill">
<P>200 smokers<BR/>44% F, av.age 43, av.cpd 23/26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:05 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Pretreatment with nicotine patch for 2 wks prior to quit date. Then active patch (15 mg) patch for 12 wks including weaning. 4 sessions of counselling over 10 wks.<BR/>2. Pretreatment with placebo patch. The active patch as 1.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 6m<BR/>Validation: CO&lt;10ppm at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 11:36:35 +0100" MODIFIED_BY="Kate Cahill">
<P>Does not contribute to main comparison.<BR/>Study was funded by the Swiss Science Foundation, and by Pfizer Inc.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 13:58:45 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Segnan-1991">
<CHAR_METHODS MODIFIED="2011-03-30 11:44:33 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Italy<BR/>Recruitment: primary care - consecutive patients attending 44 general practices<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 13:58:38 +0100" MODIFIED_BY="Kate Cahill">
<P>923 practice attenders aged 20-60. Av.cpd not stated.<BR/>Therapists: GPs who had undergone a 3hr training session</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 13:58:45 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Advice and leaflet<BR/>2. Repeated counselling (follow-up at 1, 3, 6, 9m)<BR/>3. Repeated counselling plus prescription for nicotine gum unless contraindicated, dose not stated, up to 3m<BR/>4. Repeated counselling plus spirometry<BR/>Level of support: high</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: urinary cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 12:01:05 +0100" MODIFIED_BY="Kate Cahill">
<P>3 vs 1+2+4.<BR/>Study was supported by SIMG (Italian Association of General Practice), and by Serono SPA.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:24 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_">
<CHAR_METHODS MODIFIED="2011-03-30 12:07:19 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA &amp; UK (15 sites)<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-30 12:08:16 +0100" MODIFIED_BY="Kate Cahill">
<P>917 smokers, motivated to quit, time to first cigarette &gt;30 mins.<BR/>58% F, Av age 41, cpd 17</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:42 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine lozenge, 2 mg. Recommended dose 1 every 1-2hrs, min 9, max 20/day for 6 wks, decreasing 7-12 wks, available as needed 13-24 wks<BR/>2. Placebo lozenge, same schedule<BR/>Level of support: high (brief advice at 4 visits in 4 wks from enrolment)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:52:44 +0100" MODIFIED_BY="Lindsay Stead">
<P>Continuous abstinence at 12m (Sustained from 2 wks, no slips allowed).<BR/>Validation: CO&#8804;10ppm at all follow-ups. (only abstainers continued in study)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:01:24 +0100" MODIFIED_BY="Kate Cahill">
<P>Dose based on dependence level. Low dependence group here. High dependence group in Shiffman 2002 (4 mg).<BR/>Study was supported by GlaxoSmithKline Consumer Healthcare.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:30 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_">
<CHAR_METHODS MODIFIED="2012-10-16 14:01:11 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA &amp; UK (15 sites)<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>901 smokers, time to first cigarette &lt;30 mins<BR/>55% F, Av age 44, cpd 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:30 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine lozenge, 4 mg. Recommended dose 1 every 1-2hrs, min 9, max 20/day for 6 wks, decreasing 7-12 wks, available as needed 13-24 wks.<BR/>2. Placebo lozenge, same schedule</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:52:50 +0100" MODIFIED_BY="Lindsay Stead">
<P>Continuous abstinence at 12m. (Sustained from 2 wks, no slips allowed).<BR/>Validation: CO&#8804;10ppm at all follow-ups. (only abstainers continued in study)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 15:58:44 +0100" MODIFIED_BY="Kate Cahill">
<P>Dose based on dependence level. High dependence group here. Low dependence group in Shiffman 2002 (2 mg).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:31 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_">
<CHAR_METHODS MODIFIED="2012-02-21 11:48:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-04 16:35:45 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1636 smokers wishing to quit by gradual reduction (RTQ technique)</P>
<P>64% F, av.age 42, av.cpd 9.4, av.FTND 4.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:58:55 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine gum 2 mg. Instructed to gradually reduce smoking while increasing gum use for up to 8 wks. Postquit instructed to use 1 piece every 1-2hrs for first 6 wks; 1 every 2-4hrs for next 3 wks; 1 every 4-8hrs for final 3 wks.</P>
<P>2. Placebo gum, same schedule as above.</P>
<P>Level of support: low (designed to simulate OTC setting)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:53:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Abstinence at 6m from start of treatment (initial abstinence had to be achieved within 8 wks of start of treatment, so duration of abstinence was at least 4m)</P>
<P>Validation: CO&#8804;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:01:31 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Included in main analyses</P>
<P>Dose based on dependence level. Participants read labelling which recommended 4 mg dose for smokers of &gt;25 cpd and selected appropriate dose. Low dependence group here. High dependence group reported in Shiffman 2009 (4mg).</P>
<P>Funding provided by GlaxoSmithKline Consumer Healthcare.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_">
<CHAR_METHODS MODIFIED="2012-02-21 11:48:36 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-10 15:22:59 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1661 smokers wishing to quit by gradual reduction (RTQ technique)</P>
<P>50% F, av.age 46, av.cpd 32, av.FTND 6.9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Nicotine gum 4 mg. Instructed to gradually reduce smoking while increasing gum use for up to 8 wks. Postquit instructed to use 1 piece every 1-2hrs for first 6 wks; 1 every 2-4hrs for next 3 wks; 1 every 4-8hrs for final 3 wks.</P>
<P>2. Placebo gum, same schedule as above.</P>
<P>Level of support: low (designed to simulate OTC setting)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:53:09 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Abstinence at 6m from start of treatment (initial abstinence had to be achieved within 8 wks of start of treatment, so duration of abstinence was at least 4m)</P>
<P>Validation: CO&#8804;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-03 12:43:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Dose based on dependence level. High dependence group here. Low dependence group reported in Shiffman 2009 (2mg).</P>
<P>Funding provided by GlaxoSmithKline Consumer Healthcare.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:26:11 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Smith-2009">
<CHAR_METHODS MODIFIED="2012-02-21 11:48:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA</P>
<P>Recruitment: primary care (12 clinics)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-31 09:43:46 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1346 smokers of &gt;10 cpd for past 6m. 56% F, av.age 44, av.cpd 20.3, motivated to quit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:26:11 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Bupropion only (up-titrated during wk pre-quitting, 150mg bid for 8 wks postquit)</P>
<P>2. Nicotine lozenge only (4 mg lozenge if first cig of day smoked &gt;30 min after waking, 2 mg otherwise. 1 lozenge every 1-2hrs postquit wk 1-6; 1 lozenge every 2-4hrs wk 7-9; 1 lozenge every 4-8hrs wk 10-12)</P>
<P>3. Nicotine patch only (21 mg post-quit wk 1-4; 14 mg wk 5-6; 7mg wk 7-8)</P>
<P>4. Bupropion and lozenge (dosage as above)</P>
<P>5. Patch and lozenge (dosage as above)</P>
<P>Level of support: high (behavioural support optional)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-07 10:01:36 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>7d PP at 6m and number of days to relapse.</P>
<P>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 14:06:58 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>No control so does not contribute to primary analysis. Interventions 1, 2, 3 and 4 used in direct comparisons and combinations of NRT and bupropion. 2, 3 and 5 used in <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>combinations of different types of NRT. 2 and 3 used in <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK> comparisons between NRT types. Numbers used for bupropion comparison divided between analysis 16.1.1 and 16.1.2 to avoid double counting. Bupropion as adjunct to NRT not assessed in this review.</P>
<P>Analyses completed on ITT basis.</P>
<P>Majority of funding from National Institutes of Health, National Institute on Drug Abuse, and National Cancer Institute. Medication provided to participants at no cost by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:54 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Sonderskov-1997">
<CHAR_METHODS MODIFIED="2012-10-16 14:07:41 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: customers seeking to buy nicotine patches OTC at 42 pharmacies<BR/>Randomization: sequential treatment packages, stratified by smoking level</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>522 smokers of &gt;10 cpd. Smokers of &gt;20 cpd used a higher dose patch than lower rate smokers.<BR/>50% F, av.age 39</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:54 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (24 hr). &gt;20/day smokers used 21 mg for 4 wks, 14 mg for 4 wks, 7mg for 4 wks. Smokers of &lt;20/day used 14 mg for first 8 wks, 7mg for 4 wks<BR/>2. Placebo patches<BR/>Level of support: Low (brief instructions on patch use at baseline, visit to collect further patches at 4 &amp; 8 wks, no behavioural support)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:53:19 +0100" MODIFIED_BY="Kate Cahill">
<P>Abstinence at 6m - no reported smoking in the last 4 wks, by telephone interview with neutral independent assessor<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 13:03:22 +0100" MODIFIED_BY="Kate Cahill">
<P>Study was partly funded by Ciba-Geigy.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:26:41 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Stapleton-1995">
<CHAR_METHODS MODIFIED="2011-03-30 13:46:33 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Setting: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:09:21 +0100" MODIFIED_BY="Kate Cahill">
<P>1200 smokers considered by GP to be highly dependent and motivated to give up. Av.cpd 23-4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:26:34 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch standard dose (15 mg/16hr for 18 wks)<BR/>2. Nicotine patch with dose increase to 25 mg at 1 wk if required<BR/>3. Placebo patch group<BR/>The nicotine patch groups were further randomized to gradual tapering or abrupt withdrawal at wk 12.<BR/>Level of support: High (physician advice &amp; brief support at 1, 3, 6, 12 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 16:26:41 +0100" MODIFIED_BY="Kate Cahill">
<P>The dose increase after 1 wk did not affect cessation, 1+2 vs 3 in comparison 1.<BR/>Study as funded by Kabi Pharmacia (Sweden).<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:53:23 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Sutherland-1992">
<CHAR_METHODS MODIFIED="2011-03-30 14:22:05 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: UK<BR/>Recruitment: smoking cessation clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:10:55 +0100" MODIFIED_BY="Kate Cahill">
<P>227 smokers, motivated to quit. Av.cpd 25-27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:53:23 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine nasal spray, maximum 40mg/day<BR/>2. Placebo spray<BR/>Level of support: High (4 wks group support)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 14:11:21 +0100" MODIFIED_BY="Kate Cahill">
<P>Follow-up beyond 1yr reported in Stapleton 1998<BR/>Abstinence for 3yrs 19/116 vs 7/111, OR 2.9.<BR/>Study was funded by the Medical Research Council and by the Imperial Cancer Research Fund.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:26:50 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-TNSG-1991">
<CHAR_METHODS MODIFIED="2011-03-30 14:40:58 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA (9 sites)<BR/>Recruitment: community volunteers (treated at smoking cessation clinics)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:12:05 +0100" MODIFIED_BY="Kate Cahill">
<P>808 unselected smokers<BR/>60% F, av.age 43, av.cpd 31</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:26:50 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (21 mg /24 hr, 6 wks+)<BR/>2. Nicotine patch 14 mg<BR/>3. Placebo patch<BR/>Abstainers at end of wk 6 entered a randomized blinded trial of weaning.<BR/>Level of support: high (group therapy, 6+ sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 6m<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 14:41:53 +0100" MODIFIED_BY="Kate Cahill">
<P>2 trials pooled and data relating to a 7mg patch group used in only 1 trial omitted.<BR/>Long-term (4-5 yr) follow-up data reported for 7/9 sites (Daughton 1999). Data not used in MA -OR would be higher.<BR/>Study was supported by Alza Corp.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:01:50 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Tonnesen-1988">
<CHAR_METHODS MODIFIED="2011-03-30 15:04:31 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: primary care<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:15:09 +0100" MODIFIED_BY="Kate Cahill">
<P>113 low to medium dependence smokers, motivated to quit (19 or less on Horn-Russell scale)<BR/>56% F, av.age 45, av.cpd 20<BR/>60 highly dependent smokers<BR/>58% F, av.age 45, av.cpd 26-28</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:01:50 +0100" MODIFIED_BY="Kate Cahill">
<P>Group A: Low/medium dependence<BR/>1. Nicotine Gum (2 mg) for 16 wks<BR/>2. Placebo<BR/>Group B: High dependence<BR/>1. Nicotine gum 4 mg for 6 wks then 2 mg<BR/>2. Nicotine gum 2 mg<BR/>Level of support: high (informal group support, 6 sessions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-03 14:12:58 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (24m also reported)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 15:17:15 +0100" MODIFIED_BY="Kate Cahill">
<P>Group A in comparison 1, Group B in comparison 2,<BR/>Abstinence at 24m 17/60 vs 5/53, OR 3.8, relative effect greater than at 12m.<BR/>Study was supported by A.B. Leo (Sweden) and H. Lundbeck A.S. (Denmark)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:09 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Tonnesen-1991">
<CHAR_METHODS MODIFIED="2011-03-30 15:18:04 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:16:46 +0100" MODIFIED_BY="Kate Cahill">
<P>289 smokers (&#8805;10 cpd)<BR/>70% F, av.age 45, av.cpd 22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:09 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (15 mg/16hr for 12 wks with tapering)<BR/>2. Placebo patch<BR/>Level of support: High (7 clinic visits including a few minutes of advice)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-03 14:13:02 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (also reported 24m in Tonnesen 1992, 3 yrs in Mikkelsen 1994)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-04 16:46:48 +0100" MODIFIED_BY="Kate Cahill">
<P>Classification of support corrected to high in 2008 update.<BR/>2 yr abstinence 17/145 vs 6/144, OR 4.6. 3 yr abstinence 15/145 vs 4/144, OR 4.0.<BR/>Study was supported in part by Kabi Pharmacia Therapeutics.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:27:05 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Tonnesen-1993">
<CHAR_METHODS MODIFIED="2011-03-30 15:30:42 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:18:07 +0100" MODIFIED_BY="Kate Cahill">
<P>286 smokers (&#8805;10 cpd)<BR/>60% F, av.age 39, av.cpd 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:42:19 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine inhaler (2-10/day) up to 6m<BR/>2. Placebo inhaler<BR/>Level of support: High (brief advice at 8 clinic visits, 0, 1, 2, 3, 6,12, 24, 52 wks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:27:05 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sustained abstinence at 12m (from wk 2, paper also reports with slips outcome)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-30 15:32:09 +0100" MODIFIED_BY="Kate Cahill">
<P>Study was supported by Kabi Pharmacia Therapeutics.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:27:13 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Tonnesen-2000">
<CHAR_METHODS MODIFIED="2011-03-30 15:53:08 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: referrals to lung clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:20:06 +0100" MODIFIED_BY="Kate Cahill">
<P>446 smokers &#8805;10 cpd<BR/>52% F, av.age 49, av.cpd 18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:12 +0100" MODIFIED_BY="Kate Cahill">
<P>1. 5 mg nicotine patch (placebo)<BR/>2. 15 mg (16hr) nicotine patch for 12 wks (up to 9m on request)<BR/>3. Nicotine inhaler (4-12/day ad lib)<BR/>4. Combination, 15 mg patch and inhaler<BR/>Level of support: High (Physician advice at baseline, brief (15min) nurse counselling at 2, 6 wks, 3, 6, 9, 12m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:27:13 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m, (from wk 2, paper also reports PP and with slips rates)<BR/>Validation: CO&lt;10ppm at all visits</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-16 14:21:26 +0100" MODIFIED_BY="Kate Cahill">
<P>In main comparison for patch vs placebo but not inhaler. Also 1 &amp; 2 vs 4 in combination, and 3 vs 2 in head-to-head comparisons.<BR/>Study funding and support not reported.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:59:11 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Tonnesen-2006">
<CHAR_METHODS MODIFIED="2011-03-31 08:45:07 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: lung clinic patients &amp; newspaper adverts<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>370 smokers (at least 1 cpd) with COPD (Mean FEV1 was 56% of predicted)<BR/>52% F, av.age 61, av. cpd 20 (8% &lt;7/day), 71% had previously tried NRT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:59:11 +0100" MODIFIED_BY="Kate Cahill">
<P>2x2 factorial trial of lozenge and behavioural support.<BR/>1. Nicotine sublingual tablet (2 mg), recommended dose depended on baseline cpd, from min 3 to max 40 per day<BR/>2. Placebo<BR/>Level of support: high -Either 4 clinic visits (0, 2 wks, 6, 12m) &amp; 6 phone calls, total time 2.5hrs, or 7 visits (0, 2, 4, 8, 12 wks) &amp; 5 calls, total 4.5h.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:42:18 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12 months (from 2 wks)<BR/>Validation: CO&lt;10ppm at all visits</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 08:47:34 +0100" MODIFIED_BY="Kate Cahill">
<P>New for 2008 update<BR/>Behavioural support arms collapsed. Both involved multiple clinic visits.</P>
<P>Study was funded by the Danish Medical Research Council, and supported by Pfizer Consumer Healthcare (Sweden).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:27:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-T_x00f8_nnesen-2012">
<CHAR_METHODS MODIFIED="2012-03-26 10:50:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: Germany (2 sites) and Denmark (1 site)</P>
<P>Recruitment: Community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:22:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>479 adult smokers of &#8805;1 cpd motivated to quit.</P>
<P>56% M, av.age 47, av.cpd 22.7, av.FTND 5.3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:27:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1 mg/spray oral nicotine spray (in development, name not provided)</P>
<P>Active: wks 1-6: 1-2 sprays when participants would normally have smoked a cigarette or experienced a craving, up to 4 sprays/hr and 64 sprays/day. Tapered down wks 7-12 (end of wk 9 instructed to be using half as much as in wks 1-6, reducing to max 4 sprays/day by wk 12). Occasional use (max 4 sprays/day) permitted wks 13-24.</P>
<P>Control: placebo on same schedule.</P>
<P>Level of support: high. General written and oral advice (less than 10min) at study start and less than 3mins at subsequent visits up to and including wk 24 (9 visits total).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:42:18 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Prolonged abstinence from wk 2-52 (also recorded AEs and prolonged abstinence to wks 6 and 24)</P>
<P>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-26 10:58:53 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update.</P>
<P>Funded by McNeil AB, Sweden.</P>
<P>Setting: smoking cessation clinics.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:59:12 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Villa-1999">
<CHAR_METHODS MODIFIED="2011-03-31 09:01:12 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Spain<BR/>Recruitment: volunteers working in a university health and safety department<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>47 smokers (excludes 5 who did not attend at least 2 sessions)<BR/>72% F, av.age 36, cpd 24-26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:59:12 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine gum (2 mg)<BR/>2. No gum<BR/>Level of support: High (8 weekly group sessions, 5 before TQD. Reduction prior to quitting)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (not defined)<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 09:02:26 +0100" MODIFIED_BY="Kate Cahill">
<P>No placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:28:10 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Wallstrom-2000">
<CHAR_METHODS MODIFIED="2011-03-31 09:15:04 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Sweden<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:27:04 +0100" MODIFIED_BY="Kate Cahill">
<P>247 smokers (&#8805;10 cpd), motivated to quit.<BR/>59% F, av.age 45, av.cpd 18-20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:42:18 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine sublingual tablet. Recommended dosage 1 tab/hr for smokers with FTND&lt;7, 2 tabs/hr for scores &#8805;7. After 3m treatment, tapering period of 3m if necessary<BR/>2. Placebo tablet<BR/>Level of support: High (brief 5 mins counselling at study visits (0, 1, 2, 3, 6 wks, 3, 6m)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 16:28:10 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 12m (from wk 2, paper also reports with slips rates<BR/>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 09:16:52 +0100" MODIFIED_BY="Kate Cahill">
<P>study was supported by Pharmacia &amp; Upjohn Consumer Health Care</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-09 14:37:33 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Wennike-2003a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-10-09 14:37:33 +0100" MODIFIED_BY="Kate Cahill">
<P>Excluded study, but contributing data on adverse events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:13 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Westman-1993">
<CHAR_METHODS MODIFIED="2012-09-27 14:56:51 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:28:24 +0100" MODIFIED_BY="Kate Cahill">
<P>158 smokers motivated to quit (excludes 1 participant who used nicotine gum throughout)<BR/>57% F, av.age 41, av.cpd 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:13 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (25 mg/24hr, 6 wks incl weaning)<BR/>2. Placebo patches<BR/>Level of support: High (Brief counsellor support at 3 clinic visits, 4 telephone counselling sessions, self help materials)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:54:27 +0100" MODIFIED_BY="Kate Cahill">
<P>Sustained abstinence at 6m (from 2 wks post-TQD)<BR/>Validation: CO&lt;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 09:39:43 +0100" MODIFIED_BY="Kate Cahill">
<P>study was supported by TBS Laboratories, Piscataway, NJ</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:13 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Wisborg-2000">
<CHAR_METHODS MODIFIED="2011-03-31 09:58:44 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: Denmark<BR/>Recruitment: volunteers, antenatal clinic<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:29:41 +0100" MODIFIED_BY="Kate Cahill">
<P>250 pregnant women who continued to smoke after 1st trimester<BR/>Av.age 28, av.cpd 14; 43% primiparous</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:13 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Nicotine patch (15 mg/16hr, tapering to 10mg, 11 wks total)<BR/>2. Placebo patch<BR/>Level of support: high. 4x15-20 min sessions of midwife counselling at 0, 4,11 wks from enrolment, and 4 wks before expected delivery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 15:54:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 4 wks prior to delivery and at 1yr postpartum (telephone interview). (Rates at 3m postpartum also reported)<BR/>Validation: Cotinine &lt;26ng/ml at 4 wks pre-delivery visit only</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-04 16:09:50 +0100" MODIFIED_BY="Kate Cahill">
<P>First long-term study of nicotine patch in pregnancy. Compliance with patch use was low. Only 17% of active and 8% of placebo used all patches. Data used in <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK> from 2012 is abstinence at 4th prenatal visit rather than continuous abstinence from 2nd to 4th prenatal visit, for consistency with <LINK REF="REF-Coleman-2012a" TYPE="REFERENCE">Coleman 2012a</LINK>. The effect estimate is not altered.<BR/>Study was funded by the Danish Cancer Society and the Department of Health, and supported by Pharmacia &amp; Upjohn.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:06:15 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Wittchen-2011">
<CHAR_METHODS MODIFIED="2012-02-14 09:31:08 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Country: Germany</P>
<P>Recruitment: 167 primary care clinics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-14 09:32:19 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>467 'current regular smokers' attending primary care clinic for any reason and willing to consider treatment in next 7d.</P>
<P>48% M, av.age 43, av.cpd 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:06:15 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1. Minimal intervention (not used in review)</P>
<P>2. CBT</P>
<P>3. CBT + bupropion SR (9-12 wks, 150mg;1/d for first 6d; 2/d thereafter)</P>
<P>4. CBT + NRT for 9-12 wks, patient's choice of patch (7mg-52.5 mg), gum (2 or 4 mg) or spray (10mg/ml)</P>
<P>Level of support: high for 2, 3 and 4 (1 excluded from analysis). 4-5 one on one counselling sessions for 20-30min.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 14:33:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Abstinence at 12m (from EoT)</P>
<P>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-04 14:25:20 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>New for 2012 update</P>
<P>4 vs 2 included in primary analyses. 4 vs 3 included in <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK> comparison of NRT with bupropion. 1 not used as results vs. NRT would be confounded with CBT.</P>
<P>Patients covered all costs for pharmaceutical treatments.</P>
<P>Sponsored by the Federal Ministry of Education and Research; additional support provided by GlaxoSmithKline GmbH &amp; Co and Pharmacia GmbH.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 16:03:58 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Wong-1999">
<CHAR_METHODS MODIFIED="2011-03-31 09:59:57 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:36:06 +0100" MODIFIED_BY="Kate Cahill">
<P>100 smokers (&gt;10 cpd for &gt;1yr)<BR/>53% F, av.age 42, av.cpd 28</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 16:03:58 +0100" MODIFIED_BY="Kate Cahill">
<P>Factorial study of nicotine patch and naltrexone, no placebo patch<BR/>Nicotine patch: 21 mg (24hr) for 8 wks, tapering to 14 mg for 4 wks<BR/>Naltrexone: 50mg/day for 12 wks<BR/>Level of support: High (individual counselling, 15-20 mins at 8 study visits)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-16 14:36:36 +0100" MODIFIED_BY="Lindsay Stead">
<P>Continuous abstinence at 6m<BR/>Validation: CO&#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 10:01:03 +0100" MODIFIED_BY="Kate Cahill">
<P>One site from a multicentre trial. No significant main effects of naltrexone, so arms collapsed.<BR/>Study was funded by DuPont Merck Pharmaceutical Company<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-16 15:59:14 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Zelman-1992">
<CHAR_METHODS MODIFIED="2011-03-31 10:14:28 +0100" MODIFIED_BY="Kate Cahill">
<P>Country: USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-16 14:37:21 +0100" MODIFIED_BY="Kate Cahill">
<P>116 smokers (excludes 10 early treatment drop-outs evenly distributed across conditions)<BR/>54% F, av.age 29-35, av.cpd 25-27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-16 15:59:14 +0100" MODIFIED_BY="Kate Cahill">
<P>1. Rapid smoking + support counselling<BR/>2. Rapid smoking + skills training<BR/>3. Nicotine gum 2 mg, average 10 pieces/day, duration not stated + skills training<BR/>4. Nicotine gum + support counselling.<BR/>Level of support: high (6x60-75 min group sessions over 2 wks, starting on quit day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sustained abstinence at 12m (not more than 2 consecutive days of smoking)<BR/>Validation: Independent observer report</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 10:15:08 +0100" MODIFIED_BY="Kate Cahill">
<P>No placebo. Group support variants collapsed; 3 &amp; 4 compared to 1 &amp; 2.<BR/>Study was funded by National Institutes of Health.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALA=American Lung Association; CBT=cognitive behavioural therapy; CO=carbon monoxide in exhaled air; cpd=cigarettes per day; COPD=chronic obstructive pulmonary disease; EOT=end of treatment; FTND=Fagerstrom Test for Nicotine Dependence; hr=hour; ITT=intention to treat; m=month(s); MA=meta-analysis; RTQ=reduce-to-quit; OTC=over-the-counter; PP=point prevalence; pts=participants; SC=smoking cessation; TQD=target quit date; wk=week; yr=year</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:54:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Adelman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:54:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Study of Nicotine nasal spray in adolescents. 12 wks follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Allen-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Short-term study of effect of nicotine patch on weight change during early abstinence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 12:10:11 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Allen-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 12:10:11 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of NRT for reduction of agitation and aggression in smokers with schizophrenia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aubin-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Short-term study of the effect of different types of nicotine patch on sleep and smoking urges</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:54:14 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Batra-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:54:14 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, <LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 13:05:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Berlin-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 13:05:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of standard NRT dosing vs. dose adaptation according to salivary cotinine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 08:48:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Bock-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 08:48:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of computer software quit programme, treatment group offered free NRT. Control group could also use NRT (unsubsidised).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:54:23 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Bolliger-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:54:23 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of nicotine inhaler for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, <LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bolliger-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study, not powered to detect efficacy differences between gum, inhaler and mouth spray</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brantmark-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind gum/placebo only for 1st week of clinic, then both groups offered active gum during 6m follow-up period</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carpenter-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared 2 methods of reducing smoking. Control group also offered NRT if a quit attempt planned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:44:58 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Carpenter-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:44:58 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Measured effect of providing NRT samples on participants not initially motivated to quit. Participants were encouraged but not required to make a practice quit attempt. Intervention participants were provided with up to 2 boxes of nicotine lozenges.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:54:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Chan-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:54:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NOTES="&lt;p&gt;New for 2012&lt;/p&gt;" NOTES_MODIFIED="2012-10-16 15:54:56 +0100" NOTES_MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Measured effect of counselling + 2 wks free NRT. No data on whether control group also using NRT; unclear if outcome due to counselling or free NRT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:54:46 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Chan-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:54:46 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Measured effect of adherence counselling as opposed to effect of NRT itself.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:45:20 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Chou-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:45:20 +0100" MODIFIED_BY="Kate Cahill">
<P>Only 3m follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 16:08:52 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Christen-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 16:08:52 +0100" MODIFIED_BY="Kate Cahill">
<P>Only 15 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Cohen-1989a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Primarily a trial of training dentists. Included in Cochrane review of training of health professionals (<LINK REF="REF-Carson-2012" TYPE="REFERENCE">Carson 2012</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Cohen-1989b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 16:59:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Primarily a trial of training doctors. Included in Cochrane review of training of health professionals (<LINK REF="REF-Carson-2012" TYPE="REFERENCE">Carson 2012</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Croghan-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provides a short-term comparison between nicotine patch, bupropion, and combination therapy. Initial failures randomized to retreatment so no long-term control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 13:58:25 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Cummings-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 13:58:25 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Compared provision of free NRT, but participants able to use additional NRT as desired.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:54:58 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Dey-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:54:58 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Compared free and paid prescription for nicotine patch. Only 14 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 14:21:07 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Donny-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 14:21:07 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Endpoint not cessation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 14:21:20 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Ebbert-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 14:21:20 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Study of NRT for smokeless tobacco users</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 14:22:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Ebbert-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 14:22:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Study of mailed NRT for smokeless tobacco users</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:59:02 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Elan-Pharm-88_x002d_02">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:59:02 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>No long-term follow-up. Long-term follow-up for 1 site included as <LINK REF="STD-Hurt-1990" TYPE="STUDY">Hurt 1990</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:59:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Elan-Pharm-90_x002d_03">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:59:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>No long-term follow-up. Long-term follow-up for 1 site included as <LINK REF="STD-Fiore-1994A" TYPE="STUDY">Fiore 1994A</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:59:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Etter-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:59:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of a choice of NRT products for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, <LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fagerstrom-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Endpoint withdrawal symptoms not cessation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:00 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fagerstrom-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:00 +0100" MODIFIED_BY="Kate Cahill">
<P>Short-term crossover trial of different types of NRT. For 2 wks smokers could choose a method, for other 2 they were randomly assigned to one of gum, patch, spray, inhaler or tablet. Smoking reduction assessed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fagerstrom-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Short-term crossover trial comparing 2 nicotine delivery devices</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-22 14:05:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NOTES="&lt;p&gt;JHB emailed author to see if he can provide results broken down by behavioural therapy group.&lt;/p&gt;&lt;p&gt;Large trial with negative outcome wreaking havoc on MAs. LS to consider if we include - not placebo controlled and control group more likely to go out and seek their own treatment than treatment group - levels of NRT use therefore similar. Not really a test of clinical efficacy of NRT but rather a comparison of the offer of free NRT vs. participants having to get their own via NHS.&lt;/p&gt;&lt;p&gt;LS, JHB, CB consulted and decided to exclude.&lt;/p&gt;" NOTES_MODIFIED="2012-08-22 14:05:39 +0100" NOTES_MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Ferguson-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-22 14:05:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Study of offer of free NRT via NHS Quitline services. Control group had access to and used free NRT and other stop smoking medications at high levels; study conditions were very similar for both groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:47:20 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Finland-unpublished">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:47:20 +0100" MODIFIED_BY="Kate Cahill">
<P>Only 3m follow-up. Comparison of patch &amp; nasal spray (n=51) versus nasal spray alone (n=50). Sustained abstinence rates 18% in each group. Used in a sensitivity analysis of combination therapies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:59:52 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Foulds-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:59:52 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Follow-up less than 6m</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-14 10:23:30 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Garvey-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-14 10:23:30 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Not enough information currently available (abstract only)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 11:59:57 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Glover-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 11:59:57 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Follow-up less than 6m</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-17 15:15:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gross-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-17 15:15:22 +0100" MODIFIED_BY="[Empty name]">
<P>Study of weight gain. Abstinence outcomes not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:00:03 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Guo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:00:03 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 3m follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 16:29:43 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Hajek-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 16:29:43 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Follow-up less than 6m. There were no significant differences in 12 wk abstinence rates between gum, patch, spray or inhaler groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:01 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Hanson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:01 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Follow-up only 10 wks; primary outcomes were withdrawal, craving, safety and compliance among adolescents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:00:24 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Haustein-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:00:24 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, <LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-14 10:24:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Hoch-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-14 10:24:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Not enough information currently available (abstract only)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hotham-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of nicotine patch as adjunct to counselling for pregnant smokers. Only 20 people in each condition, with high withdrawal and low compliance. Results favoured patch condition at delivery (3 versus 0).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:00:39 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Hughes-1989b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:00:39 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>No long-term follow-up, primarily a trial of the effect of instructions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hurt-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analysis of prior nicotine patch studies (to determine if recovering alcoholic smokers were more nicotine-dependent than non-alcoholics and whether the efficacy of nicotine patch therapy was comparable)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hurt-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants received nicotine patch</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jarvik-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reports subgroup analysis by level of nicotine dependence. See Schneider 1985A for main outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Jibrail-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 12 wks follow-up. Study of NRT for smoking abstinence and relationship between CRP and depressed mood during nicotine abstinence.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:03 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Kapur-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:03 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 12 wks follow-up. Trial of nicotine patch in pregnant smokers. 30 participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Korberly-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data in unpublished abstracts to include.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kozak-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label study in which smokers with higher nicotine dependence scores were given higher patch doses</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:04 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Kras-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:04 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Study of NRT and Hypericum perforatum extract. Only 10 wks follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:06 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Krumpe-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:06 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 10 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kupecz-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were randomized by month of treatment to group therapy with nicotine patch (n=21) or gum (n=17).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:06 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Landfeldt-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:06 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 12 wks follow-up reported in abstract. No evidence of benefit from combining patch and nasal spray compared to nasal spray alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:07 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Leischow-1996b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:07 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 10 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:08 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Levin-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:08 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 9 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:10 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Lin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:10 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 8 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 16:01:59 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Marsh-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 16:01:59 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 3m follow-up, safety study comparing 4 mg lozenge to 4 mg gum</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:01:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-McCarthy-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:01:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 3m follow-up, study of withdrawal symptoms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 15:08:07 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-McRobbie-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 15:08:07 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Short-term cross-over study assessing withdrawal symptoms and user satisfaction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:01:41 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Meier-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:01:41 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Short-term follow-up. Compared dependence individualized to standard dose patch.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:01:46 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Merz-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:01:46 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 3m follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-09 14:14:07 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Miller-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-09 14:14:07 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>1377 low-income smokers with quitline and subsidized NRT. Participants informed what group they would be in when first invited to participate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:01:52 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Millie-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:01:52 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 2m follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:10 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Minneker-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:10 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 9 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:51:22 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Molander-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:51:22 +0100" MODIFIED_BY="Kate Cahill">
<P>Crossover study with 2-day smoke-free periods</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mooney-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants used nicotine gum</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:11 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Mulligan-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:11 +0100" MODIFIED_BY="Kate Cahill">
<P>Only 6 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:02:06 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Nackaerts-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:02:06 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Insufficient data in published abstract to include (longest follow-up reported in abstract 1m); NRT delivered for max. 7d. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okuyemi-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention combined nicotine gum and multiple sessions of motivational interviewing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 15:11:34 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Oncken-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 15:11:34 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Study of short-term effects of NRT in pregnant smokers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Pomerleau-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Compared extended treatment (18 wks) to 10 wk treatment with nicotine patch. No follow-up beyond 18 wks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:02:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Rennard-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:02:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of nicotine inhaler for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, <LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-09 15:53:45 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Rey-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-09 15:53:45 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>All study participants received nicotine nasal spray. Comparison between different types of instructional guidance for dosing.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-08 13:25:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Rigotti-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-08 13:25:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Assessed effectiveness of adding NRT to rimonabant which has not been licensed for smoking cessation and results may not be generalisable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:28 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Roddy-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:28 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 13 wks follow-up. At this point there were no quitters in either the treatment or control group. There were particularly high losses to follow-up (64% overall) and low compliance (median duration of patch use 1wk).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:30 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Rose-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:30 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 3 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:31 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Rubinstein-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:31 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 12 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:32 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Sachs-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:32 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 6 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 16:10:30 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Schneider-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 16:10:30 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Short-term cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:59:55 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Schneider-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:59:55 +0100" MODIFIED_BY="Kate Cahill">
<P>Outcome was craving and withdrawal, not abstinence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-13 16:16:37 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Shahab-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-13 16:16:37 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Short-term cross-over trial of withdrawal symptom relief</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Shiffman-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Compared 10 and 6 wks of patch treatment without longer follow-up. Main outcome was craving and withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:34 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Shiffman-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:34 +0100" MODIFIED_BY="Kate Cahill">
<P>Comparison between 24 and 16hr patches. Assessment of craving and abstinence over 2 wks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:35 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Shiffman-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:35 +0100" MODIFIED_BY="Kate Cahill">
<P>Only 10 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shiffman-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized trial. Compared prescription and OTC patch in different populations using different methods.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 16:06:19 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Shiffman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 16:06:19 +0100" MODIFIED_BY="Kate Cahill">
<P>Only 6 wks follow-up. High dose (35 mg) patch.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:37 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Stapleton-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:37 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 12 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:55:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Sun-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:55:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 3m follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:03:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Sussman-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:03:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Presents Project EX program for adolescent tobacco use cessation. Mentions trial of nicotine gum vs herbal gum but insufficient detail provided.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:38 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Sutherland-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:38 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 3m follow-up. Comparison of patch &amp; nasal spray (n=104) versus patch alone (n=138) or nasal spray alone (n=138). Sustained abstinence rates after 12 wks of treatment 41%, 39%, 40%. Used in a sensitivity analysis of combination therapies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Sutherland-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 12 wks follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutton-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control group received no treatment so effect of nicotine gum is confounded with the brief counselling</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutton-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control group received no treatment so effect of nicotine gum is confounded with the behavioural support</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:56:30 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Thorsteinsson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:56:30 +0100" MODIFIED_BY="Kate Cahill">
<P>No long-term follow-up reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-17 14:43:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tonnesen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-17 14:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>All study participants received nicotine nasal spray. Comparison between ad lib and fixed schedule dosing.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:04:06 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Tsukahara-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:04:06 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Follow-up less than 6m. Direct comparison of varenicline and nicotine patch for smoking cessation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 15:55:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Tundulawessa-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 15:55:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Only 4 wks follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:04:24 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Tzivoni-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:04:24 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Follow-up less than 6m</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uyar-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unpublished, insufficient detail in abstract on nicotine patch dose, length of treatment, level of support.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Velicer-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were sent nicotine patches if they were assessed as potentially ready to quit. They did not have to set a quit date.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vial-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment groups differed from control in amount of counselling as well as use of NRT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-14 08:18:11 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Vikhireva-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-14 08:18:11 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of free choice of NRT product vs assigned NRT product from the outcome; no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:57:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Walker-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:57:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of familiarisation with NRT and choice of NRT product pre-quit date vs. standard care. Choice of NRT versus patch and/or gum confounded by familiarisation period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Warner-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Goal of intervention was relief of stress and withdrawal postoperatively</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:04:32 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Wennike-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:04:32 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, <LINK REF="REF-Stead-2007" TYPE="REFERENCE">Stead 2007</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 14:57:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Williams-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 14:57:59 +0100" MODIFIED_BY="[Empty name]">
<P>Only short-term outcomes reported in conference abstract. Trial terminated early when no benefit of higher dose detected in interim analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-16 16:30:22 +0100" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Wiseman-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-16 16:30:22 +0100" MODIFIED_BY="Kate Cahill">
<P>2 wk crossover study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-21 12:04:47 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Working-Group-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-21 12:04:47 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Follow-up less than 6m</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>OTC=over the counter; m=month(s); wk=week</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-02-14 13:32:34 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-05-03 11:40:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-02-14 13:28:34 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" STUDY_ID="STD-Williams-2009">
<CHAR_STUDY_NAME MODIFIED="2012-02-14 08:31:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Double-Blind, Placebo-Controlled Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2012-02-14 08:29:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>60 individuals with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-14 08:29:52 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Nicotine nasal spray or placebo spray with behavioural intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-14 08:30:29 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Abstinence at 12m</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-02-14 08:32:09 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>August 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-02-14 13:28:34 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">
<P>Mia H Zimmerman, hanosma@umdnj.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-10-16 16:31:03 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-10-16 15:57:02 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 08:30:48 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Abelin-1989">
<DESCRIPTION>
<P>Method not stated; described as "randomised, between-subjects, double-blind, and placebo-controlled"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 09:02:44 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-1998">
<DESCRIPTION>
<P>"a computer-generated random numbers table with a block size set at 20"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 09:49:57 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-2006">
<DESCRIPTION>
<P>"Randomization codes were generated in blocks of 36". For counselling support "a sealed envelope with pre-assigned randomization numbers was drawn"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 10:13:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Areechon-1988">
<DESCRIPTION>
<P>"The subjects were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 11:17:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1989">
<DESCRIPTION>
<P>Assignment was by group (6 to active gum, 6 to placebo); whether randomized or not is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-15 15:13:56 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1997">
<DESCRIPTION>
<P>"computer-generated randomization code", with spray dispensed by University pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 13:35:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>"computer generated randomisation code at a local pharmacy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 14:09:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Bohadana-2000">
<DESCRIPTION>
<P>"computer-generated randomization code"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 14:30:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Bolin-1999">
<DESCRIPTION>
<P>"Participants were randomly assigned ... random assignment took place on the first day of patch administration"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bolliger-2000a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 14:53:24 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Br-Thor-Society-1983">
<DESCRIPTION>
<P>Each physician had a balanced block of 12 treatments. Assignment was by numbered envelope.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brantmark-1973a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 09:28:53 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Buchkremer-1988">
<DESCRIPTION>
<P>"smokers were randomly assigned ... Randomization included matching by age, sex and initial cigarette consumption"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-21 11:31:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Bullen-2010">
<DESCRIPTION>
<P>"People giving verbal consent by telephone were allocated randomly using central computerized randomization." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 11:40:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-CEASE-1999">
<DESCRIPTION>
<P>"A computer-generated allocation list was prepared centrally and allocated subjects to treatment numbers". Randomization stratified by centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 15:38:14 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1987">
<DESCRIPTION>
<P>"in a double-blind random fashion". Control pts were recruited sequentially after the gum cohort had been assembled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-16 15:57:02 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1991">
<DESCRIPTION>
<P>"those who had agreed were given packages of identical appearance randomly containing either nicotine (2 mg) or placebo gum"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-15 15:31:08 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1996">
<DESCRIPTION>
<P>Pts stratified by inpatient/outpatient status, and outpatients also by FTND score. Pts "were randomized".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 13:13:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1996">
<DESCRIPTION>
<P>"Sixty-four participants ... were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 14:10:40 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Clavel-1985">
<DESCRIPTION>
<P>"Treatment ... was allocated by balanced randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 14:40:39 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Clavel_x002d_Chapelon-1992">
<DESCRIPTION>
<P>"Participants were randomly allocated"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 13:52:04 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Coleman-2012">
<DESCRIPTION>
<P>"computer-generated sequence, in random permuted blocks of randomly varying size and with stratification by recruiting site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-09 11:14:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Cooney-2009">
<DESCRIPTION>
<P>"urn randomization computer program that balanced the two groups for history of previous substance use treatment, age, sex, baseline drinks/drinking day and baseline cpd."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 15:24:49 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cooper-2005">
<DESCRIPTION>
<P>"Eligible participants ... were randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-17 14:58:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Croghan-2003">
<DESCRIPTION>
<P>Randomization by Mayo Clinic Co-ordinating Centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-17 15:08:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Dale-1995">
<DESCRIPTION>
<P>"subjects ... were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-02 11:57:30 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Daughton-1991">
<DESCRIPTION>
<P>"All 158 study-eligible volunteers were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 08:36:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Daughton-1998">
<DESCRIPTION>
<P>"a random code was generated" for equal numbers of active and placebo within blocks of ten.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 08:59:57 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Dautzenberg-2001">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 09:08:23 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Davidson-1998">
<DESCRIPTION>
<P>"a computer-generated randomization schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 09:16:42 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ehrsam-1991">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-09 11:37:36 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Etter-2009">
<DESCRIPTION>
<P>"randomization was based on a list of random numbers generated by a computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 09:28:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fagerstrom-1982">
<DESCRIPTION>
<P>"patients were randomly assigned... in blocks of ten"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-16 10:18:56 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Fagerstrom-1984">
<DESCRIPTION>
<P>"Patients were randomly assigned" by birthdate; Pts born 1st-20th received active gum, 21st-31st no gum. Those born on even dates got long follow-up, odd dates short follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 10:26:53 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fee-1982">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 11:15:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Fiore-1994A">
<DESCRIPTION>
<P>"a pregenerated computer sequence" and stratified by FTQ score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 11:45:58 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Fiore-1994B">
<DESCRIPTION>
<P>"a pregenerated computer sequence" and stratified by FTQ score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 13:30:40 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fortmann-1995">
<DESCRIPTION>
<P>"Randomization was stratified by gender and cigarette consumption". No further detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 14:07:49 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-1989">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-09 13:59:35 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>Computerized &#8216;urn randomization&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 14:45:28 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Garvey-2000">
<DESCRIPTION>
<P>Stratified by dependence level (high/low) and then allocated "using a randomized, double-blind procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 15:14:31 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gilbert-1989">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 15:35:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Glavas-2003a">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 08:13:44 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Glavas-2003b">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 08:39:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Glover-2002">
<DESCRIPTION>
<P>"a computer-generated randomization code"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 08:57:22 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-1989">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 09:21:24 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gourlay-1995">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 10:00:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gross-1995">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 10:09:57 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1985">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 10:24:43 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 11:08:16 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1996">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 11:20:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hand-2002">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 11:31:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Harackiewicz-1988">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-27 14:53:26 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hays-1999">
<DESCRIPTION>
<P> "Computer-generated random schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 13:45:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Herrera-1995">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 14:01:55 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hilleman-1994">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 14:40:11 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1984">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:04:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1994">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:34:25 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hjalmarson-1997">
<DESCRIPTION>
<P>"All numbers were on a list for random allocation to medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:42:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1988">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:52:11 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1989">
<DESCRIPTION>
<P>A 4th random digit (1-9) was added to their 3-digit subject ID number. Only exception was members of same household got the same treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 09:16:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1990">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 11:46:50 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 12:51:27 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 13:19:11 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-16 16:17:25 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Hughes-2010">
<DESCRIPTION>
<P>"upon receipt of consent, our statistician generated a concealed allocation sequence and randomized participants&#8230;using blocked randomization (stratified by city and counsellor)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 13:37:20 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1990">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 13:59:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 14:40:46 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-ICRF-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 15:13:50 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jamrozik-1984">
<DESCRIPTION>
<P>"The codes were balanced to give equal numbers of patients receiving either the active gum ... or a placebo".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 15:55:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jarvis-1982">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 13:10:01 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1991">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 13:55:11 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 14:09:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 14:30:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Joseph-1996">
<DESCRIPTION>
<P>"a computer-generated schedule" at the Minneapolis VAMC Co-ordinating Center.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 14:50:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2006">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:08:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1984">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:25:52 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1990">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:44:32 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1997">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:52:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1999">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 09:55:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kornitzer-1987">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 11:26:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Kornitzer-1995">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 11:41:13 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kralikova-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 11:48:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Leischow-1996">
<DESCRIPTION>
<P>"the randomization code was generated by computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 13:06:44 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Leischow-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 13:33:07 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Leischow-2004">
<DESCRIPTION>
<P>"computer-generated random allocation sequence was created by the study statistician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 14:31:44 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Lerman-2004">
<DESCRIPTION>
<P>"computer-generated randomization scheme", stratified by study site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 08:48:32 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Lewis-1998">
<DESCRIPTION>
<P>See below</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 11:06:09 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Llivina-1988">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 11:35:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1980">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 11:47:42 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-1985">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 09:43:24 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-McGovern-1992">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 10:16:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Molyneux-2003">
<DESCRIPTION>
<P>"Patients were randomised ... using a list generated for each centre, allocating equally in random permuted blocks of nine".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:29:39 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Moolchan-2005">
<DESCRIPTION>
<P>"randomized ... according to an algorithm held by the National Institute on Drug Abuse Pharmacy, with true replacement of the non-completers". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:38:14 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:49:53 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-1990">
<DESCRIPTION>
<P>"Assignment was done ... by individual randomisation based on their screen's numbers [or] by group randomisation by worksite unit". 15 members for Group 3 were chosen from 19 applicants, based on distribution of employment..</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 13:39:01 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Nebot-1992">
<DESCRIPTION>
<P>Not applicable; "each PCT was randomly allocated to perform the three different interventions successively". No information about avoidance of selection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 13:54:45 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-1994">
<DESCRIPTION>
<P>Pts stratified on level of nicotine dependence. "Within each of the high- and low-dependence groups, subjects were randomly assigned".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 15:06:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-1999">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 15:29:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ockene-1991">
<DESCRIPTION>
<P>"Patients were randomly assigned to the physician and follow-up conditions".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 08:32:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Oncken-2007">
<DESCRIPTION>
<P>Assignment ratio was 3:5; "152 women were randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-09 15:17:38 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Oncken-2008">
<DESCRIPTION>
<P>"computerized urn randomization program to balance participant assignment in the two treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-07 09:53:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Ortega-2011">
<DESCRIPTION>
<P>Participants were randomized "using a "computerized algorithm."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 09:02:25 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Otero-2006">
<DESCRIPTION>
<P>Not stated. Randomization was stratified by age and sex by an independent specialist.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-16 13:18:06 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Page-1986">
<DESCRIPTION>
<P>Randomized by day of attendance. Post hoc tests of results by day of attendance showed no interaction.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 10:03:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Paoletti-1996">
<DESCRIPTION>
<P>Randomization stratified on plasma cotinine levels. No detail on methods used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 10:22:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Perng-1998">
<DESCRIPTION>
<P>"Randomization was performed by an independent outside facility"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 10:57:28 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>"Randomization was conducted in double-blind fashion using blocked randomization within each of the 10 cohorts"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-02 12:22:23 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>"Randomization was double-blind and used a block randomization scheme with sex and self-reported race as the blocking variables."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 11:14:48 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Pirie-1992">
<DESCRIPTION>
<P>"Participants were randomized to one of four groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-14 11:39:53 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Pollak-2007">
<DESCRIPTION>
<P>"computerised random number generator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 11:41:09 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Prapavessis-2007">
<DESCRIPTION>
<P>"Using a computer-generated program, participants were then randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 11:56:12 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Puska-1979">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 12:05:21 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Puska-1995">
<DESCRIPTION>
<P>"The subjects were randomly allocated"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 13:06:03 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Richmond-1993">
<DESCRIPTION>
<P>"random weekly assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 13:44:57 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Richmond-1994">
<DESCRIPTION>
<P>"Treatment and control patches were arranged in random order by Marion Merrell Dow, Sydney, then issued sequentially to patients as they attended"; married couples were assigned to same condition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 14:37:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-1994">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 14:47:20 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-1998">
<DESCRIPTION>
<P>"participants were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 14:57:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2006">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 10:19:21 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2009">
<DESCRIPTION>
<P>"a total of 400 subjects were randomly assigned to one of four treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 11:33:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2010">
<DESCRIPTION>
<P>"Randomized" but method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 15:21:37 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Roto-1987">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:34:17 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Russell-1983">
<DESCRIPTION>
<P>Pts assigned "according to their week of attendance".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 08:47:22 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Sachs-1993">
<DESCRIPTION>
<P>"Subjects were sequentially and randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:21:56 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985A">
<DESCRIPTION>
<P>"subjects were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:22:42 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985B">
<DESCRIPTION>
<P>"subjects were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:47:30 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1995">
<DESCRIPTION>
<P>"Subjects were randomly assigned to conditions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 10:17:23 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Schneider-1996">
<DESCRIPTION>
<P>"A computer generated randomization list was prepared by the manufacturers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 11:43:26 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Schnoll-2010a">
<DESCRIPTION>
<P>"computer-based randomization table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 12:29:19 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010b">
<DESCRIPTION>
<P>"Randomization was coordinated by Fox Chase Cancer Center and was stratified at each site."        </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 11:29:32 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Schuurmans-2004">
<DESCRIPTION>
<P>"a computer-generated list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 11:49:59 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Segnan-1991">
<DESCRIPTION>
<P>"a predetermined randomized sequence of the four interventions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 12:09:55 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>"smokers were randomized" after stratification for dependency by time to first cigarette of the day.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 12:34:46 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above (Shiffman 2002 2mg)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 15:19:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>"using a 1:1 computer-generated randomization scheme, balanced across study sites and generated separately for the 2- and 4-mg groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 15:25:52 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above (Shiffman 2009 2mg)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-21 11:49:45 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>"Smokers were randomized to the 5 treatment conditions within each clinic with blocking on sex and self-identified race." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 13:41:04 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Sonderskov-1997">
<DESCRIPTION>
<P>"randomized sequential treatment packages"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 13:56:50 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Stapleton-1995">
<DESCRIPTION>
<P>" a computer generated list, complied in blocks of six (four active, two placebo)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 14:27:51 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Sutherland-1992">
<DESCRIPTION>
<P>"They drew a card marked A or P for allocation to active or placebo group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 14:52:52 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-TNSG-1991">
<DESCRIPTION>
<P>Not stated: "patients were ... randomized", but members of same household received same assignment, with one randomly selected for inclusion in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 15:10:24 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-1988">
<DESCRIPTION>
<P>Pts stratified by dependence, then "subjects on each list were then randomly assigned to treatment in blocks of two".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 15:19:48 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1991">
<DESCRIPTION>
<P>"subjects were sequentially and randomly assigned to either active treatment or placebo according to a computer-generated randomization code".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 15:36:42 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1993">
<DESCRIPTION>
<P>"The randomization code for assignment to either active or placebo inhaler was generated by a computer program"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 08:21:06 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-2000">
<DESCRIPTION>
<P>"a computer-generated list with random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 08:49:51 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-2006">
<DESCRIPTION>
<P>"Patients were allocated to one of the four treatment groups using a block randomization list at each center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-26 10:59:20 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-T_x00f8_nnesen-2012">
<DESCRIPTION>
<P>"Subject randomization list stratified by study site&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 09:11:29 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Villa-1999">
<DESCRIPTION>
<P>"Los participantes fueron distribuidos aleatoriamente"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 09:18:43 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wallstrom-2000">
<DESCRIPTION>
<P>"Subjects were randomized ... using a computer program".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wennike-2003a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-04 16:47:07 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Westman-1993">
<DESCRIPTION>
<P>"Using simple randomization, the subjects were assigned to active or placebo treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 09:53:20 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wisborg-2000">
<DESCRIPTION>
<P>Block randomization. "Pharmacia &amp; Upjohn ... generated the randomization list, supplied the patches with randomization numbers, and kept the code between patch number and the specific treatment until data collection was finished".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-08 11:29:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>"Generated by the study center"; used to put 4 different coloured questionnaires in random order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-04 16:47:16 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wong-1999">
<DESCRIPTION>
<P>"Identification numbers were randomized to the medication kits by computer-generated randomization schedules...[which] were retained by the study sponsor in sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 10:15:52 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Zelman-1992">
<DESCRIPTION>
<P>"subjects were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-10-10 16:04:42 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 08:30:56 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Abelin-1989">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 09:18:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-1998">
<DESCRIPTION>
<P>Study staff blinded - see below.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 09:50:37 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-2006">
<DESCRIPTION>
<P>"Study staff ... were blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-04 16:43:55 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Areechon-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 11:18:20 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1989">
<DESCRIPTION>
<P>Probably. "Each subgroup knew they would either get nicotine gum or a placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 12:47:55 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 13:36:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>"Pharmacy staff were blinded to the content of the bottles"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 14:11:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Bohadana-2000">
<DESCRIPTION>
<P>"sealed randomization envelopes were provided for each subject and were held by the hospital pharmacy, which was responsible for dispensing medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 14:32:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Bolin-1999">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bolliger-2000a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 14:51:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Br-Thor-Society-1983">
<DESCRIPTION>
<P>Physician opened envelope at first treatment session.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brantmark-1973a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 15:13:01 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Buchkremer-1988">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 17:45:20 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Bullen-2010">
<DESCRIPTION>
<P>"randomization sequence concealed until interventions were assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 11:41:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-CEASE-1999">
<DESCRIPTION>
<P>See process above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 15:30:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1987">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 15:54:37 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 11:21:03 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 13:14:07 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 14:10:50 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Clavel-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 14:40:51 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Clavel_x002d_Chapelon-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 13:52:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Coleman-2012">
<DESCRIPTION>
<P>"eligibility criteria were entered into a secure online database before randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 15:21:26 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Cooney-2009">
<DESCRIPTION>
<P>Randomization procedure required participant characteristics to be provided before allocation assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 15:25:23 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cooper-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-17 14:59:03 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Croghan-2003">
<DESCRIPTION>
<P>"Treatment assignment was carried out using a dynamic allocation procedure" which took account of stratification by gender, cpd, yrs smoking, study site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-17 15:08:51 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Dale-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-17 15:45:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Daughton-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 08:36:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Daughton-1998">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 09:00:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Dautzenberg-2001">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 09:08:30 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Davidson-1998">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 09:16:49 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ehrsam-1991">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 14:55:26 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Etter-2009">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 09:42:55 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fagerstrom-1982">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 10:15:03 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Fagerstrom-1984">
<DESCRIPTION>
<P>Not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 10:26:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fee-1982">
<DESCRIPTION>
<P>"Allocation was carried out by external staff, using a random selection procedure unknown to the authors"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 11:15:25 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Fiore-1994A">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 11:49:12 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fiore-1994B">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 13:01:47 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fortmann-1995">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 14:07:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-1989">
<DESCRIPTION>
<P>"La asignación a los grupos de estudio se realizaba aleatoriamente al acudir a la primera entrevista" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-09 13:59:45 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 14:45:39 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Garvey-2000">
<DESCRIPTION>
<P>No further detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 15:15:20 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gilbert-1989">
<DESCRIPTION>
<P>"physicians were presented with a sealed envelope indicating treatment allocation by the receptionist"; "allocation was balanced within each block of four patients for each physician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 15:34:35 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Glavas-2003a">
<DESCRIPTION>
<P>"each examinee received a presealed envelope, labeled after random numbering, which contained either 8 transdermal nicotine system patches or matching placebo stickers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 08:14:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Glavas-2003b">
<DESCRIPTION>
<P>"presealed numbered envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 08:39:52 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Glover-2002">
<DESCRIPTION>
<P>"subjects were sequentially randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 08:56:25 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-1989">
<DESCRIPTION>
<P>"each subject was assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 09:21:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gourlay-1995">
<DESCRIPTION>
<P>"Subjects were randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 10:00:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gross-1995">
<DESCRIPTION>
<P>"Random assignment", stratified by dependence measures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 10:09:49 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1985">
<DESCRIPTION>
<P>"Subjects were randomly assigned within time constraints to one of the three treatment conditions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 10:24:37 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>"Within their time constraints, subjects were randomly assigned to 5-6 member groups across conditions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-04 16:44:43 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1996">
<DESCRIPTION>
<P>"Patients were stratified according to depression history and number of cigarettes smoked per day; they were then randomly assigned from within stratified blocks"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 11:27:13 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Hand-2002">
<DESCRIPTION>
<P>"randomised, according to month of entry"; unequal months, with imbalance in favour of NRT group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 11:31:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Harackiewicz-1988">
<DESCRIPTION>
<P>"randomly assigned to one of three conditions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 11:54:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hays-1999">
<DESCRIPTION>
<P>2-stage process. 1. random allocation to 1 of 2 trials, i.e. open-label pay trial or placebo-controlled. 2. Those in placebo trial were then assigned "by means of a computer-generated code, in blocks of 20".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 13:44:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Herrera-1995">
<DESCRIPTION>
<P>Stratified on dependency scores, to determine dosage. Then "randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 14:01:47 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hilleman-1994">
<DESCRIPTION>
<P>"open-label, randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 14:40:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1984">
<DESCRIPTION>
<P>26 groups "were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:08:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1994">
<DESCRIPTION>
<P>"Subjects ... were randomized" to 26 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:34:27 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hjalmarson-1997">
<DESCRIPTION>
<P>Pts received "a subject number consecutively" at the first group session.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:42:21 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1988">
<DESCRIPTION>
<P>"225 interested subjects ... were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 15:50:52 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hughes-1989">
<DESCRIPTION>
<P>2:1 randomization scheme. "Subjects were assigned randomly in a double-blind manner"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 09:15:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1990">
<DESCRIPTION>
<P>"Subjects were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 11:49:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hughes-1991">
<DESCRIPTION>
<P>"Physician opened a sealed envelope" which assigned to a price group. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 12:51:22 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1999">
<DESCRIPTION>
<P>"Subjects were randomly assigned in a double-blind manner"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 13:14:13 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2003">
<DESCRIPTION>
<P>"Subjects were randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-08 10:36:41 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Hughes-2010">
<DESCRIPTION>
<P>Allocation unknown until consent obtained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 13:37:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1990">
<DESCRIPTION>
<P>"subjects were assigned randomly"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 13:59:48 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1994">
<DESCRIPTION>
<P>"subjects were randomly assigned to active or placebo patches"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 14:40:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-ICRF-1994">
<DESCRIPTION>
<P>"prior random allocation of study numbers to each intervention group and by sequential allocation of a study number to patients on entry"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 15:15:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Jamrozik-1984">
<DESCRIPTION>
<P>"allocated to next available of ten alphabetical codes" from lists held in each practice.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 15:57:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jarvis-1982">
<DESCRIPTION>
<P>"treated in groups of about ten, taken in order from the waiting list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 13:10:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1991">
<DESCRIPTION>
<P>"smokers were randomised to 24 smaller groups and each group was randomly allocated to treatment". No further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 13:55:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1995">
<DESCRIPTION>
<P>"randomly assigned"; "All participants were also randomly assigned to one of the three types of counselling"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 14:09:20 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>"subjects were randomly assigned to one of four treatments with use of an unequal-cell design... Randomization was not balanced within sites"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 14:31:42 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-1996">
<DESCRIPTION>
<P>Pts were randomly assigned in blocks of ten</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 14:50:28 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2006">
<DESCRIPTION>
<P>"pts were randomly assigned".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-04 14:14:41 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1984">
<DESCRIPTION>
<P>Pts "were blocked on sex and Fagerström score and assigned randomly to treatment group".<BR/>"Therapists were assigned randomly to treatment conditions".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:25:47 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1990">
<DESCRIPTION>
<P>"randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:44:24 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1997">
<DESCRIPTION>
<P>"Pts were randomized to treatment conditions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 15:52:01 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Killen-1999">
<DESCRIPTION>
<P>"Smokers ... were randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 09:52:16 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kornitzer-1987">
<DESCRIPTION>
<P>"subjects were randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 11:29:39 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Kornitzer-1995">
<DESCRIPTION>
<P>"randomized list generated by a computer program". Randomization balanced between companies 2/2/1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 11:41:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kralikova-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 11:48:32 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Leischow-1996">
<DESCRIPTION>
<P>"subjects were sequentially and randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 13:06:39 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Leischow-1999">
<DESCRIPTION>
<P>"subjects were randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 13:34:32 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Leischow-2004">
<DESCRIPTION>
<P>"Each participant ... was given the next available number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-08 14:33:35 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Lerman-2004">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 08:48:17 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Lewis-1998">
<DESCRIPTION>
<P>"using a predetermined computer-generated randomization code"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 11:06:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Llivina-1988">
<DESCRIPTION>
<P>"asignados al azar"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 11:36:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1980">
<DESCRIPTION>
<P>"randomly allocated" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-08 10:38:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-1985">
<DESCRIPTION>
<P>"Patients were assigned randomly"; married couples were allocated to the same group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 09:44:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-McGovern-1992">
<DESCRIPTION>
<P>"Participants were randomly assigned .... Assignment to condition was by clinic group rather than individual subject".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 10:11:51 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Molyneux-2003">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:31:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Moolchan-2005">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:38:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:45:30 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-1990">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 13:27:43 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Nebot-1992">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:01:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-1994">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 15:07:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-1999">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 15:30:13 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ockene-1991">
<DESCRIPTION>
<P>Physicians opened "a packet containing the intervention materials, which they received at the beginning of the clinic encounter"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 15:58:35 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Oncken-2007">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-23 15:27:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Oncken-2008">
<DESCRIPTION>
<P>Urn randomization procedure implies that allocation not known until after enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-02 12:15:37 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Ortega-2011">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 08:53:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Otero-2006">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 09:29:53 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Page-1986">
<DESCRIPTION>
<P>Not applicable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 10:03:07 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Paoletti-1996">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 10:23:43 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Perng-1998">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 10:57:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-08 11:15:31 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>"Staff did not know to which type(s) of medication a participant would be assigned until the moment of randomization, and study staff were blinded to whether the medication was active or placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 11:14:58 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Pirie-1992">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-14 11:40:18 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Pollak-2007">
<DESCRIPTION>
<P>"each support specialist had a handheld device that contained a randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 11:41:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Prapavessis-2007">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 11:56:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Puska-1979">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 12:05:27 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Puska-1995">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 13:07:57 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Richmond-1993">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 13:40:35 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Richmond-1994">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 14:37:17 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-1994">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 14:47:27 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-1998">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 14:57:12 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2006">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 10:19:45 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2009">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 11:33:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2010">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 15:21:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Roto-1987">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:35:05 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Russell-1983">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 08:47:29 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Sachs-1993">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:22:02 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985A">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:22:49 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985B">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 09:47:37 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1995">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 10:18:01 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Schneider-1996">
<DESCRIPTION>
<P>"An independent "randomizer" packaged drug from the list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 12:22:57 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010a">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 12:29:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010b">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 11:30:09 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Schuurmans-2004">
<DESCRIPTION>
<P>"Numbering of identical boxes containing patches was carried out prior to the study by a person not involved in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 11:51:18 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Segnan-1991">
<DESCRIPTION>
<P>"a package of closed numbered envelopes ... was provided to each GP". Research staff checked the integrity of the process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 12:09:31 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 12:33:53 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 15:19:28 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 15:25:54 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-21 11:49:47 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 13:28:01 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Sonderskov-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 13:57:46 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Stapleton-1995">
<DESCRIPTION>
<P>Numbered packages</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 14:29:06 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Sutherland-1992">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 14:46:03 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-TNSG-1991">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 15:11:39 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-1988">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 15:29:17 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1991">
<DESCRIPTION>
<P>"Patches were packaged and labeled with consecutive numbers". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 15:39:22 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1993">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 08:22:23 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2000">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 08:49:55 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2006">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-26 10:59:48 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-T_x00f8_nnesen-2012">
<DESCRIPTION>
<P>"The supply or resupply of study medication to a subject was determined via an Interactive Voice Response System involving a dispenser pack number randomization list. Both randomization lists were computer-generated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 09:10:04 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Villa-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 09:20:29 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Wallstrom-2000">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wennike-2003a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 09:42:05 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Westman-1993">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 09:54:12 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wisborg-2000">
<DESCRIPTION>
<P>"Women ... were assigned consecutive numbers on the randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-08 11:29:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>No concealment: "questionnaires were distributed consecutively to all attending patients on the target days by nurses. Thus, the assignment of patients was entirely dependent on the consecutive attendance of patients and the random assignment of a color. Doctors were not allowed to interfere with this study procedure." But numbers allocated to groups very uneven and discussion states: "Random checks of this procedure [randomization] and quality assurance tests by study monitors revealed that in some cases in the latter part of the study treatment was based on patient and physician preferences."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 10:07:11 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wong-1999">
<DESCRIPTION>
<P>Kits assigned sequentially from the appropriate strata (gender stratification).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 10:16:08 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Zelman-1992">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-10-16 16:26:58 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 08:42:03 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Abelin-1989">
<DESCRIPTION>
<P>"Double-blind", no further details. 75% of NRT group and 76% of placebo group correctly guessed their assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 09:10:52 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-1998">
<DESCRIPTION>
<P>"Both study staff and patients were blinded to patch treatment". 63% of NRT pts and 44% of placebo pts correctly guessed their assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 09:51:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-2006">
<DESCRIPTION>
<P>"Study staff and participants were blinded". "Assignment to MI counselling versus HE was not blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 10:16:55 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Areechon-1988">
<DESCRIPTION>
<P>Described as double-blind. "Neither the investigators nor the subjects knew which subjects received the active gum and which received the placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 11:18:47 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1989">
<DESCRIPTION>
<P>Described as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 12:48:09 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1997">
<DESCRIPTION>
<P>"Subject and therapist were blind to treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 13:38:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>Clinic staff, pharmacy staff and pts all blinded to assignment. Codes not broken until after data entry and analyses completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 14:17:56 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Bohadana-2000">
<DESCRIPTION>
<P>Described as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 14:32:23 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Bolin-1999">
<DESCRIPTION>
<P>"Both participants and experimenters were unaware of assignment during the baseline phase of the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Bolliger-2000a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 14:53:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Br-Thor-Society-1983">
<DESCRIPTION>
<P>"Placebo and nicotine gums were indistinguishable in appearance and taste, and neither the physician nor the patient knew which gum had been issued"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Brantmark-1973a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 15:15:47 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Buchkremer-1988">
<DESCRIPTION>
<P>Described as double-blind; "checked by questioning both the training personnel and the probands of nicotine- and placebo-groups". No significant differences in right and wrong guesses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 17:45:32 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Bullen-2010">
<DESCRIPTION>
<P>No placebo. Single blinding: "Participants were aware of the group to which they were allocated but 3- and 6- month follow-up methods were identical for all participants, and all follow-up telephone calls and outcome verification procedures were made by research assistants blind to treatment allocation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-16 11:43:39 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-CEASE-1999">
<DESCRIPTION>
<P>"Active and placebo patches were identical in appearance and packaging. In order to maintain blinding, all subjects continued to use two patches for a total of 26 weeks", i.e. non-tapered groups were switched to placebo patches.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 15:30:27 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1987">
<DESCRIPTION>
<P>Described as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 15:57:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-16 11:37:47 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1996">
<DESCRIPTION>
<P>Abstract describes the trial as "double-blind", but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-16 13:23:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-16 14:17:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Clavel-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-16 14:48:44 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Clavel_x002d_Chapelon-1992">
<DESCRIPTION>
<P>"Treatments were administrated blindly"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-02 13:52:38 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Coleman-2012">
<DESCRIPTION>
<P>"identically packaged study patches were dispensed, and all participants and study personnel were unaware of the study assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-09 10:47:53 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Cooney-2009">
<DESCRIPTION>
<P>"Double blind." "Research assistants who collected these data were blind to medication assignment and did not conduct psychosocial treatments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-16 15:26:16 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cooper-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-16 15:54:23 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Croghan-2003">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-17 15:10:20 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Dale-1995">
<DESCRIPTION>
<P>"To blind the subjects, staff, and investigators, each subject simultaneously wore three patches during the 6-day inpatient phase"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-17 15:45:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Daughton-1991">
<DESCRIPTION>
<P>Described as "double-blind"; "All of the patches were physically identical in appearance".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 08:36:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Daughton-1998">
<DESCRIPTION>
<P>"Participants were assigned randomly, in a double-blind fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 09:00:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Dautzenberg-2001">
<DESCRIPTION>
<P>Described as "double-blind", but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 09:09:07 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1998">
<DESCRIPTION>
<P>Described as "double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 09:19:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ehrsam-1991">
<DESCRIPTION>
<P>Described as "doppelblinden" but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-21 11:41:24 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Etter-2009">
<DESCRIPTION>
<P>No placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 09:48:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Fagerstrom-1982">
<DESCRIPTION>
<P>"All patients were told that the chewing gum they received contained nicotine"; pts did not know that they were involved in a study.<BR/>"the experimenter's guess of nicotine or placebo gum was in the direction of better than chance, but not significantly so".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-07 10:29:26 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Fagerstrom-1984">
<DESCRIPTION>
<P>Not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 10:30:16 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fee-1982">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 11:43:53 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fiore-1994A">
<DESCRIPTION>
<P>Described as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 11:49:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fiore-1994B">
<DESCRIPTION>
<P>Described as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 13:33:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fortmann-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 14:00:58 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-1989">
<DESCRIPTION>
<P>Described as double-blind ("doble ciego")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-09 14:00:47 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>&#8216;double-blind, double-dummy&#8217; for medication component. 'Neither the nurses nor the participants knew which of the two formulations contained the active formulation.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 14:47:35 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Garvey-2000">
<DESCRIPTION>
<P>Described as double-blind, but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 15:18:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Gilbert-1989">
<DESCRIPTION>
<P>No placebo gum used. Control group pts could request gum, and physician would decide whether or not to prescribe.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 15:44:12 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Glavas-2003a">
<DESCRIPTION>
<P>Described as double-blind, but no further detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-21 15:48:56 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Glavas-2003b">
<DESCRIPTION>
<P>"The envelopes were prepared well in advance and the distribution was commissioned to a nurse not taking part in the evaluation process"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 08:43:34 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Glover-2002">
<DESCRIPTION>
<P>"All tablets were identical in appearance... each placebo tablet contained 3&#956;g of capsaicin to mimic the oral effects of nicotine and to maintain blinding"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 09:02:46 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Goldstein-1989">
<DESCRIPTION>
<P>Not relevant; placebo gum not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 16:19:56 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Gourlay-1995">
<DESCRIPTION>
<P>Pts invited at wk 11 to guess their assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 09:58:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Gross-1995">
<DESCRIPTION>
<P>No placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 11:01:16 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Hall-1985">
<DESCRIPTION>
<P>No placebo; no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 10:26:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>Group leaders blinded to gum use. Leaders and pts tried to guess assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 11:12:45 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1996">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 11:24:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Hand-2002">
<DESCRIPTION>
<P>No placebo, so not applicable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-04 16:44:52 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Harackiewicz-1988">
<DESCRIPTION>
<P>No placebo, so not applicable; but researchers were blinded to treatment condition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 13:01:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hays-1999">
<DESCRIPTION>
<P>"The randomization code was not revealed to any of the investigators until completion of the study." Packaging identical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 13:45:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Herrera-1995">
<DESCRIPTION>
<P>Described as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 14:31:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Hilleman-1994">
<DESCRIPTION>
<P>Not relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 14:49:28 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hjalmarson-1984">
<DESCRIPTION>
<P>Both therapists and nurse distributing gum were blinded to assignment of groups. Placebo gum was flavoured with capsaicin to mimic nicotine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 15:13:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hjalmarson-1994">
<DESCRIPTION>
<P>"Procedure was blind to both subject and therapist", but where more than one household member was enrolled all members got the same treatment (6 couples thus affected, 3 in active and 3 in placebo). At 12m, 60% of responders correctly guessed their assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 16:08:37 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hjalmarson-1997">
<DESCRIPTION>
<P>"The randomization was blinded to both the participant and the therapist", but members of the same household received the same treatment. At 12m follow-up, 86% of the active group and 90% of placebo group correctly guessed their assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 15:45:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1988">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-22 15:52:57 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hughes-1989">
<DESCRIPTION>
<P>Pharmacists dispensed gum from numbered bins, and were unaware of assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-01 09:54:03 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1990">
<DESCRIPTION>
<P>"in a double-blind manner"; subjects guessed which group they had been assigned to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-01 11:50:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Hughes-1991">
<DESCRIPTION>
<P>Double-blind, as described above. But physicians knew how much each pt paid, and therefore which group they were in, so could have managed them differently ("no anecdotal evidence that this occurred".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-01 12:55:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1999">
<DESCRIPTION>
<P>Described as "double-blind" but no further detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-01 13:19:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-16 16:17:46 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2010">
<DESCRIPTION>
<P>No placebo. "All follow-ups... were collected via phone by research assistants who were blind to study condition and had no role in the intervention."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 15:49:05 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1990">
<DESCRIPTION>
<P>Not stated; initial double-blind was broken after 6 wks of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 12:02:05 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1994">
<DESCRIPTION>
<P>Described as double-blind; no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-01 15:02:12 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-ICRF-1994">
<DESCRIPTION>
<P>Pts and nurses blinded to patches but not to support materials. Pts invited to guess assignment at end of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-01 15:15:40 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Jamrozik-1984">
<DESCRIPTION>
<P>Treatments were "identical in appearance and packaging". "No one doctor or member of staff was likely to see sufficient numbers of patients to be able to break the 10 code system".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-01 15:57:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Jarvis-1982">
<DESCRIPTION>
<P>"Therapists and subjects were blind to the allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-02 13:22:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Jensen-1991">
<DESCRIPTION>
<P>"The study was not blind", because of restrictions on use of silver acetate gum.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 15:49:26 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1995">
<DESCRIPTION>
<P>"in a double-blind manner" for wks 1-4, then open-label for wks 5-8.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-02 14:16:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>Medications were identical, but other blinding procedures not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-02 14:33:53 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-1996">
<DESCRIPTION>
<P>Described as double-blind, but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 15:49:45 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2006">
<DESCRIPTION>
<P>double-blind for 4 wks, then open-label dose tapering phase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-04 14:16:39 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Killen-1984">
<DESCRIPTION>
<P>No blinding reported. "Interpretation of this data is hampered by the lack of a placebo control condition." Unclear if therapists aware of gum allocation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-02 15:25:58 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Killen-1990">
<DESCRIPTION>
<P>"Assignment to gum condition was double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 12:16:22 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Killen-1997">
<DESCRIPTION>
<P>"Assignment to the patch condition was double-blind"; pts invited to guess assignment at 6m follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-02 15:55:30 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Killen-1999">
<DESCRIPTION>
<P>"Assignment to treatment dose was double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-08 09:56:40 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kornitzer-1987">
<DESCRIPTION>
<P>"in a double-blind way"; blinding was broken at 3m.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-08 11:27:16 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Kornitzer-1995">
<DESCRIPTION>
<P>"The investigator and the subjects were completely blind concerning treatment". "unblinding was never requested during the whole study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-08 11:41:46 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kralikova-2002">
<DESCRIPTION>
<P>Described as "double-blind" - no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-08 12:05:46 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Leischow-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-10 09:26:51 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Leischow-1999">
<DESCRIPTION>
<P>Blinding not applicable due to nature of intervention. Use of CO minimizes detection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-10 09:26:45 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Leischow-2004">
<DESCRIPTION>
<P>Blinding not applicable due to nature of intervention. Use of CO minimizes detection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-08 14:33:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Lerman-2004">
<DESCRIPTION>
<P>Open-label treatment; Outcome assessment "interviewers were blinded to study group assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-09 08:49:32 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Lewis-1998">
<DESCRIPTION>
<P>"Both patients and study staff were blinded with respect to patch dose"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-09 11:06:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Llivina-1988">
<DESCRIPTION>
<P>Described as "doble ciego"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-09 11:41:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1980">
<DESCRIPTION>
<P>"The trial was double blind between the gum groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-10 09:26:29 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Marshall-1985">
<DESCRIPTION>
<P>Blinding not applicable due to nature of intervention. Use of CO minimizes detection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 09:45:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-McGovern-1992">
<DESCRIPTION>
<P>Not relevant, as no placebo gum used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 10:24:31 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Molyneux-2003">
<DESCRIPTION>
<P>Not relevant to pts, as NRT group chose their own type. Assessment and delivery blinding not reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 11:31:29 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Moolchan-2005">
<DESCRIPTION>
<P>Described as "double-blind, double-dummy", but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 11:38:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Described as "double blind", but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 12:00:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Nakamura-1990">
<DESCRIPTION>
<P>Described as an "open controlled trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 13:39:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Nebot-1992">
<DESCRIPTION>
<P>Not applicable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 14:04:23 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Niaura-1994">
<DESCRIPTION>
<P>No placebo - not relevant. But therapist and pt were blinded to FTQ score (level of dependency), and to match or mismatch status for gum use.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 15:09:14 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-1999">
<DESCRIPTION>
<P>"Counselors were kept blind to the relapse prevention condition to which subjects were assigned". Pts not blinded, and no placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 15:34:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ockene-1991">
<DESCRIPTION>
<P>Pts not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 08:50:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Oncken-2007">
<DESCRIPTION>
<P>Described as double-blind, but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-09 15:18:26 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Oncken-2008">
<DESCRIPTION>
<P>"double blind", methods not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-10 14:51:59 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Ortega-2011">
<DESCRIPTION>
<P>Participants not blinded; no placebo group. Not specified as to whether study personnel were blinded. "...the one-year abstinence in the telephone follow-up group was self declared and not validated, which may entail bias when evaluating whether these patients truly had stopped smoking."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 13:17:25 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Otero-2006">
<DESCRIPTION>
<P>29% of control group participants asked for nicotine patch after the 3m follow-up which might have increased control group quit rates at 12m.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 09:32:22 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Page-1986">
<DESCRIPTION>
<P>Single-blinding: "subjects were not aware of their treatment group nor the fact that they were being evaluated against other experimental groups". Follow-up interviewers "remained blind to the patient's experimental group until the final section in the interview"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 10:09:46 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Paoletti-1996">
<DESCRIPTION>
<P>Described as double-blind. All pts got 2 patches, to ensure maintenance of blinding. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 10:26:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Perng-1998">
<DESCRIPTION>
<P>Described as double-blind. No further detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 11:11:55 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>Described as double-blind, but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-21 11:46:45 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>"Double blind."</P>
<P>"Study staff were blinded to whether the medication was active or placebo" (Type of medication (i.e. patch, gum, pill) would have been apparent to both groups).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 11:25:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Pirie-1992">
<DESCRIPTION>
<P>No placebo. No detail reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-21 11:47:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Pollak-2007">
<DESCRIPTION>
<P>Open label, unblinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 11:47:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Prapavessis-2007">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 11:55:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Puska-1979">
<DESCRIPTION>
<P>"Neither the subjects nor the course leaders were aware who received active and who placebo gum"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 12:05:48 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Puska-1995">
<DESCRIPTION>
<P>"The study was carried out in a strictly double blind fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 13:14:22 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Richmond-1993">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 13:48:58 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Richmond-1994">
<DESCRIPTION>
<P>Described as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 14:41:54 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-1994">
<DESCRIPTION>
<P>Assessment of blinding indicated higher-than-chance subject awareness of treatment regimen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 14:48:20 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Rose-1998">
<DESCRIPTION>
<P>Placebo patches not used, but pts were blinded to mecamylamine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 15:00:23 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2006">
<DESCRIPTION>
<P>Patch assignment was blinded, but not cigarette type. After quit-date, all pts received mecamylamine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-10 10:19:42 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Rose-2009">
<DESCRIPTION>
<P>"two members of the study team&#8230;placed the required number of active or placebo patches into individual plastic bags labelled with subject number and session number&#8230; In order to maintain blinding, these members of the study team did not interact with study participants."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-02 11:33:43 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2010">
<DESCRIPTION>
<P>Placebo used, method of blinding not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-25 15:23:56 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Roto-1987">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 09:41:20 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Russell-1983">
<DESCRIPTION>
<P>Not stated. Correct procedure was not followed by 10.4% in Grp 1, 15.4% in Grp 2 and 16.2% in Grp 3. Only 53% of Grp 3 ever tried the gum.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 09:06:09 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Sachs-1993">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 09:22:24 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985A">
<DESCRIPTION>
<P>"gum was dispensed in a double-blind procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 09:23:08 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985B">
<DESCRIPTION>
<P>"gum was dispensed in a double-blind procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 09:56:14 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1995">
<DESCRIPTION>
<P>"the trial was double-blind". Pt guesses reported as confirmation of blinding success.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-04 16:46:21 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Schneider-1996">
<DESCRIPTION>
<P>"Subjects and all personnel connected with the trial (including the PI) were kept blind". Pts guessed their allocation as a test of the blinding at final assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-10 12:23:09 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Schnoll-2010a">
<DESCRIPTION>
<P>"supply of patches was prepackaged and coded with participant information. The computer program linked the randomization to the patch supply, and only the database manager could link identification with treatment allocation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-08 11:17:19 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Schnoll-2010b">
<DESCRIPTION>
<P>Open-label trial and although both treatments were active, 2/3 participants had preference for patch</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 11:31:02 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Schuurmans-2004">
<DESCRIPTION>
<P>"The treatment code was broken only after the last follow-up visit had been completed and the data recorded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 11:52:55 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Segnan-1991">
<DESCRIPTION>
<P>Interviews were conducted by "trained interviewers, independent of the study staff". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 12:31:59 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>Described as double-blind, but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 12:33:57 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-10 15:19:39 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>"Double-blind", method not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-10 15:25:54 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-21 11:49:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 13:41:15 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Sonderskov-1997">
<DESCRIPTION>
<P>Placebo patches contained "a pharmacologically negligible amount of nicotine". "The blinding procedure was not broken until all the main results were tabulated".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 14:18:09 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Stapleton-1995">
<DESCRIPTION>
<P>"Both subjects and their doctors or nurses were blind to whether the dose increase was real or placebo". Study conduct throughout was monitored by clinical research associates of the pharmaceutical company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 14:28:30 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Sutherland-1992">
<DESCRIPTION>
<P>"Subjects and therapists were blind to spray assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 14:46:57 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-TNSG-1991">
<DESCRIPTION>
<P>Described as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 16:01:53 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-1988">
<DESCRIPTION>
<P>Gum was packaged and produced to be indistinguishable between 2 mg, 4 mg and placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-16 16:26:58 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1991">
<DESCRIPTION>
<P>"The placebo patches were identical to the active patches in appearance, packaging and labeling, but contained no nicotine".<BR/>Blinding code was broken after wk 26.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-30 15:51:39 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1993">
<DESCRIPTION>
<P>"The placebo inhaler contained only the additive and was identical in appearance to the active inhaler". Pts were asked at 12m to guess their assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 08:19:35 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2000">
<DESCRIPTION>
<P>Not used - open trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 08:59:25 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2006">
<DESCRIPTION>
<P>Described as double-blind, but no further detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-26 11:19:35 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-T_x00f8_nnesen-2012">
<DESCRIPTION>
<P>"Double blind....The supply or resupply of study medication to a subject was determined via an Interactive Voice Response System...the placebo was identical in appearance, but contained capsaicin instead of nicotine to mimic the taste of nicotine"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 09:12:59 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Villa-1999">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 09:20:25 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wallstrom-2000">
<DESCRIPTION>
<P>"All medication was dispensed by staff who were not involved in treating the subjects"; placebo tablets identical, but without nicotine and with capsaicin.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Wennike-2003a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 09:46:14 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Westman-1993">
<DESCRIPTION>
<P>"At all times, the subjects and study staff were masked to the treatment assignments". Subject blinding was assessed at wk 6.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 09:54:50 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wisborg-2000">
<DESCRIPTION>
<P>"Treatment status was not known by the women or the midwife throughout the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-08-08 11:29:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>Neither participants nor providers were blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 10:13:04 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Wong-1999">
<DESCRIPTION>
<P>See above. Nicotine patch supply was open-label, and placebo patches not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-31 10:18:59 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Zelman-1992">
<DESCRIPTION>
<P>Placebos not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-10-16 16:31:03 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 10:01:54 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Abelin-1989">
<DESCRIPTION>
<P>Drop-outs similar between groups (NRT 20, placebo 21); 36/41 drop-outs continued to smoke, but all 41 counted as treatment failures in ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 09:12:09 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-1998">
<DESCRIPTION>
<P>Losses similar between groups at 6m: NRT 53, placebo 58. Counted as treatment failures for ITT analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 10:01:03 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Ahluwalia-2006">
<DESCRIPTION>
<P>Pts receiving active gum and HE counselling were more likely to remain in the study, but interaction not statistically significant. Losses to follow up at wk 26: NRT+MI: 32; NRT+HE 21; Placebo+MI 39; Placebo+HE 26.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 10:19:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Areechon-1988">
<DESCRIPTION>
<P>Significant differences between NRT (20 drop-outs) and placebo (37 drop-outs; P&lt;0.01) at 6m.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 11:34:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1989">
<DESCRIPTION>
<P>7/59 claiming abstinence at 12m were not CO-confirmed (4 missing and 3 &gt;10ppm), and counted as continuing smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-15 15:06:13 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1997">
<DESCRIPTION>
<P>One pt lost to follow-up, assumed to be a smoker. Drop-out rates not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 13:39:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>All pts followed up for at least 12m.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 14:17:04 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Bohadana-2000">
<DESCRIPTION>
<P>Losses over 12m were steep but similar in both groups, i.e. 148 from NRT group and 155 from placebo group. Losses counted as continuing smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 10:57:22 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Bolin-1999">
<DESCRIPTION>
<P>Drop-out rates not reported; any drop-outs counted as treatment failures in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Bolliger-2000a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 14:59:11 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Br-Thor-Society-1983">
<DESCRIPTION>
<P>Lower losses from gum groups (10 and 10) than from Advice groups (24 and 24), but 18 VA and VAB pts were prescribed Nicorette in error; removing these made differences non-significant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Brantmark-1973a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 15:19:49 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Buchkremer-1988">
<DESCRIPTION>
<P>Drop-out rates not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-15 15:24:59 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Bullen-2010">
<DESCRIPTION>
<P>Similar rates of drop-outs in treatment and control groups (148 treatment, 139 control). Participants lost to follow-up included as smokers in outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-16 11:53:19 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-CEASE-1999">
<DESCRIPTION>
<P>22% lost to 12m follow-up, and 54% withdrew. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 15:35:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1987">
<DESCRIPTION>
<P>37% losses at 12m.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 15:57:45 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1991">
<DESCRIPTION>
<P>"Non-attenders were classified as failures"; rate of drop-outs not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 15:42:27 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Campbell-1996">
<DESCRIPTION>
<P>57 NRT and 56 placebo pts did not complete the 12 wk course. By 52 wks, 28 pts had dropped out of the NRT group, and 40 from the placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-16 14:00:11 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1996">
<DESCRIPTION>
<P>Drop-outs not reported, but failures and missing were counted as non-abstinent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-16 14:13:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Clavel-1985">
<DESCRIPTION>
<P>Those still smoking at 1m were not followed and were counted as failures, as were the 6% non-responders. Half the abstainers were visited at home at 13m and tested for expired CO</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-15 15:38:02 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Clavel_x002d_Chapelon-1992">
<DESCRIPTION>
<P>Only pts abstinent at 1m were followed up. Two pts were lost between ms 9 and 12, and 32 between yr1 and yr4. Losses "were considered successes until the date of the last follow-up and afterwards were not considered anymore".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-02 13:53:03 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Coleman-2012">
<DESCRIPTION>
<P>981/1050 participants provided data at delivery; participants missing data counted as smokers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:31:00 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Cooney-2009">
<DESCRIPTION>
<P>26 drop-outs at 12m included as smokers; all previously verified as having relapsed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 10:58:12 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Cooper-2005">
<DESCRIPTION>
<P>Drop-outs not reported, all analyses conducted as ITT. Drop-outs (if any) counted as treatment failures in our analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-16 16:00:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Croghan-2003">
<DESCRIPTION>
<P>Drop-outs reported in detail. 34% of pts completed study. Losses to follow-up similar across groups, treated as non-abstinent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:18:20 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Dale-1995">
<DESCRIPTION>
<P>Apart from one light smoker dropping out from 44 mg group for nicotine toxicity in wk 1, apparently no drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 11:00:05 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Daughton-1991">
<DESCRIPTION>
<P>Drop-outs (if any) not reported; included as treatment failures in our analysis; results presented on an ITT basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 08:51:17 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Daughton-1998">
<DESCRIPTION>
<P>Losses low at 3m (1.1%), 6m (1.6%) and 12m (2.2%). Those lost to follow-up were included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 11:00:40 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Dautzenberg-2001">
<DESCRIPTION>
<P>Higher losses in placebo than active group (44% vs 37%); analyses conducted as ITT counting drop-outs as treatment failures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 09:12:14 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Davidson-1998">
<DESCRIPTION>
<P>Losses were included as failures. 67.5% withdrew before study completion; placebo losses higher than active, but differences not statistically significant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 10:12:59 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ehrsam-1991">
<DESCRIPTION>
<P>Drop-outs included as failures. 36% dropped out of active group, and 55% out of placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 10:14:57 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Etter-2009">
<DESCRIPTION>
<P>Missing data included as smokers. Similar number of drop-outs in both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 11:02:19 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Fagerstrom-1982">
<DESCRIPTION>
<P>Four early drop-outs (3 active, 1 placebo) excluded from analysis; all other drop-outs counted as smokers in final analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 10:19:03 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Fagerstrom-1984">
<DESCRIPTION>
<P>Only pts abstinent at one follow-up were seen again for the next one. All losses counted as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 10:29:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fee-1982">
<DESCRIPTION>
<P>Significantly higher losses from placebo (47.7%) than from active group (36.7%). Losses taken as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 10:20:31 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Fiore-1994A">
<DESCRIPTION>
<P>Ten placebo and 1 active pt failed to complete the NRT course. 25 pts lost to follow-up at 6m were included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 10:21:28 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Fiore-1994B">
<DESCRIPTION>
<P>29% did not complete treatment phase and were included as failures (15 on active patch, 18 on placebo). 36% lost to follow-up, and were included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 13:54:42 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Fortmann-1995">
<DESCRIPTION>
<P>3.9% dropped out at 6m, and 6.2% at 12m. Unclear whether drop-outs were included, though disconfirmations were reclassified as smokers..</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 14:15:25 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Garcia-1989">
<DESCRIPTION>
<P>Drop-outs reported at 1, 3 and 6m. Analyses appear to be ITT-based, counting drop-outs as failures. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-09 14:01:21 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>Missing data included as smokers. Similar losses to follow-up across both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 15:00:45 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Garvey-2000">
<DESCRIPTION>
<P>Relapsers were included as failures. Drop-out rates not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 10:29:00 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gilbert-1989">
<DESCRIPTION>
<P>Follow-up at 1yr of 91.5%; those lost to follow-up were included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 15:44:26 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Glavas-2003a">
<DESCRIPTION>
<P>5 drop-outs by yr1 and yr5, classified as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 15:53:30 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Glavas-2003b">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:35 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Glover-2002">
<DESCRIPTION>
<P>Losses to follow-up included as failures. Drop-out rates not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 09:05:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Goldstein-1989">
<DESCRIPTION>
<P>18 early drop-outs (16.8%) not included. Drop-out rate by EoT was 7.9%, by 6m 3.4%; losses included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 11:09:44 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Gourlay-1995">
<DESCRIPTION>
<P>Drop-outs at each stage reported in full. Losses to follow-up included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 10:02:26 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gross-1995">
<DESCRIPTION>
<P>Relapsers or non-quitters included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 10:12:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1985">
<DESCRIPTION>
<P>Drop-outs reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 10:29:37 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>Drop-out rates reported, but no detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 11:12:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1996">
<DESCRIPTION>
<P>Six pts excluded from analyses for protocol violations. No further information on drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 11:26:33 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hand-2002">
<DESCRIPTION>
<P>Drop-out rates not reported, but all included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 11:16:35 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Harackiewicz-1988">
<DESCRIPTION>
<P>11% of pts did not return for any follow-up, and were not included in the analyses. Remaining 175 included in all analyses, whether or not they attended all follow-ups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 13:17:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hays-1999">
<DESCRIPTION>
<P>Pts who missed follow-up visits classified as failures. Drop-out rates not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:20:48 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Herrera-1995">
<DESCRIPTION>
<P>68 pts dropped out in Phase 1 (wks 1-2) and 10 pts in Phase 2 (wks 4-6), i.e. before randomization. Drop-out rates not reported, but classified as relapsed "and not further analyzed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 14:33:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hilleman-1994">
<DESCRIPTION>
<P>"The number of patients discontinuing therapy among the three treatment groups was not significantly different"; analyses included all randomized.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 11:29:15 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hjalmarson-1984">
<DESCRIPTION>
<P>Three drop-outs from each cohort during follow-up; they were counted as smokers. Three more from each cohort relapsed and were re-treated, but counted as smokers within the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 15:09:42 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1994">
<DESCRIPTION>
<P>By 12m, 20% had relapsed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-22 15:39:30 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hjalmarson-1997">
<DESCRIPTION>
<P>Drop-outs and relapsers all counted as failures. Details fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 11:37:04 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1988">
<DESCRIPTION>
<P>10% had dropped out after 1yr.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 11:38:43 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hughes-1989">
<DESCRIPTION>
<P>Drop-outs and lost to follow-up were included as smokers. Full details of losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 09:55:16 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1990">
<DESCRIPTION>
<P>"Subjects unable to be contacted were counted as smokers". Losses not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 11:52:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1991">
<DESCRIPTION>
<P>Losses at 6m reported; all were counted as failures, but distribution across the groups not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 12:53:45 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Hughes-1999">
<DESCRIPTION>
<P>Early termination by sponsor, resulting in incomplete long-term follow-up data collection. Losses were included as failures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 13:21:07 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2003">
<DESCRIPTION>
<P>"we assumed that missing data indicated smoking". Losses reported, but not distribution across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-16 16:18:25 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Hughes-2010">
<DESCRIPTION>
<P>Similar number lost to follow-up in both groups. Missing data counted as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 15:49:06 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hurt-1990">
<DESCRIPTION>
<P>4 drop-outs from each group in first 6 wks; smoking status of all drop-outs ascertained "at last contact". Early drop-outs were excluded from later analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 14:04:28 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Hurt-1994">
<DESCRIPTION>
<P>"subjects with missing information or who dropped out... were considered to be smoking". Drop-out rates and reasons fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 15:01:09 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-ICRF-1994">
<DESCRIPTION>
<P>Disconfirmations and drop-outs counted as smokers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 15:17:27 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jamrozik-1984">
<DESCRIPTION>
<P>Lost to follow-up included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-01 15:58:25 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Jarvis-1982">
<DESCRIPTION>
<P>One subject lost to follow-up counted as a failure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 11:03:35 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1991">
<DESCRIPTION>
<P>21 trial-wide losses reported, but not included in the analyses. Distribution not stated, so not possible to include those lost to follow-up in the final denominator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-02 14:01:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Jorenby-1995">
<DESCRIPTION>
<P>Losses reported, but included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 10:36:59 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>311 discontinued treatment, with 177 withdrawing completely from the trial. Full details reported. All were included in ITT analyses with losses to follow-up counted as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-02 14:44:45 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Joseph-1996">
<DESCRIPTION>
<P>Losses and withdrawals fully reported, as primary and secondary endpoints.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-02 14:57:23 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Kalman-2006">
<DESCRIPTION>
<P>10 dropped out before treatment, and 4 excluded for protocol violation. Analyses were ITT, with drop-outs reported and counted as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-02 15:08:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Killen-1984">
<DESCRIPTION>
<P>11/75 recruited dropped out before full treatment, and are excluded from analyses. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-02 15:37:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Killen-1990">
<DESCRIPTION>
<P>8 deaths removed from final analyses. Pts moving out of the area were removed from the analyses. Unconfirmed claims of abstinence counted as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-04 16:45:13 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Killen-1997">
<DESCRIPTION>
<P>Pts leaving the area (10) were excluded from analyses; all other unconfirmed claims of abstinence were counted as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-08 10:27:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Killen-1999">
<DESCRIPTION>
<P>Pts leaving the area were excluded from analyses; all other unconfirmed claims of abstinence were counted as failures. Losses fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-08 09:59:15 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kornitzer-1987">
<DESCRIPTION>
<P>Losses evident in Tables II and IV</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-04 16:45:31 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kornitzer-1995">
<DESCRIPTION>
<P>Withdrawals counted as treatment failures. All analyses conducted on ITT basis. Drop-out and withdrawal rates not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-08 11:43:44 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Kralikova-2002">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:42 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Leischow-1996">
<DESCRIPTION>
<P>Drop-outs reported at 12m visit. Losses to follow-up counted as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-08 13:25:00 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Leischow-1999">
<DESCRIPTION>
<P>Drop-outs were included as treatment failures, in 1 of 3 analytical approaches, i.e. excluded from protocol completer and patch users analyses. Drop-out rates reported as "high" across both groups, but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-08 13:37:18 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Leischow-2004">
<DESCRIPTION>
<P>Losses fully described in flow chart. Drop-outs included in ITT analyses as treatment failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-08 15:11:37 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Lerman-2004">
<DESCRIPTION>
<P>Drop-outs and withdrawals fully tabulated in Fig 1. ITT analyses confined to those known to have received treatment, with drop-outs included as treatment failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 11:05:27 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1998">
<DESCRIPTION>
<P>Drop-out rates not reported, but analyses count those lost to follow-up as treatment failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-09 11:21:26 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Llivina-1988">
<DESCRIPTION>
<P>Drop-outs and withdrawals reported (Tabla 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-09 11:42:14 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1980">
<DESCRIPTION>
<P>Only the 1m quitters were followed up at 6m (77/82 pts).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-09 11:49:02 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-1985">
<DESCRIPTION>
<P>"Non-contacts were classified as smokers".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 12:43:04 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-McGovern-1992">
<DESCRIPTION>
<P>% response rates at follow-up reported, with no differences between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 12:44:35 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Molyneux-2003">
<DESCRIPTION>
<P>Losses to follow-up counted as failures. All losses fully detailed in flow chart.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 12:46:09 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Moolchan-2005">
<DESCRIPTION>
<P>Losses to follow-up were included as failures for cessation. Losses fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 11:41:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 11:58:37 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-1990">
<DESCRIPTION>
<P>ITT analyses conducted, with all drop-outs and non-compliers included as failures. But "smoking on one or two occasions in a single day was not considered a failure ... although occasional smoking was considered a failure".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 13:32:58 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Nebot-1992">
<DESCRIPTION>
<P>Only those quit at 2m were followed up at 12m. All non-responders were included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 12:58:31 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Niaura-1994">
<DESCRIPTION>
<P>Drop-out rates fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:43 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Niaura-1999">
<DESCRIPTION>
<P>Losses to follow-up fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 15:44:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ockene-1991">
<DESCRIPTION>
<P>Losses and drop-outs were included as failures. 62 pts removed from denominator (4 deaths, 58 not contacted by study staff).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:44 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Oncken-2007">
<DESCRIPTION>
<P>Drop-outs or missed visits included as failures. Losses at each follow-up fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-09 15:21:44 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Oncken-2008">
<DESCRIPTION>
<P>Significantly higher loss to follow-up in placebo group (50% as opposed to 35%). Those lost to follow-up considered to be smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-04 11:52:14 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Ortega-2011">
<DESCRIPTION>
<P>Number lost not specified. Participants lost to follow-up included as smokers in outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-02 12:07:44 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Otero-2006">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-25 09:56:24 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Page-1986">
<DESCRIPTION>
<P>Losses reported, but not included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:45 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Paoletti-1996">
<DESCRIPTION>
<P>Losses to follow-up fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-25 10:27:30 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Perng-1998">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:21:01 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>Losses to follow-up were included as failures. ITT analyses conducted unless otherwise noted. All losses fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:31:03 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>90 drop-outs (out of 1504). Analyses conducted using ITT. Individuals with missing data considered to be smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:26:11 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Pirie-1992">
<DESCRIPTION>
<P>No losses to follow-up. Moved away completed assessments by phone or mail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:48 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Pollak-2007">
<DESCRIPTION>
<P>All women lost to follow-up considered smokers; similar numbers in both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-25 11:49:07 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Prapavessis-2007">
<DESCRIPTION>
<P>"Analyses were conducted by intent to treat". Missing data on smoking abstinence were counted as failures. % losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:33:26 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Puska-1979">
<DESCRIPTION>
<P>Losses to follow-up were reported, but were not included in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:49 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Puska-1995">
<DESCRIPTION>
<P>Losses to follow-up fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:08:50 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Richmond-1993">
<DESCRIPTION>
<P>Losses to follow-up were included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:35:52 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Richmond-1994">
<DESCRIPTION>
<P>Losses to follow-up included as failures. Drop-out rates fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-25 14:41:05 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Rose-1994">
<DESCRIPTION>
<P>Drop-out rate reported (low).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 15:50:56 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-1998">
<DESCRIPTION>
<P>Early drop-outs (up to 4 wks pre-cessation) reported, but not long-term.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-25 15:06:12 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2006">
<DESCRIPTION>
<P>8.3% of pts dropped out before TQD, and were excluded from analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-10 10:20:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Rose-2009">
<DESCRIPTION>
<P>High number lost to follow-up (169/379).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 15:51:46 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2010">
<DESCRIPTION>
<P>197 lost to follow-up before 10 wks (not known how many lost at 6m); similar numbers across groups; participants lost to follow-up counted as smokers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-25 15:23:59 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Roto-1987">
<DESCRIPTION>
<P>Drop-outs classified as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:45:27 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Russell-1983">
<DESCRIPTION>
<P>16 deaths and 152 who moved away were excluded from analyses. 327 with no or inadequate data at follow-up were included as failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-05 10:39:56 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Sachs-1993">
<DESCRIPTION>
<P>Drop-out rates not fully reported, but all pts included in ITT analyses with drop-outs counted as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 09:42:12 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985A">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 09:42:20 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985B">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 10:04:44 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1995">
<DESCRIPTION>
<P>Limited information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 10:25:25 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1996">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:52:48 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Schnoll-2010a">
<DESCRIPTION>
<P>Drop-outs included as smokers in outcome data. Similar number of drop-outs in both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:54:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Schnoll-2010b">
<DESCRIPTION>
<P>46% loss to follow-up by 6m, similar between groups. Missing data reported as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 13:56:58 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Schuurmans-2004">
<DESCRIPTION>
<P>Drop-outs fully recorded at all stages, ITT analyses used and participants lost to follow-up counted as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 11:58:50 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Segnan-1991">
<DESCRIPTION>
<P>Drop-out rates reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 12:20:33 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>Only abstainers were followed up. "Participants who did not appear for a visit were counted as treatment failures". Losses fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 12:34:16 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-10 15:20:51 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_">
<DESCRIPTION>
<P>Those who had not succeeded at 28d follow-up not followed up at 6m. All missing data considered to be smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-10 15:25:55 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-23 15:31:25 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>158 individuals who did not pick up study medication at first point not included in analyses; 122 withdrawals &amp; 9 deaths considered to be smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 13:41:08 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Sonderskov-1997">
<DESCRIPTION>
<P>"Participants lost to follow-up (n=19) were classified as smokers". Losses and reasons fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 14:10:45 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Stapleton-1995">
<DESCRIPTION>
<P>ITT analyses, with losses/failures included as smokers. Number of drop-outs not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 14:35:48 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Sutherland-1992">
<DESCRIPTION>
<P>Losses to follow-up briefly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 14:55:34 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-TNSG-1991">
<DESCRIPTION>
<P>"All pts were included in outcome evaluations except for the excluded members of couples (49 pts) and nine pts with major protocol infractions". Losses and withdrawals were included as treatment failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 14:16:20 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1988">
<DESCRIPTION>
<P>All subjects who attended 1st counselling session were included in analyses, regardless of attendance or level of gum use. Only 2/173 were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-30 15:25:38 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1991">
<DESCRIPTION>
<P>All who attended the 1st session were included in the analyses. Losses to follow-up were included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 14:19:24 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-1993">
<DESCRIPTION>
<P>"Subjects unavailable for follow-up were assumed to be smokers". Relapsers were dropped from the study, but were all contacted at one year. Six were lost to follow-up and 7 excluded for protocol violations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 14:21:38 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2000">
<DESCRIPTION>
<P>Non-attenders or lost to follow-up were included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 14:22:32 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Tonnesen-2006">
<DESCRIPTION>
<P>Losses to follow-up fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 16:27:51 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-T_x00f8_nnesen-2012">
<DESCRIPTION>
<P>Similar percentage lost in both groups (151/318 active, 81/161 placebo). 9% of active group and 7.5% of placebo group withdrew due to adverse events. Those not present at 52 wk follow-up counted as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Villa-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-31 09:36:56 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Wallstrom-2000">
<DESCRIPTION>
<P>Analyses were based on intention-to-treat. Losses not reported in detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Wennike-2003a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-31 09:48:05 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Westman-1993">
<DESCRIPTION>
<P>Drop-outs fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-31 09:56:33 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wisborg-2000">
<DESCRIPTION>
<P>Missing data reported, and included as smokers. Analyses were intention-to-treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-16 14:35:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="YES" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>Similar number of drop-outs between groups; participants lost to follow-up considered smokers for MA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-31 10:10:20 +0100" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Wong-1999">
<DESCRIPTION>
<P>Missing data assumed to be smoking, and included in the analyses. Losses fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-31 10:20:10 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Zelman-1992">
<DESCRIPTION>
<P>Early drop-out rates reported, but nor included in the analyses. Four 12m drop-outs included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-10-16 15:42:26 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 08:44:52 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Abelin-1989">
<DESCRIPTION>
<P>If smoking from 0-3 cigs/wk, and CO 0-11 ppm, counted as abstinent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ahluwalia-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ahluwalia-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 10:26:36 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Areechon-1988">
<DESCRIPTION>
<P>10/93 quitters did not provide CO validation, but distribution not reported. All are included in MA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-16 09:25:28 +0000" MODIFIED_BY="Kate Cahill" RESULT="YES" STUDY_ID="STD-Blondal-1989">
<DESCRIPTION>
<P>44/92 in NRT group were highly nicotine-dependent, compared with 28/90 in placebo group (P=0.03)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bohadana-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bolin-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bolliger-2000a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Br-Thor-Society-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brantmark-1973a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Buchkremer-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bullen-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-CEASE-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-02 15:31:21 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1987">
<DESCRIPTION>
<P>Placebo gum was actually Wrigleys gum, repackaged and labelled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Campbell-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clavel-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clavel_x002d_Chapelon-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Coleman-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cooney-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cooper-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Croghan-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dale-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Daughton-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Daughton-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dautzenberg-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-16 15:42:26 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Ehrsam-1991">
<DESCRIPTION>
<P>Abstinence defined as 0-3 cigs per wk, with CO&lt;12ppm. Relapse defined as &#8805;1 cpd, or &#8805;14 cigs over 2 wks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Etter-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fagerstrom-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 10:23:01 +0000" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Fagerstrom-1984">
<DESCRIPTION>
<P>Physicians selected for the study were personal acquaintances of the author, and all except one were non-smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fee-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiore-1994A">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fiore-1994B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fortmann-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garcia-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Garvey-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 15:21:10 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Gilbert-1989">
<DESCRIPTION>
<P>Pts using gum were required to pay for their prescription.<BR/>Pts claiming abstinence were visited for validation test without being aware this would happen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Glavas-2003a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 15:49:38 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Glavas-2003b">
<DESCRIPTION>
<P>Abstinence defined as &#8804;2 cigs per wk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Glover-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-16 11:07:31 +0100" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Goldstein-1989">
<DESCRIPTION>
<P>Each pt paid US$130 at start of study, of which they recovered $30 for supplying follow-up information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gourlay-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gross-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hall-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hall-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hall-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hand-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Harackiewicz-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hays-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Herrera-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hilleman-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hjalmarson-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Huber-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 12:53:06 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 16:37:15 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Hughes-2010">
<DESCRIPTION>
<P>"Counseling time in the gradual condition was spent mostly on teaching gradual reduction, not on problem-solving ways to cope with high-risk-for-smoking situations"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ICRF-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jamrozik-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-16 12:05:54 +0100" MODIFIED_BY="Kate Cahill" RESULT="NO" STUDY_ID="STD-Jarvis-1982">
<DESCRIPTION>
<P>"Placebo" patch contained nicotine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Joseph-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kornitzer-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kornitzer-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kralikova-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leischow-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leischow-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leischow-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lerman-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Llivina-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 11:38:11 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1980">
<DESCRIPTION>
<P>16 pts with dentures who could not chew gum were allocated to Controls but analysed separately. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-09 11:51:08 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Marshall-1985">
<DESCRIPTION>
<P>Only smokers abstinent at one timepoint were followed up subsequently.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McGovern-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:31:51 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Molyneux-2003">
<DESCRIPTION>
<P>4% of counselling+NRT group refused NRT, and counselling-only group were advised about NRT but not given it; usage across groups not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Moolchan-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mori-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nakamura-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 13:42:48 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Nebot-1992">
<DESCRIPTION>
<P>Unequal assignments to the 3 groups, with nurse and NRT groups outnumbered 1:2 by the medical advice group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Niaura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Niaura-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ockene-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Oncken-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Oncken-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-10 14:52:01 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Ortega-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Otero-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Page-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Paoletti-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Perng-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piper-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pirie-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-14 11:41:09 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Pollak-2007">
<DESCRIPTION>
<P>Women in CBT+NRT group significantly more likely to attend CBT sessions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Prapavessis-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Puska-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Puska-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 13:23:41 +0000" MODIFIED_BY="Kate Cahill" RESULT="UNKNOWN" STUDY_ID="STD-Richmond-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Richmond-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rose-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rose-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rose-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rose-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rose-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roto-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Russell-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sachs-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985A">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1985B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 12:29:56 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="NO" STUDY_ID="STD-Schnoll-2010b">
<DESCRIPTION>
<P>Lower adherence in lozenge group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schuurmans-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Segnan-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-10 15:10:02 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smith-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sonderskov-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stapleton-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sutherland-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-TNSG-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-T_x00f8_nnesen-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Villa-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wallstrom-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wennike-2003a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Westman-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wisborg-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-08 11:29:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" RESULT="UNKNOWN" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wong-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zelman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-10-11 08:53:17 +0100" MODIFIED_BY="Jamie Hartmann-Boyce">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-10-11 08:53:17 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-10-11 08:49:07 +0100" MODIFIED_BY="Grade Profiler">Nicotine replacement therapy</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Nicotine replacement therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people who smoke cigarettes<BR/>
<B>Settings:</B> clinical and non-clinical, including over the counter<BR/>
<B>Intervention:</B> nicotine replacement therapy of any form<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Nicotine replacement therapy of any form</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Smoking cessation at 6+ months follow-up</B>
<BR/>Follow-up: 6 - 24 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.6 </B>
<BR/>(1.53 to 1.68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>51265<BR/>(117 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>161 per 1000</B>
<BR/>(154 to 169)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Limited behavioural support</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
<BR/>(61 to 67)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Intensive behavioural support</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>240 per 1000</B>
<BR/>(229 to 252)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Most studies judged to be at low or unclear risk of bias, and given the large number of studies it is unlikely that limitations would affect overall confidence in the effect.<BR/>
<SUP>2</SUP> There are likely to be some unpublished trials with less favourable results that we were unable to identify, and a funnel plot showed some evidence of asymmetry. However, given the large number of trials in the review, this does not suggest the results would be altered significantly were smaller studies with lower RRs included.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-10-16 16:06:32 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-10-16 16:06:32 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-02-21 12:05:32 +0000" MODIFIED_BY="Jamie Hartmann-Boyce">Nicotine replacement therapies available in the UK</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TH>
<P>Type</P>
</TH>
<TH>
<P>Available doses</P>
</TH>
</TR>
<TR>
<TD>
<P>Nicotine transdermal patches</P>
</TD>
<TD>
<P>Worn over 16 hours: 5 mg, 10mg, 15 mg, 25 mg doses<BR/>Worn over 24 hours: 7mg, 14 mg, 20mg, 21 mg, 30mg doses*</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine chewing gum</P>
</TD>
<TD>
<P>2 mg and 4 mg doses</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine sublingual tablet</P>
</TD>
<TD>
<P>2 mg dose</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine lozenge</P>
</TD>
<TD>
<P>1 mg, 1.5 mg, 2 mg and 4 mg doses</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine inhalation cartridge plus mouthpiece</P>
</TD>
<TD>
<P>Cartridge containing 10mg</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine metered nasal spray</P>
</TD>
<TD>
<P>0.5 mg dose/spray</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine oral spray</P>
</TD>
<TD>
<P>1 mg dose/spray</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Information extracted from British National Formulary</P>
<P>* 35 mg/24hr and 53.5 mg/24hr patches available in other regions.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-15 13:39:55 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-10-03 15:39:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Any type of NRT versus placebo/ no NRT control</NAME>
<DICH_OUTCOME CHI2="171.7444655495129" CI_END="1.6773083763330077" CI_START="1.529843570392087" CI_STUDY="95" CI_TOTAL="95" DF="121" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6018799690044954" ESTIMABLE="YES" EVENTS_1="4704" EVENTS_2="2466" I2="29.546492451533222" I2_Q="46.48606478860549" ID="CMP-001.01" LOG_CI_END="0.22461291581284337" LOG_CI_START="0.18464702559620808" LOG_EFFECT_SIZE="0.20462997070452577" METHOD="MH" MODIFIED="2012-10-03 15:39:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.001671379889711111" P_Q="0.06013739626025505" P_Z="0.0" Q="14.949377145219907" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="119" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27258" TOTAL_2="24007" WEIGHT="100.00000000000003" Z="20.070483633136643">
<NAME>Smoking cessation at 6+ months follow up</NAME>
<GROUP_LABEL_1>NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="91.04835096754314" CI_END="1.5990473702721755" CI_START="1.3955853254401211" DF="55" EFFECT_SIZE="1.4938564337430367" ESTIMABLE="YES" EVENTS_1="1732" EVENTS_2="1196" I2="39.59253581692395" ID="CMP-001.01.01" LOG_CI_END="0.2038613295017609" LOG_CI_START="0.14475639419977196" LOG_EFFECT_SIZE="0.1743088618507664" MODIFIED="2012-10-03 14:39:48 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.001609314740238954" P_Z="6.538423525183951E-31" STUDIES="56" TAU2="0.0" TOTAL_1="10596" TOTAL_2="11985" WEIGHT="45.18792127440537" Z="11.56042518845878">
<NAME>Gum</NAME>
<DICH_DATA CI_END="5.2337006044292" CI_START="0.0477673483631121" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="37" O_E="0.0" SE="1.1981168018885897" STUDY_ID="STD-Niaura-1999" TOTAL_1="31" TOTAL_2="31" VAR="1.435483870967742" WEIGHT="0.08037998737183127"/>
<DICH_DATA CI_END="5.106444992004984" CI_START="0.06810951693167992" EFFECT_SIZE="0.5897435897435898" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.7081186579322872" LOG_CI_START="-1.1667921999500996" LOG_EFFECT_SIZE="-0.22933677100890631" ORDER="52" O_E="0.0" SE="1.101331918878542" STUDY_ID="STD-Schneider-1985B" TOTAL_1="13" TOTAL_2="23" VAR="1.2129319955406912" WEIGHT="0.0870783196528172"/>
<DICH_DATA CI_END="2.1484187548221616" CI_START="0.3773842535875269" EFFECT_SIZE="0.9004329004329005" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.33211893493424877" LOG_CI_START="-0.42321622479301435" LOG_EFFECT_SIZE="-0.04554864492938274" ORDER="19" O_E="0.0" SE="0.4436876117931363" STUDY_ID="STD-Harackiewicz-1988" TOTAL_1="99" TOTAL_2="52" VAR="0.19685869685869684" WEIGHT="0.36889623343496075"/>
<DICH_DATA CI_END="1.4411817402647455" CI_START="0.5631316900126799" EFFECT_SIZE="0.9008746355685131" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.1587187509855719" LOG_CI_START="-0.2493900322214436" LOG_EFFECT_SIZE="-0.04533564061793586" ORDER="18" O_E="0.0" SE="0.23972511942685867" STUDY_ID="STD-Hall-1996" TOTAL_1="98" TOTAL_2="103" VAR="0.05746813288422166" WEIGHT="1.097326792777637"/>
<DICH_DATA CI_END="1.7885616742580424" CI_START="0.4637248589977451" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.25250392034639924" LOG_CI_START="-0.33373962216292735" LOG_EFFECT_SIZE="-0.04061785090826406" ORDER="42" O_E="0.0" SE="0.3443623588223159" STUDY_ID="STD-Richmond-1993" TOTAL_1="200" TOTAL_2="150" VAR="0.11858543417366944" WEIGHT="0.6430398989746502"/>
<DICH_DATA CI_END="2.3062603685392586" CI_START="0.40470386503207123" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.36290833601880523" LOG_CI_START="-0.39286264795811077" LOG_EFFECT_SIZE="-0.014977155969652801" MODIFIED="2012-10-03 14:39:43 +0100" MODIFIED_BY="Lindsay Stead" ORDER="24" O_E="0.0" SE="0.4439436171147473" STUDY_ID="STD-Hughes-1990" TOTAL_1="59" TOTAL_2="19" VAR="0.19708593517692535" WEIGHT="0.3040012342909003"/>
<DICH_DATA CI_END="1.6866842429902695" CI_START="0.5709226264033885" EFFECT_SIZE="0.9813084112149533" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.22703378776870237" LOG_CI_START="-0.2434227449992455" LOG_EFFECT_SIZE="-0.00819447861527157" ORDER="5" O_E="0.0" SE="0.27634849614528817" STUDY_ID="STD-Campbell-1991" TOTAL_1="107" TOTAL_2="105" VAR="0.07636849132176235" WEIGHT="0.8519520359646456"/>
<DICH_DATA CI_END="1.5943886308104427" CI_START="0.6300188787817181" EFFECT_SIZE="1.0022449488650536" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="19" LOG_CI_END="0.20259418885732536" LOG_CI_START="-0.20064643653390796" LOG_EFFECT_SIZE="9.738761617086915E-4" ORDER="27" O_E="0.0" SE="0.2368655394280984" STUDY_ID="STD-Jensen-1991" TOTAL_1="211" TOTAL_2="82" VAR="0.05610528376856404" WEIGHT="1.0998067214118483"/>
<DICH_DATA CI_END="1.4649325789876566" CI_START="0.731529381659314" EFFECT_SIZE="1.0352010547132497" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="111" LOG_CI_END="0.16581763749053177" LOG_CI_START="-0.13576822588009327" LOG_EFFECT_SIZE="0.015024705805219264" ORDER="3" O_E="0.0" SE="0.17715302901800556" STUDY_ID="STD-Br-Thor-Society-1983" TOTAL_1="410" TOTAL_2="1208" VAR="0.03138319569025432" WEIGHT="2.260873439611892"/>
<DICH_DATA CI_END="1.5563577448421877" CI_START="0.7903376452759279" EFFECT_SIZE="1.1090753424657533" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="40" LOG_CI_END="0.19210943118401463" LOG_CI_START="-0.10218733130102724" LOG_EFFECT_SIZE="0.04496104994149371" ORDER="32" O_E="0.0" SE="0.17287137507618275" STUDY_ID="STD-McGovern-1992" TOTAL_1="146" TOTAL_2="127" VAR="0.029884512320730257" WEIGHT="1.7194839789432037"/>
<DICH_DATA CI_END="2.1977726928730594" CI_START="0.5924633768247419" EFFECT_SIZE="1.141095890410959" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.34198277301205143" LOG_CI_START="-0.227338490439388" LOG_EFFECT_SIZE="0.0573221412863317" ORDER="7" O_E="0.0" SE="0.3344221283370807" STUDY_ID="STD-Cooper-2005" TOTAL_1="146" TOTAL_2="147" VAR="0.11183815992150285" WEIGHT="0.600792397079558"/>
<DICH_DATA CI_END="2.6472555462718894" CI_START="0.4986090900333425" EFFECT_SIZE="1.1488888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4227958668694923" LOG_CI_START="-0.3022398082322946" LOG_EFFECT_SIZE="0.06027802931859881" MODIFIED="2012-02-09 15:25:16 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="608" O_E="0.0" SE="0.4258895445392638" STUDY_ID="STD-Oncken-2008" TOTAL_1="100" TOTAL_2="94" VAR="0.1813819041478616" WEIGHT="0.37289684863220696"/>
<DICH_DATA CI_END="3.1707363665085917" CI_START="0.4225351138657811" EFFECT_SIZE="1.1574746008708272" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.5011601337551542" LOG_CI_START="-0.3741371941119684" LOG_EFFECT_SIZE="0.06351146982159289" ORDER="35" O_E="0.0" SE="0.5141539831807991" STUDY_ID="STD-Nebot-1992" TOTAL_1="106" TOTAL_2="319" VAR="0.26435431842068147" WEIGHT="0.2606202884667847"/>
<DICH_DATA CI_END="1.485983274795411" CI_START="0.9440549662841833" EFFECT_SIZE="1.184419642857143" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="112" LOG_CI_END="0.17201392133240373" LOG_CI_START="-0.02500271877507291" LOG_EFFECT_SIZE="0.07350560127866544" MODIFIED="2012-10-03 12:13:46 +0100" MODIFIED_BY="Lindsay Stead" ORDER="29" O_E="0.0" SE="0.11572854964722892" STUDY_ID="STD-Killen-1990" TOTAL_1="600" TOTAL_2="617" VAR="0.013393097203451129" WEIGHT="4.438401932117553"/>
<DICH_DATA CI_END="1.7823920735615897" CI_START="0.8054121897023883" EFFECT_SIZE="1.1981486981486982" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.25100324215604675" LOG_CI_START="-0.09398180174569425" LOG_EFFECT_SIZE="0.07851072020517626" ORDER="51" O_E="0.0" SE="0.2026459224913915" STUDY_ID="STD-Clavel_x002d_Chapelon-1992" TOTAL_1="481" TOTAL_2="515" VAR="0.04106536990238705" WEIGHT="1.6303579366322645"/>
<DICH_DATA CI_END="2.808418875797395" CI_START="0.5224543870988805" EFFECT_SIZE="1.2113095238095237" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.44846188332970094" LOG_CI_START="-0.28195161965894905" LOG_EFFECT_SIZE="0.08325513183537596" ORDER="14" O_E="0.0" SE="0.42904850726068444" STUDY_ID="STD-Gilbert-1989" TOTAL_1="112" TOTAL_2="111" VAR="0.1840826215826216" WEIGHT="0.3633319608556319"/>
<DICH_DATA CI_END="2.631581726997257" CI_START="0.5583097867724814" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.42021686211038434" LOG_CI_START="-0.25312475921023436" LOG_EFFECT_SIZE="0.08354605145007492" ORDER="28" O_E="0.0" SE="0.3955242014585124" STUDY_ID="STD-Killen-1984" TOTAL_1="44" TOTAL_2="20" VAR="0.15643939393939393" WEIGHT="0.331567447908804"/>
<DICH_DATA CI_END="2.9759103499496" CI_START="0.5044612640758793" EFFECT_SIZE="1.2252475247524752" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4736198438400234" LOG_CI_START="-0.29717217619409586" LOG_EFFECT_SIZE="0.08822383382296375" ORDER="25" O_E="0.0" SE="0.45276704805007617" STUDY_ID="STD-Jamrozik-1984" TOTAL_1="101" TOTAL_2="99" VAR="0.20499799979997999" WEIGHT="0.32473514898219835"/>
<DICH_DATA CI_END="1.6021401580365628" CI_START="0.9571701414032476" EFFECT_SIZE="1.2383540372670807" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="84" LOG_CI_END="0.20470050625464503" LOG_CI_START="-0.01901085751583178" LOG_EFFECT_SIZE="0.09284482436940662" ORDER="11" O_E="0.0" SE="0.13140916246788847" STUDY_ID="STD-Fortmann-1995" TOTAL_1="552" TOTAL_2="522" VAR="0.017268367980511908" WEIGHT="3.4702600134609614"/>
<DICH_DATA CI_END="1.8384227647603988" CI_START="0.8616023404348749" EFFECT_SIZE="1.2585663895187704" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="42" LOG_CI_END="0.2644453891448034" LOG_CI_START="-0.06469313000189131" LOG_EFFECT_SIZE="0.09987612957145608" ORDER="50" O_E="0.0" SE="0.19333759540871465" STUDY_ID="STD-Ahluwalia-2006" TOTAL_1="378" TOTAL_2="377" VAR="0.03737942579842384" WEIGHT="1.6902154695565474"/>
<DICH_DATA CI_END="1.9666586390042697" CI_START="0.8154730132353284" EFFECT_SIZE="1.2663952962460425" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="33" LOG_CI_END="0.29372898418861887" LOG_CI_START="-0.08859040666160824" LOG_EFFECT_SIZE="0.10256928876350531" MODIFIED="2012-10-03 14:39:45 +0100" MODIFIED_BY="Lindsay Stead" ORDER="38" O_E="0.0" SE="0.22457630269693016" STUDY_ID="STD-Ockene-1991" TOTAL_1="402" TOTAL_2="420" VAR="0.0504345157330232" WEIGHT="1.2972273874388245"/>
<DICH_DATA CI_END="2.116689578474571" CI_START="0.7645244377176588" EFFECT_SIZE="1.272108843537415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="37" LOG_CI_END="0.32565717155714285" LOG_CI_START="-0.11660862798049704" LOG_EFFECT_SIZE="0.1045242717883229" ORDER="46" O_E="0.0" SE="0.25978911989942516" STUDY_ID="STD-Segnan-1991" TOTAL_1="294" TOTAL_2="629" VAR="0.0674903868181179" WEIGHT="0.9473169042587005"/>
<DICH_DATA CI_END="2.102418926599776" CI_START="0.7765893032666391" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3227192575452336" LOG_CI_START="-0.10980859571666014" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2012-10-03 14:39:48 +0100" MODIFIED_BY="Lindsay Stead" ORDER="49" O_E="0.0" SE="0.2540690020534404" STUDY_ID="STD-Zelman-1992" TOTAL_1="58" TOTAL_2="58" VAR="0.0645510578044311" WEIGHT="0.7234198863464815"/>
<DICH_DATA CI_END="1.899800104778201" CI_START="0.8955275068880978" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.27870790729028233" LOG_CI_START="-0.04792106988614322" LOG_EFFECT_SIZE="0.11539341870206957" ORDER="8" O_E="0.0" SE="0.19186347803294543" STUDY_ID="STD-Fagerstrom-1982" TOTAL_1="50" TOTAL_2="50" VAR="0.036811594202898534" WEIGHT="0.9243698547760597"/>
<DICH_DATA CI_END="2.681155502451401" CI_START="0.6431234010669704" EFFECT_SIZE="1.3131313131313131" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.42832200305341434" LOG_CI_START="-0.19170568763484058" LOG_EFFECT_SIZE="0.11830815770928686" MODIFIED="2012-10-03 14:39:42 +0100" MODIFIED_BY="Lindsay Stead" ORDER="22" O_E="0.0" SE="0.36420733469684907" STUDY_ID="STD-Huber-1988" TOTAL_1="54" TOTAL_2="60" VAR="0.13264698264698266" WEIGHT="0.4188220394637524"/>
<DICH_DATA CI_END="4.765941874451098" CI_START="0.3680380540851699" EFFECT_SIZE="1.3244047619047619" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6781487413761358" LOG_CI_START="-0.4341072741939607" LOG_EFFECT_SIZE="0.12202073359108753" ORDER="36" O_E="0.0" SE="0.6533446893019474" STUDY_ID="STD-Niaura-1994" TOTAL_1="84" TOTAL_2="89" VAR="0.4268592830390583" WEIGHT="0.15611373269904802"/>
<DICH_DATA CI_END="2.1282902638036596" CI_START="0.8361335572587889" EFFECT_SIZE="1.3339920948616601" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.328030858290107" LOG_CI_START="-0.0777243463076554" LOG_EFFECT_SIZE="0.12515325599122584" ORDER="2" O_E="0.0" SE="0.2383426157013814" STUDY_ID="STD-Blondal-1989" TOTAL_1="92" TOTAL_2="90" VAR="0.056807202459376385" WEIGHT="0.8938961232999257"/>
<DICH_DATA CI_END="2.214103369188008" CI_START="0.8173356122679534" EFFECT_SIZE="1.3452380952380953" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.34519789279382823" LOG_CI_START="-0.08759957795075202" LOG_EFFECT_SIZE="0.1287991574215381" ORDER="41" O_E="0.0" SE="0.2542273766973985" STUDY_ID="STD-Puska-1979" TOTAL_1="116" TOTAL_2="113" VAR="0.06463155906244096" WEIGHT="0.855046503221751"/>
<DICH_DATA CI_END="3.0527184886055982" CI_START="0.601296168019352" EFFECT_SIZE="1.3548387096774193" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.48468675697401153" LOG_CI_START="-0.22091156384675606" LOG_EFFECT_SIZE="0.13188759656362775" MODIFIED="2012-10-03 14:39:45 +0100" MODIFIED_BY="Lindsay Stead" ORDER="39" O_E="0.0" SE="0.4144719464181376" STUDY_ID="STD-Page-1986" TOTAL_1="93" TOTAL_2="182" VAR="0.17178699436763953" WEIGHT="0.3533796535728873"/>
<DICH_DATA CI_END="2.5688705692797895" CI_START="0.7220233680433636" EFFECT_SIZE="1.361904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4097422231983706" LOG_CI_START="-0.14144874640812305" LOG_EFFECT_SIZE="0.13414673839512375" MODIFIED="2012-10-03 14:39:48 +0100" MODIFIED_BY="Lindsay Stead" ORDER="48" O_E="0.0" SE="0.3237723039861576" STUDY_ID="STD-Villa-1999" TOTAL_1="21" TOTAL_2="26" VAR="0.10482850482850484" WEIGHT="0.3591446244273312"/>
<DICH_DATA CI_END="3.247959524638751" CI_START="0.6065321080428522" EFFECT_SIZE="1.4035639412997905" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5116106085200087" LOG_CI_START="-0.21714620390418088" LOG_EFFECT_SIZE="0.1472322023079139" ORDER="4" O_E="0.0" SE="0.4280753590223699" STUDY_ID="STD-Campbell-1987" TOTAL_1="424" TOTAL_2="412" VAR="0.18324851300213088" WEIGHT="0.3669019519269236"/>
<DICH_DATA CI_END="2.3736710298145747" CI_START="0.8553867175906704" EFFECT_SIZE="1.4249233912155261" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.37542052934643694" LOG_CI_START="-0.0678374977334798" LOG_EFFECT_SIZE="0.15379151580647857" ORDER="33" O_E="0.0" SE="0.26037195926936413" STUDY_ID="STD-Mori-1992" TOTAL_1="178" TOTAL_2="186" VAR="0.06779355717376741" WEIGHT="0.8647473366705805"/>
<DICH_DATA CI_END="2.712769410117531" CI_START="0.7913564709479441" EFFECT_SIZE="1.4651851851851851" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4334128795818624" LOG_CI_START="-0.10162784204955344" LOG_EFFECT_SIZE="0.16589251876615446" ORDER="10" O_E="0.0" SE="0.31428556838058" STUDY_ID="STD-Fee-1982" TOTAL_1="180" TOTAL_2="172" VAR="0.09877541849230424" WEIGHT="0.6165510394998422"/>
<DICH_DATA CI_END="3.691402296267391" CI_START="0.6095244623635621" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5671913780399481" LOG_CI_START="-0.21500885992858565" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="45" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-Schneider-1985A" TOTAL_1="30" TOTAL_2="30" VAR="0.21111111111111114" WEIGHT="0.24113996211549382"/>
<DICH_DATA CI_END="2.078053930950937" CI_START="1.135942042364552" EFFECT_SIZE="1.5364077669902914" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="50" LOG_CI_END="0.3176568144485229" LOG_CI_START="0.055356173519918124" LOG_EFFECT_SIZE="0.18650649398422053" ORDER="40" O_E="0.0" SE="0.15407669489057554" STUDY_ID="STD-Pirie-1992" TOTAL_1="206" TOTAL_2="211" VAR="0.023739627908403504" WEIGHT="1.9854049638605806"/>
<DICH_DATA CI_END="2.103496146183185" CI_START="1.133452288226358" EFFECT_SIZE="1.5440895440895441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="37" LOG_CI_END="0.32294172068250876" LOG_CI_START="0.05440324356608751" LOG_EFFECT_SIZE="0.1886724821242981" ORDER="1" O_E="0.0" SE="0.15774083074508602" STUDY_ID="STD-Areechon-1988" TOTAL_1="99" TOTAL_2="101" VAR="0.024882169684149878" WEIGHT="1.4721594687150898"/>
<DICH_DATA CI_END="2.9681504720636167" CI_START="0.8415818958233378" EFFECT_SIZE="1.5804878048780489" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.4724859139689923" LOG_CI_START="-0.07490361566727656" LOG_EFFECT_SIZE="0.19879114915085785" ORDER="16" O_E="0.0" SE="0.32153931933021623" STUDY_ID="STD-Hall-1985" TOTAL_1="41" TOTAL_2="36" VAR="0.10338753387533876" WEIGHT="0.4279973353565042"/>
<DICH_DATA CI_END="3.0608139772913443" CI_START="0.9364950419934288" EFFECT_SIZE="1.6930555555555555" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.48583693590546406" LOG_CI_START="-0.02849451753123709" LOG_EFFECT_SIZE="0.22867120918711345" ORDER="47" O_E="0.0" SE="0.3021208417304738" STUDY_ID="STD-Tonnesen-1988" TOTAL_1="60" TOTAL_2="53" VAR="0.09127700300793001" WEIGHT="0.5121556717497214"/>
<DICH_DATA CI_END="3.1300417111171157" CI_START="1.067386158715058" EFFECT_SIZE="1.8278301886792452" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.49555012501842827" LOG_CI_START="0.02832156680872703" LOG_EFFECT_SIZE="0.26193584591357766" ORDER="21" O_E="0.0" SE="0.27445236791104227" STUDY_ID="STD-Hjalmarson-1984" TOTAL_1="106" TOTAL_2="100" VAR="0.0753241022519781" WEIGHT="0.6617692164205138"/>
<DICH_DATA CI_END="4.563039307727768" CI_START="0.8050798740413305" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.6592542099639247" LOG_CI_START="-0.09416103002398857" LOG_EFFECT_SIZE="0.28254658996996806" ORDER="23" O_E="0.0" SE="0.44255984143448623" STUDY_ID="STD-Hughes-1989" TOTAL_1="210" TOTAL_2="105" VAR="0.19585921325051758" WEIGHT="0.3215199494873251"/>
<DICH_DATA CI_END="2.641674335804446" CI_START="1.4565130470266645" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="78" LOG_CI_END="0.42187927698755906" LOG_CI_START="0.1633143792666777" LOG_EFFECT_SIZE="0.2925968281271184" MODIFIED="2012-10-03 14:39:46 +0100" MODIFIED_BY="Lindsay Stead" ORDER="44" O_E="0.0" SE="0.15188230083813165" STUDY_ID="STD-Russell-1983" TOTAL_1="729" TOTAL_2="1377" VAR="0.023068233307884725" WEIGHT="2.1702596590394445"/>
<DICH_DATA CI_END="2.843419595821319" CI_START="1.3868203879402838" EFFECT_SIZE="1.9857774968394437" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="28" LOG_CI_END="0.45384095209413783" LOG_CI_START="0.14202021768646272" LOG_EFFECT_SIZE="0.2979305848903003" ORDER="30" O_E="0.0" SE="0.18316504292859753" STUDY_ID="STD-Llivina-1988" TOTAL_1="113" TOTAL_2="103" VAR="0.03354943295103498" WEIGHT="1.177417963168862"/>
<DICH_DATA CI_END="3.5225719722255557" CI_START="1.1957150368524538" EFFECT_SIZE="2.052313883299799" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.5468598752579272" LOG_CI_START="0.07762769079924374" LOG_EFFECT_SIZE="0.31224378302858546" ORDER="17" O_E="0.0" SE="0.2756293078878044" STUDY_ID="STD-Hall-1987" TOTAL_1="71" TOTAL_2="68" VAR="0.07597151536671005" WEIGHT="0.5748036507021603"/>
<DICH_DATA CI_END="4.7927472328753025" CI_START="0.978339288206984" EFFECT_SIZE="2.1653944020356235" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.6805845251190232" LOG_CI_START="-0.009510505700700772" LOG_EFFECT_SIZE="0.33553700970916117" ORDER="15" O_E="0.0" SE="0.40536523712900135" STUDY_ID="STD-Gross-1995" TOTAL_1="131" TOTAL_2="46" VAR="0.1643209754726515" WEIGHT="0.3569416388376236"/>
<DICH_DATA CI_END="3.6414111243083065" CI_START="1.3428793600393683" EFFECT_SIZE="2.2113289760348582" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="17" LOG_CI_END="0.561269714621607" LOG_CI_START="0.1280369988023339" LOG_EFFECT_SIZE="0.34465335671197045" ORDER="13" O_E="0.0" SE="0.25448304180877096" STUDY_ID="STD-Garvey-2000" TOTAL_1="405" TOTAL_2="203" VAR="0.06476161856824468" WEIGHT="0.9102240346300301"/>
<DICH_DATA CI_END="5.720321996351251" CI_START="0.9630026289815542" EFFECT_SIZE="2.347058823529412" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.7574204758739058" LOG_CI_START="-0.016372527256957148" LOG_EFFECT_SIZE="0.37052397430847434" ORDER="12" O_E="0.0" SE="0.45452984037620925" STUDY_ID="STD-Garcia-1989" TOTAL_1="68" TOTAL_2="38" VAR="0.20659737579242224" WEIGHT="0.25782260100398713"/>
<DICH_DATA CI_END="4.183776315605878" CI_START="1.3407548251623347" EFFECT_SIZE="2.3684210526315788" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="0.6215684570506804" LOG_CI_START="0.12734936859434903" LOG_EFFECT_SIZE="0.3744589128225147" ORDER="20" O_E="0.0" SE="0.29030673898319226" STUDY_ID="STD-Herrera-1995" TOTAL_1="76" TOTAL_2="78" VAR="0.08427800269905533" WEIGHT="0.5156845943075928"/>
<DICH_DATA CI_END="4.848340156021888" CI_START="1.232444187018039" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.6855930820123821" LOG_CI_START="0.09076726075338054" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="26" O_E="0.0" SE="0.34940363184284007" STUDY_ID="STD-Jarvis-1982" TOTAL_1="58" TOTAL_2="58" VAR="0.1220828979449669" WEIGHT="0.36170994317324073"/>
<DICH_DATA CI_END="6.386765392813436" CI_START="1.0584387533017163" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8052809633667104" LOG_CI_START="0.0246657325749255" LOG_EFFECT_SIZE="0.414973347970818" ORDER="34" O_E="0.0" SE="0.45853725067480644" STUDY_ID="STD-Nakamura-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.2102564102564103" WEIGHT="0.20094996842957819"/>
<DICH_DATA CI_END="5.687760780817803" CI_START="1.2441491632011088" EFFECT_SIZE="2.66015466015466" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.7549413222935226" LOG_CI_START="0.09487245179503367" LOG_EFFECT_SIZE="0.42490688704427815" MODIFIED="2012-07-04 17:07:26 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="614" O_E="0.0" SE="0.38772772192441723" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_" TOTAL_1="819" TOTAL_2="817" VAR="0.1503327863486982" WEIGHT="0.3621521313678291"/>
<DICH_DATA CI_END="6.940756990800773" CI_START="1.177115040228752" EFFECT_SIZE="2.8583333333333334" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="5" LOG_CI_END="0.8414068391867146" LOG_CI_START="0.07081890880357672" LOG_EFFECT_SIZE="0.45611287399514566" MODIFIED="2012-10-03 14:39:41 +0100" MODIFIED_BY="Lindsay Stead" ORDER="9" O_E="0.0" SE="0.4526471647788296" STUDY_ID="STD-Fagerstrom-1984" TOTAL_1="96" TOTAL_2="49" VAR="0.20488945578231293" WEIGHT="0.26608547543778627"/>
<DICH_DATA CI_END="6.610228606916726" CI_START="1.3759720864046632" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.8202164793049521" LOG_CI_START="0.13860962369354227" LOG_EFFECT_SIZE="0.47941305149924723" MODIFIED="2012-10-03 14:39:46 +0100" MODIFIED_BY="Lindsay Stead" ORDER="43" O_E="0.0" SE="0.40037924099449274" STUDY_ID="STD-Roto-1987" TOTAL_1="54" TOTAL_2="60" VAR="0.1603035366193261" WEIGHT="0.26652311602238793"/>
<DICH_DATA CI_END="12.85331251038475" CI_START="0.8550075403053737" EFFECT_SIZE="3.315068493150685" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.1090150669349643" LOG_CI_START="-0.06803005521501355" LOG_EFFECT_SIZE="0.5204925058599754" ORDER="31" O_E="0.0" SE="0.6914021312182197" STUDY_ID="STD-Malcolm-1980" TOTAL_1="73" TOTAL_2="121" VAR="0.4780369070530963" WEIGHT="0.09073823316717035"/>
<DICH_DATA CI_END="15.439929239254754" CI_START="0.7835721582188115" EFFECT_SIZE="3.4782608695652173" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.188645305645338" LOG_CI_START="-0.10592100369663676" LOG_EFFECT_SIZE="0.5413621509743507" ORDER="53" O_E="0.0" SE="0.7604346583140575" STUDY_ID="STD-Moolchan-2005" TOTAL_1="46" TOTAL_2="40" VAR="0.5782608695652174" WEIGHT="0.08598789346754042"/>
<DICH_DATA CI_END="6.50670193022576" CI_START="2.728382244752736" EFFECT_SIZE="4.213403614457832" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="24" LOG_CI_END="0.8133609123089041" LOG_CI_START="0.4359052146492433" LOG_EFFECT_SIZE="0.6246330634790737" MODIFIED="2012-10-03 11:58:24 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="615" O_E="0.0" SE="0.2217193452411218" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_" TOTAL_1="830" TOTAL_2="831" VAR="0.049159468054151764" WEIGHT="0.9639791381377959"/>
<DICH_DATA CI_END="10.383127352642541" CI_START="1.8071326338889435" EFFECT_SIZE="4.331707317073171" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="1.0163281808182514" LOG_CI_START="0.25699002862744214" LOG_EFFECT_SIZE="0.6366591047228467" ORDER="6" O_E="0.0" SE="0.44603898938135556" STUDY_ID="STD-Clavel-1985" TOTAL_1="205" TOTAL_2="222" VAR="0.198950780048341" WEIGHT="0.23153954207810884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="51.68000725044099" CI_END="1.7807101432298271" CI_START="1.5150124756752976" DF="42" EFFECT_SIZE="1.6424975137134104" ESTIMABLE="YES" EVENTS_1="1873" EVENTS_2="766" I2="18.730661556473343" ID="CMP-001.01.02" LOG_CI_END="0.25059323252295695" LOG_CI_START="0.18041620913841055" LOG_EFFECT_SIZE="0.2155047208306838" MODIFIED="2012-10-03 14:39:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14548997719302592" P_Z="2.2541678570239438E-33" STUDIES="43" TAU2="0.0" TOTAL_1="11746" TOTAL_2="7840" WEIGHT="33.89122959878685" Z="12.03760065490356">
<NAME>Patch</NAME>
<DICH_DATA CI_END="1.3007062234518165" CI_START="0.5135491607972068" EFFECT_SIZE="0.8172983479105929" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.11417921820578969" LOG_CI_START="-0.2894179761348311" LOG_EFFECT_SIZE="-0.08761937896452072" ORDER="75" O_E="0.0" SE="0.23707498979401342" STUDY_ID="STD-Joseph-1996" TOTAL_1="294" TOTAL_2="290" VAR="0.05620455078583157" WEIGHT="1.4162843665344929"/>
<DICH_DATA CI_END="1.9396324884607696" CI_START="0.46529433043070706" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.2877194498511332" LOG_CI_START="-0.3322722392734377" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="77" O_E="0.0" SE="0.3641861872001304" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="150" TOTAL_2="75" VAR="0.13263157894736843" WEIGHT="0.5358665824788752"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" ORDER="89" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="0.7176325272557097"/>
<DICH_DATA CI_END="1.9175853297600345" CI_START="0.6255505122219942" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2827546985242227" LOG_CI_START="-0.20373761595687537" LOG_EFFECT_SIZE="0.039508541283673655" ORDER="76" O_E="0.0" SE="0.28576799370199224" STUDY_ID="STD-Killen-1997" TOTAL_1="212" TOTAL_2="212" VAR="0.08166334622446189" WEIGHT="0.8439898674042283"/>
<DICH_DATA CI_END="1.8298847059469658" CI_START="0.6989802602453846" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.2624237273542518" LOG_CI_START="-0.15553508890031958" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="94" O_E="0.0" SE="0.24551107759744292" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="0.06027568922305764" WEIGHT="0.8439898674042283"/>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-03-02 13:55:36 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="645" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="1.595351368408537"/>
<DICH_DATA CI_END="3.393314017187208" CI_START="0.5239060602034752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5306240511043927" LOG_CI_START="-0.28074657788779284" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="71" O_E="0.0" SE="0.4766031238193982" STUDY_ID="STD-Hurt-1990" TOTAL_1="31" TOTAL_2="31" VAR="0.2271505376344086" WEIGHT="0.24113996211549382"/>
<DICH_DATA CI_END="1.8113081221041267" CI_START="1.1243557445017534" EFFECT_SIZE="1.427079077048801" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="71" LOG_CI_END="0.25799233454774956" LOG_CI_START="0.050903743110311706" LOG_EFFECT_SIZE="0.1544480388290306" ORDER="57" O_E="0.0" SE="0.12164486371541124" STUDY_ID="STD-CEASE-1999" TOTAL_1="2861" TOTAL_2="714" VAR="0.014797472868340973" WEIGHT="4.567179640511177"/>
<DICH_DATA CI_END="2.014402311568503" CI_START="1.025628178913287" EFFECT_SIZE="1.437368350289069" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.30414621112601403" LOG_CI_START="0.010989944486001551" LOG_EFFECT_SIZE="0.15756807780600784" ORDER="73" O_E="0.0" SE="0.17220144217126704" STUDY_ID="STD-ICRF-1994" TOTAL_1="842" TOTAL_2="844" VAR="0.02965333668586423" WEIGHT="2.1275428923222672"/>
<DICH_DATA CI_END="3.204629081127771" CI_START="0.6457386936581349" EFFECT_SIZE="1.4385245901639345" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5057777694736735" LOG_CI_START="-0.18994318921948414" LOG_EFFECT_SIZE="0.15791729012709468" ORDER="70" O_E="0.0" SE="0.4086699350106484" STUDY_ID="STD-Hughes-2003" TOTAL_1="61" TOTAL_2="54" VAR="0.1670111157816076" WEIGHT="0.3410907290213362"/>
<DICH_DATA CI_END="3.103911528273855" CI_START="0.6721904713072535" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49190933393600517" LOG_CI_START="-0.1725076482009813" LOG_EFFECT_SIZE="0.15970084286751188" MODIFIED="2011-06-28 13:56:36 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.39028182422437036" STUDY_ID="STD-Glavas-2003a" TOTAL_1="56" TOTAL_2="56" VAR="0.15231990231990233" WEIGHT="0.36170994317324073"/>
<DICH_DATA CI_END="2.8593078037343456" CI_START="0.7422768702931712" EFFECT_SIZE="1.4568452380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.45626090956152343" LOG_CI_START="-0.12943407206289823" LOG_EFFECT_SIZE="0.1634134187493126" MODIFIED="2012-10-03 14:39:50 +0100" MODIFIED_BY="Lindsay Stead" ORDER="56" O_E="0.0" SE="0.34404013144310264" STUDY_ID="STD-Buchkremer-1988" TOTAL_1="42" TOTAL_2="89" VAR="0.11836361204338733" WEIGHT="0.41233092758679857"/>
<DICH_DATA CI_END="2.361530435285525" CI_START="0.9005753554279192" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.37319354711423586" LOG_CI_START="-0.04547994183689675" LOG_EFFECT_SIZE="0.16385680263866959" MODIFIED="2012-10-03 14:39:51 +0100" MODIFIED_BY="Lindsay Stead" ORDER="55" O_E="0.0" SE="0.24593087987708992" STUDY_ID="STD-Ahluwalia-1998" TOTAL_1="205" TOTAL_2="205" VAR="0.06048199767711963" WEIGHT="0.9645598484619753"/>
<DICH_DATA CI_END="2.5728675834146997" CI_START="0.8294790996379331" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4104174351523806" LOG_CI_START="-0.08119455240787828" LOG_EFFECT_SIZE="0.16461144137225117" ORDER="58" O_E="0.0" SE="0.28877531501148174" STUDY_ID="STD-Campbell-1996" TOTAL_1="115" TOTAL_2="119" VAR="0.08339118255998051" WEIGHT="0.6715507491962827"/>
<DICH_DATA CI_END="2.9427867387446707" CI_START="0.7847299161094201" EFFECT_SIZE="1.5196357427433125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.46875879028775475" LOG_CI_START="-0.10527979054919413" LOG_EFFECT_SIZE="0.18173949986928026" MODIFIED="2012-10-03 14:39:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="83" O_E="0.0" SE="0.33719310392042656" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="251" TOTAL_2="267" VAR="0.11369918933149159" WEIGHT="0.5452804548737743"/>
<DICH_DATA CI_END="3.0985703046290562" CI_START="0.7554774524569775" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4911613544686127" LOG_CI_START="-0.12177849283341506" LOG_EFFECT_SIZE="0.1846914308175988" MODIFIED="2011-06-28 13:56:41 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.3600439004063886" STUDY_ID="STD-Abelin-1989" TOTAL_1="100" TOTAL_2="99" VAR="0.12963161021984548" WEIGHT="0.44431148798499703"/>
<DICH_DATA CI_END="2.8436645298032195" CI_START="0.8678996274243392" EFFECT_SIZE="1.570991847826087" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.45387836088728595" LOG_CI_START="-0.06153049806810565" LOG_EFFECT_SIZE="0.19617393140959016" ORDER="61" O_E="0.0" SE="0.30275371506539595" STUDY_ID="STD-Daughton-1998" TOTAL_1="184" TOTAL_2="185" VAR="0.09165981198589895" WEIGHT="0.6412972434218733"/>
<DICH_DATA CI_END="3.0007141337297876" CI_START="0.8411651795025185" EFFECT_SIZE="1.588740458015267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="8" LOG_CI_END="0.4772246238629811" LOG_CI_START="-0.07511871347371944" LOG_EFFECT_SIZE="0.20105295519463082" MODIFIED="2012-02-07 13:36:10 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="601" O_E="0.0" SE="0.3244492104951934" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1052672901909543" WEIGHT="0.5634663997704292"/>
<DICH_DATA CI_END="1.9414129420303619" CI_START="1.310754497312224" EFFECT_SIZE="1.5952165197572563" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="122" LOG_CI_END="0.2881179204326567" LOG_CI_START="0.1175213564903053" LOG_EFFECT_SIZE="0.20281963846148102" MODIFIED="2012-10-03 14:39:54 +0100" MODIFIED_BY="Lindsay Stead" ORDER="91" O_E="0.0" SE="0.10020926612634813" STUDY_ID="STD-Otero-2006" TOTAL_1="597" TOTAL_2="602" VAR="0.010041897017581264" WEIGHT="4.882732277097547"/>
<DICH_DATA CI_END="3.4000401052481815" CI_START="0.8169838271878318" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5314840398026245" LOG_CI_START="-0.08778654056991181" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="64" O_E="0.0" SE="0.3637626043496394" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="44" VAR="0.1323232323232323" WEIGHT="0.36170994317324073"/>
<DICH_DATA CI_END="2.358871489270788" CI_START="1.1945432704943428" EFFECT_SIZE="1.678622668579627" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="34" LOG_CI_END="0.3727042812752382" LOG_CI_START="0.07720188602106627" LOG_EFFECT_SIZE="0.22495308364815225" ORDER="69" O_E="0.0" SE="0.17357956973274816" STUDY_ID="STD-Hughes-1999" TOTAL_1="779" TOTAL_2="260" VAR="0.030129867028605983" WEIGHT="2.0490320938694158"/>
<DICH_DATA CI_END="4.843896772402742" CI_START="0.5969505892682352" EFFECT_SIZE="1.7004608294930876" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6851948793815098" LOG_CI_START="-0.2240616147604481" LOG_EFFECT_SIZE="0.23056663231053087" ORDER="78" O_E="0.0" SE="0.5341017655512216" STUDY_ID="STD-Lewis-1998" TOTAL_1="62" TOTAL_2="123" VAR="0.28526469596493204" WEIGHT="0.18856710551013392"/>
<DICH_DATA CI_END="3.788507155734091" CI_START="0.775708053172369" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.578468111881843" LOG_CI_START="-0.1103016998151071" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="59" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Cinciripini-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.16369047619047616" WEIGHT="0.28132995580140946"/>
<DICH_DATA CI_END="3.6638765871680388" CI_START="0.8345587993406903" EFFECT_SIZE="1.7486338797814207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.563940836607552" LOG_CI_START="-0.078543059428599" LOG_EFFECT_SIZE="0.2426988885894765" ORDER="74" O_E="0.0" SE="0.37739822087821245" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.14242941712204005" WEIGHT="0.4369169610607463"/>
<DICH_DATA CI_END="2.6170951223873518" CI_START="1.2476508655425136" EFFECT_SIZE="1.8069922508560101" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="31" LOG_CI_END="0.4178195080342886" LOG_CI_START="0.09609307222018122" LOG_EFFECT_SIZE="0.25695629012723487" ORDER="85" O_E="0.0" SE="0.18898370096874859" STUDY_ID="STD-TNSG-1991" TOTAL_1="537" TOTAL_2="271" VAR="0.03571483923184539" WEIGHT="1.6560465962609843"/>
<DICH_DATA CI_END="3.2899905062299095" CI_START="1.1453425421228474" EFFECT_SIZE="1.9411764705882353" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5171946447287246" LOG_CI_START="0.05893539227050256" LOG_EFFECT_SIZE="0.2880650184996135" ORDER="72" O_E="0.0" SE="0.26918375331384387" STUDY_ID="STD-Hurt-1994" TOTAL_1="120" TOTAL_2="120" VAR="0.07245989304812835" WEIGHT="0.6832298926605658"/>
<DICH_DATA CI_END="4.551776484470188" CI_START="0.8367371518627194" EFFECT_SIZE="1.9515738498789346" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6581809278280224" LOG_CI_START="-0.07741094753064312" LOG_EFFECT_SIZE="0.2903849901486896" ORDER="93" O_E="0.0" SE="0.43209030882418825" STUDY_ID="STD-Prapavessis-2007" TOTAL_1="59" TOTAL_2="62" VAR="0.18670203497978238" WEIGHT="0.2743548329303001"/>
<DICH_DATA CI_END="3.2993612898922677" CI_START="1.2444698588327163" EFFECT_SIZE="2.026315789473684" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="19" LOG_CI_END="0.5184298746891502" LOG_CI_START="0.09498438242219312" LOG_EFFECT_SIZE="0.30670712855567167" ORDER="84" O_E="0.0" SE="0.24873397824660265" STUDY_ID="STD-Stapleton-1995" TOTAL_1="800" TOTAL_2="400" VAR="0.061868591934381406" WEIGHT="1.0181465067098627"/>
<DICH_DATA CI_END="3.7386899573042225" CI_START="1.1327257863865658" EFFECT_SIZE="2.0578898225957047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5727194514032413" LOG_CI_START="0.05412478729254229" LOG_EFFECT_SIZE="0.31342211934789177" ORDER="81" O_E="0.0" SE="0.30462507278361334" STUDY_ID="STD-Richmond-1994" TOTAL_1="153" TOTAL_2="152" VAR="0.09279643496842171" WEIGHT="0.564504698198238"/>
<DICH_DATA CI_END="3.6866872656583496" CI_START="1.1538560077024487" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5666362988322253" LOG_CI_START="0.06215161561170004" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2012-10-03 14:39:52 +0100" MODIFIED_BY="Lindsay Stead" ORDER="62" O_E="0.0" SE="0.2963368001631935" STUDY_ID="STD-Davidson-1998" TOTAL_1="401" TOTAL_2="401" VAR="0.08781549913096048" WEIGHT="0.6430398989746502"/>
<DICH_DATA CI_END="3.9419707258706516" CI_START="1.2752972552091766" EFFECT_SIZE="2.242138364779874" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="14" LOG_CI_END="0.5957133947683748" LOG_CI_START="0.10561142496649092" LOG_EFFECT_SIZE="0.35066240986743286" ORDER="68" O_E="0.0" SE="0.28788832310550383" STUDY_ID="STD-Hays-1999" TOTAL_1="636" TOTAL_2="322" VAR="0.08287968658049898" WEIGHT="0.7470808012095884"/>
<DICH_DATA CI_END="7.237905645439162" CI_START="0.8039754134848986" EFFECT_SIZE="2.412280701754386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8596129172728425" LOG_CI_START="-0.09475723228526235" LOG_EFFECT_SIZE="0.3824278424937901" ORDER="65" O_E="0.0" SE="0.5606017500588621" STUDY_ID="STD-Fiore-1994B" TOTAL_1="57" TOTAL_2="55" VAR="0.314274322169059" WEIGHT="0.1636306885783708"/>
<DICH_DATA CI_END="4.390778670369073" CI_START="1.3301234738135557" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6425415458131081" LOG_CI_START="0.12389195788955437" LOG_EFFECT_SIZE="0.38321675185133125" MODIFIED="2011-06-28 13:56:37 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.3046573353031615" STUDY_ID="STD-Glavas-2003b" TOTAL_1="80" TOTAL_2="80" VAR="0.09281609195402299" WEIGHT="0.48227992423098764"/>
<DICH_DATA CI_END="5.191155779737516" CI_START="1.3541372015357949" EFFECT_SIZE="2.651327433628319" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7152640616789412" LOG_CI_START="0.1316626694090771" LOG_EFFECT_SIZE="0.42346336554400915" ORDER="82" O_E="0.0" SE="0.3428103466928011" STUDY_ID="STD-Sachs-1993" TOTAL_1="113" TOTAL_2="107" VAR="0.11751893379963846" WEIGHT="0.4128608442280425"/>
<DICH_DATA CI_END="10.709518607104284" CI_START="0.9561587570525513" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0297699497322355" LOG_CI_START="-0.01946999309242347" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2012-10-03 14:39:55 +0100" MODIFIED_BY="Lindsay Stead" ORDER="80" O_E="0.0" SE="0.6163287362366865" STUDY_ID="STD-Perng-1998" TOTAL_1="30" TOTAL_2="32" VAR="0.3798611111111111" WEIGHT="0.11668062683007766"/>
<DICH_DATA CI_END="9.51135034004292" CI_START="1.1889010697860327" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9782421787248091" LOG_CI_START="0.07514571783689675" LOG_EFFECT_SIZE="0.5266939482808529" ORDER="90" O_E="0.0" SE="0.5304833315251388" STUDY_ID="STD-Wong-1999" TOTAL_1="51" TOTAL_2="49" VAR="0.28141256502601036" WEIGHT="0.1639751742385358"/>
<DICH_DATA CI_END="9.275880948360145" CI_START="1.27126435723578" EFFECT_SIZE="3.4339622641509435" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.9673551660329998" LOG_CI_START="0.1042358707355719" LOG_EFFECT_SIZE="0.5357955183842857" MODIFIED="2012-10-03 14:39:52 +0100" MODIFIED_BY="Lindsay Stead" ORDER="60" O_E="0.0" SE="0.507000546567127" STUDY_ID="STD-Daughton-1991" TOTAL_1="106" TOTAL_2="52" VAR="0.25704955421936554" WEIGHT="0.21570325725099027"/>
<DICH_DATA CI_END="16.118289185653534" CI_START="0.760006217713441" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2073189433834552" LOG_CI_START="-0.11918285468290388" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2011-06-28 13:56:38 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.7791937224739794" STUDY_ID="STD-Ehrsam-1991" TOTAL_1="56" TOTAL_2="56" VAR="0.607142857142857" WEIGHT="0.08037998737183127"/>
<DICH_DATA CI_END="10.644319166426266" CI_START="1.3211272398102434" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0271178882524812" LOG_CI_START="0.12094464720295672" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="79" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Paoletti-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.2833333333333333" WEIGHT="0.16075997474366255"/>
<DICH_DATA CI_END="9.428558561934224" CI_START="1.673646214316064" EFFECT_SIZE="3.972413793103448" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9744453028701352" LOG_CI_START="0.22366365950633915" LOG_EFFECT_SIZE="0.5990544811882371" ORDER="86" O_E="0.0" SE="0.44101285374096627" STUDY_ID="STD-Tonnesen-1991" TOTAL_1="145" TOTAL_2="144" VAR="0.19449233716475092" WEIGHT="0.24197435644807339"/>
<DICH_DATA CI_END="21.316258689645682" CI_START="1.043519004284947" EFFECT_SIZE="4.716346153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.328710982107621" LOG_CI_START="0.018500362726752817" LOG_EFFECT_SIZE="0.6736056724171869" ORDER="87" O_E="0.0" SE="0.7696242034714872" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="104" TOTAL_2="109" VAR="0.5923214145691211" WEIGHT="0.07849313320817326"/>
<DICH_DATA CI_END="22.85043813806692" CI_START="1.2265708644863083" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3588945317196774" LOG_CI_START="0.0886926444024243" LOG_EFFECT_SIZE="0.723793588061051" ORDER="92" O_E="0.0" SE="0.7461228762109019" STUDY_ID="STD-Moolchan-2005" TOTAL_1="34" TOTAL_2="40" VAR="0.5566993464052288" WEIGHT="0.07386269109843956"/>
<DICH_DATA CI_END="34.51060023583957" CI_START="1.9508246278682124" EFFECT_SIZE="8.205128205128204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5379525129526281" LOG_CI_START="0.2902182296341853" LOG_EFFECT_SIZE="0.9140853712934067" ORDER="88" O_E="0.0" SE="0.7329252944055672" STUDY_ID="STD-Westman-1993" TOTAL_1="78" TOTAL_2="80" VAR="0.5371794871794873" WEIGHT="0.07936251917725114"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.927954462966726" CI_END="2.666002774214407" CI_START="1.3564593215155194" DF="3" EFFECT_SIZE="1.9016635649528986" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="44" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.4258605970003392" LOG_CI_START="0.13240677435545753" LOG_EFFECT_SIZE="0.27913368567789837" NO="3" P_CHI2="0.5874940951574545" P_Z="1.9251521559817745E-4" STUDIES="4" TAU2="0.0" TOTAL_1="490" TOTAL_2="486" WEIGHT="1.77033674900823" Z="3.7286409552937334">
<NAME>Inhaler/ Inhalator</NAME>
<DICH_DATA CI_END="2.5695685313696033" CI_START="1.0010682086703633" EFFECT_SIZE="1.6038433111603843" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" LOG_CI_END="0.4098602049745912" LOG_CI_START="4.636695272218084E-4" LOG_EFFECT_SIZE="0.2051619372509065" ORDER="95" O_E="0.0" SE="0.24048155146731892" STUDY_ID="STD-Hjalmarson-1997" TOTAL_1="123" TOTAL_2="124" VAR="0.057831376596128754" WEIGHT="0.8806001855391717"/>
<DICH_DATA CI_END="3.6162983248620826" CI_START="0.7544720597746652" EFFECT_SIZE="1.6517857142857142" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5582642502041109" LOG_CI_START="-0.12235683873844654" LOG_EFFECT_SIZE="0.21795370573283215" ORDER="97" O_E="0.0" SE="0.3998001967735851" STUDY_ID="STD-Schneider-1996" TOTAL_1="112" TOTAL_2="111" VAR="0.15984019734019733" WEIGHT="0.3633319608556319"/>
<DICH_DATA CI_END="5.138806492602952" CI_START="0.7783908589976669" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.7108622641578292" LOG_CI_START="-0.1088022728298668" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="96" O_E="0.0" SE="0.4814750064314676" STUDY_ID="STD-Leischow-1996" TOTAL_1="110" TOTAL_2="110" VAR="0.2318181818181818" WEIGHT="0.24113996211549382"/>
<DICH_DATA CI_END="6.927386308466684" CI_START="1.348286218918342" EFFECT_SIZE="3.0561576354679802" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="7" LOG_CI_END="0.8405694069175346" LOG_CI_START="0.1297820955391742" LOG_EFFECT_SIZE="0.48517575122835443" ORDER="98" O_E="0.0" SE="0.4175199851575851" STUDY_ID="STD-Tonnesen-1993" TOTAL_1="145" TOTAL_2="141" VAR="0.17432293800599008" WEIGHT="0.28526464049793265"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6308656216461883" CI_END="2.7298865346508334" CI_START="1.488472296102131" DF="3" EFFECT_SIZE="2.015777884175242" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="52" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.43614459634511443" LOG_CI_START="0.17274075583733586" LOG_EFFECT_SIZE="0.3044426760912251" MODIFIED="2012-07-05 12:36:38 +0100" MODIFIED_BY="Lindsay Stead" NO="4" P_CHI2="0.6524117340150213" P_Z="5.879957970106562E-6" STUDIES="4" TAU2="0.0" TOTAL_1="448" TOTAL_2="439" WEIGHT="2.110355278733354" Z="4.530660444020168">
<NAME>Intranasal Spray</NAME>
<DICH_DATA CI_END="2.8357284087598496" CI_START="0.8136613285448909" EFFECT_SIZE="1.518987341772152" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.4526646340480194" LOG_CI_START="-0.0895563245336525" LOG_EFFECT_SIZE="0.18155415475718342" ORDER="105" O_E="0.0" SE="0.3185032751079066" STUDY_ID="STD-Blondal-1997" TOTAL_1="79" TOTAL_2="78" VAR="0.10144433625446284" WEIGHT="0.5257977517889855"/>
<DICH_DATA CI_END="3.108350593493938" CI_START="1.111406732885492" EFFECT_SIZE="1.8586666666666667" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.49252999733372615" LOG_CI_START="0.045873023406854965" LOG_EFFECT_SIZE="0.26920151037029055" ORDER="106" O_E="0.0" SE="0.2623685174723234" STUDY_ID="STD-Hjalmarson-1994" TOTAL_1="125" TOTAL_2="123" VAR="0.0688372389606249" WEIGHT="0.7292539176879853"/>
<DICH_DATA CI_END="4.598422490931164" CI_START="1.132489812810138" EFFECT_SIZE="2.28203125" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.6626088705980535" LOG_CI_START="0.0540343040533092" LOG_EFFECT_SIZE="0.3583215873256814" ORDER="107" O_E="0.0" SE="0.3574797128810721" STUDY_ID="STD-Schneider-1995" TOTAL_1="128" TOTAL_2="127" VAR="0.12779174512153374" WEIGHT="0.40347601504291775"/>
<DICH_DATA CI_END="4.949080498510858" CI_START="1.3761399424347236" EFFECT_SIZE="2.609717868338558" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="11" LOG_CI_END="0.6945245178189854" LOG_CI_START="0.13866260042336714" LOG_EFFECT_SIZE="0.4165935591211763" ORDER="108" O_E="0.0" SE="0.3265160418390539" STUDY_ID="STD-Sutherland-1992" TOTAL_1="116" TOTAL_2="111" VAR="0.1066127255782428" WEIGHT="0.4518275942134657"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.878006862788645" CI_END="2.362934424475668" CI_START="1.6090771772138273" DF="6" EFFECT_SIZE="1.949908678291547" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="134" I2="23.838604046656936" ID="CMP-001.01.05" LOG_CI_END="0.3734516693752663" LOG_CI_START="0.20657687494692692" LOG_EFFECT_SIZE="0.2900142721610966" MODIFIED="2012-07-05 12:36:38 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="5" P_CHI2="0.24717800539777546" P_Z="9.591497863715693E-12" STUDIES="7" TAU2="0.0" TOTAL_1="1808" TOTAL_2="1597" WEIGHT="5.605980427067267" Z="6.812503115111742">
<NAME>Tablets/ Lozenges</NAME>
<DICH_DATA CI_END="2.599030005476736" CI_START="0.8216081753741146" EFFECT_SIZE="1.4612954186413902" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.41481129340549555" LOG_CI_START="-0.0853352479621405" LOG_EFFECT_SIZE="0.1647380227216775" ORDER="99" O_E="0.0" SE="0.2937885541646578" STUDY_ID="STD-Dautzenberg-2001" TOTAL_1="211" TOTAL_2="222" VAR="0.08631171455816007" WEIGHT="0.7050420139450697"/>
<DICH_DATA CI_END="2.515139905583403" CI_START="0.877566144632535" EFFECT_SIZE="1.4856653829696191" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="19" LOG_CI_END="0.4005621478543411" LOG_CI_START="-0.05672013962988632" LOG_EFFECT_SIZE="0.17192100411222738" ORDER="102" O_E="0.0" SE="0.26860987925206486" STUDY_ID="STD-Wallstrom-2000" TOTAL_1="123" TOTAL_2="124" VAR="0.07215126723180887" WEIGHT="0.7605183420565574"/>
<DICH_DATA CI_END="2.840592039873378" CI_START="0.7981931035871063" EFFECT_SIZE="1.5057692307692307" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="8" LOG_CI_END="0.45340886569971645" LOG_CI_START="-0.09789202885342803" LOG_EFFECT_SIZE="0.17775841842314424" MODIFIED="2012-02-07 13:37:06 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="602" O_E="0.0" SE="0.32383687444395765" STUDY_ID="STD-Piper-2009" TOTAL_1="260" TOTAL_2="36" VAR="0.1048703212496316" WEIGHT="0.5648323436939495"/>
<DICH_DATA CI_END="3.5641314400155784" CI_START="0.9588207106381352" EFFECT_SIZE="1.8486111111111112" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5519537118128934" LOG_CI_START="-0.01826259372608003" LOG_EFFECT_SIZE="0.2668455590434067" ORDER="100" O_E="0.0" SE="0.334947880489828" STUDY_ID="STD-Glover-2002" TOTAL_1="120" TOTAL_2="121" VAR="0.1121900826446281" WEIGHT="0.48027876271965575"/>
<DICH_DATA CI_END="2.619490937555498" CI_START="1.320112782911037" EFFECT_SIZE="1.8595761536938007" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="44" LOG_CI_END="0.4182169002924789" LOG_CI_START="0.12061103643579552" LOG_EFFECT_SIZE="0.26941396836413717" ORDER="101" O_E="0.0" SE="0.17481515760220095" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_" TOTAL_1="459" TOTAL_2="458" VAR="0.03056033932748236" WEIGHT="1.7702881406341378"/>
<DICH_DATA CI_END="3.6546005624652707" CI_START="1.5736990483666073" EFFECT_SIZE="2.398174603174603" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="28" LOG_CI_END="0.5628399167256342" LOG_CI_START="0.19692168219681386" LOG_EFFECT_SIZE="0.37988079946122405" ORDER="103" O_E="0.0" SE="0.21494218228670267" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_" TOTAL_1="450" TOTAL_2="451" VAR="0.04620014172617012" WEIGHT="1.1240708555883174"/>
<DICH_DATA CI_END="13.247535015101889" CI_START="2.041134442684999" EFFECT_SIZE="5.2" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.1221350760894007" LOG_CI_START="0.3098716111801976" LOG_EFFECT_SIZE="0.7160033436347992" ORDER="104" O_E="0.0" SE="0.47712758005666334" STUDY_ID="STD-Tonnesen-2006" TOTAL_1="185" TOTAL_2="185" VAR="0.22765072765072766" WEIGHT="0.20094996842957819"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.942316708730255" CI_START="1.2396162884442532" DF="0" EFFECT_SIZE="2.475192173305381" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="9" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="0.6939305719941906" LOG_CI_START="0.09328727419436869" LOG_EFFECT_SIZE="0.39360892309427964" MODIFIED="2012-07-05 12:36:27 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="6" P_CHI2="1.0" P_Z="0.010205814012119178" STUDIES="1" TAU2="0.0" TOTAL_1="318" TOTAL_2="161" WEIGHT="0.48026622934902113" Z="2.5687768966515314">
<NAME>Oral spray</NAME>
<DICH_DATA CI_END="4.942316708730255" CI_START="1.2396162884442532" EFFECT_SIZE="2.475192173305381" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="9" LOG_CI_END="0.6939305719941906" LOG_CI_START="0.09328727419436869" LOG_EFFECT_SIZE="0.39360892309427964" MODIFIED="2012-03-26 11:06:09 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="652" O_E="0.0" SE="0.35282084635989114" STUDY_ID="STD-T_x00f8_nnesen-2012" TOTAL_1="318" TOTAL_2="161" VAR="0.12448254962610993" WEIGHT="0.48026622934902113"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.804996325822154" CI_END="1.8396109998804204" CI_START="1.3852763294828927" DF="4" EFFECT_SIZE="1.596361354327617" ESTIMABLE="YES" EVENTS_1="400" EVENTS_2="241" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="0.264725997756254" LOG_CI_START="0.14153641340004305" LOG_EFFECT_SIZE="0.20313120557814857" MODIFIED="2012-10-03 15:14:21 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="7" P_CHI2="0.771568161897429" P_Z="1.0217784831466099E-10" STUDIES="5" TAU2="0.0" TOTAL_1="1449" TOTAL_2="1349" WEIGHT="9.657503531295253" Z="6.463693325210904">
<NAME>Choice of NRT product</NAME>
<DICH_DATA CI_END="2.299855211296886" CI_START="0.8333337779552569" EFFECT_SIZE="1.3843941028407047" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.36170049562015144" LOG_CI_START="-0.07918101433146914" LOG_EFFECT_SIZE="0.14125974064434116" MODIFIED="2012-02-14 09:41:54 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="620" O_E="0.0" SE="0.2589759813442534" STUDY_ID="STD-Wittchen-2011" TOTAL_1="103" TOTAL_2="175" VAR="0.06706855891321911" WEIGHT="0.8040890103635352"/>
<DICH_DATA CI_END="3.032697319684326" CI_START="0.6940612593880049" EFFECT_SIZE="1.4508196721311475" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.48182906743215864" LOG_CI_START="-0.15860219605804193" LOG_EFFECT_SIZE="0.16161343568705838" MODIFIED="2012-02-14 11:42:47 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="623" O_E="0.0" SE="0.3761924943600262" STUDY_ID="STD-Pollak-2007" TOTAL_1="122" TOTAL_2="59" VAR="0.14152079281281835" WEIGHT="0.4334302081486593"/>
<DICH_DATA CI_END="1.8360840296926577" CI_START="1.3454872537228346" EFFECT_SIZE="1.5717594150236638" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="193" LOG_CI_END="0.2638925531161746" LOG_CI_START="0.12887958789385867" LOG_EFFECT_SIZE="0.19638607050501666" MODIFIED="2012-10-03 14:40:00 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="579" O_E="0.0" SE="0.07930728409654485" STUDY_ID="STD-Ortega-2011" TOTAL_1="924" TOTAL_2="919" VAR="0.006289645310770075" WEIGHT="7.7777123754711965"/>
<DICH_DATA CI_END="4.322321894176437" CI_START="1.0965113068646202" EFFECT_SIZE="2.1770334928229667" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="9" LOG_CI_END="0.6357171067533638" LOG_CI_START="0.0400131143387531" LOG_EFFECT_SIZE="0.33786511054605844" ORDER="111" O_E="0.0" SE="0.34991947392666206" STUDY_ID="STD-Kralikova-2002" TOTAL_1="209" TOTAL_2="105" VAR="0.12244363823311191" WEIGHT="0.48151196256819945"/>
<DICH_DATA CI_END="7.6815771425743335" CI_START="0.8136349976048579" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8854503963333015" LOG_CI_START="-0.08957037898922633" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="110" O_E="0.0" SE="0.5727320298551304" STUDY_ID="STD-Molyneux-2003" TOTAL_1="91" TOTAL_2="91" VAR="0.32802197802197797" WEIGHT="0.16075997474366255"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.986952364978265" CI_START="0.5747317596118325" DF="0" EFFECT_SIZE="1.0686274509803921" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="0.29818745549679826" LOG_CI_START="-0.24053480313938616" LOG_EFFECT_SIZE="0.028826326178706067" MODIFIED="2012-10-03 15:23:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="8" P_CHI2="1.0" P_Z="0.8338626130749921" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="109" WEIGHT="0.6692864254634114" Z="0.2097502384991418">
<NAME>Patch and inhaler</NAME>
<DICH_DATA CI_END="1.986952364978265" CI_START="0.5747317596118325" EFFECT_SIZE="1.0686274509803921" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.29818745549679826" LOG_CI_START="-0.24053480313938616" LOG_EFFECT_SIZE="0.028826326178706067" MODIFIED="2012-10-03 15:23:39 +0100" MODIFIED_BY="Lindsay Stead" ORDER="109" O_E="0.0" SE="0.31644812144108325" STUDY_ID="STD-Hand-2002" TOTAL_1="136" TOTAL_2="109" VAR="0.10013941356359057" WEIGHT="0.6692864254634114"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.311666379724095" CI_START="1.0064243785295333" DF="0" EFFECT_SIZE="1.8256346233874323" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="9" I2="0.0" ID="CMP-001.01.09" LOG_CI_END="0.5200465790963031" LOG_CI_START="0.002781148105786916" LOG_EFFECT_SIZE="0.261413863601045" MODIFIED="2012-10-03 15:23:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="9" P_CHI2="1.0" P_Z="0.047586786701920306" STUDIES="1" TAU2="0.0" TOTAL_1="267" TOTAL_2="41" WEIGHT="0.627120485891268" Z="1.9810400116489066">
<NAME>Patch and lozenge</NAME>
<DICH_DATA CI_END="3.311666379724095" CI_START="1.0064243785295333" EFFECT_SIZE="1.8256346233874323" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="9" LOG_CI_END="0.5200465790963031" LOG_CI_START="0.002781148105786916" LOG_EFFECT_SIZE="0.261413863601045" MODIFIED="2012-10-03 15:23:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="603" O_E="0.0" SE="0.30384427466900793" STUDY_ID="STD-Piper-2009" TOTAL_1="267" TOTAL_2="41" VAR="0.09232134324913552" WEIGHT="0.627120485891268"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-10-03 15:53:33 +0100" MODIFIED_BY="L S" NO="2">
<NAME>Subgroup: Definition of abstinence</NAME>
<DICH_OUTCOME CHI2="91.04835096754316" CI_END="1.599047370272176" CI_START="1.3955853254401214" CI_STUDY="95" CI_TOTAL="95" DF="55" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4938564337430371" ESTIMABLE="YES" EVENTS_1="1732" EVENTS_2="1196" I2="39.592535816923956" I2_Q="88.12233741442849" ID="CMP-002.01" LOG_CI_END="0.20386132950176103" LOG_CI_START="0.14475639419977204" LOG_EFFECT_SIZE="0.17430886185076655" METHOD="MH" MODIFIED="2012-10-03 15:53:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.001609314740238732" P_Q="1.3640074020604409E-5" P_Z="6.538423525183016E-31" Q="25.257494716546972" RANDOM="NO" SCALE="9.915828890600691" SORT_BY="EFFECT_SIZE" STUDIES="56" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10596" TOTAL_2="11985" WEIGHT="99.99999999999997" Z="11.560425188458792">
<NAME>Nicotine gum. Smoking cessation</NAME>
<GROUP_LABEL_1>Nicotine gum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="47.8664082047033" CI_END="1.5621124248056983" CI_START="1.3090841153927546" DF="31" EFFECT_SIZE="1.430012783778802" ESTIMABLE="YES" EVENTS_1="1007" EVENTS_2="760" I2="35.23641910329513" ID="CMP-002.01.01" LOG_CI_END="0.1937122867216424" LOG_CI_START="0.116967553103272" LOG_EFFECT_SIZE="0.1553399199124572" NO="1" P_CHI2="0.02710306307556376" P_Z="2.1156239339129374E-15" STUDIES="32" TAU2="0.0" TOTAL_1="6246" TOTAL_2="7491" WEIGHT="61.254377670118814" Z="7.934372406678697">
<NAME>Sustained 12m</NAME>
<DICH_DATA CI_END="5.2337006044292" CI_START="0.0477673483631121" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="134" O_E="0.0" SE="1.1981168018885897" STUDY_ID="STD-Niaura-1999" TOTAL_1="31" TOTAL_2="31" VAR="1.435483870967742" WEIGHT="0.17787936489426173"/>
<DICH_DATA CI_END="5.106444992004984" CI_START="0.06810951693167992" EFFECT_SIZE="0.5897435897435898" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.7081186579322872" LOG_CI_START="-1.1667921999500996" LOG_EFFECT_SIZE="-0.22933677100890631" ORDER="139" O_E="0.0" SE="1.101331918878542" STUDY_ID="STD-Schneider-1985B" TOTAL_1="13" TOTAL_2="23" VAR="1.2129319955406912" WEIGHT="0.19270264530211687"/>
<DICH_DATA CI_END="2.1484187548221616" CI_START="0.3773842535875269" EFFECT_SIZE="0.9004329004329005" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.33211893493424877" LOG_CI_START="-0.42321622479301435" LOG_EFFECT_SIZE="-0.04554864492938274" ORDER="123" O_E="0.0" SE="0.4436876117931363" STUDY_ID="STD-Harackiewicz-1988" TOTAL_1="99" TOTAL_2="52" VAR="0.19685869685869684" WEIGHT="0.8163602640511483"/>
<DICH_DATA CI_END="1.4411817402647455" CI_START="0.5631316900126799" EFFECT_SIZE="0.9008746355685131" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.1587187509855719" LOG_CI_START="-0.2493900322214436" LOG_EFFECT_SIZE="-0.04533564061793586" ORDER="122" O_E="0.0" SE="0.23972511942685867" STUDY_ID="STD-Hall-1996" TOTAL_1="98" TOTAL_2="103" VAR="0.05746813288422166" WEIGHT="2.4283630709942994"/>
<DICH_DATA CI_END="1.7885616742580424" CI_START="0.4637248589977451" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.25250392034639924" LOG_CI_START="-0.33373962216292735" LOG_EFFECT_SIZE="-0.04061785090826406" ORDER="136" O_E="0.0" SE="0.3443623588223159" STUDY_ID="STD-Richmond-1993" TOTAL_1="200" TOTAL_2="150" VAR="0.11858543417366944" WEIGHT="1.4230349191540939"/>
<DICH_DATA CI_END="1.6866842429902695" CI_START="0.5709226264033885" EFFECT_SIZE="0.9813084112149533" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.22703378776870237" LOG_CI_START="-0.2434227449992455" LOG_EFFECT_SIZE="-0.00819447861527157" ORDER="115" O_E="0.0" SE="0.27634849614528817" STUDY_ID="STD-Campbell-1991" TOTAL_1="107" TOTAL_2="105" VAR="0.07636849132176235" WEIGHT="1.885353457157576"/>
<DICH_DATA CI_END="1.5943886308104427" CI_START="0.6300188787817181" EFFECT_SIZE="1.0022449488650536" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="19" LOG_CI_END="0.20259418885732536" LOG_CI_START="-0.20064643653390796" LOG_EFFECT_SIZE="9.738761617086915E-4" ORDER="128" O_E="0.0" SE="0.2368655394280984" STUDY_ID="STD-Jensen-1991" TOTAL_1="211" TOTAL_2="82" VAR="0.05610528376856404" WEIGHT="2.43385110532797"/>
<DICH_DATA CI_END="1.4649325789876566" CI_START="0.731529381659314" EFFECT_SIZE="1.0352010547132497" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="111" LOG_CI_END="0.16581763749053177" LOG_CI_START="-0.13576822588009327" LOG_EFFECT_SIZE="0.015024705805219264" ORDER="113" O_E="0.0" SE="0.17715302901800556" STUDY_ID="STD-Br-Thor-Society-1983" TOTAL_1="410" TOTAL_2="1208" VAR="0.03138319569025432" WEIGHT="5.003269404411528"/>
<DICH_DATA CI_END="2.1977726928730594" CI_START="0.5924633768247419" EFFECT_SIZE="1.141095890410959" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.34198277301205143" LOG_CI_START="-0.227338490439388" LOG_EFFECT_SIZE="0.0573221412863317" ORDER="118" O_E="0.0" SE="0.3344221283370807" STUDY_ID="STD-Cooper-2005" TOTAL_1="146" TOTAL_2="147" VAR="0.11183815992150285" WEIGHT="1.3295420106431166"/>
<DICH_DATA CI_END="1.485983274795411" CI_START="0.9440549662841833" EFFECT_SIZE="1.184419642857143" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="112" LOG_CI_END="0.17201392133240373" LOG_CI_START="-0.02500271877507291" LOG_EFFECT_SIZE="0.07350560127866544" ORDER="130" O_E="0.0" SE="0.11572854964722892" STUDY_ID="STD-Killen-1990" TOTAL_1="600" TOTAL_2="617" VAR="0.013393097203451129" WEIGHT="9.822098045106317"/>
<DICH_DATA CI_END="1.7823920735615897" CI_START="0.8054121897023883" EFFECT_SIZE="1.1981486981486982" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.25100324215604675" LOG_CI_START="-0.09398180174569425" LOG_EFFECT_SIZE="0.07851072020517626" ORDER="117" O_E="0.0" SE="0.2026459224913915" STUDY_ID="STD-Clavel_x002d_Chapelon-1992" TOTAL_1="481" TOTAL_2="515" VAR="0.04106536990238705" WEIGHT="3.6079507325239715"/>
<DICH_DATA CI_END="2.808418875797395" CI_START="0.5224543870988805" EFFECT_SIZE="1.2113095238095237" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.44846188332970094" LOG_CI_START="-0.28195161965894905" LOG_EFFECT_SIZE="0.08325513183537596" ORDER="121" O_E="0.0" SE="0.42904850726068444" STUDY_ID="STD-Gilbert-1989" TOTAL_1="112" TOTAL_2="111" VAR="0.1840826215826216" WEIGHT="0.8040466359346"/>
<DICH_DATA CI_END="2.631581726997257" CI_START="0.5583097867724814" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.42021686211038434" LOG_CI_START="-0.25312475921023436" LOG_EFFECT_SIZE="0.08354605145007492" ORDER="129" O_E="0.0" SE="0.3955242014585124" STUDY_ID="STD-Killen-1984" TOTAL_1="44" TOTAL_2="20" VAR="0.15643939393939393" WEIGHT="0.7337523801888296"/>
<DICH_DATA CI_END="1.9666586390042697" CI_START="0.8154730132353284" EFFECT_SIZE="1.2663952962460425" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="33" LOG_CI_END="0.29372898418861887" LOG_CI_START="-0.08859040666160824" LOG_EFFECT_SIZE="0.10256928876350531" ORDER="143" O_E="0.0" SE="0.22457630269693016" STUDY_ID="STD-Ockene-1991" TOTAL_1="402" TOTAL_2="420" VAR="0.0504345157330232" WEIGHT="2.870739239278925"/>
<DICH_DATA CI_END="2.116689578474571" CI_START="0.7645244377176588" EFFECT_SIZE="1.272108843537415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="37" LOG_CI_END="0.32565717155714285" LOG_CI_START="-0.11660862798049704" LOG_EFFECT_SIZE="0.1045242717883229" ORDER="140" O_E="0.0" SE="0.25978911989942516" STUDY_ID="STD-Segnan-1991" TOTAL_1="294" TOTAL_2="629" VAR="0.0674903868181179" WEIGHT="2.096394075102686"/>
<DICH_DATA CI_END="2.102418926599776" CI_START="0.7765893032666391" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3227192575452336" LOG_CI_START="-0.10980859571666014" LOG_EFFECT_SIZE="0.10645533091428677" ORDER="142" O_E="0.0" SE="0.2540690020534404" STUDY_ID="STD-Zelman-1992" TOTAL_1="58" TOTAL_2="58" VAR="0.0645510578044311" WEIGHT="1.6009142840483557"/>
<DICH_DATA CI_END="4.765941874451098" CI_START="0.3680380540851699" EFFECT_SIZE="1.3244047619047619" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6781487413761358" LOG_CI_START="-0.4341072741939607" LOG_EFFECT_SIZE="0.12202073359108753" ORDER="133" O_E="0.0" SE="0.6533446893019474" STUDY_ID="STD-Niaura-1994" TOTAL_1="84" TOTAL_2="89" VAR="0.4268592830390583" WEIGHT="0.3454766855749823"/>
<DICH_DATA CI_END="2.1282902638036596" CI_START="0.8361335572587889" EFFECT_SIZE="1.3339920948616601" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.328030858290107" LOG_CI_START="-0.0777243463076554" LOG_EFFECT_SIZE="0.12515325599122584" ORDER="112" O_E="0.0" SE="0.2383426157013814" STUDY_ID="STD-Blondal-1989" TOTAL_1="92" TOTAL_2="90" VAR="0.056807202459376385" WEIGHT="1.9781749150878336"/>
<DICH_DATA CI_END="3.247959524638751" CI_START="0.6065321080428522" EFFECT_SIZE="1.4035639412997905" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5116106085200087" LOG_CI_START="-0.21714620390418088" LOG_EFFECT_SIZE="0.1472322023079139" ORDER="114" O_E="0.0" SE="0.4280753590223699" STUDY_ID="STD-Campbell-1987" TOTAL_1="424" TOTAL_2="412" VAR="0.18324851300213088" WEIGHT="0.8119469574599315"/>
<DICH_DATA CI_END="3.691402296267391" CI_START="0.6095244623635621" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5671913780399481" LOG_CI_START="-0.21500885992858565" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="138" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-Schneider-1985A" TOTAL_1="30" TOTAL_2="30" VAR="0.21111111111111114" WEIGHT="0.5336380946827852"/>
<DICH_DATA CI_END="2.078053930950937" CI_START="1.135942042364552" EFFECT_SIZE="1.5364077669902914" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="50" LOG_CI_END="0.3176568144485229" LOG_CI_START="0.055356173519918124" LOG_EFFECT_SIZE="0.18650649398422053" ORDER="135" O_E="0.0" SE="0.15407669489057554" STUDY_ID="STD-Pirie-1992" TOTAL_1="206" TOTAL_2="211" VAR="0.023739627908403504" WEIGHT="4.393662969810301"/>
<DICH_DATA CI_END="3.0608139772913443" CI_START="0.9364950419934288" EFFECT_SIZE="1.6930555555555555" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.48583693590546406" LOG_CI_START="-0.02849451753123709" LOG_EFFECT_SIZE="0.22867120918711345" ORDER="141" O_E="0.0" SE="0.3021208417304738" STUDY_ID="STD-Tonnesen-1988" TOTAL_1="60" TOTAL_2="53" VAR="0.09127700300793001" WEIGHT="1.133390643574057"/>
<DICH_DATA CI_END="3.1300417111171157" CI_START="1.067386158715058" EFFECT_SIZE="1.8278301886792452" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.49555012501842827" LOG_CI_START="0.02832156680872703" LOG_EFFECT_SIZE="0.26193584591357766" ORDER="125" O_E="0.0" SE="0.27445236791104227" STUDY_ID="STD-Hjalmarson-1984" TOTAL_1="106" TOTAL_2="100" VAR="0.0753241022519781" WEIGHT="1.464482538158582"/>
<DICH_DATA CI_END="4.563039307727768" CI_START="0.8050798740413305" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.6592542099639247" LOG_CI_START="-0.09416103002398857" LOG_EFFECT_SIZE="0.28254658996996806" ORDER="126" O_E="0.0" SE="0.44255984143448623" STUDY_ID="STD-Hughes-1989" TOTAL_1="210" TOTAL_2="105" VAR="0.19585921325051758" WEIGHT="0.7115174595770469"/>
<DICH_DATA CI_END="2.641674335804446" CI_START="1.4565130470266645" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="78" LOG_CI_END="0.42187927698755906" LOG_CI_START="0.1633143792666777" LOG_EFFECT_SIZE="0.2925968281271184" ORDER="137" O_E="0.0" SE="0.15188230083813165" STUDY_ID="STD-Russell-1983" TOTAL_1="729" TOTAL_2="1377" VAR="0.023068233307884725" WEIGHT="4.802742852145067"/>
<DICH_DATA CI_END="2.843419595821319" CI_START="1.3868203879402838" EFFECT_SIZE="1.9857774968394437" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="28" LOG_CI_END="0.45384095209413783" LOG_CI_START="0.14202021768646272" LOG_EFFECT_SIZE="0.2979305848903003" ORDER="131" O_E="0.0" SE="0.18316504292859753" STUDY_ID="STD-Llivina-1988" TOTAL_1="113" TOTAL_2="103" VAR="0.03354943295103498" WEIGHT="2.605603289469649"/>
<DICH_DATA CI_END="3.6414111243083065" CI_START="1.3428793600393683" EFFECT_SIZE="2.2113289760348582" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="17" LOG_CI_END="0.561269714621607" LOG_CI_START="0.1280369988023339" LOG_EFFECT_SIZE="0.34465335671197045" ORDER="120" O_E="0.0" SE="0.25448304180877096" STUDY_ID="STD-Garvey-2000" TOTAL_1="405" TOTAL_2="203" VAR="0.06476161856824468" WEIGHT="2.014308268580579"/>
<DICH_DATA CI_END="4.183776315605878" CI_START="1.3407548251623347" EFFECT_SIZE="2.3684210526315788" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="0.6215684570506804" LOG_CI_START="0.12734936859434903" LOG_EFFECT_SIZE="0.3744589128225147" ORDER="124" O_E="0.0" SE="0.29030673898319226" STUDY_ID="STD-Herrera-1995" TOTAL_1="76" TOTAL_2="78" VAR="0.08427800269905533" WEIGHT="1.1412000812696792"/>
<DICH_DATA CI_END="4.848340156021888" CI_START="1.232444187018039" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.6855930820123821" LOG_CI_START="0.09076726075338054" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="127" O_E="0.0" SE="0.34940363184284007" STUDY_ID="STD-Jarvis-1982" TOTAL_1="58" TOTAL_2="58" VAR="0.1220828979449669" WEIGHT="0.8004571420241778"/>
<DICH_DATA CI_END="6.940756990800773" CI_START="1.177115040228752" EFFECT_SIZE="2.8583333333333334" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="5" LOG_CI_END="0.8414068391867146" LOG_CI_START="0.07081890880357672" LOG_EFFECT_SIZE="0.45611287399514566" ORDER="119" O_E="0.0" SE="0.4526471647788296" STUDY_ID="STD-Fagerstrom-1984" TOTAL_1="96" TOTAL_2="49" VAR="0.20488945578231293" WEIGHT="0.5888420355120388"/>
<DICH_DATA CI_END="15.439929239254754" CI_START="0.7835721582188115" EFFECT_SIZE="3.4782608695652173" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.188645305645338" LOG_CI_START="-0.10592100369663676" LOG_EFFECT_SIZE="0.5413621509743507" ORDER="132" O_E="0.0" SE="0.7604346583140575" STUDY_ID="STD-Moolchan-2005" TOTAL_1="46" TOTAL_2="40" VAR="0.5782608695652174" WEIGHT="0.19028955314269858"/>
<DICH_DATA CI_END="10.383127352642541" CI_START="1.8071326338889435" EFFECT_SIZE="4.331707317073171" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="1.0163281808182514" LOG_CI_START="0.25699002862744214" LOG_EFFECT_SIZE="0.6366591047228467" ORDER="116" O_E="0.0" SE="0.44603898938135556" STUDY_ID="STD-Clavel-1985" TOTAL_1="205" TOTAL_2="222" VAR="0.198950780048341" WEIGHT="0.5123925499296064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.779193182452449" CI_END="3.5867375969154134" CI_START="2.1358218600036953" DF="7" EFFECT_SIZE="2.76778477587927" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="70" I2="45.22345894565596" ID="CMP-002.01.02" LOG_CI_END="0.5546996051732648" LOG_CI_START="0.32956502717502684" LOG_EFFECT_SIZE="0.4421323161741458" MODIFIED="2012-10-03 15:53:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.0776746277636805" P_Z="1.3801629661178664E-14" STUDIES="8" TAU2="0.0" TOTAL_1="2103" TOTAL_2="2084" WEIGHT="6.395436030921518" Z="7.698181450469009">
<NAME>Sustained 6m</NAME>
<DICH_DATA CI_END="2.3062603685392586" CI_START="0.40470386503207123" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.36290833601880523" LOG_CI_START="-0.39286264795811077" LOG_EFFECT_SIZE="-0.014977155969652801" ORDER="146" O_E="0.0" SE="0.4439436171147473" STUDY_ID="STD-Hughes-1990" TOTAL_1="59" TOTAL_2="19" VAR="0.19708593517692535" WEIGHT="0.6727488800488104"/>
<DICH_DATA CI_END="3.0527184886055982" CI_START="0.601296168019352" EFFECT_SIZE="1.3548387096774193" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.48468675697401153" LOG_CI_START="-0.22091156384675606" LOG_EFFECT_SIZE="0.13188759656362775" ORDER="149" O_E="0.0" SE="0.4144719464181376" STUDY_ID="STD-Page-1986" TOTAL_1="93" TOTAL_2="182" VAR="0.17178699436763953" WEIGHT="0.7820223714805907"/>
<DICH_DATA CI_END="4.7927472328753025" CI_START="0.978339288206984" EFFECT_SIZE="2.1653944020356235" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.6805845251190232" LOG_CI_START="-0.009510505700700772" LOG_EFFECT_SIZE="0.33553700970916117" ORDER="145" O_E="0.0" SE="0.40536523712900135" STUDY_ID="STD-Gross-1995" TOTAL_1="131" TOTAL_2="46" VAR="0.1643209754726515" WEIGHT="0.7899049763101114"/>
<DICH_DATA CI_END="5.720321996351251" CI_START="0.9630026289815542" EFFECT_SIZE="2.347058823529412" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.7574204758739058" LOG_CI_START="-0.016372527256957148" LOG_EFFECT_SIZE="0.37052397430847434" ORDER="144" O_E="0.0" SE="0.45452984037620925" STUDY_ID="STD-Garcia-1989" TOTAL_1="68" TOTAL_2="38" VAR="0.20659737579242224" WEIGHT="0.5705564534344244"/>
<DICH_DATA CI_END="6.386765392813436" CI_START="1.0584387533017163" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8052809633667104" LOG_CI_START="0.0246657325749255" LOG_EFFECT_SIZE="0.414973347970818" ORDER="148" O_E="0.0" SE="0.45853725067480644" STUDY_ID="STD-Nakamura-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.2102564102564103" WEIGHT="0.4446984122356543"/>
<DICH_DATA CI_END="5.687760780817803" CI_START="1.2441491632011088" EFFECT_SIZE="2.66015466015466" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.7549413222935226" LOG_CI_START="0.09487245179503367" LOG_EFFECT_SIZE="0.42490688704427815" MODIFIED="2012-10-03 15:53:32 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="614" O_E="0.0" SE="0.38772772192441723" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_" TOTAL_1="819" TOTAL_2="817" VAR="0.1503327863486982" WEIGHT="0.8014356959875326"/>
<DICH_DATA CI_END="12.85331251038475" CI_START="0.8550075403053737" EFFECT_SIZE="3.315068493150685" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.1090150669349643" LOG_CI_START="-0.06803005521501355" LOG_EFFECT_SIZE="0.5204925058599754" ORDER="147" O_E="0.0" SE="0.6914021312182197" STUDY_ID="STD-Malcolm-1980" TOTAL_1="73" TOTAL_2="121" VAR="0.4780369070530963" WEIGHT="0.20080196346310988"/>
<DICH_DATA CI_END="6.50670193022576" CI_START="2.728382244752736" EFFECT_SIZE="4.213403614457832" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="24" LOG_CI_END="0.8133609123089041" LOG_CI_START="0.4359052146492433" LOG_EFFECT_SIZE="0.6246330634790737" MODIFIED="2012-10-03 15:53:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="615" O_E="0.0" SE="0.2217193452411218" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_" TOTAL_1="830" TOTAL_2="831" VAR="0.049159468054151764" WEIGHT="2.1332672779612847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.304913548334328" CI_END="1.5460950285610642" CI_START="1.1151931317582267" DF="7" EFFECT_SIZE="1.3130858909061653" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="197" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.18923618370349266" LOG_CI_START="0.04735008603308784" LOG_EFFECT_SIZE="0.11829313486829024" NO="3" P_CHI2="0.7440635256375314" P_Z="0.0010826506022138215" STUDIES="8" TAU2="0.0" TOTAL_1="1171" TOTAL_2="1330" WEIGHT="17.366771360570414" Z="3.2681184100047087">
<NAME>PP/uncertain 12m</NAME>
<DICH_DATA CI_END="1.5563577448421877" CI_START="0.7903376452759279" EFFECT_SIZE="1.1090753424657533" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="40" LOG_CI_END="0.19210943118401463" LOG_CI_START="-0.10218733130102724" LOG_EFFECT_SIZE="0.04496104994149371" ORDER="155" O_E="0.0" SE="0.17287137507618275" STUDY_ID="STD-McGovern-1992" TOTAL_1="146" TOTAL_2="127" VAR="0.029884512320730257" WEIGHT="3.8051849486538036"/>
<DICH_DATA CI_END="3.1707363665085917" CI_START="0.4225351138657811" EFFECT_SIZE="1.1574746008708272" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.5011601337551542" LOG_CI_START="-0.3741371941119684" LOG_EFFECT_SIZE="0.06351146982159289" ORDER="156" O_E="0.0" SE="0.5141539831807991" STUDY_ID="STD-Nebot-1992" TOTAL_1="106" TOTAL_2="319" VAR="0.26435431842068147" WEIGHT="0.5767476819395121"/>
<DICH_DATA CI_END="1.6021401580365628" CI_START="0.9571701414032476" EFFECT_SIZE="1.2383540372670807" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="84" LOG_CI_END="0.20470050625464503" LOG_CI_START="-0.01901085751583178" LOG_EFFECT_SIZE="0.09284482436940662" ORDER="151" O_E="0.0" SE="0.13140916246788847" STUDY_ID="STD-Fortmann-1995" TOTAL_1="552" TOTAL_2="522" VAR="0.017268367980511908" WEIGHT="7.679618613982428"/>
<DICH_DATA CI_END="2.681155502451401" CI_START="0.6431234010669704" EFFECT_SIZE="1.3131313131313131" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.42832200305341434" LOG_CI_START="-0.19170568763484058" LOG_EFFECT_SIZE="0.11830815770928686" ORDER="154" O_E="0.0" SE="0.36420733469684907" STUDY_ID="STD-Huber-1988" TOTAL_1="54" TOTAL_2="60" VAR="0.13264698264698266" WEIGHT="0.926845111817469"/>
<DICH_DATA CI_END="2.5688705692797895" CI_START="0.7220233680433636" EFFECT_SIZE="1.361904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4097422231983706" LOG_CI_START="-0.14144874640812305" LOG_EFFECT_SIZE="0.13414673839512375" ORDER="157" O_E="0.0" SE="0.3237723039861576" STUDY_ID="STD-Villa-1999" TOTAL_1="21" TOTAL_2="26" VAR="0.10482850482850484" WEIGHT="0.7947801410169141"/>
<DICH_DATA CI_END="2.712769410117531" CI_START="0.7913564709479441" EFFECT_SIZE="1.4651851851851851" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4334128795818624" LOG_CI_START="-0.10162784204955344" LOG_EFFECT_SIZE="0.16589251876615446" ORDER="150" O_E="0.0" SE="0.31428556838058" STUDY_ID="STD-Fee-1982" TOTAL_1="180" TOTAL_2="172" VAR="0.09877541849230424" WEIGHT="1.3644155829957576"/>
<DICH_DATA CI_END="2.9681504720636167" CI_START="0.8415818958233378" EFFECT_SIZE="1.5804878048780489" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.4724859139689923" LOG_CI_START="-0.07490361566727656" LOG_EFFECT_SIZE="0.19879114915085785" ORDER="152" O_E="0.0" SE="0.32153931933021623" STUDY_ID="STD-Hall-1985" TOTAL_1="41" TOTAL_2="36" VAR="0.10338753387533876" WEIGHT="0.9471498650213936"/>
<DICH_DATA CI_END="3.5225719722255557" CI_START="1.1957150368524538" EFFECT_SIZE="2.052313883299799" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.5468598752579272" LOG_CI_START="0.07762769079924374" LOG_EFFECT_SIZE="0.31224378302858546" ORDER="153" O_E="0.0" SE="0.2756293078878044" STUDY_ID="STD-Hall-1987" TOTAL_1="71" TOTAL_2="68" VAR="0.07597151536671005" WEIGHT="1.272029415143138"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.806257897060353" CI_END="1.682222968541061" CI_START="1.199711200819852" DF="7" EFFECT_SIZE="1.4206272338777448" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="169" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.22588355839967847" LOG_CI_START="0.0790767135598162" LOG_EFFECT_SIZE="0.15248013597974736" MODIFIED="2012-08-14 13:21:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="4" P_CHI2="0.6835928398535593" P_Z="4.672901567745598E-5" STUDIES="8" TAU2="0.0" TOTAL_1="1076" TOTAL_2="1080" WEIGHT="14.983414938389231" Z="4.0714119999522955">
<NAME>PP/uncertain 6m</NAME>
<DICH_DATA CI_END="2.6472555462718894" CI_START="0.4986090900333425" EFFECT_SIZE="1.1488888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4227958668694923" LOG_CI_START="-0.3022398082322946" LOG_EFFECT_SIZE="0.06027802931859881" MODIFIED="2012-08-14 13:21:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="610" O_E="0.0" SE="0.4258895445392638" STUDY_ID="STD-Oncken-2008" TOTAL_1="100" TOTAL_2="94" VAR="0.1813819041478616" WEIGHT="0.8252135484785339"/>
<DICH_DATA CI_END="2.9759103499496" CI_START="0.5044612640758793" EFFECT_SIZE="1.2252475247524752" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4736198438400234" LOG_CI_START="-0.29717217619409586" LOG_EFFECT_SIZE="0.08822383382296375" ORDER="161" O_E="0.0" SE="0.45276704805007617" STUDY_ID="STD-Jamrozik-1984" TOTAL_1="101" TOTAL_2="99" VAR="0.20499799979997999" WEIGHT="0.7186326341728174"/>
<DICH_DATA CI_END="1.8384227647603988" CI_START="0.8616023404348749" EFFECT_SIZE="1.2585663895187704" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="42" LOG_CI_END="0.2644453891448034" LOG_CI_START="-0.06469313000189131" LOG_EFFECT_SIZE="0.09987612957145608" ORDER="158" O_E="0.0" SE="0.19333759540871465" STUDY_ID="STD-Ahluwalia-2006" TOTAL_1="378" TOTAL_2="377" VAR="0.03737942579842384" WEIGHT="3.740414300743443"/>
<DICH_DATA CI_END="1.899800104778201" CI_START="0.8955275068880978" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.27870790729028233" LOG_CI_START="-0.04792106988614322" LOG_EFFECT_SIZE="0.11539341870206957" ORDER="160" O_E="0.0" SE="0.19186347803294543" STUDY_ID="STD-Fagerstrom-1982" TOTAL_1="50" TOTAL_2="50" VAR="0.036811594202898534" WEIGHT="2.0456126962840098"/>
<DICH_DATA CI_END="2.214103369188008" CI_START="0.8173356122679534" EFFECT_SIZE="1.3452380952380953" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.34519789279382823" LOG_CI_START="-0.08759957795075202" LOG_EFFECT_SIZE="0.1287991574215381" ORDER="163" O_E="0.0" SE="0.2542273766973985" STUDY_ID="STD-Puska-1979" TOTAL_1="116" TOTAL_2="113" VAR="0.06463155906244096" WEIGHT="1.8922014536350287"/>
<DICH_DATA CI_END="2.3736710298145747" CI_START="0.8553867175906704" EFFECT_SIZE="1.4249233912155261" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.37542052934643694" LOG_CI_START="-0.0678374977334798" LOG_EFFECT_SIZE="0.15379151580647857" ORDER="162" O_E="0.0" SE="0.26037195926936413" STUDY_ID="STD-Mori-1992" TOTAL_1="178" TOTAL_2="186" VAR="0.06779355717376741" WEIGHT="1.9136692113349698"/>
<DICH_DATA CI_END="2.103496146183185" CI_START="1.133452288226358" EFFECT_SIZE="1.5440895440895441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="37" LOG_CI_END="0.32294172068250876" LOG_CI_START="0.05440324356608751" LOG_EFFECT_SIZE="0.1886724821242981" ORDER="159" O_E="0.0" SE="0.15774083074508602" STUDY_ID="STD-Areechon-1988" TOTAL_1="99" TOTAL_2="101" VAR="0.024882169684149878" WEIGHT="3.257860568038404"/>
<DICH_DATA CI_END="6.610228606916726" CI_START="1.3759720864046632" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.8202164793049521" LOG_CI_START="0.13860962369354227" LOG_EFFECT_SIZE="0.47941305149924723" ORDER="164" O_E="0.0" SE="0.40037924099449274" STUDY_ID="STD-Roto-1987" TOTAL_1="54" TOTAL_2="60" VAR="0.1603035366193261" WEIGHT="0.5898105257020257"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.68000725044098" CI_END="1.7807101432298271" CI_START="1.5150124756752974" CI_STUDY="95" CI_TOTAL="95" DF="42" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6424975137134101" ESTIMABLE="YES" EVENTS_1="1873" EVENTS_2="766" I2="18.730661556473333" I2_Q="26.6940028473761" ID="CMP-002.02" LOG_CI_END="0.25059323252295695" LOG_CI_START="0.1804162091384105" LOG_EFFECT_SIZE="0.21550472083068373" METHOD="MH" MODIFIED="2012-08-22 14:02:46 +0100" MODIFIED_BY="L S" NO="2" P_CHI2="0.14548997719302603" P_Q="0.25165440097380365" P_Z="2.2541678570241053E-33" Q="4.092434611801224" RANDOM="NO" SCALE="8.63109980429522" SORT_BY="STUDY" STUDIES="43" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11746" TOTAL_2="7840" WEIGHT="100.0" Z="12.037600654903555">
<NAME>Nicotine patch: Smoking cessation</NAME>
<GROUP_LABEL_1>Nicotine gum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="27.430280216135724" CI_END="1.7015263935775" CI_START="1.3468063748562127" DF="20" EFFECT_SIZE="1.5138119413772235" ESTIMABLE="YES" EVENTS_1="921" EVENTS_2="379" I2="27.087875725618357" ID="CMP-002.02.01" LOG_CI_END="0.23083869013248254" LOG_CI_START="0.1293051633726621" LOG_EFFECT_SIZE="0.18007192675257233" NO="1" P_CHI2="0.12358664471308023" P_Z="3.5994467012921107E-12" STUDIES="21" TAU2="0.0" TOTAL_1="6796" TOTAL_2="4132" WEIGHT="50.52332582191057" Z="6.952077847086905">
<NAME>Sustained 12m</NAME>
<DICH_DATA CI_END="3.0985703046290562" CI_START="0.7554774524569775" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4911613544686127" LOG_CI_START="-0.12177849283341506" LOG_EFFECT_SIZE="0.1846914308175988" ORDER="165" O_E="0.0" SE="0.3600439004063886" STUDY_ID="STD-Abelin-1989" TOTAL_1="100" TOTAL_2="99" VAR="0.12963161021984548" WEIGHT="1.310992528878036"/>
<DICH_DATA CI_END="2.5728675834146997" CI_START="0.8294790996379331" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4104174351523806" LOG_CI_START="-0.08119455240787828" LOG_EFFECT_SIZE="0.16461144137225117" ORDER="167" O_E="0.0" SE="0.28877531501148174" STUDY_ID="STD-Campbell-1996" TOTAL_1="115" TOTAL_2="119" VAR="0.08339118255998051" WEIGHT="1.981488299912026"/>
<DICH_DATA CI_END="1.8113081221041267" CI_START="1.1243557445017534" EFFECT_SIZE="1.427079077048801" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="71" LOG_CI_END="0.25799233454774956" LOG_CI_START="0.050903743110311706" LOG_EFFECT_SIZE="0.1544480388290306" ORDER="166" O_E="0.0" SE="0.12164486371541124" STUDY_ID="STD-CEASE-1999" TOTAL_1="2861" TOTAL_2="714" VAR="0.014797472868340973" WEIGHT="13.475992740831872"/>
<DICH_DATA CI_END="3.788507155734091" CI_START="0.775708053172369" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.578468111881843" LOG_CI_START="-0.1103016998151071" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="168" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Cinciripini-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.16369047619047616" WEIGHT="0.8300966330577746"/>
<DICH_DATA CI_END="2.8436645298032195" CI_START="0.8678996274243392" EFFECT_SIZE="1.570991847826087" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.45387836088728595" LOG_CI_START="-0.06153049806810565" LOG_EFFECT_SIZE="0.19617393140959016" ORDER="169" O_E="0.0" SE="0.30275371506539595" STUDY_ID="STD-Daughton-1998" TOTAL_1="184" TOTAL_2="185" VAR="0.09165981198589895" WEIGHT="1.8922218255687868"/>
<DICH_DATA CI_END="16.118289185653534" CI_START="0.760006217713441" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2073189433834552" LOG_CI_START="-0.11918285468290388" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="170" O_E="0.0" SE="0.7791937224739794" STUDY_ID="STD-Ehrsam-1991" TOTAL_1="56" TOTAL_2="56" VAR="0.607142857142857" WEIGHT="0.23717046658793559"/>
<DICH_DATA CI_END="3.393314017187208" CI_START="0.5239060602034752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5306240511043927" LOG_CI_START="-0.28074657788779284" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="171" O_E="0.0" SE="0.4766031238193982" STUDY_ID="STD-Hurt-1990" TOTAL_1="31" TOTAL_2="31" VAR="0.2271505376344086" WEIGHT="0.7115113997638067"/>
<DICH_DATA CI_END="3.2899905062299095" CI_START="1.1453425421228474" EFFECT_SIZE="1.9411764705882353" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5171946447287246" LOG_CI_START="0.05893539227050256" LOG_EFFECT_SIZE="0.2880650184996135" ORDER="172" O_E="0.0" SE="0.26918375331384387" STUDY_ID="STD-Hurt-1994" TOTAL_1="120" TOTAL_2="120" VAR="0.07245989304812835" WEIGHT="2.0159489659974525"/>
<DICH_DATA CI_END="2.014402311568503" CI_START="1.025628178913287" EFFECT_SIZE="1.437368350289069" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.30414621112601403" LOG_CI_START="0.010989944486001551" LOG_EFFECT_SIZE="0.15756807780600784" ORDER="173" O_E="0.0" SE="0.17220144217126704" STUDY_ID="STD-ICRF-1994" TOTAL_1="842" TOTAL_2="844" VAR="0.02965333668586423" WEIGHT="6.277561827967506"/>
<DICH_DATA CI_END="3.6638765871680388" CI_START="0.8345587993406903" EFFECT_SIZE="1.7486338797814207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.563940836607552" LOG_CI_START="-0.078543059428599" LOG_EFFECT_SIZE="0.2426988885894765" ORDER="174" O_E="0.0" SE="0.37739822087821245" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.14242941712204005" WEIGHT="1.2891741203641252"/>
<DICH_DATA CI_END="1.3007062234518165" CI_START="0.5135491607972068" EFFECT_SIZE="0.8172983479105929" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.11417921820578969" LOG_CI_START="-0.2894179761348311" LOG_EFFECT_SIZE="-0.08761937896452072" ORDER="175" O_E="0.0" SE="0.23707498979401342" STUDY_ID="STD-Joseph-1996" TOTAL_1="294" TOTAL_2="290" VAR="0.05620455078583157" WEIGHT="4.178911132174413"/>
<DICH_DATA CI_END="1.9175853297600345" CI_START="0.6255505122219942" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2827546985242227" LOG_CI_START="-0.20373761595687537" LOG_EFFECT_SIZE="0.039508541283673655" ORDER="176" O_E="0.0" SE="0.28576799370199224" STUDY_ID="STD-Killen-1997" TOTAL_1="212" TOTAL_2="212" VAR="0.08166334622446189" WEIGHT="2.4902898991733236"/>
<DICH_DATA CI_END="1.9396324884607696" CI_START="0.46529433043070706" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.2877194498511332" LOG_CI_START="-0.3322722392734377" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="177" O_E="0.0" SE="0.3641861872001304" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="150" TOTAL_2="75" VAR="0.13263157894736843" WEIGHT="1.5811364439195705"/>
<DICH_DATA CI_END="1.8298847059469658" CI_START="0.6989802602453846" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.2624237273542518" LOG_CI_START="-0.15553508890031958" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="178" O_E="0.0" SE="0.24551107759744292" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="0.06027568922305764" WEIGHT="2.4902898991733236"/>
<DICH_DATA CI_END="4.551776484470188" CI_START="0.8367371518627194" EFFECT_SIZE="1.9515738498789346" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6581809278280224" LOG_CI_START="-0.07741094753064312" LOG_EFFECT_SIZE="0.2903849901486896" ORDER="179" O_E="0.0" SE="0.43209030882418825" STUDY_ID="STD-Prapavessis-2007" TOTAL_1="59" TOTAL_2="62" VAR="0.18670203497978238" WEIGHT="0.8095157248001438"/>
<DICH_DATA CI_END="3.7386899573042225" CI_START="1.1327257863865658" EFFECT_SIZE="2.0578898225957047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5727194514032413" LOG_CI_START="0.05412478729254229" LOG_EFFECT_SIZE="0.31342211934789177" ORDER="180" O_E="0.0" SE="0.30462507278361334" STUDY_ID="STD-Richmond-1994" TOTAL_1="153" TOTAL_2="152" VAR="0.09279643496842171" WEIGHT="1.665636522725764"/>
<DICH_DATA CI_END="5.191155779737516" CI_START="1.3541372015357949" EFFECT_SIZE="2.651327433628319" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7152640616789412" LOG_CI_START="0.1316626694090771" LOG_EFFECT_SIZE="0.42346336554400915" ORDER="181" O_E="0.0" SE="0.3428103466928011" STUDY_ID="STD-Sachs-1993" TOTAL_1="113" TOTAL_2="107" VAR="0.11751893379963846" WEIGHT="1.2181937602016693"/>
<DICH_DATA CI_END="3.2993612898922677" CI_START="1.2444698588327163" EFFECT_SIZE="2.026315789473684" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="19" LOG_CI_END="0.5184298746891502" LOG_CI_START="0.09498438242219312" LOG_EFFECT_SIZE="0.30670712855567167" ORDER="182" O_E="0.0" SE="0.24873397824660265" STUDY_ID="STD-Stapleton-1995" TOTAL_1="800" TOTAL_2="400" VAR="0.061868591934381406" WEIGHT="3.0041592434471838"/>
<DICH_DATA CI_END="9.428558561934224" CI_START="1.673646214316064" EFFECT_SIZE="3.972413793103448" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9744453028701352" LOG_CI_START="0.22366365950633915" LOG_EFFECT_SIZE="0.5990544811882371" ORDER="183" O_E="0.0" SE="0.44101285374096627" STUDY_ID="STD-Tonnesen-1991" TOTAL_1="145" TOTAL_2="144" VAR="0.19449233716475092" WEIGHT="0.7139733769256192"/>
<DICH_DATA CI_END="21.316258689645682" CI_START="1.043519004284947" EFFECT_SIZE="4.716346153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.328710982107621" LOG_CI_START="0.018500362726752817" LOG_EFFECT_SIZE="0.6736056724171869" ORDER="184" O_E="0.0" SE="0.7696242034714872" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="104" TOTAL_2="109" VAR="0.5923214145691211" WEIGHT="0.23160308474314836"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" ORDER="185" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="2.117457925697089"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.754430859314102" CI_END="2.091540566795779" CI_START="1.484695930286021" DF="8" EFFECT_SIZE="1.7621866437894174" ESTIMABLE="YES" EVENTS_1="470" EVENTS_2="163" I2="31.94055845195708" ID="CMP-002.02.02" LOG_CI_END="0.32046629242355723" LOG_CI_START="0.17163751808376107" LOG_EFFECT_SIZE="0.2460519052536592" MODIFIED="2012-08-22 14:02:46 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.1625015344694466" P_Z="9.13342095331412E-11" STUDIES="9" TAU2="0.0" TOTAL_1="2739" TOTAL_2="1901" WEIGHT="22.743823629047665" Z="6.480640249359111">
<NAME>Sustained 6m</NAME>
<DICH_DATA CI_END="2.361530435285525" CI_START="0.9005753554279192" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.37319354711423586" LOG_CI_START="-0.04547994183689675" LOG_EFFECT_SIZE="0.16385680263866959" ORDER="186" O_E="0.0" SE="0.24593087987708992" STUDY_ID="STD-Ahluwalia-1998" TOTAL_1="205" TOTAL_2="205" VAR="0.06048199767711963" WEIGHT="2.846045599055227"/>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-08-14 13:34:52 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="645" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="4.707269070183408"/>
<DICH_DATA CI_END="9.275880948360145" CI_START="1.27126435723578" EFFECT_SIZE="3.4339622641509435" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.9673551660329998" LOG_CI_START="0.1042358707355719" LOG_EFFECT_SIZE="0.5357955183842857" ORDER="187" O_E="0.0" SE="0.507000546567127" STUDY_ID="STD-Daughton-1991" TOTAL_1="106" TOTAL_2="52" VAR="0.25704955421936554" WEIGHT="0.6364574546410423"/>
<DICH_DATA CI_END="3.6866872656583496" CI_START="1.1538560077024487" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5666362988322253" LOG_CI_START="0.06215161561170004" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="188" O_E="0.0" SE="0.2963368001631935" STUDY_ID="STD-Davidson-1998" TOTAL_1="401" TOTAL_2="401" VAR="0.08781549913096048" WEIGHT="1.8973637327034847"/>
<DICH_DATA CI_END="2.358871489270788" CI_START="1.1945432704943428" EFFECT_SIZE="1.678622668579627" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="34" LOG_CI_END="0.3727042812752382" LOG_CI_START="0.07720188602106627" LOG_EFFECT_SIZE="0.22495308364815225" ORDER="189" O_E="0.0" SE="0.17357956973274816" STUDY_ID="STD-Hughes-1999" TOTAL_1="779" TOTAL_2="260" VAR="0.030129867028605983" WEIGHT="6.045906619873015"/>
<DICH_DATA CI_END="3.204629081127771" CI_START="0.6457386936581349" EFFECT_SIZE="1.4385245901639345" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5057777694736735" LOG_CI_START="-0.18994318921948414" LOG_EFFECT_SIZE="0.15791729012709468" ORDER="190" O_E="0.0" SE="0.4086699350106484" STUDY_ID="STD-Hughes-2003" TOTAL_1="61" TOTAL_2="54" VAR="0.1670111157816076" WEIGHT="1.0064277190861963"/>
<DICH_DATA CI_END="2.6170951223873518" CI_START="1.2476508655425136" EFFECT_SIZE="1.8069922508560101" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="31" LOG_CI_END="0.4178195080342886" LOG_CI_START="0.09609307222018122" LOG_EFFECT_SIZE="0.25695629012723487" ORDER="191" O_E="0.0" SE="0.18898370096874859" STUDY_ID="STD-TNSG-1991" TOTAL_1="537" TOTAL_2="271" VAR="0.03571483923184539" WEIGHT="4.886357372882876"/>
<DICH_DATA CI_END="34.51060023583957" CI_START="1.9508246278682124" EFFECT_SIZE="8.205128205128204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5379525129526281" LOG_CI_START="0.2902182296341853" LOG_EFFECT_SIZE="0.9140853712934067" ORDER="192" O_E="0.0" SE="0.7329252944055672" STUDY_ID="STD-Westman-1993" TOTAL_1="78" TOTAL_2="80" VAR="0.5371794871794873" WEIGHT="0.23416830878302503"/>
<DICH_DATA CI_END="9.51135034004292" CI_START="1.1889010697860327" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9782421787248091" LOG_CI_START="0.07514571783689675" LOG_EFFECT_SIZE="0.5266939482808529" ORDER="193" O_E="0.0" SE="0.5304833315251388" STUDY_ID="STD-Wong-1999" TOTAL_1="51" TOTAL_2="49" VAR="0.28141256502601036" WEIGHT="0.4838277518393886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.040532862855514" CI_END="2.0533816870171853" CI_START="1.4587663179179258" DF="5" EFFECT_SIZE="1.7307235604943263" ESTIMABLE="YES" EVENTS_1="303" EVENTS_2="168" I2="0.8041384504048577" ID="CMP-002.02.03" LOG_CI_END="0.31246968446951323" LOG_CI_START="0.16398572714567983" LOG_EFFECT_SIZE="0.2382277058075965" NO="3" P_CHI2="0.4109537610361571" P_Z="3.1924261611337393E-10" STUDIES="6" TAU2="0.0" TOTAL_1="1421" TOTAL_2="1161" WEIGHT="19.71393375140357" Z="6.289133613056621">
<NAME>PP/uncertain 12m</NAME>
<DICH_DATA CI_END="2.8593078037343456" CI_START="0.7422768702931712" EFFECT_SIZE="1.4568452380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.45626090956152343" LOG_CI_START="-0.12943407206289823" LOG_EFFECT_SIZE="0.1634134187493126" ORDER="194" O_E="0.0" SE="0.34404013144310264" STUDY_ID="STD-Buchkremer-1988" TOTAL_1="42" TOTAL_2="89" VAR="0.11836361204338733" WEIGHT="1.2166301797487993"/>
<DICH_DATA CI_END="3.103911528273855" CI_START="0.6721904713072535" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49190933393600517" LOG_CI_START="-0.1725076482009813" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="195" O_E="0.0" SE="0.39028182422437036" STUDY_ID="STD-Glavas-2003a" TOTAL_1="56" TOTAL_2="56" VAR="0.15231990231990233" WEIGHT="1.06726709964571"/>
<DICH_DATA CI_END="3.9419707258706516" CI_START="1.2752972552091766" EFFECT_SIZE="2.242138364779874" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="14" LOG_CI_END="0.5957133947683748" LOG_CI_START="0.10561142496649092" LOG_EFFECT_SIZE="0.35066240986743286" ORDER="196" O_E="0.0" SE="0.28788832310550383" STUDY_ID="STD-Hays-1999" TOTAL_1="636" TOTAL_2="322" VAR="0.08287968658049898" WEIGHT="2.204348470249456"/>
<DICH_DATA CI_END="1.9414129420303619" CI_START="1.310754497312224" EFFECT_SIZE="1.5952165197572563" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="122" LOG_CI_END="0.2881179204326567" LOG_CI_START="0.1175213564903053" LOG_EFFECT_SIZE="0.20281963846148102" ORDER="197" O_E="0.0" SE="0.10020926612634813" STUDY_ID="STD-Otero-2006" TOTAL_1="597" TOTAL_2="602" VAR="0.010041897017581264" WEIGHT="14.407067359020601"/>
<DICH_DATA CI_END="10.644319166426266" CI_START="1.3211272398102434" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0271178882524812" LOG_CI_START="0.12094464720295672" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="198" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Paoletti-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.2833333333333333" WEIGHT="0.47434093317587117"/>
<DICH_DATA CI_END="10.709518607104284" CI_START="0.9561587570525513" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0297699497322355" LOG_CI_START="-0.01946999309242347" LOG_EFFECT_SIZE="0.505149978319906" ORDER="199" O_E="0.0" SE="0.6163287362366865" STUDY_ID="STD-Perng-1998" TOTAL_1="30" TOTAL_2="32" VAR="0.3798611111111111" WEIGHT="0.3442797095631323"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.615202089390876" CI_END="2.5829623442418588" CI_START="1.4468335630671194" DF="6" EFFECT_SIZE="1.9331623345667708" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="56" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="0.4121180748503678" LOG_CI_START="0.16041857479636767" LOG_EFFECT_SIZE="0.2862683248233677" MODIFIED="2012-02-07 13:39:25 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="4" P_CHI2="0.7285848650304126" P_Z="8.261325010051367E-6" STUDIES="7" TAU2="0.0" TOTAL_1="790" TOTAL_2="646" WEIGHT="7.018916797638191" Z="4.458297346224684">
<NAME>PP/uncertain 6m</NAME>
<DICH_DATA CI_END="3.4000401052481815" CI_START="0.8169838271878318" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5314840398026245" LOG_CI_START="-0.08778654056991181" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="200" O_E="0.0" SE="0.3637626043496394" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="44" VAR="0.1323232323232323" WEIGHT="1.06726709964571"/>
<DICH_DATA CI_END="7.237905645439162" CI_START="0.8039754134848986" EFFECT_SIZE="2.412280701754386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8596129172728425" LOG_CI_START="-0.09475723228526235" LOG_EFFECT_SIZE="0.3824278424937901" ORDER="201" O_E="0.0" SE="0.5606017500588621" STUDY_ID="STD-Fiore-1994B" TOTAL_1="57" TOTAL_2="55" VAR="0.314274322169059" WEIGHT="0.4828113069825831"/>
<DICH_DATA CI_END="4.390778670369073" CI_START="1.3301234738135557" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6425415458131081" LOG_CI_START="0.12389195788955437" LOG_EFFECT_SIZE="0.38321675185133125" ORDER="202" O_E="0.0" SE="0.3046573353031615" STUDY_ID="STD-Glavas-2003b" TOTAL_1="80" TOTAL_2="80" VAR="0.09281609195402299" WEIGHT="1.4230227995276135"/>
<DICH_DATA CI_END="4.843896772402742" CI_START="0.5969505892682352" EFFECT_SIZE="1.7004608294930876" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6851948793815098" LOG_CI_START="-0.2240616147604481" LOG_EFFECT_SIZE="0.23056663231053087" ORDER="203" O_E="0.0" SE="0.5341017655512216" STUDY_ID="STD-Lewis-1998" TOTAL_1="62" TOTAL_2="123" VAR="0.28526469596493204" WEIGHT="0.5563890945900759"/>
<DICH_DATA CI_END="22.85043813806692" CI_START="1.2265708644863083" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3588945317196774" LOG_CI_START="0.0886926444024243" LOG_EFFECT_SIZE="0.723793588061051" ORDER="204" O_E="0.0" SE="0.7461228762109019" STUDY_ID="STD-Moolchan-2005" TOTAL_1="34" TOTAL_2="40" VAR="0.5566993464052288" WEIGHT="0.21794042875648137"/>
<DICH_DATA CI_END="3.0007141337297876" CI_START="0.8411651795025185" EFFECT_SIZE="1.588740458015267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="8" LOG_CI_END="0.4772246238629811" LOG_CI_START="-0.07511871347371944" LOG_EFFECT_SIZE="0.20105295519463082" MODIFIED="2012-02-07 13:39:25 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="604" O_E="0.0" SE="0.3244492104951934" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1052672901909543" WEIGHT="1.6625729029040568"/>
<DICH_DATA CI_END="2.9427867387446707" CI_START="0.7847299161094201" EFFECT_SIZE="1.5196357427433125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.46875879028775475" LOG_CI_START="-0.10527979054919413" LOG_EFFECT_SIZE="0.18173949986928026" ORDER="205" O_E="0.0" SE="0.33719310392042656" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="251" TOTAL_2="267" VAR="0.11369918933149159" WEIGHT="1.6089131652316713"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-08-23 10:21:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3">
<NAME>Subgroup: Level of behavioural support</NAME>
<DICH_OUTCOME CHI2="90.90269972514197" CI_END="1.608390585220009" CI_START="1.4019812527550837" CI_STUDY="95" CI_TOTAL="95" DF="54" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5016435820747314" ESTIMABLE="YES" EVENTS_1="1699" EVENTS_2="1167" I2="40.595823706801724" I2_Q="72.82781180721946" ID="CMP-003.01" LOG_CI_END="0.2063915222778237" LOG_CI_START="0.14674220629864704" LOG_EFFECT_SIZE="0.17656686428823537" METHOD="MH" MODIFIED="2012-02-10 15:59:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.0012467371009445838" P_Q="0.025217158128090333" P_Z="3.964512433459277E-31" Q="7.360467202017192" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="55" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10194" TOTAL_2="11565" WEIGHT="99.99999999999997" Z="11.60330807444373">
<NAME>Nicotine gum. Smoking cessation</NAME>
<GROUP_LABEL_1>Nicotine gum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="42.615163326491455" CI_END="1.8809180110490697" CI_START="1.4571579378604849" DF="16" EFFECT_SIZE="1.655534539133783" ESTIMABLE="YES" EVENTS_1="531" EVENTS_2="413" I2="62.4546786846322" ID="CMP-003.01.01" LOG_CI_END="0.27436986512772366" LOG_CI_START="0.16350662646039604" LOG_EFFECT_SIZE="0.21893824579405988" MODIFIED="2012-02-10 15:59:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="3.192611438953552E-4" P_Z="9.84293945041766E-15" STUDIES="17" TAU2="0.0" TOTAL_1="4885" TOTAL_2="6372" WEIGHT="30.364443904176696" Z="7.741269004099515">
<NAME>Low intensity support</NAME>
<DICH_DATA CI_END="1.4649325789876566" CI_START="0.731529381659314" EFFECT_SIZE="1.0352010547132497" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="111" LOG_CI_END="0.16581763749053177" LOG_CI_START="-0.13576822588009327" LOG_EFFECT_SIZE="0.015024705805219264" ORDER="206" O_E="0.0" SE="0.17715302901800556" STUDY_ID="STD-Br-Thor-Society-1983" TOTAL_1="410" TOTAL_2="1208" VAR="0.03138319569025432" WEIGHT="5.132590185356544"/>
<DICH_DATA CI_END="3.247959524638751" CI_START="0.6065321080428522" EFFECT_SIZE="1.4035639412997905" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5116106085200087" LOG_CI_START="-0.21714620390418088" LOG_EFFECT_SIZE="0.1472322023079139" ORDER="207" O_E="0.0" SE="0.4280753590223699" STUDY_ID="STD-Campbell-1987" TOTAL_1="424" TOTAL_2="412" VAR="0.18324851300213088" WEIGHT="0.8329335576482134"/>
<DICH_DATA CI_END="6.940756990800773" CI_START="1.177115040228752" EFFECT_SIZE="2.8583333333333334" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="5" LOG_CI_END="0.8414068391867146" LOG_CI_START="0.07081890880357672" LOG_EFFECT_SIZE="0.45611287399514566" ORDER="208" O_E="0.0" SE="0.4526471647788296" STUDY_ID="STD-Fagerstrom-1984" TOTAL_1="96" TOTAL_2="49" VAR="0.20488945578231293" WEIGHT="0.6040619858546141"/>
<DICH_DATA CI_END="1.6021401580365628" CI_START="0.9571701414032476" EFFECT_SIZE="1.2383540372670807" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="84" LOG_CI_END="0.20470050625464503" LOG_CI_START="-0.01901085751583178" LOG_EFFECT_SIZE="0.09284482436940662" ORDER="209" O_E="0.0" SE="0.13140916246788847" STUDY_ID="STD-Fortmann-1995" TOTAL_1="552" TOTAL_2="522" VAR="0.017268367980511908" WEIGHT="7.878115675852495"/>
<DICH_DATA CI_END="2.808418875797395" CI_START="0.5224543870988805" EFFECT_SIZE="1.2113095238095237" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.44846188332970094" LOG_CI_START="-0.28195161965894905" LOG_EFFECT_SIZE="0.08325513183537596" ORDER="210" O_E="0.0" SE="0.42904850726068444" STUDY_ID="STD-Gilbert-1989" TOTAL_1="112" TOTAL_2="111" VAR="0.1840826215826216" WEIGHT="0.824829034496547"/>
<DICH_DATA CI_END="2.1484187548221616" CI_START="0.3773842535875269" EFFECT_SIZE="0.9004329004329005" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.33211893493424877" LOG_CI_START="-0.42321622479301435" LOG_EFFECT_SIZE="-0.04554864492938274" ORDER="211" O_E="0.0" SE="0.4436876117931363" STUDY_ID="STD-Harackiewicz-1988" TOTAL_1="99" TOTAL_2="52" VAR="0.19685869685869684" WEIGHT="0.8374609361010058"/>
<DICH_DATA CI_END="4.563039307727768" CI_START="0.8050798740413305" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.6592542099639247" LOG_CI_START="-0.09416103002398857" LOG_EFFECT_SIZE="0.28254658996996806" ORDER="212" O_E="0.0" SE="0.44255984143448623" STUDY_ID="STD-Hughes-1989" TOTAL_1="210" TOTAL_2="105" VAR="0.19585921325051758" WEIGHT="0.7299082329076587"/>
<DICH_DATA CI_END="2.3062603685392586" CI_START="0.40470386503207123" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.36290833601880523" LOG_CI_START="-0.39286264795811077" LOG_EFFECT_SIZE="-0.014977155969652801" ORDER="213" O_E="0.0" SE="0.4439436171147473" STUDY_ID="STD-Hughes-1990" TOTAL_1="59" TOTAL_2="19" VAR="0.19708593517692535" WEIGHT="0.690137592012049"/>
<DICH_DATA CI_END="2.9759103499496" CI_START="0.5044612640758793" EFFECT_SIZE="1.2252475247524752" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4736198438400234" LOG_CI_START="-0.29717217619409586" LOG_EFFECT_SIZE="0.08822383382296375" ORDER="214" O_E="0.0" SE="0.45276704805007617" STUDY_ID="STD-Jamrozik-1984" TOTAL_1="101" TOTAL_2="99" VAR="0.20499799979997999" WEIGHT="0.7372073152367353"/>
<DICH_DATA CI_END="2.3736710298145747" CI_START="0.8553867175906704" EFFECT_SIZE="1.4249233912155261" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.37542052934643694" LOG_CI_START="-0.0678374977334798" LOG_EFFECT_SIZE="0.15379151580647857" ORDER="215" O_E="0.0" SE="0.26037195926936413" STUDY_ID="STD-Mori-1992" TOTAL_1="178" TOTAL_2="186" VAR="0.06779355717376741" WEIGHT="1.9631323077379064"/>
<DICH_DATA CI_END="3.1707363665085917" CI_START="0.4225351138657811" EFFECT_SIZE="1.1574746008708272" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.5011601337551542" LOG_CI_START="-0.3741371941119684" LOG_EFFECT_SIZE="0.06351146982159289" ORDER="216" O_E="0.0" SE="0.5141539831807991" STUDY_ID="STD-Nebot-1992" TOTAL_1="106" TOTAL_2="319" VAR="0.26435431842068147" WEIGHT="0.5916550264392668"/>
<DICH_DATA CI_END="3.0527184886055982" CI_START="0.601296168019352" EFFECT_SIZE="1.3548387096774193" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.48468675697401153" LOG_CI_START="-0.22091156384675606" LOG_EFFECT_SIZE="0.13188759656362775" ORDER="217" O_E="0.0" SE="0.4144719464181376" STUDY_ID="STD-Page-1986" TOTAL_1="93" TOTAL_2="182" VAR="0.17178699436763953" WEIGHT="0.8022355032594176"/>
<DICH_DATA CI_END="6.610228606916726" CI_START="1.3759720864046632" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.8202164793049521" LOG_CI_START="0.13860962369354227" LOG_EFFECT_SIZE="0.47941305149924723" ORDER="218" O_E="0.0" SE="0.40037924099449274" STUDY_ID="STD-Roto-1987" TOTAL_1="54" TOTAL_2="60" VAR="0.1603035366193261" WEIGHT="0.6050555088576645"/>
<DICH_DATA CI_END="2.641674335804446" CI_START="1.4565130470266645" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="78" LOG_CI_END="0.42187927698755906" LOG_CI_START="0.1633143792666777" LOG_EFFECT_SIZE="0.2925968281271184" ORDER="219" O_E="0.0" SE="0.15188230083813165" STUDY_ID="STD-Russell-1983" TOTAL_1="729" TOTAL_2="1377" VAR="0.023068233307884725" WEIGHT="4.926880572126696"/>
<DICH_DATA CI_END="5.106444992004984" CI_START="0.06810951693167992" EFFECT_SIZE="0.5897435897435898" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.7081186579322872" LOG_CI_START="-1.1667921999500996" LOG_EFFECT_SIZE="-0.22933677100890631" ORDER="220" O_E="0.0" SE="1.101331918878542" STUDY_ID="STD-Schneider-1985B" TOTAL_1="13" TOTAL_2="23" VAR="1.2129319955406912" WEIGHT="0.19768347974582423"/>
<DICH_DATA CI_END="5.687760780817803" CI_START="1.2441491632011088" EFFECT_SIZE="2.66015466015466" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.7549413222935226" LOG_CI_START="0.09487245179503367" LOG_EFFECT_SIZE="0.42490688704427815" MODIFIED="2012-02-10 15:59:33 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="616" O_E="0.0" SE="0.38772772192441723" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_" TOTAL_1="819" TOTAL_2="817" VAR="0.1503327863486982" WEIGHT="0.8221506089184525"/>
<DICH_DATA CI_END="6.50670193022576" CI_START="2.728382244752736" EFFECT_SIZE="4.213403614457832" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="24" LOG_CI_END="0.8133609123089041" LOG_CI_START="0.4359052146492433" LOG_EFFECT_SIZE="0.6246330634790737" MODIFIED="2012-02-10 15:59:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="617" O_E="0.0" SE="0.2217193452411218" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_" TOTAL_1="830" TOTAL_2="831" VAR="0.049159468054151764" WEIGHT="2.188406381625611"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.41678897907536" CI_END="1.4854302463141633" CI_START="1.1809069299590869" DF="17" EFFECT_SIZE="1.3244451184715917" ESTIMABLE="YES" EVENTS_1="605" EVENTS_2="414" I2="2.3930299642264297" ID="CMP-003.01.02" LOG_CI_END="0.17185226276902432" LOG_CI_START="0.07221567119696357" LOG_EFFECT_SIZE="0.12203396698299393" MODIFIED="2012-02-09 15:26:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.42649229880725426" P_Z="1.5780339764051814E-6" STUDIES="18" TAU2="0.0" TOTAL_1="3465" TOTAL_2="3426" WEIGHT="37.94244145300579" Z="4.801091173501918">
<NAME>High intensity individual support</NAME>
<DICH_DATA CI_END="1.8384227647603988" CI_START="0.8616023404348749" EFFECT_SIZE="1.2585663895187704" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="42" LOG_CI_END="0.2644453891448034" LOG_CI_START="-0.06469313000189131" LOG_EFFECT_SIZE="0.09987612957145608" ORDER="221" O_E="0.0" SE="0.19333759540871465" STUDY_ID="STD-Ahluwalia-2006" TOTAL_1="378" TOTAL_2="377" VAR="0.03737942579842384" WEIGHT="3.837093743590063"/>
<DICH_DATA CI_END="2.103496146183185" CI_START="1.133452288226358" EFFECT_SIZE="1.5440895440895441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="37" LOG_CI_END="0.32294172068250876" LOG_CI_START="0.05440324356608751" LOG_EFFECT_SIZE="0.1886724821242981" ORDER="222" O_E="0.0" SE="0.15774083074508602" STUDY_ID="STD-Areechon-1988" TOTAL_1="99" TOTAL_2="101" VAR="0.024882169684149878" WEIGHT="3.3420673214259424"/>
<DICH_DATA CI_END="1.6866842429902695" CI_START="0.5709226264033885" EFFECT_SIZE="0.9813084112149533" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.22703378776870237" LOG_CI_START="-0.2434227449992455" LOG_EFFECT_SIZE="-0.00819447861527157" ORDER="223" O_E="0.0" SE="0.27634849614528817" STUDY_ID="STD-Campbell-1991" TOTAL_1="107" TOTAL_2="105" VAR="0.07636849132176235" WEIGHT="1.934084669037157"/>
<DICH_DATA CI_END="1.7823920735615897" CI_START="0.8054121897023883" EFFECT_SIZE="1.1981486981486982" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.25100324215604675" LOG_CI_START="-0.09398180174569425" LOG_EFFECT_SIZE="0.07851072020517626" ORDER="224" O_E="0.0" SE="0.2026459224913915" STUDY_ID="STD-Clavel_x002d_Chapelon-1992" TOTAL_1="481" TOTAL_2="515" VAR="0.04106536990238705" WEIGHT="3.7012063557230226"/>
<DICH_DATA CI_END="2.1977726928730594" CI_START="0.5924633768247419" EFFECT_SIZE="1.141095890410959" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.34198277301205143" LOG_CI_START="-0.227338490439388" LOG_EFFECT_SIZE="0.0573221412863317" ORDER="225" O_E="0.0" SE="0.3344221283370807" STUDY_ID="STD-Cooper-2005" TOTAL_1="146" TOTAL_2="147" VAR="0.11183815992150285" WEIGHT="1.3639070222421268"/>
<DICH_DATA CI_END="1.899800104778201" CI_START="0.8955275068880978" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.27870790729028233" LOG_CI_START="-0.04792106988614322" LOG_EFFECT_SIZE="0.11539341870206957" ORDER="226" O_E="0.0" SE="0.19186347803294543" STUDY_ID="STD-Fagerstrom-1982" TOTAL_1="50" TOTAL_2="50" VAR="0.036811594202898534" WEIGHT="2.0984861696095187"/>
<DICH_DATA CI_END="3.6414111243083065" CI_START="1.3428793600393683" EFFECT_SIZE="2.2113289760348582" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="17" LOG_CI_END="0.561269714621607" LOG_CI_START="0.1280369988023339" LOG_EFFECT_SIZE="0.34465335671197045" ORDER="227" O_E="0.0" SE="0.25448304180877096" STUDY_ID="STD-Garvey-2000" TOTAL_1="405" TOTAL_2="203" VAR="0.06476161856824468" WEIGHT="2.066372608375506"/>
<DICH_DATA CI_END="4.7927472328753025" CI_START="0.978339288206984" EFFECT_SIZE="2.1653944020356235" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.6805845251190232" LOG_CI_START="-0.009510505700700772" LOG_EFFECT_SIZE="0.33553700970916117" ORDER="228" O_E="0.0" SE="0.40536523712900135" STUDY_ID="STD-Gross-1995" TOTAL_1="131" TOTAL_2="46" VAR="0.1643209754726515" WEIGHT="0.810321851787316"/>
<DICH_DATA CI_END="1.5943886308104427" CI_START="0.6300188787817181" EFFECT_SIZE="1.0022449488650536" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="19" LOG_CI_END="0.20259418885732536" LOG_CI_START="-0.20064643653390796" LOG_EFFECT_SIZE="9.738761617086915E-4" ORDER="229" O_E="0.0" SE="0.2368655394280984" STUDY_ID="STD-Jensen-1991" TOTAL_1="211" TOTAL_2="82" VAR="0.05610528376856404" WEIGHT="2.4967594758761122"/>
<DICH_DATA CI_END="1.485983274795411" CI_START="0.9440549662841833" EFFECT_SIZE="1.184419642857143" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="112" LOG_CI_END="0.17201392133240373" LOG_CI_START="-0.02500271877507291" LOG_EFFECT_SIZE="0.07350560127866544" ORDER="230" O_E="0.0" SE="0.11572854964722892" STUDY_ID="STD-Killen-1990" TOTAL_1="600" TOTAL_2="617" VAR="0.013393097203451129" WEIGHT="10.075972319514106"/>
<DICH_DATA CI_END="12.85331251038475" CI_START="0.8550075403053737" EFFECT_SIZE="3.315068493150685" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.1090150669349643" LOG_CI_START="-0.06803005521501355" LOG_EFFECT_SIZE="0.5204925058599754" ORDER="231" O_E="0.0" SE="0.6914021312182197" STUDY_ID="STD-Malcolm-1980" TOTAL_1="73" TOTAL_2="121" VAR="0.4780369070530963" WEIGHT="0.20599214304997068"/>
<DICH_DATA CI_END="15.439929239254754" CI_START="0.7835721582188115" EFFECT_SIZE="3.4782608695652173" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.188645305645338" LOG_CI_START="-0.10592100369663676" LOG_EFFECT_SIZE="0.5413621509743507" ORDER="232" O_E="0.0" SE="0.7604346583140575" STUDY_ID="STD-Moolchan-2005" TOTAL_1="46" TOTAL_2="40" VAR="0.5782608695652174" WEIGHT="0.19520801577762964"/>
<DICH_DATA CI_END="6.386765392813436" CI_START="1.0584387533017163" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8052809633667104" LOG_CI_START="0.0246657325749255" LOG_EFFECT_SIZE="0.414973347970818" ORDER="233" O_E="0.0" SE="0.45853725067480644" STUDY_ID="STD-Nakamura-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.2102564102564103" WEIGHT="0.45619264556728667"/>
<DICH_DATA CI_END="4.765941874451098" CI_START="0.3680380540851699" EFFECT_SIZE="1.3244047619047619" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6781487413761358" LOG_CI_START="-0.4341072741939607" LOG_EFFECT_SIZE="0.12202073359108753" ORDER="234" O_E="0.0" SE="0.6533446893019474" STUDY_ID="STD-Niaura-1994" TOTAL_1="84" TOTAL_2="89" VAR="0.4268592830390583" WEIGHT="0.35440630961990366"/>
<DICH_DATA CI_END="2.6472555462718894" CI_START="0.4986090900333425" EFFECT_SIZE="1.1488888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4227958668694923" LOG_CI_START="-0.3022398082322946" LOG_EFFECT_SIZE="0.06027802931859881" MODIFIED="2012-02-09 15:26:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="609" O_E="0.0" SE="0.4258895445392638" STUDY_ID="STD-Oncken-2008" TOTAL_1="100" TOTAL_2="94" VAR="0.1813819041478616" WEIGHT="0.8465430536300166"/>
<DICH_DATA CI_END="1.7885616742580424" CI_START="0.4637248589977451" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.25250392034639924" LOG_CI_START="-0.33373962216292735" LOG_EFFECT_SIZE="-0.04061785090826406" ORDER="235" O_E="0.0" SE="0.3443623588223159" STUDY_ID="STD-Richmond-1993" TOTAL_1="200" TOTAL_2="150" VAR="0.11858543417366944" WEIGHT="1.4598164658153174"/>
<DICH_DATA CI_END="3.691402296267391" CI_START="0.6095244623635621" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5671913780399481" LOG_CI_START="-0.21500885992858565" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="236" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-Schneider-1985A" TOTAL_1="30" TOTAL_2="30" VAR="0.21111111111111114" WEIGHT="0.5474311746807441"/>
<DICH_DATA CI_END="2.116689578474571" CI_START="0.7645244377176588" EFFECT_SIZE="1.272108843537415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="37" LOG_CI_END="0.32565717155714285" LOG_CI_START="-0.11660862798049704" LOG_EFFECT_SIZE="0.1045242717883229" ORDER="237" O_E="0.0" SE="0.25978911989942516" STUDY_ID="STD-Segnan-1991" TOTAL_1="294" TOTAL_2="629" VAR="0.0674903868181179" WEIGHT="2.1505801076840494"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.318513791784763" CI_END="1.7575086613061863" CI_START="1.395970749448983" DF="19" EFFECT_SIZE="1.5663430923928117" ESTIMABLE="YES" EVENTS_1="563" EVENTS_2="340" I2="24.956100676947973" ID="CMP-003.01.03" LOG_CI_END="0.24489747397534037" LOG_CI_START="0.14487631836881237" LOG_EFFECT_SIZE="0.19488689617207638" NO="3" P_CHI2="0.15032300680769795" P_Z="2.209473670121944E-14" STUDIES="20" TAU2="0.0" TOTAL_1="1844" TOTAL_2="1767" WEIGHT="31.693114642817488" Z="7.637810126063707">
<NAME>High intensity group-based support</NAME>
<DICH_DATA CI_END="2.1282902638036596" CI_START="0.8361335572587889" EFFECT_SIZE="1.3339920948616601" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.328030858290107" LOG_CI_START="-0.0777243463076554" LOG_EFFECT_SIZE="0.12515325599122584" ORDER="238" O_E="0.0" SE="0.2383426157013814" STUDY_ID="STD-Blondal-1989" TOTAL_1="92" TOTAL_2="90" VAR="0.056807202459376385" WEIGHT="2.029305306875139"/>
<DICH_DATA CI_END="10.383127352642541" CI_START="1.8071326338889435" EFFECT_SIZE="4.331707317073171" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="1.0163281808182514" LOG_CI_START="0.25699002862744214" LOG_EFFECT_SIZE="0.6366591047228467" ORDER="250" O_E="0.0" SE="0.44603898938135556" STUDY_ID="STD-Clavel-1985" TOTAL_1="205" TOTAL_2="222" VAR="0.198950780048341" WEIGHT="0.5256364909112531"/>
<DICH_DATA CI_END="2.712769410117531" CI_START="0.7913564709479441" EFFECT_SIZE="1.4651851851851851" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4334128795818624" LOG_CI_START="-0.10162784204955344" LOG_EFFECT_SIZE="0.16589251876615446" ORDER="239" O_E="0.0" SE="0.31428556838058" STUDY_ID="STD-Fee-1982" TOTAL_1="180" TOTAL_2="172" VAR="0.09877541849230424" WEIGHT="1.3996819807178116"/>
<DICH_DATA CI_END="5.720321996351251" CI_START="0.9630026289815542" EFFECT_SIZE="2.347058823529412" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.7574204758739058" LOG_CI_START="-0.016372527256957148" LOG_EFFECT_SIZE="0.37052397430847434" ORDER="251" O_E="0.0" SE="0.45452984037620925" STUDY_ID="STD-Garcia-1989" TOTAL_1="68" TOTAL_2="38" VAR="0.20659737579242224" WEIGHT="0.5853037716712358"/>
<DICH_DATA CI_END="2.9681504720636167" CI_START="0.8415818958233378" EFFECT_SIZE="1.5804878048780489" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.4724859139689923" LOG_CI_START="-0.07490361566727656" LOG_EFFECT_SIZE="0.19879114915085785" ORDER="240" O_E="0.0" SE="0.32153931933021623" STUDY_ID="STD-Hall-1985" TOTAL_1="41" TOTAL_2="36" VAR="0.10338753387533876" WEIGHT="0.971631089260195"/>
<DICH_DATA CI_END="3.5225719722255557" CI_START="1.1957150368524538" EFFECT_SIZE="2.052313883299799" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.5468598752579272" LOG_CI_START="0.07762769079924374" LOG_EFFECT_SIZE="0.31224378302858546" ORDER="241" O_E="0.0" SE="0.2756293078878044" STUDY_ID="STD-Hall-1987" TOTAL_1="71" TOTAL_2="68" VAR="0.07597151536671005" WEIGHT="1.304907884011174"/>
<DICH_DATA CI_END="1.4411817402647455" CI_START="0.5631316900126799" EFFECT_SIZE="0.9008746355685131" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.1587187509855719" LOG_CI_START="-0.2493900322214436" LOG_EFFECT_SIZE="-0.04533564061793586" ORDER="242" O_E="0.0" SE="0.23972511942685867" STUDY_ID="STD-Hall-1996" TOTAL_1="98" TOTAL_2="103" VAR="0.05746813288422166" WEIGHT="2.4911295909186757"/>
<DICH_DATA CI_END="3.6083819127439694" CI_START="1.3827864938038017" EFFECT_SIZE="2.23374613003096" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="17" LOG_CI_END="0.5573124972234184" LOG_CI_START="0.14075512897340187" LOG_EFFECT_SIZE="0.34903381309841014" ORDER="256" O_E="0.0" SE="0.2446878601022879" STUDY_ID="STD-Herrera-1995" TOTAL_1="76" TOTAL_2="78" VAR="0.05987214888143681" WEIGHT="1.5309114235660635"/>
<DICH_DATA CI_END="3.1300417111171157" CI_START="1.067386158715058" EFFECT_SIZE="1.8278301886792452" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.49555012501842827" LOG_CI_START="0.02832156680872703" LOG_EFFECT_SIZE="0.26193584591357766" ORDER="243" O_E="0.0" SE="0.27445236791104227" STUDY_ID="STD-Hjalmarson-1984" TOTAL_1="106" TOTAL_2="100" VAR="0.0753241022519781" WEIGHT="1.5023353920041131"/>
<DICH_DATA CI_END="2.681155502451401" CI_START="0.6431234010669704" EFFECT_SIZE="1.3131313131313131" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.42832200305341434" LOG_CI_START="-0.19170568763484058" LOG_EFFECT_SIZE="0.11830815770928686" ORDER="244" O_E="0.0" SE="0.36420733469684907" STUDY_ID="STD-Huber-1988" TOTAL_1="54" TOTAL_2="60" VAR="0.13264698264698266" WEIGHT="0.950801513919187"/>
<DICH_DATA CI_END="4.848340156021888" CI_START="1.232444187018039" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.6855930820123821" LOG_CI_START="0.09076726075338054" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="245" O_E="0.0" SE="0.34940363184284007" STUDY_ID="STD-Jarvis-1982" TOTAL_1="58" TOTAL_2="58" VAR="0.1220828979449669" WEIGHT="0.821146762021116"/>
<DICH_DATA CI_END="2.631581726997257" CI_START="0.5583097867724814" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.42021686211038434" LOG_CI_START="-0.25312475921023436" LOG_EFFECT_SIZE="0.08354605145007492" ORDER="246" O_E="0.0" SE="0.3955242014585124" STUDY_ID="STD-Killen-1984" TOTAL_1="44" TOTAL_2="20" VAR="0.15643939393939393" WEIGHT="0.752717865186023"/>
<DICH_DATA CI_END="2.843419595821319" CI_START="1.3868203879402838" EFFECT_SIZE="1.9857774968394437" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="28" LOG_CI_END="0.45384095209413783" LOG_CI_START="0.14202021768646272" LOG_EFFECT_SIZE="0.2979305848903003" ORDER="249" O_E="0.0" SE="0.18316504292859753" STUDY_ID="STD-Llivina-1988" TOTAL_1="113" TOTAL_2="103" VAR="0.03354943295103498" WEIGHT="2.672950982546102"/>
<DICH_DATA CI_END="1.5563577448421877" CI_START="0.7903376452759279" EFFECT_SIZE="1.1090753424657533" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="40" LOG_CI_END="0.19210943118401463" LOG_CI_START="-0.10218733130102724" LOG_EFFECT_SIZE="0.04496104994149371" ORDER="252" O_E="0.0" SE="0.17287137507618275" STUDY_ID="STD-McGovern-1992" TOTAL_1="146" TOTAL_2="127" VAR="0.029884512320730257" WEIGHT="3.9035385349640355"/>
<DICH_DATA CI_END="5.2337006044292" CI_START="0.0477673483631121" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="253" O_E="0.0" SE="1.1981168018885897" STUDY_ID="STD-Niaura-1999" TOTAL_1="31" TOTAL_2="31" VAR="1.435483870967742" WEIGHT="0.18247705822691468"/>
<DICH_DATA CI_END="2.078053930950937" CI_START="1.135942042364552" EFFECT_SIZE="1.5364077669902914" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="50" LOG_CI_END="0.3176568144485229" LOG_CI_START="0.055356173519918124" LOG_EFFECT_SIZE="0.18650649398422053" ORDER="247" O_E="0.0" SE="0.15407669489057554" STUDY_ID="STD-Pirie-1992" TOTAL_1="206" TOTAL_2="211" VAR="0.023739627908403504" WEIGHT="4.507227097691178"/>
<DICH_DATA CI_END="2.214103369188008" CI_START="0.8173356122679534" EFFECT_SIZE="1.3452380952380953" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.34519789279382823" LOG_CI_START="-0.08759957795075202" LOG_EFFECT_SIZE="0.1287991574215381" ORDER="248" O_E="0.0" SE="0.2542273766973985" STUDY_ID="STD-Puska-1979" TOTAL_1="116" TOTAL_2="113" VAR="0.06463155906244096" WEIGHT="1.9411096674269177"/>
<DICH_DATA CI_END="3.0608139772913443" CI_START="0.9364950419934288" EFFECT_SIZE="1.6930555555555555" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.48583693590546406" LOG_CI_START="-0.02849451753123709" LOG_EFFECT_SIZE="0.22867120918711345" ORDER="257" O_E="0.0" SE="0.3021208417304738" STUDY_ID="STD-Tonnesen-1988" TOTAL_1="60" TOTAL_2="53" VAR="0.09127700300793001" WEIGHT="1.1626856807378634"/>
<DICH_DATA CI_END="2.5688705692797895" CI_START="0.7220233680433636" EFFECT_SIZE="1.361904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4097422231983706" LOG_CI_START="-0.14144874640812305" LOG_EFFECT_SIZE="0.13414673839512375" ORDER="254" O_E="0.0" SE="0.3237723039861576" STUDY_ID="STD-Villa-1999" TOTAL_1="21" TOTAL_2="26" VAR="0.10482850482850484" WEIGHT="0.815323026120257"/>
<DICH_DATA CI_END="2.102418926599776" CI_START="0.7765893032666391" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3227192575452336" LOG_CI_START="-0.10980859571666014" LOG_EFFECT_SIZE="0.10645533091428677" ORDER="255" O_E="0.0" SE="0.2540690020534404" STUDY_ID="STD-Zelman-1992" TOTAL_1="58" TOTAL_2="58" VAR="0.0645510578044311" WEIGHT="1.642293524042232"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.04588286907147" CI_END="1.7823779041715944" CI_START="1.516333942702075" CI_STUDY="95" CI_TOTAL="95" DF="43" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6439830032021545" ESTIMABLE="YES" EVENTS_1="1873" EVENTS_2="765" I2="15.762060359908954" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2509997896539637" LOG_CI_START="0.18079485664014244" LOG_EFFECT_SIZE="0.21589732314705307" METHOD="MH" MODIFIED="2012-03-02 13:58:37 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.1868294850703952" P_Q="0.5802035932514189" P_Z="1.8311758572706916E-33" Q="1.0887528354056188" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="43" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11746" TOTAL_2="7839" WEIGHT="100.00000000000001" Z="12.054736314427492">
<NAME>Nicotine patch. Smoking cessation</NAME>
<GROUP_LABEL_1>Nicotine patch</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.163014356346316" CI_END="2.1206497410805265" CI_START="1.4874834616330292" DF="11" EFFECT_SIZE="1.7760719067013162" ESTIMABLE="YES" EVENTS_1="328" EVENTS_2="167" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.32646894382188124" LOG_CI_START="0.1724521457878518" LOG_EFFECT_SIZE="0.24946054480486654" NO="1" P_CHI2="0.5157863791394073" P_Z="2.1658448845140378E-10" STUDIES="12" TAU2="0.0" TOTAL_1="2337" TOTAL_2="2051" WEIGHT="20.14764809306818" Z="6.349095548308318">
<NAME>Low intensity support</NAME>
<DICH_DATA CI_END="3.0985703046290562" CI_START="0.7554774524569775" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4911613544686127" LOG_CI_START="-0.12177849283341506" LOG_EFFECT_SIZE="0.1846914308175988" ORDER="258" O_E="0.0" SE="0.3600439004063886" STUDY_ID="STD-Abelin-1989" TOTAL_1="100" TOTAL_2="99" VAR="0.12963161021984548" WEIGHT="1.3123990954152767"/>
<DICH_DATA CI_END="9.275880948360145" CI_START="1.27126435723578" EFFECT_SIZE="3.4339622641509435" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.9673551660329998" LOG_CI_START="0.1042358707355719" LOG_EFFECT_SIZE="0.5357955183842857" ORDER="259" O_E="0.0" SE="0.507000546567127" STUDY_ID="STD-Daughton-1991" TOTAL_1="106" TOTAL_2="52" VAR="0.25704955421936554" WEIGHT="0.6371403111321023"/>
<DICH_DATA CI_END="2.8436645298032195" CI_START="0.8678996274243392" EFFECT_SIZE="1.570991847826087" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.45387836088728595" LOG_CI_START="-0.06153049806810565" LOG_EFFECT_SIZE="0.19617393140959016" ORDER="260" O_E="0.0" SE="0.30275371506539595" STUDY_ID="STD-Daughton-1998" TOTAL_1="184" TOTAL_2="185" VAR="0.09165981198589895" WEIGHT="1.8942519941946594"/>
<DICH_DATA CI_END="3.6866872656583496" CI_START="1.1538560077024487" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5666362988322253" LOG_CI_START="0.06215161561170004" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="261" O_E="0.0" SE="0.2963368001631935" STUDY_ID="STD-Davidson-1998" TOTAL_1="401" TOTAL_2="401" VAR="0.08781549913096048" WEIGHT="1.8993994180919276"/>
<DICH_DATA CI_END="3.103911528273855" CI_START="0.6721904713072535" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49190933393600517" LOG_CI_START="-0.1725076482009813" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="262" O_E="0.0" SE="0.39028182422437036" STUDY_ID="STD-Glavas-2003a" TOTAL_1="56" TOTAL_2="56" VAR="0.15231990231990233" WEIGHT="1.0684121726767093"/>
<DICH_DATA CI_END="4.390778670369073" CI_START="1.3301234738135557" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6425415458131081" LOG_CI_START="0.12389195788955437" LOG_EFFECT_SIZE="0.38321675185133125" ORDER="263" O_E="0.0" SE="0.3046573353031615" STUDY_ID="STD-Glavas-2003b" TOTAL_1="80" TOTAL_2="80" VAR="0.09281609195402299" WEIGHT="1.4245495635689456"/>
<DICH_DATA CI_END="3.9419707258706516" CI_START="1.2752972552091766" EFFECT_SIZE="2.242138364779874" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="14" LOG_CI_END="0.5957133947683748" LOG_CI_START="0.10561142496649092" LOG_EFFECT_SIZE="0.35066240986743286" ORDER="264" O_E="0.0" SE="0.28788832310550383" STUDY_ID="STD-Hays-1999" TOTAL_1="636" TOTAL_2="322" VAR="0.08287968658049898" WEIGHT="2.2067135201840453"/>
<DICH_DATA CI_END="1.9175853297600345" CI_START="0.6255505122219942" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2827546985242227" LOG_CI_START="-0.20373761595687537" LOG_EFFECT_SIZE="0.039508541283673655" ORDER="265" O_E="0.0" SE="0.28576799370199224" STUDY_ID="STD-Killen-1997" TOTAL_1="212" TOTAL_2="212" VAR="0.08166334622446189" WEIGHT="2.492961736245655"/>
<DICH_DATA CI_END="4.843896772402742" CI_START="0.5969505892682352" EFFECT_SIZE="1.7004608294930876" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6851948793815098" LOG_CI_START="-0.2240616147604481" LOG_EFFECT_SIZE="0.23056663231053087" ORDER="269" O_E="0.0" SE="0.5341017655512216" STUDY_ID="STD-Lewis-1998" TOTAL_1="62" TOTAL_2="123" VAR="0.28526469596493204" WEIGHT="0.5569860455756058"/>
<DICH_DATA CI_END="2.1387818059489785" CI_START="1.0522861826123664" EFFECT_SIZE="1.5002035002035001" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="39" LOG_CI_END="0.3301664810157491" LOG_CI_START="0.022133867790199133" LOG_EFFECT_SIZE="0.17615017440297406" ORDER="266" O_E="0.0" SE="0.18093988179471496" STUDY_ID="STD-Otero-2006" TOTAL_1="189" TOTAL_2="194" VAR="0.03273924082388542" WEIGHT="4.569345010037727"/>
<DICH_DATA CI_END="10.644319166426266" CI_START="1.3211272398102434" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0271178882524812" LOG_CI_START="0.12094464720295672" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="267" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Paoletti-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.2833333333333333" WEIGHT="0.4748498545229819"/>
<DICH_DATA CI_END="2.9427867387446707" CI_START="0.7847299161094201" EFFECT_SIZE="1.5196357427433125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.46875879028775475" LOG_CI_START="-0.10527979054919413" LOG_EFFECT_SIZE="0.18173949986928026" ORDER="268" O_E="0.0" SE="0.33719310392042656" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="251" TOTAL_2="267" VAR="0.11369918933149159" WEIGHT="1.6106393714225469"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="36.239785360397654" CI_END="1.7840030770675892" CI_START="1.4104621115047768" DF="21" EFFECT_SIZE="1.5862751170625387" ESTIMABLE="YES" EVENTS_1="1015" EVENTS_2="361" I2="42.052636926077064" ID="CMP-003.02.02" LOG_CI_END="0.25139559911651793" LOG_CI_START="0.1493614244258701" LOG_EFFECT_SIZE="0.20037851177119398" MODIFIED="2012-03-02 13:58:37 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.020547059276665225" P_Z="1.3810372189081716E-14" STUDIES="22" TAU2="0.0" TOTAL_1="7237" TOTAL_2="4322" WEIGHT="49.94733156510496" Z="7.698100514616552">
<NAME>High intensity individual support</NAME>
<DICH_DATA CI_END="2.361530435285525" CI_START="0.9005753554279192" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.37319354711423586" LOG_CI_START="-0.04547994183689675" LOG_EFFECT_SIZE="0.16385680263866959" ORDER="270" O_E="0.0" SE="0.24593087987708992" STUDY_ID="STD-Ahluwalia-1998" TOTAL_1="205" TOTAL_2="205" VAR="0.06048199767711963" WEIGHT="2.849099127137891"/>
<DICH_DATA CI_END="2.5728675834146997" CI_START="0.8294790996379331" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4104174351523806" LOG_CI_START="-0.08119455240787828" LOG_EFFECT_SIZE="0.16461144137225117" ORDER="272" O_E="0.0" SE="0.28877531501148174" STUDY_ID="STD-Campbell-1996" TOTAL_1="115" TOTAL_2="119" VAR="0.08339118255998051" WEIGHT="1.9836142427188668"/>
<DICH_DATA CI_END="1.8113081221041267" CI_START="1.1243557445017534" EFFECT_SIZE="1.427079077048801" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="71" LOG_CI_END="0.25799233454774956" LOG_CI_START="0.050903743110311706" LOG_EFFECT_SIZE="0.1544480388290306" ORDER="271" O_E="0.0" SE="0.12164486371541124" STUDY_ID="STD-CEASE-1999" TOTAL_1="2861" TOTAL_2="714" VAR="0.014797472868340973" WEIGHT="13.490451160714382"/>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-03-02 13:58:37 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="647" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="4.712319508694735"/>
<DICH_DATA CI_END="16.118289185653534" CI_START="0.760006217713441" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2073189433834552" LOG_CI_START="-0.11918285468290388" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="273" O_E="0.0" SE="0.7791937224739794" STUDY_ID="STD-Ehrsam-1991" TOTAL_1="56" TOTAL_2="56" VAR="0.607142857142857" WEIGHT="0.23742492726149095"/>
<DICH_DATA CI_END="7.237905645439162" CI_START="0.8039754134848986" EFFECT_SIZE="2.412280701754386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8596129172728425" LOG_CI_START="-0.09475723228526235" LOG_EFFECT_SIZE="0.3824278424937901" ORDER="274" O_E="0.0" SE="0.5606017500588621" STUDY_ID="STD-Fiore-1994B" TOTAL_1="57" TOTAL_2="55" VAR="0.314274322169059" WEIGHT="0.48332931621089226"/>
<DICH_DATA CI_END="3.393314017187208" CI_START="0.5239060602034752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5306240511043927" LOG_CI_START="-0.28074657788779284" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="275" O_E="0.0" SE="0.4766031238193982" STUDY_ID="STD-Hurt-1990" TOTAL_1="31" TOTAL_2="31" VAR="0.2271505376344086" WEIGHT="0.7122747817844728"/>
<DICH_DATA CI_END="3.2899905062299095" CI_START="1.1453425421228474" EFFECT_SIZE="1.9411764705882353" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5171946447287246" LOG_CI_START="0.05893539227050256" LOG_EFFECT_SIZE="0.2880650184996135" ORDER="276" O_E="0.0" SE="0.26918375331384387" STUDY_ID="STD-Hurt-1994" TOTAL_1="120" TOTAL_2="120" VAR="0.07245989304812835" WEIGHT="2.018111881722673"/>
<DICH_DATA CI_END="2.014402311568503" CI_START="1.025628178913287" EFFECT_SIZE="1.437368350289069" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.30414621112601403" LOG_CI_START="0.010989944486001551" LOG_EFFECT_SIZE="0.15756807780600784" ORDER="277" O_E="0.0" SE="0.17220144217126704" STUDY_ID="STD-ICRF-1994" TOTAL_1="842" TOTAL_2="844" VAR="0.02965333668586423" WEIGHT="6.284297036756403"/>
<DICH_DATA CI_END="3.6638765871680388" CI_START="0.8345587993406903" EFFECT_SIZE="1.7486338797814207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.563940836607552" LOG_CI_START="-0.078543059428599" LOG_EFFECT_SIZE="0.2426988885894765" ORDER="278" O_E="0.0" SE="0.37739822087821245" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.14242941712204005" WEIGHT="1.2905572778867183"/>
<DICH_DATA CI_END="1.3436041393550384" CI_START="0.526827168615168" EFFECT_SIZE="0.8413365346138455" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.12827133313947087" LOG_CI_START="-0.2783318364524714" LOG_EFFECT_SIZE="-0.07503025165650026" ORDER="279" O_E="0.0" SE="0.23884071453645703" STUDY_ID="STD-Joseph-1996" TOTAL_1="294" TOTAL_2="290" VAR="0.05704488692028535" WEIGHT="4.063869131688122"/>
<DICH_DATA CI_END="1.9396324884607696" CI_START="0.46529433043070706" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.2877194498511332" LOG_CI_START="-0.3322722392734377" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="280" O_E="0.0" SE="0.3641861872001304" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="150" TOTAL_2="75" VAR="0.13263157894736843" WEIGHT="1.5828328484099397"/>
<DICH_DATA CI_END="22.85043813806692" CI_START="1.2265708644863083" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3588945317196774" LOG_CI_START="0.0886926444024243" LOG_EFFECT_SIZE="0.723793588061051" ORDER="281" O_E="0.0" SE="0.7461228762109019" STUDY_ID="STD-Moolchan-2005" TOTAL_1="34" TOTAL_2="40" VAR="0.5566993464052288" WEIGHT="0.21817425748353222"/>
<DICH_DATA CI_END="10.709518607104284" CI_START="0.9561587570525513" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0297699497322355" LOG_CI_START="-0.01946999309242347" LOG_EFFECT_SIZE="0.505149978319906" ORDER="289" O_E="0.0" SE="0.6163287362366865" STUDY_ID="STD-Perng-1998" TOTAL_1="30" TOTAL_2="32" VAR="0.3798611111111111" WEIGHT="0.3446490879602288"/>
<DICH_DATA CI_END="3.0007141337297876" CI_START="0.8411651795025185" EFFECT_SIZE="1.588740458015267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="8" LOG_CI_END="0.4772246238629811" LOG_CI_START="-0.07511871347371944" LOG_EFFECT_SIZE="0.20105295519463082" MODIFIED="2012-02-07 13:41:11 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="605" O_E="0.0" SE="0.3244492104951934" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1052672901909543" WEIGHT="1.6643566807360703"/>
<DICH_DATA CI_END="5.191155779737516" CI_START="1.3541372015357949" EFFECT_SIZE="2.651327433628319" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7152640616789412" LOG_CI_START="0.1316626694090771" LOG_EFFECT_SIZE="0.42346336554400915" ORDER="282" O_E="0.0" SE="0.3428103466928011" STUDY_ID="STD-Sachs-1993" TOTAL_1="113" TOTAL_2="107" VAR="0.11751893379963846" WEIGHT="1.2195007627522036"/>
<DICH_DATA CI_END="3.2993612898922677" CI_START="1.2444698588327163" EFFECT_SIZE="2.026315789473684" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="19" LOG_CI_END="0.5184298746891502" LOG_CI_START="0.09498438242219312" LOG_EFFECT_SIZE="0.30670712855567167" ORDER="283" O_E="0.0" SE="0.24873397824660265" STUDY_ID="STD-Stapleton-1995" TOTAL_1="800" TOTAL_2="400" VAR="0.061868591934381406" WEIGHT="3.007382411978885"/>
<DICH_DATA CI_END="9.428558561934224" CI_START="1.673646214316064" EFFECT_SIZE="3.972413793103448" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9744453028701352" LOG_CI_START="0.22366365950633915" LOG_EFFECT_SIZE="0.5990544811882371" ORDER="284" O_E="0.0" SE="0.44101285374096627" STUDY_ID="STD-Tonnesen-1991" TOTAL_1="145" TOTAL_2="144" VAR="0.19449233716475092" WEIGHT="0.7147394004065645"/>
<DICH_DATA CI_END="21.316258689645682" CI_START="1.043519004284947" EFFECT_SIZE="4.716346153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.328710982107621" LOG_CI_START="0.018500362726752817" LOG_EFFECT_SIZE="0.6736056724171869" ORDER="285" O_E="0.0" SE="0.7696242034714872" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="104" TOTAL_2="109" VAR="0.5923214145691211" WEIGHT="0.23185157216145594"/>
<DICH_DATA CI_END="34.51060023583957" CI_START="1.9508246278682124" EFFECT_SIZE="8.205128205128204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5379525129526281" LOG_CI_START="0.2902182296341853" LOG_EFFECT_SIZE="0.9140853712934067" ORDER="286" O_E="0.0" SE="0.7329252944055672" STUDY_ID="STD-Westman-1993" TOTAL_1="78" TOTAL_2="80" VAR="0.5371794871794873" WEIGHT="0.23441954843539614"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" ORDER="287" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="2.1197297505905914"/>
<DICH_DATA CI_END="9.51135034004292" CI_START="1.1889010697860327" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9782421787248091" LOG_CI_START="0.07514571783689675" LOG_EFFECT_SIZE="0.5266939482808529" ORDER="288" O_E="0.0" SE="0.5304833315251388" STUDY_ID="STD-Wong-1999" TOTAL_1="51" TOTAL_2="49" VAR="0.28141256502601036" WEIGHT="0.48434685161344154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5455967634251104" CI_END="1.904891825634306" CI_START="1.4315989817102477" DF="9" EFFECT_SIZE="1.6513755471867224" ESTIMABLE="YES" EVENTS_1="530" EVENTS_2="237" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.27987031814076774" LOG_CI_START="0.1558213808064148" LOG_EFFECT_SIZE="0.21784584947359126" NO="3" P_CHI2="0.9387021536175704" P_Z="5.823721821168423E-12" STUDIES="10" TAU2="0.0" TOTAL_1="2172" TOTAL_2="1466" WEIGHT="29.905020341826866" Z="6.883896441594615">
<NAME>High intensity group-based support</NAME>
<DICH_DATA CI_END="2.8593078037343456" CI_START="0.7422768702931712" EFFECT_SIZE="1.4568452380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.45626090956152343" LOG_CI_START="-0.12943407206289823" LOG_EFFECT_SIZE="0.1634134187493126" ORDER="290" O_E="0.0" SE="0.34404013144310264" STUDY_ID="STD-Buchkremer-1988" TOTAL_1="42" TOTAL_2="89" VAR="0.11836361204338733" WEIGHT="1.2179355047307017"/>
<DICH_DATA CI_END="3.788507155734091" CI_START="0.775708053172369" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.578468111881843" LOG_CI_START="-0.1103016998151071" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="291" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Cinciripini-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.16369047619047616" WEIGHT="0.8309872454152183"/>
<DICH_DATA CI_END="3.3180338251609367" CI_START="0.7995548248992429" EFFECT_SIZE="1.628787878787879" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.520880809055993" LOG_CI_START="-0.097151751636482" LOG_EFFECT_SIZE="0.2118645287097555" ORDER="293" O_E="0.0" SE="0.3630353854612752" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="43" VAR="0.13179469109701664" WEIGHT="1.0806927723626485"/>
<DICH_DATA CI_END="2.358871489270788" CI_START="1.1945432704943428" EFFECT_SIZE="1.678622668579627" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="34" LOG_CI_END="0.3727042812752382" LOG_CI_START="0.07720188602106627" LOG_EFFECT_SIZE="0.22495308364815225" ORDER="296" O_E="0.0" SE="0.17357956973274816" STUDY_ID="STD-Hughes-1999" TOTAL_1="779" TOTAL_2="260" VAR="0.030129867028605983" WEIGHT="6.052393285320355"/>
<DICH_DATA CI_END="3.204629081127771" CI_START="0.6457386936581349" EFFECT_SIZE="1.4385245901639345" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5057777694736735" LOG_CI_START="-0.18994318921948414" LOG_EFFECT_SIZE="0.15791729012709468" ORDER="294" O_E="0.0" SE="0.4086699350106484" STUDY_ID="STD-Hughes-2003" TOTAL_1="61" TOTAL_2="54" VAR="0.1670111157816076" WEIGHT="1.0075075174226746"/>
<DICH_DATA CI_END="1.8298847059469658" CI_START="0.6989802602453846" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.2624237273542518" LOG_CI_START="-0.15553508890031958" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="292" O_E="0.0" SE="0.24551107759744292" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="0.06027568922305764" WEIGHT="2.492961736245655"/>
<DICH_DATA CI_END="2.07470394355916" CI_START="1.2940930343094075" EFFECT_SIZE="1.6385542168674698" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="83" LOG_CI_END="0.31695613244478194" LOG_CI_START="0.11196549954350524" LOG_EFFECT_SIZE="0.2144608159941436" ORDER="298" O_E="0.0" SE="0.12041251248620802" STUDY_ID="STD-Otero-2006" TOTAL_1="408" TOTAL_2="408" VAR="0.0144991731632412" WEIGHT="9.853134481351875"/>
<DICH_DATA CI_END="4.551776484470188" CI_START="0.8367371518627194" EFFECT_SIZE="1.9515738498789346" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6581809278280224" LOG_CI_START="-0.07741094753064312" LOG_EFFECT_SIZE="0.2903849901486896" ORDER="297" O_E="0.0" SE="0.43209030882418825" STUDY_ID="STD-Prapavessis-2007" TOTAL_1="59" TOTAL_2="62" VAR="0.18670203497978238" WEIGHT="0.810384255859469"/>
<DICH_DATA CI_END="3.7386899573042225" CI_START="1.1327257863865658" EFFECT_SIZE="2.0578898225957047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5727194514032413" LOG_CI_START="0.05412478729254229" LOG_EFFECT_SIZE="0.31342211934789177" ORDER="295" O_E="0.0" SE="0.30462507278361334" STUDY_ID="STD-Richmond-1994" TOTAL_1="153" TOTAL_2="152" VAR="0.09279643496842171" WEIGHT="1.6674235875216838"/>
<DICH_DATA CI_END="2.6170951223873518" CI_START="1.2476508655425136" EFFECT_SIZE="1.8069922508560101" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="31" LOG_CI_END="0.4178195080342886" LOG_CI_START="0.09609307222018122" LOG_EFFECT_SIZE="0.25695629012723487" ORDER="299" O_E="0.0" SE="0.18898370096874859" STUDY_ID="STD-TNSG-1991" TOTAL_1="537" TOTAL_2="271" VAR="0.03571483923184539" WEIGHT="4.891599955596584"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.13812191120458478" CI_END="1.4662049241946113" CI_START="0.8831405714703505" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1379213745447754" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.16619467373435362" LOG_CI_START="-0.05397016329112653" LOG_EFFECT_SIZE="0.05611225522161353" METHOD="MH" NO="3" P_CHI2="0.9332698026818852" P_Q="0.7124709061194987" P_Z="0.31776978384029253" Q="0.13582155268265084" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="485" TOTAL_2="315" WEIGHT="100.0" Z="0.9990514453763945">
<NAME>Long versus short support</NAME>
<GROUP_LABEL_1>NRT &amp; longer support</GROUP_LABEL_1>
<GROUP_LABEL_2>NRT &amp; briefsupport</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.8340480071417356E-4" CI_END="1.9232688831103737" CI_START="0.7740503406125752" DF="1" EFFECT_SIZE="1.2201257861635217" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.2840400051370188" LOG_CI_START="-0.11123079391746998" LOG_EFFECT_SIZE="0.08640460560977446" NO="1" P_CHI2="0.982458749710471" P_Z="0.3915109530115656" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="146" WEIGHT="31.17938182836866" Z="0.8568804753533047">
<NAME>Nicotine gum</NAME>
<DICH_DATA CI_END="2.30863410903439" CI_START="0.6517754828375432" EFFECT_SIZE="1.2266666666666666" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.363355107876507" LOG_CI_START="-0.18590197996879662" LOG_EFFECT_SIZE="0.08872656395385518" ORDER="300" O_E="0.0" SE="0.3226363322667655" STUDY_ID="STD-Fagerstrom-1984" TOTAL_1="50" TOTAL_2="46" VAR="0.10409420289855072" WEIGHT="14.70725557941918"/>
<DICH_DATA CI_END="2.327854432133079" CI_START="0.6334115121482276" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.36695581906292224" LOG_CI_START="-0.1983140476628505" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="301" O_E="0.0" SE="0.33204231784568683" STUDY_ID="STD-Marshall-1985" TOTAL_1="100" TOTAL_2="100" VAR="0.11025210084033613" WEIGHT="16.47212624894948"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4934489732471041" CI_START="0.8112048146789198" DF="0" EFFECT_SIZE="1.1006784260515603" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="44" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.1741903886302779" LOG_CI_START="-0.09086948036985937" LOG_EFFECT_SIZE="0.04166045413020925" NO="2" P_CHI2="1.0" P_Z="0.5378220667287736" STUDIES="1" TAU2="0.0" TOTAL_1="335" TOTAL_2="169" WEIGHT="68.82061817163134" Z="0.6161097866893672">
<NAME>Nicotine patch</NAME>
<DICH_DATA CI_END="1.4934489732471041" CI_START="0.8112048146789198" EFFECT_SIZE="1.1006784260515603" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="44" LOG_CI_END="0.1741903886302779" LOG_CI_START="-0.09086948036985937" LOG_EFFECT_SIZE="0.04166045413020925" ORDER="302" O_E="0.0" SE="0.1556974791181929" STUDY_ID="STD-Jorenby-1995" TOTAL_1="335" TOTAL_2="169" VAR="0.024241705003760113" WEIGHT="68.82061817163134"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-10-04 16:49:52 +0100" MODIFIED_BY="Lindsay Stead" NO="4">
<NAME>Subgroup: Recruitment /treatment setting</NAME>
<DICH_OUTCOME CHI2="91.77874902766351" CI_END="1.703414276232349" CI_START="1.506961181489485" CI_STUDY="95" CI_TOTAL="95" DF="68" EFFECT_MEASURE="RR" EFFECT_SIZE="1.602179512500755" ESTIMABLE="YES" EVENTS_1="2894" EVENTS_2="1298" I2="25.908774394491072" I2_Q="64.9305196959219" ID="CMP-004.01" LOG_CI_END="0.23132028272572142" LOG_CI_START="0.17810206526616096" LOG_EFFECT_SIZE="0.20471117399594121" METHOD="MH" MODIFIED="2012-10-03 17:44:39 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.02896780528959486" P_Q="0.008891276429408568" P_Z="2.2416909380242044E-51" Q="17.108893396695937" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="66" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14175" TOTAL_2="10024" WEIGHT="100.0" Z="15.078540673401607">
<NAME>Community volunteer (treatment provided in medical setting)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="33.51137332879708" CI_END="1.526041551725056" CI_START="1.2752759194269307" DF="27" EFFECT_SIZE="1.3950354988170985" ESTIMABLE="YES" EVENTS_1="951" EVENTS_2="630" I2="19.430338664162438" ID="CMP-004.01.01" LOG_CI_END="0.18356635893945492" LOG_CI_START="0.10560415913888102" LOG_EFFECT_SIZE="0.14458525903916797" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.18071465960932231" P_Z="3.602184256747823E-13" STUDIES="28" TAU2="0.0" TOTAL_1="4302" TOTAL_2="4034" WEIGHT="46.0170813831158" Z="7.2697256141322315">
<NAME>Nicotine gum</NAME>
<DICH_DATA CI_END="1.8384227647603988" CI_START="0.8616023404348749" EFFECT_SIZE="1.2585663895187704" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="42" LOG_CI_END="0.2644453891448034" LOG_CI_START="-0.06469313000189131" LOG_EFFECT_SIZE="0.09987612957145608" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="324" O_E="0.0" SE="0.19333759540871465" STUDY_ID="STD-Ahluwalia-2006" TOTAL_1="378" TOTAL_2="377" VAR="0.03737942579842384" WEIGHT="3.015410115039296"/>
<DICH_DATA CI_END="2.103496146183185" CI_START="1.133452288226358" EFFECT_SIZE="1.5440895440895441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="37" LOG_CI_END="0.32294172068250876" LOG_CI_START="0.05440324356608751" LOG_EFFECT_SIZE="0.1886724821242981" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="303" O_E="0.0" SE="0.15774083074508602" STUDY_ID="STD-Areechon-1988" TOTAL_1="99" TOTAL_2="101" VAR="0.024882169684149878" WEIGHT="2.6263897312920923"/>
<DICH_DATA CI_END="2.1282902638036596" CI_START="0.8361335572587889" EFFECT_SIZE="1.3339920948616601" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.328030858290107" LOG_CI_START="-0.0777243463076554" LOG_EFFECT_SIZE="0.12515325599122584" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="325" O_E="0.0" SE="0.2383426157013814" STUDY_ID="STD-Blondal-1989" TOTAL_1="92" TOTAL_2="90" VAR="0.056807202459376385" WEIGHT="1.5947454395859977"/>
<DICH_DATA CI_END="10.383127352642541" CI_START="1.8071326338889435" EFFECT_SIZE="4.331707317073171" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="1.0163281808182514" LOG_CI_START="0.25699002862744214" LOG_EFFECT_SIZE="0.6366591047228467" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="304" O_E="0.0" SE="0.44603898938135556" STUDY_ID="STD-Clavel-1985" TOTAL_1="205" TOTAL_2="222" VAR="0.198950780048341" WEIGHT="0.41307554556761655"/>
<DICH_DATA CI_END="1.7823920735615897" CI_START="0.8054121897023883" EFFECT_SIZE="1.1981486981486982" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.25100324215604675" LOG_CI_START="-0.09398180174569425" LOG_EFFECT_SIZE="0.07851072020517626" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="327" O_E="0.0" SE="0.2026459224913915" STUDY_ID="STD-Clavel_x002d_Chapelon-1992" TOTAL_1="481" TOTAL_2="515" VAR="0.04106536990238705" WEIGHT="2.9086219489787073"/>
<DICH_DATA CI_END="2.1977726928730594" CI_START="0.5924633768247419" EFFECT_SIZE="1.141095890410959" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.34198277301205143" LOG_CI_START="-0.227338490439388" LOG_EFFECT_SIZE="0.0573221412863317" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="329" O_E="0.0" SE="0.3344221283370807" STUDY_ID="STD-Cooper-2005" TOTAL_1="146" TOTAL_2="147" VAR="0.11183815992150285" WEIGHT="1.0718369958285336"/>
<DICH_DATA CI_END="1.6021401580365628" CI_START="0.9571701414032476" EFFECT_SIZE="1.2383540372670807" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="84" LOG_CI_END="0.20470050625464503" LOG_CI_START="-0.01901085751583178" LOG_EFFECT_SIZE="0.09284482436940662" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="328" O_E="0.0" SE="0.13140916246788847" STUDY_ID="STD-Fortmann-1995" TOTAL_1="552" TOTAL_2="522" VAR="0.017268367980511908" WEIGHT="6.1910787913638226"/>
<DICH_DATA CI_END="3.6414111243083065" CI_START="1.3428793600393683" EFFECT_SIZE="2.2113289760348582" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="17" LOG_CI_END="0.561269714621607" LOG_CI_START="0.1280369988023339" LOG_EFFECT_SIZE="0.34465335671197045" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="305" O_E="0.0" SE="0.25448304180877096" STUDY_ID="STD-Garvey-2000" TOTAL_1="405" TOTAL_2="203" VAR="0.06476161856824468" WEIGHT="1.6238750682452237"/>
<DICH_DATA CI_END="4.7927472328753025" CI_START="0.978339288206984" EFFECT_SIZE="2.1653944020356235" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.6805845251190232" LOG_CI_START="-0.009510505700700772" LOG_EFFECT_SIZE="0.33553700970916117" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="306" O_E="0.0" SE="0.40536523712900135" STUDY_ID="STD-Gross-1995" TOTAL_1="131" TOTAL_2="46" VAR="0.1643209754726515" WEIGHT="0.636797761951654"/>
<DICH_DATA CI_END="2.9681504720636167" CI_START="0.8415818958233378" EFFECT_SIZE="1.5804878048780489" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.4724859139689923" LOG_CI_START="-0.07490361566727656" LOG_EFFECT_SIZE="0.19879114915085785" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="307" O_E="0.0" SE="0.32153931933021623" STUDY_ID="STD-Hall-1985" TOTAL_1="41" TOTAL_2="36" VAR="0.10338753387533876" WEIGHT="0.7635638872613518"/>
<DICH_DATA CI_END="3.5225719722255557" CI_START="1.1957150368524538" EFFECT_SIZE="2.052313883299799" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.5468598752579272" LOG_CI_START="0.07762769079924374" LOG_EFFECT_SIZE="0.31224378302858546" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="308" O_E="0.0" SE="0.2756293078878044" STUDY_ID="STD-Hall-1987" TOTAL_1="71" TOTAL_2="68" VAR="0.07597151536671005" WEIGHT="1.025472061821536"/>
<DICH_DATA CI_END="1.4411817402647455" CI_START="0.5631316900126799" EFFECT_SIZE="0.9008746355685131" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.1587187509855719" LOG_CI_START="-0.2493900322214436" LOG_EFFECT_SIZE="-0.04533564061793586" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="309" O_E="0.0" SE="0.23972511942685867" STUDY_ID="STD-Hall-1996" TOTAL_1="98" TOTAL_2="103" VAR="0.05746813288422166" WEIGHT="1.957673663532053"/>
<DICH_DATA CI_END="4.183776315605878" CI_START="1.3407548251623347" EFFECT_SIZE="2.3684210526315788" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="0.6215684570506804" LOG_CI_START="0.12734936859434903" LOG_EFFECT_SIZE="0.3744589128225147" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="310" O_E="0.0" SE="0.29030673898319226" STUDY_ID="STD-Herrera-1995" TOTAL_1="76" TOTAL_2="78" VAR="0.08427800269905533" WEIGHT="0.9200013666027019"/>
<DICH_DATA CI_END="2.681155502451401" CI_START="0.6431234010669704" EFFECT_SIZE="1.3131313131313131" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.42832200305341434" LOG_CI_START="-0.19170568763484058" LOG_EFFECT_SIZE="0.11830815770928686" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="311" O_E="0.0" SE="0.36420733469684907" STUDY_ID="STD-Huber-1988" TOTAL_1="54" TOTAL_2="60" VAR="0.13264698264698266" WEIGHT="0.7471948026435539"/>
<DICH_DATA CI_END="2.3062603685392586" CI_START="0.40470386503207123" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.36290833601880523" LOG_CI_START="-0.39286264795811077" LOG_EFFECT_SIZE="-0.014977155969652801" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="312" O_E="0.0" SE="0.4439436171147473" STUDY_ID="STD-Hughes-1990" TOTAL_1="59" TOTAL_2="19" VAR="0.19708593517692535" WEIGHT="0.5423500218618388"/>
<DICH_DATA CI_END="2.631581726997257" CI_START="0.5583097867724814" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.42021686211038434" LOG_CI_START="-0.25312475921023436" LOG_EFFECT_SIZE="0.08354605145007492" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="313" O_E="0.0" SE="0.3955242014585124" STUDY_ID="STD-Killen-1984" TOTAL_1="44" TOTAL_2="20" VAR="0.15643939393939393" WEIGHT="0.5915292187594802"/>
<DICH_DATA CI_END="1.485983274795411" CI_START="0.9440549662841833" EFFECT_SIZE="1.184419642857143" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="112" LOG_CI_END="0.17201392133240373" LOG_CI_START="-0.02500271877507291" LOG_EFFECT_SIZE="0.07350560127866544" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="314" O_E="0.0" SE="0.11572854964722892" STUDY_ID="STD-Killen-1990" TOTAL_1="600" TOTAL_2="617" VAR="0.013393097203451129" WEIGHT="7.918281616620516"/>
<DICH_DATA CI_END="12.85331251038475" CI_START="0.8550075403053737" EFFECT_SIZE="3.315068493150685" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.1090150669349643" LOG_CI_START="-0.06803005521501355" LOG_EFFECT_SIZE="0.5204925058599754" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="315" O_E="0.0" SE="0.6914021312182197" STUDY_ID="STD-Malcolm-1980" TOTAL_1="73" TOTAL_2="121" VAR="0.4780369070530963" WEIGHT="0.1618805359679177"/>
<DICH_DATA CI_END="1.5563577448421877" CI_START="0.7903376452759279" EFFECT_SIZE="1.1090753424657533" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="40" LOG_CI_END="0.19210943118401463" LOG_CI_START="-0.10218733130102724" LOG_EFFECT_SIZE="0.04496104994149371" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="316" O_E="0.0" SE="0.17287137507618275" STUDY_ID="STD-McGovern-1992" TOTAL_1="146" TOTAL_2="127" VAR="0.029884512320730257" WEIGHT="3.0676262737754367"/>
<DICH_DATA CI_END="15.439929239254754" CI_START="0.7835721582188115" EFFECT_SIZE="3.4782608695652173" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.188645305645338" LOG_CI_START="-0.10592100369663676" LOG_EFFECT_SIZE="0.5413621509743507" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="326" O_E="0.0" SE="0.7604346583140575" STUDY_ID="STD-Moolchan-2005" TOTAL_1="46" TOTAL_2="40" VAR="0.5782608695652174" WEIGHT="0.1534057452455875"/>
<DICH_DATA CI_END="6.386765392813436" CI_START="1.0584387533017163" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8052809633667104" LOG_CI_START="0.0246657325749255" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="317" O_E="0.0" SE="0.45853725067480644" STUDY_ID="STD-Nakamura-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.2102564102564103" WEIGHT="0.3585025568239274"/>
<DICH_DATA CI_END="5.2337006044292" CI_START="0.0477673483631121" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="318" O_E="0.0" SE="1.1981168018885897" STUDY_ID="STD-Niaura-1999" TOTAL_1="31" TOTAL_2="31" VAR="1.435483870967742" WEIGHT="0.14340102272957095"/>
<DICH_DATA CI_END="2.078053930950937" CI_START="1.135942042364552" EFFECT_SIZE="1.5364077669902914" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="50" LOG_CI_END="0.3176568144485229" LOG_CI_START="0.055356173519918124" LOG_EFFECT_SIZE="0.18650649398422053" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="319" O_E="0.0" SE="0.15407669489057554" STUDY_ID="STD-Pirie-1992" TOTAL_1="206" TOTAL_2="211" VAR="0.023739627908403504" WEIGHT="3.54203965015487"/>
<DICH_DATA CI_END="2.214103369188008" CI_START="0.8173356122679534" EFFECT_SIZE="1.3452380952380953" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.34519789279382823" LOG_CI_START="-0.08759957795075202" LOG_EFFECT_SIZE="0.1287991574215381" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="320" O_E="0.0" SE="0.2542273766973985" STUDY_ID="STD-Puska-1979" TOTAL_1="116" TOTAL_2="113" VAR="0.06463155906244096" WEIGHT="1.5254362068525538"/>
<DICH_DATA CI_END="3.691402296267391" CI_START="0.6095244623635621" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5671913780399481" LOG_CI_START="-0.21500885992858565" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="321" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-Schneider-1985A" TOTAL_1="30" TOTAL_2="30" VAR="0.21111111111111114" WEIGHT="0.43020306818871284"/>
<DICH_DATA CI_END="5.106444992004984" CI_START="0.06810951693167992" EFFECT_SIZE="0.5897435897435898" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.7081186579322872" LOG_CI_START="-1.1667921999500996" LOG_EFFECT_SIZE="-0.22933677100890631" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="330" O_E="0.0" SE="1.101331918878542" STUDY_ID="STD-Schneider-1985B" TOTAL_1="13" TOTAL_2="23" VAR="1.2129319955406912" WEIGHT="0.1553511079570352"/>
<DICH_DATA CI_END="2.5688705692797895" CI_START="0.7220233680433636" EFFECT_SIZE="1.361904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4097422231983706" LOG_CI_START="-0.14144874640812305" LOG_EFFECT_SIZE="0.13414673839512375" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="322" O_E="0.0" SE="0.3237723039861576" STUDY_ID="STD-Villa-1999" TOTAL_1="21" TOTAL_2="26" VAR="0.10482850482850484" WEIGHT="0.6407279738980829"/>
<DICH_DATA CI_END="2.102418926599776" CI_START="0.7765893032666391" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3227192575452336" LOG_CI_START="-0.10980859571666014" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="323" O_E="0.0" SE="0.2540690020534404" STUDY_ID="STD-Zelman-1992" TOTAL_1="58" TOTAL_2="58" VAR="0.0645510578044311" WEIGHT="1.2906092045661386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="32.86973565684052" CI_END="1.8926521283887325" CI_START="1.5545468735803278" DF="27" EFFECT_SIZE="1.7152890278206345" ESTIMABLE="YES" EVENTS_1="1385" EVENTS_2="478" I2="17.857568792522276" ID="CMP-004.01.02" LOG_CI_END="0.2770707974796161" LOG_CI_START="0.19160382167054119" LOG_EFFECT_SIZE="0.23433730957507865" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.20140288273117224" P_Z="6.066567435435548E-27" STUDIES="28" TAU2="0.0" TOTAL_1="7051" TOTAL_2="3765" WEIGHT="39.26974866800116" Z="10.747839914850465">
<NAME>Nicotine patch</NAME>
<DICH_DATA CI_END="2.8593078037343456" CI_START="0.7422768702931712" EFFECT_SIZE="1.4568452380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.45626090956152343" LOG_CI_START="-0.12943407206289823" LOG_EFFECT_SIZE="0.1634134187493126" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="356" O_E="0.0" SE="0.34404013144310264" STUDY_ID="STD-Buchkremer-1988" TOTAL_1="42" TOTAL_2="89" VAR="0.11836361204338733" WEIGHT="0.7356144066738296"/>
<DICH_DATA CI_END="1.8113081221041267" CI_START="1.1243557445017534" EFFECT_SIZE="1.427079077048801" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="71" LOG_CI_END="0.25799233454774956" LOG_CI_START="0.050903743110311706" LOG_EFFECT_SIZE="0.1544480388290306" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="357" O_E="0.0" SE="0.12164486371541124" STUDY_ID="STD-CEASE-1999" TOTAL_1="2861" TOTAL_2="714" VAR="0.014797472868340973" WEIGHT="8.148026055407126"/>
<DICH_DATA CI_END="3.788507155734091" CI_START="0.775708053172369" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.578468111881843" LOG_CI_START="-0.1103016998151071" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="358" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Cinciripini-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.16369047619047616" WEIGHT="0.5019035795534983"/>
<DICH_DATA CI_END="9.275880948360145" CI_START="1.27126435723578" EFFECT_SIZE="3.4339622641509435" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.9673551660329998" LOG_CI_START="0.1042358707355719" LOG_EFFECT_SIZE="0.5357955183842857" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="359" O_E="0.0" SE="0.507000546567127" STUDY_ID="STD-Daughton-1991" TOTAL_1="106" TOTAL_2="52" VAR="0.25704955421936554" WEIGHT="0.38482299770467143"/>
<DICH_DATA CI_END="3.4000401052481815" CI_START="0.8169838271878318" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5314840398026245" LOG_CI_START="-0.08778654056991181" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="360" O_E="0.0" SE="0.3637626043496394" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="44" VAR="0.1323232323232323" WEIGHT="0.6453046022830693"/>
<DICH_DATA CI_END="7.237905645439162" CI_START="0.8039754134848986" EFFECT_SIZE="2.412280701754386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8596129172728425" LOG_CI_START="-0.09475723228526235" LOG_EFFECT_SIZE="0.3824278424937901" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="361" O_E="0.0" SE="0.5606017500588621" STUDY_ID="STD-Fiore-1994B" TOTAL_1="57" TOTAL_2="55" VAR="0.314274322169059" WEIGHT="0.2919235105566266"/>
<DICH_DATA CI_END="3.103911528273855" CI_START="0.6721904713072535" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49190933393600517" LOG_CI_START="-0.1725076482009813" LOG_EFFECT_SIZE="0.15970084286751188" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="362" O_E="0.0" SE="0.39028182422437036" STUDY_ID="STD-Glavas-2003a" TOTAL_1="56" TOTAL_2="56" VAR="0.15231990231990233" WEIGHT="0.6453046022830693"/>
<DICH_DATA CI_END="4.390778670369073" CI_START="1.3301234738135557" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6425415458131081" LOG_CI_START="0.12389195788955437" LOG_EFFECT_SIZE="0.38321675185133125" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="363" O_E="0.0" SE="0.3046573353031615" STUDY_ID="STD-Glavas-2003b" TOTAL_1="80" TOTAL_2="80" VAR="0.09281609195402299" WEIGHT="0.8604061363774257"/>
<DICH_DATA CI_END="2.358871489270788" CI_START="1.1945432704943428" EFFECT_SIZE="1.678622668579627" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="34" LOG_CI_END="0.3727042812752382" LOG_CI_START="0.07720188602106627" LOG_EFFECT_SIZE="0.22495308364815225" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="380" O_E="0.0" SE="0.17357956973274816" STUDY_ID="STD-Hughes-1999" TOTAL_1="779" TOTAL_2="260" VAR="0.030129867028605983" WEIGHT="3.655552923980189"/>
<DICH_DATA CI_END="3.204629081127771" CI_START="0.6457386936581349" EFFECT_SIZE="1.4385245901639345" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5057777694736735" LOG_CI_START="-0.18994318921948414" LOG_EFFECT_SIZE="0.15791729012709468" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="364" O_E="0.0" SE="0.4086699350106484" STUDY_ID="STD-Hughes-2003" TOTAL_1="61" TOTAL_2="54" VAR="0.1670111157816076" WEIGHT="0.6085191225393968"/>
<DICH_DATA CI_END="3.393314017187208" CI_START="0.5239060602034752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5306240511043927" LOG_CI_START="-0.28074657788779284" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="365" O_E="0.0" SE="0.4766031238193982" STUDY_ID="STD-Hurt-1990" TOTAL_1="31" TOTAL_2="31" VAR="0.2271505376344086" WEIGHT="0.43020306818871284"/>
<DICH_DATA CI_END="3.2899905062299095" CI_START="1.1453425421228474" EFFECT_SIZE="1.9411764705882353" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5171946447287246" LOG_CI_START="0.05893539227050256" LOG_EFFECT_SIZE="0.2880650184996135" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="366" O_E="0.0" SE="0.26918375331384387" STUDY_ID="STD-Hurt-1994" TOTAL_1="120" TOTAL_2="120" VAR="0.07245989304812835" WEIGHT="1.218908693201353"/>
<DICH_DATA CI_END="3.6638765871680388" CI_START="0.8345587993406903" EFFECT_SIZE="1.7486338797814207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.563940836607552" LOG_CI_START="-0.078543059428599" LOG_EFFECT_SIZE="0.2426988885894765" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="367" O_E="0.0" SE="0.37739822087821245" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.14242941712204005" WEIGHT="0.7794768463221233"/>
<DICH_DATA CI_END="1.9175853297600345" CI_START="0.6255505122219942" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2827546985242227" LOG_CI_START="-0.20373761595687537" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="368" O_E="0.0" SE="0.28576799370199224" STUDY_ID="STD-Killen-1997" TOTAL_1="212" TOTAL_2="212" VAR="0.08166334622446189" WEIGHT="1.5057107386604949"/>
<DICH_DATA CI_END="1.9396324884607696" CI_START="0.46529433043070706" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.2877194498511332" LOG_CI_START="-0.3322722392734377" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="381" O_E="0.0" SE="0.3641861872001304" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="150" TOTAL_2="75" VAR="0.13263157894736843" WEIGHT="0.9560068181971397"/>
<DICH_DATA CI_END="22.85043813806692" CI_START="1.2265708644863083" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3588945317196774" LOG_CI_START="0.0886926444024243" LOG_EFFECT_SIZE="0.723793588061051" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="377" O_E="0.0" SE="0.7461228762109019" STUDY_ID="STD-Moolchan-2005" TOTAL_1="34" TOTAL_2="40" VAR="0.5566993464052288" WEIGHT="0.13177391277852465"/>
<DICH_DATA CI_END="1.8298847059469658" CI_START="0.6989802602453846" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.2624237273542518" LOG_CI_START="-0.15553508890031958" LOG_EFFECT_SIZE="0.0534443192269661" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="379" O_E="0.0" SE="0.24551107759744292" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="0.06027568922305764" WEIGHT="1.5057107386604949"/>
<DICH_DATA CI_END="1.9414129420303619" CI_START="1.310754497312224" EFFECT_SIZE="1.5952165197572563" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="122" LOG_CI_END="0.2881179204326567" LOG_CI_START="0.1175213564903053" LOG_EFFECT_SIZE="0.20281963846148102" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="382" O_E="0.0" SE="0.10020926612634813" STUDY_ID="STD-Otero-2006" TOTAL_1="597" TOTAL_2="602" VAR="0.010041897017581264" WEIGHT="8.710984228094722"/>
<DICH_DATA CI_END="10.644319166426266" CI_START="1.3211272398102434" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0271178882524812" LOG_CI_START="0.12094464720295672" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="369" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Paoletti-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.2833333333333333" WEIGHT="0.2868020454591419"/>
<DICH_DATA CI_END="10.709518607104284" CI_START="0.9561587570525513" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0297699497322355" LOG_CI_START="-0.01946999309242347" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="370" O_E="0.0" SE="0.6163287362366865" STUDY_ID="STD-Perng-1998" TOTAL_1="30" TOTAL_2="32" VAR="0.3798611111111111" WEIGHT="0.20816277493002236"/>
<DICH_DATA CI_END="3.0007141337297876" CI_START="0.8411651795025185" EFFECT_SIZE="1.588740458015267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="8" LOG_CI_END="0.4772246238629811" LOG_CI_START="-0.07511871347371944" LOG_EFFECT_SIZE="0.20105295519463082" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="606" O_E="0.0" SE="0.3244492104951934" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1052672901909543" WEIGHT="1.0052459653551193"/>
<DICH_DATA CI_END="4.551776484470188" CI_START="0.8367371518627194" EFFECT_SIZE="1.9515738498789346" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6581809278280224" LOG_CI_START="-0.07741094753064312" LOG_EFFECT_SIZE="0.2903849901486896" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="378" O_E="0.0" SE="0.43209030882418825" STUDY_ID="STD-Prapavessis-2007" TOTAL_1="59" TOTAL_2="62" VAR="0.18670203497978238" WEIGHT="0.48945968915134547"/>
<DICH_DATA CI_END="3.7386899573042225" CI_START="1.1327257863865658" EFFECT_SIZE="2.0578898225957047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5727194514032413" LOG_CI_START="0.05412478729254229" LOG_EFFECT_SIZE="0.31342211934789177" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="371" O_E="0.0" SE="0.30462507278361334" STUDY_ID="STD-Richmond-1994" TOTAL_1="153" TOTAL_2="152" VAR="0.09279643496842171" WEIGHT="1.0070983301204621"/>
<DICH_DATA CI_END="5.191155779737516" CI_START="1.3541372015357949" EFFECT_SIZE="2.651327433628319" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7152640616789412" LOG_CI_START="0.1316626694090771" LOG_EFFECT_SIZE="0.42346336554400915" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="372" O_E="0.0" SE="0.3428103466928011" STUDY_ID="STD-Sachs-1993" TOTAL_1="113" TOTAL_2="107" VAR="0.11751893379963846" WEIGHT="0.7365597985655236"/>
<DICH_DATA CI_END="2.6170951223873518" CI_START="1.2476508655425136" EFFECT_SIZE="1.8069922508560101" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="31" LOG_CI_END="0.4178195080342886" LOG_CI_START="0.09609307222018122" LOG_EFFECT_SIZE="0.25695629012723487" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="373" O_E="0.0" SE="0.18898370096874859" STUDY_ID="STD-TNSG-1991" TOTAL_1="537" TOTAL_2="271" VAR="0.03571483923184539" WEIGHT="2.954451516558376"/>
<DICH_DATA CI_END="9.428558561934224" CI_START="1.673646214316064" EFFECT_SIZE="3.972413793103448" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9744453028701352" LOG_CI_START="0.22366365950633915" LOG_EFFECT_SIZE="0.5990544811882371" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="374" O_E="0.0" SE="0.44101285374096627" STUDY_ID="STD-Tonnesen-1991" TOTAL_1="145" TOTAL_2="144" VAR="0.19449233716475092" WEIGHT="0.4316916601201617"/>
<DICH_DATA CI_END="34.51060023583957" CI_START="1.9508246278682124" EFFECT_SIZE="8.205128205128204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5379525129526281" LOG_CI_START="0.2902182296341853" LOG_EFFECT_SIZE="0.9140853712934067" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="375" O_E="0.0" SE="0.7329252944055672" STUDY_ID="STD-Westman-1993" TOTAL_1="78" TOTAL_2="80" VAR="0.5371794871794873" WEIGHT="0.1415858199102093"/>
<DICH_DATA CI_END="9.51135034004292" CI_START="1.1889010697860327" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9782421787248091" LOG_CI_START="0.07514571783689675" LOG_EFFECT_SIZE="0.5266939482808529" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="376" O_E="0.0" SE="0.5304833315251388" STUDY_ID="STD-Wong-1999" TOTAL_1="51" TOTAL_2="49" VAR="0.28141256502601036" WEIGHT="0.29253808636832473"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09350418934642911" CI_END="3.2707803847344508" CI_START="0.9803770916978085" DF="1" EFFECT_SIZE="1.7906976744186047" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.5146513845713445" LOG_CI_START="-0.008606845385553645" LOG_EFFECT_SIZE="0.25302226959289537" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="0.7597687137720697" P_Z="0.05802793798993608" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="221" WEIGHT="1.078401413082917" Z="1.8954868066939288">
<NAME>Nicotine inhaler/inhalator</NAME>
<DICH_DATA CI_END="5.138806492602952" CI_START="0.7783908589976669" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.7108622641578292" LOG_CI_START="-0.1088022728298668" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="397" O_E="0.0" SE="0.4814750064314676" STUDY_ID="STD-Leischow-1996" TOTAL_1="110" TOTAL_2="110" VAR="0.2318181818181818" WEIGHT="0.43020306818871284"/>
<DICH_DATA CI_END="3.6162983248620826" CI_START="0.7544720597746652" EFFECT_SIZE="1.6517857142857142" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5582642502041109" LOG_CI_START="-0.12235683873844654" LOG_EFFECT_SIZE="0.21795370573283215" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="398" O_E="0.0" SE="0.3998001967735851" STUDY_ID="STD-Schneider-1996" TOTAL_1="112" TOTAL_2="111" VAR="0.15984019734019733" WEIGHT="0.648198344894204"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.878006862788645" CI_END="2.362934424475668" CI_START="1.6090771772138273" DF="6" EFFECT_SIZE="1.949908678291547" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="134" I2="23.838604046656936" ID="CMP-004.01.04" LOG_CI_END="0.3734516693752663" LOG_CI_START="0.20657687494692692" LOG_EFFECT_SIZE="0.2900142721610966" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="4" P_CHI2="0.24717800539777546" P_Z="9.591497863715656E-12" STUDIES="7" TAU2="0.0" TOTAL_1="1808" TOTAL_2="1597" WEIGHT="10.001287048287423" Z="6.812503115111743">
<NAME>Nicotine tablet/lozenge</NAME>
<DICH_DATA CI_END="2.599030005476736" CI_START="0.8216081753741146" EFFECT_SIZE="1.4612954186413902" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.41481129340549555" LOG_CI_START="-0.0853352479621405" LOG_EFFECT_SIZE="0.1647380227216775" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="401" O_E="0.0" SE="0.2937885541646578" STUDY_ID="STD-Dautzenberg-2001" TOTAL_1="211" TOTAL_2="222" VAR="0.08631171455816007" WEIGHT="1.2578223656510634"/>
<DICH_DATA CI_END="3.5641314400155784" CI_START="0.9588207106381352" EFFECT_SIZE="1.8486111111111112" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5519537118128934" LOG_CI_START="-0.01826259372608003" LOG_EFFECT_SIZE="0.2668455590434067" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="402" O_E="0.0" SE="0.334947880489828" STUDY_ID="STD-Glover-2002" TOTAL_1="120" TOTAL_2="121" VAR="0.1121900826446281" WEIGHT="0.8568359864339509"/>
<DICH_DATA CI_END="2.840592039873378" CI_START="0.7981931035871063" EFFECT_SIZE="1.5057692307692307" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="8" LOG_CI_END="0.45340886569971645" LOG_CI_START="-0.09789202885342803" LOG_EFFECT_SIZE="0.17775841842314424" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="607" O_E="0.0" SE="0.32383687444395765" STUDY_ID="STD-Piper-2009" TOTAL_1="260" TOTAL_2="36" VAR="0.1048703212496316" WEIGHT="1.0076828624240122"/>
<DICH_DATA CI_END="2.619490937555498" CI_START="1.320112782911037" EFFECT_SIZE="1.8595761536938007" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="44" LOG_CI_END="0.4182169002924789" LOG_CI_START="0.12061103643579552" LOG_EFFECT_SIZE="0.26941396836413717" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="403" O_E="0.0" SE="0.17481515760220095" STUDY_ID="STD-Shiffman-2002-_x0028_2mg_x0029_" TOTAL_1="459" TOTAL_2="458" VAR="0.03056033932748236" WEIGHT="3.158262873551161"/>
<DICH_DATA CI_END="3.6546005624652707" CI_START="1.5736990483666073" EFFECT_SIZE="2.398174603174603" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="28" LOG_CI_END="0.5628399167256342" LOG_CI_START="0.19692168219681386" LOG_EFFECT_SIZE="0.37988079946122405" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="405" O_E="0.0" SE="0.21494218228670267" STUDY_ID="STD-Shiffman-2002-_x0028_4mg_x0029_" TOTAL_1="450" TOTAL_2="451" VAR="0.04620014172617012" WEIGHT="2.0053861114235225"/>
<DICH_DATA CI_END="13.247535015101889" CI_START="2.041134442684999" EFFECT_SIZE="5.2" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="1.1221350760894007" LOG_CI_START="0.3098716111801976" LOG_EFFECT_SIZE="0.7160033436347992" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="406" O_E="0.0" SE="0.47712758005666334" STUDY_ID="STD-Tonnesen-2006" TOTAL_1="185" TOTAL_2="185" VAR="0.22765072765072766" WEIGHT="0.3585025568239274"/>
<DICH_DATA CI_END="2.515139905583403" CI_START="0.877566144632535" EFFECT_SIZE="1.4856653829696191" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="19" LOG_CI_END="0.4005621478543411" LOG_CI_START="-0.05672013962988632" LOG_EFFECT_SIZE="0.17192100411222738" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="404" O_E="0.0" SE="0.26860987925206486" STUDY_ID="STD-Wallstrom-2000" TOTAL_1="123" TOTAL_2="124" VAR="0.07215126723180887" WEIGHT="1.3567942919797866"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7279091128648988" CI_END="2.9467427802815105" CI_START="1.1618147701413821" DF="1" EFFECT_SIZE="1.8502889736304813" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="23" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="0.46934222815404764" LOG_CI_START="0.06513689335739421" LOG_EFFECT_SIZE="0.26723956075572086" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="5" P_CHI2="0.3935617934614186" P_Z="0.009551615494829005" STUDIES="2" TAU2="0.0" TOTAL_1="207" TOTAL_2="205" WEIGHT="1.6578605311669357" Z="2.5916526539117477">
<NAME>Nicotine intranasal spray</NAME>
<DICH_DATA CI_END="2.8357284087598496" CI_START="0.8136613285448909" EFFECT_SIZE="1.518987341772152" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.4526646340480194" LOG_CI_START="-0.0895563245336525" LOG_EFFECT_SIZE="0.18155415475718342" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="407" O_E="0.0" SE="0.3185032751079066" STUDY_ID="STD-Blondal-1997" TOTAL_1="79" TOTAL_2="78" VAR="0.10144433625446284" WEIGHT="0.9380436327596775"/>
<DICH_DATA CI_END="4.598422490931164" CI_START="1.132489812810138" EFFECT_SIZE="2.28203125" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.6626088705980535" LOG_CI_START="0.0540343040533092" LOG_EFFECT_SIZE="0.3583215873256814" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="408" O_E="0.0" SE="0.3574797128810721" STUDY_ID="STD-Schneider-1995" TOTAL_1="128" TOTAL_2="127" VAR="0.12779174512153374" WEIGHT="0.719816898407258"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.311666379724095" CI_START="1.0064243785295333" DF="0" EFFECT_SIZE="1.8256346233874323" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="9" I2="0.0" ID="CMP-004.01.06" LOG_CI_END="0.5200465790963031" LOG_CI_START="0.002781148105786916" LOG_EFFECT_SIZE="0.261413863601045" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="6" P_CHI2="1.0" P_Z="0.047586786701920306" STUDIES="1" TAU2="0.0" TOTAL_1="267" TOTAL_2="41" WEIGHT="1.1188073299323342" Z="1.9810400116489066">
<NAME>Combination of NRT</NAME>
<DICH_DATA CI_END="3.311666379724095" CI_START="1.0064243785295333" EFFECT_SIZE="1.8256346233874323" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="9" LOG_CI_END="0.5200465790963031" LOG_CI_START="0.002781148105786916" LOG_EFFECT_SIZE="0.261413863601045" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="608" O_E="0.0" SE="0.30384427466900793" STUDY_ID="STD-Piper-2009" TOTAL_1="267" TOTAL_2="41" VAR="0.09232134324913552" WEIGHT="1.1188073299323342"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.942316708730255" CI_START="1.2396162884442532" DF="0" EFFECT_SIZE="2.475192173305381" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="9" I2="0.0" ID="CMP-004.01.07" LOG_CI_END="0.6939305719941906" LOG_CI_START="0.09328727419436869" LOG_EFFECT_SIZE="0.39360892309427964" MODIFIED="2012-08-22 16:38:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="7" P_CHI2="1.0" P_Z="0.010205814012119178" STUDIES="1" TAU2="0.0" TOTAL_1="318" TOTAL_2="161" WEIGHT="0.8568136264134281" Z="2.5687768966515314">
<NAME>Nicotine oral spray</NAME>
<DICH_DATA CI_END="4.942316708730255" CI_START="1.2396162884442532" EFFECT_SIZE="2.475192173305381" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="9" LOG_CI_END="0.6939305719941906" LOG_CI_START="0.09328727419436869" LOG_EFFECT_SIZE="0.39360892309427964" MODIFIED="2012-08-22 16:38:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="652" O_E="0.0" SE="0.35282084635989114" STUDY_ID="STD-T_x00f8_nnesen-2012" TOTAL_1="318" TOTAL_2="161" VAR="0.12448254962610993" WEIGHT="0.8568136264134281"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.979350634536788" CI_END="2.0340674310537463" CI_START="1.4774796030646828" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.733578132257121" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="168" I2="30.659088783287224" I2_Q="14.098962865281328" ID="CMP-004.02" LOG_CI_END="0.308365346054344" LOG_CI_START="0.16952149406253092" LOG_EFFECT_SIZE="0.23894342005843747" METHOD="MH" MODIFIED="2012-10-04 16:49:38 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.16354290453767772" P_Q="0.3121941056941172" P_Z="1.519738307003853E-11" Q="2.3282605969743977" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1227" TOTAL_2="1064" WEIGHT="99.99999999999997" Z="6.7460026632648855">
<NAME>Smoking clinic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.145303234225718" CI_END="1.9131274914205725" CI_START="1.3026425894663802" DF="5" EFFECT_SIZE="1.5786454159827705" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="110" I2="38.61493112999748" ID="CMP-004.02.01" LOG_CI_END="0.2817439125131849" LOG_CI_START="0.11482527318388473" LOG_EFFECT_SIZE="0.19828459284853484" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.14840755098932912" P_Z="3.215865274792603E-6" STUDIES="6" TAU2="0.0" TOTAL_1="718" TOTAL_2="565" WEIGHT="67.35169878688168" Z="4.656528021482596">
<NAME>Nicotine gum</NAME>
<DICH_DATA CI_END="1.899800104778201" CI_START="0.8955275068880978" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.27870790729028233" LOG_CI_START="-0.04792106988614322" LOG_EFFECT_SIZE="0.11539341870206957" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="331" O_E="0.0" SE="0.19186347803294543" STUDY_ID="STD-Fagerstrom-1982" TOTAL_1="50" TOTAL_2="50" VAR="0.036811594202898534" WEIGHT="12.858881757630249"/>
<DICH_DATA CI_END="2.712769410117531" CI_START="0.7913564709479441" EFFECT_SIZE="1.4651851851851851" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4334128795818624" LOG_CI_START="-0.10162784204955344" LOG_EFFECT_SIZE="0.16589251876615446" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="332" O_E="0.0" SE="0.31428556838058" STUDY_ID="STD-Fee-1982" TOTAL_1="180" TOTAL_2="172" VAR="0.09877541849230424" WEIGHT="8.576823306719781"/>
<DICH_DATA CI_END="3.1300417111171157" CI_START="1.067386158715058" EFFECT_SIZE="1.8278301886792452" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.49555012501842827" LOG_CI_START="0.02832156680872703" LOG_EFFECT_SIZE="0.26193584591357766" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="333" O_E="0.0" SE="0.27445236791104227" STUDY_ID="STD-Hjalmarson-1984" TOTAL_1="106" TOTAL_2="100" VAR="0.0753241022519781" WEIGHT="9.205852030789744"/>
<DICH_DATA CI_END="4.848340156021888" CI_START="1.232444187018039" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.6855930820123821" LOG_CI_START="0.09076726075338054" LOG_EFFECT_SIZE="0.3881801713828814" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="334" O_E="0.0" SE="0.34940363184284007" STUDY_ID="STD-Jarvis-1982" TOTAL_1="58" TOTAL_2="58" VAR="0.1220828979449669" WEIGHT="5.031736339942271"/>
<DICH_DATA CI_END="1.5943886308104427" CI_START="0.6300188787817181" EFFECT_SIZE="1.0022449488650536" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="19" LOG_CI_END="0.20259418885732536" LOG_CI_START="-0.20064643653390796" LOG_EFFECT_SIZE="9.738761617086915E-4" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="335" O_E="0.0" SE="0.2368655394280984" STUDY_ID="STD-Jensen-1991" TOTAL_1="211" TOTAL_2="82" VAR="0.05610528376856404" WEIGHT="15.299378829600732"/>
<DICH_DATA CI_END="2.843419595821319" CI_START="1.3868203879402838" EFFECT_SIZE="1.9857774968394437" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="28" LOG_CI_END="0.45384095209413783" LOG_CI_START="0.14202021768646272" LOG_EFFECT_SIZE="0.2979305848903003" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="336" O_E="0.0" SE="0.18316504292859753" STUDY_ID="STD-Llivina-1988" TOTAL_1="113" TOTAL_2="103" VAR="0.03354943295103498" WEIGHT="16.379026522198917"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8266244629053903" CI_END="2.945634773472726" CI_START="1.303098208392857" DF="1" EFFECT_SIZE="1.959196620018524" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="29" I2="45.25420959218836" ID="CMP-004.02.02" LOG_CI_END="0.46917889807404234" LOG_CI_START="0.11497714768176164" LOG_EFFECT_SIZE="0.292078022877902" MODIFIED="2012-10-04 16:49:38 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.1765269316585385" P_Z="0.0012275136467544921" STUDIES="2" TAU2="0.0" TOTAL_1="268" TOTAL_2="265" WEIGHT="16.218311172667157" Z="3.232408676029116">
<NAME>Nicotine inhaler/inhalator</NAME>
<DICH_DATA CI_END="2.5695685313696033" CI_START="1.0010682086703633" EFFECT_SIZE="1.6038433111603843" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" LOG_CI_END="0.4098602049745912" LOG_CI_START="4.636695272218084E-4" LOG_EFFECT_SIZE="0.2051619372509065" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="399" O_E="0.0" SE="0.24048155146731892" STUDY_ID="STD-Hjalmarson-1997" TOTAL_1="123" TOTAL_2="124" VAR="0.057831376596128754" WEIGHT="12.250003181181993"/>
<DICH_DATA CI_END="6.927386308466684" CI_START="1.348286218918342" EFFECT_SIZE="3.0561576354679802" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="7" LOG_CI_END="0.8405694069175346" LOG_CI_START="0.1297820955391742" LOG_EFFECT_SIZE="0.48517575122835443" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="400" O_E="0.0" SE="0.4175199851575851" STUDY_ID="STD-Tonnesen-1993" TOTAL_1="145" TOTAL_2="141" VAR="0.17432293800599008" WEIGHT="3.968307991485163"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6591647898013876" CI_END="3.2022488701946967" CI_START="1.4381296434051258" DF="1" EFFECT_SIZE="2.145984395513529" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="29" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="0.505455081097397" LOG_CI_START="0.1577980382565902" LOG_EFFECT_SIZE="0.33162655967699356" MODIFIED="2012-10-04 16:49:38 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="0.41685525453600225" P_Z="1.8462157329825419E-4" STUDIES="2" TAU2="0.0" TOTAL_1="241" TOTAL_2="234" WEIGHT="16.429990040451134" Z="3.739179899665985">
<NAME>Nicotine intranasal spray</NAME>
<DICH_DATA CI_END="3.108350593493938" CI_START="1.111406732885492" EFFECT_SIZE="1.8586666666666667" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.49252999733372615" LOG_CI_START="0.045873023406854965" LOG_EFFECT_SIZE="0.26920151037029055" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="409" O_E="0.0" SE="0.2623685174723234" STUDY_ID="STD-Hjalmarson-1994" TOTAL_1="125" TOTAL_2="123" VAR="0.0688372389606249" WEIGHT="10.144629717625547"/>
<DICH_DATA CI_END="4.949080498510858" CI_START="1.3761399424347236" EFFECT_SIZE="2.609717868338558" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="11" LOG_CI_END="0.6945245178189854" LOG_CI_START="0.13866260042336714" LOG_EFFECT_SIZE="0.4165935591211763" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="410" O_E="0.0" SE="0.3265160418390539" STUDY_ID="STD-Sutherland-1992" TOTAL_1="116" TOTAL_2="111" VAR="0.1066127255782428" WEIGHT="6.285360322825588"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.25781834382008" CI_END="1.7139737604342398" CI_START="1.3429233905627282" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5171471430609158" ESTIMABLE="YES" EVENTS_1="592" EVENTS_2="423" I2="9.307590286227375" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.2340041689373274" LOG_CI_START="0.12805123827939752" LOG_EFFECT_SIZE="0.18102770360836248" METHOD="MH" MODIFIED="2012-10-04 16:49:45 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="0.3338616888900444" P_Q="0.734696663350185" P_Z="2.1207265496894523E-11" Q="0.6165952449990733" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5511" TOTAL_2="6194" WEIGHT="100.0" Z="6.697460411394993">
<NAME>Primary care</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.535200581005759" CI_END="1.8492724392956763" CI_START="1.3483493275939107" DF="15" EFFECT_SIZE="1.5790710085560675" ESTIMABLE="YES" EVENTS_1="339" EVENTS_2="260" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.26700089718774284" LOG_CI_START="0.1298024229056959" LOG_EFFECT_SIZE="0.19840166004671939" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.48538580626830674" P_Z="1.4398774273209944E-8" STUDIES="16" TAU2="0.0" TOTAL_1="3132" TOTAL_2="4145" WEIGHT="57.60605208158605" Z="5.668577733089463">
<NAME>Nicotine gum</NAME>
<DICH_DATA CI_END="3.247959524638751" CI_START="0.6065321080428522" EFFECT_SIZE="1.4035639412997905" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5116106085200087" LOG_CI_START="-0.21714620390418088" LOG_EFFECT_SIZE="0.1472322023079139" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="337" O_E="0.0" SE="0.4280753590223699" STUDY_ID="STD-Campbell-1987" TOTAL_1="424" TOTAL_2="412" VAR="0.18324851300213088" WEIGHT="2.38124611444872"/>
<DICH_DATA CI_END="6.940756990800773" CI_START="1.177115040228752" EFFECT_SIZE="2.8583333333333334" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="5" LOG_CI_END="0.8414068391867146" LOG_CI_START="0.07081890880357672" LOG_EFFECT_SIZE="0.45611287399514566" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="338" O_E="0.0" SE="0.4526471647788296" STUDY_ID="STD-Fagerstrom-1984" TOTAL_1="96" TOTAL_2="49" VAR="0.20488945578231293" WEIGHT="1.7269327709209539"/>
<DICH_DATA CI_END="5.720321996351251" CI_START="0.9630026289815542" EFFECT_SIZE="2.347058823529412" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.7574204758739058" LOG_CI_START="-0.016372527256957148" LOG_EFFECT_SIZE="0.37052397430847434" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="339" O_E="0.0" SE="0.45452984037620925" STUDY_ID="STD-Garcia-1989" TOTAL_1="68" TOTAL_2="38" VAR="0.20659737579242224" WEIGHT="1.6733055347170407"/>
<DICH_DATA CI_END="2.808418875797395" CI_START="0.5224543870988805" EFFECT_SIZE="1.2113095238095237" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.44846188332970094" LOG_CI_START="-0.28195161965894905" LOG_EFFECT_SIZE="0.08325513183537596" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="340" O_E="0.0" SE="0.42904850726068444" STUDY_ID="STD-Gilbert-1989" TOTAL_1="112" TOTAL_2="111" VAR="0.1840826215826216" WEIGHT="2.358076362087132"/>
<DICH_DATA CI_END="2.1484187548221616" CI_START="0.3773842535875269" EFFECT_SIZE="0.9004329004329005" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.33211893493424877" LOG_CI_START="-0.42321622479301435" LOG_EFFECT_SIZE="-0.04554864492938274" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="341" O_E="0.0" SE="0.4436876117931363" STUDY_ID="STD-Harackiewicz-1988" TOTAL_1="99" TOTAL_2="52" VAR="0.19685869685869684" WEIGHT="2.394189286506513"/>
<DICH_DATA CI_END="4.563039307727768" CI_START="0.8050798740413305" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.6592542099639247" LOG_CI_START="-0.09416103002398857" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="342" O_E="0.0" SE="0.44255984143448623" STUDY_ID="STD-Hughes-1989" TOTAL_1="210" TOTAL_2="105" VAR="0.19585921325051758" WEIGHT="2.086710431529486"/>
<DICH_DATA CI_END="2.9759103499496" CI_START="0.5044612640758793" EFFECT_SIZE="1.2252475247524752" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4736198438400234" LOG_CI_START="-0.29717217619409586" LOG_EFFECT_SIZE="0.08822383382296375" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="343" O_E="0.0" SE="0.45276704805007617" STUDY_ID="STD-Jamrozik-1984" TOTAL_1="101" TOTAL_2="99" VAR="0.20499799979997999" WEIGHT="2.107577535844781"/>
<DICH_DATA CI_END="3.1707363665085917" CI_START="0.4225351138657811" EFFECT_SIZE="1.1574746008708272" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.5011601337551542" LOG_CI_START="-0.3741371941119684" LOG_EFFECT_SIZE="0.06351146982159289" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="344" O_E="0.0" SE="0.5141539831807991" STUDY_ID="STD-Nebot-1992" TOTAL_1="106" TOTAL_2="319" VAR="0.26435431842068147" WEIGHT="1.6914629262633127"/>
<DICH_DATA CI_END="4.765941874451098" CI_START="0.3680380540851699" EFFECT_SIZE="1.3244047619047619" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6781487413761358" LOG_CI_START="-0.4341072741939607" LOG_EFFECT_SIZE="0.12202073359108753" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="345" O_E="0.0" SE="0.6533446893019474" STUDY_ID="STD-Niaura-1994" TOTAL_1="84" TOTAL_2="89" VAR="0.4268592830390583" WEIGHT="1.0132004407426405"/>
<DICH_DATA CI_END="1.9666586390042697" CI_START="0.8154730132353284" EFFECT_SIZE="1.2663952962460425" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="33" LOG_CI_END="0.29372898418861887" LOG_CI_START="-0.08859040666160824" LOG_EFFECT_SIZE="0.10256928876350531" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="352" O_E="0.0" SE="0.22457630269693016" STUDY_ID="STD-Ockene-1991" TOTAL_1="402" TOTAL_2="420" VAR="0.0504345157330232" WEIGHT="8.419191175386302"/>
<DICH_DATA CI_END="3.0527184886055982" CI_START="0.601296168019352" EFFECT_SIZE="1.3548387096774193" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.48468675697401153" LOG_CI_START="-0.22091156384675606" LOG_EFFECT_SIZE="0.13188759656362775" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="346" O_E="0.0" SE="0.4144719464181376" STUDY_ID="STD-Page-1986" TOTAL_1="93" TOTAL_2="182" VAR="0.17178699436763953" WEIGHT="2.293484465199226"/>
<DICH_DATA CI_END="1.7885616742580424" CI_START="0.4637248589977451" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.25250392034639924" LOG_CI_START="-0.33373962216292735" LOG_EFFECT_SIZE="-0.04061785090826406" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="347" O_E="0.0" SE="0.3443623588223159" STUDY_ID="STD-Richmond-1993" TOTAL_1="200" TOTAL_2="150" VAR="0.11858543417366944" WEIGHT="4.173420863058972"/>
<DICH_DATA CI_END="6.610228606916726" CI_START="1.3759720864046632" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.8202164793049521" LOG_CI_START="0.13860962369354227" LOG_EFFECT_SIZE="0.47941305149924723" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="348" O_E="0.0" SE="0.40037924099449274" STUDY_ID="STD-Roto-1987" TOTAL_1="54" TOTAL_2="60" VAR="0.1603035366193261" WEIGHT="1.7297731208731266"/>
<DICH_DATA CI_END="2.641674335804446" CI_START="1.4565130470266645" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="78" LOG_CI_END="0.42187927698755906" LOG_CI_START="0.1633143792666777" LOG_EFFECT_SIZE="0.2925968281271184" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="349" O_E="0.0" SE="0.15188230083813165" STUDY_ID="STD-Russell-1983" TOTAL_1="729" TOTAL_2="1377" VAR="0.023068233307884725" WEIGHT="14.085295412824031"/>
<DICH_DATA CI_END="2.116689578474571" CI_START="0.7645244377176588" EFFECT_SIZE="1.272108843537415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="37" LOG_CI_END="0.32565717155714285" LOG_CI_START="-0.11660862798049704" LOG_EFFECT_SIZE="0.1045242717883229" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="350" O_E="0.0" SE="0.25978911989942516" STUDY_ID="STD-Segnan-1991" TOTAL_1="294" TOTAL_2="629" VAR="0.0674903868181179" WEIGHT="6.148222121933301"/>
<DICH_DATA CI_END="3.0608139772913443" CI_START="0.9364950419934288" EFFECT_SIZE="1.6930555555555555" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.48583693590546406" LOG_CI_START="-0.02849451753123709" LOG_EFFECT_SIZE="0.22867120918711345" MODIFIED="2012-07-05 12:59:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="351" O_E="0.0" SE="0.3021208417304738" STUDY_ID="STD-Tonnesen-1988" TOTAL_1="60" TOTAL_2="53" VAR="0.09127700300793001" WEIGHT="3.323963519250509"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.003481755098235" CI_END="1.771031106821714" CI_START="1.170562118321228" DF="5" EFFECT_SIZE="1.43982704656289" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="136" I2="44.46592844852779" ID="CMP-004.03.02" LOG_CI_END="0.24822618931112328" LOG_CI_START="0.06839446538702955" LOG_EFFECT_SIZE="0.1583103273490764" MODIFIED="2012-07-05 13:00:23 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.10892550726319272" P_Z="5.589072461589393E-4" STUDIES="6" TAU2="0.0" TOTAL_1="2276" TOTAL_2="1874" WEIGHT="37.1752953014324" Z="3.4508098261450812">
<NAME>Nicotine patch</NAME>
<DICH_DATA CI_END="3.0985703046290562" CI_START="0.7554774524569775" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4911613544686127" LOG_CI_START="-0.12177849283341506" LOG_EFFECT_SIZE="0.1846914308175988" MODIFIED="2012-07-05 13:00:23 +0100" MODIFIED_BY="Lindsay Stead" ORDER="386" O_E="0.0" SE="0.3600439004063886" STUDY_ID="STD-Abelin-1989" TOTAL_1="100" TOTAL_2="99" VAR="0.12963161021984548" WEIGHT="2.8836450686965263"/>
<DICH_DATA CI_END="2.8436645298032195" CI_START="0.8678996274243392" EFFECT_SIZE="1.570991847826087" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.45387836088728595" LOG_CI_START="-0.06153049806810565" LOG_EFFECT_SIZE="0.19617393140959016" MODIFIED="2012-07-05 13:00:23 +0100" MODIFIED_BY="Lindsay Stead" ORDER="387" O_E="0.0" SE="0.30275371506539595" STUDY_ID="STD-Daughton-1998" TOTAL_1="184" TOTAL_2="185" VAR="0.09165981198589895" WEIGHT="4.162110779419246"/>
<DICH_DATA CI_END="16.118289185653534" CI_START="0.760006217713441" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2073189433834552" LOG_CI_START="-0.11918285468290388" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2012-07-05 13:00:23 +0100" MODIFIED_BY="Lindsay Stead" ORDER="388" O_E="0.0" SE="0.7791937224739794" STUDY_ID="STD-Ehrsam-1991" TOTAL_1="56" TOTAL_2="56" VAR="0.607142857142857" WEIGHT="0.5216776078823715"/>
<DICH_DATA CI_END="2.014402311568503" CI_START="1.025628178913287" EFFECT_SIZE="1.437368350289069" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.30414621112601403" LOG_CI_START="0.010989944486001551" LOG_EFFECT_SIZE="0.15756807780600784" MODIFIED="2012-07-05 13:00:23 +0100" MODIFIED_BY="Lindsay Stead" ORDER="389" O_E="0.0" SE="0.17220144217126704" STUDY_ID="STD-ICRF-1994" TOTAL_1="842" TOTAL_2="844" VAR="0.02965333668586423" WEIGHT="13.808057490722842"/>
<DICH_DATA CI_END="1.3007062234518165" CI_START="0.5135491607972068" EFFECT_SIZE="0.8172983479105929" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.11417921820578969" LOG_CI_START="-0.2894179761348311" LOG_EFFECT_SIZE="-0.08761937896452072" MODIFIED="2012-07-05 13:00:23 +0100" MODIFIED_BY="Lindsay Stead" ORDER="390" O_E="0.0" SE="0.23707498979401342" STUDY_ID="STD-Joseph-1996" TOTAL_1="294" TOTAL_2="290" VAR="0.05620455078583157" WEIGHT="9.191887988201374"/>
<DICH_DATA CI_END="3.2993612898922677" CI_START="1.2444698588327163" EFFECT_SIZE="2.026315789473684" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="19" LOG_CI_END="0.5184298746891502" LOG_CI_START="0.09498438242219312" LOG_EFFECT_SIZE="0.30670712855567167" MODIFIED="2012-07-05 13:00:23 +0100" MODIFIED_BY="Lindsay Stead" ORDER="391" O_E="0.0" SE="0.24873397824660265" STUDY_ID="STD-Stapleton-1995" TOTAL_1="800" TOTAL_2="400" VAR="0.061868591934381406" WEIGHT="6.607916366510039"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.299855211296886" CI_START="0.8333337779552569" DF="0" EFFECT_SIZE="1.3843941028407047" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.36170049562015144" LOG_CI_START="-0.07918101433146914" LOG_EFFECT_SIZE="0.14125974064434116" MODIFIED="2012-10-04 16:49:45 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="1.0" P_Z="0.20913175823367092" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="175" WEIGHT="5.218652616981565" Z="1.2559565229159135">
<NAME>Choice of NRT products</NAME>
<DICH_DATA CI_END="2.299855211296886" CI_START="0.8333337779552569" EFFECT_SIZE="1.3843941028407047" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.36170049562015144" LOG_CI_START="-0.07918101433146914" LOG_EFFECT_SIZE="0.14125974064434116" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="621" O_E="0.0" SE="0.2589759813442534" STUDY_ID="STD-Wittchen-2011" TOTAL_1="103" TOTAL_2="175" VAR="0.06706855891321911" WEIGHT="5.218652616981565"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.912142689238383" CI_END="1.6209231941613456" CI_START="1.2750560740020465" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4376258081316649" ESTIMABLE="YES" EVENTS_1="499" EVENTS_2="416" I2="17.523072632876666" I2_Q="57.43564710678233" ID="CMP-004.04" LOG_CI_END="0.20976243672256065" LOG_CI_START="0.1055292844516784" LOG_EFFECT_SIZE="0.15764586058711955" METHOD="MH" MODIFIED="2012-10-04 16:49:48 +0100" MODIFIED_BY="Lindsay Stead" NO="4" P_CHI2="0.28177940526979683" P_Q="0.07037885023202006" P_Z="3.0546137867316566E-9" Q="7.048151319312149" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2332" TOTAL_2="3174" WEIGHT="100.0" Z="5.928635992118814">
<NAME>Hospitals</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2737424814054568" CI_END="1.4277801788740656" CI_START="0.8604398363526052" DF="2" EFFECT_SIZE="1.1083857376644173" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="154" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.15466134858113426" LOG_CI_START="-0.065279491000035" LOG_EFFECT_SIZE="0.04469092879054963" MODIFIED="2012-07-05 12:58:18 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.5289448055025134" P_Z="0.4257352932999129" STUDIES="3" TAU2="0.0" TOTAL_1="695" TOTAL_2="1499" WEIGHT="27.453305357325462" Z="0.7965106528821392">
<NAME>Nicotine gum</NAME>
<DICH_DATA CI_END="1.4649325789876566" CI_START="0.731529381659314" EFFECT_SIZE="1.0352010547132497" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="111" LOG_CI_END="0.16581763749053177" LOG_CI_START="-0.13576822588009327" LOG_EFFECT_SIZE="0.015024705805219264" MODIFIED="2012-07-05 12:58:18 +0100" MODIFIED_BY="Lindsay Stead" ORDER="353" O_E="0.0" SE="0.17715302901800556" STUDY_ID="STD-Br-Thor-Society-1983" TOTAL_1="410" TOTAL_2="1208" VAR="0.03138319569025432" WEIGHT="15.604604074329092"/>
<DICH_DATA CI_END="1.6866842429902695" CI_START="0.5709226264033885" EFFECT_SIZE="0.9813084112149533" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.22703378776870237" LOG_CI_START="-0.2434227449992455" LOG_EFFECT_SIZE="-0.00819447861527157" MODIFIED="2012-07-05 12:58:18 +0100" MODIFIED_BY="Lindsay Stead" ORDER="354" O_E="0.0" SE="0.27634849614528817" STUDY_ID="STD-Campbell-1991" TOTAL_1="107" TOTAL_2="105" VAR="0.07636849132176235" WEIGHT="5.880193901445905"/>
<DICH_DATA CI_END="2.3736710298145747" CI_START="0.8553867175906704" EFFECT_SIZE="1.4249233912155261" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.37542052934643694" LOG_CI_START="-0.0678374977334798" LOG_EFFECT_SIZE="0.15379151580647857" MODIFIED="2012-07-05 12:58:18 +0100" MODIFIED_BY="Lindsay Stead" ORDER="355" O_E="0.0" SE="0.26037195926936413" STUDY_ID="STD-Mori-1992" TOTAL_1="178" TOTAL_2="186" VAR="0.06779355717376741" WEIGHT="5.968507381550467"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2441392198223515" CI_END="2.2619490314911204" CI_START="1.1567884547039453" DF="3" EFFECT_SIZE="1.617589726957271" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="50" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.35448281473994786" LOG_CI_START="0.0632539455076913" LOG_EFFECT_SIZE="0.20886838012381956" MODIFIED="2012-07-05 13:02:03 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.5233068289792615" P_Z="0.004933265388123743" STUDIES="4" TAU2="0.0" TOTAL_1="486" TOTAL_2="556" WEIGHT="13.135731911010524" Z="2.811359352052628">
<NAME>Nicotine patch</NAME>
<DICH_DATA CI_END="2.361530435285525" CI_START="0.9005753554279192" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.37319354711423586" LOG_CI_START="-0.04547994183689675" LOG_EFFECT_SIZE="0.16385680263866959" MODIFIED="2012-07-05 13:02:03 +0100" MODIFIED_BY="Lindsay Stead" ORDER="392" O_E="0.0" SE="0.24593087987708992" STUDY_ID="STD-Ahluwalia-1998" TOTAL_1="205" TOTAL_2="205" VAR="0.06048199767711963" WEIGHT="6.657415792291225"/>
<DICH_DATA CI_END="2.5728675834146997" CI_START="0.8294790996379331" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4104174351523806" LOG_CI_START="-0.08119455240787828" LOG_EFFECT_SIZE="0.16461144137225117" MODIFIED="2012-07-05 13:02:03 +0100" MODIFIED_BY="Lindsay Stead" ORDER="393" O_E="0.0" SE="0.28877531501148174" STUDY_ID="STD-Campbell-1996" TOTAL_1="115" TOTAL_2="119" VAR="0.08339118255998051" WEIGHT="4.6350597841628725"/>
<DICH_DATA CI_END="4.843896772402742" CI_START="0.5969505892682352" EFFECT_SIZE="1.7004608294930876" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6851948793815098" LOG_CI_START="-0.2240616147604481" LOG_EFFECT_SIZE="0.23056663231053087" MODIFIED="2012-07-05 13:02:03 +0100" MODIFIED_BY="Lindsay Stead" ORDER="394" O_E="0.0" SE="0.5341017655512216" STUDY_ID="STD-Lewis-1998" TOTAL_1="62" TOTAL_2="123" VAR="0.28526469596493204" WEIGHT="1.3014947990335097"/>
<DICH_DATA CI_END="21.316258689645682" CI_START="1.043519004284947" EFFECT_SIZE="4.716346153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.328710982107621" LOG_CI_START="0.018500362726752817" LOG_EFFECT_SIZE="0.6736056724171869" MODIFIED="2012-07-05 13:02:03 +0100" MODIFIED_BY="Lindsay Stead" ORDER="395" O_E="0.0" SE="0.7696242034714872" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="104" TOTAL_2="109" VAR="0.5923214145691211" WEIGHT="0.5417615355229166"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.986952364978265" CI_START="0.5747317596118325" DF="0" EFFECT_SIZE="1.0686274509803921" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.29818745549679826" LOG_CI_START="-0.24053480313938616" LOG_EFFECT_SIZE="0.028826326178706067" MODIFIED="2012-10-04 16:49:48 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="1.0" P_Z="0.8338626130749921" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="109" WEIGHT="4.619431366079626" Z="0.2097502384991418">
<NAME>Combination of NRT</NAME>
<DICH_DATA CI_END="1.986952364978265" CI_START="0.5747317596118325" EFFECT_SIZE="1.0686274509803921" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.29818745549679826" LOG_CI_START="-0.24053480313938616" LOG_EFFECT_SIZE="0.028826326178706067" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="411" O_E="0.0" SE="0.31644812144108325" STUDY_ID="STD-Hand-2002" TOTAL_1="136" TOTAL_2="109" VAR="0.10013941356359057" WEIGHT="4.619431366079626"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6458772065082513" CI_END="1.8554597724017585" CI_START="1.3634741844131633" DF="1" EFFECT_SIZE="1.5905569778813085" ESTIMABLE="YES" EVENTS_1="315" EVENTS_2="197" I2="0.0" ID="CMP-004.04.04" LOG_CI_END="0.2684515429945176" LOG_CI_START="0.13464691956180877" LOG_EFFECT_SIZE="0.20154923127816318" MODIFIED="2012-10-04 16:49:48 +0100" MODIFIED_BY="Lindsay Stead" NO="4" P_CHI2="0.4215908144348016" P_Z="3.5357247735194304E-9" STUDIES="2" TAU2="0.0" TOTAL_1="1015" TOTAL_2="1010" WEIGHT="54.79153136558439" Z="5.904567783722306">
<NAME>Choice of NRT products</NAME>
<DICH_DATA CI_END="7.6815771425743335" CI_START="0.8136349976048579" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8854503963333015" LOG_CI_START="-0.08957037898922633" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="412" O_E="0.0" SE="0.5727320298551304" STUDY_ID="STD-Molyneux-2003" TOTAL_1="91" TOTAL_2="91" VAR="0.32802197802197797" WEIGHT="1.1095692987152042"/>
<DICH_DATA CI_END="1.8360840296926577" CI_START="1.3454872537228346" EFFECT_SIZE="1.5717594150236638" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="193" LOG_CI_END="0.2638925531161746" LOG_CI_START="0.12887958789385867" LOG_EFFECT_SIZE="0.19638607050501666" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="600" O_E="0.0" SE="0.07930728409654485" STUDY_ID="STD-Ortega-2011" TOTAL_1="924" TOTAL_2="919" VAR="0.006289645310770075" WEIGHT="53.68196206686918"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.42115991191643876" CI_END="1.6236248556970292" CI_START="0.9194718004549868" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2218335685891166" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.2104856912098182" LOG_CI_START="-0.036461585723991226" LOG_EFFECT_SIZE="0.08701205274291349" METHOD="MH" MODIFIED="2012-10-04 16:49:52 +0100" MODIFIED_BY="Lindsay Stead" NO="5" P_CHI2="0.9358375053937277" P_Q="0.8813325328824778" P_Z="0.1672207107940475" Q="0.25264056130526963" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="808" WEIGHT="100.0" Z="1.3811894726235103">
<NAME>Antenatal clinic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6472555462718894" CI_START="0.4986090900333425" DF="0" EFFECT_SIZE="1.1488888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.4227958668694923" LOG_CI_START="-0.3022398082322946" LOG_EFFECT_SIZE="0.06027802931859881" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="1.0" P_Z="0.7445037662277285" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="94" WEIGHT="11.9544621974897" Z="0.32589504373537814">
<NAME>Nicotine gum</NAME>
<DICH_DATA CI_END="2.6472555462718894" CI_START="0.4986090900333425" EFFECT_SIZE="1.1488888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4227958668694923" LOG_CI_START="-0.3022398082322946" LOG_EFFECT_SIZE="0.06027802931859881" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="610" O_E="0.0" SE="0.4258895445392638" STUDY_ID="STD-Oncken-2008" TOTAL_1="100" TOTAL_2="94" VAR="0.1813819041478616" WEIGHT="11.9544621974897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.16417438653220856" CI_END="1.6592650317843547" CI_START="0.8544314210620203" DF="1" EFFECT_SIZE="1.1906839123067148" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="58" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.2199157607371196" LOG_CI_START="-0.0683227891744404" LOG_EFFECT_SIZE="0.0757964857813396" MODIFIED="2012-10-04 15:59:54 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.6853422138492508" P_Z="0.3026338723657701" STUDIES="2" TAU2="0.0" TOTAL_1="645" TOTAL_2="655" WEIGHT="74.15047524682282" Z="1.0308016213078366">
<NAME>Nicotine patch</NAME>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="653" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="51.14435183699784"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" MODIFIED="2012-10-04 15:59:54 +0100" MODIFIED_BY="Lindsay Stead" ORDER="396" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="23.00612340982498"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.032697319684326" CI_START="0.6940612593880049" DF="0" EFFECT_SIZE="1.4508196721311475" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="0.48182906743215864" LOG_CI_START="-0.15860219605804193" LOG_EFFECT_SIZE="0.16161343568705838" MODIFIED="2012-10-04 16:49:52 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="1.0" P_Z="0.3225665175813903" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="59" WEIGHT="13.895062555687478" Z="0.9891975342932693">
<NAME>Choice of NRT products</NAME>
<DICH_DATA CI_END="3.032697319684326" CI_START="0.6940612593880049" EFFECT_SIZE="1.4508196721311475" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.48182906743215864" LOG_CI_START="-0.15860219605804193" LOG_EFFECT_SIZE="0.16161343568705838" MODIFIED="2012-10-04 15:59:52 +0100" MODIFIED_BY="Lindsay Stead" ORDER="624" O_E="0.0" SE="0.3761924943600262" STUDY_ID="STD-Pollak-2007" TOTAL_1="122" TOTAL_2="59" VAR="0.14152079281281835" WEIGHT="13.895062555687478"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.195801461479995" CI_END="3.4907405766725295" CI_START="2.111607513431169" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7149721967528073" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="77" I2="51.19452296642528" I2_Q="83.93864090370943" ID="CMP-004.06" LOG_CI_END="0.5429175743065795" LOG_CI_START="0.32461319861964427" LOG_EFFECT_SIZE="0.43376538646311186" METHOD="MH" MODIFIED="2012-10-03 17:45:40 +0100" MODIFIED_BY="Lindsay Stead" NO="6" P_CHI2="0.08466347338781177" P_Q="0.012587990006551864" P_Z="6.764871272922857E-15" Q="6.226123169308584" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2937" TOTAL_2="2638" WEIGHT="100.00000000000003" Z="7.788799766679866">
<NAME>Community volunteer (treatment provided in 'over-the-counter' setting)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0615759437099133" CI_END="5.517449645529943" CI_START="2.602334499227885" DF="1" EFFECT_SIZE="3.7892280955776783" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="33" I2="5.80042756947962" ID="CMP-004.06.01" LOG_CI_END="0.741738378305233" LOG_CI_START="0.41536311921712343" LOG_EFFECT_SIZE="0.5785507487611783" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.30285641017053744" P_Z="3.6871962721920225E-12" STUDIES="2" TAU2="0.0" TOTAL_1="1649" TOTAL_2="1648" WEIGHT="40.65976040949674" Z="6.948680080523308">
<NAME>Nicotine gum</NAME>
<DICH_DATA CI_END="5.687760780817803" CI_START="1.2441491632011088" EFFECT_SIZE="2.66015466015466" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.7549413222935226" LOG_CI_START="0.09487245179503367" LOG_EFFECT_SIZE="0.42490688704427815" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="618" O_E="0.0" SE="0.38772772192441723" STUDY_ID="STD-Shiffman-2009-_x0028_2mg_x0029_" TOTAL_1="819" TOTAL_2="817" VAR="0.1503327863486982" WEIGHT="11.103741561492576"/>
<DICH_DATA CI_END="6.50670193022576" CI_START="2.728382244752736" EFFECT_SIZE="4.213403614457832" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="24" LOG_CI_END="0.8133609123089041" LOG_CI_START="0.4359052146492433" LOG_EFFECT_SIZE="0.6246330634790737" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="619" O_E="0.0" SE="0.2217193452411218" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_" TOTAL_1="830" TOTAL_2="831" VAR="0.049159468054151764" WEIGHT="29.556018848004168"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8209995672170773" CI_END="2.7948321665920033" CI_START="1.4011668099336827" DF="2" EFFECT_SIZE="1.9788951642681225" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="44" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="0.4463557330412354" LOG_CI_START="0.14648984143942242" LOG_EFFECT_SIZE="0.29642278724032883" MODIFIED="2012-08-22 14:02:46 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.6633189238988332" P_Z="1.0666026904814302E-4" STUDIES="3" TAU2="0.0" TOTAL_1="1288" TOTAL_2="990" WEIGHT="59.34023959050328" Z="3.874918778421756">
<NAME>Nicotine patch</NAME>
<DICH_DATA CI_END="3.6866872656583496" CI_START="1.1538560077024487" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5666362988322253" LOG_CI_START="0.06215161561170004" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="383" O_E="0.0" SE="0.2963368001631935" STUDY_ID="STD-Davidson-1998" TOTAL_1="401" TOTAL_2="401" VAR="0.08781549913096048" WEIGHT="19.715882452423664"/>
<DICH_DATA CI_END="3.9419707258706516" CI_START="1.2752972552091766" EFFECT_SIZE="2.242138364779874" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="14" LOG_CI_END="0.5957133947683748" LOG_CI_START="0.10561142496649092" LOG_EFFECT_SIZE="0.35066240986743286" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="384" O_E="0.0" SE="0.28788832310550383" STUDY_ID="STD-Hays-1999" TOTAL_1="636" TOTAL_2="322" VAR="0.08287968658049898" WEIGHT="22.905821680112254"/>
<DICH_DATA CI_END="2.9427867387446707" CI_START="0.7847299161094201" EFFECT_SIZE="1.5196357427433125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.46875879028775475" LOG_CI_START="-0.10527979054919413" LOG_EFFECT_SIZE="0.18173949986928026" MODIFIED="2012-07-04 13:49:56 +0100" MODIFIED_BY="Lindsay Stead" ORDER="385" O_E="0.0" SE="0.33719310392042656" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="251" TOTAL_2="267" VAR="0.11369918933149159" WEIGHT="16.718535457967363"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-10-15 13:39:22 +0100" MODIFIED_BY="L S" NO="5">
<NAME>Nicotine gum: 4mg versus 2mg dose</NAME>
<DICH_OUTCOME CHI2="16.095010113779825" CI_END="1.8298526428500048" CI_START="1.1150625728484442" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4284257754149676" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="81" I2="62.72136545684386" I2_Q="89.96978855853501" ID="CMP-005.01" LOG_CI_END="0.2624161176135758" LOG_CI_START="0.047299238936022274" LOG_EFFECT_SIZE="0.15485767827479902" METHOD="MH" MODIFIED="2012-02-21 12:15:00 +0000" MODIFIED_BY="L S" NO="1" P_CHI2="0.013253026732990225" P_Q="0.0015912270551740049" P_Z="0.0047745164985009015" Q="9.969879556735863" RANDOM="NO" SCALE="6.849237792442749" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="426" TOTAL_2="430" WEIGHT="100.0" Z="2.8218657133180813">
<NAME>Smoking Cessation</NAME>
<GROUP_LABEL_1>4 mg dose</GROUP_LABEL_1>
<GROUP_LABEL_2>2 mg dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 4mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.457292158576588" CI_END="2.5037418127552216" CI_START="1.360851539256747" DF="3" EFFECT_SIZE="1.8458658943134036" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="51" I2="13.226887911169799" ID="CMP-005.01.01" LOG_CI_END="0.3985895421594288" LOG_CI_START="0.1338107488635836" LOG_EFFECT_SIZE="0.2662001455115062" NO="1" P_CHI2="0.32634368461686236" P_Z="8.115262963947595E-5" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="315" WEIGHT="61.19943847686833" Z="3.940970433375419">
<NAME>High dependency smokers</NAME>
<DICH_DATA CI_END="2.3003455290421613" CI_START="0.7595635232061289" EFFECT_SIZE="1.3218390804597702" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.3617930751852523" LOG_CI_START="-0.119435899715266" LOG_EFFECT_SIZE="0.12117858773499318" ORDER="413" O_E="0.0" SE="0.28267628197840855" STUDY_ID="STD-Garvey-2000" TOTAL_1="116" TOTAL_2="115" VAR="0.07990588039313674" WEIGHT="22.20086640480201"/>
<DICH_DATA CI_END="3.822686306596525" CI_START="1.2075876879651979" EFFECT_SIZE="2.1485411140583555" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="0.5823686608482753" LOG_CI_START="0.08191867649743843" LOG_EFFECT_SIZE="0.3321436686728569" ORDER="414" O_E="0.0" SE="0.29396679807505705" STUDY_ID="STD-Herrera-1995" TOTAL_1="87" TOTAL_2="81" VAR="0.08641647837050136" WEIGHT="16.535020291076496"/>
<DICH_DATA CI_END="3.063877124529042" CI_START="1.0192069025320298" EFFECT_SIZE="1.7671232876712328" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.48627134411687933" LOG_CI_START="0.00826235624070682" LOG_EFFECT_SIZE="0.24726685017879305" ORDER="415" O_E="0.0" SE="0.280784845661115" STUDY_ID="STD-Kornitzer-1987" TOTAL_1="73" TOTAL_2="86" VAR="0.07884012955293618" WEIGHT="18.042517177964594"/>
<DICH_DATA CI_END="10.075687011378102" CI_START="1.3343451845280756" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="1.003274668220418" LOG_CI_START="0.1252681926567072" LOG_EFFECT_SIZE="0.5642714304385625" ORDER="416" O_E="0.0" SE="0.5157453499482725" STUDY_ID="STD-Tonnesen-1988" TOTAL_1="27" TOTAL_2="33" VAR="0.265993265993266" WEIGHT="4.4210346030252285"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6427423324663284" CI_END="1.2064090552180564" CI_START="0.49146472851963846" DF="2" EFFECT_SIZE="0.7700048693393929" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.0814945883205225" LOG_CI_START="-0.30850764519492935" LOG_EFFECT_SIZE="-0.11350652843720342" MODIFIED="2012-02-21 12:15:00 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.43982838786962064" P_Z="0.25392877487299237" STUDIES="3" TAU2="0.0" TOTAL_1="123" TOTAL_2="115" WEIGHT="38.80056152313166" Z="1.1408586342789548">
<NAME>Low dependency Smokers</NAME>
<DICH_DATA CI_END="1.7401808288856153" CI_START="0.5090351152507456" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24059437983818457" LOG_CI_START="-0.2932522572828829" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="417" O_E="0.0" SE="0.31358415722838784" STUDY_ID="STD-Garvey-2000" TOTAL_1="87" TOTAL_2="87" VAR="0.09833502366463827" WEIGHT="20.877107847619133"/>
<DICH_DATA CI_END="1.6578630011980628" CI_START="0.2610743375367926" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2195486394338172" LOG_CI_START="-0.5832358153233622" LOG_EFFECT_SIZE="-0.1818435879447725" ORDER="418" O_E="0.0" SE="0.4715595625715076" STUDY_ID="STD-Hughes-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.2223684210526316" WEIGHT="9.57261053646488"/>
<DICH_DATA CI_END="1.1705914917121045" CI_START="0.18918067384321638" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.06840536317820263" LOG_CI_START="-0.7231232319508635" LOG_EFFECT_SIZE="-0.32735893438633035" ORDER="419" O_E="0.0" SE="0.46494781490855003" STUDY_ID="STD-Kornitzer-1987" TOTAL_1="17" TOTAL_2="8" VAR="0.2161764705882353" WEIGHT="8.350843139047653"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-10-15 13:39:27 +0100" MODIFIED_BY="L S" NO="6">
<NAME>Nicotine gum: Fixed versus ad lib dose schedule</NAME>
<DICH_OUTCOME CHI2="0.5321783353463246" CI_END="1.6086944971774055" CI_START="0.9195335364403401" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2162436187054197" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="69" I2="0.0" I2_Q="100.0" ID="CMP-006.01" LOG_CI_END="0.2064735762385327" LOG_CI_START="-0.03643242692032061" LOG_EFFECT_SIZE="0.08502057465910606" METHOD="MH" MODIFIED="2008-05-08 11:16:11 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.4656925569055915" P_Q="0.0" P_Z="0.17005383610818395" Q="3.7839795166220205E-32" RANDOM="NO" SCALE="6.849237792442749" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="346" TOTAL_2="343" WEIGHT="100.0" Z="1.3720308441102698">
<NAME>Smoking cessation</NAME>
<GROUP_LABEL_1>Fixed dosing</GROUP_LABEL_1>
<GROUP_LABEL_2>Ad lib dosing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ad lib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fixed dosing</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8827110289082996" CI_START="0.49778683972759075" EFFECT_SIZE="0.9680851063829787" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.27478366670745547" LOG_CI_START="-0.3029565892646656" LOG_EFFECT_SIZE="-0.014086461278605055" ORDER="420" O_E="0.0" SE="0.3393674862184142" STUDY_ID="STD-Goldstein-1989" TOTAL_1="47" TOTAL_2="42" VAR="0.11517029070220558" WEIGHT="18.240355492885776"/>
<DICH_DATA CI_END="1.7310451813273269" CI_START="0.934108862822596" EFFECT_SIZE="1.271607111424045" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="57" LOG_CI_END="0.2383084033722557" LOG_CI_START="-0.029602507315874164" LOG_EFFECT_SIZE="0.10435294802819076" ORDER="421" O_E="0.0" SE="0.15737219511860376" STUDY_ID="STD-Killen-1990" TOTAL_1="299" TOTAL_2="301" VAR="0.024766007796447897" WEIGHT="81.75964450711422"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2012-10-15 13:39:31 +0100" MODIFIED_BY="L S" NO="7">
<NAME>Nicotine patch: High versus standard dose patches</NAME>
<DICH_OUTCOME CHI2="8.057415941762235" CI_END="1.2877481454908786" CI_START="1.0145480825905464" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1430146157715144" ESTIMABLE="YES" EVENTS_1="468" EVENTS_2="409" I2="13.123511922495688" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.10983093311782097" LOG_CI_START="0.006272634423983356" LOG_EFFECT_SIZE="0.05805178377090214" METHOD="MH" MODIFIED="2012-03-02 11:20:39 +0000" MODIFIED_BY="L S" NO="1" P_CHI2="0.3275584030111055" P_Q="0.7759566300888492" P_Z="0.027992025437387623" Q="0.5073173265309389" RANDOM="NO" SCALE="5.805923162305186" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2551" TOTAL_2="2550" WEIGHT="100.0" Z="2.1973981199837094">
<NAME>Smoking cessation at maximum follow up</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.4547458902907255" CI_END="1.3190282104435829" CI_START="0.8892777877168446" DF="3" EFFECT_SIZE="1.0830431611525821" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="141" I2="53.52257004396375" ID="CMP-007.01.01" LOG_CI_END="0.12025408402927996" LOG_CI_START="-0.050962555308850535" LOG_EFFECT_SIZE="0.03464576436021473" NO="1" P_CHI2="0.09146454237150292" P_Z="0.42766178271550437" STUDIES="4" TAU2="0.0" TOTAL_1="594" TOTAL_2="594" WEIGHT="34.4787521265047" Z="0.7931991963559084">
<NAME>44mg vs 22mg (Intensive counselling)</NAME>
<DICH_DATA CI_END="3.887552204421078" CI_START="0.9177757743060899" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.589676234045126" LOG_CI_START="-0.03726341016722782" LOG_EFFECT_SIZE="0.27620641193894907" ORDER="422" O_E="0.0" SE="0.36826745041162645" STUDY_ID="STD-Dale-1995" TOTAL_1="18" TOTAL_2="17" VAR="0.13562091503267976" WEIGHT="1.5083383556787113"/>
<DICH_DATA CI_END="1.7790050218902682" CI_START="0.9404006310227322" EFFECT_SIZE="1.2934362934362935" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="52" LOG_CI_END="0.2501771740401667" LOG_CI_START="-0.026687088128979783" LOG_EFFECT_SIZE="0.11174504295559344" ORDER="423" O_E="0.0" SE="0.1626314380983575" STUDY_ID="STD-Hughes-1999" TOTAL_1="259" TOTAL_2="260" VAR="0.026448984657939885" WEIGHT="12.684659496535913"/>
<DICH_DATA CI_END="1.2517553816387057" CI_START="0.7125795676422554" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="72" LOG_CI_END="0.09751946722570555" LOG_CI_START="-0.14716663467576985" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="424" O_E="0.0" SE="0.14372982747266527" STUDY_ID="STD-Jorenby-1995" TOTAL_1="252" TOTAL_2="252" VAR="0.02065826330532213" WEIGHT="17.597280816251633"/>
<DICH_DATA CI_END="1.3871919690508412" CI_START="0.21447692013427483" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.14213656585373244" LOG_CI_START="-0.6686194354028954" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="425" O_E="0.0" SE="0.47624208844507515" STUDY_ID="STD-Kalman-2006" TOTAL_1="65" TOTAL_2="65" VAR="0.2268065268065268" WEIGHT="2.6884734580384437"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5286999828743593" CI_START="0.8208483157392367" DF="0" EFFECT_SIZE="1.1201923076923077" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="56" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.18432226071186544" LOG_CI_START="-0.0857370885853506" LOG_EFFECT_SIZE="0.049292586063257426" MODIFIED="2012-03-02 11:20:39 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="1.0" P_Z="0.4743094727632866" STUDIES="1" TAU2="0.0" TOTAL_1="234" TOTAL_2="233" WEIGHT="13.716081835365298" Z="0.7154849009318969">
<NAME>42mg vs 21mg (pre- and post-cessation)</NAME>
<DICH_DATA CI_END="1.5286999828743593" CI_START="0.8208483157392367" EFFECT_SIZE="1.1201923076923077" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="56" LOG_CI_END="0.18432226071186544" LOG_CI_START="-0.0857370885853506" LOG_EFFECT_SIZE="0.049292586063257426" MODIFIED="2012-03-02 11:19:52 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="644" O_E="0.0" SE="0.15863419859252362" STUDY_ID="STD-Rose-2010" TOTAL_1="234" TOTAL_2="233" VAR="0.025164808963092224" WEIGHT="13.716081835365298"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.205484225688842" CI_END="1.4091100452934793" CI_START="1.0032231582137485" DF="2" EFFECT_SIZE="1.1889709121379053" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="212" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="0.14894491092163034" LOG_CI_START="0.0013975487740797085" LOG_EFFECT_SIZE="0.07517122984785503" MODIFIED="2012-03-02 11:17:59 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" P_CHI2="0.547309047389799" P_Z="0.045815079574791605" STUDIES="3" TAU2="0.0" TOTAL_1="1723" TOTAL_2="1723" WEIGHT="51.80516603813" Z="1.997093015164066">
<NAME>25mg vs 15mg patches</NAME>
<DICH_DATA CI_END="1.476511189805332" CI_START="1.027362502983963" EFFECT_SIZE="1.2316299085529854" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="182" LOG_CI_END="0.16923674263350133" LOG_CI_START="0.011723710654103763" LOG_EFFECT_SIZE="0.09048022664380252" ORDER="426" O_E="0.0" SE="0.0925239346867813" STUDY_ID="STD-CEASE-1999" TOTAL_1="1430" TOTAL_2="1431" VAR="0.008560678489923772" WEIGHT="44.46646768066381"/>
<DICH_DATA CI_END="1.7665311324124338" CI_START="0.5443108639666197" EFFECT_SIZE="0.9805825242718447" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.24712129561506885" LOG_CI_START="-0.2641529974601281" LOG_EFFECT_SIZE="-0.008515850922529627" ORDER="427" O_E="0.0" SE="0.3003250506009384" STUDY_ID="STD-Killen-1999" TOTAL_1="206" TOTAL_2="202" VAR="0.09019513601845622" WEIGHT="4.936056438109799"/>
<DICH_DATA CI_END="1.998730658700265" CI_START="0.34266694557574773" EFFECT_SIZE="0.8275862068965517" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.30075427419749845" LOG_CI_START="-0.4651277865721986" LOG_EFFECT_SIZE="-0.08218675618735007" ORDER="428" O_E="0.0" SE="0.4498829136734642" STUDY_ID="STD-Paoletti-1996" TOTAL_1="87" TOTAL_2="90" VAR="0.20239463601532567" WEIGHT="2.4026419193563906"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2012-10-15 13:39:35 +0100" MODIFIED_BY="L S" NO="8">
<NAME>Nicotine patch: 16hr or 24hr use, subgroups &amp; direct comparison</NAME>
<DICH_OUTCOME CHI2="59.79246951275378" CI_END="1.7842783807150706" CI_START="1.498849730511009" CI_STUDY="95" CI_TOTAL="95" DF="43" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6353486386980003" ESTIMABLE="YES" EVENTS_1="1691" EVENTS_2="665" I2="28.084589329718074" I2_Q="69.78192208331464" ID="CMP-008.01" LOG_CI_END="0.2514626133678324" LOG_CI_START="0.17575809416836652" LOG_EFFECT_SIZE="0.21361035376809942" METHOD="MH" MODIFIED="2012-10-03 16:24:28 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.045767005267473015" P_Q="0.03654265864804174" P_Z="1.9479596995192653E-28" Q="6.618554646375012" RANDOM="NO" SCALE="5.25" SORT_BY="YEAR" STUDIES="42" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="11200" TOTAL_2="7344" WEIGHT="300.0" Z="11.060597294257404">
<NAME>Smoking Cessation</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2/>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.291898588856217" CI_END="1.9022347956161052" CI_START="1.4008877518513532" DF="10" EFFECT_SIZE="1.632426851752955" ESTIMABLE="YES" EVENTS_1="688" EVENTS_2="200" I2="53.03377968729471" ID="CMP-008.01.01" LOG_CI_END="0.27926412151149527" LOG_CI_START="0.14640333820901444" LOG_EFFECT_SIZE="0.2128337298602549" MODIFIED="2012-03-02 13:59:30 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.019147653783399554" P_Z="3.3976881607598403E-10" STUDIES="11" TAU2="0.0" TOTAL_1="5117" TOTAL_2="2501" WEIGHT="100.0" Z="6.279451842034076">
<NAME>16 hour patch, active versus placebo</NAME>
<DICH_DATA CI_END="11.155294326080863" CI_START="1.4473652287433074" EFFECT_SIZE="4.0181818181818185" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="1.0474810333833258" LOG_CI_START="0.16057813499840803" LOG_EFFECT_SIZE="0.6040295841908669" ORDER="430" O_E="0.0" SE="0.5209711527514526" STUDY_ID="STD-Daughton-1991" TOTAL_1="55" TOTAL_2="52" VAR="0.2714109419991773" WEIGHT="1.630686186822517"/>
<DICH_DATA CI_END="9.428558561934224" CI_START="1.673646214316064" EFFECT_SIZE="3.972413793103448" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9744453028701352" LOG_CI_START="0.22366365950633915" LOG_EFFECT_SIZE="0.5990544811882371" ORDER="436" O_E="0.0" SE="0.44101285374096627" STUDY_ID="STD-Tonnesen-1991" TOTAL_1="145" TOTAL_2="144" VAR="0.19449233716475092" WEIGHT="2.387552329841273"/>
<DICH_DATA CI_END="5.191155779737516" CI_START="1.3541372015357949" EFFECT_SIZE="2.651327433628319" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7152640616789412" LOG_CI_START="0.1316626694090771" LOG_EFFECT_SIZE="0.42346336554400915" ORDER="434" O_E="0.0" SE="0.3428103466928011" STUDY_ID="STD-Sachs-1993" TOTAL_1="113" TOTAL_2="107" VAR="0.11751893379963846" WEIGHT="4.073683199353525"/>
<DICH_DATA CI_END="1.9396324884607696" CI_START="0.46529433043070706" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.2877194498511332" LOG_CI_START="-0.3322722392734377" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="432" O_E="0.0" SE="0.3641861872001304" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="150" TOTAL_2="75" VAR="0.13263157894736843" WEIGHT="5.287376423939677"/>
<DICH_DATA CI_END="3.2993612898922677" CI_START="1.2444698588327163" EFFECT_SIZE="2.026315789473684" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="19" LOG_CI_END="0.5184298746891502" LOG_CI_START="0.09498438242219312" LOG_EFFECT_SIZE="0.30670712855567167" ORDER="435" O_E="0.0" SE="0.24873397824660265" STUDY_ID="STD-Stapleton-1995" TOTAL_1="800" TOTAL_2="400" VAR="0.061868591934381406" WEIGHT="10.046015205485386"/>
<DICH_DATA CI_END="10.644319166426266" CI_START="1.3211272398102434" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0271178882524812" LOG_CI_START="0.12094464720295672" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="433" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Paoletti-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.2833333333333333" WEIGHT="1.5862129271819032"/>
<DICH_DATA CI_END="1.8113081221041267" CI_START="1.1243557445017534" EFFECT_SIZE="1.427079077048801" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="71" LOG_CI_END="0.25799233454774956" LOG_CI_START="0.050903743110311706" LOG_EFFECT_SIZE="0.1544480388290306" ORDER="429" O_E="0.0" SE="0.12164486371541124" STUDY_ID="STD-CEASE-1999" TOTAL_1="2861" TOTAL_2="714" VAR="0.014797472868340973" WEIGHT="45.06419833725695"/>
<DICH_DATA CI_END="2.8436645298032195" CI_START="0.8678996274243392" EFFECT_SIZE="1.570991847826087" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.45387836088728595" LOG_CI_START="-0.06153049806810565" LOG_EFFECT_SIZE="0.19617393140959016" ORDER="431" O_E="0.0" SE="0.30275371506539595" STUDY_ID="STD-Daughton-1998" TOTAL_1="184" TOTAL_2="185" VAR="0.09165981198589895" WEIGHT="6.3276569886497605"/>
<DICH_DATA CI_END="21.316258689645682" CI_START="1.043519004284947" EFFECT_SIZE="4.716346153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.328710982107621" LOG_CI_START="0.018500362726752817" LOG_EFFECT_SIZE="0.6736056724171869" ORDER="437" O_E="0.0" SE="0.7696242034714872" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="104" TOTAL_2="109" VAR="0.5923214145691211" WEIGHT="0.7744889409714457"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" ORDER="438" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="7.080854506940017"/>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-03-02 13:59:30 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="648" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="15.741274953557554"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="32.19182399423019" CI_END="1.8589624206469288" CI_START="1.4991181152156638" DF="31" EFFECT_SIZE="1.6693724091097744" ESTIMABLE="YES" EVENTS_1="992" EVENTS_2="448" I2="3.702256804223967" ID="CMP-008.01.02" LOG_CI_END="0.2692706104977552" LOG_CI_START="0.17583585217149947" LOG_EFFECT_SIZE="0.22255323133462732" MODIFIED="2012-02-07 13:54:54 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.4074955021969312" P_Z="9.917943229485565E-21" STUDIES="32" TAU2="0.0" TOTAL_1="6032" TOTAL_2="4788" WEIGHT="100.00000000000003" Z="9.336917564141805">
<NAME>24 hour patch, active versus placebo</NAME>
<DICH_DATA CI_END="2.8593078037343456" CI_START="0.7422768702931712" EFFECT_SIZE="1.4568452380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.45626090956152343" LOG_CI_START="-0.12943407206289823" LOG_EFFECT_SIZE="0.1634134187493126" ORDER="441" O_E="0.0" SE="0.34404013144310264" STUDY_ID="STD-Buchkremer-1988" TOTAL_1="42" TOTAL_2="89" VAR="0.11836361204338733" WEIGHT="2.1716956886492196"/>
<DICH_DATA CI_END="3.0985703046290562" CI_START="0.7554774524569775" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4911613544686127" LOG_CI_START="-0.12177849283341506" LOG_EFFECT_SIZE="0.1846914308175988" ORDER="439" O_E="0.0" SE="0.3600439004063886" STUDY_ID="STD-Abelin-1989" TOTAL_1="100" TOTAL_2="99" VAR="0.12963161021984548" WEIGHT="2.3401333208778463"/>
<DICH_DATA CI_END="3.393314017187208" CI_START="0.5239060602034752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5306240511043927" LOG_CI_START="-0.28074657788779284" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="454" O_E="0.0" SE="0.4766031238193982" STUDY_ID="STD-Hurt-1990" TOTAL_1="31" TOTAL_2="31" VAR="0.2271505376344086" WEIGHT="1.2700541750582492"/>
<DICH_DATA CI_END="16.118289185653534" CI_START="0.760006217713441" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2073189433834552" LOG_CI_START="-0.11918285468290388" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="446" O_E="0.0" SE="0.7791937224739794" STUDY_ID="STD-Ehrsam-1991" TOTAL_1="56" TOTAL_2="56" VAR="0.607142857142857" WEIGHT="0.42335139168608305"/>
<DICH_DATA CI_END="2.6170951223873518" CI_START="1.2476508655425136" EFFECT_SIZE="1.8069922508560101" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="31" LOG_CI_END="0.4178195080342886" LOG_CI_START="0.09609307222018122" LOG_EFFECT_SIZE="0.25695629012723487" ORDER="464" O_E="0.0" SE="0.18898370096874859" STUDY_ID="STD-TNSG-1991" TOTAL_1="537" TOTAL_2="271" VAR="0.03571483923184539" WEIGHT="8.72219135816612"/>
<DICH_DATA CI_END="8.233684468800423" CI_START="0.9548551675504815" EFFECT_SIZE="2.803921568627451" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.915594219950208" LOG_CI_START="-0.02006249721595711" LOG_EFFECT_SIZE="0.44776586136712543" ORDER="444" O_E="0.0" SE="0.5496093872388524" STUDY_ID="STD-Daughton-1991" TOTAL_1="51" TOTAL_2="52" VAR="0.30207047854106683" WEIGHT="0.8384823679996208"/>
<DICH_DATA CI_END="34.51060023583957" CI_START="1.9508246278682124" EFFECT_SIZE="8.205128205128204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5379525129526281" LOG_CI_START="0.2902182296341853" LOG_EFFECT_SIZE="0.9140853712934067" ORDER="465" O_E="0.0" SE="0.7329252944055672" STUDY_ID="STD-Westman-1993" TOTAL_1="78" TOTAL_2="80" VAR="0.5371794871794873" WEIGHT="0.41799251331030984"/>
<DICH_DATA CI_END="3.3180338251609367" CI_START="0.7995548248992429" EFFECT_SIZE="1.628787878787879" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.520880809055993" LOG_CI_START="-0.097151751636482" LOG_EFFECT_SIZE="0.2118645287097555" ORDER="447" O_E="0.0" SE="0.3630353854612752" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="43" VAR="0.13179469109701664" WEIGHT="1.9269787483642402"/>
<DICH_DATA CI_END="3.2899905062299095" CI_START="1.1453425421228474" EFFECT_SIZE="1.9411764705882353" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5171946447287246" LOG_CI_START="0.05893539227050256" LOG_EFFECT_SIZE="0.2880650184996135" ORDER="455" O_E="0.0" SE="0.26918375331384387" STUDY_ID="STD-Hurt-1994" TOTAL_1="120" TOTAL_2="120" VAR="0.07245989304812835" WEIGHT="3.598486829331706"/>
<DICH_DATA CI_END="7.237905645439162" CI_START="0.8039754134848986" EFFECT_SIZE="2.412280701754386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8596129172728425" LOG_CI_START="-0.09475723228526235" LOG_EFFECT_SIZE="0.3824278424937901" ORDER="448" O_E="0.0" SE="0.5606017500588621" STUDY_ID="STD-Fiore-1994B" TOTAL_1="57" TOTAL_2="55" VAR="0.314274322169059" WEIGHT="0.8618224759323833"/>
<DICH_DATA CI_END="2.014402311568503" CI_START="1.025628178913287" EFFECT_SIZE="1.437368350289069" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.30414621112601403" LOG_CI_START="0.010989944486001551" LOG_EFFECT_SIZE="0.15756807780600784" ORDER="456" O_E="0.0" SE="0.17220144217126704" STUDY_ID="STD-ICRF-1994" TOTAL_1="842" TOTAL_2="844" VAR="0.02965333668586423" WEIGHT="11.205503680535672"/>
<DICH_DATA CI_END="3.7386899573042225" CI_START="1.1327257863865658" EFFECT_SIZE="2.0578898225957047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5727194514032413" LOG_CI_START="0.05412478729254229" LOG_EFFECT_SIZE="0.31342211934789177" ORDER="462" O_E="0.0" SE="0.30462507278361334" STUDY_ID="STD-Richmond-1994" TOTAL_1="153" TOTAL_2="152" VAR="0.09279643496842171" WEIGHT="2.973176003251114"/>
<DICH_DATA CI_END="2.358871489270788" CI_START="1.1945432704943428" EFFECT_SIZE="1.678622668579627" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="34" LOG_CI_END="0.3727042812752382" LOG_CI_START="0.07720188602106627" LOG_EFFECT_SIZE="0.22495308364815225" ORDER="452" O_E="0.0" SE="0.17357956973274816" STUDY_ID="STD-Hughes-1999" TOTAL_1="779" TOTAL_2="260" VAR="0.030129867028605983" WEIGHT="10.7919970742999"/>
<DICH_DATA CI_END="3.788507155734091" CI_START="0.775708053172369" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.578468111881843" LOG_CI_START="-0.1103016998151071" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="443" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Cinciripini-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.16369047619047616" WEIGHT="1.4817298709012907"/>
<DICH_DATA CI_END="2.5728675834146997" CI_START="0.8294790996379331" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4104174351523806" LOG_CI_START="-0.08119455240787828" LOG_EFFECT_SIZE="0.16461144137225117" ORDER="442" O_E="0.0" SE="0.28877531501148174" STUDY_ID="STD-Campbell-1996" TOTAL_1="115" TOTAL_2="119" VAR="0.08339118255998051" WEIGHT="3.5369742339585146"/>
<DICH_DATA CI_END="1.3007062234518165" CI_START="0.5135491607972068" EFFECT_SIZE="0.8172983479105929" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.11417921820578969" LOG_CI_START="-0.2894179761348311" LOG_EFFECT_SIZE="-0.08761937896452072" ORDER="458" O_E="0.0" SE="0.23707498979401342" STUDY_ID="STD-Joseph-1996" TOTAL_1="294" TOTAL_2="290" VAR="0.05620455078583157" WEIGHT="7.459393528167457"/>
<DICH_DATA CI_END="3.6638765871680388" CI_START="0.8345587993406903" EFFECT_SIZE="1.7486338797814207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.563940836607552" LOG_CI_START="-0.078543059428599" LOG_EFFECT_SIZE="0.2426988885894765" ORDER="457" O_E="0.0" SE="0.37739822087821245" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.14242941712204005" WEIGHT="2.301187267679798"/>
<DICH_DATA CI_END="1.9175853297600345" CI_START="0.6255505122219942" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2827546985242227" LOG_CI_START="-0.20373761595687537" LOG_EFFECT_SIZE="0.039508541283673655" ORDER="459" O_E="0.0" SE="0.28576799370199224" STUDY_ID="STD-Killen-1997" TOTAL_1="212" TOTAL_2="212" VAR="0.08166334622446189" WEIGHT="4.445189612703872"/>
<DICH_DATA CI_END="2.9427867387446707" CI_START="0.7847299161094201" EFFECT_SIZE="1.5196357427433125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.46875879028775475" LOG_CI_START="-0.10527979054919413" LOG_EFFECT_SIZE="0.18173949986928026" ORDER="463" O_E="0.0" SE="0.33719310392042656" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="251" TOTAL_2="267" VAR="0.11369918933149159" WEIGHT="2.8719243057623474"/>
<DICH_DATA CI_END="3.9419707258706516" CI_START="1.2752972552091766" EFFECT_SIZE="2.242138364779874" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="14" LOG_CI_END="0.5957133947683748" LOG_CI_START="0.10561142496649092" LOG_EFFECT_SIZE="0.35066240986743286" ORDER="451" O_E="0.0" SE="0.28788832310550383" STUDY_ID="STD-Hays-1999" TOTAL_1="636" TOTAL_2="322" VAR="0.08287968658049898" WEIGHT="3.934781619595912"/>
<DICH_DATA CI_END="3.6866872656583496" CI_START="1.1538560077024487" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5666362988322253" LOG_CI_START="0.06215161561170004" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="445" O_E="0.0" SE="0.2963368001631935" STUDY_ID="STD-Davidson-1998" TOTAL_1="401" TOTAL_2="401" VAR="0.08781549913096048" WEIGHT="3.3868111334886644"/>
<DICH_DATA CI_END="10.709518607104284" CI_START="0.9561587570525513" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0297699497322355" LOG_CI_START="-0.01946999309242347" LOG_EFFECT_SIZE="0.505149978319906" ORDER="461" O_E="0.0" SE="0.6163287362366865" STUDY_ID="STD-Perng-1998" TOTAL_1="30" TOTAL_2="32" VAR="0.3798611111111111" WEIGHT="0.6145423427701205"/>
<DICH_DATA CI_END="4.843896772402742" CI_START="0.5969505892682352" EFFECT_SIZE="1.7004608294930876" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6851948793815098" LOG_CI_START="-0.2240616147604481" LOG_EFFECT_SIZE="0.23056663231053087" ORDER="460" O_E="0.0" SE="0.5341017655512216" STUDY_ID="STD-Lewis-1998" TOTAL_1="62" TOTAL_2="123" VAR="0.28526469596493204" WEIGHT="0.9931594810365407"/>
<DICH_DATA CI_END="2.361530435285525" CI_START="0.9005753554279192" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.37319354711423586" LOG_CI_START="-0.04547994183689675" LOG_EFFECT_SIZE="0.16385680263866959" ORDER="440" O_E="0.0" SE="0.24593087987708992" STUDY_ID="STD-Ahluwalia-1998" TOTAL_1="205" TOTAL_2="205" VAR="0.06048199767711963" WEIGHT="5.080216700232997"/>
<DICH_DATA CI_END="9.51135034004292" CI_START="1.1889010697860327" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9782421787248091" LOG_CI_START="0.07514571783689675" LOG_EFFECT_SIZE="0.5266939482808529" ORDER="466" O_E="0.0" SE="0.5304833315251388" STUDY_ID="STD-Wong-1999" TOTAL_1="51" TOTAL_2="49" VAR="0.28141256502601036" WEIGHT="0.8636368390396094"/>
<DICH_DATA CI_END="3.103911528273855" CI_START="0.6721904713072535" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49190933393600517" LOG_CI_START="-0.1725076482009813" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="449" O_E="0.0" SE="0.39028182422437036" STUDY_ID="STD-Glavas-2003a" TOTAL_1="56" TOTAL_2="56" VAR="0.15231990231990233" WEIGHT="1.9050812625873736"/>
<DICH_DATA CI_END="3.204629081127771" CI_START="0.6457386936581349" EFFECT_SIZE="1.4385245901639345" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5057777694736735" LOG_CI_START="-0.18994318921948414" LOG_EFFECT_SIZE="0.15791729012709468" ORDER="453" O_E="0.0" SE="0.4086699350106484" STUDY_ID="STD-Hughes-2003" TOTAL_1="61" TOTAL_2="54" VAR="0.1670111157816076" WEIGHT="1.7964824273287698"/>
<DICH_DATA CI_END="4.390778670369073" CI_START="1.3301234738135557" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6425415458131081" LOG_CI_START="0.12389195788955437" LOG_EFFECT_SIZE="0.38321675185133125" ORDER="450" O_E="0.0" SE="0.3046573353031615" STUDY_ID="STD-Glavas-2003b" TOTAL_1="80" TOTAL_2="80" VAR="0.09281609195402299" WEIGHT="2.5401083501164985"/>
<DICH_DATA CI_END="22.85043813806692" CI_START="1.2265708644863083" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3588945317196774" LOG_CI_START="0.0886926444024243" LOG_EFFECT_SIZE="0.723793588061051" ORDER="467" O_E="0.0" SE="0.7461228762109019" STUDY_ID="STD-Moolchan-2005" TOTAL_1="34" TOTAL_2="40" VAR="0.5566993464052288" WEIGHT="0.38902560317099527"/>
<DICH_DATA CI_END="4.551776484470188" CI_START="0.8367371518627194" EFFECT_SIZE="1.9515738498789346" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6581809278280224" LOG_CI_START="-0.07741094753064312" LOG_EFFECT_SIZE="0.2903849901486896" ORDER="468" O_E="0.0" SE="0.43209030882418825" STUDY_ID="STD-Prapavessis-2007" TOTAL_1="59" TOTAL_2="62" VAR="0.18670203497978238" WEIGHT="1.4449927666640685"/>
<DICH_DATA CI_END="1.8298847059469658" CI_START="0.6989802602453846" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.2624237273542518" LOG_CI_START="-0.15553508890031958" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="469" O_E="0.0" SE="0.24551107759744292" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="0.06027568922305764" WEIGHT="4.445189612703872"/>
<DICH_DATA CI_END="3.0007141337297876" CI_START="0.8411651795025185" EFFECT_SIZE="1.588740458015267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="8" LOG_CI_END="0.4772246238629811" LOG_CI_START="-0.07511871347371944" LOG_EFFECT_SIZE="0.20105295519463082" MODIFIED="2012-02-07 13:54:54 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="611" O_E="0.0" SE="0.3244492104951934" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1052672901909543" WEIGHT="2.967707414628863"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3444054047301763" CI_START="0.3621948781633169" DF="0" EFFECT_SIZE="0.6978085351787774" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="0.12853024973598015" LOG_CI_START="-0.44105769538346296" LOG_EFFECT_SIZE="-0.1562637228237414" NO="3" P_CHI2="1.0" P_Z="0.2821896786179311" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="55" WEIGHT="100.0" Z="1.07541345089548">
<NAME>24 hour versus 16 hour nicotine patch</NAME>
<DICH_DATA CI_END="1.3444054047301763" CI_START="0.3621948781633169" EFFECT_SIZE="0.6978085351787774" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.12853024973598015" LOG_CI_START="-0.44105769538346296" LOG_EFFECT_SIZE="-0.1562637228237414" ORDER="470" O_E="0.0" SE="0.33457877846896167" STUDY_ID="STD-Daughton-1991" TOTAL_1="51" TOTAL_2="55" VAR="0.11194295900178253" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2012-10-15 13:39:39 +0100" MODIFIED_BY="L S" NO="9">
<NAME>Nicotine patch: Duration of therapy, subgroups &amp; direct comparison</NAME>
<DICH_OUTCOME CHI2="50.68947473940049" CI_END="1.824051287063385" CI_START="1.5381252215169403" CI_STUDY="95" CI_TOTAL="95" DF="42" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6749982955133502" ESTIMABLE="YES" EVENTS_1="1482" EVENTS_2="704" I2="17.142562206599933" I2_Q="42.055984994870215" ID="CMP-009.01" LOG_CI_END="0.26103704527281524" LOG_CI_START="0.1869916935928853" LOG_EFFECT_SIZE="0.22401436943285025" METHOD="MH" MODIFIED="2012-08-22 14:02:46 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.1682082754393195" P_Q="0.188947782128287" P_Z="1.927600570584552E-32" Q="1.7258037778560391" RANDOM="NO" SCALE="5.25" SORT_BY="STUDY" STUDIES="42" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8929" TOTAL_2="7168" WEIGHT="200.00000000000006" Z="11.85922103539268">
<NAME>Smoking Cessation: Indirect comparison</NAME>
<GROUP_LABEL_1>Nicotine patch</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.546523336975614" CI_END="2.039893475689982" CI_START="1.5729527181943785" DF="16" EFFECT_SIZE="1.7912721701108225" ESTIMABLE="YES" EVENTS_1="630" EVENTS_2="294" I2="3.3029496640803586" ID="CMP-009.01.01" LOG_CI_END="0.30960748893180784" LOG_CI_START="0.19671566824573145" LOG_EFFECT_SIZE="0.25316157858876964" MODIFIED="2012-08-22 14:02:46 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.41551101817298397" P_Z="1.4890047405214051E-18" STUDIES="17" TAU2="0.0" TOTAL_1="3370" TOTAL_2="2821" WEIGHT="100.00000000000004" Z="8.790496482168848">
<NAME>Patch provided for 8 weeks or less</NAME>
<DICH_DATA CI_END="2.8593078037343456" CI_START="0.7422768702931712" EFFECT_SIZE="1.4568452380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.45626090956152343" LOG_CI_START="-0.12943407206289823" LOG_EFFECT_SIZE="0.1634134187493126" ORDER="471" O_E="0.0" SE="0.34404013144310264" STUDY_ID="STD-Buchkremer-1988" TOTAL_1="42" TOTAL_2="89" VAR="0.11836361204338733" WEIGHT="3.43271189838512"/>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-03-02 14:00:49 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="649" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="13.281520395503563"/>
<DICH_DATA CI_END="9.275880948360145" CI_START="1.27126435723578" EFFECT_SIZE="3.4339622641509435" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.9673551660329998" LOG_CI_START="0.1042358707355719" LOG_EFFECT_SIZE="0.5357955183842857" ORDER="472" O_E="0.0" SE="0.507000546567127" STUDY_ID="STD-Daughton-1991" TOTAL_1="106" TOTAL_2="52" VAR="0.25704955421936554" WEIGHT="1.7957593965105403"/>
<DICH_DATA CI_END="3.6866872656583496" CI_START="1.1538560077024487" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5666362988322253" LOG_CI_START="0.06215161561170004" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="473" O_E="0.0" SE="0.2963368001631935" STUDY_ID="STD-Davidson-1998" TOTAL_1="401" TOTAL_2="401" VAR="0.08781549913096048" WEIGHT="5.353395936767271"/>
<DICH_DATA CI_END="3.3180338251609367" CI_START="0.7995548248992429" EFFECT_SIZE="1.628787878787879" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.520880809055993" LOG_CI_START="-0.097151751636482" LOG_EFFECT_SIZE="0.2118645287097555" ORDER="484" O_E="0.0" SE="0.3630353854612752" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="43" VAR="0.13179469109701664" WEIGHT="3.0458976881606885"/>
<DICH_DATA CI_END="7.237905645439162" CI_START="0.8039754134848986" EFFECT_SIZE="2.412280701754386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8596129172728425" LOG_CI_START="-0.09475723228526235" LOG_EFFECT_SIZE="0.3824278424937901" ORDER="474" O_E="0.0" SE="0.5606017500588621" STUDY_ID="STD-Fiore-1994B" TOTAL_1="57" TOTAL_2="55" VAR="0.314274322169059" WEIGHT="1.3622480731952429"/>
<DICH_DATA CI_END="3.103911528273855" CI_START="0.6721904713072535" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49190933393600517" LOG_CI_START="-0.1725076482009813" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="475" O_E="0.0" SE="0.39028182422437036" STUDY_ID="STD-Glavas-2003a" TOTAL_1="56" TOTAL_2="56" VAR="0.15231990231990233" WEIGHT="3.01128521443159"/>
<DICH_DATA CI_END="4.390778670369073" CI_START="1.3301234738135557" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6425415458131081" LOG_CI_START="0.12389195788955437" LOG_EFFECT_SIZE="0.38321675185133125" ORDER="476" O_E="0.0" SE="0.3046573353031615" STUDY_ID="STD-Glavas-2003b" TOTAL_1="80" TOTAL_2="80" VAR="0.09281609195402299" WEIGHT="4.015046952575453"/>
<DICH_DATA CI_END="3.9419707258706516" CI_START="1.2752972552091766" EFFECT_SIZE="2.242138364779874" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="14" LOG_CI_END="0.5957133947683748" LOG_CI_START="0.10561142496649092" LOG_EFFECT_SIZE="0.35066240986743286" ORDER="477" O_E="0.0" SE="0.28788832310550383" STUDY_ID="STD-Hays-1999" TOTAL_1="636" TOTAL_2="322" VAR="0.08287968658049898" WEIGHT="6.219550811713959"/>
<DICH_DATA CI_END="3.2899905062299095" CI_START="1.1453425421228474" EFFECT_SIZE="1.9411764705882353" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5171946447287246" LOG_CI_START="0.05893539227050256" LOG_EFFECT_SIZE="0.2880650184996135" ORDER="478" O_E="0.0" SE="0.26918375331384387" STUDY_ID="STD-Hurt-1994" TOTAL_1="120" TOTAL_2="120" VAR="0.07245989304812835" WEIGHT="5.687983182815225"/>
<DICH_DATA CI_END="3.6638765871680388" CI_START="0.8345587993406903" EFFECT_SIZE="1.7486338797814207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.563940836607552" LOG_CI_START="-0.078543059428599" LOG_EFFECT_SIZE="0.2426988885894765" ORDER="479" O_E="0.0" SE="0.37739822087821245" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.14242941712204005" WEIGHT="3.6373940213926135"/>
<DICH_DATA CI_END="4.843896772402742" CI_START="0.5969505892682352" EFFECT_SIZE="1.7004608294930876" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6851948793815098" LOG_CI_START="-0.2240616147604481" LOG_EFFECT_SIZE="0.23056663231053087" ORDER="480" O_E="0.0" SE="0.5341017655512216" STUDY_ID="STD-Lewis-1998" TOTAL_1="62" TOTAL_2="123" VAR="0.28526469596493204" WEIGHT="1.5698471868628348"/>
<DICH_DATA CI_END="22.85043813806692" CI_START="1.2265708644863083" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3588945317196774" LOG_CI_START="0.0886926444024243" LOG_EFFECT_SIZE="0.723793588061051" ORDER="483" O_E="0.0" SE="0.7461228762109019" STUDY_ID="STD-Moolchan-2005" TOTAL_1="34" TOTAL_2="40" VAR="0.5566993464052288" WEIGHT="0.6149171008448893"/>
<DICH_DATA CI_END="1.9414129420303619" CI_START="1.310754497312224" EFFECT_SIZE="1.5952165197572563" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="122" LOG_CI_END="0.2881179204326567" LOG_CI_START="0.1175213564903053" LOG_EFFECT_SIZE="0.20281963846148102" ORDER="485" O_E="0.0" SE="0.10020926612634813" STUDY_ID="STD-Otero-2006" TOTAL_1="597" TOTAL_2="602" VAR="0.010041897017581264" WEIGHT="40.6494203146901"/>
<DICH_DATA CI_END="10.709518607104284" CI_START="0.9561587570525513" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0297699497322355" LOG_CI_START="-0.01946999309242347" LOG_EFFECT_SIZE="0.505149978319906" ORDER="481" O_E="0.0" SE="0.6163287362366865" STUDY_ID="STD-Perng-1998" TOTAL_1="30" TOTAL_2="32" VAR="0.3798611111111111" WEIGHT="0.9713823272359967"/>
<DICH_DATA CI_END="3.0007141337297876" CI_START="0.8411651795025185" EFFECT_SIZE="1.588740458015267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="8" LOG_CI_END="0.4772246238629811" LOG_CI_START="-0.07511871347371944" LOG_EFFECT_SIZE="0.20105295519463082" MODIFIED="2012-02-07 13:56:37 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="612" O_E="0.0" SE="0.3244492104951934" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1052672901909543" WEIGHT="4.690935570010117"/>
<DICH_DATA CI_END="34.51060023583957" CI_START="1.9508246278682124" EFFECT_SIZE="8.205128205128204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5379525129526281" LOG_CI_START="0.2902182296341853" LOG_EFFECT_SIZE="0.9140853712934067" ORDER="482" O_E="0.0" SE="0.7329252944055672" STUDY_ID="STD-Westman-1993" TOTAL_1="78" TOTAL_2="80" VAR="0.5371794871794873" WEIGHT="0.6607039289048214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="32.65778984887957" CI_END="1.7868695103429593" CI_START="1.4255398254620961" DF="25" EFFECT_SIZE="1.596011795037193" ESTIMABLE="YES" EVENTS_1="852" EVENTS_2="410" I2="23.448585725841127" ID="CMP-009.01.02" LOG_CI_END="0.2520928384557275" LOG_CI_START="0.15397935474742586" LOG_EFFECT_SIZE="0.20303609660157668" NO="2" P_CHI2="0.13984747055210311" P_Z="4.983386600749359E-16" STUDIES="26" TAU2="0.0" TOTAL_1="5559" TOTAL_2="4347" WEIGHT="100.0" Z="8.111901073328507">
<NAME>Patch provided for more than 8 weeks</NAME>
<DICH_DATA CI_END="3.0985703046290562" CI_START="0.7554774524569775" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4911613544686127" LOG_CI_START="-0.12177849283341506" LOG_EFFECT_SIZE="0.1846914308175988" ORDER="486" O_E="0.0" SE="0.3600439004063886" STUDY_ID="STD-Abelin-1989" TOTAL_1="100" TOTAL_2="99" VAR="0.12963161021984548" WEIGHT="2.512752505428382"/>
<DICH_DATA CI_END="2.361530435285525" CI_START="0.9005753554279192" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.37319354711423586" LOG_CI_START="-0.04547994183689675" LOG_EFFECT_SIZE="0.16385680263866959" ORDER="487" O_E="0.0" SE="0.24593087987708992" STUDY_ID="STD-Ahluwalia-1998" TOTAL_1="205" TOTAL_2="205" VAR="0.06048199767711963" WEIGHT="5.4549572572390685"/>
<DICH_DATA CI_END="2.5728675834146997" CI_START="0.8294790996379331" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4104174351523806" LOG_CI_START="-0.08119455240787828" LOG_EFFECT_SIZE="0.16461144137225117" ORDER="488" O_E="0.0" SE="0.28877531501148174" STUDY_ID="STD-Campbell-1996" TOTAL_1="115" TOTAL_2="119" VAR="0.08339118255998051" WEIGHT="3.79787800495099"/>
<DICH_DATA CI_END="3.788507155734091" CI_START="0.775708053172369" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.578468111881843" LOG_CI_START="-0.1103016998151071" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="489" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Cinciripini-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.16369047619047616" WEIGHT="1.5910292000280617"/>
<DICH_DATA CI_END="2.8436645298032195" CI_START="0.8678996274243392" EFFECT_SIZE="1.570991847826087" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.45387836088728595" LOG_CI_START="-0.06153049806810565" LOG_EFFECT_SIZE="0.19617393140959016" ORDER="490" O_E="0.0" SE="0.30275371506539595" STUDY_ID="STD-Daughton-1998" TOTAL_1="184" TOTAL_2="185" VAR="0.09165981198589895" WEIGHT="3.6267827834940873"/>
<DICH_DATA CI_END="16.118289185653534" CI_START="0.760006217713441" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2073189433834552" LOG_CI_START="-0.11918285468290388" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="491" O_E="0.0" SE="0.7791937224739794" STUDY_ID="STD-Ehrsam-1991" TOTAL_1="56" TOTAL_2="56" VAR="0.607142857142857" WEIGHT="0.45457977143658906"/>
<DICH_DATA CI_END="3.3180338251609367" CI_START="0.7995548248992429" EFFECT_SIZE="1.628787878787879" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.520880809055993" LOG_CI_START="-0.097151751636482" LOG_EFFECT_SIZE="0.2118645287097555" ORDER="492" O_E="0.0" SE="0.3630353854612752" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="43" VAR="0.13179469109701664" WEIGHT="2.069121718263095"/>
<DICH_DATA CI_END="2.358871489270788" CI_START="1.1945432704943428" EFFECT_SIZE="1.678622668579627" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="34" LOG_CI_END="0.3727042812752382" LOG_CI_START="0.07720188602106627" LOG_EFFECT_SIZE="0.22495308364815225" ORDER="493" O_E="0.0" SE="0.17357956973274816" STUDY_ID="STD-Hughes-1999" TOTAL_1="779" TOTAL_2="260" VAR="0.030129867028605983" WEIGHT="11.588065280336378"/>
<DICH_DATA CI_END="3.204629081127771" CI_START="0.6457386936581349" EFFECT_SIZE="1.4385245901639345" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5057777694736735" LOG_CI_START="-0.18994318921948414" LOG_EFFECT_SIZE="0.15791729012709468" ORDER="494" O_E="0.0" SE="0.4086699350106484" STUDY_ID="STD-Hughes-2003" TOTAL_1="61" TOTAL_2="54" VAR="0.1670111157816076" WEIGHT="1.9289993779222216"/>
<DICH_DATA CI_END="3.393314017187208" CI_START="0.5239060602034752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5306240511043927" LOG_CI_START="-0.28074657788779284" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="495" O_E="0.0" SE="0.4766031238193982" STUDY_ID="STD-Hurt-1990" TOTAL_1="31" TOTAL_2="31" VAR="0.2271505376344086" WEIGHT="1.3637393143097671"/>
<DICH_DATA CI_END="2.014402311568503" CI_START="1.025628178913287" EFFECT_SIZE="1.437368350289069" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.30414621112601403" LOG_CI_START="0.010989944486001551" LOG_EFFECT_SIZE="0.15756807780600784" ORDER="496" O_E="0.0" SE="0.17220144217126704" STUDY_ID="STD-ICRF-1994" TOTAL_1="842" TOTAL_2="844" VAR="0.02965333668586423" WEIGHT="12.032074068878543"/>
<DICH_DATA CI_END="1.3007062234518165" CI_START="0.5135491607972068" EFFECT_SIZE="0.8172983479105929" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.11417921820578969" LOG_CI_START="-0.2894179761348311" LOG_EFFECT_SIZE="-0.08761937896452072" ORDER="497" O_E="0.0" SE="0.23707498979401342" STUDY_ID="STD-Joseph-1996" TOTAL_1="294" TOTAL_2="290" VAR="0.05620455078583157" WEIGHT="8.009633301511133"/>
<DICH_DATA CI_END="1.9175853297600345" CI_START="0.6255505122219942" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2827546985242227" LOG_CI_START="-0.20373761595687537" LOG_EFFECT_SIZE="0.039508541283673655" ORDER="498" O_E="0.0" SE="0.28576799370199224" STUDY_ID="STD-Killen-1997" TOTAL_1="212" TOTAL_2="212" VAR="0.08166334622446189" WEIGHT="4.773087600084185"/>
<DICH_DATA CI_END="1.9396324884607696" CI_START="0.46529433043070706" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.2877194498511332" LOG_CI_START="-0.3322722392734377" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="499" O_E="0.0" SE="0.3641861872001304" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="150" TOTAL_2="75" VAR="0.13263157894736843" WEIGHT="3.0305318095772606"/>
<DICH_DATA CI_END="1.8298847059469658" CI_START="0.6989802602453846" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.2624237273542518" LOG_CI_START="-0.15553508890031958" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="511" O_E="0.0" SE="0.24551107759744292" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="0.06027568922305764" WEIGHT="4.773087600084185"/>
<DICH_DATA CI_END="10.644319166426266" CI_START="1.3211272398102434" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0271178882524812" LOG_CI_START="0.12094464720295672" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="500" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Paoletti-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.2833333333333333" WEIGHT="0.9091595428731781"/>
<DICH_DATA CI_END="4.551776484470188" CI_START="0.8367371518627194" EFFECT_SIZE="1.9515738498789346" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6581809278280224" LOG_CI_START="-0.07741094753064312" LOG_EFFECT_SIZE="0.2903849901486896" ORDER="510" O_E="0.0" SE="0.43209030882418825" STUDY_ID="STD-Prapavessis-2007" TOTAL_1="59" TOTAL_2="62" VAR="0.18670203497978238" WEIGHT="1.5515821950686883"/>
<DICH_DATA CI_END="3.7386899573042225" CI_START="1.1327257863865658" EFFECT_SIZE="2.0578898225957047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5727194514032413" LOG_CI_START="0.05412478729254229" LOG_EFFECT_SIZE="0.31342211934789177" ORDER="501" O_E="0.0" SE="0.30462507278361334" STUDY_ID="STD-Richmond-1994" TOTAL_1="153" TOTAL_2="152" VAR="0.09279643496842171" WEIGHT="3.192491378416963"/>
<DICH_DATA CI_END="5.191155779737516" CI_START="1.3541372015357949" EFFECT_SIZE="2.651327433628319" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7152640616789412" LOG_CI_START="0.1316626694090771" LOG_EFFECT_SIZE="0.42346336554400915" ORDER="502" O_E="0.0" SE="0.3428103466928011" STUDY_ID="STD-Sachs-1993" TOTAL_1="113" TOTAL_2="107" VAR="0.11751893379963846" WEIGHT="2.3348870078333896"/>
<DICH_DATA CI_END="2.9427867387446707" CI_START="0.7847299161094201" EFFECT_SIZE="1.5196357427433125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.46875879028775475" LOG_CI_START="-0.10527979054919413" LOG_EFFECT_SIZE="0.18173949986928026" ORDER="503" O_E="0.0" SE="0.33719310392042656" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="251" TOTAL_2="267" VAR="0.11369918933149159" WEIGHT="3.083770881907672"/>
<DICH_DATA CI_END="3.2993612898922677" CI_START="1.2444698588327163" EFFECT_SIZE="2.026315789473684" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="19" LOG_CI_END="0.5184298746891502" LOG_CI_START="0.09498438242219312" LOG_EFFECT_SIZE="0.30670712855567167" ORDER="504" O_E="0.0" SE="0.24873397824660265" STUDY_ID="STD-Stapleton-1995" TOTAL_1="800" TOTAL_2="400" VAR="0.061868591934381406" WEIGHT="5.758010438196795"/>
<DICH_DATA CI_END="2.6170951223873518" CI_START="1.2476508655425136" EFFECT_SIZE="1.8069922508560101" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="31" LOG_CI_END="0.4178195080342886" LOG_CI_START="0.09609307222018122" LOG_EFFECT_SIZE="0.25695629012723487" ORDER="505" O_E="0.0" SE="0.18898370096874859" STUDY_ID="STD-TNSG-1991" TOTAL_1="537" TOTAL_2="271" VAR="0.03571483923184539" WEIGHT="9.36558100879319"/>
<DICH_DATA CI_END="9.428558561934224" CI_START="1.673646214316064" EFFECT_SIZE="3.972413793103448" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9744453028701352" LOG_CI_START="0.22366365950633915" LOG_EFFECT_SIZE="0.5990544811882371" ORDER="506" O_E="0.0" SE="0.44101285374096627" STUDY_ID="STD-Tonnesen-1991" TOTAL_1="145" TOTAL_2="144" VAR="0.19449233716475092" WEIGHT="1.3684581354665484"/>
<DICH_DATA CI_END="21.316258689645682" CI_START="1.043519004284947" EFFECT_SIZE="4.716346153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.328710982107621" LOG_CI_START="0.018500362726752817" LOG_EFFECT_SIZE="0.6736056724171869" ORDER="507" O_E="0.0" SE="0.7696242034714872" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="104" TOTAL_2="109" VAR="0.5923214145691211" WEIGHT="0.443908884783148"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" ORDER="508" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="4.0584881993858675"/>
<DICH_DATA CI_END="9.51135034004292" CI_START="1.1889010697860327" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9782421787248091" LOG_CI_START="0.07514571783689675" LOG_EFFECT_SIZE="0.5266939482808529" ORDER="509" O_E="0.0" SE="0.5304833315251388" STUDY_ID="STD-Wong-1999" TOTAL_1="51" TOTAL_2="49" VAR="0.28141256502601036" WEIGHT="0.9273427337306417"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6464651133903556" CI_END="1.1837441481839182" CI_START="0.8788169023825079" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.019948217077912" ESTIMABLE="YES" EVENTS_1="291" EVENTS_2="287" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.07325784509034554" LOG_CI_START="-0.056101598837482766" LOG_EFFECT_SIZE="0.008578123126431398" METHOD="MH" MODIFIED="2012-10-04 16:48:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.800417767963401" P_Q="0.8004742564815561" P_Z="0.7949104682103358" Q="1.646152505064923" RANDOM="NO" SCALE="5.25" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1869" TOTAL_2="1878" WEIGHT="500.0" Z="0.2599394659138425">
<NAME>Smoking Cessation: Direct comparisons</NAME>
<GROUP_LABEL_1>Longer duration</GROUP_LABEL_1>
<GROUP_LABEL_2>Shorter duration</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter duration</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer duration</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2589085063356311" CI_START="0.8778277666755017" DF="0" EFFECT_SIZE="1.0512396694214876" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="198" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="0.09999416804475982" LOG_CI_START="-0.05659068605286977" LOG_EFFECT_SIZE="0.02170174099594499" MODIFIED="2012-10-04 16:48:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="1.0" P_Z="0.5869377295659339" STUDIES="1" TAU2="0.0" TOTAL_1="1430" TOTAL_2="1431" WEIGHT="99.99999999999999" Z="0.5432789907936887">
<NAME>28 weeks versus 12 weeks</NAME>
<DICH_DATA CI_END="1.2589085063356311" CI_START="0.8778277666755016" EFFECT_SIZE="1.0512396694214876" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="198" LOG_CI_END="0.09999416804475982" LOG_CI_START="-0.05659068605286983" LOG_EFFECT_SIZE="0.02170174099594499" MODIFIED="2012-08-14 14:17:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="512" O_E="0.0" SE="0.09197871840447618" STUDY_ID="STD-CEASE-1999" TOTAL_1="1430" TOTAL_2="1431" VAR="0.008460084639329924" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5136174982710993" CI_START="0.6795441996567738" DF="0" EFFECT_SIZE="1.0141843971631206" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" I2="0.0" ID="CMP-009.02.02" LOG_CI_END="0.1800161397756446" LOG_CI_START="-0.16778229015628074" LOG_EFFECT_SIZE="0.006116924809681917" MODIFIED="2012-10-04 16:48:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="1.0" P_Z="0.9450358205318228" STUDIES="1" TAU2="0.0" TOTAL_1="282" TOTAL_2="286" WEIGHT="100.0" Z="0.06894195770499989">
<NAME>24 weeks versus 8 weeks</NAME>
<DICH_DATA CI_END="1.5136174982710993" CI_START="0.6795441996567737" EFFECT_SIZE="1.0141843971631206" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1800161397756446" LOG_CI_START="-0.16778229015628082" LOG_EFFECT_SIZE="0.006116924809681917" MODIFIED="2012-08-14 14:17:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="612" O_E="0.0" SE="0.20429851937200724" STUDY_ID="STD-Schnoll-2010a" TOTAL_1="282" TOTAL_2="286" VAR="0.041737885017594414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4129097144401381" CI_START="0.261322443689495" DF="0" EFFECT_SIZE="0.6076388888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-009.02.03" LOG_CI_END="0.15011441112442434" LOG_CI_START="-0.5828232892702973" LOG_EFFECT_SIZE="-0.21635443907293644" MODIFIED="2012-10-04 16:48:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" P_CHI2="1.0" P_Z="0.247225059021716" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.00000000000001" Z="1.1571158319457484">
<NAME>12 weeks versus 3 weeks</NAME>
<DICH_DATA CI_END="1.4129097144401381" CI_START="0.261322443689495" EFFECT_SIZE="0.6076388888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.15011441112442434" LOG_CI_START="-0.5828232892702973" LOG_EFFECT_SIZE="-0.21635443907293644" MODIFIED="2012-08-14 14:17:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="513" O_E="0.0" SE="0.4305312333119896" STUDY_ID="STD-Bolin-1999" TOTAL_1="48" TOTAL_2="50" VAR="0.18535714285714283" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7067854733789867" CI_START="0.6203539874445471" DF="0" EFFECT_SIZE="1.0289855072463767" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" I2="0.0" ID="CMP-009.02.04" LOG_CI_END="0.23217893787945032" LOG_CI_START="-0.20736042191581044" LOG_EFFECT_SIZE="0.01240925798181993" MODIFIED="2012-10-04 16:48:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="4" P_CHI2="1.0" P_Z="0.9118788004477304" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="71" WEIGHT="100.0" Z="0.11066903646837187">
<NAME>12 weeks versus 6 weeks</NAME>
<DICH_DATA CI_END="1.7067854733789867" CI_START="0.6203539874445471" EFFECT_SIZE="1.0289855072463767" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.23217893787945032" LOG_CI_START="-0.20736042191581044" LOG_EFFECT_SIZE="0.01240925798181993" MODIFIED="2012-08-14 14:17:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="514" O_E="0.0" SE="0.2581875956986573" STUDY_ID="STD-Hilleman-1994" TOTAL_1="69" TOTAL_2="71" VAR="0.06666083457265332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.669861922264878" CI_START="0.5216665518844816" DF="0" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-009.02.05" LOG_CI_END="0.22268056164002456" LOG_CI_START="-0.28260700839491093" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2012-10-04 16:48:54 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="5" P_CHI2="1.0" P_Z="0.816189160940698" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.23244917216727468">
<NAME>6 weeks versus 3 weeks</NAME>
<DICH_DATA CI_END="1.669861922264878" CI_START="0.5216665518844816" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.22268056164002456" LOG_CI_START="-0.28260700839491093" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2012-08-14 14:17:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="515" O_E="0.0" SE="0.29680841985233186" STUDY_ID="STD-Glavas-2003b" TOTAL_1="40" TOTAL_2="40" VAR="0.08809523809523812" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2012-10-15 13:39:44 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="10">
<NAME>Nicotine patch: Effect of weaning/tapering dose at end of treatment</NAME>
<DICH_OUTCOME CHI2="49.284511625728165" CI_END="1.755333805539689" CI_START="1.4876601212494371" CI_STUDY="95" CI_TOTAL="95" DF="40" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6159641400669786" ESTIMABLE="YES" EVENTS_1="1734" EVENTS_2="733" I2="18.838599226133628" I2_Q="52.19035250251573" ID="CMP-010.01" LOG_CI_END="0.244359716880953" LOG_CI_START="0.17250372131322322" LOG_EFFECT_SIZE="0.20843171909708813" METHOD="MH" MODIFIED="2012-10-15 12:08:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.14907964397778284" P_Q="0.14810821320659762" P_Z="5.8662546722508776E-30" Q="2.0916280548870803" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="41" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10310" TOTAL_2="7117" WEIGHT="100.00000000000003" Z="11.370482294160183">
<NAME>Smoking Cessation: Indirect comparison</NAME>
<GROUP_LABEL_1>Nicotine patch</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.910048896544165" CI_END="2.373086771255791" CI_START="1.503479530767894" DF="8" EFFECT_SIZE="1.8888852229077218" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="100" I2="19.273859458052097" ID="CMP-010.01.01" LOG_CI_END="0.37531361836424665" LOG_CI_START="0.17709751974277732" LOG_EFFECT_SIZE="0.276205569053512" MODIFIED="2012-10-15 12:08:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.27139625040522963" P_Z="4.7013667767807914E-8" STUDIES="9" TAU2="0.0" TOTAL_1="1419" TOTAL_2="1388" WEIGHT="12.59434514379214" Z="5.46225025554649">
<NAME>Nicotine patch versus placebo. No weaning</NAME>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-03-02 14:02:19 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="650" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="4.965276782140431"/>
<DICH_DATA CI_END="9.275880948360145" CI_START="1.27126435723578" EFFECT_SIZE="3.4339622641509435" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.9673551660329998" LOG_CI_START="0.1042358707355719" LOG_EFFECT_SIZE="0.5357955183842857" ORDER="547" O_E="0.0" SE="0.507000546567127" STUDY_ID="STD-Daughton-1991" TOTAL_1="106" TOTAL_2="52" VAR="0.25704955421936554" WEIGHT="0.671341997925399"/>
<DICH_DATA CI_END="3.6866872656583496" CI_START="1.1538560077024487" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.5666362988322253" LOG_CI_START="0.06215161561170004" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="548" O_E="0.0" SE="0.2963368001631935" STUDY_ID="STD-Davidson-1998" TOTAL_1="401" TOTAL_2="401" VAR="0.08781549913096048" WEIGHT="2.001359163626661"/>
<DICH_DATA CI_END="3.3180338251609367" CI_START="0.7995548248992429" EFFECT_SIZE="1.628787878787879" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.520880809055993" LOG_CI_START="-0.097151751636482" LOG_EFFECT_SIZE="0.2118645287097555" ORDER="549" O_E="0.0" SE="0.3630353854612752" STUDY_ID="STD-Fiore-1994A" TOTAL_1="44" TOTAL_2="43" VAR="0.13179469109701664" WEIGHT="1.1387043517186175"/>
<DICH_DATA CI_END="3.2899905062299095" CI_START="1.1453425421228474" EFFECT_SIZE="1.9411764705882353" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.5171946447287246" LOG_CI_START="0.05893539227050256" LOG_EFFECT_SIZE="0.2880650184996135" ORDER="550" O_E="0.0" SE="0.26918375331384387" STUDY_ID="STD-Hurt-1994" TOTAL_1="120" TOTAL_2="120" VAR="0.07245989304812835" WEIGHT="2.1264441113533272"/>
<DICH_DATA CI_END="22.85043813806692" CI_START="1.2265708644863083" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3588945317196774" LOG_CI_START="0.0886926444024243" LOG_EFFECT_SIZE="0.723793588061051" ORDER="553" O_E="0.0" SE="0.7461228762109019" STUDY_ID="STD-Moolchan-2005" TOTAL_1="34" TOTAL_2="40" VAR="0.5566993464052288" WEIGHT="0.2298858498760354"/>
<DICH_DATA CI_END="10.709518607104284" CI_START="0.9561587570525513" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0297699497322355" LOG_CI_START="-0.01946999309242347" LOG_EFFECT_SIZE="0.505149978319906" ORDER="551" O_E="0.0" SE="0.6163287362366865" STUDY_ID="STD-Perng-1998" TOTAL_1="30" TOTAL_2="32" VAR="0.3798611111111111" WEIGHT="0.36314984823870866"/>
<DICH_DATA CI_END="4.551776484470188" CI_START="0.8367371518627194" EFFECT_SIZE="1.9515738498789346" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6581809278280224" LOG_CI_START="-0.07741094753064312" LOG_EFFECT_SIZE="0.2903849901486896" ORDER="554" O_E="0.0" SE="0.43209030882418825" STUDY_ID="STD-Prapavessis-2007" TOTAL_1="59" TOTAL_2="62" VAR="0.18670203497978238" WEIGHT="0.8538856762167469"/>
<DICH_DATA CI_END="21.316258689645682" CI_START="1.043519004284947" EFFECT_SIZE="4.716346153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.328710982107621" LOG_CI_START="0.018500362726752817" LOG_EFFECT_SIZE="0.6736056724171869" ORDER="552" O_E="0.0" SE="0.7696242034714872" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="104" TOTAL_2="109" VAR="0.5923214145691211" WEIGHT="0.24429736269621213"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.70759174229957" CI_END="1.7230562013485098" CI_START="1.442663167714746" DF="31" EFFECT_SIZE="1.5766387403549293" ESTIMABLE="YES" EVENTS_1="1536" EVENTS_2="633" I2="17.78843843473339" ID="CMP-010.01.02" LOG_CI_END="0.23629944316913654" LOG_CI_START="0.15916494406737575" LOG_EFFECT_SIZE="0.19773219361825614" MODIFIED="2012-10-15 12:08:39 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.18928152816711152" P_Z="9.31544651635023E-24" STUDIES="32" TAU2="0.0" TOTAL_1="8891" TOTAL_2="5729" WEIGHT="87.40565485620789" Z="10.048628890805512">
<NAME>Nicotine patch versus placebo. With Weaning</NAME>
<DICH_DATA CI_END="3.0985703046290562" CI_START="0.7554774524569775" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4911613544686127" LOG_CI_START="-0.12177849283341506" LOG_EFFECT_SIZE="0.1846914308175988" ORDER="516" O_E="0.0" SE="0.3600439004063886" STUDY_ID="STD-Abelin-1989" TOTAL_1="100" TOTAL_2="99" VAR="0.12963161021984548" WEIGHT="1.3828486683350045"/>
<DICH_DATA CI_END="2.361530435285525" CI_START="0.9005753554279192" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.37319354711423586" LOG_CI_START="-0.04547994183689675" LOG_EFFECT_SIZE="0.16385680263866959" ORDER="517" O_E="0.0" SE="0.24593087987708992" STUDY_ID="STD-Ahluwalia-1998" TOTAL_1="205" TOTAL_2="205" VAR="0.06048199767711963" WEIGHT="3.0020387454399913"/>
<DICH_DATA CI_END="2.8593078037343456" CI_START="0.7422768702931712" EFFECT_SIZE="1.4568452380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.45626090956152343" LOG_CI_START="-0.12943407206289823" LOG_EFFECT_SIZE="0.1634134187493126" ORDER="518" O_E="0.0" SE="0.34404013144310264" STUDY_ID="STD-Buchkremer-1988" TOTAL_1="42" TOTAL_2="89" VAR="0.11836361204338733" WEIGHT="1.2833142728598437"/>
<DICH_DATA CI_END="2.5728675834146997" CI_START="0.8294790996379331" EFFECT_SIZE="1.4608695652173913" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4104174351523806" LOG_CI_START="-0.08119455240787828" LOG_EFFECT_SIZE="0.16461144137225117" ORDER="520" O_E="0.0" SE="0.28877531501148174" STUDY_ID="STD-Campbell-1996" TOTAL_1="115" TOTAL_2="119" VAR="0.08339118255998051" WEIGHT="2.0900946393643816"/>
<DICH_DATA CI_END="1.8113081221041267" CI_START="1.1243557445017534" EFFECT_SIZE="1.427079077048801" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="71" LOG_CI_END="0.25799233454774956" LOG_CI_START="0.050903743110311706" LOG_EFFECT_SIZE="0.1544480388290306" ORDER="519" O_E="0.0" SE="0.12164486371541124" STUDY_ID="STD-CEASE-1999" TOTAL_1="2861" TOTAL_2="714" VAR="0.014797472868340973" WEIGHT="14.214618470861792"/>
<DICH_DATA CI_END="3.788507155734091" CI_START="0.775708053172369" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.578468111881843" LOG_CI_START="-0.1103016998151071" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="521" O_E="0.0" SE="0.4045867968563435" STUDY_ID="STD-Cinciripini-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.16369047619047616" WEIGHT="0.8755946340866642"/>
<DICH_DATA CI_END="2.8436645298032195" CI_START="0.8678996274243392" EFFECT_SIZE="1.570991847826087" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.45387836088728595" LOG_CI_START="-0.06153049806810565" LOG_EFFECT_SIZE="0.19617393140959016" ORDER="522" O_E="0.0" SE="0.30275371506539595" STUDY_ID="STD-Daughton-1998" TOTAL_1="184" TOTAL_2="185" VAR="0.09165981198589895" WEIGHT="1.995935426055857"/>
<DICH_DATA CI_END="16.118289185653534" CI_START="0.760006217713441" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2073189433834552" LOG_CI_START="-0.11918285468290388" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="523" O_E="0.0" SE="0.7791937224739794" STUDY_ID="STD-Ehrsam-1991" TOTAL_1="56" TOTAL_2="56" VAR="0.607142857142857" WEIGHT="0.2501698954533326"/>
<DICH_DATA CI_END="7.237905645439162" CI_START="0.8039754134848986" EFFECT_SIZE="2.412280701754386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8596129172728425" LOG_CI_START="-0.09475723228526235" LOG_EFFECT_SIZE="0.3824278424937901" ORDER="524" O_E="0.0" SE="0.5606017500588621" STUDY_ID="STD-Fiore-1994B" TOTAL_1="57" TOTAL_2="55" VAR="0.314274322169059" WEIGHT="0.5092744300299985"/>
<DICH_DATA CI_END="3.103911528273855" CI_START="0.6721904713072535" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.49190933393600517" LOG_CI_START="-0.1725076482009813" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="525" O_E="0.0" SE="0.39028182422437036" STUDY_ID="STD-Glavas-2003a" TOTAL_1="56" TOTAL_2="56" VAR="0.15231990231990233" WEIGHT="1.1257645295399967"/>
<DICH_DATA CI_END="4.390778670369073" CI_START="1.3301234738135557" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6425415458131081" LOG_CI_START="0.12389195788955437" LOG_EFFECT_SIZE="0.38321675185133125" ORDER="526" O_E="0.0" SE="0.3046573353031615" STUDY_ID="STD-Glavas-2003b" TOTAL_1="80" TOTAL_2="80" VAR="0.09281609195402299" WEIGHT="1.5010193727199956"/>
<DICH_DATA CI_END="2.358871489270788" CI_START="1.1945432704943428" EFFECT_SIZE="1.678622668579627" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="34" LOG_CI_END="0.3727042812752382" LOG_CI_START="0.07720188602106627" LOG_EFFECT_SIZE="0.22495308364815225" ORDER="527" O_E="0.0" SE="0.17357956973274816" STUDY_ID="STD-Hughes-1999" TOTAL_1="779" TOTAL_2="260" VAR="0.030129867028605983" WEIGHT="6.377285708351269"/>
<DICH_DATA CI_END="3.204629081127771" CI_START="0.6457386936581349" EFFECT_SIZE="1.4385245901639345" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5057777694736735" LOG_CI_START="-0.18994318921948414" LOG_EFFECT_SIZE="0.15791729012709468" ORDER="528" O_E="0.0" SE="0.4086699350106484" STUDY_ID="STD-Hughes-2003" TOTAL_1="61" TOTAL_2="54" VAR="0.1670111157816076" WEIGHT="1.061590512880229"/>
<DICH_DATA CI_END="3.393314017187208" CI_START="0.5239060602034752" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5306240511043927" LOG_CI_START="-0.28074657788779284" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="529" O_E="0.0" SE="0.4766031238193982" STUDY_ID="STD-Hurt-1990" TOTAL_1="31" TOTAL_2="31" VAR="0.2271505376344086" WEIGHT="0.7505096863599978"/>
<DICH_DATA CI_END="2.014402311568503" CI_START="1.025628178913287" EFFECT_SIZE="1.437368350289069" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="53" LOG_CI_END="0.30414621112601403" LOG_CI_START="0.010989944486001551" LOG_EFFECT_SIZE="0.15756807780600784" ORDER="530" O_E="0.0" SE="0.17220144217126704" STUDY_ID="STD-ICRF-1994" TOTAL_1="842" TOTAL_2="844" VAR="0.02965333668586423" WEIGHT="6.621638051305114"/>
<DICH_DATA CI_END="3.6638765871680388" CI_START="0.8345587993406903" EFFECT_SIZE="1.7486338797814207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.563940836607552" LOG_CI_START="-0.078543059428599" LOG_EFFECT_SIZE="0.2426988885894765" ORDER="531" O_E="0.0" SE="0.37739822087821245" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.14242941712204005" WEIGHT="1.3598343822166299"/>
<DICH_DATA CI_END="1.3007062234518165" CI_START="0.5135491607972068" EFFECT_SIZE="0.8172983479105929" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.11417921820578969" LOG_CI_START="-0.2894179761348311" LOG_EFFECT_SIZE="-0.08761937896452072" ORDER="532" O_E="0.0" SE="0.23707498979401342" STUDY_ID="STD-Joseph-1996" TOTAL_1="294" TOTAL_2="290" VAR="0.05620455078583157" WEIGHT="4.407959288039029"/>
<DICH_DATA CI_END="1.9175853297600345" CI_START="0.6255505122219942" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2827546985242227" LOG_CI_START="-0.20373761595687537" LOG_EFFECT_SIZE="0.039508541283673655" ORDER="533" O_E="0.0" SE="0.28576799370199224" STUDY_ID="STD-Killen-1997" TOTAL_1="212" TOTAL_2="212" VAR="0.08166334622446189" WEIGHT="2.6267839022599926"/>
<DICH_DATA CI_END="1.9396324884607696" CI_START="0.46529433043070706" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.2877194498511332" LOG_CI_START="-0.3322722392734377" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="534" O_E="0.0" SE="0.3641861872001304" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="150" TOTAL_2="75" VAR="0.13263157894736843" WEIGHT="1.6677993030222176"/>
<DICH_DATA CI_END="4.843896772402742" CI_START="0.5969505892682352" EFFECT_SIZE="1.7004608294930876" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6851948793815098" LOG_CI_START="-0.2240616147604481" LOG_EFFECT_SIZE="0.23056663231053087" ORDER="535" O_E="0.0" SE="0.5341017655512216" STUDY_ID="STD-Lewis-1998" TOTAL_1="62" TOTAL_2="123" VAR="0.28526469596493204" WEIGHT="0.5868850520364668"/>
<DICH_DATA CI_END="1.8298847059469658" CI_START="0.6989802602453846" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.2624237273542518" LOG_CI_START="-0.15553508890031958" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="545" O_E="0.0" SE="0.24551107759744292" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="0.06027568922305764" WEIGHT="2.6267839022599926"/>
<DICH_DATA CI_END="1.9414129420303619" CI_START="1.310754497312224" EFFECT_SIZE="1.5952165197572563" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="122" LOG_CI_END="0.2881179204326567" LOG_CI_START="0.1175213564903053" LOG_EFFECT_SIZE="0.20281963846148102" ORDER="546" O_E="0.0" SE="0.10020926612634813" STUDY_ID="STD-Otero-2006" TOTAL_1="597" TOTAL_2="602" VAR="0.010041897017581264" WEIGHT="15.196725742658908"/>
<DICH_DATA CI_END="10.644319166426266" CI_START="1.3211272398102434" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0271178882524812" LOG_CI_START="0.12094464720295672" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="536" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Paoletti-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.2833333333333333" WEIGHT="0.5003397909066652"/>
<DICH_DATA CI_END="3.0007141337297876" CI_START="0.8411651795025185" EFFECT_SIZE="1.588740458015267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="8" LOG_CI_END="0.4772246238629811" LOG_CI_START="-0.07511871347371944" LOG_EFFECT_SIZE="0.20105295519463082" MODIFIED="2012-02-16 09:03:33 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="613" O_E="0.0" SE="0.3244492104951934" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1052672901909543" WEIGHT="1.7536993340139972"/>
<DICH_DATA CI_END="3.7386899573042225" CI_START="1.1327257863865658" EFFECT_SIZE="2.0578898225957047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5727194514032413" LOG_CI_START="0.05412478729254229" LOG_EFFECT_SIZE="0.31342211934789177" ORDER="537" O_E="0.0" SE="0.30462507278361334" STUDY_ID="STD-Richmond-1994" TOTAL_1="153" TOTAL_2="152" VAR="0.09279643496842171" WEIGHT="1.7569308723312735"/>
<DICH_DATA CI_END="5.191155779737516" CI_START="1.3541372015357949" EFFECT_SIZE="2.651327433628319" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7152640616789412" LOG_CI_START="0.1316626694090771" LOG_EFFECT_SIZE="0.42346336554400915" ORDER="538" O_E="0.0" SE="0.3428103466928011" STUDY_ID="STD-Sachs-1993" TOTAL_1="113" TOTAL_2="107" VAR="0.11751893379963846" WEIGHT="1.2849635539193904"/>
<DICH_DATA CI_END="2.9427867387446707" CI_START="0.7847299161094201" EFFECT_SIZE="1.5196357427433125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.46875879028775475" LOG_CI_START="-0.10527979054919413" LOG_EFFECT_SIZE="0.18173949986928026" ORDER="539" O_E="0.0" SE="0.33719310392042656" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="251" TOTAL_2="267" VAR="0.11369918933149159" WEIGHT="1.6970984799672024"/>
<DICH_DATA CI_END="2.6170951223873518" CI_START="1.2476508655425136" EFFECT_SIZE="1.8069922508560101" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="31" LOG_CI_END="0.4178195080342886" LOG_CI_START="0.09609307222018122" LOG_EFFECT_SIZE="0.25695629012723487" ORDER="540" O_E="0.0" SE="0.18898370096874859" STUDY_ID="STD-TNSG-1991" TOTAL_1="537" TOTAL_2="271" VAR="0.03571483923184539" WEIGHT="5.15418100199459"/>
<DICH_DATA CI_END="9.428558561934224" CI_START="1.673646214316064" EFFECT_SIZE="3.972413793103448" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9744453028701352" LOG_CI_START="0.22366365950633915" LOG_EFFECT_SIZE="0.5990544811882371" ORDER="541" O_E="0.0" SE="0.44101285374096627" STUDY_ID="STD-Tonnesen-1991" TOTAL_1="145" TOTAL_2="144" VAR="0.19449233716475092" WEIGHT="0.7531066056899632"/>
<DICH_DATA CI_END="34.51060023583957" CI_START="1.9508246278682124" EFFECT_SIZE="8.205128205128204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5379525129526281" LOG_CI_START="0.2902182296341853" LOG_EFFECT_SIZE="0.9140853712934067" ORDER="542" O_E="0.0" SE="0.7329252944055672" STUDY_ID="STD-Westman-1993" TOTAL_1="78" TOTAL_2="80" VAR="0.5371794871794873" WEIGHT="0.2470031879159487"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" ORDER="543" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="2.233516826607354"/>
<DICH_DATA CI_END="9.51135034004292" CI_START="1.1889010697860327" EFFECT_SIZE="3.3627450980392157" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9782421787248091" LOG_CI_START="0.07514571783689675" LOG_EFFECT_SIZE="0.5266939482808529" ORDER="544" O_E="0.0" SE="0.5304833315251388" STUDY_ID="STD-Wong-1999" TOTAL_1="51" TOTAL_2="49" VAR="0.28141256502601036" WEIGHT="0.5103465867247986"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.042645349304628904" CI_END="1.3244550320101853" CI_START="0.7408081700009634" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9905387970756283" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.12203721768695616" LOG_CI_START="-0.13029423668415405" LOG_EFFECT_SIZE="-0.004128509498598972" METHOD="MH" MODIFIED="2012-10-04 16:49:15 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.8363946232451995" P_Q="1.0" P_Z="0.9488621588315722" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="127" WEIGHT="100.0" Z="0.06413572138481627">
<NAME>Smoking Cessation: Direct comparison</NAME>
<GROUP_LABEL_1>Abrupt withdrawal</GROUP_LABEL_1>
<GROUP_LABEL_2>Weaning</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weaning</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours abrupt withdrawal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.042645349304628904" CI_END="1.3244550320101853" CI_START="0.7408081700009634" DF="1" EFFECT_SIZE="0.9905387970756283" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="50" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.12203721768695616" LOG_CI_START="-0.13029423668415405" LOG_EFFECT_SIZE="-0.004128509498598972" MODIFIED="2012-10-04 16:49:15 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.8363946232451995" P_Z="0.9488621588315722" STUDIES="2" TAU2="0.0" TOTAL_1="137" TOTAL_2="127" WEIGHT="100.0" Z="0.06413572138481627">
<NAME>Nicotine patch. Abrupt withdrawal versus weaning</NAME>
<DICH_DATA CI_END="1.7067854733789867" CI_START="0.6203539874445471" EFFECT_SIZE="1.0289855072463767" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.23217893787945032" LOG_CI_START="-0.20736042191581044" LOG_EFFECT_SIZE="0.01240925798181993" MODIFIED="2012-08-14 14:24:50 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="555" O_E="0.0" SE="0.2581875956986573" STUDY_ID="STD-Hilleman-1994" TOTAL_1="69" TOTAL_2="71" VAR="0.06666083457265332" WEIGHT="39.42372673097008"/>
<DICH_DATA CI_END="1.3659308482098016" CI_START="0.6824822388501527" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" LOG_CI_END="0.13542871325393827" LOG_CI_START="-0.16590864636741198" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2012-08-14 14:24:50 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="556" O_E="0.0" SE="0.17700705668556824" STUDY_ID="STD-Stapleton-1995" TOTAL_1="68" TOTAL_2="56" VAR="0.031331498116487964" WEIGHT="60.57627326902992"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2012-10-15 13:39:47 +0100" MODIFIED_BY="L S" NO="11">
<NAME>Combinations of different types of NRT compared to a single type</NAME>
<DICH_OUTCOME CHI2="12.118629466182952" CI_END="1.5131566673042252" CI_START="1.1837263336852082" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3383435261842749" ESTIMABLE="YES" EVENTS_1="368" EVENTS_2="448" I2="33.98593444643218" I2_Q="32.34019052009307" ID="CMP-011.01" LOG_CI_END="0.17988389578478053" LOG_CI_START="0.07325130922132668" LOG_EFFECT_SIZE="0.1265676025030536" METHOD="MH" MODIFIED="2012-10-04 16:49:22 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.14598901616527615" P_Q="0.18114513646058994" P_Z="3.275206043179238E-6" Q="8.867893726159297" RANDOM="NO" SCALE="4.97" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1785" TOTAL_2="2879" WEIGHT="99.99999999999999" Z="4.652760483643507">
<NAME>Long-term smoking cessation</NAME>
<GROUP_LABEL_1>Combination NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>Single NRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6781679613755873" CI_END="2.9385551538453294" CI_START="1.0439002768473629" DF="1" EFFECT_SIZE="1.7514447004203084" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="19" I2="62.66104238337725" ID="CMP-011.01.01" LOG_CI_END="0.4681338464153635" LOG_CI_START="0.018659012762513666" LOG_EFFECT_SIZE="0.24339642958893853" MODIFIED="2012-08-08 13:09:03 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.10173276562426148" P_Z="0.0337796999928934" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="201" WEIGHT="5.862388944712112" Z="2.1226916402995104">
<NAME>Patch plus gum versus patch alone</NAME>
<DICH_DATA CI_END="253.7891016868548" CI_START="0.850951405640367" EFFECT_SIZE="14.695652173913043" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.4044729685117026" LOG_CI_START="-0.07009523999157885" LOG_EFFECT_SIZE="1.1671888642600619" MODIFIED="2012-08-08 13:09:03 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="605" O_E="0.0" SE="1.453573614985014" STUDY_ID="STD-Cooney-2009" TOTAL_1="45" TOTAL_2="51" VAR="2.112876254180602" WEIGHT="0.14179923244565074"/>
<DICH_DATA CI_END="2.4582346594114513" CI_START="0.832543568276938" EFFECT_SIZE="1.4305898975626987" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.39062333763229673" LOG_CI_START="-0.07959302993316558" LOG_EFFECT_SIZE="0.15551515384956557" ORDER="557" O_E="0.0" SE="0.2762074219165112" STUDY_ID="STD-Kornitzer-1995" TOTAL_1="149" TOTAL_2="150" VAR="0.07629053992176563" WEIGHT="5.720589712266461"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1732844790904684" CI_START="0.8821485552208754" DF="0" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="0.3371165784202792" LOG_CI_START="-0.05445827282734059" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2012-08-08 13:09:02 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="1.0" P_Z="0.15712714461473806" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="150" WEIGHT="7.854444440685175" Z="1.414799998335296">
<NAME>Patch plus gum versus gum alone</NAME>
<DICH_DATA CI_END="2.1732844790904684" CI_START="0.8821485552208754" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" LOG_CI_END="0.3371165784202792" LOG_CI_START="-0.05445827282734059" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2012-08-08 13:09:02 +0100" MODIFIED_BY="Lindsay Stead" ORDER="558" O_E="0.0" SE="0.23001300594962648" STUDY_ID="STD-Puska-1995" TOTAL_1="150" TOTAL_2="150" VAR="0.052905982905982904" WEIGHT="7.854444440685175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.488103404189134" CI_START="1.373030883343706" DF="0" EFFECT_SIZE="2.4823989569752283" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" I2="0.0" ID="CMP-011.01.03" LOG_CI_END="0.6520628543424483" LOG_CI_START="0.1376803058565009" LOG_EFFECT_SIZE="0.3948715800994746" NO="3" P_CHI2="1.0" P_Z="0.0026195642622675224" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="119" WEIGHT="3.9106516624508467" Z="3.0091770328967016">
<NAME>Nasal spray plus patch versus patch alone</NAME>
<DICH_DATA CI_END="4.488103404189134" CI_START="1.373030883343706" EFFECT_SIZE="2.4823989569752283" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" LOG_CI_END="0.6520628543424483" LOG_CI_START="0.1376803058565009" LOG_EFFECT_SIZE="0.3948715800994746" ORDER="559" O_E="0.0" SE="0.30215085521532564" STUDY_ID="STD-Blondal-1999" TOTAL_1="118" TOTAL_2="119" VAR="0.09129513930735267" WEIGHT="3.9106516624508467"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.781062782611974" CI_START="0.8530596844868262" DF="0" EFFECT_SIZE="1.232620320855615" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="68" I2="0.0" ID="CMP-011.01.04" LOG_CI_END="0.25067922864986186" LOG_CI_START="-0.06902058227152587" LOG_EFFECT_SIZE="0.09082932318916799" MODIFIED="2012-02-16 09:43:02 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="4" P_CHI2="1.0" P_Z="0.26541500822019504" STUDIES="1" TAU2="0.0" TOTAL_1="462" TOTAL_2="922" WEIGHT="13.714719127866024" Z="1.1136835000174123">
<NAME>Nasal spray plus patch versus either patch or spray alone</NAME>
<DICH_DATA CI_END="1.7810627826119738" CI_START="0.8530596844868262" EFFECT_SIZE="1.232620320855615" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="68" LOG_CI_END="0.2506792286498618" LOG_CI_START="-0.06902058227152587" LOG_EFFECT_SIZE="0.09082932318916799" ORDER="560" O_E="0.0" SE="0.18779325147481007" STUDY_ID="STD-Croghan-2003" TOTAL_1="462" TOTAL_2="922" VAR="0.03526630529948126" WEIGHT="13.714719127866024"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1717178624308815" CI_START="0.8933255345777718" DF="0" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" I2="0.0" ID="CMP-011.01.05" LOG_CI_END="0.3368034034452061" LOG_CI_START="-0.048990252076646194" LOG_EFFECT_SIZE="0.14390657568427997" MODIFIED="2012-08-08 13:08:59 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="5" P_CHI2="1.0" P_Z="0.1436893032868426" STUDIES="1" TAU2="0.0" TOTAL_1="200" TOTAL_2="200" WEIGHT="8.458632474584036" Z="1.4621894447598043">
<NAME>Patch plus inhaler versus inhaler alone</NAME>
<DICH_DATA CI_END="2.1717178624308815" CI_START="0.8933255345777718" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" LOG_CI_END="0.3368034034452061" LOG_CI_START="-0.048990252076646194" LOG_EFFECT_SIZE="0.14390657568427997" MODIFIED="2012-08-08 13:08:59 +0100" MODIFIED_BY="Lindsay Stead" ORDER="561" O_E="0.0" SE="0.2266171029629303" STUDY_ID="STD-Bohadana-2000" TOTAL_1="200" TOTAL_2="200" VAR="0.05135531135531136" WEIGHT="8.458632474584036"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.515416540009633" CI_START="0.17487016092210295" DF="0" EFFECT_SIZE="0.5147826086956522" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" I2="0.0" ID="CMP-011.01.06" LOG_CI_END="0.180532023045199" LOG_CI_START="-0.7572842903065827" LOG_EFFECT_SIZE="-0.2883761336306919" MODIFIED="2012-02-16 09:42:59 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="6" P_CHI2="1.0" P_Z="0.22806133330628076" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="222" WEIGHT="3.0926538827167147" Z="1.2053678910681367">
<NAME>Patch plus inhaler versus either patch or inhaler alone</NAME>
<DICH_DATA CI_END="1.515416540009633" CI_START="0.17487016092210295" EFFECT_SIZE="0.5147826086956522" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="0.180532023045199" LOG_CI_START="-0.7572842903065827" LOG_EFFECT_SIZE="-0.2883761336306919" ORDER="562" O_E="0.0" SE="0.5508779447284572" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="115" TOTAL_2="222" VAR="0.3034665099882491" WEIGHT="3.0926538827167147"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.364742682563195" CI_END="1.4846876691041309" CI_START="1.0917405729342395" DF="1" EFFECT_SIZE="1.273143262361367" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="279" I2="26.72611381056483" ID="CMP-011.01.07" LOG_CI_END="0.17163510156491885" LOG_CI_START="0.038119450522100945" LOG_EFFECT_SIZE="0.1048772760435099" MODIFIED="2012-10-04 16:49:22 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="7" P_CHI2="0.24271739859433838" P_Z="0.00207609612783468" STUDIES="2" TAU2="0.0" TOTAL_1="546" TOTAL_2="1065" WEIGHT="57.10650946698508" Z="3.0791249151161164">
<NAME>Patch plus lozenge versus either patch or lozenge alone</NAME>
<DICH_DATA CI_END="1.4282647140270255" CI_START="0.9779818592286291" EFFECT_SIZE="1.1818701199771473" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="177" LOG_CI_END="0.15480870687074696" LOG_CI_START="-0.009669200948566964" LOG_EFFECT_SIZE="0.07256975296108999" MODIFIED="2012-07-04 17:33:18 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="586" O_E="0.0" SE="0.09661513723183958" STUDY_ID="STD-Piper-2009" TOTAL_1="267" TOTAL_2="522" VAR="0.009334484742327195" WEIGHT="36.1892551255085"/>
<DICH_DATA CI_END="1.8575400928076231" CI_START="1.1024914741022012" EFFECT_SIZE="1.431056293485136" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="102" LOG_CI_END="0.2689381962669083" LOG_CI_START="0.0423752396231555" LOG_EFFECT_SIZE="0.1556567179450319" MODIFIED="2012-07-04 17:34:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="585" O_E="0.0" SE="0.1330842022372632" STUDY_ID="STD-Smith-2009" TOTAL_1="279" TOTAL_2="543" VAR="0.017711404885128772" WEIGHT="20.91725434147658"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2012-10-15 13:39:51 +0100" MODIFIED_BY="L S" NO="12">
<NAME>Direct comparisons between NRT types</NAME>
<DICH_OUTCOME CHI2="4.057045900014594" CI_END="1.0720176699034334" CI_START="0.783844048438357" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9166758807640579" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="261" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.030201943825326153" LOG_CI_START="-0.10577033481530854" LOG_EFFECT_SIZE="-0.037784195494991214" METHOD="MH" MODIFIED="2012-08-13 15:49:15 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.5412324348504026" P_Q="0.6554921308254719" P_Z="0.2760322587910753" Q="0.8447380140875452" RANDOM="NO" SCALE="4.971573063840914" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1598" TOTAL_2="1603" WEIGHT="100.0" Z="1.0892758891057102">
<NAME>Smoking cessation</NAME>
<GROUP_LABEL_1>NRT type 1</GROUP_LABEL_1>
<GROUP_LABEL_2>NRT type 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours type 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours type 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5952499957073314" CI_START="0.2164170105891786" DF="0" EFFECT_SIZE="0.5875706214689266" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="0.2028287521257832" LOG_CI_START="-0.6647086062518357" LOG_EFFECT_SIZE="-0.23093992706302624" NO="1" P_CHI2="1.0" P_Z="0.2967207199455283" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="104" WEIGHT="3.687702378091088" Z="1.0434915229064232">
<NAME>Inhaler versus patch</NAME>
<DICH_DATA CI_END="1.5952499957073316" CI_START="0.2164170105891785" EFFECT_SIZE="0.5875706214689266" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.20282875212578325" LOG_CI_START="-0.6647086062518358" LOG_EFFECT_SIZE="-0.23093992706302624" ORDER="564" O_E="0.0" SE="0.5095957386901963" STUDY_ID="STD-Tonnesen-2000" TOTAL_1="118" TOTAL_2="104" VAR="0.25968781689120674" WEIGHT="3.687702378091088"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01748774419319104" CI_END="1.2654952790989367" CI_START="0.6382500902346562" DF="1" EFFECT_SIZE="0.898722691421791" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="62" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="0.10226052937170833" LOG_CI_START="-0.19500911512393068" LOG_EFFECT_SIZE="-0.04637429287611118" NO="2" P_CHI2="0.8947934921497168" P_Z="0.5408608293550499" STUDIES="2" TAU2="0.0" TOTAL_1="638" TOTAL_2="634" WEIGHT="23.95734332051065" Z="0.6115117740992468">
<NAME>Nasal spray versus patch</NAME>
<DICH_DATA CI_END="1.3936027165142435" CI_START="0.5572105876360022" EFFECT_SIZE="0.8812095032397408" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" LOG_CI_END="0.1441389842235737" LOG_CI_START="-0.2539806400797202" LOG_EFFECT_SIZE="-0.0549208279280732" ORDER="565" O_E="0.0" SE="0.2338574380396786" STUDY_ID="STD-Croghan-2003" TOTAL_1="463" TOTAL_2="459" VAR="0.054689301326482115" WEIGHT="13.935960021856337"/>
<DICH_DATA CI_END="1.54291873609964" CI_START="0.5522461980539033" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" LOG_CI_END="0.1883430528337922" LOG_CI_START="-0.25786726535221605" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="566" O_E="0.0" SE="0.26210614967915896" STUDY_ID="STD-Lerman-2004" TOTAL_1="175" TOTAL_2="175" VAR="0.0686996336996337" WEIGHT="10.021383298654312"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1390039554736577" CI_END="1.1226867802427802" CI_START="0.7860257197310925" DF="2" EFFECT_SIZE="0.9393937856260889" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="190" I2="36.28552151033491" ID="CMP-012.01.03" LOG_CI_END="0.05025860881181122" LOG_CI_START="-0.10456324307695287" LOG_EFFECT_SIZE="-0.02715231713257081" MODIFIED="2012-08-13 15:49:15 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" P_CHI2="0.2081489295736415" P_Z="0.4917876260243219" STUDIES="3" TAU2="0.0" TOTAL_1="842" TOTAL_2="865" WEIGHT="72.35495430139827" Z="0.6874683777182079">
<NAME>Lozenge versus patch</NAME>
<DICH_DATA CI_END="1.23781249438915" CI_START="0.7665747515817831" EFFECT_SIZE="0.9741025641025641" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="90" LOG_CI_END="0.09265486211578408" LOG_CI_START="-0.11544548905934182" LOG_EFFECT_SIZE="-0.011395313471778848" MODIFIED="2012-02-06 11:47:14 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="587" O_E="0.0" SE="0.1222391763936207" STUDY_ID="STD-Piper-2009" TOTAL_1="260" TOTAL_2="262" VAR="0.014942416245390715" WEIGHT="34.556494133290734"/>
<DICH_DATA CI_END="1.0477290046279149" CI_START="0.4676781857098783" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="50" LOG_CI_END="0.020248966794738338" LOG_CI_START="-0.3300528867662248" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2012-08-13 15:49:15 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="613" O_E="0.0" SE="0.20576904280385083" STUDY_ID="STD-Schnoll-2010b" TOTAL_1="321" TOTAL_2="321" VAR="0.042340898976412994" WEIGHT="19.2718909589506"/>
<DICH_DATA CI_END="1.5942629775082016" CI_START="0.7919976987115507" EFFECT_SIZE="1.1236781609195403" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="50" LOG_CI_END="0.20255996088730685" LOG_CI_START="-0.10127608032758582" LOG_EFFECT_SIZE="0.05064194027986052" MODIFIED="2012-07-04 17:33:14 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="584" O_E="0.0" SE="0.1784747946222884" STUDY_ID="STD-Smith-2009" TOTAL_1="261" TOTAL_2="282" VAR="0.031853252315468025" WEIGHT="18.52656920915693"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2012-10-15 13:39:54 +0100" MODIFIED_BY="L S" NO="13">
<NAME>Purchased NRT without support versus physician support</NAME>
<DICH_OUTCOME CHI2="0.1041023529821873" CI_END="17.880721718278927" CI_START="1.1755158290443548" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.584656084656085" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="1.252385044210475" LOG_CI_START="0.07022848154290834" LOG_EFFECT_SIZE="0.6613067628766917" METHOD="MH" MODIFIED="2008-05-08 13:10:47 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.7469611391357169" P_Q="0.7479020968555266" P_Z="0.028319233282190638" Q="0.10330238486627939" RANDOM="NO" SCALE="25.470754107738983" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="411" TOTAL_2="409" WEIGHT="100.0" Z="2.1928354989567844">
<NAME>Smoking cessation using physician prescribed NRT versus NRT without support (all NRT purchased)</NAME>
<GROUP_LABEL_1>NRT, brief support</GROUP_LABEL_1>
<GROUP_LABEL_2>NRT, no support</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OTC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours more support</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="132.58894408396768" CI_START="0.3599018758688564" DF="0" EFFECT_SIZE="6.907894736842105" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="2.1225073119759417" LOG_CI_START="-0.44381588972561065" LOG_EFFECT_SIZE="0.8393457111251655" NO="1" P_CHI2="1.0" P_Z="0.1998223640914454" STUDIES="1" TAU2="0.0" TOTAL_1="151" TOTAL_2="149" WEIGHT="20.105820105820108" Z="1.2820578197576522">
<NAME>Nicotine patch</NAME>
<DICH_DATA CI_END="132.58894408396756" CI_START="0.3599018758688566" EFFECT_SIZE="6.907894736842105" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1225073119759417" LOG_CI_START="-0.4438158897256104" LOG_EFFECT_SIZE="0.8393457111251655" ORDER="567" O_E="0.0" SE="1.5074709521842196" STUDY_ID="STD-Leischow-1999" TOTAL_1="151" TOTAL_2="149" VAR="2.2724686716791975" WEIGHT="20.105820105820108"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.65691980382615" CI_START="0.857590650988312" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-013.01.02" LOG_CI_END="1.2708399447362393" LOG_CI_START="-0.06671996208031465" LOG_EFFECT_SIZE="0.6020599913279624" NO="2" P_CHI2="1.0" P_Z="0.07765948868052869" STUDIES="1" TAU2="0.0" TOTAL_1="260" TOTAL_2="260" WEIGHT="79.8941798941799" Z="1.764430727209503">
<NAME>Nicotine inhaler</NAME>
<DICH_DATA CI_END="18.65691980382615" CI_START="0.857590650988312" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2708399447362393" LOG_CI_START="-0.06671996208031465" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="568" O_E="0.0" SE="0.7856893102923651" STUDY_ID="STD-Leischow-2004" TOTAL_1="260" TOTAL_2="260" VAR="0.6173076923076923" WEIGHT="79.8941798941799"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2012-10-15 13:39:55 +0100" MODIFIED_BY="L S" NO="14">
<NAME>Pre-cessation initiation of NRT versus post quit day only</NAME>
<DICH_OUTCOME CHI2="12.43424871709442" CI_END="1.4083562778964864" CI_START="0.9826316269436052" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1763908451979999" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="187" I2="35.66157327220164" I2_Q="65.8361760530931" ID="CMP-014.01" LOG_CI_END="0.14871253403302778" LOG_CI_START="-0.007609261790815195" LOG_EFFECT_SIZE="0.07055163612110628" METHOD="MH" MODIFIED="2012-08-14 15:17:56 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.13285495974476824" P_Q="0.053553660233439104" P_Z="0.0768681769344424" Q="5.854145610597183" RANDOM="NO" SCALE="10.76233389465076" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1385" TOTAL_2="1389" WEIGHT="100.0" Z="1.7691540084860327">
<NAME>Smoking cessation</NAME>
<GROUP_LABEL_1>Precessation NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>Post cessation NRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.972521056022993" CI_END="1.6537856231578827" CI_START="1.0808989700324827" DF="5" EFFECT_SIZE="1.337002309917931" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="122" I2="16.28325872609948" ID="CMP-014.01.01" LOG_CI_END="0.21847921216110255" LOG_CI_START="0.03378510301169857" LOG_EFFECT_SIZE="0.12613215758640056" MODIFIED="2012-08-07 12:14:52 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.30890220439430804" P_Z="0.007428122324578958" STUDIES="6" TAU2="0.0" TOTAL_1="901" TOTAL_2="871" WEIGHT="67.31121502914256" Z="2.6770153883110304">
<NAME>Patch</NAME>
<DICH_DATA CI_END="1.4130994248532402" CI_START="0.8190552902652446" EFFECT_SIZE="1.075828313253012" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="80" LOG_CI_END="0.15017271963061282" LOG_CI_START="-0.08668678023395557" LOG_EFFECT_SIZE="0.03174296969832863" MODIFIED="2012-08-07 12:14:52 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1111" O_E="0.0" SE="0.13913244269388123" STUDY_ID="STD-Bullen-2010" TOTAL_1="498" TOTAL_2="471" VAR="0.019357836609966147" WEIGHT="44.514591715761576"/>
<DICH_DATA CI_END="4.650853923417994" CI_START="0.48378212626089867" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6675326991654031" LOG_CI_START="-0.3153501810540406" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2012-02-22 08:33:46 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="571" O_E="0.0" SE="0.5773502691896257" STUDY_ID="STD-Rose-1994" TOTAL_1="24" TOTAL_2="24" VAR="0.33333333333333326" WEIGHT="2.1653935427998476"/>
<DICH_DATA CI_END="4.805060921608276" CI_START="0.8324556265274534" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6816988983002098" LOG_CI_START="-0.07963890697224736" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-02-22 08:33:47 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="572" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Rose-1998" TOTAL_1="40" TOTAL_2="40" VAR="0.2" WEIGHT="3.2480903141997715"/>
<DICH_DATA CI_END="4.2228834310614225" CI_START="0.657791725280843" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6256090932777347" LOG_CI_START="-0.18191159404502183" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-22 08:33:48 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="570" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Rose-2006" TOTAL_1="48" TOTAL_2="48" VAR="0.22499999999999998" WEIGHT="3.2480903141997715"/>
<DICH_DATA CI_END="3.619897146930813" CI_START="1.0705642197813257" EFFECT_SIZE="1.968586387434555" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="14" LOG_CI_END="0.5586962309875918" LOG_CI_START="0.029612724372275388" LOG_EFFECT_SIZE="0.2941544776799335" MODIFIED="2012-02-22 08:34:21 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="611" O_E="0.0" SE="0.3107862707914333" STUDY_ID="STD-Rose-2009" TOTAL_1="191" TOTAL_2="188" VAR="0.09658810611244609" WEIGHT="7.6388685137820485"/>
<DICH_DATA CI_END="3.499397716951176" CI_START="0.9604827410242053" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5439933041466549" LOG_CI_START="-0.01751043459749203" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2012-02-22 08:33:49 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="569" O_E="0.0" SE="0.3298300756266457" STUDY_ID="STD-Schuurmans-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.1087878787878788" WEIGHT="6.496180628399543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.98052088275348" CI_END="1.4349542724682114" CI_START="0.648598120473462" DF="1" EFFECT_SIZE="0.9647324209791263" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="45" I2="0.0" ID="CMP-014.01.02" LOG_CI_END="0.15683806167548206" LOG_CI_START="-0.18802431417243046" LOG_EFFECT_SIZE="-0.015593126248474172" MODIFIED="2012-08-08 10:17:11 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.3220704630927388" P_Z="0.8593186836959454" STUDIES="2" TAU2="0.0" TOTAL_1="187" TOTAL_2="219" WEIGHT="21.898149363281014" Z="0.17724152006001173">
<NAME>Gum</NAME>
<DICH_DATA CI_END="1.615104864530463" CI_START="0.2524406883083346" EFFECT_SIZE="0.6385281385281385" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="0.20820072518627417" LOG_CI_START="-0.5978406443421993" LOG_EFFECT_SIZE="-0.19481995957796253" MODIFIED="2012-08-07 12:17:27 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1112" O_E="0.0" SE="0.47347269043015383" STUDY_ID="STD-Bullen-2010" TOTAL_1="33" TOTAL_2="59" VAR="0.22417638858316827" WEIGHT="5.4370207433344"/>
<DICH_DATA CI_END="1.6679064727548036" CI_START="0.6896097586177113" EFFECT_SIZE="1.0724759111855886" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" LOG_CI_END="0.22217169408031395" LOG_CI_START="-0.16139660147012397" LOG_EFFECT_SIZE="0.03038754630509501" MODIFIED="2012-08-08 10:17:11 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="636" O_E="0.0" SE="0.22530991550001198" STUDY_ID="STD-Etter-2009" TOTAL_1="154" TOTAL_2="160" VAR="0.05076455802262254" WEIGHT="16.461128619946614"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2132693846649236" CI_START="0.30072860514325234" DF="0" EFFECT_SIZE="0.604040404040404" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" I2="0.0" ID="CMP-014.01.03" LOG_CI_END="0.083957238858748" LOG_CI_START="-0.5218252600770261" LOG_EFFECT_SIZE="-0.21893401060913906" MODIFIED="2012-08-14 15:17:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" P_CHI2="1.0" P_Z="0.1565738026061431" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="299" WEIGHT="10.790635607576423" Z="1.4166892458552747">
<NAME>Lozenge</NAME>
<DICH_DATA CI_END="1.2132693846649236" CI_START="0.30072860514325234" EFFECT_SIZE="0.604040404040404" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.083957238858748" LOG_CI_START="-0.5218252600770261" LOG_EFFECT_SIZE="-0.21893401060913906" MODIFIED="2012-08-14 15:17:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="672" O_E="0.0" SE="0.3558396385466054" STUDY_ID="STD-Hughes-2010" TOTAL_1="297" TOTAL_2="299" VAR="0.12662184836097878" WEIGHT="10.790635607576423"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2012-10-04 16:12:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="15">
<NAME>NRT in pregnancy</NAME>
<DICH_OUTCOME CHI2="4.291572985819304" CI_END="1.5768839378317534" CI_START="1.0191228710870357" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2676902169276716" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="122" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.1977997294645099" LOG_CI_START="0.008226548106654802" LOG_EFFECT_SIZE="0.10301313878558234" METHOD="MH" MODIFIED="2012-10-04 16:12:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.6372837177938455" P_Q="0.7465793001489279" P_Z="0.03316586188200733" Q="0.10442795045826109" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1213" TOTAL_2="1087" WEIGHT="200.0" Z="2.130069670277247">
<NAME>Smoking cessation</NAME>
<GROUP_LABEL_1>NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9357773863513748" CI_END="1.6818066710705633" CI_START="1.0012082463398002" DF="3" EFFECT_SIZE="1.2976281084444556" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="87" I2="23.77617671153089" ID="CMP-015.01.01" LOG_CI_END="0.22577607082402723" LOG_CI_START="5.244179688688492E-4" LOG_EFFECT_SIZE="0.11315024439644805" MODIFIED="2012-10-04 16:12:34 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.26848310658391117" P_Z="0.04894274138677787" STUDIES="4" TAU2="0.0" TOTAL_1="867" TOTAL_2="808" WEIGHT="100.0" Z="1.969090135836174">
<NAME>Abstinence at end of pregnancy</NAME>
<DICH_DATA CI_END="1.8550792517683696" CI_START="0.8339607415037522" EFFECT_SIZE="1.243809980806142" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.2683624680591328" LOG_CI_START="-0.07885439318670767" LOG_EFFECT_SIZE="0.09475403743621255" MODIFIED="2012-08-08 18:35:41 +0100" MODIFIED_BY="Lindsay Stead" ORDER="652" O_E="0.0" SE="0.20395690304698946" STUDY_ID="STD-Coleman-2012" TOTAL_1="521" TOTAL_2="529" VAR="0.04159841830051906" WEIGHT="45.511470136607066"/>
<DICH_DATA CI_END="2.290103838659432" CI_START="0.6378072789984092" EFFECT_SIZE="1.2085714285714286" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.3598551747129851" LOG_CI_START="-0.19531052866345158" LOG_EFFECT_SIZE="0.08227232302476672" MODIFIED="2012-07-04 14:06:50 +0100" MODIFIED_BY="Lindsay Stead" ORDER="625" O_E="0.0" SE="0.32610708227787166" STUDY_ID="STD-Oncken-2008" TOTAL_1="100" TOTAL_2="94" VAR="0.10634582911178656" WEIGHT="16.547742520532577"/>
<DICH_DATA CI_END="60.30553776708799" CI_START="1.120791968338818" EFFECT_SIZE="8.221311475409836" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="1.7803571945822778" LOG_CI_START="0.04952501010906199" LOG_EFFECT_SIZE="0.9149411023456698" MODIFIED="2012-10-04 16:12:34 +0100" MODIFIED_BY="Lindsay Stead" ORDER="627" O_E="0.0" SE="1.0166993929170591" STUDY_ID="STD-Pollak-2007" TOTAL_1="122" TOTAL_2="59" VAR="1.0336776555579166" WEIGHT="1.5455878846723168"/>
<DICH_DATA CI_END="1.6751422837019678" CI_START="0.7373643741843219" EFFECT_SIZE="1.111391129032258" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.22405170116525713" LOG_CI_START="-0.13231784919386216" LOG_EFFECT_SIZE="0.04586692598569747" MODIFIED="2012-10-04 16:04:09 +0100" MODIFIED_BY="Lindsay Stead" ORDER="626" O_E="0.0" SE="0.2093332379386713" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.04382040450588837" WEIGHT="36.39519945818804"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4014987297214363" CI_END="1.796142193959173" CI_START="0.8001525295690051" DF="2" EFFECT_SIZE="1.1988276439764203" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="35" I2="0.0" ID="CMP-015.01.02" LOG_CI_END="0.25434071518615414" LOG_CI_START="-0.09682721746310363" LOG_EFFECT_SIZE="0.07875674886152523" MODIFIED="2012-08-08 11:35:16 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.8181175314014102" P_Z="0.3793330906417711" STUDIES="3" TAU2="0.0" TOTAL_1="346" TOTAL_2="279" WEIGHT="100.0" Z="0.8791257797575078">
<NAME>Abstinence at longest post partum follow-up</NAME>
<DICH_DATA CI_END="2.6472555462718894" CI_START="0.4986090900333425" EFFECT_SIZE="1.1488888888888888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4227958668694923" LOG_CI_START="-0.3022398082322946" LOG_EFFECT_SIZE="0.06027802931859881" MODIFIED="2012-08-08 11:34:01 +0100" MODIFIED_BY="Lindsay Stead" ORDER="610" O_E="0.0" SE="0.4258895445392638" STUDY_ID="STD-Oncken-2008" TOTAL_1="100" TOTAL_2="94" VAR="0.1813819041478616" WEIGHT="24.468946062499857"/>
<DICH_DATA CI_END="3.032697319684326" CI_START="0.6940612593880049" EFFECT_SIZE="1.4508196721311475" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.48182906743215864" LOG_CI_START="-0.15860219605804193" LOG_EFFECT_SIZE="0.16161343568705838" MODIFIED="2012-08-08 11:34:01 +0100" MODIFIED_BY="Lindsay Stead" ORDER="624" O_E="0.0" SE="0.3761924943600262" STUDY_ID="STD-Pollak-2007" TOTAL_1="122" TOTAL_2="59" VAR="0.14152079281281835" WEIGHT="28.44105661914041"/>
<DICH_DATA CI_END="1.9447920860809431" CI_START="0.5915435632468572" EFFECT_SIZE="1.0725806451612903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2888731785695607" LOG_CI_START="-0.22801326695985924" LOG_EFFECT_SIZE="0.030429955804850695" MODIFIED="2012-08-08 11:34:01 +0100" MODIFIED_BY="Lindsay Stead" ORDER="396" O_E="0.0" SE="0.30362165673315167" STUDY_ID="STD-Wisborg-2000" TOTAL_1="124" TOTAL_2="126" VAR="0.09218611043738378" WEIGHT="47.08999731835973"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2012-10-15 13:19:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="16">
<NAME>NRT and bupropion; direct comparisons and combinations</NAME>
<DICH_OUTCOME CHI2="9.950859348815982" CI_END="1.1790062548821632" CI_START="0.8717792700362479" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0138210947940187" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="215" I2="39.7037000556749" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.07151610912698285" LOG_CI_START="-0.05959346224642206" LOG_EFFECT_SIZE="0.00596132344028041" METHOD="MH" MODIFIED="2012-10-15 13:19:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.1267368259588567" P_Q="0.7631875310170776" P_Z="0.8585405559754893" Q="0.5405030367305553" RANDOM="NO" SCALE="5.48" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1539" TOTAL_2="1005" WEIGHT="100.0" Z="0.1782322849621346">
<NAME>NRT versus bupropion</NAME>
<GROUP_LABEL_1>NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>Bupropion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours bupropion</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.524888001402305" CI_END="1.1820592332412052" CI_START="0.7898799669637925" DF="3" EFFECT_SIZE="0.9662737231767244" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="129" I2="68.50356666074894" ID="CMP-016.01.01" LOG_CI_END="0.07263923967997052" LOG_CI_START="-0.10243890066649376" LOG_EFFECT_SIZE="-0.014899830493261606" MODIFIED="2012-10-15 13:19:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="0.023068140147220695" P_Z="0.7386805796896342" STUDIES="4" TAU2="0.0" TOTAL_1="915" TOTAL_2="637" WEIGHT="58.47282828598955" Z="0.33360111187786184">
<NAME>Patch versus bupropion</NAME>
<DICH_DATA CI_END="2.399250946061376" CI_START="0.8717211269393952" EFFECT_SIZE="1.4461942257217848" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.38007567472480325" LOG_CI_START="-0.059622428372471774" LOG_EFFECT_SIZE="0.16022662317616576" MODIFIED="2012-08-08 10:32:04 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="607" O_E="0.0" SE="0.2582808423000525" STUDY_ID="STD-Gariti-2009" TOTAL_1="127" TOTAL_2="133" VAR="0.06670899349922457" WEIGHT="7.983389586664801"/>
<DICH_DATA CI_END="0.8469843399453723" CI_START="0.3358319995181849" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="45" LOG_CI_END="-0.07212461934837683" LOG_CI_START="-0.47387792477909857" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2012-10-15 13:19:34 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="573" O_E="0.0" SE="0.2359918803209413" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="244" VAR="0.05569216757741348" WEIGHT="17.511371984247877"/>
<DICH_DATA CI_END="1.4582451134347747" CI_START="0.7992841264013847" EFFECT_SIZE="1.0796074154852782" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="42" LOG_CI_END="0.16383052978789667" LOG_CI_START="-0.09729881193283896" LOG_EFFECT_SIZE="0.033265858927528855" MODIFIED="2012-07-04 14:40:48 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="588" O_E="0.0" SE="0.15338866793784858" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="132" VAR="0.023528083451747575" WEIGHT="21.73662011445726"/>
<DICH_DATA CI_END="1.7203249631715416" CI_START="0.6789106954684437" EFFECT_SIZE="1.0807159743329957" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="21" LOG_CI_END="0.23561049131565154" LOG_CI_START="-0.16818734945443786" LOG_EFFECT_SIZE="0.033711570930606845" MODIFIED="2012-07-05 11:17:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="581" O_E="0.0" SE="0.23719285049989908" STUDY_ID="STD-Smith-2009" TOTAL_1="282" TOTAL_2="128" VAR="0.05626044832826747" WEIGHT="11.241446600619613"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12447914594324012" CI_END="1.4019983621521455" CI_START="0.8457106881258639" DF="1" EFFECT_SIZE="1.088891638138077" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="64" I2="0.0" ID="CMP-016.01.02" LOG_CI_END="0.14674750627778613" LOG_CI_START="-0.07277818074283376" LOG_EFFECT_SIZE="0.036984662767476174" MODIFIED="2012-07-05 11:16:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.7242264388063504" P_Z="0.5089900154451037" STUDIES="2" TAU2="0.0" TOTAL_1="521" TOTAL_2="260" WEIGHT="33.16892654996502" Z="0.6604111617954213">
<NAME>Lozenge versus bupropion</NAME>
<DICH_DATA CI_END="1.4236825977828613" CI_START="0.7768334439481402" EFFECT_SIZE="1.0516483516483517" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="42" LOG_CI_END="0.1534131765225277" LOG_CI_START="-0.10967208561102776" LOG_EFFECT_SIZE="0.02187054545574998" MODIFIED="2012-07-04 14:40:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="589" O_E="0.0" SE="0.15453758527030118" STUDY_ID="STD-Piper-2009" TOTAL_1="260" TOTAL_2="132" VAR="0.023881865261175604" WEIGHT="21.680746266211656"/>
<DICH_DATA CI_END="1.8204885508158137" CI_START="0.7380950593710358" EFFECT_SIZE="1.1591779867641936" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="22" LOG_CI_END="0.26018795196913863" LOG_CI_START="-0.13188770172477804" LOG_EFFECT_SIZE="0.0641501251221803" MODIFIED="2012-07-05 11:16:42 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="583" O_E="0.0" SE="0.23030717978559334" STUDY_ID="STD-Smith-2009" TOTAL_1="261" TOTAL_2="128" VAR="0.05304139706079362" WEIGHT="11.488180283753362"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.773758219207221" CI_START="0.6198386321812259" DF="0" EFFECT_SIZE="1.0485436893203883" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-016.01.03" LOG_CI_END="0.24889442089573277" LOG_CI_START="-0.20772135933217784" LOG_EFFECT_SIZE="0.02058653078177749" MODIFIED="2012-02-16 13:44:59 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" P_CHI2="1.0" P_Z="0.8597204564090598" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="108" WEIGHT="8.358245164045432" Z="0.17673002399860013">
<NAME>Choice of NRT versus bupropion</NAME>
<DICH_DATA CI_END="1.773758219207221" CI_START="0.6198386321812259" EFFECT_SIZE="1.0485436893203883" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.24889442089573277" LOG_CI_START="-0.20772135933217784" LOG_EFFECT_SIZE="0.02058653078177749" MODIFIED="2012-02-16 13:38:00 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="622" O_E="0.0" SE="0.2682183695904402" STUDY_ID="STD-Wittchen-2011" TOTAL_1="103" TOTAL_2="108" VAR="0.07194109378575399" WEIGHT="8.358245164045432"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.902360338627092" CI_END="1.4503421102180274" CI_START="1.0618359987604846" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2409776239512733" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="214" I2="56.536607003674455" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.16147045675581065" LOG_CI_START="0.026057444868403296" LOG_EFFECT_SIZE="0.09376395081210696" METHOD="MH" MODIFIED="2012-10-04 14:35:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="0.07507592725023238" P_Q="0.7388907845207116" P_Z="0.006642132826317095" Q="0.6052104101191488" RANDOM="NO" SCALE="3.7" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1003" TOTAL_2="988" WEIGHT="100.00000000000001" Z="2.7142733785837128">
<NAME>Combination therapy versus bupropion alone</NAME>
<GROUP_LABEL_1>NRT + bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Bupropion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours bupropion alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRT + bupropion</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7305079447608867" CI_START="0.8561980569328245" DF="0" EFFECT_SIZE="1.217233560090703" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="45" I2="0.0" ID="CMP-016.02.01" LOG_CI_END="0.23817359748041683" LOG_CI_START="-0.06742576209422266" LOG_EFFECT_SIZE="0.08537391769309711" MODIFIED="2012-10-03 17:55:40 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="1.0" P_Z="0.27347607229560655" STUDIES="1" TAU2="0.0" TOTAL_1="245" TOTAL_2="244" WEIGHT="20.96045380121617" Z="1.0950926345556604">
<NAME>Patch plus bupropion versus bupropion alone</NAME>
<DICH_DATA CI_END="1.730507944760887" CI_START="0.8561980569328245" EFFECT_SIZE="1.217233560090703" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="45" LOG_CI_END="0.23817359748041694" LOG_CI_START="-0.06742576209422266" LOG_EFFECT_SIZE="0.08537391769309711" MODIFIED="2012-02-16 13:41:22 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="576" O_E="0.0" SE="0.17951057655537034" STUDY_ID="STD-Jorenby-1999" TOTAL_1="245" TOTAL_2="244" VAR="0.03222404709524147" WEIGHT="20.96045380121617"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5965925307473947" CI_START="0.7570584034438295" DF="0" EFFECT_SIZE="1.0994152046783625" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" I2="0.0" ID="CMP-016.02.02" LOG_CI_END="0.20319409320336632" LOG_CI_START="-0.12087061546031427" LOG_EFFECT_SIZE="0.041161738871525994" MODIFIED="2012-10-03 17:55:50 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="1.0" P_Z="0.6185561974147358" STUDIES="1" TAU2="0.0" TOTAL_1="228" TOTAL_2="224" WEIGHT="19.695936917026486" Z="0.4978976332344763">
<NAME>Gum plus bupropion versus bupropion alone</NAME>
<DICH_DATA CI_END="1.5965925307473947" CI_START="0.7570584034438295" EFFECT_SIZE="1.0994152046783625" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.20319409320336632" LOG_CI_START="-0.12087061546031427" LOG_EFFECT_SIZE="0.041161738871525994" MODIFIED="2012-10-03 17:53:50 +0100" MODIFIED_BY="Lindsay Stead" ORDER="577" O_E="0.0" SE="0.1903572140152252" STUDY_ID="STD-Piper-2007" TOTAL_1="228" TOTAL_2="224" VAR="0.03623586892763825" WEIGHT="19.695936917026486"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.51670339174396" CI_END="1.577632344521812" CI_START="1.0652156728945332" DF="1" EFFECT_SIZE="1.2963482168962095" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="127" I2="84.65481793652134" ID="CMP-016.02.03" LOG_CI_END="0.1980058015673096" LOG_CI_START="0.027437547742060073" LOG_EFFECT_SIZE="0.11272167465468481" MODIFIED="2012-10-03 17:55:50 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" P_CHI2="0.010686620757175747" P_Z="0.009583044517793161" STUDIES="2" TAU2="0.0" TOTAL_1="530" TOTAL_2="520" WEIGHT="59.34360928175735" Z="2.5905221827101674">
<NAME>Lozenge plus bupropion versus bupropion alone</NAME>
<DICH_DATA CI_END="1.335112365371753" CI_START="0.8157693537137074" EFFECT_SIZE="1.043620501635769" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="84" LOG_CI_END="0.1255178182154402" LOG_CI_START="-0.08843261400179513" LOG_EFFECT_SIZE="0.018542602106822518" MODIFIED="2012-02-16 13:41:27 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="591" O_E="0.0" SE="0.125675542956124" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="264" VAR="0.015794342097316564" WEIGHT="38.89786594393211"/>
<DICH_DATA CI_END="2.4686546308355366" CI_START="1.2793608886881855" EFFECT_SIZE="1.7771607080874696" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="43" LOG_CI_END="0.3924603356128052" LOG_CI_START="0.10699306977803046" LOG_EFFECT_SIZE="0.2497267026954178" MODIFIED="2012-07-05 11:35:56 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="580" O_E="0.0" SE="0.1676848850371025" STUDY_ID="STD-Smith-2009" TOTAL_1="268" TOTAL_2="256" VAR="0.028118220669906283" WEIGHT="20.44574333782524"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.176844418754404" CI_END="4.122422398628605" CI_START="1.651240499306901" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6090440432973625" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="17" I2="76.05848100278979" I2_Q="75.37138254067648" ID="CMP-016.03" LOG_CI_END="0.6151524891401856" LOG_CI_START="0.21781033184259438" LOG_EFFECT_SIZE="0.41648141049139" METHOD="MH" MODIFIED="2012-10-10 14:52:53 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" P_CHI2="0.04098006502873652" P_Q="0.043902344607122945" P_Z="3.9781707878313465E-5" Q="4.06031723726106" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="507" TOTAL_2="197" WEIGHT="100.0" Z="4.108743810852184">
<NAME>Combination therapy versus placebo</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.84621156317256" CI_START="2.029963095403797" DF="0" EFFECT_SIZE="3.9909297052154193" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="9" I2="0.0" ID="CMP-016.03.01" LOG_CI_END="0.8946600141528954" LOG_CI_START="0.3074881425397271" LOG_EFFECT_SIZE="0.6010740783463112" MODIFIED="2012-10-10 14:52:53 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" P_CHI2="1.0" P_Z="6.001842561216583E-5" STUDIES="1" TAU2="0.0" TOTAL_1="245" TOTAL_2="160" WEIGHT="43.714754587498135" Z="4.012738356702156">
<NAME>Patch plus bupropion versus placebo</NAME>
<DICH_DATA CI_END="7.84621156317256" CI_START="2.029963095403797" EFFECT_SIZE="3.9909297052154193" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="9" LOG_CI_END="0.8946600141528954" LOG_CI_START="0.3074881425397271" LOG_EFFECT_SIZE="0.6010740783463112" MODIFIED="2012-02-16 13:39:39 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="574" O_E="0.0" SE="0.3449076639332157" STUDY_ID="STD-Jorenby-1999" TOTAL_1="245" TOTAL_2="160" VAR="0.11896129663986807" WEIGHT="43.714754587498135"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.904046072230443" CI_START="0.8121867397378303" DF="0" EFFECT_SIZE="1.5357824427480915" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="8" I2="0.0" ID="CMP-016.03.02" LOG_CI_END="0.46300350209580077" LOG_CI_START="-0.0903441053479518" LOG_EFFECT_SIZE="0.18632969837392446" MODIFIED="2012-10-10 14:52:53 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="2" P_CHI2="1.0" P_Z="0.18684699260177212" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="37" WEIGHT="56.28524541250186" Z="1.3199641352031175">
<NAME>Lozenge plus bupropion versus placebo</NAME>
<DICH_DATA CI_END="2.904046072230442" CI_START="0.8121867397378304" EFFECT_SIZE="1.5357824427480915" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="8" LOG_CI_END="0.4630035020958006" LOG_CI_START="-0.09034410534795174" LOG_EFFECT_SIZE="0.18632969837392446" MODIFIED="2012-02-16 13:39:44 +0000" MODIFIED_BY="Jamie Hartmann-Boyce" ORDER="610" O_E="0.0" SE="0.3250391237272929" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="37" VAR="0.1056504319534064" WEIGHT="56.28524541250186"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2012-10-09 14:57:32 +0100" MODIFIED_BY="Kate Cahill" NO="17">
<NAME>Palpitations in NRT vs placebo users</NAME>
<DICH_OUTCOME CHI2="15.496429426233298" CI_END="2.567161853358749" CI_START="1.3713229691823081" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="OR" EFFECT_SIZE="1.876275037173249" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="62" I2="9.656607887363084" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.4094532507535098" LOG_CI_START="0.1371397503512871" LOG_EFFECT_SIZE="0.27329650055239846" METHOD="MH" MODIFIED="2012-10-09 14:54:43 +0100" MODIFIED_BY="Kate Cahill" NO="1" P_CHI2="0.3450831715735928" P_Q="1.0" P_Z="8.351660309981597E-5" Q="0.0" RANDOM="NO" SCALE="200.91948244537667" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6673" TOTAL_2="4401" WEIGHT="100.0" Z="3.934078166468752">
<NAME>Palpitations/chest pains</NAME>
<GROUP_LABEL_1>NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo users</GRAPH_LABEL_1>
<GRAPH_LABEL_2>NRT users</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.530727743231221" CI_START="0.04474885795286514" EFFECT_SIZE="0.49748743718592964" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7427822803237059" LOG_CI_START="-1.3492180439480193" LOG_EFFECT_SIZE="-0.30321788181215675" MODIFIED="2012-10-09 14:46:17 +0100" MODIFIED_BY="Kate Cahill" ORDER="1333" O_E="0.0" SE="1.228851346045829" STUDY_ID="STD-Bolliger-2000a" TOTAL_1="200" TOTAL_2="200" VAR="1.5100756306786456" WEIGHT="3.2322058198058428"/>
<DICH_DATA CI_END="3.151755641239112" CI_START="0.13937993896983558" EFFECT_SIZE="0.6627906976744186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49855253883804795" LOG_CI_START="-0.8557997299802007" LOG_EFFECT_SIZE="-0.17862359557107635" MODIFIED="2012-10-09 14:46:29 +0100" MODIFIED_BY="Kate Cahill" ORDER="1334" O_E="0.0" SE="0.7955532268556931" STUDY_ID="STD-Brantmark-1973a" TOTAL_1="46" TOTAL_2="42" VAR="0.6329049367605059" WEIGHT="6.349239390207915"/>
<DICH_DATA CI_END="73.07464909842314" CI_START="1.155122293318291" EFFECT_SIZE="9.1875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.8637667385695436" LOG_CI_START="0.06262796561495865" LOG_EFFECT_SIZE="0.9631973520922513" MODIFIED="2012-10-09 14:46:43 +0100" MODIFIED_BY="Kate Cahill" ORDER="1335" O_E="0.0" SE="1.0579978310142413" STUDY_ID="STD-Bullen-2010" TOTAL_1="249" TOTAL_2="246" VAR="1.119359410430839" WEIGHT="1.5750051200515758"/>
<DICH_DATA CI_END="6.743374768183771" CI_START="1.2611132004112522" EFFECT_SIZE="2.916189111747851" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="6" LOG_CI_END="0.8288772965936462" LOG_CI_START="0.1007540715908683" LOG_EFFECT_SIZE="0.4648156840922572" MODIFIED="2012-10-09 14:46:59 +0100" MODIFIED_BY="Kate Cahill" ORDER="1336" O_E="0.0" SE="0.4277031866347244" STUDY_ID="STD-CEASE-1999" TOTAL_1="2861" TOTAL_2="714" VAR="0.18293001585749788" WEIGHT="15.221818714098458"/>
<DICH_DATA CI_END="5.7085314818221295" CI_START="0.31501459348676714" EFFECT_SIZE="1.3409961685823755" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.756524400475763" LOG_CI_START="-0.5016693264517738" LOG_EFFECT_SIZE="0.12742753701199466" MODIFIED="2012-10-09 14:47:21 +0100" MODIFIED_BY="Kate Cahill" ORDER="1337" O_E="0.0" SE="0.7390692233566298" STUDY_ID="STD-Gourlay-1995" TOTAL_1="179" TOTAL_2="143" VAR="0.546223316912972" WEIGHT="5.266117662656918"/>
<DICH_DATA CI_END="13.145027273330191" CI_START="0.48757824209170536" EFFECT_SIZE="2.5316455696202533" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1187614915184194" LOG_CI_START="-0.3119556827713397" LOG_EFFECT_SIZE="0.4034029043735398" MODIFIED="2012-10-09 14:47:35 +0100" MODIFIED_BY="Kate Cahill" ORDER="1338" O_E="0.0" SE="0.8404103503420369" STUDY_ID="STD-Hays-1999" TOTAL_1="321" TOTAL_2="322" VAR="0.7062895569620253" WEIGHT="3.1928758537904023"/>
<DICH_DATA CI_END="20.92319362327858" CI_START="0.9319832267961893" EFFECT_SIZE="4.41588785046729" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3206279740341986" LOG_CI_START="-0.030591903714054347" LOG_EFFECT_SIZE="0.6450180351600722" MODIFIED="2012-10-09 14:47:47 +0100" MODIFIED_BY="Kate Cahill" ORDER="1339" O_E="0.0" SE="0.7937132448355917" STUDY_ID="STD-Hjalmarson-1994" TOTAL_1="116" TOTAL_2="107" VAR="0.6299807150274439" WEIGHT="3.117344775169346"/>
<DICH_DATA CI_END="27.369434820490568" CI_START="0.1029470304847831" EFFECT_SIZE="1.6785714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.4372658293108715" LOG_CI_START="-0.9873861761238749" LOG_EFFECT_SIZE="0.22493982659349826" MODIFIED="2012-10-09 14:47:59 +0100" MODIFIED_BY="Kate Cahill" ORDER="1340" O_E="0.0" SE="1.4242525902133663" STUDY_ID="STD-Oncken-2007" TOTAL_1="57" TOTAL_2="95" VAR="2.028495440729483" WEIGHT="1.1967966537234012"/>
<DICH_DATA CI_END="5.63442067171747" CI_START="1.1657341752389538" EFFECT_SIZE="2.5628571428571427" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.7508492687387331" LOG_CI_START="0.06659952864889969" LOG_EFFECT_SIZE="0.40872439869381644" MODIFIED="2012-10-09 14:48:11 +0100" MODIFIED_BY="Kate Cahill" ORDER="1341" O_E="0.0" SE="0.4019316844196079" STUDY_ID="STD-Schneider-1995" TOTAL_1="128" TOTAL_2="127" VAR="0.16154907894038328" WEIGHT="13.375962600438012"/>
<DICH_DATA CI_END="3.0495281720901755" CI_START="0.006914063446231258" EFFECT_SIZE="0.14520547945205478" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.4842326498028499" LOG_CI_START="-2.160266639514221" LOG_EFFECT_SIZE="-0.8380169948556857" MODIFIED="2012-10-09 14:48:25 +0100" MODIFIED_BY="Kate Cahill" ORDER="1342" O_E="0.0" SE="1.5533919730274504" STUDY_ID="STD-Schnoll-2010a" TOTAL_1="182" TOTAL_2="134" VAR="2.4130266218661154" WEIGHT="4.660705746614886"/>
<DICH_DATA CI_END="3.105087345019569" CI_START="0.32166022208506834" EFFECT_SIZE="0.9993913572732805" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.49207382123610566" LOG_CI_START="-0.49260264253938524" LOG_EFFECT_SIZE="-2.6441065163977537E-4" MODIFIED="2012-10-09 14:48:42 +0100" MODIFIED_BY="Kate Cahill" ORDER="1343" O_E="0.0" SE="0.5784038290488295" STUDY_ID="STD-Shiffman-2009-_x0028_4mg_x0029_" TOTAL_1="1649" TOTAL_2="1648" VAR="0.3345509894583475" WEIGHT="9.712830141500953"/>
<DICH_DATA CI_END="2.33171710054984" CI_START="0.028737449645758716" EFFECT_SIZE="0.2588582677165354" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.36767585778378836" LOG_CI_START="-1.5415517767000735" LOG_EFFECT_SIZE="-0.5869379594581426" MODIFIED="2012-10-09 14:48:55 +0100" MODIFIED_BY="Kate Cahill" ORDER="1344" O_E="0.0" SE="1.1214897633250323" STUDY_ID="STD-Sonderskov-1997" TOTAL_1="255" TOTAL_2="267" VAR="1.257739289242837" WEIGHT="6.32264986411509"/>
<DICH_DATA CI_END="3.6206453845573656" CI_START="0.8894175193476764" EFFECT_SIZE="1.7945098039215686" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.5587859909667944" LOG_CI_START="-0.050894320264769165" LOG_EFFECT_SIZE="0.2539458353510126" MODIFIED="2012-10-09 14:49:08 +0100" MODIFIED_BY="Kate Cahill" ORDER="1345" O_E="0.0" SE="0.3581292327836342" STUDY_ID="STD-Sutherland-1992" TOTAL_1="111" TOTAL_2="103" VAR="0.12825654737419442" WEIGHT="19.354071386147794"/>
<DICH_DATA CI_END="31.375219011577983" CI_START="0.050240186115449836" EFFECT_SIZE="1.2555066079295154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4965867660488656" LOG_CI_START="-1.2989487604180907" LOG_EFFECT_SIZE="0.09881900281538748" MODIFIED="2012-10-09 14:49:21 +0100" MODIFIED_BY="Kate Cahill" ORDER="1346" O_E="0.0" SE="1.6421114063707245" STUDY_ID="STD-Tonnesen-1988" TOTAL_1="114" TOTAL_2="47" VAR="2.6965298709328387" WEIGHT="1.1309780822762991"/>
<DICH_DATA CI_END="5.477421812206002" CI_START="0.4232557992041265" EFFECT_SIZE="1.5226130653266332" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7385761869137394" LOG_CI_START="-0.3733970827285427" LOG_EFFECT_SIZE="0.18258955209259836" MODIFIED="2012-10-09 14:52:28 +0100" MODIFIED_BY="Kate Cahill" ORDER="1347" O_E="0.0" SE="0.6531786029443343" STUDY_ID="STD-Wennike-2003a" TOTAL_1="205" TOTAL_2="206" VAR="0.4266422873443123" WEIGHT="6.2913981894031"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-10-16 16:41:33 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-10-16 16:31:04 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-10-16 16:41:33 +0100" MODIFIED_BY="Lindsay Stead" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any type of NRT versus placebo/ no NRT control, outcome: 1.1 Smoking cessation at 6+ months follow up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-10-16 16:41:33 +0100" MODIFIED_BY="Jamie Hartmann-Boyce" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Any type of NRT versus placebo/ no NRT control, outcome: 1.1 Smoking cessation at 6+ months follow up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-10-16 15:35:28 +0100" MODIFIED_BY="Kate Cahill">
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>How should efficacy be measured?</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The comment (December 2002) states that NRT is not more effective than abrupt cessation. We summarise the supporting arguments and our response to each below:</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>1. Pierce &amp; Gilpin (Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002;288:1260-4) found no difference in long-term cessation rates between those who did and who did not use NRT.</P>
<P>This point is addressed in a letter commenting on the study (Stead LF et al. Effectiveness of over-the-counter nicotine replacement therapy. JAMA 2002;288:3109-10). The main limitation of their study is that the comparison between groups of people who chose or did not chose to use NRT, These two groups probably differ in many respects related to their chance of successful quitting, and it is impossible to adjust for these possible confounders. Therefore the conclusions of the study are stronger than the evidence justifies.</P>
<P>The criticism authors also cite the Minnesota insurance review (Boyle RG et al. Does insurance coverage for drug therapy affect smoking cessation? Health Affairs 2002 Nov-Dec;21:162-8) but it does not seem to give further support to the point made. The main finding of Boyle et al was that introducing an insurance benefit did not increase use of NRT. </P>
<P>2. In the real-world those relying exclusively upon NRT are relapsing and dying at pre-NRT rates. </P>
<P>This is an assertion which is not supported by evidence.</P>
<P>3. NRT study instruction is designed and sequenced in order to foster device transfer. In fact the placebo group must be deprived of critical abrupt cessation instructional tips because if given and followed many could have a negative impact upon the active group. </P>
<P>The review does not make the assertion or implication attributed to it. In the studies involving behavioural support as well as active versus placebo NRT, both active and placebo groups are typically given instructions designed to maximise their chances of success. In these circumstances NRT if anything shows a larger advantage over placebo than it does in minimal support settings. If it is being asserted that placebo groups are being deprived of progressive cigarette weaning or some form of lapse management strategy, there is no evidence to suggest that this approach is effective.</P>
<P>4. The duration of abstinence for NRT groups should begin from the time they stop using NRT. </P>
<P>In response to this it should be noted that it is cigarettes which are causing the harm to health and the aim is to help people stop smoking. Secondly, studies that have followed up smokers long-term show that the medication genuinely improves long-term cessation rates and does not simply set the relapse clock back by the time period when nicotine replacement is being used.</P>
<P>5. There are clinic programmes achieving success rates at least as good as those using NRT. </P>
<P>It is necessary to make direct comparisons ensuring that the same criteria are applied to both groups to be able to draw conclusions.</P>
<P>Finally it must be noted that the Cochrane review shows that NRT is estimated to help some 7% smokers to stop long-term who would not have stopped had they used a similar approach but without NRT. This effect is small but given the health benefits from stopping smoking it is a highly cost-effective life-preserving medication. That is not to say that other interventions, including a different kind of behavioural intervention that was incompatible with NRT could not get better results. However, it is not enough just to assert the possibility; with so many lives at stake it would be imperative to demonstrate the effectiveness of such approaches.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment by John R. Polito. Response by Tim Lancaster &amp; Lindsay Stead on behalf of review authors. Criticism editor Robert West.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" NO="2">
<TITLE>How should effectiveness be measured</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The comment (October 2003) suggests that randomised controlled trials (RCTs) alone cannot establish the effectiveness of an intervention in a population.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>RCTs establish the size of effect of an intervention in a particular context in a sample who are eligible and willing to receive the intervention. It always remains possible that the effect size would be different in a different population under different conditions which is why it is important to assess in RCTs how representative the samples are, and how far the context of the trial represents the likely clinical scenarios in which the intervention will be applied. In other words an RCT seeks to achieve internal validity (corresponding to efficacy) and aspires to maximise external validity (corresponding to effectiveness). A 'real-world' comparison of two groups that are not comparable, and where the differences are not adequately controlled for by design or analysis, does not permit attribution of differences or similarities in outcome to the intervention under investigation.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment by John Pierce. Reply by Lindsay Stead &amp; Tim Lancaster on behalf of review authors. <BR/>Criticism Editors: Robert West (internal), Lisa Bero (external).</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-03" MODIFIED="2012-10-16 15:35:28 +0100" MODIFIED_BY="Kate Cahill" NO="3">
<TITLE>Impact of failure to assess blinding on validity</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The comment (May 2004) drew attention to a recent paper (Mooney M, White T, Hatsukami D. The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials. Addictive Behaviors 2004; 29(4):673-684) that notes that most NRT trials do not report whether blinding was maintained, and of those that did, blinding failure was common.<BR/>The comment also suggests that smokers failing to quit with an NRT-assisted attempt will not benefit from NRT use in subsequent attempts, and questions whether people who quit smoking but continue to use NRT should be regarded as having quit or not.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-10-16 15:35:28 +0100" MODIFIED_BY="Kate Cahill">
<P>The issue of possible failure of blinding, and hence of possible bias in estimates of treatment effect, is a potential problem in many areas of medicine. Failure to report whether the success of blinding has been tested is widespread (1). There are problems with how best to test the effectiveness of blinding. If participants' guesses are influenced by their success in quitting, then apparent breaking of the blind might be more common where treatment was effective (2).</P>
<P>Where there is evidence that blinding has failed, there still needs to be an assessment of whether this has lead to bias in effect estimates. Mooney's paper makes it clear that there are insufficient data to try to assess whether there was evidence of a bias in treatment estimates in the existing trials. There are many potential sources of bias in trials, and we don't have any evidence to suggest that failure of blinding is more of a problem in trials of NRT. We focus on outcomes at least six months after the quit attempt, so that any differential effect of guessing the treatment assignment on the likelihood of successful quitting would need to be long lasting.</P>
<P>Small amounts of nicotine have been used in placebo products in attempts to improve maintenance of the blind by giving a characteristic taste or smell. In most cases the amounts are small. If there were sufficient nicotine to be pharmacologically active it would seem more likely to decrease the effect of active NRT than inflate the treatment effect.</P>
<P>We do not think there is evidence to state that an initial failure with NRT means that subsequent attempts will also fail. People who have a failed quit attempt in a trial seem to have a low chance of success if they immediately try again, as noted in the studies by Gourlay, and Tonnesen (which was uncontrolled ). A recent study found a similar poor outcome when people who had failed to quit using nicotine patch were randomized to second line therapy with bupropion or placebo (5). In contrast, two recent studies have found that people who reported failed quit attempts using NRT do at least as well when enrolled in trials and treated with NRT as do NRT-naïve participants. (6,7).</P>
<P>It is important that smokers realise that their chance of a successful long-term quit from each attempt is low and that NRT, although increasing the likelihood of success, is not a 'magic bullet', and this point is made in the review.</P>
<P>We do not agree that people who give up smoking cannot regard themselves as quitters whilst they are using NRT. In the context of a history of chronic smoking over a period of years we do not think that it is a major concern that 6.7% of new gum users may be still using it after six months. The rate of persistent use appears to fall rapidly, with the same study noting a rate of 2.8% for use after a year or more. Rates of persistent patch use are lower.</P>
<P>References<BR/>(1) Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 2004 Feb 21;328(7437):432 2004<BR/>(2) Altman DG, Schulz KF, Moher D. Turning a blind eye: testing the success of blinding and the CONSORT statement. BMJ. 2004 May 8;328(7448):1135<BR/>(3) Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers, BMJ 1995;311:363-366<BR/>(4) Tonnesen P, Norregaard J, Sawe U, Simonsen K. Recycling with nicotine patches in smoking cessation. Addiction. 1993 Apr;88(4):533-9<BR/>(5) Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncology 2003; 21(5):914-920.<BR/>(6) Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ et al. Impact of prior nicotine replacement therapy on smoking cessation efficacy. Am J Health Behav 2002; 26(3):213-220.<BR/>(7) Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 2004; 99(1):83-92.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment by John R. Polito. Reply by Lindsay Stead, Tim Lancaster<BR/>Criticism editor Robert West</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2012-10-16 15:42:16 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-10-02 16:11:51 +0100" MODIFIED_BY="Lindsay Stead" NO="1">
<TITLE MODIFIED="2012-10-02 16:07:30 +0100" MODIFIED_BY="Lindsay Stead">Specialized Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-02 16:11:51 +0100" MODIFIED_BY="Lindsay Stead">
<P>#1 NRT: TI,AB,KY,XKY,MH,EMT</P>
<P>#2 (nicotine NEAR2 patch*):TI,AB,KY,XKY,MH,EMT</P>
<P>#3 (nicotine NEAR2 gum):TI,AB,KY,XKY,MH,EMT</P>
<P>#4 (nicotine NEAR2 nasal spray):TI,AB,KY,XKY,MH,EMT</P>
<P>#5 (nicotine NEAR2 lozenge*):TI,AB,KY,XKY,MH,EMT</P>
<P>#6 (nicotine NEAR2 tablet*):TI,AB,KY,XKY,MH,EMT</P>
<P>#7 (nicotine NEAR2 sublingual):TI,AB,KY,XKY,MH,EMT</P>
<P>#8 (nicotine NEAR2 inhal*):TI,AB,KY,XKY,MH,EMT</P>
<P>#9 (nicotine NEAR2 replacement):TI,AB,KY,XKY,MH,EMT</P>
<P>#10 (nicotine NEAR3 therap*):TI,AB,KY,XKY,MH,EMT</P>
<P>#11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10</P>
<P>The specialised register was transferred from Reference Manager to the <A HREF="http://www.metaxis.com/CRSHelp/General.html">CRS</A> in May 2012. This is the search used for the CRS: KY, XKY, MH &amp; EMT are keyword fields.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-10-10 15:52:27 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-06-21 11:05:05 +0100" MODIFIED_BY="[Empty name]">Glossary of terms</TITLE>
<APPENDIX_BODY MODIFIED="2012-02-20 14:47:23 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3"> </HEADING>
<TABLE COLS="2" ROWS="28">
<TR>
<TH>
<P>Term</P>
</TH>
<TH>
<P>Definition</P>
</TH>
</TR>
<TR>
<TD>
<P>Abstinence</P>
</TD>
<TD>
<P>A period of being quit, ie stopping the use of cigarettes or other tobacco products, May be defined in various ways; see also:<BR/>point prevalence abstinence; prolonged abstinence; continuous/sustained abstinence<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Biochemical verification</P>
</TD>
<TD>
<P>Also called 'biochemical validation' or 'biochemical confirmation':<BR/>A procedure for checking a tobacco user's report that he or she has not smoked or used tobacco. It can be measured by testing levels of nicotine or cotinine or other chemicals in blood, urine, or saliva, or by measuring levels of carbon monoxide in exhaled breath or in blood.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Bupropion</P>
</TD>
<TD>
<P>A pharmaceutical drug originally developed as an antidepressant, but now also licensed for smoking cessation; trade names Zyban, Wellbutrin (when prescribed as an antidepressant)</P>
</TD>
</TR>
<TR>
<TD>
<P>Carbon monoxide (CO)</P>
</TD>
<TD>
<P>A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs of people who have recently smoked, or (in smaller amounts) in people who have been exposed to tobacco smoke. May be used for biochemical verification of abstinence.</P>
</TD>
</TR>
<TR>
<TD>
<P>Cessation</P>
</TD>
<TD>
<P>Also called 'quitting'<BR/>The goal of treatment to help people achieve abstinence from smoking or other tobacco use, also used to describe the process of changing the behaviour<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuous abstinence</P>
</TD>
<TD>
<P>Also called 'sustained abstinence'<BR/>A measure of cessation often used in clinical trials involving avoidance of all tobacco use since the quit day until the time the assessment is made. The definition occasionally allows for lapses. This is the most rigorous measure of abstinence<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>'Cold Turkey'</P>
</TD>
<TD>
<P>Quitting abruptly, and/or quitting without behavioural or pharmaceutical support.</P>
</TD>
</TR>
<TR>
<TD>
<P>Craving</P>
</TD>
<TD>
<P>A very intense urge or desire [to smoke].<BR/>See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in smoking cessation trials'<BR/>Nicotine &amp; Tobacco Research 2004: 6(4): 599-614<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Dopamine</P>
</TD>
<TD>
<P>A neurotransmitter in the brain which regulates mood, attention, pleasure, reward, motivation and movement</P>
</TD>
</TR>
<TR>
<TD>
<P>Efficacy</P>
</TD>
<TD>
<P>Also called 'treatment effect' or 'effect size':<BR/>The difference in outcome between the experimental and control groups<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Harm reduction</P>
</TD>
<TD>
<P>Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing the number of cigarettes smoked, or switching to different brands or products, e.g. potentially reduced exposure products (PREPs), smokeless tobacco.</P>
</TD>
</TR>
<TR>
<TD>
<P>Lapse/slip</P>
</TD>
<TD>
<P>Terms sometimes used for a return to tobacco use after a period of abstinence. A lapse or slip might be defined as a puff or two on a cigarette. This may proceed to relapse, or abstinence may be regained. Some definitions of continuous, sustained or prolonged abstinence require complete abstinence, but some allow for a limited number or duration of slips. People who lapse are very likely to relapse, but some treatments may have their effect by helping people recover from a lapse.</P>
</TD>
</TR>
<TR>
<TD>
<P>nAChR</P>
</TD>
<TD>
<P>[neural nicotinic acetylcholine receptors]: Areas in the brain which are thought to respond to nicotine, forming the basis of nicotine addiction by stimulating the overflow of dopamine</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine</P>
</TD>
<TD>
<P>An alkaloid derived from tobacco, responsible for the psychoactive and addictive effects of smoking.</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine Replacement Therapy (NRT)</P>
</TD>
<TD>
<P>A smoking cessation treatment in which nicotine from tobacco is replaced for a limited period by pharmaceutical nicotine. This reduces the craving and withdrawal experienced during the initial period of abstinence while users are learning to be tobacco-free The nicotine dose can be taken through the skin, using patches, by inhaling a spray, or by mouth using gum or lozenges.</P>
</TD>
</TR>
<TR>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>Often used to describe the result being measured in trials that is of relevance to the review. For example smoking cessation is the outcome used in reviews of ways to help smokers quit. The exact outcome in terms of the definition of abstinence and the length of time that has elapsed since the quit attempt was made may vary from trial to trial.</P>
</TD>
</TR>
<TR>
<TD>
<P>Pharmacotherapy</P>
</TD>
<TD>
<P>A treatment using pharmaceutical drugs, e.g. NRT, bupropion</P>
</TD>
</TR>
<TR>
<TD>
<P>Point prevalence abstinence (PPA)</P>
</TD>
<TD>
<P>A measure of cessation based on behaviour at a particular point in time, or during a relatively brief specified period, e.g. 24 hours, 7 days. It may include a mixture of recent and long-term quitters. cf. prolonged abstinence, continuous abstinence</P>
</TD>
</TR>
<TR>
<TD>
<P>Prolonged abstinence</P>
</TD>
<TD>
<P>A measure of cessation which typically allows a 'grace period' following the quit date (usually of about two weeks), to allow for slips/lapses during the first few days when the effect of treatment may still be emerging.<BR/>See: Hughes et al 'Measures of abstinence in clinical trials: issues and recommendations'; Nicotine &amp; Tobacco Research, 2003: 5 (1); 13-25<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Relapse</P>
</TD>
<TD>
<P>A return to regular smoking after a period of abstinence</P>
</TD>
</TR>
<TR>
<TD>
<P>Secondhand smoke</P>
</TD>
<TD>
<P>Also called passive smoking or environmental tobacco smoke [ETS]<BR/>A mixture of smoke exhaled by smokers and smoke released from smouldering cigarettes, cigars, pipes, bidis, etc. The smoke mixture contains gases and particulates, including nicotine, carcinogens and toxins.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Self-efficacy</P>
</TD>
<TD>
<P>The belief that one will be able to change one's behaviour, e.g. to quit smoking</P>
</TD>
</TR>
<TR>
<TD>
<P>SPC [Summary of Product Characteristics]</P>
</TD>
<TD>
<P>Advice from the manufacturers of a drug, agreed with the relevant licensing authority, to enable health professionals to prescribe and use the treatment safely and effectively.</P>
</TD>
</TR>
<TR>
<TD>
<P>Tapering</P>
</TD>
<TD>
<P>A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Tar</P>
</TD>
<TD>
<P>The toxic chemicals found in cigarettes. In solid form, it is the brown, tacky residue visible in a cigarette filter and deposited in the lungs of smokers.</P>
</TD>
</TR>
<TR>
<TD>
<P>Titration</P>
</TD>
<TD>
<P>A technique of dosing at low levels at the beginning of treatment, and gradually increasing to full dose over a few days, to allow the body to get used to the drug. It is designed to limit side effects.</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawal</P>
</TD>
<TD>
<P>A variety of behavioural, affective, cognitive and physiological symptoms, usually transient, which occur after use of an addictive drug is reduced or stopped.<BR/>See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in smoking cessation trials'<BR/>Nicotine &amp; Tobacco Research 2004: 6(4): 599-614<BR/>
</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-10-16 15:42:16 +0100" MODIFIED_BY="Kate Cahill" NO="3">
<TITLE MODIFIED="2012-10-10 11:38:20 +0100" MODIFIED_BY="Kate Cahill">Main adverse events by study</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-16 15:42:16 +0100" MODIFIED_BY="Kate Cahill">
<TABLE COLS="7" ROWS="287">
<TR>
<TH VALIGN="TOP">
<P>
<I>Adverse Event</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>RCTs</I>
</P>
<P>
<I>P=patch, G=gum, S=spray, I=inhaler, L=lozenge, T=tablet.</I>
</P>
<P>
<I>EX=excluded study</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>Active n events</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>Active total</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>Control n events</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>Control total</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>Notes</I>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Headache</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Areechon-1988" TYPE="STUDY">Areechon 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Blondal-1989" TYPE="STUDY">Blondal 1989</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK> (P)   25mg</P>
<P>                             15mg</P>
</TD>
<TD VALIGN="TOP">
<P>80</P>
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>1430</P>
<P>1431</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>714</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>521</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>529</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnant women</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>  11mg</P>
<P>
<LINK REF="STD-Dale-1995" TYPE="STUDY">Dale 1995</LINK> (P) 22mg</P>
<P>44mg</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
<P>5</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
<P>17</P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Daughton-1991" TYPE="STUDY">Daughton 1991</LINK> (P) 24hr</P>
<P>16hr</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>133</P>
</TD>
<TD VALIGN="TOP">
<P>vs Bup, %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>315</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>314</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>First 6 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>321</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>322</P>
</TD>
<TD VALIGN="TOP">
<P>Excludes pay group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1994" TYPE="STUDY">Hjalmarson 1994</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>116</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>First 2 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hurt-1994" TYPE="STUDY">Hurt 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jarvis-1982" TYPE="STUDY">Jarvis 1982</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>22mg vs 44mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P>
<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>243</P>
<P>244</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>159</P>
</TD>
<TD VALIGN="TOP">
<P>P vs placebo</P>
<P>P+B vs placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>42mg vs 21mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lewis-1998" TYPE="STUDY">Lewis 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Llivina-1988" TYPE="STUDY">Llivina 1988</LINK> (G)                         </P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Paoletti-1996" TYPE="STUDY">Paoletti 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>147</P>
<P>(LC15+HC25)</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
<P>(LCP+HC15)</P>
</TD>
<TD VALIGN="TOP">
<P>Active vs placebo (Pl+Pl or lowA+Pl)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1979" TYPE="STUDY">Puska 1979</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>74</P>
</TD>
<TD VALIGN="TOP">
<P>From %; missing data removed from denominator</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1995" TYPE="STUDY">Puska 1995</LINK> (P, G)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>P+G vs Gum only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>Post-quit active vs placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sachs-1993" TYPE="STUDY">Sachs 1993</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1995" TYPE="STUDY">Schneider 1995</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>@12wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shiffman-2002-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2002 (2mg)</LINK> (L)</P>
<P>
<LINK REF="STD-Shiffman-2002-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2002 (4mg)</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>459</P>
<P>450</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>458</P>
<P>451</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stapleton-1995" TYPE="STUDY">Stapleton 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>84</P>
</TD>
<TD VALIGN="TOP">
<P>761</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>364</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sutherland-1992" TYPE="STUDY">Sutherland 1992</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1991" TYPE="STUDY">Tonnesen 1991</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>144</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Batra-2005" TYPE="STUDY">Batra 2005</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>184</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Ebbert-2009" TYPE="STUDY">Ebbert 2009</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>136</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>Smokeless (from %)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Hanson-2003" TYPE="STUDY">Hanson 2003</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>adolescents</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Mulligan-1990" TYPE="STUDY">Mulligan 1990</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Rigotti-2009" TYPE="STUDY">Rigotti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>367</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>362</P>
</TD>
<TD VALIGN="TOP">
<P>All were on rimonabant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Stapleton-2011" TYPE="STUDY">Stapleton 2011</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>320</P>
</TD>
<TD VALIGN="TOP">
<P>506</P>
</TD>
<TD VALIGN="TOP">
<P>154</P>
</TD>
<TD VALIGN="TOP">
<P>255</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Dizziness/light-headedness</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>174</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>168</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Areechon-1988" TYPE="STUDY">Areechon 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>11mg</P>
<P>
<LINK REF="STD-Dale-1995" TYPE="STUDY">Dale 1995</LINK> (P) 22mg</P>
<P>44mg</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
<P>3</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
<P>17</P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Daughton-1991" TYPE="STUDY">Daughton 1991</LINK> (P) 24hr</P>
<P>16hr</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>133</P>
</TD>
<TD VALIGN="TOP">
<P>NRT vs Bup, from %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>315</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>314</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>First 6 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1994" TYPE="STUDY">Hjalmarson 1994</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>116</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>First 2 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hughes-1989" TYPE="STUDY">Hughes 1989</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P>210</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jarvis-1982" TYPE="STUDY">Jarvis 1982</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P>
<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>243</P>
<P>244</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>159</P>
</TD>
<TD VALIGN="TOP">
<P>P vs placebo</P>
<P>P+B vs placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>42mg vs 21mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>89</P>
</TD>
<TD VALIGN="TOP">
<P>206</P>
</TD>
<TD VALIGN="TOP">
<P>81</P>
</TD>
<TD VALIGN="TOP">
<P>202</P>
</TD>
<TD VALIGN="TOP">
<P>25mg vs 15mg, no placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lewis-1998" TYPE="STUDY">Lewis 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1979" TYPE="STUDY">Puska 1979</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>74</P>
</TD>
<TD VALIGN="TOP">
<P>From %;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>Post-quit active vs placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sachs-1993" TYPE="STUDY">Sachs 1993</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1995" TYPE="STUDY">Schneider 1995</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>@12wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stapleton-1995" TYPE="STUDY">Stapleton 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>761</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>364</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sutherland-1992" TYPE="STUDY">Sutherland 1992</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1991" TYPE="STUDY">Tonnesen 1991</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>144</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Hanson-2003" TYPE="STUDY">Hanson 2003</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>adolescents</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Mulligan-1990" TYPE="STUDY">Mulligan 1990</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Oncken-2009" TYPE="STUDY">Oncken 2009</LINK> (P, S)</P>
</TD>
<TD VALIGN="TOP">
<P>P3</P>
<P>S0</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnant women</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Rigotti-2009" TYPE="STUDY">Rigotti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>367</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>362</P>
</TD>
<TD VALIGN="TOP">
<P>All were on rimonabant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Stapleton-2011" TYPE="STUDY">Stapleton 2011</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>308</P>
</TD>
<TD VALIGN="TOP">
<P>506</P>
</TD>
<TD VALIGN="TOP">
<P>139</P>
</TD>
<TD VALIGN="TOP">
<P>255</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Nausea/vomiting</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>174</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>168</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Areechon-1988" TYPE="STUDY">Areechon 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Batra-2005" TYPE="STUDY">Batra 2005</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>184</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Campbell-1996" TYPE="STUDY">Campbell 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>115</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>119</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK> (P) 25mg</P>
<P>15mg</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
<P>77</P>
</TD>
<TD VALIGN="TOP">
<P>1430</P>
<P>1431</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>714</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>521</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>529</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnant women</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>  11mg</P>
<P>
<LINK REF="STD-Dale-1995" TYPE="STUDY">Dale 1995</LINK> (P) 22mg</P>
<P>44mg</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>1</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
<P>17</P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dautzenberg-2001" TYPE="STUDY">Dautzenberg 2001</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>222`</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>133</P>
</TD>
<TD VALIGN="TOP">
<P>NRT vs Bup %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Garvey-2000" TYPE="STUDY">Garvey 2000</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>209</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>(2mg+4mg) %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Glover-2002" TYPE="STUDY">Glover 2002</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>121</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>315</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>314</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>First 6 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>321</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>322</P>
</TD>
<TD VALIGN="TOP">
<P>Excludes pay group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1994" TYPE="STUDY">Hjalmarson 1994</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>116</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>First 2 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hughes-1989" TYPE="STUDY">Hughes 1989</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>210</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hurt-1994" TYPE="STUDY">Hurt 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jarvis-1982" TYPE="STUDY">Jarvis 1982</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>22mg vs 44mg,</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P>
<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (P) P</P>
<P>P+B</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>243</P>
<P>244</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>159</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>42mg vs 21mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lewis-1998" TYPE="STUDY">Lewis 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>P+counselling vs Pl+counselling</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Richmond-1994" TYPE="STUDY">Richmond 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>156</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>157</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>Post-quit active vs placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sachs-1993" TYPE="STUDY">Sachs 1993</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1995" TYPE="STUDY">Schneider 1995</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>112</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>@12wks (ie. 4wks on placebo or patch)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shiffman-2002-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2002 (2mg)</LINK> (L)</P>
<P>
<LINK REF="STD-Shiffman-2002-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2002 (4mg)</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
<P>68</P>
</TD>
<TD VALIGN="TOP">
<P>459</P>
<P>450</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>458</P>
<P>451</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stapleton-1995" TYPE="STUDY">Stapleton 1995</LINK> (P)</P>
<P>(= Russell 1993)</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>761</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>364</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sutherland-1992" TYPE="STUDY">Sutherland 1992</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1988" TYPE="STUDY">Tonnesen 1988</LINK> (G) 2mg</P>
<P>4mg</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1991" TYPE="STUDY">Tonnesen 1991</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>144</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1993" TYPE="STUDY">Tonnesen 1993</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>141</P>
</TD>
<TD VALIGN="TOP">
<P>severe</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wallstrom-2000" TYPE="STUDY">Wallstrom 2000</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>123</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Bolliger-2000" TYPE="STUDY">Bolliger 2000</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-McRobbie-2010" TYPE="STUDY">McRobbie 2010</LINK> (L,G,S)</P>
</TD>
<TD VALIGN="TOP">
<P>L17</P>
<P>G15</P>
<P>S16</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
<P>45</P>
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Rennard-2006" TYPE="STUDY">Rennard 2006</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>215</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Rigotti-2009" TYPE="STUDY">Rigotti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>367</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>362</P>
</TD>
<TD VALIGN="TOP">
<P>All were on rimonabant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Roddy-2006" TYPE="STUDY">Roddy 2006</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>&#8220;Dizziness, nausea or headache&#8221;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Stapleton-2011" TYPE="STUDY">Stapleton 2011</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>336</P>
</TD>
<TD VALIGN="TOP">
<P>506</P>
</TD>
<TD VALIGN="TOP">
<P>168</P>
</TD>
<TD VALIGN="TOP">
<P>255</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Tsukahara-2010" TYPE="STUDY">Tsukahara 2010</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>V vs Gum, no placebo</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gastro-intestinal symptoms</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK> (P,G) serious</P>
<P>non-serious</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>249</P>
<P>249</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>246</P>
<P>249</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Campbell-1991" TYPE="STUDY">Campbell 1991</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>  11mg</P>
<P>
<LINK REF="STD-Dale-1995" TYPE="STUDY">Dale 1995</LINK> (P) 22mg</P>
<P>44mg</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>0</P>
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
<P>17</P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Daughton-1991" TYPE="STUDY">Daughton 1991</LINK> (P) 24hr</P>
<P>16hr</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dautzenberg-2001" TYPE="STUDY">Dautzenberg 2001</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>222</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Glover-2002" TYPE="STUDY">Glover 2002</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>121</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>First 6 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1984" TYPE="STUDY">Hjalmarson 1984</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>91</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hurt-1994" TYPE="STUDY">Hurt 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hughes-1989" TYPE="STUDY">Hughes 1989</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>210</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jarvis-1982" TYPE="STUDY">Jarvis 1982</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>22mg vs 44mg,</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Joseph-1996" TYPE="STUDY">Joseph 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>290</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>206 (25mg)</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>202 (15mg)</P>
</TD>
<TD VALIGN="TOP">
<P>No placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lewis-1998" TYPE="STUDY">Lewis 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Llivina-1988" TYPE="STUDY">Llivina 1988</LINK> (G)                         </P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> <LINK REF="STD-Paoletti-1996" TYPE="STUDY">Paoletti 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>147</P>
<P>(LC15+HC25)</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
<P>(LCP+HC15)</P>
</TD>
<TD VALIGN="TOP">
<P>(Pl+Pl or lowA+Pl)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1979" TYPE="STUDY">Puska 1979</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>74</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1995" TYPE="STUDY">Puska 1995</LINK> (P, G)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>P+G vs G only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>Post-quit</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sachs-1993" TYPE="STUDY">Sachs 1993</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shiffman-2002-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2002 (2mg)</LINK> (L)</P>
<P>
<LINK REF="STD-Shiffman-2002-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2002 (4mg)</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>459</P>
<P>450</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>458</P>
<P>451</P>
</TD>
<TD VALIGN="TOP">
<P>From %  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK> (G)</P>
<P>
<LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>213</P>
<P>216</P>
</TD>
<TD VALIGN="TOP">
<P>819</P>
<P>830</P>
</TD>
<TD VALIGN="TOP">
<P>118</P>
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>817</P>
<P>831</P>
</TD>
<TD VALIGN="TOP">
<P>From %  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>112</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sonderskov-1997" TYPE="STUDY">Sonderskov 1997</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>255</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>267</P>
</TD>
<TD VALIGN="TOP">
<P>First 4 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1988" TYPE="STUDY">Tonnesen 1988</LINK> (G) 2mg</P>
<P>  4mg   </P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wallstrom-2000" TYPE="STUDY">Wallstrom 2000</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>123</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Batra-2005" TYPE="STUDY">Batra 2005</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>184</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Ebbert-2010" TYPE="STUDY">Ebbert 2010</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>Smokeless (from %)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Ebbert-2009" TYPE="STUDY">Ebbert 2009</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>136</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>Smokeless (from %)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Molander-2000" TYPE="STUDY">Molander 2000</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Mulligan-1990" TYPE="STUDY">Mulligan 1990</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Oncken-2009" TYPE="STUDY">Oncken 2009</LINK> (P, S)</P>
</TD>
<TD VALIGN="TOP">
<P>P3</P>
<P>S0</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnant women</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Tsukahara-2010" TYPE="STUDY">Tsukahara 2010</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>V vs Gum, no placebo</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sleep/dream problems</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>174</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>168</P>
</TD>
<TD VALIGN="TOP">
<P>In first week</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK> (P)   25mg</P>
<P>                             15mg</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
<P>77</P>
</TD>
<TD VALIGN="TOP">
<P>1430</P>
<P>1431</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>714</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dautzenberg-2001" TYPE="STUDY">Dautzenberg 2001</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>222</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>133</P>
</TD>
<TD VALIGN="TOP">
<P>NRT vs Bup %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>315</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>314</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>321</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>322</P>
</TD>
<TD VALIGN="TOP">
<P>Excludes pay group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hurt-1994" TYPE="STUDY">Hurt 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ICRF-1994" TYPE="STUDY">ICRF 1994</LINK> (P)  Mild</P>
<P>                   Moderate</P>
<P>                   Severe</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
<P>95</P>
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>842</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
<P>40</P>
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>844</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>22mg vs 44mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P>
<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (P) P</P>
<P>P+B</P>
</TD>
<TD VALIGN="TOP">
<P>73</P>
<P>116</P>
</TD>
<TD VALIGN="TOP">
<P>243</P>
<P>244</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>159</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Joseph-1996" TYPE="STUDY">Joseph 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>290</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>206</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
</TD>
<TD VALIGN="TOP">
<P>202</P>
</TD>
<TD VALIGN="TOP">
<P>25mg vs 15mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Llivina-1988" TYPE="STUDY">Llivina 1988</LINK> (G)                         </P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Oncken-2007" TYPE="STUDY">Oncken 2007</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> <LINK REF="STD-Paoletti-1996" TYPE="STUDY">Paoletti 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>147</P>
<P>(LC15+HC25)</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
<P>(LCP+HC15)</P>
</TD>
<TD VALIGN="TOP">
<P>(Pl+Pl or lowA+Pl)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Perng-1998" TYPE="STUDY">Perng 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1979" TYPE="STUDY">Puska 1979</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>74</P>
</TD>
<TD VALIGN="TOP">
<P>From %;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Richmond-1994" TYPE="STUDY">Richmond 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>156</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>157</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sachs-1993" TYPE="STUDY">Sachs 1993</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>@12wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Ebbert-2009" TYPE="STUDY">Ebbert 2009</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>136</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>Smokeless (from %)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Ebbert-2010" TYPE="STUDY">Ebbert 2010</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>Smokeless (from %)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Hanson-2003" TYPE="STUDY">Hanson 2003</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>adolescents</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Mulligan-1990" TYPE="STUDY">Mulligan 1990</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Rigotti-2009" TYPE="STUDY">Rigotti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>367</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>362</P>
</TD>
<TD VALIGN="TOP">
<P>All were on rimonabant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Tsukahara-2010" TYPE="STUDY">Tsukahara 2010</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>V vs Gum</P>
</TD>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CV (palpitations, chest pain)</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK> (P,G)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>249</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>246</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK> (P)  25mg</P>
<P>                            15mg</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>1430</P>
<P>1431</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>714</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>179</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>143</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>321</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>322</P>
</TD>
<TD VALIGN="TOP">
<P>Excludes pay group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1994" TYPE="STUDY">Hjalmarson 1994</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>116</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>First 2 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Oncken-2007" TYPE="STUDY">Oncken 2007</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>206 (25mg)</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>202 (15mg)</P>
</TD>
<TD VALIGN="TOP">
<P>No placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1995" TYPE="STUDY">Schneider 1995</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>@12wks (ie. 4wks on placebo or patch)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shiffman-2009-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2009 (2mg)</LINK> (G)</P>
<P>
<LINK REF="STD-Shiffman-2009-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2009 (4mg)</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>819</P>
<P>830</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>817</P>
<P>831</P>
</TD>
<TD VALIGN="TOP">
<P>From %  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sonderskov-1997" TYPE="STUDY">Sonderskov 1997</LINK> (P)</P>
<P>&#8220;cardiac&#8221;</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>255</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>267</P>
</TD>
<TD VALIGN="TOP">
<P>First 4 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sutherland-1992" TYPE="STUDY">Sutherland 1992</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1988" TYPE="STUDY">Tonnesen 1988</LINK> (G) 2mg</P>
<P>4mg</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Wennike-2003" TYPE="STUDY">Wennike 2003</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>205</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>206</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Bolliger-2000" TYPE="STUDY">Bolliger 2000</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Brantmark-1973" TYPE="STUDY">Brantmark 1973</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<LINK REF="STD-Wisborg-2000" TYPE="STUDY">Wisborg 2000</LINK> states 5 women had palpitations, but no distribution info</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Skin reactions</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Abelin-1989" TYPE="STUDY">Abelin 1989</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>156</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>155</P>
</TD>
<TD VALIGN="TOP">
<P>Combined studies</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ahluwalia-1998" TYPE="STUDY">Ahluwalia 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>174</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>168</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bohadana-2000" TYPE="STUDY">Bohadana 2000</LINK> (I+P)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Buchkremer-1988" TYPE="STUDY">Buchkremer 1988</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bullen-2010" TYPE="STUDY">Bullen 2010</LINK> (P,G)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>249</P>
<P>249</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>246</P>
<P>246</P>
</TD>
<TD VALIGN="TOP">
<P>Skin SAEs</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Campbell-1996" TYPE="STUDY">Campbell 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>115</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>119</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CEASE-1999" TYPE="STUDY">CEASE 1999</LINK> (P)   25mg</P>
<P>                             15mg</P>
</TD>
<TD VALIGN="TOP">
<P>206</P>
<P>185</P>
</TD>
<TD VALIGN="TOP">
<P>1430</P>
<P>1431</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>714</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Coleman-2012" TYPE="STUDY">Coleman 2012</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>97</P>
</TD>
<TD VALIGN="TOP">
<P>521</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>529</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnant women</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Daughton-1991" TYPE="STUDY">Daughton 1991</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>51 (24hr)</P>
<P>55 (16hr)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dautzenberg-2001" TYPE="STUDY">Dautzenberg 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>222</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Davidson-1998" TYPE="STUDY">Davidson 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>401</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>401</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>133</P>
</TD>
<TD VALIGN="TOP">
<P>NRT vs Bup %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gourlay-1995" TYPE="STUDY">Gourlay 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>315</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>314</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hays-1999" TYPE="STUDY">Hays 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>321</P>
</TD>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>322</P>
</TD>
<TD VALIGN="TOP">
<P>Excludes pay group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hurt-1990" TYPE="STUDY">Hurt 1990</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>Over 6 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hurt-1994" TYPE="STUDY">Hurt 1994</LINK>            Mild</P>
<P>                     Moderate</P>
<P>                          Severe</P>
</TD>
<TD VALIGN="TOP">
<P>68</P>
<P>5</P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
<P>3</P>
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ICRF-1994" TYPE="STUDY">ICRF 1994</LINK> (P)     Mild</P>
<P>                      Moderate</P>
<P>                          Severe</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
<P>75</P>
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>842</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
<P>26</P>
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>844</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jorenby-1995" TYPE="STUDY">Jorenby 1995</LINK> (P)  Mild</P>
<P>                      Moderate</P>
<P>                          Severe</P>
</TD>
<TD VALIGN="TOP">
<P>126</P>
<P>33</P>
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>123</P>
<P>58</P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>252</P>
</TD>
<TD VALIGN="TOP">
<P>22mg vs 44mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P>
<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (P) P</P>
<P>P+B</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>243</P>
<P>244</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>159</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Joseph-1996" TYPE="STUDY">Joseph 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>294</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>290</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kalman-2006" TYPE="STUDY">Kalman 2006</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>42mg vs 21mg</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Killen-1999" TYPE="STUDY">Killen 1999</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>206 (25mg)</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>202 (15mg)</P>
</TD>
<TD VALIGN="TOP">
<P>No placebo</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kornitzer-1995" TYPE="STUDY">Kornitzer 1995</LINK> (P,G)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>149</P>
<P>150</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD VALIGN="TOP">
<P>P+G vs Pl</P>
<P>P+PlG vs Pl</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lewis-1998" TYPE="STUDY">Lewis 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Oncken-2007" TYPE="STUDY">Oncken 2007</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> <LINK REF="STD-Paoletti-1996" TYPE="STUDY">Paoletti 1996</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>147</P>
<P>(LC15+HC25)</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
<P>(LCP+HC15)</P>
</TD>
<TD VALIGN="TOP">
<P>Active vs placebo (Pl+Pl or lowA+Pl)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Perng-1998" TYPE="STUDY">Perng 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1995" TYPE="STUDY">Puska 1995</LINK> (P, G)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>P+G vs G only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Richmond-1994" TYPE="STUDY">Richmond 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>156</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>157</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schnoll-2010a" TYPE="STUDY">Schnoll 2010a</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>@12wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schuurmans-2004" TYPE="STUDY">Schuurmans 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>Pretreatment phase</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sonderskov-1997" TYPE="STUDY">Sonderskov 1997</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>75</P>
</TD>
<TD VALIGN="TOP">
<P>255</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>267</P>
</TD>
<TD VALIGN="TOP">
<P>First 4 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stapleton-1995" TYPE="STUDY">Stapleton 1995</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>108</P>
</TD>
<TD VALIGN="TOP">
<P>761</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>364</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Tonneson 1991 (P)</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>144</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Hanson-2003" TYPE="STUDY">Hanson 2003</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>adolescents</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Levin-1994" TYPE="STUDY">Levin 1994</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Mulligan-1990" TYPE="STUDY">Mulligan 1990</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Oncken-2009" TYPE="STUDY">Oncken 2009</LINK> (P, S)</P>
</TD>
<TD VALIGN="TOP">
<P>P3</P>
<P>S0</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnant women</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Roddy-2006" TYPE="STUDY">Roddy 2006</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Rose-1990" TYPE="STUDY">Rose 1990</LINK> (P) mod.</P>
<P>                           severe</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Tsukahara-2010" TYPE="STUDY">Tsukahara 2010</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>V vs Gum, no placebo</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
<TH VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Oral/nasal reactions</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Areechon-1988" TYPE="STUDY">Areechon 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bohadana-2000" TYPE="STUDY">Bohadana 2000</LINK> (I+P)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Campbell-1991" TYPE="STUDY">Campbell 1991</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cooney-2009" TYPE="STUDY">Cooney 2009</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>alcoholics</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Croghan-2003" TYPE="STUDY">Croghan 2003</LINK> (P, S)</P>
</TD>
<TD VALIGN="TOP">
<P>79</P>
</TD>
<TD VALIGN="TOP">
<P>126(S)</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>151(P)</P>
</TD>
<TD VALIGN="TOP">
<P>Spray vs patch, from %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dautzenberg-2001" TYPE="STUDY">Dautzenberg 2001</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>222</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>68</P>
</TD>
<TD VALIGN="TOP">
<P>133</P>
</TD>
<TD VALIGN="TOP">
<P>NRT v Bup, %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Garvey-2000" TYPE="STUDY">Garvey 2000</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>209</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>(2mg+4mg)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Glover-2002" TYPE="STUDY">Glover 2002</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>121</P>
</TD>
<TD VALIGN="TOP">
<P>Wks 1-2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>First 6 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1984" TYPE="STUDY">Hjalmarson 1984</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>91</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1994" TYPE="STUDY">Hjalmarson 1994</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>116</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>First 2 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hughes-1989" TYPE="STUDY">Hughes 1989</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>160</P>
</TD>
<TD VALIGN="TOP">
<P>210</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jarvis-1982" TYPE="STUDY">Jarvis 1982</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD>
<P>
<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (P) P</P>
<P>P+B</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>243</P>
<P>244</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>159</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Llivina-1988" TYPE="STUDY">Llivina 1988</LINK> (G)                        </P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>113</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Perng-1998" TYPE="STUDY">Perng 1998</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Puska-1995" TYPE="STUDY">Puska 1995</LINK> (P, G)</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>P+G vs G only</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>Post-quit</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1995" TYPE="STUDY">Schneider 1995</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>125</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>127</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>112</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shiffman-2002-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2002 (2mg)</LINK> (L)</P>
<P>
<LINK REF="STD-Shiffman-2002-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2002 (4mg)</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>459</P>
<P>450</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>458</P>
<P>451</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sutherland-1992" TYPE="STUDY">Sutherland 1992</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P>67</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1988" TYPE="STUDY">Tonnesen 1988</LINK> (G) 2mg</P>
<P>  4mg</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1993" TYPE="STUDY">Tonnesen 1993</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>72</P>
</TD>
<TD VALIGN="TOP">
<P>145</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>141</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wallstrom-2000" TYPE="STUDY">Wallstrom 2000</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>66</P>
</TD>
<TD VALIGN="TOP">
<P>123</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Adelman-2009" TYPE="STUDY">Adelman 2009</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>Open-label, no spray for controls</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Batra-2005" TYPE="STUDY">Batra 2005</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>184</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Bolliger-2000" TYPE="STUDY">Bolliger 2000</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>200</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Brantmark-1973" TYPE="STUDY">Brantmark 1973</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-McRobbie-2010" TYPE="STUDY">McRobbie 2010</LINK> (L,G,S)</P>
</TD>
<TD VALIGN="TOP">
<P>L8</P>
<P>G6</P>
<P>S16</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
<P>45</P>
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Molander-2000" TYPE="STUDY">Molander 2000</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Oncken-2009" TYPE="STUDY">Oncken 2009</LINK> (P, S)</P>
</TD>
<TD VALIGN="TOP">
<P>P1</P>
<P>S2</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnant women</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX Rennard 2002 (I)</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>215</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>214</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Rigotti-2009" TYPE="STUDY">Rigotti 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>367</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>362</P>
</TD>
<TD VALIGN="TOP">
<P>All were on rimonabant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Stapleton-2011" TYPE="STUDY">Stapleton 2011</LINK> (S)</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>506</P>
</TD>
<TD VALIGN="TOP">
<P>135</P>
</TD>
<TD VALIGN="TOP">
<P>255</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Hiccups</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Blondal-1989" TYPE="STUDY">Blondal 1989</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>90</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Glover-2002" TYPE="STUDY">Glover 2002</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>120</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>121</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Harackiewicz-1988" TYPE="STUDY">Harackiewicz 1988</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>First 6 wks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hjalmarson-1984" TYPE="STUDY">Hjalmarson 1984</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>91</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hughes-1989" TYPE="STUDY">Hughes 1989</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>210</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jarvis-1982" TYPE="STUDY">Jarvis 1982</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rose-2009" TYPE="STUDY">Rose 2009</LINK> (P)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>Post-quit</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK> (I)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>112</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shiffman-2002-_x0028_2mg_x0029_" TYPE="STUDY">Shiffman 2002 (2mg)</LINK> (L)</P>
<P>
<LINK REF="STD-Shiffman-2002-_x0028_4mg_x0029_" TYPE="STUDY">Shiffman 2002 (4mg)</LINK> (L)</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>459</P>
<P>450</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>458</P>
<P>451</P>
</TD>
<TD VALIGN="TOP">
<P>From %  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tonnesen-1988" TYPE="STUDY">Tonnesen 1988</LINK> (G) 2mg</P>
<P>4mg</P>
<P>                                               </P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wallstrom-2000" TYPE="STUDY">Wallstrom 2000</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>123</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>From %</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Batra-2005" TYPE="STUDY">Batra 2005</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>184</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Brantmark-1973" TYPE="STUDY">Brantmark 1973</LINK> (G)</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-McRobbie-2010" TYPE="STUDY">McRobbie 2010</LINK> (L,G,S)</P>
</TD>
<TD VALIGN="TOP">
<P>L17</P>
<P>G15</P>
<P>S16</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
<P>45</P>
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>EX <LINK REF="STD-Molander-2000" TYPE="STUDY">Molander 2000</LINK> (T)</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>